curated_by,assay_category,src_id,assay_cell_type,assay_strain,description,assay_subcellular_fraction,chembl_id,relationship_type,confidence_score,src_assay_id,cell_id,assay_organism,assay_tax_id,bao_format,tid,variant_id,assay_id,assay_tissue,doc_id,assay_type,assay_test_type,tissue_id
Autocuration,,1,,,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 30 uM,,CHEMBL615117,H,8,,,,,BAO_0000019,12052,,1,,11087,B,,
Autocuration,,1,,,Compound was evaluated for its ability to mobilize calcium in 1321NI cells,,CHEMBL615118,U,0,,,,,BAO_0000219,22226,,2,,684,F,,
Autocuration,,1,,,,,CHEMBL615119,U,0,,,,,BAO_0000019,22226,,3,,15453,B,,
Autocuration,,1,,,Binding affinity against A2 adenosine receptor in bovine striatal membranes using [3H]CGS-21680,,CHEMBL615120,H,4,,,Bos taurus,9913.0,BAO_0000249,104729,,4,,17841,B,,
Intermediate,,1,143B,,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),,CHEMBL615121,N,1,,163.0,Homo sapiens,9606.0,BAO_0000219,80001,,5,,17430,F,,
Intermediate,,1,143B,,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),,CHEMBL615122,N,1,,163.0,Homo sapiens,9606.0,BAO_0000219,80001,,6,,17430,F,,
Intermediate,,1,143B,,Cytotoxic Activity was evaluated against 143B (TK-) tumor cells,,CHEMBL615123,N,1,,163.0,Mus musculus,10090.0,BAO_0000219,80001,,7,,13799,F,,
Expert,,1,143B,,In vitro cell cytotoxicity was determined against 143B cell line,,CHEMBL615124,N,1,,163.0,Homo sapiens,9606.0,BAO_0000219,80001,,8,,17774,F,,
Intermediate,,1,143B,,Inhibitory activity against tumor osteosarcoma cell line 143B after 72 hr continuous exposure to compound,,CHEMBL615125,N,1,,163.0,Homo sapiens,9606.0,BAO_0000219,80001,,9,,3801,F,,
Intermediate,,1,143B,,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,,CHEMBL615126,N,1,,163.0,Homo sapiens,9606.0,BAO_0000219,80001,,10,,17430,F,,
Intermediate,,1,143B,,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,,CHEMBL615127,N,1,,163.0,Homo sapiens,9606.0,BAO_0000219,80001,,11,,17430,F,,
Expert,,1,143B,,In vitro cell cytotoxicity was determined against 143B-LTK cell line,,CHEMBL615128,N,1,,163.0,Homo sapiens,9606.0,BAO_0000219,80001,,12,,17774,F,,
Intermediate,,1,,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,CHEMBL857900,N,1,,,Staphylococcus aureus,1280.0,BAO_0000218,50185,,13,,11324,F,,
Intermediate,,1,,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,CHEMBL615129,N,1,,,Staphylococcus aureus,1280.0,BAO_0000218,50185,,14,,11324,F,,
Intermediate,,1,,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,CHEMBL615130,N,1,,,Staphylococcus aureus,1280.0,BAO_0000218,50185,,15,,11324,F,,
Intermediate,,1,,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,CHEMBL615131,N,1,,,Staphylococcus aureus,1280.0,BAO_0000218,50185,,16,,11324,F,,
Expert,,1,,,Inhibition of cytochrome P450 progesterone 15-alpha hydroxylase,,CHEMBL884521,D,9,,,Rattus norvegicus,10116.0,BAO_0000357,100122,,17,,11347,A,,
Autocuration,,1,,,Concentration that cause 50% activation of human reticulocyte 15-lipoxygenase (15-HLO),,CHEMBL615132,H,8,,,,,BAO_0000357,12054,,18,,16474,B,,
Autocuration,,1,,,Inhibition of partially purified 15-lipoxygenase from human leukocytes,,CHEMBL615133,H,8,,,,,BAO_0000019,12054,,19,,10091,B,,
Autocuration,,1,,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),,CHEMBL615134,H,8,,,,,BAO_0000357,12054,,20,,16474,B,,
Autocuration,,1,,,Compound was evaluated for the percent increase in activation concentration of human reticulocyte 15-lipoxygenase (15-HLO),,CHEMBL615135,H,8,,,,,BAO_0000357,12054,,21,,16474,B,,
Autocuration,,1,,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),,CHEMBL615136,H,8,,,,,BAO_0000357,12054,,22,,16474,B,,
Autocuration,,1,,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,,CHEMBL615137,H,8,,,,,BAO_0000357,12054,,23,,16474,B,,
Autocuration,,1,,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,,CHEMBL615138,H,8,,,,,BAO_0000357,12054,,24,,16474,B,,
Autocuration,,1,,,"Inhibitory concentration against 15-lipoxygenase, by inhibiting 15-HETE production by human umbilical vein endothelial cells (HUVEC) stimulated by calcium ionophore A 23187 at concentration of 10e-5 M.",,CHEMBL836324,U,0,,,,,BAO_0000219,22226,,25,,14352,B,,
Autocuration,,1,,,In vitro inhibitory activity of compound on rabbit reticulocyte 15-lipoxygenase,,CHEMBL615139,H,8,,,Oryctolagus cuniculus,9986.0,BAO_0000357,12054,,26,,5646,B,,
Autocuration,,1,,,Inhibition of rabbit reticulocyte 15-lipoxygenase by compound (30 uM),,CHEMBL615140,H,8,,,Oryctolagus cuniculus,9986.0,BAO_0000357,12054,,27,,5646,B,,
Autocuration,,1,,,Inhibitory activity against 15-lipoxygenase in rat polymorphonuclear leukocytes,,CHEMBL615141,H,8,,,,,BAO_0000219,12426,,28,,10997,B,,
Autocuration,,1,,,Inhibitory activity against 15-lipoxygenase was determined obtained from soya bean,,CHEMBL615142,H,8,,,soya bean,3847.0,BAO_0000357,12054,,29,,6309,B,,
Autocuration,,1,,,Inhibitory activity against soybean 15-lipoxygenase was evaluated,,CHEMBL615143,H,8,,,Glycine max,3847.0,BAO_0000357,12054,,30,,167,B,,
Autocuration,,1,,,Inhibitory activity against soybean 15-lipoxygenase was evaluated at 100 uM,,CHEMBL615144,H,8,,,Glycine max,3847.0,BAO_0000357,12054,,31,,167,B,,
Autocuration,,1,,,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 10 uM,,CHEMBL872867,H,8,,,Glycine max,3847.0,BAO_0000357,12054,,32,,11087,B,,
Autocuration,,1,,,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 100 uM,,CHEMBL615145,H,8,,,Glycine max,3847.0,BAO_0000357,12054,,33,,11087,B,,
Autocuration,,1,,,Compound was tested in vitro for inhibition of 15-lipoxygenase soybean,,CHEMBL615146,H,8,,,Glycine max,3847.0,BAO_0000357,12054,,34,,13622,B,,
Autocuration,,1,,,Compound at 100 uM was tested in vitro for inhibition of 15-lipoxygenase soybean,,CHEMBL615147,H,8,,,Glycine max,3847.0,BAO_0000357,12054,,35,,13622,B,,
Autocuration,,1,,,Inhibition of cytochrome P450 progesterone 16-alpha hydroxylase,,CHEMBL615148,U,0,,,Rattus norvegicus,10116.0,BAO_0000019,22226,,36,,11347,A,,
Autocuration,,1,,,Binding affinity against bacterial 16S rRNA using mass spectrometry based assay,,CHEMBL615149,U,0,,,Escherichia coli,562.0,BAO_0000019,22226,,37,,5926,B,,
Autocuration,,1,,,Dissociation constant with dimeric 16S rRNA RNA construct B,,CHEMBL615150,U,0,,,,,BAO_0000019,22226,,38,,4567,B,,
Intermediate,,1,,,Dissociation constant towards 16S rRNA construct A,,CHEMBL615151,M,3,,,,,BAO_0000225,22222,,39,,3782,B,,
Intermediate,,1,,,Dissociation constant towards 16S rRNA construct B,,CHEMBL615152,M,3,,,,,BAO_0000225,22222,,40,,3782,B,,
Expert,,1,,,Binding affinity of aminoglycoside to 16S ribosomal RNA A-site in Escherichia coli,,CHEMBL615153,M,3,,,Escherichia coli,562.0,BAO_0000225,100263,,41,,4466,B,,
Expert,,1,,,Binding affinity for the 16S ribosomal RNA A-site of Escherichia coli,,CHEMBL615154,M,3,,,Escherichia coli,562.0,BAO_0000225,100263,,42,,6592,B,,
Autocuration,,1,,,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,CHEMBL615155,H,8,,,,,BAO_0000019,13053,,43,,898,B,,
Autocuration,,1,,,Inhibitory constant against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,CHEMBL615156,H,8,,,,,BAO_0000019,13053,,44,,898,B,,
Autocuration,,1,,,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,,CHEMBL615157,H,8,,,Homo sapiens,9606.0,BAO_0000019,20001,,45,,13163,B,,
Autocuration,,1,,,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,,CHEMBL615158,H,8,,,Homo sapiens,9606.0,BAO_0000019,20001,,46,,13163,B,,
Expert,,1,,,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",,CHEMBL615159,D,9,,,Rattus norvegicus,10116.0,BAO_0000019,12971,,47,,10691,B,,
Expert,,1,,,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",,CHEMBL615172,D,9,,,Rattus norvegicus,10116.0,BAO_0000019,12971,,48,,10691,B,,
Expert,,1,,,"Percent inhibition of 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",,CHEMBL615173,D,9,,,Rattus norvegicus,10116.0,BAO_0000019,12971,,49,,10691,B,,
Expert,,1,,,"Percent inhibition of Steroid 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",,CHEMBL615174,D,9,,,Rattus norvegicus,10116.0,BAO_0000019,12971,,50,,10691,B,,
Autocuration,,1,,,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,CHEMBL884518,H,8,,,,,BAO_0000019,13053,,51,,898,B,,
Autocuration,,1,,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1),,CHEMBL615175,H,8,,,,,BAO_0000357,11512,,52,,912,B,,
Autocuration,,1,,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 1 uM concentration,,CHEMBL615176,H,8,,,,,BAO_0000357,11512,,53,,912,B,,
Autocuration,,1,,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 10 uM concentration,,CHEMBL615177,H,8,,,,,BAO_0000357,11512,,54,,912,B,,
Autocuration,,1,,,Selectivity ratio of binding affinity towards mu to delta receptors of rat brain membranes,Membranes,CHEMBL615178,D,5,,,Rattus norvegicus,10116.0,BAO_0000249,104740,,55,,15103,B,,
Intermediate,,1,1A9,,Cytotoxicity against ovarian cancer cell line (1A-9) of humans was determined,,CHEMBL615179,N,1,,506.0,Homo sapiens,9606.0,BAO_0000219,80002,,56,,5116,F,,
Autocuration,,1,Oocytes,,Functional antagonism by electrical assays in Xenopus oocytes expressing 1A/2A NMDA receptor subtype,,CHEMBL615180,D,7,,,Rattus norvegicus,10116.0,BAO_0000219,104835,,57,,14578,F,,
Autocuration,,1,Oocytes,,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2B NMDA receptor,,CHEMBL615181,D,7,,,Rattus norvegicus,10116.0,BAO_0000219,104821,,58,,14578,F,,
Autocuration,,1,Oocytes,,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2C NMDA receptor,,CHEMBL615182,D,7,,,Rattus norvegicus,10116.0,BAO_0000219,104848,,59,,14578,F,,
Expert,,1,1A9,,In vitro effective concentration required to reduce the number of human ovarian cancer (1A9) after 3-day incubation,,CHEMBL615183,N,1,,506.0,Homo sapiens,9606.0,BAO_0000219,80002,,60,,4787,F,,
Intermediate,,1,1A9,,In vitro effective concentration required to reduce the number of human ovarian cancer cells (1A9) after 3-day incubation,,CHEMBL615184,N,1,,506.0,Homo sapiens,9606.0,BAO_0000219,80002,,61,,4787,F,,
Intermediate,,1,1A9,,Cytotoxic activity against human ovarian cancer (1A9) cell line,,CHEMBL615185,N,1,,506.0,Homo sapiens,9606.0,BAO_0000219,80002,,62,,3547,F,,
Intermediate,,1,1A9,,Cytotoxic activity against human ovarian cancer (1A9) cell line; ND=Not determined,,CHEMBL615186,N,1,,506.0,Homo sapiens,9606.0,BAO_0000219,80002,,63,,3547,F,,
Intermediate,,1,1A9,,Effective dose of compound against replication of 1A9 cell line was evaluated,,CHEMBL615187,N,1,,506.0,Homo sapiens,9606.0,BAO_0000219,80002,,64,,6726,F,,
Expert,,1,1A9,,In vitro cytotoxic activity was determined against ovarian cancer (1A9) cell line,,CHEMBL885343,N,1,,506.0,Homo sapiens,9606.0,BAO_0000219,80002,,65,,3455,F,,
Intermediate,,1,1A9,,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line),,CHEMBL615188,N,1,,506.0,Homo sapiens,9606.0,BAO_0000219,80002,,66,,5726,F,,
Intermediate,,1,1A9,,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line); NA is not active,,CHEMBL615189,N,1,,506.0,Homo sapiens,9606.0,BAO_0000219,80002,,67,,5726,F,,
Intermediate,,1,1A9,,In vitro percent inhibition evaluated against human ovarian cancer (1A9 cell line) at >20 ug/mL,,CHEMBL615190,N,1,,506.0,Homo sapiens,9606.0,BAO_0000219,80002,,68,,5726,F,,
Intermediate,,1,1A9,,Inhibitory activity against Taxol resistant 1A9 cell lines,,CHEMBL615191,N,1,,506.0,Homo sapiens,9606.0,BAO_0000219,80002,,69,,3395,F,,
Expert,,1,1A9,,Cytotoxicity against human ovarian cancer (1A9) cell lines.,,CHEMBL615192,N,1,,506.0,Homo sapiens,9606.0,BAO_0000219,80002,,70,,3415,F,,
Expert,,1,1A9,,Percentage inhibition of human ovarian cancer (1A9) cell lines.,,CHEMBL827083,N,1,,506.0,Homo sapiens,9606.0,BAO_0000219,80002,,71,,3415,F,,
Expert,,1,1A9,,Effective dose required for inhibitory activity against 1A9 human tumor cell line.,,CHEMBL615193,N,1,,506.0,Homo sapiens,9606.0,BAO_0000219,80002,,72,,17099,F,,
Intermediate,,1,1A9,,Percent inhibition against 1A9 human tumor cell line at 0.10 ug/mL,,CHEMBL615194,N,1,,506.0,Homo sapiens,9606.0,BAO_0000219,80002,,73,,17099,F,,
Intermediate,,1,1A9,,Percent inhibition against 1A9 human tumor cell line at <0.00008 ug/mL,,CHEMBL615195,N,1,,506.0,Homo sapiens,9606.0,BAO_0000219,80002,,74,,17099,F,,
Intermediate,,1,1A9,,Percent inhibition against 1A9 human tumor cell line at >10 ug/mL,,CHEMBL615196,N,1,,506.0,Homo sapiens,9606.0,BAO_0000219,80002,,75,,17099,F,,
Intermediate,,1,Jurkat,,Inhibitory concentration against Jurkat cells,,CHEMBL615197,N,1,,503.0,Homo sapiens,9606.0,BAO_0000219,81072,,76,,17721,F,,
Intermediate,,1,,,In vitro anticancer activity against 2 NCI SCLC cell lines; inactive,,CHEMBL615198,U,0,,,,,BAO_0000019,22226,,77,,1229,F,,
Expert,,1,,,Inhibition of cytochrome P450 progesterone 2-alpha-hydroxylase,,CHEMBL615199,D,9,,,Rattus norvegicus,10116.0,BAO_0000357,100121,,78,,11347,A,,
Expert,,1,,,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",,CHEMBL615200,H,8,,,,,BAO_0000357,11231,,79,,17117,B,,
Expert,,1,,,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",,CHEMBL615201,H,8,,,,,BAO_0000357,11231,,80,,17117,B,,
Expert,,1,,,"In vitro inhibition of human 2,3-oxidosqualene cyclase at 100 nM.",,CHEMBL615202,H,8,,,,,BAO_0000357,11231,,81,,17117,B,,
Autocuration,,1,,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Candida albicans microsomes",Microsomes,CHEMBL615203,H,8,,,Candida albicans,5476.0,BAO_0000251,11231,,82,,11375,B,,
Autocuration,,1,,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Candida albicans microsomes",Microsomes,CHEMBL615204,H,8,,,Candida albicans,5476.0,BAO_0000251,11231,,83,,11375,B,,
Autocuration,,1,,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Saccharomyces cerevisiae microsomes",Microsomes,CHEMBL615205,H,8,,,Saccharomyces cerevisiae,4932.0,BAO_0000251,11231,,84,,11375,B,,
Autocuration,,1,,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Saccharomyces cerevisiae microsomes",Microsomes,CHEMBL615206,H,8,,,Saccharomyces cerevisiae,4932.0,BAO_0000251,11231,,85,,11375,B,,
Autocuration,,1,,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in pig liver microsomes",Microsomes,CHEMBL615207,H,8,,,Sus scrofa,9823.0,BAO_0000251,12083,,86,Liver,11375,B,,2107.0
Autocuration,,1,,,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase",,CHEMBL827084,H,8,,,Rattus norvegicus,10116.0,BAO_0000019,11231,,87,,791,B,,
Autocuration,,1,,,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase (OSC)",,CHEMBL615208,H,8,,,Rattus norvegicus,10116.0,BAO_0000019,11231,,88,,791,B,,
Autocuration,,1,,,"Evaluated for its activity to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase, activity expressed as Ki",,CHEMBL615209,H,8,,,Rattus norvegicus,10116.0,BAO_0000019,11231,,89,,791,B,,
Autocuration,,1,,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in rat liver microsomes",Microsomes,CHEMBL615210,D,9,,,Rattus norvegicus,10116.0,BAO_0000251,12083,,90,Liver,11375,B,,2107.0
Autocuration,,1,,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",Microsomes,CHEMBL615211,D,9,,,Rattus norvegicus,10116.0,BAO_0000251,12083,,91,Liver,11375,B,,2107.0
Autocuration,,1,,,"Compound was evaluated for inhibitory activity against 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",Microsomes,CHEMBL615212,D,9,,,Rattus norvegicus,10116.0,BAO_0000251,12083,,92,Liver,153,B,,2107.0
Expert,,1,,,Molar concentration needed to give 50% prevention of 2-5A (Adenosine dependent endoribonuclease),,CHEMBL615213,H,8,,,,,BAO_0000357,11377,,93,,8269,B,,
Expert,,1,,,Molar concentration required to displace 50% of the radiolabeled probe from 2-5A (Adenosine dependent endoribonuclease) in endonuclease-nitrocellulose complex,,CHEMBL615273,H,8,,,,,BAO_0000357,11377,,94,,8269,B,,
Expert,,1,HepG2,,In vitro cytotoxic concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,,CHEMBL615274,N,1,,726.0,Homo sapiens,9606.0,BAO_0000219,81020,,95,,17653,F,,
Intermediate,,1,HepG2,,50% Effective concentration of compound required for inhibiting intracellular viral replicative intermediate DNA in HBV-transfected 2.2.15 cell line.,,CHEMBL615275,N,1,,726.0,Homo sapiens,9606.0,BAO_0000219,81020,,96,,14277,F,,
Intermediate,,1,HepG2,,Antiviral activity against Hepatitis B virus in 2.2.15 cell line,,CHEMBL615276,N,1,,726.0,Homo sapiens,9606.0,BAO_0000219,81020,,97,,1717,F,,
Intermediate,,1,HepG2,,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells,,CHEMBL615277,N,1,,726.0,Homo sapiens,9606.0,BAO_0000219,81020,,98,,14091,F,,
Intermediate,,1,HepG2,,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells; Not determined,,CHEMBL615326,N,1,,726.0,Homo sapiens,9606.0,BAO_0000219,81020,,99,,14091,F,,
Expert,,1,,,In vitro effective concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,,CHEMBL883130,N,1,,,Hepatitis B virus,10407.0,BAO_0000218,50606,,100,,17653,F,,
Intermediate,,1,HepG2,,Ability to inhibit the episomal HBV-DNA in 2.2.15 cells.,,CHEMBL884519,N,1,,726.0,Homo sapiens,9606.0,BAO_0000219,81020,,101,,13105,F,,
Intermediate,,1,HepG2,,Concentration required to inhibit 50% of 2.2.15 cell line,,CHEMBL615327,N,1,,726.0,Homo sapiens,9606.0,BAO_0000219,81020,,102,,1717,F,,
Intermediate,,1,HepG2,,Anti viral activity against 2.2.15 cells (concentration required to reduce the log phase cell growth by 50%).,,CHEMBL615328,N,1,,726.0,Homo sapiens,9606.0,BAO_0000219,81020,,103,,13105,A,,
Intermediate,,1,2.2.15,,Cytotoxic activity of compound against uninfected 2.2.15 cells.,,CHEMBL615329,N,1,,,Homo sapiens,9606.0,BAO_0000218,50587,,104,,13600,F,,
Intermediate,,1,2.2.15,,Anti hepatitis-B virus activity was evaluated in 2.2.15 cells.,,CHEMBL615330,N,1,,,Homo sapiens,9606.0,BAO_0000218,50587,,105,,13467,F,,
Expert,,1,2.2.15,,"Inhibition of the replication of HBV in 2.2.15 cells, by DNA hybridization assay",,CHEMBL615331,N,1,,,Hepatitis B virus,10407.0,BAO_0000218,50606,,106,,17477,F,,
Intermediate,,1,2.2.15,,In vitro anti-HBV activity in 2.2.15 cells,,CHEMBL615332,N,1,,,Homo sapiens,9606.0,BAO_0000218,50587,,107,,1593,F,,
Intermediate,,1,2.2.15,,In vitro anti-HBV activity in 2.2.15 cells; Not determined,,CHEMBL615333,N,1,,,Homo sapiens,9606.0,BAO_0000218,50587,,108,,1593,F,,
Intermediate,,1,2.2.15,,The compound was tested in vitro for the anti-HBV activity against 2.2.15 cells,,CHEMBL615334,N,1,,,Homo sapiens,9606.0,BAO_0000218,50587,,109,,15089,F,,
Intermediate,,1,2.2.15,,The compound was tested in vitro for the anti-HBV activity in 2.2.15 cells,,CHEMBL615335,N,1,,,Homo sapiens,9606.0,BAO_0000218,50587,,110,,15089,F,,
Intermediate,,1,2.2.15,,Cytotoxicity in 2.2.15 cells,,CHEMBL615336,N,1,,,Homo sapiens,9606.0,BAO_0000218,50587,,111,,1593,F,,
Intermediate,,1,2.2.15,,Cytotoxicity in 2.2.15 cells; Not determined,,CHEMBL615337,N,1,,,Homo sapiens,9606.0,BAO_0000218,50587,,112,,1593,F,,
Intermediate,,1,2.2.15,,Inhibitory activity of compound against hepatitis B virus (HBV) in growing cultures of 2.2.15 cells,,CHEMBL615338,N,1,,,Homo sapiens,9606.0,BAO_0000218,50587,,113,,13600,F,,
Intermediate,,1,2.2.15,,The growth inhibition activity for the compound was evaluated in 2.2.15 cells.,,CHEMBL615339,N,1,,,Homo sapiens,9606.0,BAO_0000218,50587,,114,,13467,F,,
Intermediate,,1,2.2.15,,Selectivity index was determined from the ratio of IC50 to the EC50 values evaluated in 2.2.15 cells.,,CHEMBL615340,N,1,,,Homo sapiens,9606.0,BAO_0000218,50587,,115,,13467,F,,
Intermediate,,1,HepG2,,Antiviral activity against HBV was determined in 2.215 cell line,,CHEMBL615341,N,1,,726.0,Homo sapiens,9606.0,BAO_0000219,81020,,116,,14764,F,,
Autocuration,,1,,,Inhibition of 20-HETE synthesis in human renal microsomes,Microsomes,CHEMBL615342,U,0,,,Homo sapiens,9606.0,BAO_0000251,22226,,117,,6531,B,,
Autocuration,,1,,,Inhibitory activity against 20-HETE production from arachidonic acid using human renal microsome 20-HETE synthase.,,CHEMBL615343,U,0,,,,,BAO_0000019,22226,,118,,17322,B,,
Intermediate,,1,2008,,Inhibitory concentration against 2008 (ovarian) cells,,CHEMBL615344,N,1,,388.0,Homo sapiens,9606.0,BAO_0000219,80612,,119,,17072,F,,
Intermediate,,1,2008,,50% Growth inhibitory concentration( GI 50 ) by using 2008 human ovarian carcinoma cell lines.,,CHEMBL615345,N,1,,388.0,Homo sapiens,9606.0,BAO_0000219,80612,,120,,16936,F,,
Intermediate,,1,2008,,Compound was tested for 50% growth inhibitory concentration by using human ovarian carcinoma cell lines (2008),,CHEMBL615346,N,1,,388.0,Homo sapiens,9606.0,BAO_0000219,80612,,121,,16936,F,,
Intermediate,,1,2008,,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells,,CHEMBL615347,N,1,,388.0,Homo sapiens,9606.0,BAO_0000219,80612,,122,,17146,F,,
Intermediate,,1,2008,,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells; not detected,,CHEMBL615348,N,1,,388.0,Homo sapiens,9606.0,BAO_0000219,80612,,123,,17146,F,,
Intermediate,,1,2008/R,,In vitro inhibition of 2008/R ovarian cancer cell line,,CHEMBL827085,N,1,,561.0,Homo sapiens,9606.0,BAO_0000219,80613,,124,,10797,F,,
Intermediate,,1,2008/R,,In vitro inhibition of 2008/R ovarian cancer cell line; NA= Not achievable,,CHEMBL615349,N,1,,561.0,Homo sapiens,9606.0,BAO_0000219,80613,,125,,10797,F,,
Intermediate,,1,2008/S,,In vitro inhibition of 2008/S ovarian cancer cell line,,CHEMBL615350,N,1,,389.0,Homo sapiens,9606.0,BAO_0000219,80614,,126,,10797,F,,
Intermediate,,1,2008/S,,In vitro inhibition of 2008/S ovarian cancer cell line; NA= Not achievable,,CHEMBL615351,N,1,,389.0,Homo sapiens,9606.0,BAO_0000219,80614,,127,,10797,F,,
Expert,,1,,,Tested in vitro for inhibition of chymotrypsin like activity of purified human 20S proteasome,,CHEMBL615352,S,2,,,Homo sapiens,9606.0,BAO_0000220,100256,,128,,4823,B,,
Intermediate,,1,,,Compound was evaluated for inhibitory activity against 20S proteasome from human liver and brain,,CHEMBL615353,S,2,,,Homo sapiens,9606.0,BAO_0000220,100256,,129,,12912,B,,
Expert,,1,,,Inhibition of chymotrypsin-like activity of 20S proteasome,,CHEMBL615354,S,2,,,,,BAO_0000220,100256,,130,,2957,B,,
Expert,,1,,,Inhibition of chymotrypsin-like activity of 20S proteasome; value ranges from 10-20 uM,,CHEMBL615355,S,2,,,,,BAO_0000220,100256,,131,,2957,B,,
Intermediate,,1,,,Inhibitory activity against 20S proteosome,,CHEMBL615356,S,2,,,,,BAO_0000220,100256,,132,,3260,B,,
Autocuration,,1,,,Compound was tested for inhibitory activity against tryptase,,CHEMBL615357,U,0,,,Homo sapiens,9606.0,BAO_0000019,22226,,133,,3451,B,,
Intermediate,,1,HepG2,,Concentration required to inhibit 50% of extracellular circular replication of HBV DNA using 2215 cell line,,CHEMBL615358,N,1,,726.0,Homo sapiens,9606.0,BAO_0000219,81020,,134,,13885,F,,
Intermediate,,1,HepG2,,Concentration required to inhibit 50% of intracellular circular replication of HBV DNA using 2215 cell line,,CHEMBL827086,N,1,,726.0,Homo sapiens,9606.0,BAO_0000219,81020,,135,,13885,F,,
Autocuration,,1,,,Compound was tested for the inhibition of Alpha-glucosidase,,CHEMBL615359,U,0,,,,,BAO_0000019,22226,,136,,3676,B,,
Autocuration,,1,,,Inhibitory concentration against human neutrophil elastase (HNE),,CHEMBL615360,H,8,,,,,BAO_0000357,235,,137,,6043,B,,
Autocuration,,1,,,Change in heart rate was expressed in percent at at a dose 0.002 mg/kg iv in anesthetized rat,,CHEMBL615361,U,0,,,Rattus norvegicus,10116.0,BAO_0000218,22226,,138,Heart,11140,F,,948.0
Autocuration,,1,,,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,,CHEMBL615362,H,8,,,,,BAO_0000019,19640,,139,,10543,F,,
Expert,,1,,,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,,CHEMBL615363,H,8,,,,,BAO_0000019,19640,,140,,10543,F,,
Autocuration,,1,,,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,,CHEMBL615364,H,8,,,,,BAO_0000357,19640,,141,,10543,B,,
Expert,,1,,,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,,CHEMBL615365,H,8,,,,,BAO_0000019,19640,,142,,10543,F,,
Intermediate,,1,P338,,In Vitro evaluation for the growth inhibition of Subline (P388/AMSA) Leukemia cell lines,,CHEMBL615366,N,1,,524.0,Mus musculus,10090.0,BAO_0000219,80360,,143,,11365,F,,
Intermediate,,1,P338,,In Vitro evaluation for the growth inhibition of Subline (P388/CP) Leukemia cell lines,,CHEMBL615367,N,1,,524.0,Mus musculus,10090.0,BAO_0000219,80360,,144,,11365,F,,
Intermediate,,1,PBL,,Compound was evaluated for the inhibition of cell replication human peripheral blood lymphocytes (PBL's).,,CHEMBL615368,N,1,,554.0,Homo sapiens,9606.0,BAO_0000219,80384,,145,,11803,F,,
Autocuration,,1,,,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells,,CHEMBL615369,U,0,,,Ovis aries,9940.0,BAO_0000019,22226,,146,,11803,F,,
Autocuration,,1,,,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells.,,CHEMBL615370,U,0,,,Ovis aries,9940.0,BAO_0000019,22226,,147,,11803,F,,
Autocuration,,1,,,Compound is evaluated in vitro for the inhibition single mutant of HIV-1 RT (Y181C),,CHEMBL615673,H,8,,,,,BAO_0000357,191,,148,,12278,B,,
Autocuration,,1,,,Compound was evaluated for its inhibitory effect on thymidine [3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-5,,CHEMBL615674,U,0,,,Homo sapiens,9606.0,BAO_0000019,22226,,149,,8249,F,,
Autocuration,,1,,,Compound was evaluated for its inhibitory effect on thymidine [3H]-dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-6,,CHEMBL615675,U,0,,,Homo sapiens,9606.0,BAO_0000019,22226,,150,,8249,F,,
Autocuration,,1,CCRF-CEM,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in at conc. 10e-7,,CHEMBL615676,U,0,,635.0,Homo sapiens,9606.0,BAO_0000219,22226,,151,,8249,F,,
Autocuration,,1,CCRF-CEM,,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM cells in culture at conc. 10e-4,,CHEMBL615677,U,0,,635.0,Homo sapiens,9606.0,BAO_0000219,22226,,152,,8249,F,,
Autocuration,,1,CCRF-CEM,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-5,,CHEMBL615678,U,0,,635.0,Homo sapiens,9606.0,BAO_0000219,22226,,153,,8249,F,,
Autocuration,,1,CCRF-CEM,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-6,,CHEMBL615679,U,0,,635.0,Homo sapiens,9606.0,BAO_0000219,22226,,154,,8249,F,,
Autocuration,,1,,,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM/MTX cells in at conc. 10e-7.,,CHEMBL615680,U,0,,,Homo sapiens,9606.0,BAO_0000019,22226,,155,,8249,F,,
Autocuration,,1,,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-4,,CHEMBL615681,U,0,,,Homo sapiens,9606.0,BAO_0000019,22226,,156,,8249,F,,
Autocuration,,1,,,In vitro binding affinity towards (alpha-4)2(beta-2)3 neuronal nicotinic acetylcholine receptor in P2 membrane fractions of rat forebrain,,CHEMBL857972,H,6,,,,,BAO_0000249,104290,,157,,16992,B,,
Intermediate,,1,,,Minimum inhibitory concentration of compound against Streptococcus pyogenus septicemia in the mouse,,CHEMBL857899,N,1,,,Streptococcus pyogenes,1314.0,BAO_0000218,50264,,158,,10543,F,,
Intermediate,,1,,,Antiviral activity against 07/1 strain of thymidine kinase negative (TK-) Varicella-Zoster Virus (VZV),,CHEMBL615371,N,1,,,Human herpesvirus 3,10335.0,BAO_0000218,50527,,159,,17833,F,,
Expert,,1,HEL,,Antiviral activity against 07/1 strain of VZV in HEL (human erythroleukemia) cells.,,CHEMBL615372,N,1,,468.0,vericilla zoster virus,10335.0,BAO_0000218,50527,,160,,17290,F,,
Intermediate,,1,,,Antiviral activity against 07/1 strain of VZV; ND: No data,,CHEMBL615373,N,1,,,vericilla zoster virus,10335.0,BAO_0000218,50527,,161,,17290,F,,
Intermediate,,1,,,Antiviral activity against 07/1 strain of VZV; ND=No data,,CHEMBL615374,N,1,,,vericilla zoster virus,10335.0,BAO_0000218,50527,,162,,17290,F,,
Intermediate,,1,,,"Antibacterial activity was determined against gram negative organism, Enterobacter cloacae (MA2646)",,CHEMBL615375,N,1,,,escherichia cloac,561.0,BAO_0000218,50145,,163,,10932,F,,
Autocuration,,1,,,Ratio of Ki at A2 to Ki at A1 receptors,,CHEMBL615376,U,0,,,,,BAO_0000019,22226,,164,,9707,B,,
Expert,,1,,,"In vitro inhibition of 1,3-beta-glucan synthase in Candida albicans membrane assay.",,CHEMBL615377,H,8,,,Candida albicans,5476.0,BAO_0000249,11143,,165,,2346,B,,
Expert,,1,,,"Inhibition of 1,3-beta-glucan synthase",,CHEMBL615378,H,8,,,Candida glabrata CBS 138,284593.0,BAO_0000357,18077,,166,,2205,B,,
Intermediate,,1,1-87 tumor cell line,,Inhibition of growth of 1-87 human tumor cell line,,CHEMBL615379,N,1,,832.0,Homo sapiens,9606.0,BAO_0000219,80609,,167,,11900,F,,
Expert,,1,,,Inhibition of 1-lipoxygenase (LOX)in RBL cells,,CHEMBL615380,D,9,,,Rattus norvegicus,10116.0,BAO_0000219,12166,,168,,14864,B,,
Autocuration,,1,,,Inhibitory activity against soybean 1-lipoxygenase (SLO),,CHEMBL615381,D,9,,,Glycine max,3847.0,BAO_0000357,100171,,169,,16474,B,,
Autocuration,,1,,,Inhibitory activity against soybean 1-lipoxygenase (SLO); no effect,,CHEMBL615382,D,9,,,Glycine max,3847.0,BAO_0000357,100171,,170,,16474,B,,
Autocuration,,1,,,% inhibition against soybean 1-lipoxygenase (SLO),,CHEMBL615383,D,9,,,Glycine max,3847.0,BAO_0000357,100171,,171,,16474,B,,
Autocuration,,1,,,percent inhibition against soybean 1-lipoxygenase (SLO);NI is no inhibition,,CHEMBL615384,D,9,,,Glycine max,3847.0,BAO_0000357,100171,,172,,16474,B,,
Autocuration,,1,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 10:90,,CHEMBL615385,D,9,,,Glycine max,3847.0,BAO_0000357,100171,,173,,3094,B,,
Autocuration,,1,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 1:99,,CHEMBL615386,D,9,,,Glycine max,3847.0,BAO_0000357,100171,,174,,3094,B,,
Autocuration,,1,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 25:75,,CHEMBL615387,D,9,,,Glycine max,3847.0,BAO_0000357,100171,,175,,3094,B,,
Autocuration,,1,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 35:65,,CHEMBL615388,D,9,,,Glycine max,3847.0,BAO_0000357,100171,,176,,3094,B,,
Autocuration,,1,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 50:50,,CHEMBL615214,D,9,,,Glycine max,3847.0,BAO_0000357,100171,,177,,3094,B,,
Autocuration,,1,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 76:24,,CHEMBL827087,D,9,,,Glycine max,3847.0,BAO_0000357,100171,,178,,3094,B,,
Autocuration,,1,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 87:13,,CHEMBL615215,D,9,,,Glycine max,3847.0,BAO_0000357,100171,,179,,3094,B,,
Autocuration,,1,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 89:11,,CHEMBL615216,D,9,,,Glycine max,3847.0,BAO_0000357,100171,,180,,3094,B,,
Autocuration,,1,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 95:5,,CHEMBL615217,D,9,,,Glycine max,3847.0,BAO_0000357,100171,,181,,3094,B,,
Autocuration,,1,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 97:3,,CHEMBL615218,D,9,,,Glycine max,3847.0,BAO_0000357,100171,,182,,3094,B,,
Autocuration,,1,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 99:1,,CHEMBL615219,D,9,,,Glycine max,3847.0,BAO_0000357,100171,,183,,3094,B,,
Autocuration,,1,,,Evaluated for inhibitory activity on 10-formyltetrahydrofolate synthetase(L cell) at folate substrate concentration of 100 uM,,CHEMBL615220,U,0,,,Mus musculus,10090.0,BAO_0000019,22226,,184,,10413,B,,
Intermediate,,1,C3H 10T1/2,,Cells were harvested and were assayed for luciferase and -galactosidase activities (Transcriptional activity),,CHEMBL615221,N,1,,294.0,Mus musculus,10090.0,BAO_0000219,80049,,185,,16929,F,,
Intermediate,,1,,,In vitro anticancer activity against 11 NCI NSCLC cell lines; inactive,,CHEMBL615222,U,0,,,,,BAO_0000019,22226,,186,,1229,F,,
Autocuration,,1,,,In vitro inhibitory activity against human 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),,CHEMBL615223,H,8,,,,,BAO_0000357,11489,,187,,16587,B,,
Autocuration,,1,,,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),,CHEMBL615224,H,8,,,,,BAO_0000357,11862,,188,,16587,B,,
Autocuration,,1,,,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA).,,CHEMBL615225,H,8,,,,,BAO_0000357,11862,,189,,16587,B,,
Autocuration,,1,,,Ability to convert [3H]cortisol to the tritium labeled cortisone in the presence of human 11 beta hydroxysteroid dehydrogenase type 2,,CHEMBL615226,H,8,,,,,BAO_0000357,11489,,190,,16587,B,,
Autocuration,,1,,,Inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 2 at a concentration of 0.2 mM; NI means no inhibition,,CHEMBL615227,H,8,,,,,BAO_0000357,11862,,191,,16587,B,,
Expert,,1,,,Evaluated for inhibition of bovine adrenal cortical mitochondrial 11 beta-hydroxylase,,CHEMBL615228,D,9,,,Bos taurus,9913.0,BAO_0000019,12347,,192,,8058,F,,
Expert,,1,,,Effect on adrenal 11-beta-hydroxylase activity at 10e-4 M; No significant effect,,CHEMBL615229,D,9,,,Rattus norvegicus,10116.0,BAO_0000357,100120,,193,,9065,B,,
Expert,,1,,,Inhibition of 11 beta-hydroxylase from rat adrenal gland,,CHEMBL615230,D,9,,,Rattus norvegicus,10116.0,BAO_0000357,100120,,194,Adrenal gland,8865,B,,2369.0
Expert,,1,,,Inhibition of rat adrenal 11-beta-hydroxylase,,CHEMBL615231,D,9,,,Rattus norvegicus,10116.0,BAO_0000357,100120,,195,,9066,B,,
Expert,,1,,,Inhibition of rat adrenal 11-beta-hydroxylase,,CHEMBL884520,D,9,,,Rattus norvegicus,10116.0,BAO_0000357,100120,,196,,8394,B,,
Expert,,1,,,Inhibition of rat adrenal 11-beta-hydroxylase at 10e-5 M,,CHEMBL615232,D,9,,,Rattus norvegicus,10116.0,BAO_0000357,100120,,197,,8394,B,,
Autocuration,,1,,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 1 of wistar rat liver cytosol at 10 uM was determined using [3H]cortisone,,CHEMBL615233,H,8,,,,,BAO_0000019,10328,,198,,6431,B,,
Autocuration,,1,,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,,CHEMBL827088,H,8,,,,,BAO_0000357,11490,,199,,6431,B,,
Autocuration,,1,,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,,CHEMBL615234,H,8,,,,,BAO_0000357,11490,,200,,6431,B,,
Autocuration,,1,,,Compound was tested for the percent of inhibition against 12-LO at 10 uM,,CHEMBL615235,H,8,,,,,BAO_0000019,11134,,201,,9295,F,,
Autocuration,,1,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,CHEMBL615236,H,8,,,,,BAO_0000019,12052,,202,,10193,B,,
Autocuration,,1,,,Compound was tested in vitro for inhibition of 12-LO human platelet,,CHEMBL615237,H,8,,,,,BAO_0000019,11134,,203,,13622,B,,
Autocuration,,1,,,Inhibitory concentration against human platelet 12-lipoxygenase,,CHEMBL615238,H,8,,,,,BAO_0000019,11134,,204,,12079,F,,
Autocuration,,1,,,Compound at 100 uM was tested in vitro for inhibition of 12-LO human platelet,,CHEMBL615239,H,8,,,,,BAO_0000019,11134,,205,,13622,B,,
Autocuration,,1,,,Inhibitory concentration against human platelet 12-lipoxygenase,,CHEMBL615240,D,9,,,Homo sapiens,9606.0,BAO_0000019,11134,,206,,12079,F,,
Expert,,1,,,Tested for inhibition of 12-LO (12-lipoxygenase) as an inhibitor of 12(S)-HETE biosynthesis in mouse epidermal homogenates,,CHEMBL615241,H,8,,,,,BAO_0000019,11835,,207,,13500,B,,
Expert,,1,,,Inhibitory activity against conversion of [1-14C]arachidonic acid to 12-HPETE and its reduction product 12-HETE by porcine leukocyte type 12-lipoxygenase,,CHEMBL615242,H,8,,,,,BAO_0000357,11601,,208,,13723,B,,
Autocuration,,1,,,Inhibitory activity against human platelet 12-lipoxygenase (12-HLO),,CHEMBL615243,H,8,,,,,BAO_0000019,11134,,209,,16474,B,,
Autocuration,,1,,,Inhibitory activity against human platelet 12-lipoxygenase,,CHEMBL615244,H,8,,,,,BAO_0000019,11134,,210,,1630,B,,
Autocuration,,1,,,Inhibitory activity against human platelet 12-lipoxygenase was evaluated,,CHEMBL615245,H,8,,,,,BAO_0000019,11134,,211,,167,B,,
Autocuration,,1,,,% inhibition against human platelet 12-lipoxygenase (12-HLO),,CHEMBL615246,H,8,,,,,BAO_0000019,11134,,212,,16474,B,,
Autocuration,,1,,,Inhibitory activity against human platelet 12-lipoxygenase was evaluated at 100 uM,,CHEMBL615247,H,8,,,,,BAO_0000019,11134,,213,,167,B,,
Autocuration,,1,,,percent inhibition against human platelet 12-lipoxygenase (12-HLO); NI is no inhibition,,CHEMBL615248,H,8,,,,,BAO_0000019,11134,,214,,16474,B,,
Autocuration,,1,,,Inhibitory activity towards porcine 12-lipoxygenase,,CHEMBL615249,H,8,,,,,BAO_0000357,11601,,215,,10091,B,,
Autocuration,,1,,,Tested for inhibition against porcine 12-LO,,CHEMBL615250,H,8,,,,,BAO_0000357,11601,,216,,11966,B,,
Autocuration,,1,,,Inhibition of 12-lipoxygenase was evaluated in rat platelets stimulated by thrombin up to a concentration of 10 uM; NE means No effect,,CHEMBL615251,H,8,,,,,BAO_0000019,12052,,217,,951,B,,
Autocuration,,1,,,Inhibitory activity against 12-lipoxygenase in rat platelet rich plasma,,CHEMBL615252,H,8,,,,,BAO_0000019,12052,,218,,10997,B,,
Expert,,1,,,In vitro inhibition of rat platelet 12-lipoxygenase,,CHEMBL828340,H,8,,,,,BAO_0000019,12052,,219,,10193,B,,
Autocuration,,1,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,CHEMBL615253,H,8,,,,,BAO_0000019,12052,,220,,10193,B,,
Autocuration,,1,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 100 uM,,CHEMBL615254,H,8,,,,,BAO_0000019,12052,,221,,10193,B,,
Autocuration,,1,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 30 uM,,CHEMBL615255,H,8,,,,,BAO_0000019,12052,,222,,10193,B,,
Autocuration,,1,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,CHEMBL615256,H,8,,,,,BAO_0000019,12052,,223,,10193,B,,
Autocuration,,1,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase,,CHEMBL615257,H,8,,,,,BAO_0000019,12052,,224,,10193,B,,
Autocuration,,1,,,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 100 uM,,CHEMBL615258,H,8,,,,,BAO_0000019,12052,,225,,11087,B,,
Intermediate,,1,41M,,Cytotoxic activity in a panel of Human ovarian tumor 41M cell line after 96h of drug exposure,,CHEMBL615259,N,1,,621.0,Homo sapiens,9606.0,BAO_0000219,80007,,226,,15569,F,,
Expert,,1,41M,,In vitro antitumor activity against 41M cell line.,,CHEMBL615260,N,1,,621.0,Homo sapiens,9606.0,BAO_0000219,80007,,227,,12989,F,,
Intermediate,,1,41M,,cytotoxicity against 41M cells incubated for 24 hr in MTT assay.,,CHEMBL615261,N,1,,621.0,Homo sapiens,9606.0,BAO_0000219,80007,,228,,16745,F,,
Intermediate,,1,41M,,Cytotoxic activity in a panel of Human ovarian tumor 41M/CDDP cell line after 96h of drug exposure,,CHEMBL615262,N,1,,621.0,Homo sapiens,9606.0,BAO_0000219,80007,,229,,15569,F,,
Expert,,1,41M,,In vitro antitumor activity against 41McisR cell line.,,CHEMBL615263,N,1,,621.0,Homo sapiens,9606.0,BAO_0000219,80007,,230,,12989,F,,
Expert,,1,41M,,Resistant factor was determined between IC50 of cisplatin-resistant human tumor cell lines to that of 41McisR cell line,,CHEMBL838393,N,1,,621.0,Homo sapiens,9606.0,BAO_0000219,80007,,231,,12989,F,,
Intermediate,,1,41M,,cytotoxicity against 41McisR cells incubated for 24 hr in MTT assay,,CHEMBL615264,N,1,,621.0,Homo sapiens,9606.0,BAO_0000219,80007,,232,,16745,F,,
Expert,,1,,,Inhibition of 5'-inosine monophosphate dehydrogenase type I (IMPDH I),,CHEMBL615265,D,9,,,Homo sapiens,9606.0,BAO_0000357,84,,233,,6210,B,,
Expert,,1,,,Inhibition of 5'-inosine monophosphate dehydrogenase type II (IMPDH II),,CHEMBL615266,D,9,,,Homo sapiens,9606.0,BAO_0000357,68,,234,,6210,B,,
Expert,,1,,,Inhibitory activity against inosine 5'-inosine monophosphate dehydrogenase type II (IMPDH II),,CHEMBL615267,H,8,,,,,BAO_0000357,68,,235,,6226,B,,
Expert,,1,,,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase,,CHEMBL615268,H,8,,,,,BAO_0000357,10201,,236,,17855,B,,
Expert,,1,,,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase; nd = Not determined,,CHEMBL615269,H,8,,,,,BAO_0000357,10201,,237,,17855,B,,
Expert,,1,,,Initial dissociation constant towards human 5'-methylthioadenosine phosphorylase,,CHEMBL615270,H,8,,,,,BAO_0000357,10201,,238,,17855,B,,
Autocuration,,1,,,"Evaluated for inhibitory activity on 5,10-Methenyl Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",,CHEMBL615271,H,8,,,,,BAO_0000357,12220,,239,,10413,B,,
Autocuration,,1,,,"Inhibitory activity against 5,10-methylenetetrahydrofolate dehydrogenase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",,CHEMBL615272,H,8,,,Escherichia coli,562.0,BAO_0000357,11303,,240,,10413,B,,
Autocuration,,1,,,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",,CHEMBL615103,H,8,,,Escherichia coli,562.0,BAO_0000357,11303,,241,,10413,B,,
Autocuration,,1,,,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM;NT=Not tested",,CHEMBL615104,H,8,,,Escherichia coli,562.0,BAO_0000357,11303,,242,,10413,B,,
Autocuration,,1,,,"Evaluated for inhibitory activity on 5,10-Methylene Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",,CHEMBL615105,H,8,,,,,BAO_0000357,12220,,243,,10413,B,,
Autocuration,,1,,,"Evaluated for inhibitory activity on 5,10-methylenetetrahydrofolate dehydrogenase(L cell) at folate substrate concentration of 100 uM",,CHEMBL872866,H,8,,,,,BAO_0000357,12220,,244,,10413,B,,
Autocuration,,1,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",,CHEMBL615106,H,8,,,Sus scrofa,9823.0,BAO_0000357,11303,,245,,7587,B,,
Autocuration,,1,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (A,porcine liver) enzyme.",,CHEMBL615107,H,8,,,Sus scrofa,9823.0,BAO_0000019,11303,,246,,7587,B,,
Autocuration,,1,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-4 M inhibitory concentration",,CHEMBL615108,H,8,,,Sus scrofa,9823.0,BAO_0000357,11303,,247,,7587,B,,
Autocuration,,1,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-5 M inhibitory concentration",,CHEMBL615109,H,8,,,Sus scrofa,9823.0,BAO_0000357,11303,,248,,7587,B,,
Autocuration,,1,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",,CHEMBL615110,H,8,,,Sus scrofa,9823.0,BAO_0000357,11303,,249,,7587,B,,
Autocuration,,1,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",,CHEMBL840105,H,8,,,Sus scrofa,9823.0,BAO_0000019,11303,,250,,7587,B,,
Autocuration,,1,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-5 M inhibitory concentration",,CHEMBL615111,H,8,,,Sus scrofa,9823.0,BAO_0000019,11303,,251,,7587,B,,
Autocuration,,1,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-6 M inhibitory concentration",,CHEMBL615112,H,8,,,Sus scrofa,9823.0,BAO_0000019,11303,,252,,7587,B,,
Autocuration,,1,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-7 M inhibitory concentration",,CHEMBL615113,H,8,,,Sus scrofa,9823.0,BAO_0000019,11303,,253,,7587,B,,
Autocuration,,1,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme.",,CHEMBL615114,H,8,,,Sus scrofa,9823.0,BAO_0000019,11303,,254,,7587,B,,
Autocuration,,1,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",,CHEMBL615115,H,8,,,Sus scrofa,9823.0,BAO_0000357,11303,,255,,7587,B,,
Autocuration,,1,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",,CHEMBL615116,H,8,,,Sus scrofa,9823.0,BAO_0000019,11303,,256,,7587,B,,
Autocuration,,1,,,"Compound was tested for in vitro inhibition of 5,10-Methylene Tetrahydrofolate Cyclohydrolase, competitive against (+)-L-5,10-methenyltetrahydrofolate",,CHEMBL615698,H,8,,,,,BAO_0000357,11303,,257,,7323,B,,
Autocuration,,1,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme at 10E-4 M inhibitory concentration",,CHEMBL615699,U,0,,,Sus scrofa,9823.0,BAO_0000019,22226,,258,,7587,B,,
Autocuration,,1,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme.",,CHEMBL615700,U,0,,,Sus scrofa,9823.0,BAO_0000019,22226,,259,,7587,B,,
Expert,,1,,,Inhibition of 5-Desaturase involved in ergosterol biosynthesis,,CHEMBL615701,H,8,,,Saccharomyces cerevisiae,4932.0,BAO_0000357,100249,,260,,13750,B,,
Autocuration,,1,,,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,,CHEMBL615702,U,0,,,Rattus norvegicus,10116.0,BAO_0000019,22226,,261,,7662,B,,
Autocuration,,1,,,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,,CHEMBL615703,U,0,,,Rattus norvegicus,10116.0,BAO_0000019,22226,,262,,7662,B,,
Autocuration,,1,,,"Irreversible inhibition of Walker 256 FUDR phosphorylase; expressed as Vo/Vi, velocity without inhibitor to that of velocity with inhibitor",,CHEMBL615704,U,0,,,Rattus norvegicus,10116.0,BAO_0000019,22226,,263,,7662,B,,
Autocuration,,1,,,"Tested for 5-HT 3 receptor antagonist potency by ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",,CHEMBL615705,H,6,,,,,BAO_0000019,104698,,264,,12211,F,,
Autocuration,,1,,,"Compound was tested for its 5-HT 3 receptor antagonist potency by their ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",,CHEMBL615706,H,6,,,,,BAO_0000019,104698,,265,,12211,F,,
Intermediate,,1,,,Relative ability to increase cholinergically mediated contractions in isolated ileum of guinea pig,,CHEMBL615707,D,9,,,Cavia porcellus,10141.0,BAO_0000221,20033,,266,Ileum,12211,F,,2116.0
Expert,,1,,,Stimulatory activity of intragastric pressure was tested in the rat,,CHEMBL615708,H,8,,,,,BAO_0000019,10623,,267,,12211,F,,
Autocuration,,1,,,% Decrease of 5-HT carrier-receptor -bound radioactivity using paroxetine as a radioligand.,,CHEMBL615709,H,8,,,,,BAO_0000357,121,,268,,15453,B,,
Autocuration,,1,,,Dose to reduce neuronal firing against 5-HT cells in rats (iv),,CHEMBL615710,U,0,,,Rattus norvegicus,10116.0,BAO_0000218,22226,,269,,11884,F,,
Autocuration,,1,,,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,,CHEMBL615711,H,8,,,,,BAO_0000019,12688,,270,,7185,F,,
Expert,,1,,,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine,,CHEMBL615712,D,9,,,Homo sapiens,9606.0,BAO_0000357,121,,271,,6876,B,,
Expert,,1,,,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine; No data,,CHEMBL836325,D,9,,,Homo sapiens,9606.0,BAO_0000357,121,,272,,6876,B,,
Autocuration,,1,,,Inhibition of high affinity 5-HT uptake at concentration of 1 uM,,CHEMBL615713,H,8,,,,,BAO_0000019,12198,,273,,11863,F,,
Autocuration,,1,,,Inhibition constant of high-affinity 5-HT uptake,,CHEMBL615714,H,8,,,,,BAO_0000357,12198,,274,,11863,B,,
Autocuration,,1,,,Michaelis-Menten constant was reported for high affinity transport of 5-HT,,CHEMBL615715,H,8,,,,,BAO_0000019,12198,,275,,11863,F,,
Autocuration,,1,,,Maximum rate was determined for high affinity transport of 5-HT,,CHEMBL615716,H,8,,,,,BAO_0000019,12198,,276,,11863,F,,
Autocuration,,1,,,Compound was tested for agonistic activity against 5-HT uptake,,CHEMBL615717,H,4,,,,,BAO_0000019,104714,,277,,4639,F,,
Expert,,1,,,Inhibition affinity against 5-HT-1B receptor in rat frontal cortex using radio binding assay,,CHEMBL881818,H,8,,,,,BAO_0000019,10577,,278,,15796,B,,
Expert,,1,,,Inhibition affinity against 5-HT-1D receptor in bovine caudate nucleus using radio binding assay,,CHEMBL884540,H,8,,,Bos taurus,9913.0,BAO_0000357,105,,279,,15796,B,,
Autocuration,,1,,,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,,CHEMBL615718,D,5,,,Rattus norvegicus,10116.0,BAO_0000224,104744,,280,,12801,B,,
Autocuration,,1,,,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1 using [3H]5-HT as radioligand,,CHEMBL615719,H,4,,,,,BAO_0000224,104744,,281,,12801,B,,
Autocuration,,1,,,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M,Membranes,CHEMBL615720,H,4,,,,,BAO_0000249,104744,,282,,12120,B,,
Autocuration,,1,,,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M.,Membranes,CHEMBL615721,H,4,,,,,BAO_0000249,104744,,283,,12120,B,,
Autocuration,,1,,,Displacement of binding of [3H]-5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,CHEMBL615722,H,4,,,,,BAO_0000019,104744,,284,,11963,B,,
Autocuration,,1,,,Dose required to reduce neuronal firing of 5-HT1A cells by 50%,,CHEMBL615723,H,8,,,,,BAO_0000019,51,,285,,11701,F,,
Autocuration,,1,,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,CHEMBL615724,H,8,,,,,BAO_0000221,51,,286,Hippocampus,9995,B,,10000000.0
Autocuration,,1,,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,,CHEMBL615725,H,8,,,,,BAO_0000221,51,,287,Hippocampus,9995,B,,10000000.0
Autocuration,,1,,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,CHEMBL615726,H,8,,,,,BAO_0000221,51,,288,Hippocampus,9995,B,,10000000.0
Autocuration,,1,,,Antagonistic activity at postsynaptic 5-HT1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (.26-3.52),,CHEMBL615727,H,8,,,,,BAO_0000218,10576,,289,,16394,F,In vivo,
Intermediate,,1,,,Effect on forskolin stimulated adenylate cyclase activity at 5-HT1D receptor of guinea pig substantia nigra.,,CHEMBL615728,D,9,,,Cavia porcellus,10141.0,BAO_0000019,105570,,290,,11574,F,,
Autocuration,,1,CHO,,Binding affinity towards 5-HT1F (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,CHEMBL857971,H,8,,449.0,,,BAO_0000219,279,,291,,15779,B,,
Autocuration,,1,,,Compound was tested for the displacement of [125I]DOI from clone human 5-hydroxytryptamine 2A receptor,,CHEMBL615729,H,8,,,,,BAO_0000357,107,,292,,15363,B,,
Expert,,1,,,Efficacy against 5-hydroxytryptamine 2A receptor,,CHEMBL615730,D,9,,,Rattus norvegicus,10116.0,BAO_0000019,12687,,293,,15363,F,,
Expert,,1,,,Intrinsic activity towards 5-HT2A receptor of rat tail artery,,CHEMBL615731,H,8,,,,,BAO_0000019,12687,,294,,15329,F,,
Expert,,1,,,Relative potency towards 5-HT2A receptor of rat tail artery,,CHEMBL615732,H,8,,,,,BAO_0000019,12687,,295,,15329,F,,
Expert,,1,,,Blocking 5-HT2A receptor-mediated contractions of rat tail artery,,CHEMBL615733,H,8,,,,,BAO_0000019,12687,,296,,15329,F,,
Expert,,1,,,Partial agonism at 5-HT2A receptor was evaluated in presence of ketanserin (3-10 nM) in isolated rat tail artery,,CHEMBL615734,H,8,,,,,BAO_0000019,12687,,297,,15329,F,,
Autocuration,,1,,,Compound was tested for the intrinsic activity against 5-HT2A receptors of rat tail artery.,,CHEMBL615735,H,8,,,,,BAO_0000019,12687,,298,,15329,F,,
Expert,,1,,,Effectiveness in blocking 5-HT2A receptor-mediated contractions of rat tail artery,,CHEMBL615736,H,8,,,,,BAO_0000019,12687,,299,,15329,F,,
Intermediate,,1,,,Evaluated for the agonistic activity against 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,,CHEMBL615737,D,9,,,Cavia porcellus,10141.0,BAO_0000221,20033,,300,Ileum,273,F,,2116.0
Intermediate,,1,,,Agonistic activity against Serotonin 5-HT4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI),,CHEMBL615738,D,9,,,Cavia porcellus,10141.0,BAO_0000221,20033,,301,Ileum,273,F,,2116.0
Intermediate,,1,,,Evaluated for the agonistic activity against Serotonin 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,,CHEMBL615739,D,9,,,Cavia porcellus,10141.0,BAO_0000221,20033,,302,Ileum,273,F,,2116.0
Autocuration,,1,,,The binding affinity was measured on 5-hydroxytryptamine 4 receptor using [3H]- GR-113808 as radioligand.,,CHEMBL615278,H,8,,,,,BAO_0000357,10623,,303,,12092,B,,
Expert,,1,,,Antagonist activity against 5-HT4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,,CHEMBL615279,D,9,,,Rattus norvegicus,10116.0,BAO_0000019,10623,,304,,1317,F,,
Expert,,1,,,Binding affinity against 5-hydroxytryptamine 4 receptor,,CHEMBL615280,H,8,,,,,BAO_0000357,168,,305,,12409,B,,
Autocuration,,1,,,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of chick intestine,,CHEMBL615281,U,0,,,Gallus gallus,9031.0,BAO_0000019,22226,,306,,11126,B,,
Autocuration,,1,,,Inhibitory effect (10e-6 M) on the 25-OH-D3-1-hydroxylase activity,,CHEMBL615282,U,0,,,Homo sapiens,9606.0,BAO_0000019,22226,,307,,11126,F,,
Autocuration,,1,,,25-OH-D3-1-hydroxylase activity (10e-6 M) was measured as %control,,CHEMBL615283,U,0,,,Homo sapiens,9606.0,BAO_0000019,22226,,308,,11126,F,,
Autocuration,,1,HL-60,,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of human HL-60 cells,,CHEMBL615284,N,1,,649.0,Homo sapiens,9606.0,BAO_0000219,80156,,309,,11126,B,,
Autocuration,,1,,,Inhibitory effect (10e-6 M) on the 25-hydroxyvitamin D3-1-hydroxylase activity,,CHEMBL615285,U,0,,,Homo sapiens,9606.0,BAO_0000019,22226,,310,,11126,B,,
Autocuration,,1,,,25-hydroxyvitamin D3-1-hydroxylase activity (10e-6 M) was measured as %control,,CHEMBL615286,U,0,,,Homo sapiens,9606.0,BAO_0000019,22226,,311,,11126,B,,
Autocuration,,1,Oocytes,,Displacement of [3H]-Ro- 15-1788 from human GABA-A alpha-1-beta-3-gamma-2 receptor subunits expressed in Xenopus oocytes,,CHEMBL615287,D,7,,,Homo sapiens,9606.0,BAO_0000219,104703,,312,,17807,B,,
Intermediate,,1,,,Chymotryptic inhibitory activity against 26S proteasome,,CHEMBL615288,S,2,,,,,BAO_0000220,100256,,313,,16575,F,,
Intermediate,,1,,,Inhibitory activity against 26S proteasome degradation of IkB,,CHEMBL615289,S,2,,,,,BAO_0000220,100256,,314,,15407,B,,
Intermediate,,1,A2780,,In vitro inhibition of 2780/DOX ovarian cancer cell line,,CHEMBL615290,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,315,,10797,F,,
Intermediate,,1,A2780,,In vitro inhibition of 2780/S ovarian cancer cell line,,CHEMBL884522,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,316,,10797,F,,
Autocuration,,1,,,Relative activity on the cellular accumulation of vincristine in multidrug-resistant (MDR) human ovarian cancer 2780AD cells,,CHEMBL615291,U,0,,,Homo sapiens,9606.0,BAO_0000019,22226,,317,,3469,F,,
Intermediate,,1,,,Association constant for binding to AATT 28-mer AATT hairpin,,CHEMBL615292,M,3,,,,,BAO_0000225,22222,,318,,16037,B,,
Intermediate,,1,,,Kinetically Defined Association Constant for 28-mer AATT hairpin.,,CHEMBL615293,M,3,,,,,BAO_0000225,22222,,319,,16037,B,,
Intermediate,,1,,,Reaction Rate Parameter for 28-mer AATT hairpin,,CHEMBL615294,M,3,,,,,BAO_0000225,22222,,320,,16037,B,,
Intermediate,,1,,,Reaction Rate Parameter for 28-mer AATT hairpin,,CHEMBL615295,M,3,,,,,BAO_0000225,22222,,321,,16037,B,,
Autocuration,,1,,,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 1),,CHEMBL825021,U,0,,,Homo sapiens,9606.0,BAO_0000019,22226,,322,,16524,F,,
Autocuration,,1,,,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 2),,CHEMBL615296,U,0,,,Homo sapiens,9606.0,BAO_0000019,22226,,323,,16524,F,,
Autocuration,,1,,,Inhibitory concentration by single cycle replication assay using envelope deficient HIV-1,,CHEMBL615297,U,0,,,Homo sapiens,9606.0,BAO_0000019,22226,,324,,16524,F,,
Autocuration,,1,,,Cytotoxicity against cell line 2SC/20 determined by MTT test,,CHEMBL615298,U,0,,,Cricetulus griseus,10029.0,BAO_0000019,22226,,325,,16758,F,,
Autocuration,,1,,,Cytotoxicity against cell line 2SC/20 of hamster determined by MTT test,,CHEMBL615299,U,0,,,Cricetulus griseus,10029.0,BAO_0000019,22226,,326,,16758,F,,
Autocuration,,1,,,Inhibitory concentration against the growth of 2SC/20 cell line after 72 hr of drug exposure by MTT test,,CHEMBL615300,U,0,,,Cricetulus griseus,10029.0,BAO_0000019,22226,,327,,16758,F,,
Autocuration,,1,,,Binding affinity on 3 beta-hydroxysteroid dehydrogenase,,CHEMBL615301,H,8,,,,,BAO_0000357,241,,328,,14360,B,,
Expert,,1,,,Binding affinity for 3-beta-hydroxysteroid dehydrogenase,,CHEMBL615302,D,9,,,Homo sapiens,9606.0,BAO_0000357,241,,329,,14360,B,,
Autocuration,,1,,,Selectivity ratio of ID50 in liver and heart,,CHEMBL615303,U,0,,,Rattus norvegicus,10116.0,BAO_0000019,22226,,330,,9964,B,,
Autocuration,,1,,,"Selectivity, ratio of relative ID50 in liver and heart",,CHEMBL615304,H,8,,,,,BAO_0000019,12132,,331,,9964,B,,
Autocuration,,1,,,Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to T3,,CHEMBL615305,H,8,,,,,BAO_0000019,12132,,332,,9964,B,,
Autocuration,,1,,,"Binding affinity to the receptor was determined in nuclei of heart In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,CHEMBL615306,H,8,,,,,BAO_0000218,12132,,333,,9964,B,,
Autocuration,,1,,,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,CHEMBL615307,H,8,,,,,BAO_0000218,12132,,334,,9964,B,,
Autocuration,,1,,,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,CHEMBL615308,H,8,,,,,BAO_0000218,12132,,335,,9964,B,In vivo,
Autocuration,,1,,,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,CHEMBL615309,H,8,,,,,BAO_0000218,12132,,336,,9964,F,In vivo,
Autocuration,,1,,,"Binding affinity to the thyroid hormone receptor was determined in vitro in isolated nuclei of rat liver relative to 3,5,3' triiodothyronine",,CHEMBL615310,U,0,,,,,BAO_0000019,22226,,337,,9964,B,,
Autocuration,,1,,,Binding affinity to the receptor was determined in vitro in isolated nuclei of rat liver relative to T3,,CHEMBL615311,H,8,,,,,BAO_0000019,12132,,338,,9964,B,,
Autocuration,,1,,,"Binding affinity to thyroid hormone receptor beta, relative to 3,5,3' triiodothyronine receptor, in isolated nuclei of heart",,CHEMBL615312,U,0,,,Homo sapiens,9606.0,BAO_0000019,22226,,339,,9964,B,,
Autocuration,,1,,,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,,CHEMBL615313,H,8,,,,,BAO_0000019,12132,,340,,9964,B,,
Autocuration,,1,,,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,,CHEMBL615314,H,8,,,,,BAO_0000019,12132,,341,,9964,F,,
Autocuration,,1,,,"Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to 3,5,3' triiodothyronine receptor",,CHEMBL615315,H,8,,,,,BAO_0000019,12132,,342,,9964,B,,
Autocuration,,1,,,"In vivo binding affinity for 3,5,3'' triiodothyronine receptor of heart nuclei 1 hr after intravenous administration",,CHEMBL615316,U,0,,,Rattus norvegicus,10116.0,BAO_0000218,22226,,343,,9964,B,,
Autocuration,,1,,,Binding affinity to the receptor was determined in nuclei of heart in vivo 1 hour after intravenous administration relative to T3,,CHEMBL615317,H,8,,,,,BAO_0000218,12132,,344,,9964,B,In vivo,
Autocuration,,1,,,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,CHEMBL615318,H,8,,,,,BAO_0000218,12132,,345,,9964,B,,
Autocuration,,1,,,"In vivo binding affinity for 3,5,3' triiodothyronine receptor of liver nuclei 1 hour after intravenous administration",,CHEMBL615319,U,0,,,Rattus norvegicus,10116.0,BAO_0000218,22226,,346,,9964,B,,
Autocuration,,1,,,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",,CHEMBL615320,H,8,,,,,BAO_0000019,12132,,347,,9964,B,,
Autocuration,,1,,,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",,CHEMBL615321,H,8,,,,,BAO_0000019,12132,,348,,9964,F,,
Autocuration,,1,,,"Inhibition of [125I]L-T3 binding to rat hepatic 3,5,3''-triiodo-L-thyronine receptor",,CHEMBL615322,U,0,,,Rattus norvegicus,10116.0,BAO_0000019,22226,,349,,3796,B,,
Autocuration,,1,,,Inhibition constant for binding to Co2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,,CHEMBL615323,H,8,,,Escherichia coli,562.0,BAO_0000357,19690,,350,,4251,B,,
Autocuration,,1,,,Inhibition constant for binding to Zn2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,,CHEMBL615407,H,8,,,Escherichia coli,562.0,BAO_0000357,19690,,351,,4251,B,,
Autocuration,,1,,,Kinetics expressed as Michaelis-Menten constant against Co2+ form of 3-dehydroquinate synthase purified from Escherichia coli,,CHEMBL857267,H,8,,,Escherichia coli,562.0,BAO_0000357,19690,,352,,4251,B,,
Autocuration,,1,,,Kinetics expressed as Michaelis-Menten constant against Zn2+ form of 3-dehydroquinate synthase purified from Escherichia coli,,CHEMBL615408,H,8,,,Escherichia coli,562.0,BAO_0000357,19690,,353,,4251,B,,
Autocuration,,1,,,Type of inhibition of 3-dehydroquinate synthase was determined; R - Slowly reversible,,CHEMBL615409,H,8,,,,,BAO_0000357,19690,,354,,166,B,,
Autocuration,,1,,,Compound was evaluated for its inhibitory constant against 3-dehydroquinate synthase,,CHEMBL615410,H,8,,,,,BAO_0000357,19690,,355,,17861,B,,
Autocuration,,1,,,Inhibition constant against 3-dehydroquinate synthase,,CHEMBL615411,H,8,,,,,BAO_0000357,19690,,356,,166,B,,
Autocuration,,1,,,Association rate constant against 3-dehydroquinate synthase,,CHEMBL615412,H,8,,,,,BAO_0000357,19690,,357,,166,B,,
Autocuration,,1,,,Rate constant against 3-dehydroquinate synthase,,CHEMBL615413,H,8,,,,,BAO_0000357,19690,,358,,166,B,,
Autocuration,,1,,,Inhibitory activity against fuc-TVII,,CHEMBL615414,U,0,,,,,BAO_0000019,22226,,359,,3548,B,,
Autocuration,,1,,,Ability of compound (2.5 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,Microsomes,CHEMBL615415,D,9,,,Rattus norvegicus,10116.0,BAO_0000251,12236,,360,Liver,9877,B,,2107.0
Autocuration,,1,,,Ability of compound (2500 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,Microsomes,CHEMBL615416,D,9,,,Rattus norvegicus,10116.0,BAO_0000251,12236,,361,Liver,9877,B,,2107.0
Autocuration,,1,,,Ability of compound (250 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,Microsomes,CHEMBL615417,D,9,,,Rattus norvegicus,10116.0,BAO_0000251,12236,,362,Liver,9877,B,,2107.0
Autocuration,,1,,,Ability of compound (25 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,Microsomes,CHEMBL615418,D,9,,,Rattus norvegicus,10116.0,BAO_0000251,12236,,363,Liver,9877,B,,2107.0
Autocuration,,1,,,Ability of compound at 0 uM to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,Microsomes,CHEMBL615419,D,9,,,Rattus norvegicus,10116.0,BAO_0000251,12236,,364,Liver,9877,B,,2107.0
Autocuration,,1,,,Ability of compound to inhibit the activity of 3-hydroxy-3-methylglutarylcoenzyme A(HMGR) reductase in rat liver microsomes,Microsomes,CHEMBL615420,D,9,,,Rattus norvegicus,10116.0,BAO_0000251,12236,,365,Liver,9877,B,,2107.0
Autocuration,,1,,,Percentage inhibition of 3-hydroxy-3-methyl glutaryl coenzyme A reductase in rat liver microsomes at 250 uM,Microsomes,CHEMBL615421,D,9,,,Rattus norvegicus,10116.0,BAO_0000251,12236,,366,Liver,9877,B,,2107.0
Autocuration,,1,,,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 0 uM,Microsomes,CHEMBL615422,D,9,,,Rattus norvegicus,10116.0,BAO_0000251,12236,,367,Liver,9877,B,,2107.0
Autocuration,,1,,,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2.5 uM,Microsomes,CHEMBL615423,D,9,,,Rattus norvegicus,10116.0,BAO_0000251,12236,,368,Liver,9877,B,,2107.0
Autocuration,,1,,,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2500 uM,Microsomes,CHEMBL872868,D,9,,,Rattus norvegicus,10116.0,BAO_0000251,12236,,369,Liver,9877,B,,2107.0
Autocuration,,1,,,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 25 uM,Microsomes,CHEMBL615424,D,9,,,Rattus norvegicus,10116.0,BAO_0000251,12236,,370,Liver,9877,B,,2107.0
Autocuration,,1,,,Inhibitory activity against 3-phosphoglycerate kinase.,,CHEMBL825022,H,4,,,,,BAO_0000224,104832,,371,,3003,B,,
Autocuration,,1,,,Binding affinity was evaluated towards 3-phosphoglycerate kinase at 37 degrees Celsius in 0.1 m NaCl pH 7.1,,CHEMBL615425,H,4,,,,,BAO_0000224,104832,,372,,3003,B,,
Autocuration,,1,,,"Michaelis-Menten constant with 1,3-bisphosphoglyceric acid (1,3-BPG) against 3-phosphoglycerate kinase",,CHEMBL615426,H,4,,,,,BAO_0000224,104832,,373,,3003,B,,
Expert,,1,,,Inhibition of human 3-phosphoinositide-dependent protein kinase 1 at 10 uM,,CHEMBL615427,D,9,,,Homo sapiens,9606.0,BAO_0000357,10612,,374,,17185,B,,
Intermediate,,1,3677 melanoma cell line,,Cytotoxicity on 3677 melanoma cells,,CHEMBL615428,N,1,,844.0,Homo sapiens,9606.0,BAO_0000219,80616,,375,,6072,F,,
Intermediate,,1,3677 melanoma cell line,,Cytotoxicity on 3677 melanoma cells in combination with L-49-sFv-bL,,CHEMBL615429,N,1,,844.0,Homo sapiens,9606.0,BAO_0000219,80616,,376,,6072,F,,
Intermediate,,1,MC-38,,Antitumor activity against Mouse colon 38 at 500 ug/disk in disk diffusion assay,,CHEMBL615430,N,1,,700.0,Mus musculus,10090.0,BAO_0000219,80617,,377,,5018,F,,
Intermediate,,1,,,Compound was evaluated for inhibition of tumor cell growth using sulforhodamine-B assay in 38 human cell lines,,CHEMBL615431,U,0,,,Homo sapiens,9606.0,BAO_0000019,22226,,378,,2852,F,,
Autocuration,,1,B16,,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; NT= Not tested,,CHEMBL615432,U,0,,798.0,,,BAO_0000218,22226,,379,,8663,F,,
Autocuration,,1,B16,,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; reproducible significant activity.,,CHEMBL615433,U,0,,798.0,,,BAO_0000218,22226,,380,,8663,F,,
Expert,,1,,,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease,,CHEMBL615434,D,9,,,Human rhinovirus 14,12131.0,BAO_0000019,12464,,381,,3245,F,,
Intermediate,,1,,,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease; NI means No inhibition to 50 uM,,CHEMBL615435,N,1,,,Human rhinovirus sp.,169066.0,BAO_0000218,50085,,382,,3245,F,,
Intermediate,,1,,,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as KI,,CHEMBL615436,N,1,,,human rhinovirus type 14,169066.0,BAO_0000218,50679,,383,,3877,F,,
Intermediate,,1,,,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as kinact,,CHEMBL615437,N,1,,,human rhinovirus type 14,169066.0,BAO_0000218,50679,,384,,3877,F,,
Expert,,1,,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,,CHEMBL615438,D,9,,,Human rhinovirus 14,12131.0,BAO_0000019,12464,,385,,5861,F,,
Expert,,1,,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,,CHEMBL615439,D,9,,,Human rhinovirus 14,12131.0,BAO_0000019,12464,,386,,5861,F,,
Expert,,1,,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,,CHEMBL615440,D,9,,,Human rhinovirus 14,12131.0,BAO_0000019,12464,,387,,5861,F,,
Expert,,1,,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay; inactive,,CHEMBL615441,D,9,,,Human rhinovirus 14,12131.0,BAO_0000019,12464,,388,,5861,F,,
Intermediate,,1,,,Compound was tested for the inhibitory activity of compound towards human rhinovirus 3C protease,,CHEMBL615641,N,1,,,Enterovirus,12059.0,BAO_0000218,50665,,389,,13748,F,,
Intermediate,,1,,,Compound was tested for the inhibitory activity of compound towards human rhinovirus-16 3C protease,,CHEMBL872065,N,1,,,Enterovirus,12059.0,BAO_0000218,50665,,390,,13748,F,,
Intermediate,,1,,,Compound was tested for the inhibitory activity of compound towards human rhinovirus-2 3C protease,,CHEMBL825023,N,1,,,Enterovirus,12059.0,BAO_0000218,50665,,391,,13748,F,,
Intermediate,,1,,,Compound was tested for the inhibitory activity of compound towards human rhinovirus-89 3C protease,,CHEMBL615642,N,1,,,Enterovirus,12059.0,BAO_0000218,50665,,392,,13748,F,,
Expert,,1,,,Inhibition of human rhinovirus 3C protease,,CHEMBL615643,H,8,,,Human rhinovirus B,147712.0,BAO_0000357,12464,,393,,13748,B,,
Autocuration,,1,,,Compound was tested for inhibition of a proteinase 3CL pro of human coronavirus; Inhibited,,CHEMBL615644,U,0,,,Homo sapiens,9606.0,BAO_0000019,22226,,394,,17699,B,,
Intermediate,,1,3EM 37,,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 100 mg/kg (Dose range 200-12.5),,CHEMBL615645,N,1,,833.0,Mus musculus,10090.0,BAO_0000218,80619,,395,,7145,F,,
Intermediate,,1,3EM 37,,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 128 mg/kg (Dose range 256-16),,CHEMBL615646,N,1,,833.0,Mus musculus,10090.0,BAO_0000218,80619,,396,,7145,F,,
Intermediate,,1,3EM 37,,Compound tested for toxicity against 3EM 37 Mouse Ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (10/10),,CHEMBL615647,N,1,,833.0,Mus musculus,10090.0,BAO_0000218,80619,,397,,7145,F,,
Intermediate,,1,3EM 37,,Compound tested for toxicity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (6/6),,CHEMBL615648,N,1,,833.0,Mus musculus,10090.0,BAO_0000218,80619,,398,,7145,F,,
Intermediate,,1,3EM 37,,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as animal weight difference of the treated and the control (T-C) at OD of 100 mg/kg,,CHEMBL615649,N,1,,833.0,Mus musculus,10090.0,BAO_0000218,80619,,399,,7145,F,,
Intermediate,,1,3EM 37,,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as percentage of cured animals at OD of 100 mg/kg,,CHEMBL615650,N,1,,833.0,Mus musculus,10090.0,BAO_0000218,80619,,400,,7145,F,,
Intermediate,,1,3LL cell line,,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing 15 mg/kg b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,,CHEMBL615651,N,1,,847.0,Mus musculus,10090.0,BAO_0000218,80620,,401,,5325,F,,
Intermediate,,1,3LL cell line,,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,,CHEMBL615652,N,1,,847.0,Mus musculus,10090.0,BAO_0000218,80620,,402,,5325,F,,
Expert,,1,3LL cell line,,In vivo anti-tumor and anti-metastatic activity following p.o. administration b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor; Not tested.,,CHEMBL615653,N,1,,847.0,Mus musculus,10090.0,BAO_0000218,80620,,403,,5325,F,,
Intermediate,,1,3LL cell line,,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 1 uM dose,,CHEMBL615654,N,1,,847.0,Mus musculus,10090.0,BAO_0000219,80620,,404,,16169,F,,
Intermediate,,1,3LL cell line,,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 10 uM dose,,CHEMBL615655,N,1,,847.0,Mus musculus,10090.0,BAO_0000219,80620,,405,,16169,F,,
Intermediate,,1,3LL cell line,,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 250 uM dose,,CHEMBL825024,N,1,,847.0,Mus musculus,10090.0,BAO_0000219,80620,,406,,16169,F,,
Intermediate,,1,3LL cell line,,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 50 uM dose,,CHEMBL615656,N,1,,847.0,Mus musculus,10090.0,BAO_0000219,80620,,407,,16169,F,,
Intermediate,,1,3LL cell line,,accumulation of compound in 3LL cells was measured with DFMO by ICP-AES at 50 uM dose,,CHEMBL615657,N,1,,847.0,Mus musculus,10090.0,BAO_0000219,80620,,408,,16169,F,,
Intermediate,,1,3LL cell line,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 1 uM dose,,CHEMBL615658,N,1,,847.0,Mus musculus,10090.0,BAO_0000219,80620,,409,,16169,F,,
Intermediate,,1,3LL cell line,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 10 uM dose,,CHEMBL615659,N,1,,847.0,Mus musculus,10090.0,BAO_0000219,80620,,410,,16169,F,,
Intermediate,,1,3LL cell line,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 250 uM dose,,CHEMBL615660,N,1,,847.0,Mus musculus,10090.0,BAO_0000219,80620,,411,,16169,F,,
Intermediate,,1,3LL cell line,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,,CHEMBL615661,N,1,,847.0,Mus musculus,10090.0,BAO_0000219,80620,,412,,16169,F,,
Intermediate,,1,3LL cell line,,accumulation of compound in 3LL cells was measured without DFMO by ICP-AES at 50 uM dose,,CHEMBL615662,N,1,,847.0,Mus musculus,10090.0,BAO_0000219,80620,,413,,16169,F,,
Intermediate,,1,3LL cell line,,Effect on the growth of 3LL cells by DFMO pretreatment at 48 hr incubation,,CHEMBL615663,N,1,,847.0,Mus musculus,10090.0,BAO_0000219,80620,,414,,16169,F,,
Intermediate,,1,3LL cell line,,Effect on the growth of 3LL cells was evaluated using an MTT assay at 48 hour incubation,,CHEMBL615664,N,1,,847.0,Mus musculus,10090.0,BAO_0000219,80620,,415,,16169,F,,
Intermediate,,1,3LL cell line,,Effect on the growth of 3LL cells was evaluated using an MTT assay at 72 hour incubation,,CHEMBL615665,N,1,,847.0,Mus musculus,10090.0,BAO_0000219,80620,,416,,16169,F,,
Intermediate,,1,3LL cell line,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,,CHEMBL615666,N,1,,847.0,Mus musculus,10090.0,BAO_0000219,80620,,417,,16169,F,,
Intermediate,,1,3LL cell line,,putrescine levels in 3LL cells after the treatment of 1 uM of Compound,,CHEMBL615667,N,1,,847.0,Mus musculus,10090.0,BAO_0000219,80620,,418,,16169,F,,
Intermediate,,1,3LL cell line,,putrescine levels in 3LL cells after the treatment of 10 uM of Compound,,CHEMBL615668,N,1,,847.0,Mus musculus,10090.0,BAO_0000219,80620,,419,,16169,F,,
Intermediate,,1,3LL cell line,,putrescine levels in 3LL cells after the treatment of 250 uM of Compound,,CHEMBL615669,N,1,,847.0,Mus musculus,10090.0,BAO_0000219,80620,,420,,16169,F,,
Intermediate,,1,3LL cell line,,putrescine levels in 3LL cells after the treatment of 50 uM of Compound,,CHEMBL615670,N,1,,847.0,Mus musculus,10090.0,BAO_0000219,80620,,421,,16169,F,,
Intermediate,,1,3LL cell line,,spermidine levels in 3LL cells after the treatment of 1 uM of Compound,,CHEMBL836739,N,1,,847.0,Mus musculus,10090.0,BAO_0000219,80620,,422,,16169,F,,
Intermediate,,1,3LL cell line,,spermidine levels in 3LL cells after the treatment of 10 uM of Compound,,CHEMBL615671,N,1,,847.0,Mus musculus,10090.0,BAO_0000219,80620,,423,,16169,F,,
Intermediate,,1,3LL cell line,,spermidine levels in 3LL cells after the treatment of 250 uM of Compound,,CHEMBL615672,N,1,,847.0,Mus musculus,10090.0,BAO_0000219,80620,,424,,16169,F,,
Intermediate,,1,3LL cell line,,spermidine levels in 3LL cells after the treatment of 50 uM of Compound,,CHEMBL615791,N,1,,847.0,Mus musculus,10090.0,BAO_0000219,80620,,425,,16169,F,,
Intermediate,,1,3LL cell line,,spermine levels in 3LL cells after the treatment of 1 uM of Compound,,CHEMBL615792,N,1,,847.0,Mus musculus,10090.0,BAO_0000219,80620,,426,,16169,F,,
Intermediate,,1,3LL cell line,,spermine levels in 3LL cells after the treatment of 10 uM of Compound,,CHEMBL615793,N,1,,847.0,Mus musculus,10090.0,BAO_0000219,80620,,427,,16169,F,,
Intermediate,,1,3LL cell line,,spermine levels in 3LL cells after the treatment of 250 uM of Compound,,CHEMBL615794,N,1,,847.0,Mus musculus,10090.0,BAO_0000219,80620,,428,,16169,F,,
Intermediate,,1,3LL cell line,,spermine levels in 3LL cells after the treatment of 50 uM of Compound,,CHEMBL615795,N,1,,847.0,Mus musculus,10090.0,BAO_0000219,80620,,429,,16169,F,,
Intermediate,,1,3LLD122,,Concentration required to inhibit the colony formation of lung carcinoma (3LLD122) cell lines by 50%,,CHEMBL615590,N,1,,971.0,Homo sapiens,9606.0,BAO_0000219,80621,,430,,15547,F,,
Autocuration,,1,,,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible minimal activity,,CHEMBL615591,U,0,,,,,BAO_0000218,22226,,431,,8663,F,,
Autocuration,,1,,,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible significant activity.,,CHEMBL615592,U,0,,,,,BAO_0000218,22226,,432,,8663,F,,
Autocuration,,1,,,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; NT= Not tested,,CHEMBL615593,U,0,,,,,BAO_0000218,22226,,433,,8663,F,,
Autocuration,,1,,,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; reproducible significant activity.,,CHEMBL615594,U,0,,,,,BAO_0000218,22226,,434,,8663,F,,
Intermediate,,1,NIH3T3,,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,,CHEMBL615595,N,1,,723.0,Mus musculus,10090.0,BAO_0000219,80951,,435,,4504,F,,
Intermediate,,1,NIH3T3,,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,,CHEMBL615596,N,1,,723.0,Mus musculus,10090.0,BAO_0000219,80951,,436,,4504,F,,
Expert,,1,NIH3T3,,Inhibition of 6 nM bombesin induced [3H]thymidine incorporation measured in swiss 3T3 cells using a mitogenicity assay,,CHEMBL615597,H,8,,723.0,,,BAO_0000219,11169,,437,,12695,F,,
Intermediate,,1,NIH3T3,,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; na=Not active,,CHEMBL615598,N,1,,723.0,Mus musculus,10090.0,BAO_0000219,80951,,438,,12695,F,,
Intermediate,,1,NIH3T3,,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; nt=Not tested,,CHEMBL615599,N,1,,723.0,Mus musculus,10090.0,BAO_0000219,80951,,439,,12695,F,,
Expert,,1,NIH3T3,,Effective dose against murine 3T3 fibroblasts cells,,CHEMBL615600,N,1,,723.0,Mus musculus,10090.0,BAO_0000219,80951,,440,,17642,F,,
Expert,,1,NIH3T3,,Dose required against murine 3T3 fibroblasts cells; 1-10 uM,,CHEMBL615601,N,1,,723.0,Mus musculus,10090.0,BAO_0000219,80951,,441,,17642,F,,
Expert,,1,NIH3T3,,Cytotoxic effect on 3T3 cells,,CHEMBL615602,N,1,,723.0,Mus musculus,10090.0,BAO_0000219,80951,,442,,12340,F,,
Expert,,1,NIH3T3,,Cytotoxic effect on 3T3 cells,,CHEMBL615603,N,1,,723.0,Mus musculus,10090.0,BAO_0000219,80951,,443,,12340,F,,
Intermediate,,1,NIH3T3,,Compound was tested for the concentration necessary to inhibit swiss 3T3 Mouse Fibroblast cell growth rate by 50%.,,CHEMBL615604,N,1,,723.0,Mus musculus,10090.0,BAO_0000219,80951,,444,,12716,F,,
Intermediate,,1,NIH3T3,,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,,CHEMBL615605,N,1,,723.0,Mus musculus,10090.0,BAO_0000219,80951,,445,,6277,F,,
Intermediate,,1,NIH3T3,,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration; nd=No data,,CHEMBL615606,N,1,,723.0,Mus musculus,10090.0,BAO_0000219,80951,,446,,6277,F,,
Expert,,1,NIH3T3,,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration,,CHEMBL884526,N,1,,723.0,Mus musculus,10090.0,BAO_0000219,80951,,447,,6277,F,,
Expert,,1,NIH3T3,,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.d.=no data,,CHEMBL615607,N,1,,723.0,Mus musculus,10090.0,BAO_0000219,80951,,448,,6277,F,,
Intermediate,,1,NIH3T3,,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.t.=not tested,,CHEMBL615608,N,1,,723.0,Mus musculus,10090.0,BAO_0000219,80951,,449,,6277,F,,
Expert,,1,NIH3T3,,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration,,CHEMBL615609,N,1,,723.0,Mus musculus,10090.0,BAO_0000219,80951,,450,,6277,F,,
Expert,,1,NIH3T3,,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.d.=no data,,CHEMBL615682,N,1,,723.0,Mus musculus,10090.0,BAO_0000219,80951,,451,,6277,F,,
Intermediate,,1,NIH3T3,,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.t.=not tested,,CHEMBL615683,N,1,,723.0,Mus musculus,10090.0,BAO_0000219,80951,,452,,6277,F,,
Expert,,1,NIH3T3,,In vivo inhibition of H-ras-transformed 3T3 fibroblasts in nude mouse tumor models,,CHEMBL615684,N,1,,723.0,Mus musculus,10090.0,BAO_0000218,80951,,453,,17780,F,,
Autocuration,,1,,,Inhibition of PDGF-dependent autophosphorylation of PDGF-R in mouse BALB/c3T3 cells,,CHEMBL615685,D,7,,,Mus musculus,10090.0,BAO_0000219,104860,,454,,12751,F,,
Expert,,1,NIH3T3,,Inhibition of Swiss 3T3 Mouse fibroblast proliferation,,CHEMBL615686,N,1,,723.0,Mus musculus,10090.0,BAO_0000219,80951,,455,,12380,F,,
Intermediate,,1,NIH3T3,,Inhibitory activity against 3T3 cell line,,CHEMBL615687,N,1,,723.0,Mus musculus,10090.0,BAO_0000219,80951,,456,,14892,F,,
Intermediate,,1,NIH3T3,,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured,,CHEMBL884523,N,1,,723.0,Mus musculus,10090.0,BAO_0000219,80951,,457,,12695,F,,
Expert,,1,,,Ability of peptide to inhibit binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane.,,CHEMBL615688,H,8,,,,,BAO_0000019,11169,,458,,12695,F,,
Intermediate,,1,NIH3T3,,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured; nt=Not tested,,CHEMBL615689,N,1,,723.0,Mus musculus,10090.0,BAO_0000219,80951,,459,,12695,F,,
Intermediate,,1,NIH3T3,,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells was measured,,CHEMBL615690,N,1,,723.0,Mus musculus,10090.0,BAO_0000219,80951,,460,,12695,F,,
Expert,,1,,,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells,,CHEMBL615691,H,8,,,,,BAO_0000019,11169,,461,,12695,F,,
Expert,,1,,,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells; nt=Not tested,,CHEMBL615692,H,8,,,,,BAO_0000019,11169,,462,,12695,F,,
Intermediate,,1,NIH3T3,,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,,CHEMBL615693,N,1,,723.0,Mus musculus,10090.0,BAO_0000219,80951,,463,,6277,F,,
Expert,,1,NIH3T3,,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line was determined using NR coloration; n.d.=no data,,CHEMBL615324,N,1,,723.0,Mus musculus,10090.0,BAO_0000219,80951,,464,,6277,F,,
Expert,,1,NIH3T3,,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells,,CHEMBL615325,D,9,,723.0,Homo sapiens,9606.0,BAO_0000219,9,,465,,4959,F,,
Expert,,1,NIH3T3,,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells (Not tested),,CHEMBL615490,D,9,,723.0,Homo sapiens,9606.0,BAO_0000219,9,,466,,4959,F,,
Expert,,1,NIH3T3,,Inhibition of ligand induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells,,CHEMBL615491,D,9,,723.0,Homo sapiens,9606.0,BAO_0000219,188,,467,,4959,F,,
Expert,,1,NIH3T3,,Inhibition of ligand-induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells (Not tested),,CHEMBL615492,D,9,,723.0,Homo sapiens,9606.0,BAO_0000219,188,,468,,4959,F,,
Intermediate,,1,NIH3T3,,Inhibitory concentration of compound rwas calculated on 3T3 cells by [3H]Thd incorporation,,CHEMBL615493,N,1,,723.0,Mus musculus,10090.0,BAO_0000219,80951,,469,,12082,F,,
Intermediate,,1,NIH3T3,,Inhibitory concentration of compound was calculated on 3T3 cells by [14C]Leu incorporation,,CHEMBL615494,N,1,,723.0,Mus musculus,10090.0,BAO_0000219,80951,,470,,12082,F,,
Intermediate,,1,NIH3T3,,Inhibitory concentration of compound was calculated on 3T3 cells by using clonal assay,,CHEMBL615495,N,1,,723.0,Mus musculus,10090.0,BAO_0000219,80951,,471,,12082,F,,
Intermediate,,1,NIH3T3,,Inhibitory concentration was calculated on 3T3 cells by using growth assay,,CHEMBL615496,N,1,,723.0,Mus musculus,10090.0,BAO_0000219,80951,,472,,12082,F,,
Intermediate,,1,NIH3T3,,In vitro cytotoxicity was evaluated in mouse embryo BALB/c 3T3 cells,,CHEMBL615497,N,1,,723.0,Mus musculus,10090.0,BAO_0000219,80951,,473,,2643,F,,
Expert,,1,NIH3T3,,Inhibition of Swiss 3T3 mouse fibroblast proliferation,,CHEMBL615498,N,1,,723.0,Mus musculus,10090.0,BAO_0000219,80951,,474,,11926,F,,
Intermediate,,1,NIH3T3,,The compound was tested for cytotoxicity against 3T3 fibroblast murine cell line.,,CHEMBL615499,N,1,,723.0,Mus musculus,10090.0,BAO_0000219,80951,,475,,15204,A,,
Expert,,1,NIH3T3,,Effective concentration required to inhibit the growth of murine 3T3 fibroblasts,,CHEMBL835522,N,1,,723.0,Mus musculus,10090.0,BAO_0000219,80951,,476,,15992,F,,
Intermediate,,1,NIH3T3,,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014); Not tested,,CHEMBL615500,N,1,,723.0,Mus musculus,10090.0,BAO_0000219,80951,,477,,16279,F,,
Intermediate,,1,NIH3T3,,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,CHEMBL615501,N,1,,723.0,Mus musculus,10090.0,BAO_0000219,80951,,478,,16279,F,,
Intermediate,,1,NIH3T3,,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,CHEMBL615502,N,1,,723.0,Mus musculus,10090.0,BAO_0000219,80951,,479,,16279,F,,
Intermediate,,1,NIH3T3,,cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,CHEMBL615503,N,1,,723.0,Mus musculus,10090.0,BAO_0000219,80951,,480,,16279,F,,
Intermediate,,1,NIH3T3,,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,CHEMBL615504,N,1,,723.0,Mus musculus,10090.0,BAO_0000219,80951,,481,,16279,F,,
Intermediate,,1,NIH3T3,,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,CHEMBL615505,N,1,,723.0,Mus musculus,10090.0,BAO_0000219,80951,,482,,16279,F,,
Expert,,1,NIH3T3,,Inhibition of swiss 3T3 mouse fibroblast proliferation,,CHEMBL615506,N,1,,723.0,Mus musculus,10090.0,BAO_0000219,80951,,483,,12831,F,,
Intermediate,,1,NIH3T3,,Compound was tested for sublethal concentrations in 3T3 mouse fibroblast lysis.,,CHEMBL615507,N,1,,723.0,Mus musculus,10090.0,BAO_0000219,80951,,484,,13497,F,,
Intermediate,,1,3T3-L1,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,,CHEMBL615508,N,1,,620.0,,,BAO_0000218,80006,,485,,13715,F,,
Intermediate,,1,3T3-L1,,Concentration required to stimulate glucose uptake in 3T3-L1 adipocytes after 48 hr incubation,,CHEMBL615509,N,1,,620.0,Mus musculus,10090.0,BAO_0000219,80006,,486,,13618,F,,
Intermediate,,1,3T3-L1,,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 0.3 uM,,CHEMBL615510,N,1,,620.0,Mus musculus,10090.0,BAO_0000219,80006,,487,,11902,F,,
Intermediate,,1,3T3-L1,,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 3 uM,,CHEMBL615511,N,1,,620.0,Mus musculus,10090.0,BAO_0000219,80006,,488,,11902,F,,
Intermediate,,1,3T3-L1,,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 30 uM,,CHEMBL615512,N,1,,620.0,Mus musculus,10090.0,BAO_0000219,80006,,489,,11902,F,,
Intermediate,,1,3T3-L1,,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 24 hr",,CHEMBL615513,N,1,,620.0,Mus musculus,10090.0,BAO_0000218,80006,,490,,14840,F,,
Intermediate,,1,3T3-L1,,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 3 hr",,CHEMBL615514,N,1,,620.0,Mus musculus,10090.0,BAO_0000218,80006,,491,,14840,F,,
Intermediate,,1,3T3-L1,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes,,CHEMBL615515,N,1,,620.0,,,BAO_0000219,80006,,492,,13715,F,,
Intermediate,,1,3T3-L1,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,,CHEMBL615516,N,1,,620.0,,,BAO_0000219,80006,,493,,13715,F,,
Intermediate,,1,3T3-L1,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,,CHEMBL615517,N,1,,620.0,,,BAO_0000219,80006,,494,,13715,F,,
Intermediate,,1,3T3-L1,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,,CHEMBL615518,N,1,,620.0,,,BAO_0000219,80006,,495,,13715,F,,
Intermediate,,1,3T3-L1,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,,CHEMBL615519,N,1,,620.0,,,BAO_0000219,80006,,496,,13715,F,,
Intermediate,,1,3T3-L1,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.3 uM dose.,,CHEMBL615520,N,1,,620.0,,,BAO_0000218,80006,,497,,13715,F,,
Intermediate,,1,3T3-L1,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.5 uM dose.,,CHEMBL615521,N,1,,620.0,,,BAO_0000218,80006,,498,,13715,F,,
Intermediate,,1,3T3-L1,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,,CHEMBL615522,N,1,,620.0,,,BAO_0000218,80006,,499,,13715,F,,
Intermediate,,1,3T3-L1,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,,CHEMBL615523,N,1,,620.0,,,BAO_0000218,80006,,500,,13715,F,,
Expert,,1,3T3-L1,,In vitro measurements 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,,CHEMBL615524,N,1,,620.0,,,BAO_0000218,80006,,501,,13715,F,,
Expert,,1,3T3-L1,,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,,CHEMBL615525,N,1,,620.0,,,BAO_0000218,80006,,502,,13715,F,,
Intermediate,,1,3T3-L1,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,,CHEMBL615526,N,1,,620.0,,,BAO_0000218,80006,,503,,13715,F,,
Intermediate,,1,3T3-L1,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,,CHEMBL615527,N,1,,620.0,,,BAO_0000218,80006,,504,,13715,F,,
Intermediate,,1,3T3-L1,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 300 uM dose.,,CHEMBL615528,N,1,,620.0,,,BAO_0000218,80006,,505,,13715,F,,
Expert,,1,3T3-L1,,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,,CHEMBL615529,N,1,,620.0,,,BAO_0000218,80006,,506,,13715,F,,
Expert,,1,3T3-L1,,In vitro by measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,,CHEMBL615530,N,1,,620.0,,,BAO_0000218,80006,,507,,13715,F,,
Expert,,1,3T3-L1,,In vitro measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,,CHEMBL615531,N,1,,620.0,,,BAO_0000218,80006,,508,,13715,F,,
Intermediate,,1,3T3-L1,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,,CHEMBL615532,N,1,,620.0,,,BAO_0000219,80006,,509,,13715,F,,
Intermediate,,1,3T3-L1,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,,CHEMBL615533,N,1,,620.0,,,BAO_0000219,80006,,510,,13715,F,,
Intermediate,,1,3T3-L1,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,,CHEMBL615534,N,1,,620.0,,,BAO_0000219,80006,,511,,13715,F,,
Intermediate,,1,3T3-L1,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,,CHEMBL615535,N,1,,620.0,,,BAO_0000218,80006,,512,,13715,F,,
Intermediate,,1,3T3-L1,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,,CHEMBL615536,N,1,,620.0,,,BAO_0000218,80006,,513,,13715,F,,
Intermediate,,1,3T3-L1,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,,CHEMBL615537,N,1,,620.0,,,BAO_0000218,80006,,514,,13715,F,,
Intermediate,,1,3T3-L1,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,,CHEMBL615538,N,1,,620.0,,,BAO_0000218,80006,,515,,13715,F,,
Intermediate,,1,3T3-L1,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,,CHEMBL836166,N,1,,620.0,,,BAO_0000218,80006,,516,,13715,F,,
Expert,,1,3T3-L1,,Inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells,,CHEMBL615539,H,8,,620.0,,,BAO_0000219,11214,,517,,6411,F,,
Intermediate,,1,3T3-L1,,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; ND = No data,,CHEMBL615540,N,1,,620.0,Mus musculus,10090.0,BAO_0000219,80006,,518,,6411,F,,
Expert,,1,3T3-L1,,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; Na = Not active,,CHEMBL615541,H,8,,620.0,,,BAO_0000219,11214,,519,,6411,F,,
Expert,,1,3T3-L1,,Insulin-sensitizing activity; triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 1 uM expressed as percent activity of pioglitazone,,CHEMBL615542,N,1,,620.0,Mus musculus,10090.0,BAO_0000219,80006,,520,,3966,F,,
Intermediate,,1,3T3-L1,,Compound was tested for insulin-sensitizing activity by measuring triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 10 uM expressed as percent activity of pioglitazone,,CHEMBL615543,N,1,,620.0,Mus musculus,10090.0,BAO_0000219,80006,,521,,3966,F,,
Expert,,1,3T3-L1,,Stimulation of adipogenesis in 3T3-L1 cells is expressed as concentration equivalent to the [ 1-14C] uptake counts after treatment with 0.2 ug/mL troglitazone,,CHEMBL615544,N,1,,620.0,Mus musculus,10090.0,BAO_0000219,80006,,522,,15556,F,,
Expert,,1,3T3-L1,,Effective concentration for enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,,CHEMBL615545,N,1,,620.0,Mus musculus,10090.0,BAO_0000219,80006,,523,,5845,F,,
Expert,,1,3T3-L1,,Effective concentration for 50% enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,,CHEMBL615546,N,1,,620.0,Mus musculus,10090.0,BAO_0000219,80006,,524,,14422,F,,
Expert,,1,3T3-L1,,Percentage of rosiglitazone response for insulin-sensitizing activity at 1 uM concentration in 3T3-L1 cells,,CHEMBL615547,N,1,,620.0,Mus musculus,10090.0,BAO_0000219,80006,,525,,5845,F,,
Expert,,1,3T3-L1,,In vitro glucose transport activity in 3T3-LI adipocytes at 10 uM concentration.,,CHEMBL615548,N,1,,620.0,Mus musculus,10090.0,BAO_0000219,80006,,526,,14508,F,,
Expert,,1,3T3-L1,,In vitro glucose transport activity in 3T3-LI adipocytes at 3 uM concentration.,,CHEMBL615549,N,1,,620.0,Mus musculus,10090.0,BAO_0000219,80006,,527,,14508,F,,
Expert,,1,3T3-L1,,In vitro glucose transport activity in 3T3-LI adipocytes at 30 uM concentration.,,CHEMBL615550,N,1,,620.0,Mus musculus,10090.0,BAO_0000219,80006,,528,,14508,F,,
Intermediate,,1,3Y1 cell line,,Inhibitory activity against rat fibroblast (3Y1) cell line,,CHEMBL615551,N,1,,1118.0,Rattus norvegicus,10116.0,BAO_0000219,80622,,529,,6349,F,,
Expert,,1,3Y1 cell line,,Mean concentration causing inhibition of cell growth in 3Y1 cells.,,CHEMBL615552,N,1,,1118.0,Rattus norvegicus,10116.0,BAO_0000219,80622,,530,,15899,F,,
Expert,,1,3Y1 cell line,,Cytotoxicity in 3Y1 cells.,,CHEMBL615553,N,1,,1118.0,Rattus norvegicus,10116.0,BAO_0000219,80622,,531,,15899,F,,
Expert,,1,3Y1 cell line,,Cytostatic effect in 3Y1 cells.,,CHEMBL615554,N,1,,1118.0,Rattus norvegicus,10116.0,BAO_0000219,80622,,532,,15899,F,,
Intermediate,,1,3Y1 cell line,,"Mean averaged concentration for total growth inhibition, which signifies cytostatic effect",,CHEMBL615555,N,1,,1118.0,Rattus norvegicus,10116.0,BAO_0000219,80622,,533,,15899,F,,
Expert,,1,3Y1 cell line,,Concentration to inhibit growth of normal rat fibroblast cells (3Y1-B cells) after 72 h exposure,,CHEMBL615556,N,1,,1118.0,Rattus norvegicus,10116.0,BAO_0000219,80622,,534,,17038,F,,
Autocuration,,1,,,In vitro inhibitory activity against human adrenal 3-beta hydroxy-delta 5-teroid isomerase,,CHEMBL615557,U,0,,,,,BAO_0000019,22226,,535,,12421,B,,
Autocuration,,1,,,Inhibition of recombinant human adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,,CHEMBL615558,U,0,,,,,BAO_0000019,22226,,536,,12947,B,,
Autocuration,,1,,,Inhibition of recombinant rat adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,,CHEMBL872066,U,0,,,,,BAO_0000019,22226,,537,,12947,B,,
Expert,,1,,,In vitro inhibition against of 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) from pig liver by the enol borate method,,CHEMBL615559,D,9,,,Sus scrofa,9823.0,BAO_0000019,11607,,538,,4896,B,,
Autocuration,,1,,,In vitro inhibitory concentration required against 4-hydroxyphenylpyruvate dioxygenase (4-HPPD) taken from pig liver,,CHEMBL615560,H,8,,,,,BAO_0000019,11607,,539,,6148,B,,
Autocuration,,1,,,Inhibition of pig liver 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) enzyme,,CHEMBL615561,H,8,,,,,BAO_0000019,11607,,540,,16432,B,,
Expert,,1,,,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver,,CHEMBL857062,H,8,,,,,BAO_0000019,11607,,541,,4978,B,,
Expert,,1,,,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver; (observed value),,CHEMBL615562,H,8,,,,,BAO_0000019,11607,,542,,4978,B,,
Autocuration,,1,,,In vitro inhibitory activity against HPPD(4-hydroxyphenylpyruvate Dioxygenase) from pig liver using enol borate assay method,,CHEMBL615563,H,8,,,,,BAO_0000019,11607,,543,,3723,B,,
Autocuration,,1,,,Compound was evaluated for complete competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD),,CHEMBL615564,H,8,,,,,BAO_0000357,11607,,544,,3518,B,,
Autocuration,,1,,,In vitro inhibition of 4-hydroxyphenylpyruvate dioxygenase obtained from purified pig liver by enol-borate method,,CHEMBL615565,H,8,,,,,BAO_0000019,11607,,545,,4164,B,,
Autocuration,,1,,,Inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated,,CHEMBL615566,H,8,,,,,BAO_0000019,11607,,546,,3518,B,,
Expert,,1,,,Inhibition of 4-hydroxyphenylpyruvate dioxygenase of purified pig liver by enol-borate method,,CHEMBL615567,D,9,,,Sus scrofa,9823.0,BAO_0000019,11607,,547,,4164,B,,
Autocuration,,1,,,The inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated.,,CHEMBL615568,H,8,,,,,BAO_0000019,11607,,548,,3518,B,,
Autocuration,,1,,,Compound was evaluated for competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD) (complete inhibition was observed at a concentration of 0.5-1.0 mM),,CHEMBL615569,H,8,,,,,BAO_0000357,11607,,549,,3518,B,,
Autocuration,,1,,,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver,,CHEMBL615570,H,8,,,,,BAO_0000019,11607,,550,,4978,B,,
Autocuration,,1,,,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver; (observed value),,CHEMBL615571,H,8,,,,,BAO_0000019,11607,,551,,4978,B,,
Autocuration,,1,,,Binding affinity against melatonin (MT1) receptor (pC1),,CHEMBL615572,H,4,,,,,BAO_0000224,104733,,552,,6455,B,,
Autocuration,,1,,,Compound was tested for inhibitory activity against 5-hydroxytryptamine 1 receptor,,CHEMBL615573,U,0,,,,,BAO_0000019,22226,,553,,2222,B,,
Autocuration,,1,,,Inhibition of [3H]- 5-HT binding to 5-hydroxytryptamine 1 receptor at 10e-5 M,,CHEMBL615574,U,0,,,,,BAO_0000019,22226,,554,,13020,B,,
Autocuration,,1,,,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1 receptor of central nervous system,,CHEMBL615575,U,0,,,,,BAO_0000019,22226,,555,,13021,B,,
Autocuration,,1,,,Inhibitory activity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand at 10e-5 M concentration,,CHEMBL615576,H,8,,,,,BAO_0000357,10619,,556,,14532,B,,
Autocuration,,1,,,Binding affinity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,,CHEMBL615577,H,8,,,,,BAO_0000357,10619,,557,,14118,B,,
Autocuration,,1,,,Binding affinity at 5-hydroxytryptamine 1A receptor in bovine hippocampal preparation using [3H]8-OH-DPAT,,CHEMBL615578,H,8,,,,,BAO_0000221,51,,558,Hippocampus,11884,B,,10000000.0
Expert,,1,,,Binding affinity against 5-hydroxytryptamine 1A receptor was measured using [3H]8-OH-DPAT as radioligand,,CHEMBL615579,H,8,,,,,BAO_0000357,51,,559,,13969,B,,
Expert,,1,,,Binding affinity for 5-hydroxytryptamine 1A receptor,,CHEMBL615580,H,8,,,,,BAO_0000357,51,,560,,13392,B,,
Expert,,1,,,Affinity towards 5-hydroxytryptamine 1A receptor in membranes from bovine hippocampus using [3H]OH-DPAT,,CHEMBL615581,H,8,,,,,BAO_0000019,51,,561,,14430,B,,
Autocuration,,1,,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,CHEMBL615582,H,8,,,,,BAO_0000221,51,,562,Hippocampus,12248,B,,10000000.0
Autocuration,,1,,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,CHEMBL615583,H,8,,,,,BAO_0000221,51,,563,Hippocampus,12249,B,,10000000.0
Autocuration,,1,,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,,CHEMBL615584,H,8,,,,,BAO_0000221,51,,564,Hippocampus,9995,B,,10000000.0
Autocuration,,1,,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,CHEMBL833691,H,8,,,,,BAO_0000221,51,,565,Hippocampus,9995,B,,10000000.0
Autocuration,,1,,,In vitro inhibition of azido-[125I]-IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,,CHEMBL615585,H,8,,,,,BAO_0000221,51,,566,Hippocampus,9995,B,,10000000.0
Autocuration,,1,,,In vitro inhibition of [125I]IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,,CHEMBL615586,H,8,,,,,BAO_0000221,51,,567,Hippocampus,9995,B,,10000000.0
Autocuration,,1,,,In vitro inhibition of [125I]IPAPP (2.5 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,CHEMBL884524,H,8,,,,,BAO_0000221,51,,568,Hippocampus,9995,B,,10000000.0
Autocuration,,1,,,Inhibitory concentration against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,CHEMBL615587,H,8,,,,,BAO_0000221,51,,569,Hippocampus,12249,B,,10000000.0
Autocuration,,1,,,"Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",,CHEMBL615588,H,8,,,,,BAO_0000221,51,,570,Hippocampus,11799,B,,10000000.0
Expert,,1,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampal membranes,Membranes,CHEMBL615589,D,9,,,Rattus norvegicus,10116.0,BAO_0000249,10576,,571,,14331,B,,
Expert,,1,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of bovine hippocampus.,,CHEMBL615442,H,8,,,Bos taurus,9913.0,BAO_0000221,51,,572,Hippocampus,11884,B,,10000000.0
Autocuration,,1,,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (0.5 nM) ligand in hippocampus + frontal bovine was determined,,CHEMBL615443,H,8,,,,,BAO_0000221,51,,573,Hippocampus,14331,B,,10000000.0
Autocuration,,1,,,Compound was evaluated for its ability to displace [3H]DPAT from 5-HT1A receptor in homogenates of bovine hippocampus,,CHEMBL615444,H,8,,,,,BAO_0000221,51,,574,Hippocampus,11701,B,,10000000.0
Expert,,1,,,Ability to displace [3H]-DPAT from 5-hydroxytryptamine 1A receptor in homogenates of bovine hippocampus.,,CHEMBL615445,H,8,,,,,BAO_0000221,51,,575,Hippocampus,11701,B,,10000000.0
Autocuration,,1,,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in bovine hippocampus,,CHEMBL615446,H,8,,,,,BAO_0000221,51,,576,Hippocampus,12248,B,,10000000.0
Autocuration,,1,CHO,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in CHO cells,,CHEMBL615447,H,8,,449.0,,,BAO_0000219,51,,577,,12248,B,,
Expert,,1,,,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,CHEMBL615448,H,8,,,,,BAO_0000221,51,,578,Hippocampus,12248,B,,10000000.0
Expert,,1,,,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,CHEMBL615449,H,8,,,,,BAO_0000221,51,,579,Hippocampus,12249,B,,10000000.0
Autocuration,,1,CHO,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,CHEMBL615450,H,8,,449.0,,,BAO_0000219,51,,580,,12248,B,,
Expert,,1,,,"Binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",,CHEMBL615451,H,8,,,,,BAO_0000221,51,,581,Hippocampus,11799,B,,10000000.0
Autocuration,,1,,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,,CHEMBL615452,H,8,,,,,BAO_0000357,51,,582,,634,B,,
Autocuration,,1,,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,,CHEMBL615453,H,8,,,,,BAO_0000221,51,,583,Hippocampus,9995,B,,10000000.0
Autocuration,,1,,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,CHEMBL615454,H,8,,,,,BAO_0000221,51,,584,Hippocampus,9995,B,,10000000.0
Autocuration,,1,,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,,CHEMBL615455,H,8,,,,,BAO_0000221,51,,585,Hippocampus,9995,B,,10000000.0
Autocuration,,1,,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,CHEMBL615456,H,8,,,,,BAO_0000221,51,,586,Hippocampus,9995,B,,10000000.0
Autocuration,,1,,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,,CHEMBL615457,H,8,,,,,BAO_0000221,51,,587,Hippocampus,9995,B,,10000000.0
Expert,,1,,,In vivo binding affinity towards [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus.,,CHEMBL615458,H,8,,,,,BAO_0000218,51,,588,Hippocampus,12210,B,,10000000.0
Expert,,1,,,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,,CHEMBL615459,H,8,,,,,BAO_0000221,51,,589,Hippocampus,13311,B,,10000000.0
Expert,,1,CHO,,"Tested in vitro for the inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor, expressed in cloned CHO cells.",,CHEMBL615460,D,9,,449.0,Homo sapiens,9606.0,BAO_0000219,51,,590,,2331,B,,
Autocuration,,1,,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig,,CHEMBL615461,H,8,,,Cavia porcellus,10141.0,BAO_0000019,51,,591,,1375,F,,
Autocuration,,1,,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig; NT means not tested,,CHEMBL615462,H,8,,,Cavia porcellus,10141.0,BAO_0000019,51,,592,,1375,F,,
Autocuration,,1,,,Effect on forskolin stimulated adenylate cyclase activity at 5-hydroxytryptamine 1A receptor of guinea pig hippocampus.,,CHEMBL615463,H,8,,,Cavia porcellus,10141.0,BAO_0000221,51,,593,Hippocampus,11574,F,,10000000.0
Autocuration,,1,,,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,,CHEMBL615464,H,8,,,Cavia porcellus,10141.0,BAO_0000221,51,,594,Ileum,12867,B,,2116.0
Autocuration,,1,,,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,,CHEMBL615465,H,8,,,Cavia porcellus,10141.0,BAO_0000221,51,,595,Ileum,12867,B,,2116.0
Autocuration,,1,,,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,,CHEMBL615466,H,8,,,Cavia porcellus,10141.0,BAO_0000221,51,,596,Ileum,12867,B,,2116.0
Autocuration,,1,,,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,,CHEMBL615467,H,8,,,Cavia porcellus,10141.0,BAO_0000221,51,,597,Ileum,12867,B,,2116.0
Autocuration,,1,,,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,,CHEMBL615468,H,8,,,Cavia porcellus,10141.0,BAO_0000221,51,,598,Ileum,12867,B,,2116.0
Autocuration,,1,,,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor; Inactive at dose level of 1.0 uM,,CHEMBL615469,H,8,,,Cavia porcellus,10141.0,BAO_0000221,51,,599,Ileum,12867,B,,2116.0
Autocuration,,1,,,Binding affinity against 5-hydroxytryptamine 1A receptor,,CHEMBL615470,H,8,,,Cavia porcellus,10141.0,BAO_0000357,51,,600,,11574,B,,
Autocuration,,1,,,Compound is evaluated for in vitro receptor binding affinity against 5-hydroxytryptamine 1A receptor,,CHEMBL615471,H,8,,,Cavia porcellus,10141.0,BAO_0000357,51,,601,,13114,B,,
Autocuration,,1,,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor,,CHEMBL615472,H,8,,,Cavia porcellus,10141.0,BAO_0000357,51,,602,,13181,B,,
Autocuration,,1,,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,,CHEMBL883242,H,8,,,Cavia porcellus,10141.0,BAO_0000221,106,,603,Hippocampus,10639,B,,10000000.0
Autocuration,,1,,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,,CHEMBL615473,H,8,,,Cavia porcellus,10141.0,BAO_0000221,106,,604,Hippocampus,10639,F,,10000000.0
Autocuration,,1,CHO,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),,CHEMBL615474,H,8,,449.0,Cricetulus griseus,10029.0,BAO_0000218,11863,,605,,11883,B,,
Autocuration,,1,,,Fraction involved in salt bridge interactions with Asp3:11 part of the 5-hydroxytryptamine 1A receptor,,CHEMBL615475,H,8,,,,,BAO_0000357,51,,606,,17785,B,,
Autocuration,,1,HeLa,,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-HT 1A receptor in HeLa cells; value ranges from 85-370,,CHEMBL615476,H,8,,308.0,,,BAO_0000219,51,,607,,1558,F,,
Autocuration,,1,HeLa,,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1A receptor in HeLa cells; value ranges from 95-320,,CHEMBL615477,H,8,,308.0,,,BAO_0000219,51,,608,,1558,F,,
Autocuration,,1,,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,,CHEMBL615478,H,8,,,,,BAO_0000019,51,,609,,15740,F,,
Autocuration,,1,CHO,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,,CHEMBL615160,H,8,,449.0,,,BAO_0000219,51,,610,,17624,F,,
Expert,,1,CHO,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,,CHEMBL615161,H,8,,449.0,,,BAO_0000219,51,,611,,17624,F,,
Autocuration,,1,CHO,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=Not determined,,CHEMBL615162,H,8,,449.0,,,BAO_0000219,51,,612,,17624,F,,
Autocuration,,1,CHO,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=not determined,,CHEMBL615163,H,8,,449.0,,,BAO_0000219,51,,613,,17624,F,,
Expert,,1,CHO,,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,CHEMBL615164,H,8,,449.0,,,BAO_0000219,51,,614,,17624,B,,
Expert,,1,CHO,,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,CHEMBL615165,H,8,,449.0,,,BAO_0000219,51,,615,,17624,B,,
Autocuration,,1,CHO,,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells; nd=not determined,,CHEMBL615166,H,8,,449.0,,,BAO_0000219,51,,616,,17624,B,,
Autocuration,,1,,,In vitro potency at human 5-hydroxytryptamine 1A receptor in inhibiting forskolin-stimulated accumulation of intracellular cAMP,,CHEMBL615167,H,8,,,,,BAO_0000219,51,,617,,14256,F,,
Expert,,1,HeLa,,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,,CHEMBL615168,D,9,,308.0,Homo sapiens,9606.0,BAO_0000219,51,,618,,3445,B,,
Expert,,1,HeLa,,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells; Inverse,,CHEMBL615169,D,9,,308.0,Homo sapiens,9606.0,BAO_0000219,51,,619,,3445,B,,
Expert,,1,CHO,,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor,,CHEMBL615170,D,9,,449.0,Homo sapiens,9606.0,BAO_0000219,51,,620,,17200,B,,
Expert,,1,CHO,,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor; Not determined,,CHEMBL615171,D,9,,449.0,Homo sapiens,9606.0,BAO_0000219,51,,621,,17200,B,,
Autocuration,,1,,,Eudisimic ratio(ER) is the antilog of the defference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,,CHEMBL615694,H,8,,,,,BAO_0000019,51,,622,,15180,F,,
Autocuration,,1,,,Eudisimic ratio(ER) is the antilog of the difference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,,CHEMBL615695,H,8,,,,,BAO_0000019,51,,623,,15180,F,,
Autocuration,,1,,,"Percent of maximum effect on binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,CHEMBL615696,H,8,,,,,BAO_0000019,51,,624,,16026,F,,
Autocuration,,1,CHO,,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,,CHEMBL615697,H,8,,449.0,,,BAO_0000219,51,,625,,2759,F,,
Expert,,1,CHO,,Agonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),,CHEMBL859410,D,9,,449.0,Homo sapiens,9606.0,BAO_0000219,51,,626,,2759,F,,
Autocuration,,1,CHO,,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),,CHEMBL615841,H,8,,449.0,,,BAO_0000219,51,,627,,2759,F,,
Expert,,1,CHO,,Agonistic efficacy in adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),,CHEMBL615842,D,9,,449.0,Homo sapiens,9606.0,BAO_0000219,51,,628,,2759,F,,
Autocuration,,1,CHO,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,,CHEMBL835003,H,8,,449.0,,,BAO_0000219,51,,629,,2759,F,,
Autocuration,,1,CHO,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 1),,CHEMBL615843,H,8,,449.0,,,BAO_0000219,51,,630,,2759,F,,
Expert,,1,CHO,,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),,CHEMBL615979,D,9,,449.0,Homo sapiens,9606.0,BAO_0000219,51,,631,,2759,F,,
Autocuration,,1,CHO,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),,CHEMBL615980,H,8,,449.0,,,BAO_0000219,51,,632,,2759,F,,
Expert,,1,CHO,,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),,CHEMBL615981,D,9,,449.0,Homo sapiens,9606.0,BAO_0000219,51,,633,,2759,F,,
Expert,,1,,,Percent efficacy against cloned human 5-hydroxytryptamine 1A receptor normalized to the maximal 5-HT response,,CHEMBL615982,D,9,,,Homo sapiens,9606.0,BAO_0000019,51,,634,,3445,F,,
Expert,,1,,,"Agonist activity at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",,CHEMBL615983,D,9,,,Homo sapiens,9606.0,BAO_0000019,51,,635,,5272,F,,
Expert,,1,,,"Agonist activity at the 5-hydroxytryptamine 1A receptor in vitro using a [35S]GTP-gamma-S, No data",,CHEMBL615984,D,9,,,Homo sapiens,9606.0,BAO_0000019,51,,636,,5272,F,,
Expert,,1,,,"Agonist activity at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S,",,CHEMBL615985,D,9,,,Homo sapiens,9606.0,BAO_0000019,51,,637,,5272,F,,
Autocuration,,1,CHO,,Agonistic effect against 5-HT1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,,CHEMBL615986,H,8,,449.0,,,BAO_0000219,51,,638,,17624,F,,
Autocuration,,1,CHO,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,,CHEMBL615987,H,8,,449.0,,,BAO_0000219,51,,639,,17624,F,,
Autocuration,,1,CHO,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,,CHEMBL615988,H,8,,449.0,,,BAO_0000219,51,,640,,17624,F,,
Expert,,1,CHO,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,,CHEMBL615989,H,8,,449.0,,,BAO_0000219,51,,641,,17624,F,,
Autocuration,,1,CHO,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,,CHEMBL615990,H,8,,449.0,,,BAO_0000219,51,,642,,17624,F,,
Autocuration,,1,CHO,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=not determined,,CHEMBL615991,H,8,,449.0,,,BAO_0000219,51,,643,,17624,F,,
Autocuration,,1,CHO,,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,,CHEMBL615992,H,8,,449.0,,,BAO_0000219,51,,644,,17624,F,,
Autocuration,,1,CHO,,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=Not determined,,CHEMBL615993,H,8,,449.0,,,BAO_0000219,51,,645,,17624,F,,
Expert,,1,CHO,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,,CHEMBL615994,H,8,,449.0,,,BAO_0000219,51,,646,,17624,F,,
Autocuration,,1,CHO,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=not determined,,CHEMBL615995,H,8,,449.0,,,BAO_0000219,51,,647,,17624,F,,
Autocuration,,1,CHO,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,,CHEMBL615996,H,8,,449.0,,,BAO_0000219,51,,648,,17624,F,,
Autocuration,,1,CHO,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35]GTPgammaS as radioligand in CHO cells relative to 5-HT; nd=Not determined,,CHEMBL615997,H,8,,449.0,,,BAO_0000219,51,,649,,17624,F,,
Autocuration,,1,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,CHEMBL615998,H,8,,,,,BAO_0000019,51,,650,,6563,F,,
Autocuration,,1,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,CHEMBL615999,H,8,,,,,BAO_0000019,51,,651,,6563,F,,
Autocuration,,1,,,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,,CHEMBL616000,H,8,,,,,BAO_0000019,51,,652,,6563,F,,
Autocuration,,1,HEK293,,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,CHEMBL616001,H,8,,722.0,,,BAO_0000219,51,,653,,17296,F,,
Expert,,1,,,"Evaluated for stimulation at 1 uM concentration expressed as percent of the maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine",,CHEMBL616002,D,9,,,Homo sapiens,9606.0,BAO_0000019,51,,654,,6876,F,,
Expert,,1,,,"Stimulation of percent maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine at 1 uM; nd = not determined",,CHEMBL616003,H,8,,,,,BAO_0000019,51,,655,,6876,F,,
Expert,,1,,,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor,,CHEMBL616004,D,9,,,Homo sapiens,9606.0,BAO_0000019,51,,656,,5272,F,,
Expert,,1,,,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor; No data,,CHEMBL616005,D,9,,,Homo sapiens,9606.0,BAO_0000019,51,,657,,5272,F,,
Autocuration,,1,,,"Maximal response as a result of 5-HT1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,CHEMBL616006,H,8,,,,,BAO_0000019,51,,658,,5548,F,,
Expert,,1,,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding",,CHEMBL616007,H,8,,,,,BAO_0000019,51,,659,,5548,F,,
Autocuration,,1,,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,CHEMBL616008,H,8,,,,,BAO_0000019,51,,660,,5548,F,,
Autocuration,,1,,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,CHEMBL616009,H,8,,,,,BAO_0000019,51,,661,,5548,F,,
Expert,,1,,,"Maximal stimulation of expressed human 5-hydroxytryptamine 1A receptor assayed by [35S]GTP-gamma-S, binding",,CHEMBL616010,H,8,,,,,BAO_0000019,51,,662,,5929,F,,
Expert,,1,,,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND means not determined",,CHEMBL616011,D,9,,,Homo sapiens,9606.0,BAO_0000019,51,,663,,5929,F,,
Expert,,1,,,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND=Not determined",,CHEMBL615740,D,9,,,Homo sapiens,9606.0,BAO_0000019,51,,664,,5929,F,,
Autocuration,,1,,,"Maximal stimulation was expressed as percentage of the maximal 5-HT response in the [35S]GTP-gamma-S, binding assay on 5-hydroxytryptamine 1A receptor",,CHEMBL615741,H,8,,,,,BAO_0000019,51,,665,,16245,F,,
Expert,,1,,,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",,CHEMBL615742,H,8,,,,,BAO_0000019,51,,666,,5640,F,,
Autocuration,,1,,,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Emin (%): not determined",,CHEMBL615743,H,8,,,,,BAO_0000019,51,,667,,5640,F,,
Autocuration,,1,CHO,,Antagonist activity was measured against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay,,CHEMBL615744,H,8,,449.0,,,BAO_0000219,51,,668,,14509,F,,
Expert,,1,CHO,,Antagonist activity against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay.,,CHEMBL615745,H,8,,449.0,,,BAO_0000219,51,,669,,14509,F,,
Autocuration,,1,,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,CHEMBL615746,H,8,,,,,BAO_0000357,51,,670,,15331,B,,
Autocuration,,1,,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,CHEMBL615747,H,8,,,,,BAO_0000357,51,,671,,15331,B,,
Autocuration,,1,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,CHEMBL615748,H,8,,,,,BAO_0000019,51,,672,,6563,F,,
Autocuration,,1,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay; NA indicates not available",,CHEMBL615749,H,8,,,,,BAO_0000019,51,,673,,6563,F,,
Autocuration,,1,,,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,,CHEMBL615750,H,8,,,,,BAO_0000019,51,,674,,6563,F,,
Expert,,1,,,Forskolin stimulated cAMP assessment of agonist activity for 5-hydroxytryptamine 1A receptor,,CHEMBL616259,D,9,,,Homo sapiens,9606.0,BAO_0000019,51,,675,,6563,F,,
Autocuration,,1,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,CHEMBL616260,H,8,,,,,BAO_0000019,51,,676,,6563,F,,
Expert,,1,,,Antagonism of 5-hydroxytryptamine 1A receptor determined in vitro,,CHEMBL616261,D,9,,,Homo sapiens,9606.0,BAO_0000019,51,,677,,5272,F,,
Expert,,1,,,"Antagonism of 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",,CHEMBL616262,D,9,,,Homo sapiens,9606.0,BAO_0000019,51,,678,,5272,F,,
Expert,,1,,,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",,CHEMBL616263,D,9,,,Homo sapiens,9606.0,BAO_0000019,51,,679,,5272,F,,
Expert,,1,,,Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro; No data,,CHEMBL616264,D,9,,,Homo sapiens,9606.0,BAO_0000019,51,,680,,5272,F,,
Expert,,1,,,Antagonism at the 5-hydroxytryptamine 1A receptor in vitro,,CHEMBL616265,D,9,,,Homo sapiens,9606.0,BAO_0000019,51,,681,,5272,F,,
Expert,,1,,,"Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",,CHEMBL616266,D,9,,,Homo sapiens,9606.0,BAO_0000019,51,,682,,5272,F,,
Expert,,1,,,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",,CHEMBL616267,D,9,,,Homo sapiens,9606.0,BAO_0000019,51,,683,,5272,F,,
Expert,,1,,,Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro; No data,,CHEMBL616268,D,9,,,Homo sapiens,9606.0,BAO_0000019,51,,684,,5272,F,,
Expert,,1,,,Inhibition of human 5-hydroxytryptamine 1A receptor,,CHEMBL616269,D,9,,,Homo sapiens,9606.0,BAO_0000357,51,,685,,16146,B,,
Autocuration,,1,CHO,,Binding affinity against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,CHEMBL884528,H,8,,449.0,,,BAO_0000219,51,,686,,17624,B,,
Expert,,1,HEK293,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor alpha expressed in HEK 293 cells,,CHEMBL616270,D,9,,722.0,,,BAO_0000219,105,,687,,13706,B,,
Autocuration,,1,CHO,,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1A receptor stably expressed in CHO cells,,CHEMBL616271,H,8,,449.0,,,BAO_0000219,51,,688,,15250,B,,
Autocuration,,1,CHO,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,,CHEMBL616272,H,8,,449.0,,,BAO_0000219,51,,689,,17624,F,,
Expert,,1,,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in human CYP3A4 assay,,CHEMBL616273,H,8,,,,,BAO_0000357,51,,690,,6861,B,,
Expert,,1,,,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,,CHEMBL616274,D,9,,,Homo sapiens,9606.0,BAO_0000357,51,,691,,17200,B,,
Autocuration,,1,CHO,,Inhibition concentration against 5-HT 1A receptor using cAMP as radioligand in CHO cells,,CHEMBL616275,H,8,,449.0,,,BAO_0000219,51,,692,,17624,B,,
Autocuration,,1,CHO,,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,CHEMBL616276,H,8,,449.0,,,BAO_0000219,51,,693,,17624,B,,
Autocuration,,1,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,,CHEMBL616277,U,0,,,Rattus norvegicus,10116.0,BAO_0000218,22226,,694,,12058,F,In vivo,
Autocuration,,1,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration; Inactive,,CHEMBL616278,U,0,,,Rattus norvegicus,10116.0,BAO_0000218,22226,,695,,12058,F,In vivo,
Autocuration,,1,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration,,CHEMBL616279,U,0,,,Rattus norvegicus,10116.0,BAO_0000218,22226,,696,,12058,F,In vivo,
Autocuration,,1,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,,CHEMBL616280,U,0,,,Rattus norvegicus,10116.0,BAO_0000218,22226,,697,,12058,F,In vivo,
Autocuration,,1,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Partial response at the highest dose tested,,CHEMBL616281,U,0,,,Rattus norvegicus,10116.0,BAO_0000218,22226,,698,,12058,F,In vivo,
Autocuration,,1,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,,CHEMBL616282,U,0,,,Rattus norvegicus,10116.0,BAO_0000218,22226,,699,,12058,F,In vivo,
Autocuration,,1,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration,,CHEMBL616283,U,0,,,Rattus norvegicus,10116.0,BAO_0000218,22226,,700,,12058,F,In vivo,
Autocuration,,1,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration; Inactive,,CHEMBL616284,U,0,,,Rattus norvegicus,10116.0,BAO_0000218,22226,,701,,12058,F,In vivo,
Autocuration,,1,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration,,CHEMBL616285,U,0,,,Rattus norvegicus,10116.0,BAO_0000218,22226,,702,,12058,F,In vivo,
Autocuration,,1,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; Inactive,,CHEMBL616286,U,0,,,Rattus norvegicus,10116.0,BAO_0000218,22226,,703,,12058,F,In vivo,
Autocuration,,1,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; partial response at the highest dose tested,,CHEMBL616287,U,0,,,Rattus norvegicus,10116.0,BAO_0000218,22226,,704,,12058,F,In vivo,
Autocuration,,1,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration,,CHEMBL616288,U,0,,,Rattus norvegicus,10116.0,BAO_0000218,22226,,705,,12058,F,In vivo,
Autocuration,,1,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Inactive,,CHEMBL616289,U,0,,,Rattus norvegicus,10116.0,BAO_0000218,22226,,706,,12058,F,In vivo,
Autocuration,,1,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Partial response at the highest dose tested,,CHEMBL615610,U,0,,,Rattus norvegicus,10116.0,BAO_0000218,22226,,707,,12058,F,In vivo,
Autocuration,,1,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration,,CHEMBL615611,U,0,,,Rattus norvegicus,10116.0,BAO_0000218,22226,,708,,12058,F,In vivo,
Autocuration,,1,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Inactive,,CHEMBL615612,U,0,,,Rattus norvegicus,10116.0,BAO_0000218,22226,,709,,12058,F,In vivo,
Autocuration,,1,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Partial response at the highest dose tested,,CHEMBL615613,U,0,,,Rattus norvegicus,10116.0,BAO_0000218,22226,,710,,12058,F,In vivo,
Autocuration,,1,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; partial response at the highest dose tested,,CHEMBL615614,U,0,,,Rattus norvegicus,10116.0,BAO_0000218,22226,,711,,12058,F,In vivo,
Autocuration,,1,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,,CHEMBL615615,U,0,,,Rattus norvegicus,10116.0,BAO_0000218,22226,,712,,12058,F,In vivo,
Autocuration,,1,,,Affinity in displacing [125I](R)-DOI from rat cortical homogenate 5-HT2 receptor.,,CHEMBL615616,H,4,,,,,BAO_0000019,105093,,713,,11440,B,,
Autocuration,,1,,,Binding affinity towards 5-HT 7 receptor in rat hypothalamus membranes using [3H]5-CT as radioligand,,CHEMBL615617,H,8,,,,,BAO_0000249,11923,,714,Hypothalamus,6238,B,,1898.0
Autocuration,,1,,,Inhibitory activity against 5-HT1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data,,CHEMBL615618,H,8,,,,,BAO_0000019,10577,,715,,10046,B,,
Autocuration,,1,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data.,,CHEMBL615619,H,8,,,,,BAO_0000019,10577,,716,,10046,B,,
Expert,,1,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,,CHEMBL615620,H,8,,,,,BAO_0000019,10577,,717,,10046,B,,
Autocuration,,1,,,"Inhibitory activity against human whole blood, LTB4 5-lipoxygenase was evaluated",,CHEMBL615621,H,8,,,,,BAO_0000357,55,,718,,167,B,,
Autocuration,,1,,,"Inhibitory activity against intact human PMNL, LTB4 5-lipoxygenase was evaluated",,CHEMBL615622,H,8,,,,,BAO_0000357,55,,719,,167,B,,
Autocuration,,1,,,Compound was evaluated for the inhibition of 5-LO (lipoxygenase),,CHEMBL615623,H,8,,,,,BAO_0000019,12166,,720,,11520,F,,
Autocuration,,1,,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,CHEMBL615624,H,8,,,,,BAO_0000019,12166,,721,,11520,F,,
Autocuration,,1,,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,CHEMBL615625,H,8,,,,,BAO_0000019,12166,,722,,11520,F,,
Autocuration,,1,,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,CHEMBL767045,H,8,,,,,BAO_0000019,12166,,723,,11520,F,,
Autocuration,,1,,,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN,,CHEMBL615626,H,8,,,Cavia porcellus,10141.0,BAO_0000019,55,,724,,135,F,,
Autocuration,,1,,,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN; not active at the highest concentration (3 ug/mL) tested; No activity,,CHEMBL615627,H,8,,,Cavia porcellus,10141.0,BAO_0000019,55,,725,,135,F,,
Autocuration,,1,,,The compound was tested for inhibitory activity against 5-Lipoxygenase in guinea pig polymorphonuclear leukocytes,,CHEMBL615628,H,8,,,Cavia porcellus,10141.0,BAO_0000019,55,,726,,11311,B,,
Autocuration,,1,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,,CHEMBL615629,H,8,,,Cavia porcellus,10141.0,BAO_0000357,55,,727,,10193,B,,
Expert,,1,,,Inhibitory concentration against 5-lipoxygenase from human whole blood,,CHEMBL615630,D,9,,,Homo sapiens,9606.0,BAO_0000357,55,,728,,12281,B,,
Autocuration,,1,,,The compound was tested for inhibitory activity against 5-Lipoxygenase in human polymorphonuclear leukocytes[PMNS],,CHEMBL615631,H,8,,,,,BAO_0000219,55,,729,,11311,B,,
Autocuration,,1,,,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,,CHEMBL615632,H,8,,,,,BAO_0000218,17087,,730,,12576,F,,
Autocuration,,1,,,Inhibitory concentration against 5-lipoxygenase from mouse macrophage,,CHEMBL615633,H,8,,,,,BAO_0000357,17087,,731,,12281,B,,
Autocuration,,1,,,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,,CHEMBL615634,H,8,,,,,BAO_0000218,17087,,732,,12576,F,,
Expert,,1,,,Inhibition of arachidonate 5-lipoxygenase purified from porcine leukocytes.,,CHEMBL615635,H,8,,,Sus scrofa,9823.0,BAO_0000019,55,,733,,11089,B,,
Expert,,1,,,In vitro inhibition of rat 5-Lipoxygenase,,CHEMBL615636,H,8,,,,,BAO_0000357,12166,,734,,11006,B,,
Expert,,1,,,Inhibitory activity against 5-Lipoxygenase,,CHEMBL615637,D,9,,,Rattus norvegicus,10116.0,BAO_0000357,12166,,735,,11481,B,,
Expert,,1,RBL-1,,Inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells,,CHEMBL615638,H,8,,702.0,,,BAO_0000219,12166,,736,,10864,B,,
Autocuration,,1,RBL-1,,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),,CHEMBL615639,H,8,,702.0,,,BAO_0000219,12166,,737,,3595,B,,
Autocuration,,1,RBL-1,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat RBL-1,,CHEMBL615640,H,8,,702.0,,,BAO_0000219,12166,,738,,11311,B,,
Autocuration,,1,,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat blood,,CHEMBL615796,H,8,,,,,BAO_0000019,12166,,739,,11311,B,,
Autocuration,,1,,,The compound was tested for inhibitory activity against 5-Lipoxygenase receptor in rat polymorphonuclear leukocytes[PMNS],,CHEMBL615845,H,8,,,,,BAO_0000219,12166,,740,,11311,B,,
Autocuration,,1,,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,,CHEMBL615846,H,8,,,,,BAO_0000357,12166,,741,,11006,B,,
Autocuration,,1,RBL-1,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,,CHEMBL615847,H,8,,702.0,,,BAO_0000219,12166,,742,,3595,B,,
Autocuration,,1,,,The compound was tested for inhibition of isolated 5-Lipoxygenase,,CHEMBL615848,H,8,,,,,BAO_0000357,12166,,743,,11311,B,,
Autocuration,,1,,,Ratio of IC50 against 5-LO and COX,,CHEMBL615849,U,0,,,Rattus norvegicus,10116.0,BAO_0000019,22226,,744,,11481,B,,
Autocuration,,1,,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,,CHEMBL615850,H,8,,,,,BAO_0000357,12166,,745,,11006,B,,
Autocuration,,1,,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM; range is 20-35%,,CHEMBL615851,H,8,,,,,BAO_0000357,12166,,746,,11006,B,,
Autocuration,,1,,,The compound was tested for inhibition against 5-Lipoxygenase in rat polymorphonuclear leukocytes at 10 uM concentration,,CHEMBL615852,H,8,,,,,BAO_0000219,12166,,747,,11311,B,,
Autocuration,,1,,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) ex vivo,,CHEMBL615853,H,8,,,,,BAO_0000019,12166,,748,,11006,F,,
Autocuration,,1,,,Compound was tested for the inhibition of type 2 5-alpha-reductase of human prostates,,CHEMBL884527,H,8,,,,,BAO_0000357,120,,749,Prostate gland,4288,B,,2367.0
Autocuration,,1,,,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-4 M inhibitory concentration,,CHEMBL872871,U,0,,,Columba livia,8932.0,BAO_0000019,22226,,750,,7587,B,,
Autocuration,,1,,,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-5 M inhibitory concentration,,CHEMBL615854,U,0,,,Columba livia,8932.0,BAO_0000019,22226,,751,,7587,B,,
Autocuration,,1,,,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme.,,CHEMBL767046,U,0,,,Columba livia,8932.0,BAO_0000019,22226,,752,,7587,B,,
Autocuration,,1,,,Compound was evaluated for the inhibition of 5-aminoimidazole-4-carboxamide ribonucleotide transformylase obtained from human at 100 uM,,CHEMBL615855,H,8,,,,,BAO_0000357,10732,,753,,11249,B,,
Expert,,1,,,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT); NT = Not Tested,,CHEMBL615856,D,9,,,Rattus norvegicus,10116.0,BAO_0000019,12198,,754,,8003,F,,
Expert,,1,,,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),,CHEMBL615857,D,9,,,Rattus norvegicus,10116.0,BAO_0000019,12198,,755,,8003,F,,
Expert,,1,,,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),,CHEMBL615858,D,9,,,Rattus norvegicus,10116.0,BAO_0000019,12198,,756,,8003,F,,
Expert,,1,,,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,,CHEMBL615859,H,8,,,,,BAO_0000221,10576,,757,Hippocampus,12416,B,,10000000.0
Autocuration,,1,,,Binding affinity towards human 5-hydroxytryptamine 1 receptor,,CHEMBL615860,H,8,,,,,BAO_0000357,51,,758,,16293,B,,
Autocuration,,1,,,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,,CHEMBL615861,U,0,,,Oryctolagus cuniculus,9986.0,BAO_0000019,22226,,759,,13047,B,,
Autocuration,,1,,,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,,CHEMBL615862,U,0,,,Oryctolagus cuniculus,9986.0,BAO_0000019,22226,,760,,13047,B,,
Autocuration,,1,,,Binding affinity against 5-hydroxytryptamine 1D receptor using rabbit saphenous vein assay.,,CHEMBL615863,U,0,,,Oryctolagus cuniculus,9986.0,BAO_0000019,22226,,761,,13047,B,,
Autocuration,,1,,,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,,CHEMBL615864,U,0,,,Oryctolagus cuniculus,9986.0,BAO_0000019,22226,,762,,13047,B,,
Autocuration,,1,,,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,,CHEMBL615865,H,4,,,,,BAO_0000221,104744,,763,Hippocampus,10085,B,,10000000.0
Autocuration,,1,,,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,,CHEMBL615866,H,4,,,,,BAO_0000221,104744,,764,Hippocampus,10085,B,,10000000.0
Autocuration,,1,,,Ability to bind at serotonin 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,,CHEMBL615867,H,4,,,,,BAO_0000221,104744,,765,Hippocampus,10085,B,,10000000.0
Autocuration,,1,,,Ability to inhibit binding of titreated serotonin to the 5-hydroxytryptamine 1 receptor in rat brain frontal cortex membranes,Membranes,CHEMBL615868,H,4,,,,,BAO_0000249,104744,,766,,9841,B,,
Autocuration,,1,,,Binding affinity towards 5-hydroxytryptamine 1 receptor in brain cortical membranes of rat,,CHEMBL615869,D,5,,,Rattus norvegicus,10116.0,BAO_0000249,104744,,767,,8822,B,,
Autocuration,,1,,,Binding affinity towards 5-hydroxytryptamine 1 receptor in rat frontal cortex homogenates using [3H]5-HT as a radioligand,,CHEMBL615870,D,5,,,Rattus norvegicus,10116.0,BAO_0000019,104744,,768,,9806,B,,
Autocuration,,1,,,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as a radioligand from rat frontal cortex homogenates,,CHEMBL615871,D,5,,,Rattus norvegicus,10116.0,BAO_0000019,104744,,769,,9806,B,,
Autocuration,,1,,,Binding affinity towards 5-hydroxytryptamine 1 receptor was measured using radioligand ([3H]5-HT) binding assay,,CHEMBL615872,H,4,,,,,BAO_0000224,104744,,770,,8868,B,,
Autocuration,,1,,,Binding affinity towards hippocampus 5-hydroxytryptamine 1 receptor was measured using radioligand [3H]5-HT,,CHEMBL833492,H,4,,,,,BAO_0000221,104744,,771,Hippocampus,9036,B,,10000000.0
Autocuration,,1,,,Compound was evaluated for the inhibition of [3H]5-HT (concentration of 12 nM) specific binding to rat hippocampus,,CHEMBL615873,H,4,,,,,BAO_0000221,104744,,772,Hippocampus,11374,B,,10000000.0
Autocuration,,1,,,Inhibitory activity against 5-hydroxytryptamine 1 receptor by 3H ligand binding experiments.,,CHEMBL615479,H,4,,,,,BAO_0000224,104744,,773,,10881,B,,
Autocuration,,1,,,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat,,CHEMBL615480,H,4,,,,,BAO_0000019,104744,,774,,8822,B,,
Autocuration,,1,,,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat cortical membrane homogenates using radioligand ([3H]5-HT) binding assay.,,CHEMBL615481,D,5,,,Rattus norvegicus,10116.0,BAO_0000249,104744,,775,,9806,B,,
Autocuration,,1,,,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,CHEMBL872869,H,4,,,,,BAO_0000019,104744,,776,,15463,B,,
Autocuration,,1,,,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,CHEMBL615482,H,4,,,,,BAO_0000019,104744,,777,,15463,B,,
Autocuration,,1,,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,,CHEMBL615483,H,4,,,,,BAO_0000221,104744,,778,Brain,14542,B,,955.0
Autocuration,,1,,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,,CHEMBL615484,H,4,,,,,BAO_0000221,104744,,779,Brain,14542,B,,955.0
Autocuration,,1,,,Percent inhibition of 5-hydroxytryptamine 1 receptor from rat cortex membrane using [3H]- serotonin as radioligand at 33 uM,,CHEMBL615485,H,4,,,,,BAO_0000019,104744,,780,,8569,B,,
Autocuration,,1,,,Inhibition of [3H]5-HT radioligand binding against 5-hydroxytryptamine 1 receptor,,CHEMBL615486,D,5,,,Rattus norvegicus,10116.0,BAO_0000224,104744,,781,,10062,B,,
Autocuration,,1,,,Ancillary Binding affinity towards rat 5-hydroxytryptamine 1 receptor,,CHEMBL615487,H,4,,,,,BAO_0000224,104744,,782,,4771,B,,
Autocuration,,1,,,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,CHEMBL615488,H,4,,,,,BAO_0000224,104744,,783,,10062,B,,
Autocuration,,1,,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,CHEMBL615489,H,4,,,,,BAO_0000224,104744,,784,,10062,B,,
Autocuration,,1,,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,CHEMBL615389,H,4,,,,,BAO_0000224,104744,,785,,10062,B,,
Autocuration,,1,,,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,,CHEMBL615390,H,4,,,,,BAO_0000019,104744,,786,,15463,B,,
Autocuration,,1,,,Binding affinity towards central 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,,CHEMBL615391,H,4,,,,,BAO_0000019,104744,,787,,15463,B,,
Autocuration,,1,,,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined,,CHEMBL615392,H,4,,,,,BAO_0000224,104744,,788,,9098,B,,
Autocuration,,1,,,Affinity for 5-hydroxytryptamine 1 receptor,,CHEMBL615393,U,0,,,Rattus norvegicus,10116.0,BAO_0000019,22226,,789,,3070,B,,
Autocuration,,1,,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex,,CHEMBL615394,H,4,,,,,BAO_0000221,104744,,790,Brain,14542,B,,955.0
Autocuration,,1,,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,,CHEMBL615395,H,4,,,,,BAO_0000221,104744,,791,Brain,14542,B,,955.0
Autocuration,,1,,,Compound was evaluated for 5-hydroxytryptamine 1 receptor binding,,CHEMBL615396,H,4,,,,,BAO_0000224,104744,,792,,6398,B,,
Autocuration,,1,,,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 1 receptor in rat brain using [3H]HT radioligand assay,,CHEMBL615397,H,4,,,,,BAO_0000221,104744,,793,Brain,1344,B,,955.0
Autocuration,,1,,,Displacement of binding of [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,CHEMBL615398,H,4,,,,,BAO_0000019,104744,,794,,11963,B,,
Autocuration,,1,,,Displacement of [3H]spiperone from 5-hydroxytryptamine 1 receptor of rat cortex,,CHEMBL615399,U,0,,,Rattus norvegicus,10116.0,BAO_0000019,22226,,795,,8908,B,,
Autocuration,,1,,,Evaluated for binding affinity towards rat cortical membranes at 5-hydroxytryptamine 1 receptor binding site by using [3H]-5-HT as a radioligand.,,CHEMBL615400,H,4,,,,,BAO_0000019,104744,,796,,9098,B,,
Autocuration,,1,,,Binding affinity for 5-hydroxytryptamine 1 receptor of rat prefrontal cortex,,CHEMBL615401,D,5,,,Rattus norvegicus,10116.0,BAO_0000019,104744,,797,,8841,B,,
Autocuration,,1,,,Displacement of [3H]5-HT from 5-hydroxytryptamine 1 receptor of rat cortical membrane homogenates,,CHEMBL615402,U,0,,,Rattus norvegicus,10116.0,BAO_0000019,22226,,798,,8814,B,,
Autocuration,,1,,,The ability to inhibit [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cortex,,CHEMBL615403,H,4,,,,,BAO_0000019,104744,,799,,11752,B,,
Autocuration,,1,,,The binding affinity was measured on serotonin 5-hydroxytryptamine 1 receptor in rat brain tissue,,CHEMBL615404,H,4,,,,,BAO_0000221,104744,,800,Brain,11642,B,,955.0
Autocuration,,1,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1 receptor by displacing [3H]5-HT radioligand in rat cerebral cortex,,CHEMBL615781,H,4,,,,,BAO_0000019,104744,,801,,11642,B,,
Autocuration,,1,,,Tested for 5-hydroxytryptamine 1 receptor binding ability by displacement of [3H]5-HT from rat brain synaptosomes,,CHEMBL615782,H,4,,,,,BAO_0000220,104744,,802,Brain,9231,B,,955.0
Autocuration,,1,,,Inhibition constant (1 uM) was measured on 5-hydroxytryptamine 1 receptor/uptake using [3H]- serotonin as radioligand in rat brain cortex.,,CHEMBL615783,H,4,,,,,BAO_0000221,104744,,803,Brain,11351,B,,955.0
Autocuration,,1,,,Compound was tested for binding affinity against 5-HT1 receptor,,CHEMBL873481,U,0,,,,,BAO_0000019,22226,,804,,4639,B,,
Autocuration,,1,,,Inhibitory concentration against 5-hydroxytryptamine 1 receptor,,CHEMBL615784,U,0,,,,,BAO_0000019,22226,,805,,1205,B,,
Expert,,1,,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,,CHEMBL615785,H,8,,,,,BAO_0000357,10576,,806,,10025,B,,
Autocuration,,1,,,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",,CHEMBL615786,H,8,,,,,BAO_0000249,10576,,807,,13241,F,,
Autocuration,,1,,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,,CHEMBL615787,H,8,,,,,BAO_0000218,10576,,808,,16245,F,In vivo,
Autocuration,,1,,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,,CHEMBL615788,H,8,,,,,BAO_0000218,10576,,809,,16245,F,In vivo,
Autocuration,,1,,,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor,,CHEMBL767044,H,8,,,,,BAO_0000019,10576,,810,,12438,F,,
Autocuration,,1,,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,,CHEMBL615789,H,8,,,,,BAO_0000218,10576,,811,,16245,F,In vivo,
Autocuration,,1,,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,,CHEMBL615790,H,8,,,,,BAO_0000218,10576,,812,,16245,F,In vivo,
Autocuration,,1,,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats,,CHEMBL615813,H,8,,,,,BAO_0000019,10576,,813,,15740,F,,
Autocuration,,1,,,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 10 uM concentration,,CHEMBL615814,H,8,,,,,BAO_0000219,10576,,814,,15535,F,,
Expert,,1,,,Percent inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation in GH4ZD10 cells expressing 5-HT1A receptor at 50 uM relative to 5-HT,,CHEMBL615815,H,8,,,,,BAO_0000219,51,,815,,15535,F,,
Autocuration,,1,,,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 50 uM concentration; No effect,,CHEMBL615816,H,8,,,,,BAO_0000219,10576,,816,,15535,F,,
Expert,,1,,,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes expressed as Hill values,,CHEMBL615817,H,8,,,,,BAO_0000249,10576,,817,,9888,B,,
Autocuration,,1,,,Ability to bind at 5-hydroxytryptamine 1A receptor of rat hippocampus by displacing [3H]8-OH-DPAT,,CHEMBL615818,H,8,,,,,BAO_0000221,10576,,818,Hippocampus,10085,B,,10000000.0
Autocuration,,1,,,Ability to bind at serotonin 5-hydroxytryptamine 1A receptors of rat hippocampus by displacing [3H]8-OH-DPAT,,CHEMBL615819,H,8,,,,,BAO_0000221,10576,,819,Hippocampus,10085,B,,10000000.0
Expert,,1,,,Binding affinity against 5-hydroxytryptamine 1A receptor (5-HT1A) by displacement of [3H]8-OH-DPAT from rat hippocampus membranes,Membranes,CHEMBL615820,H,8,,,,,BAO_0000249,10576,,820,,17331,B,,
Expert,,1,,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]8-OH-DPAT,,CHEMBL615821,D,9,,,Rattus norvegicus,10116.0,BAO_0000221,10576,,821,Hippocampus,10845,B,,10000000.0
Expert,,1,,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,,CHEMBL615822,D,9,,,Rattus norvegicus,10116.0,BAO_0000221,10576,,822,Hippocampus,10845,B,,10000000.0
Expert,,1,,,Binding affinity against 5-hydroxytryptamine 1A receptor using in rat hippocampal tissue using [3H]8-OH-DPAT as radioligand,,CHEMBL615823,H,8,,,,,BAO_0000221,10576,,823,Hippocampus,10845,B,,10000000.0
Expert,,1,,,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor; IA-Inactive,,CHEMBL615824,D,9,,,Rattus norvegicus,10116.0,BAO_0000221,10576,,824,Hippocampus,10845,B,,10000000.0
Expert,,1,,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,,CHEMBL615825,D,9,,,Rattus norvegicus,10116.0,BAO_0000221,10576,,825,Hippocampus,10845,B,,10000000.0
Expert,,1,,,Binding affinity towards rat 5-hydroxytryptamine 1A receptor was evaluated using [3H]8-OH-DPAT as radioligand,,CHEMBL615826,H,8,,,,,BAO_0000357,10576,,826,,13730,B,,
Expert,,1,,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using [3H]8-OH-DPAT as radioligand,,CHEMBL615827,H,8,,,,,BAO_0000249,10576,,827,,13508,B,,
Expert,,1,,,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus membrane using [3H]8-OH-DPAT as radioligand,,CHEMBL615828,H,8,,,,,BAO_0000249,10576,,828,Hippocampus,13508,B,,10000000.0
Expert,,1,,,Binding affinity by measuring displacement of [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,CHEMBL615829,H,8,,,,,BAO_0000221,10576,,829,Hippocampus,12073,B,,10000000.0
Autocuration,,1,,,Binding affinity to 5-hydroxytryptamine 1A receptor of rat hippocampus with [3H]8-OH-DPAT as radioligand,,CHEMBL615830,H,8,,,,,BAO_0000221,10576,,830,Hippocampus,4671,B,,10000000.0
Expert,,1,,,Binding affinity towards serotonin 5-HT1A receptor was determined in rat hippocampus using [3H]8-OH-DPAT as ligand,,CHEMBL615831,H,8,,,,,BAO_0000221,10576,,831,Hippocampus,13631,B,,10000000.0
Autocuration,,1,,,Binding affinity was measured against serotonin 5-hydroxytryptamine 1A receptor,,CHEMBL615832,H,8,,,,,BAO_0000357,10576,,832,,12438,B,,
Autocuration,,1,,,Binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH- DPAT as radioligand,,CHEMBL615833,H,8,,,,,BAO_0000019,10576,,833,,10483,B,,
Autocuration,,1,,,Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]-8-OH- DPAT as radioligand,,CHEMBL615834,H,8,,,,,BAO_0000221,10576,,834,Hippocampus,10483,B,,10000000.0
Intermediate,,1,,,Binding affinity against 5-hydroxytryptamine 1A (5-HT1A) receptor in rat hippocampus membranes,,CHEMBL615835,H,8,,,,,BAO_0000249,10576,,835,,12352,B,,
Autocuration,,1,,,Binding affinity was measured at the serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampal membrane.,,CHEMBL615836,H,8,,,,,BAO_0000249,10576,,836,Hippocampus,14732,B,,10000000.0
Expert,,1,,,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand.,,CHEMBL615837,D,9,,,Rattus norvegicus,10116.0,BAO_0000019,10576,,837,,11049,B,,
Expert,,1,,,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand; ND-Not determined,,CHEMBL615838,D,9,,,Rattus norvegicus,10116.0,BAO_0000019,10576,,838,,11049,B,,
Expert,,1,,,"Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding (NSB)",,CHEMBL615839,H,8,,,,,BAO_0000249,10576,,839,,13657,B,,
Autocuration,,1,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH-DPAT as radioligand,,CHEMBL884525,H,8,,,,,BAO_0000019,10576,,840,,11473,B,,
Autocuration,,1,,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonin 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,,CHEMBL615840,H,8,,,,,BAO_0000249,10576,,841,,2014,B,,
Expert,,1,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,CHEMBL615405,H,8,,,,,BAO_0000221,10576,,842,Hippocampus,3086,B,,10000000.0
Expert,,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,CHEMBL615406,H,8,,,,,BAO_0000019,10576,,843,,15854,B,,
Expert,,1,,,Affinity for 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,,CHEMBL615900,H,8,,,,,BAO_0000221,10576,,844,Hippocampus,10922,B,,10000000.0
Expert,,1,,,Inhibition of [3H]8-OH-DPAT binding at serotonin 5-hydroxytryptamine 1A receptor from rat hippocampus tissue.,,CHEMBL615901,H,8,,,,,BAO_0000221,10576,,845,Hippocampus,13346,B,,10000000.0
Expert,,1,,,In vitro inhibition of [3H]8-OH-DPAT binding to rat 5-HT 1a receptors.,,CHEMBL615902,H,8,,,,,BAO_0000357,10576,,846,,15311,B,,
Autocuration,,1,,,Compound was measured for affinity at 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,,CHEMBL615903,H,8,,,,,BAO_0000221,10576,,847,Hippocampus,10922,B,,10000000.0
Autocuration,,1,,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor<br>at 1 uM,,CHEMBL615904,H,8,,,,,BAO_0000357,10576,,848,,10025,B,,
Expert,,1,,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,,CHEMBL615905,H,8,,,,,BAO_0000357,10576,,849,,10025,B,,
Autocuration,,1,,,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,,CHEMBL615906,H,8,,,,,BAO_0000019,10576,,850,,9742,B,,
Autocuration,,1,,,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,,CHEMBL615907,H,8,,,,,BAO_0000019,10576,,851,,9742,F,,
Expert,,1,,,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,CHEMBL615908,H,8,,,,,BAO_0000019,10576,,852,,12304,B,,
Autocuration,,1,,,In vitro affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT in rat hippocampus,,CHEMBL615909,H,8,,,,,BAO_0000221,10576,,853,Hippocampus,15789,B,,10000000.0
Autocuration,,1,,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]-8-OH-DPAT as the radioligand",,CHEMBL615910,H,8,,,,,BAO_0000019,10576,,854,,9912,B,,
Autocuration,,1,,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand.",,CHEMBL615911,H,8,,,,,BAO_0000019,10576,,855,,9912,B,,
Autocuration,,1,,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand",,CHEMBL615912,H,8,,,,,BAO_0000019,10576,,856,,9912,B,,
Expert,,1,,,In vitro binding affinity for serotonin 5-hydroxytryptamine 1A receptor fof rat cerebral cortex using [3H]8-OH-DPAT as radioligand,,CHEMBL615913,H,8,,,,,BAO_0000019,10576,,857,,16693,B,,
Expert,,1,,,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,CHEMBL615914,H,8,,,,,BAO_0000357,10576,,858,,13276,B,,
Autocuration,,1,,,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,,CHEMBL615915,H,8,,,,,BAO_0000221,10576,,859,Hippocampus,12678,B,,10000000.0
Autocuration,,1,,,In vitro binding affinity towards the 5-hydroxytryptamine 1A receptor was evaluated,,CHEMBL615916,H,8,,,,,BAO_0000357,10576,,860,,11825,B,,
Expert,,1,,,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 1A receptor by displacement of [3H]- tetralin,,CHEMBL615917,H,8,,,,,BAO_0000357,10576,,861,,12443,B,,
Expert,,1,,,In vitro inhibitory activity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,CHEMBL615918,H,8,,,,,BAO_0000357,10576,,862,,13830,B,,
Expert,,1,,,In vitro inhibitory concentration against radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane.,,CHEMBL615919,H,8,,,,,BAO_0000249,10576,,863,Hippocampus,14286,B,,10000000.0
Expert,,1,,,In vitro radioligand binding assay on 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,,CHEMBL615920,D,9,,,Rattus norvegicus,10116.0,BAO_0000221,10576,,864,Hippocampus,14356,B,,10000000.0
Autocuration,,1,,,Inhibition concentration against 5-hydroxytryptamine 1A receptor,,CHEMBL615921,H,8,,,,,BAO_0000357,10576,,865,,15306,B,,
Expert,,1,,,Inhibitory concentration against 5-hydroxytryptamine 1A receptor (Inactive at >1000 nM concentration),,CHEMBL615922,H,8,,,,,BAO_0000357,10576,,866,,15306,B,,
Expert,,1,,,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",,CHEMBL881290,D,9,,,Rattus norvegicus,10116.0,BAO_0000249,10576,,867,,16616,F,,
Autocuration,,1,,,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Residual radioligand binding higher than 50%",,CHEMBL615923,H,8,,,,,BAO_0000221,10576,,868,Hippocampus,3651,B,,10000000.0
Autocuration,,1,,,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,,CHEMBL615924,H,8,,,,,BAO_0000221,10576,,869,Hippocampus,14331,F,,10000000.0
Autocuration,,1,,,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,,CHEMBL615925,H,8,,,,,BAO_0000221,10576,,870,Hippocampus,14331,F,,10000000.0
Expert,,1,,,Inhibition of radiolabeled [3H]-8-OH-DPAT ligand binding to 5-hydroxytryptamine 1A receptor,,CHEMBL615926,D,9,,,Rattus norvegicus,10116.0,BAO_0000357,10576,,871,,14178,B,,
Expert,,1,,,Displacement of [3H]8-OH-DPAT from rat cortex 5-hydroxytryptamine 1A receptor,,CHEMBL615927,D,9,,,Rattus norvegicus,10116.0,BAO_0000019,10576,,872,,10639,B,,
Autocuration,,1,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,CHEMBL615928,H,8,,,,,BAO_0000221,10576,,873,Hippocampus,12306,B,,10000000.0
Expert,,1,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor subtype,,CHEMBL615929,D,9,,,Rattus norvegicus,10116.0,BAO_0000357,10576,,874,,1348,B,,
Autocuration,,1,,,Inhibitory activity against [3H]DPAT binding to 5-HT1A receptor in rat hippocampus,,CHEMBL615930,H,8,,,,,BAO_0000221,10576,,875,Hippocampus,13605,B,,10000000.0
Autocuration,,1,CHO,,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,CHEMBL615931,H,8,,449.0,,,BAO_0000219,51,,876,,17624,B,,
Autocuration,,1,CHO,,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,,CHEMBL615932,H,8,,449.0,,,BAO_0000219,51,,877,,17624,F,,
Autocuration,,1,CHO,,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,,CHEMBL615933,H,8,,449.0,,,BAO_0000219,51,,878,,17624,F,,
Autocuration,,1,,,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,,CHEMBL615934,H,8,,,,,BAO_0000357,51,,879,,15267,B,,
Autocuration,,1,,,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT; Not tested,,CHEMBL615935,H,8,,,,,BAO_0000357,51,,880,,16532,B,,
Autocuration,,1,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,CHEMBL615936,H,8,,,,,BAO_0000019,51,,881,,6563,F,,
Autocuration,,1,CHO,,Ability to displace [3H]-8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor at a concentration of 1 uM,,CHEMBL615937,H,8,,449.0,,,BAO_0000219,51,,882,,4751,B,,
Autocuration,,1,,,Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor,,CHEMBL615938,H,8,,,,,BAO_0000357,51,,883,,15463,B,,
Autocuration,,1,,,In vitro binding affinity against human 5-hydroxytryptamine 1A receptor at a concentration of 100 (nM),,CHEMBL615797,H,8,,,,,BAO_0000357,51,,884,,3805,B,,
Autocuration,,1,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,CHEMBL615798,H,8,,,,,BAO_0000357,51,,885,,5640,B,,
Autocuration,,1,,,Inhibition of [3H]8-OH-DPAT binding to human 5-hydroxytryptamine 1A receptor at 1000 nM compound concentration,,CHEMBL872870,H,8,,,,,BAO_0000357,51,,886,,6563,B,,
Autocuration,,1,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand at 100 nM concentration,,CHEMBL615799,H,8,,,,,BAO_0000357,51,,887,,5548,B,,
Autocuration,,1,,,Percent binding affinity against 5-hydroxytryptamine 1A receptor,,CHEMBL615800,H,8,,,,,BAO_0000357,51,,888,,6347,B,,
Autocuration,,1,HEK293,,Intrinsic activity for human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,CHEMBL615801,H,8,,722.0,,,BAO_0000219,51,,889,,17296,F,,
Autocuration,,1,,,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the absence of endothelium,,CHEMBL615802,H,8,,,,,BAO_0000019,51,,890,,13047,B,,
Autocuration,,1,,,Dissociation constant against human 5-hydroxytryptamine 1A receptor receptor,,CHEMBL615803,H,8,,,,,BAO_0000357,51,,891,,15740,B,,
Expert,,1,,,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",,CHEMBL835002,H,8,,,,,BAO_0000019,51,,892,,5640,F,,
Autocuration,,1,,,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Ki (nM): not determined",,CHEMBL615804,H,8,,,,,BAO_0000019,51,,893,,5640,F,,
Expert,,1,HeLa,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor,,CHEMBL615805,H,8,,308.0,,,BAO_0000219,51,,894,,17211,B,,
Autocuration,,1,CHO,,Ability to displace [3H]8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor,,CHEMBL615806,H,8,,449.0,,,BAO_0000219,51,,895,,4751,B,,
Expert,,1,,,Affinity towards human 5-hydroxytryptamine 1A serotonin receptor,,CHEMBL615807,D,9,,,Homo sapiens,9606.0,BAO_0000357,51,,896,,6491,B,,
Autocuration,,1,,,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT-as radioligand,,CHEMBL615808,H,8,,,,,BAO_0000357,51,,897,,4707,B,,
Expert,,1,,,Binding affinity against 5-hydroxytryptamine 1A receptor,,CHEMBL615809,D,9,,,Homo sapiens,9606.0,BAO_0000357,51,,898,,13910,B,,
Autocuration,,1,HeLa,,Binding affinity against 5-hydroxytryptamine 1A receptor in HeLa cells was determined using [3H]5-HT,,CHEMBL615810,H,8,,308.0,,,BAO_0000219,51,,899,,16190,B,,
Autocuration,,1,,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,CHEMBL615811,H,8,,,,,BAO_0000357,51,,900,,16633,B,,
Autocuration,,1,CHO,,Binding affinity against [3H]- -8-OH-DPAT -labeled 5-hydroxytryptamine 1A sites in cloned CHO cells,,CHEMBL615812,H,8,,449.0,,,BAO_0000219,51,,901,,11898,B,,
Autocuration,,1,CHO,,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,CHEMBL615751,H,8,,449.0,,,BAO_0000219,51,,902,,11898,B,,
Autocuration,,1,,,Binding affinity against human 5-hydroxytryptamine 1A receptor,,CHEMBL615752,H,8,,,,,BAO_0000357,51,,903,,14331,B,,
Expert,,1,CHO,,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand,,CHEMBL615753,H,8,,449.0,,,BAO_0000219,51,,904,,17624,B,,
Autocuration,,1,CHO,,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand; nd=not determined,,CHEMBL615754,H,8,,449.0,,,BAO_0000219,51,,905,,17624,B,,
Autocuration,,1,,,Binding affinity of compound to human 5-hydroxytryptamine 1A receptor,,CHEMBL615755,H,8,,,,,BAO_0000357,51,,906,,3307,B,,
Expert,,1,CHO,,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,,CHEMBL615756,D,9,,449.0,Homo sapiens,9606.0,BAO_0000219,51,,907,,6563,B,,
Autocuration,,1,,,Binding affinity for 5-hydroxytryptamine 1A receptor in HeLa transfected cell type using [3H]8-OH-DPAT as radioligand,,CHEMBL615757,H,8,,,,,BAO_0000019,51,,908,,14165,B,,
Autocuration,,1,,,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,,CHEMBL615758,H,8,,,,,BAO_0000357,51,,909,,5732,B,,
Expert,,1,,,In vitro affinity at human cloned 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,,CHEMBL615759,H,8,,,,,BAO_0000357,51,,910,,13366,B,,
Autocuration,,1,,,Binding affinity towards human 5-hydroxytryptamine 1A receptor,,CHEMBL615760,H,8,,,,,BAO_0000357,51,,911,,17626,B,,
Expert,,1,HeLa,,Binding affinity towards human 5-hydroxytryptamine 1A receptor by the displacement of [3H]5-HT radioligand from the cloned receptor expressed in HeLa cells,,CHEMBL615761,H,8,,308.0,,,BAO_0000219,51,,912,,6588,B,,
Autocuration,,1,,,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]-5-HT as radioligand,,CHEMBL872104,H,8,,,,,BAO_0000357,51,,913,,16209,B,,
Autocuration,,1,,,Binding affinity towards recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,CHEMBL615762,H,8,,,,,BAO_0000357,51,,914,,15463,B,,
Autocuration,,1,,,Binding affinity towards recombinant human Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,CHEMBL615763,H,8,,,,,BAO_0000357,51,,915,,15463,B,,
Autocuration,,1,,,Binding affinity for recombinant human 5-hydroxytryptamine 1A receptor using [3H]5-HT as radioligand.,,CHEMBL615764,H,8,,,,,BAO_0000357,51,,916,,14770,B,,
Autocuration,,1,Cell line,,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines (He La),,CHEMBL615765,H,8,,1167.0,,,BAO_0000219,51,,917,,16245,B,,
Autocuration,,1,,,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines(He La),,CHEMBL615766,H,8,,,,,BAO_0000019,51,,918,,16245,B,,
Autocuration,,1,,,Binding affinity towards 5-HT1A receptor using [3H]8-OH-DPAT as radioligand,,CHEMBL615767,H,8,,,,,BAO_0000357,51,,919,,5548,B,,
Expert,,1,,,Binding affinity was determined towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,CHEMBL615768,H,8,,,,,BAO_0000357,51,,920,,5548,B,,
Autocuration,,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,CHEMBL615769,H,8,,,,,BAO_0000357,51,,921,,5548,B,,
Expert,,1,,,Binding affinity was evaluated at 5-hydroxytryptamine 1A receptor labeled with [3H]-8-OH-DPAT,,CHEMBL615770,H,8,,,,,BAO_0000357,51,,922,,6876,B,,
Autocuration,,1,,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,CHEMBL615771,H,8,,,,,BAO_0000357,51,,923,,2598,B,,
Expert,,1,,,Binding affinity to human 5-hydroxytryptamine 1A receptor was measured using [3H]-8-hydroxy-2-(di-n-propylamine) tetraline [3H]8-OH-DPAT) as radioligand,,CHEMBL615772,H,8,,,,,BAO_0000357,51,,924,,17785,B,,
Autocuration,,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,,CHEMBL615773,H,8,,,,,BAO_0000357,51,,925,,6013,B,,
Expert,,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,,CHEMBL615774,H,8,,,,,BAO_0000357,51,,926,,5929,B,,
Autocuration,,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,CHEMBL615775,H,8,,,,,BAO_0000357,51,,927,,16633,B,,
Autocuration,,1,,,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,,CHEMBL615776,H,8,,,,,BAO_0000357,51,,928,,1558,B,,
Expert,,1,,,Binding affinity towards human cloned 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,CHEMBL615777,H,8,,,,,BAO_0000357,51,,929,,16026,B,,
Autocuration,,1,,,Binding affinity was measured on 5-hydroxytryptamine 1A receptor in AK cells transfected with human 5-HT1A gene labeled with [3H]-8-OH-DPAT,,CHEMBL615778,H,8,,,,,BAO_0000219,51,,930,,12469,B,,
Expert,,1,,,Binding affinity was measured on cloned Human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,CHEMBL615779,D,9,,,Homo sapiens,9606.0,BAO_0000357,51,,931,,15874,B,,
Autocuration,,1,,,Binding affinity was measured on cloned human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,CHEMBL615780,H,8,,,,,BAO_0000357,51,,932,,15874,B,,
Autocuration,,1,,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1A receptor,,CHEMBL616298,H,8,,,,,BAO_0000357,51,,933,,3935,B,,
Autocuration,,1,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1A receptor,,CHEMBL616299,H,8,,,,,BAO_0000357,51,,934,,15818,B,,
Autocuration,,1,CHO-K1,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells.,,CHEMBL616300,H,8,,485.0,,,BAO_0000219,51,,935,,13706,B,,
Expert,,1,CHO-K1,,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1A receptor in CHO-K1 cells,,CHEMBL616301,H,8,,485.0,,,BAO_0000219,51,,936,,13729,F,,
Autocuration,,1,,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor,,CHEMBL616302,H,8,,,,,BAO_0000019,51,,937,,15413,B,,
Autocuration,,1,,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 1),,CHEMBL616117,H,8,,,,,BAO_0000019,51,,938,,15413,B,,
Autocuration,,1,,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 2),,CHEMBL616118,H,8,,,,,BAO_0000019,51,,939,,15413,B,,
Autocuration,,1,,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor by Panlabs assay,,CHEMBL616119,H,8,,,,,BAO_0000019,51,,940,,15413,B,,
Expert,,1,HeLa,,Displacement of specific [3H]- 5-HT binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,,CHEMBL616120,D,9,,308.0,Homo sapiens,9606.0,BAO_0000219,51,,941,,3445,B,,
Autocuration,,1,,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,,CHEMBL616121,H,8,,,,,BAO_0000357,51,,942,,15740,B,,
Autocuration,,1,,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor receptor,,CHEMBL616122,H,8,,,,,BAO_0000357,51,,943,,15740,B,,
Autocuration,,1,,,In vitro binding affinity tested on human 5-hydroxytryptamine 1A receptor,,CHEMBL616123,H,8,,,,,BAO_0000357,51,,944,,17626,B,,
Expert,,1,,,In vitro binding affinity to human 5-hydroxytryptamine 1A receptor,,CHEMBL616124,D,9,,,Homo sapiens,9606.0,BAO_0000357,51,,945,,4234,B,,
Expert,,1,,,In vitro binding affinity at 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,,CHEMBL616125,H,8,,,,,BAO_0000357,51,,946,,5640,B,,
Expert,,1,,,In vitro binding affinity towards Human 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT,,CHEMBL616126,H,8,,,Rattus norvegicus,10116.0,BAO_0000357,51,,947,,5272,B,,
Autocuration,,1,CHO,,In vitro binding affinity towards cloned human 5-hydroxytryptamine 1A receptor expressed in Chinese hamster ovary (CHO) cells using [3H]8-OH-DPAT as radioligand,,CHEMBL616127,H,8,,449.0,,,BAO_0000219,51,,948,,4622,B,,
Expert,,1,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor,,CHEMBL616128,H,8,,,,,BAO_0000019,51,,949,,17085,B,,
Autocuration,,1,,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,,CHEMBL616129,H,8,,,,,BAO_0000357,51,,950,,3025,B,,
Expert,,1,,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor,,CHEMBL616130,H,8,,,,,BAO_0000357,51,,951,,15315,B,,
Autocuration,,1,,,Inhibition of [3H]- OH-DPAT binding against 5-hydroxytryptamine 1A receptor from human recombinant,,CHEMBL616131,H,8,,,,,BAO_0000357,51,,952,,15267,B,,
Autocuration,,1,HeLa,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor serotonergic receptor in human HeLa cells,,CHEMBL616132,H,8,,308.0,,,BAO_0000219,51,,953,,17158,B,,
Expert,,1,HeLa,,Receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor in HeLa cells,,CHEMBL616133,D,9,,308.0,Homo sapiens,9606.0,BAO_0000219,51,,954,,14214,B,,
Autocuration,,1,,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,CHEMBL616134,H,8,,,,,BAO_0000357,51,,955,,17133,B,,
Autocuration,,1,,,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT,,CHEMBL616135,H,8,,,,,BAO_0000357,51,,956,,16532,B,,
Expert,,1,,,Affinity for 5-hydroxytryptamine 1A receptor subtype,,CHEMBL616136,D,9,,,Homo sapiens,9606.0,BAO_0000357,51,,957,,2391,B,,
Autocuration,,1,,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes,,CHEMBL616137,H,8,,,,,BAO_0000019,51,,958,,14447,B,,
Autocuration,,1,,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes.,,CHEMBL872105,H,8,,,,,BAO_0000019,51,,959,,14447,B,,
Autocuration,,1,,,The compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor receptor,,CHEMBL616138,H,8,,,,,BAO_0000357,51,,960,,15086,B,,
Expert,,1,,,Binding affinity for cloned human 5-hydroxytryptamine 1A receptor,,CHEMBL616139,D,9,,,Homo sapiens,9606.0,BAO_0000357,51,,961,,13051,B,,
Autocuration,,1,,,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor; Not active",,CHEMBL616140,H,8,,,,,BAO_0000019,51,,962,,16026,F,,
Expert,,1,,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor; ND means not determined,,CHEMBL616141,H,8,,,,,BAO_0000019,51,,963,,17085,B,,
Autocuration,,1,,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,CHEMBL616142,H,8,,,,,BAO_0000357,51,,964,,17133,B,,
Autocuration,,1,,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; ND means Not determined,,CHEMBL616143,H,8,,,,,BAO_0000357,51,,965,,17133,B,,
Autocuration,,1,HeLa,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,,CHEMBL616144,H,8,,308.0,,,BAO_0000219,51,,966,,17211,B,,
Autocuration,,1,HeLa,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT=not tested,,CHEMBL616145,H,8,,308.0,,,BAO_0000219,51,,967,,17211,B,,
Autocuration,,1,HeLa,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,,CHEMBL616012,H,8,,308.0,,,BAO_0000219,51,,968,,17211,B,,
Autocuration,,1,HeLa,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,,CHEMBL616013,H,8,,308.0,,,BAO_0000219,51,,969,,17211,B,,
Autocuration,,1,,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,CHEMBL616014,H,8,,,,,BAO_0000019,51,,970,,16394,F,,
Autocuration,,1,,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,CHEMBL616015,H,8,,,,,BAO_0000019,51,,971,,16394,F,,
Autocuration,,1,,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,CHEMBL616016,H,8,,,,,BAO_0000019,51,,972,,16394,F,,
Autocuration,,1,,,Antagonist induction of hypothermia by 8-OH-DPAT in 5-hydroxytryptamine 1A receptor after subcutaneous administration; NT is not tested,,CHEMBL616017,H,8,,,,,BAO_0000218,51,,973,,16394,F,In vivo,
Autocuration,,1,,,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]-8-OH-DPAT binding in Chinese hamster ovary cell line; NT is not tested,,CHEMBL616018,H,8,,,,,BAO_0000019,51,,974,,16394,B,,
Autocuration,,1,,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor receptor; Not tested,,CHEMBL616019,H,8,,,,,BAO_0000019,51,,975,,15740,F,,
Autocuration,,1,,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor; Not tested,,CHEMBL616020,H,8,,,,,BAO_0000019,51,,976,,15740,F,,
Autocuration,,1,,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,,CHEMBL858018,H,8,,,,,BAO_0000357,51,,977,,15740,B,,
Autocuration,,1,HEK293,,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,CHEMBL616021,H,8,,722.0,,,BAO_0000219,51,,978,,17296,F,,
Expert,,1,,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at 1 uM.",,CHEMBL616022,H,8,,,,,BAO_0000019,51,,979,,5640,F,,
Autocuration,,1,,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means Not determined",,CHEMBL616023,H,8,,,,,BAO_0000019,51,,980,,5640,F,,
Autocuration,,1,,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means not determined",,CHEMBL616024,H,8,,,,,BAO_0000019,51,,981,,5640,F,,
Autocuration,,1,,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; Not determined",,CHEMBL616025,H,8,,,,,BAO_0000019,51,,982,,5640,F,,
Autocuration,,1,CHO,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,,CHEMBL616026,H,8,,449.0,,,BAO_0000219,51,,983,,2759,F,,
Autocuration,,1,,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT",,CHEMBL616027,H,8,,,,,BAO_0000019,51,,984,,16394,F,,
Expert,,1,,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared to 5-HT",,CHEMBL616028,D,9,,,Homo sapiens,9606.0,BAO_0000019,51,,985,,16394,F,,
Expert,,1,,,Percent efficacy against human 5-hydroxytryptamine 1A receptor relative to maximal 5-HT response,,CHEMBL616029,D,9,,,Homo sapiens,9606.0,BAO_0000019,51,,986,,3445,F,,
Expert,,1,CHO,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by incubating human 5-hydroxytryptamine 1A receptor transfected CHO cells with [3H]8-OH-DPAT,,CHEMBL616030,H,8,,449.0,,,BAO_0000219,51,,987,,4316,B,,
Expert,,1,,,In vitro inhibition of [3H]8-OH-DPAT binding to human cloned 5-hydroxytryptamine 1A receptor on CHO cell membranes.,,CHEMBL616031,H,8,,,,,BAO_0000019,51,,988,,4316,B,,
Expert,,1,,,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,,CHEMBL616032,D,9,,,Homo sapiens,9606.0,BAO_0000019,51,,989,,15180,F,,
Expert,,1,,,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,,CHEMBL616033,D,9,,,Homo sapiens,9606.0,BAO_0000019,51,,990,,15180,F,,
Autocuration,,1,,,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,CHEMBL616034,H,8,,,,,BAO_0000019,51,,991,,15042,F,,
Autocuration,,1,,,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,CHEMBL616035,H,8,,,,,BAO_0000019,51,,992,,15042,F,,
Autocuration,,1,,,Maximum binding affinity was evaluated as ([35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,,CHEMBL616036,H,8,,,,,BAO_0000019,51,,993,,15042,F,,
Autocuration,,1,,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,CHEMBL616037,H,8,,,,,BAO_0000019,51,,994,,15042,F,,
Autocuration,,1,,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,CHEMBL616038,H,8,,,,,BAO_0000019,51,,995,,15042,F,,
Autocuration,,1,,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,CHEMBL616039,H,8,,,,,BAO_0000019,51,,996,,15042,F,,
Autocuration,,1,,,Agonist efficacy was evaluated as [35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,,CHEMBL616040,H,8,,,,,BAO_0000019,51,,997,,15042,F,,
Expert,,1,HeLa,,Concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,,CHEMBL616041,D,9,,308.0,Homo sapiens,9606.0,BAO_0000219,51,,998,,15180,F,,
Expert,,1,HeLa,,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,,CHEMBL616042,D,9,,308.0,Homo sapiens,9606.0,BAO_0000219,51,,999,,15180,F,,
Expert,,1,HeLa,,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,,CHEMBL616043,D,9,,308.0,Homo sapiens,9606.0,BAO_0000219,51,,1000,,15180,F,,
Autocuration,,1,,,"Potency (pD2) for the stimulation of [35S]GTP-gamma-S, binding on 5-hydroxytryptamine 1A receptor",,CHEMBL616044,H,8,,,,,BAO_0000019,51,,1001,,16245,F,,
Autocuration,,1,,,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,CHEMBL616045,H,8,,,,,BAO_0000019,51,,1002,,16026,F,,
Autocuration,,1,HEK293,,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,CHEMBL616046,H,8,,722.0,,,BAO_0000219,51,,1003,,17296,F,,
Autocuration,,1,CHO,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),,CHEMBL616047,H,8,,449.0,,,BAO_0000219,51,,1004,,2759,F,,
Autocuration,,1,CHO,,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells,,CHEMBL616048,H,8,,449.0,,,BAO_0000219,51,,1005,,2759,F,,
Expert,,1,CHO,,Potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 1),,CHEMBL616049,D,9,,449.0,Homo sapiens,9606.0,BAO_0000219,51,,1006,,2759,F,,
Autocuration,,1,CHO,,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),,CHEMBL616050,H,8,,449.0,,,BAO_0000219,51,,1007,,2759,F,,
Expert,,1,,,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor,,CHEMBL616051,H,8,,,,,BAO_0000219,51,,1008,,15419,F,,
Autocuration,,1,,,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor; Not tested,,CHEMBL616212,H,8,,,,,BAO_0000219,51,,1009,,15419,F,,
Autocuration,,1,,,"ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,CHEMBL616213,H,8,,,,,BAO_0000019,51,,1010,,16026,F,,
Expert,,1,,,Ability to bind to 5-hydroxytryptamine 1A receptor from cloned human expressed in Ha7 cells,,CHEMBL616214,H,8,,,,,BAO_0000219,51,,1011,,1414,B,In vitro,
Expert,,1,,,Ability to bind to 5-hydroxytryptamine 1A receptor subtype from cloned human expressed in Ha7 cells,,CHEMBL616215,H,8,,,,,BAO_0000219,51,,1012,,1414,B,In vitro,
Autocuration,,1,,,Binding activity radioligand.,,CHEMBL616216,H,8,,,,,BAO_0000357,51,,1013,,12861,B,,
Autocuration,,1,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,CHEMBL616217,H,8,,,,,BAO_0000019,51,,1014,,12861,B,,
Autocuration,,1,,,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,,CHEMBL616218,H,8,,,,,BAO_0000357,51,,1015,,5104,B,,
Autocuration,,1,,,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,,CHEMBL616219,H,8,,,,,BAO_0000357,51,,1016,,5105,B,,
Autocuration,,1,,,binding affinity towards human recombinant 5-hydroxytryptamine 1A receptor,,CHEMBL616220,H,8,,,,,BAO_0000357,51,,1017,,16312,B,,
Expert,,1,,,Displacement of [3H]8-hydroxy-2-(di-n-propylamino)tetralin from human 5-hydroxytryptamine 1A receptor,,CHEMBL833493,D,9,,,Homo sapiens,9606.0,BAO_0000357,51,,1018,,15180,B,,
Autocuration,,1,,,Ability to displace the radioligand [3H]-8-OH-DPAT from human 5-hydroxytryptamine 1A receptor,,CHEMBL616221,H,8,,,,,BAO_0000357,51,,1019,,5033,B,,
Expert,,1,CHO,,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,,CHEMBL616222,D,9,,449.0,Homo sapiens,9606.0,BAO_0000219,51,,1020,,16909,B,,
Autocuration,,1,,,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor,,CHEMBL616223,H,8,,,,,BAO_0000019,51,,1021,,2590,F,,
Autocuration,,1,,,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor; Not determined,,CHEMBL616224,H,8,,,,,BAO_0000019,51,,1022,,2590,F,,
Expert,,1,,,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding in Chinese hamster ovary cell line,,CHEMBL616225,H,8,,,,,BAO_0000019,51,,1023,,16394,B,,
Expert,,1,HEK293,,Binding affinity to human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]-8-OH- DPAT as radioligand,,CHEMBL616226,D,9,,722.0,Homo sapiens,9606.0,BAO_0000219,51,,1024,,4540,B,,
Autocuration,,1,HEK293,,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells,,CHEMBL616227,H,8,,722.0,,,BAO_0000219,51,,1025,,17296,B,,
Autocuration,,1,HEK293,,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells using [3H]8-OH-DPAT as radioligand,,CHEMBL616228,H,8,,722.0,,,BAO_0000219,51,,1026,,17296,B,,
Autocuration,,1,HEK293,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,,CHEMBL616229,H,8,,722.0,,,BAO_0000219,51,,1027,,15779,B,,
Autocuration,,1,HEK293,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand; ND means no data,,CHEMBL616230,H,8,,722.0,,,BAO_0000219,51,,1028,,15779,B,,
Autocuration,,1,HEK293,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;ND means no data.,,CHEMBL616231,H,8,,722.0,,,BAO_0000219,51,,1029,,15779,B,,
Autocuration,,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,,CHEMBL616232,H,8,,,,,BAO_0000357,51,,1030,,6166,B,,
Autocuration,,1,HEK293,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,,CHEMBL616233,H,8,,722.0,,,BAO_0000219,51,,1031,,15779,B,,
Autocuration,,1,HEK293,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT as the radioligand,,CHEMBL857973,H,8,,722.0,,,BAO_0000219,51,,1032,,4199,B,,
Autocuration,,1,,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT binding from human 5-hydroxytryptamine 1A receptor in mammalian cells,,CHEMBL616234,H,8,,,,,BAO_0000219,51,,1033,,15316,B,,
Autocuration,,1,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1A receptor,,CHEMBL616235,H,8,,,,,BAO_0000357,51,,1034,,14875,B,,
Expert,,1,HeLa,,Binding affinity at human cloned 5-hydroxytryptamine 1A receptor expressed in HeLa cells by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,,CHEMBL616236,H,8,,308.0,,,BAO_0000219,51,,1035,,14727,B,,
Expert,,1,,,Binding affinity at native 5-hydroxytryptamine 1A receptor in rat by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,,CHEMBL616237,H,8,,,,,BAO_0000019,51,,1036,,14727,B,,
Autocuration,,1,HEK293,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor in human cloned receptors in HEK 293 cells using [3H]8-OH-DPAT,,CHEMBL616238,H,8,,722.0,,,BAO_0000219,51,,1037,,15146,B,,
Autocuration,,1,HEK293,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1A receptor in HEK 293 using [3H]5-CT as a radioligand,,CHEMBL616239,H,8,,722.0,,,BAO_0000219,51,,1038,,5213,B,,
Autocuration,,1,,,In vitro binding affinity at human recombinant 5-hydroxytryptamine 1A receptor in mammalian cells using 3[H]8-OH-DPAT as the radioligand,,CHEMBL616240,H,8,,,,,BAO_0000219,51,,1039,,16429,B,,
Expert,,1,HeLa,,The binding affinity was evaluated on cloned human 5-hydroxytryptamine 1A receptor expressed in HeLa cells by using DPAT as radioligand.,,CHEMBL616241,D,9,,308.0,Homo sapiens,9606.0,BAO_0000219,51,,1040,,15042,B,,
Autocuration,,1,HEK293,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT.,,CHEMBL616242,H,8,,722.0,,,BAO_0000219,51,,1041,,14818,B,,
Autocuration,,1,HEK293,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1A receptor in HEK293 cells, using [3H]8-OH-DPAT as radioligand",,CHEMBL616243,H,8,,722.0,,,BAO_0000219,51,,1042,,4829,B,,
Expert,,1,,,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,,CHEMBL616244,D,9,,,,,BAO_0000357,51,,1043,,17200,B,,
Autocuration,,1,,,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor,,CHEMBL616245,D,9,,,Homo sapiens,9606.0,BAO_0000357,51,,1044,,13051,B,,
Autocuration,,1,,,Binding affinity towards 5-HT1B receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,,CHEMBL616246,H,8,,,,,BAO_0000357,106,,1045,,5486,B,,
Autocuration,,1,,,Binding affinity against 5-HT1D receptor,,CHEMBL616247,H,8,,,,,BAO_0000357,105,,1046,,5254,B,,
Autocuration,,1,,,Binding affinity against 5-hydroxytryptamine 1A receptor,,CHEMBL616248,H,8,,,,,BAO_0000357,105,,1047,,5254,B,,
Autocuration,,1,,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,CHEMBL616249,H,8,,,,,BAO_0000357,107,,1048,,15331,B,,
Autocuration,,1,,,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,,CHEMBL616250,H,8,,,Homo sapiens,9606.0,BAO_0000357,10576,,1049,,13506,B,,
Autocuration,,1,,,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,,CHEMBL616251,H,8,,,,,BAO_0000357,51,,1050,,15267,B,,
Autocuration,,1,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 15 min after administration of the compound,,CHEMBL616252,H,8,,,,,BAO_0000218,11863,,1051,,16616,F,In vivo,
Autocuration,,1,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 30 min after administration of the compound,,CHEMBL616253,H,8,,,,,BAO_0000218,11863,,1052,,16616,F,In vivo,
Autocuration,,1,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 60 min after administration of the compound,,CHEMBL616254,H,8,,,,,BAO_0000218,11863,,1053,,16616,F,In vivo,
Expert,,1,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 15 min,,CHEMBL616255,D,9,,,Mus musculus,10090.0,BAO_0000218,11863,,1054,,16616,F,,
Expert,,1,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 30 min,,CHEMBL832872,D,9,,,Mus musculus,10090.0,BAO_0000218,11863,,1055,,16616,F,,
Expert,,1,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 60 min,,CHEMBL616256,D,9,,,Mus musculus,10090.0,BAO_0000218,11863,,1056,,16616,F,,
Expert,,1,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 15 min,,CHEMBL616257,D,9,,,Mus musculus,10090.0,BAO_0000218,11863,,1057,,16616,F,,
Expert,,1,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 30 min,,CHEMBL616258,D,9,,,Mus musculus,10090.0,BAO_0000218,11863,,1058,,16616,F,,
Expert,,1,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 60 min,,CHEMBL616384,D,9,,,Mus musculus,10090.0,BAO_0000218,11863,,1059,,16616,F,,
Autocuration,,1,,,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,,CHEMBL616385,H,8,,,,,BAO_0000221,11863,,1060,Hippocampus,10297,B,,10000000.0
Expert,,1,,,Inhibitory activity against serotonin 5-hydroxytryptamine 1A receptor from mice.,,CHEMBL616386,H,8,,,,,BAO_0000357,11863,,1061,,13704,B,,
Expert,,1,,,Inhibitory activity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,,CHEMBL616387,D,9,,,Mus musculus,10090.0,BAO_0000221,11863,,1062,Hippocampus,10297,B,,10000000.0
Autocuration,,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,,CHEMBL616388,H,8,,,,,BAO_0000221,11863,,1063,Hippocampus,10297,B,,10000000.0
Expert,,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,,CHEMBL616389,D,9,,,Mus musculus,10090.0,BAO_0000221,11863,,1064,Hippocampus,10297,B,,10000000.0
Autocuration,,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,,CHEMBL616390,H,8,,,,,BAO_0000221,11863,,1065,Hippocampus,10297,B,,10000000.0
Autocuration,,1,,,Compound was tested for binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as a radioligand,,CHEMBL616391,H,8,,,,,BAO_0000357,11863,,1066,,217,B,,
Expert,,1,,,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,,CHEMBL616392,D,9,,,Mus musculus,10090.0,BAO_0000221,11863,,1067,Hippocampus,10297,B,,10000000.0
Autocuration,,1,,,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor,,CHEMBL616393,H,8,,,Sus scrofa,9823.0,BAO_0000357,51,,1068,,4921,B,,
Autocuration,,1,,,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor; ND denotes not determined,,CHEMBL616394,H,8,,,Sus scrofa,9823.0,BAO_0000357,51,,1069,,4921,B,,
Autocuration,,1,,,Binding affinity of compound measured for 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT-labeled porcine brain homogenates,,CHEMBL616395,H,8,,,Sus scrofa,9823.0,BAO_0000019,51,,1070,,4996,B,,
Autocuration,,1,,,Compound was evaluated for the binding affinity at 5- HT1A receptor,,CHEMBL616396,H,8,,,Sus scrofa,9823.0,BAO_0000357,51,,1071,,12918,B,,
Autocuration,,1,,,Compound was tested in vitro for its ability to compete with [3H]8-OH-DPAT at 5-hydroxytryptamine 1A receptor in porcine brain homogenate,,CHEMBL872907,H,8,,,Sus scrofa,9823.0,BAO_0000019,51,,1072,,5333,B,,
Autocuration,,1,,,In vitro for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in porcine brain homogenate,,CHEMBL616397,H,8,,,Sus scrofa,9823.0,BAO_0000019,51,,1073,,4437,B,,
Autocuration,,1,,,Compound was tested for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in pig cortex,,CHEMBL616398,H,8,,,Sus scrofa,9823.0,BAO_0000019,51,,1074,,1742,B,,
Expert,,1,,,Displacement of [3H]- 8-OH-DPAT from porcine 5-hydroxytryptamine 1A receptor,,CHEMBL616399,H,8,,,Sus scrofa,9823.0,BAO_0000357,51,,1075,,16688,B,,
Autocuration,,1,,,Binding activity radioligand.,,CHEMBL857065,H,8,,,Sus scrofa,9823.0,BAO_0000357,51,,1076,,12861,B,,
Expert,,1,,,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,,CHEMBL616400,H,8,,,Sus scrofa,9823.0,BAO_0000019,51,,1077,,12861,B,,
Autocuration,,1,,,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,,CHEMBL616401,H,8,,,Sus scrofa,9823.0,BAO_0000019,51,,1078,,12861,B,,
Expert,,1,,,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor from pig cortex,,CHEMBL616402,H,8,,,,,BAO_0000019,10624,,1079,,12490,B,,
Expert,,1,,,Displacement of [3H]8-OH-DPAT from pig cortex 5-hydroxytryptamine 1A receptor,,CHEMBL616403,H,8,,,Sus scrofa,9823.0,BAO_0000019,51,,1080,,11828,B,,
Autocuration,,1,,,Binding affinity for 5-hydroxytryptamine 1A receptor in piglet hippocampus using [3H]8-OH-DPAT,,CHEMBL616404,H,8,,,Sus scrofa,9823.0,BAO_0000221,51,,1081,Hippocampus,11866,B,,10000000.0
Autocuration,,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in pig frontal cortex membranes using [8H]-OH-DPAT,,CHEMBL616405,H,8,,,Sus scrofa,9823.0,BAO_0000249,51,,1082,,12827,B,,
Autocuration,,1,,,Binding affinity was evaluated by 5-hydroxytryptamine 1A receptor agonism in the pig cortex by displacing 8-OH-DPAT,,CHEMBL616406,H,8,,,Sus scrofa,9823.0,BAO_0000019,51,,1083,,12918,B,,
Expert,,1,,,Agonistic activity against 5-hydroxytryptamine 1A receptor in pig cortex using [3H]8-OH-DPAT,,CHEMBL616407,H,8,,,Sus scrofa,9823.0,BAO_0000019,51,,1084,,12919,F,,
Autocuration,,1,,,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the presence of endothelium,,CHEMBL616408,H,8,,,Oryctolagus cuniculus,9986.0,BAO_0000019,51,,1085,,13047,B,,
Expert,,1,,,Inhibition activity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using radio binding assays,,CHEMBL616409,D,9,,,Rattus norvegicus,10116.0,BAO_0000249,10576,,1086,,15796,B,,
Expert,,1,,,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Less active",,CHEMBL616410,D,9,,,Rattus norvegicus,10116.0,BAO_0000221,10576,,1087,Hippocampus,3651,B,,10000000.0
Autocuration,,1,,,Tested for the effect on binding at 5-hydroxytryptamine 1A receptor; No activity,,CHEMBL616411,H,8,,,,,BAO_0000357,10576,,1088,,188,B,,
Expert,,1,,,"Antagonist activity to stimulate binding of [35S]GTP-gamma-S, to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",Membranes,CHEMBL616412,D,9,,,Rattus norvegicus,10116.0,BAO_0000249,10576,,1089,,16616,F,,
Expert,,1,,,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",Membranes,CHEMBL616413,D,9,,,Rattus norvegicus,10116.0,BAO_0000249,10576,,1090,Hippocampus,16616,F,,10000000.0
Autocuration,,1,,,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,CHEMBL616414,H,8,,,,,BAO_0000221,10576,,1091,Hippocampus,12306,B,,10000000.0
Expert,,1,,,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding,,CHEMBL616415,D,9,,,Rattus norvegicus,10116.0,BAO_0000221,10576,,1092,Hippocampus,17167,B,,10000000.0
Autocuration,,1,,,Binding affinity measured at the 5-hydroxytryptamine 1A receptor by the inhibition of [3H]8-OH-DPAT binding to rat cortex using unlabeled buspirone for nonspecific binding.,,CHEMBL616416,H,8,,,,,BAO_0000019,10576,,1093,,14776,B,,
Expert,,1,,,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand.,,CHEMBL616417,H,8,,,,,BAO_0000357,10576,,1094,,12158,B,,
Autocuration,,1,,,Binding affinity of [3H]- -8-OH-DPAT labelled towards Rat Hippocampal 5-hydroxytryptamine 1A receptor using radioligand binding assay,,CHEMBL616418,H,8,,,,,BAO_0000357,10576,,1095,,13481,B,,
Autocuration,,1,,,Binding affinity of [3H]-8-OH-DPAT towards 5-hydroxytryptamine 1A receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,,CHEMBL616419,H,8,,,,,BAO_0000219,10576,,1096,,13427,B,In vitro,
Autocuration,,1,,,Binding affinity of compound against 5-hydroxytryptamine 1A receptor binding site using radioligand [3H]8-OH-DPAT,,CHEMBL616420,H,8,,,,,BAO_0000357,10576,,1097,,10210,B,,
Autocuration,,1,,,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,Membranes,CHEMBL616421,H,8,,,,,BAO_0000249,10576,,1098,,10205,B,,
Autocuration,,1,,,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,Membranes,CHEMBL616422,H,8,,,,,BAO_0000249,10576,,1099,,10205,B,,
Expert,,1,,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor in rat striatal membranes by [3H]OH-DPAT displacement.,Membranes,CHEMBL616423,H,8,,,,,BAO_0000249,10576,,1100,,10205,B,,
Expert,,1,,,Binding affinity for 5-hydroxytryptamine 1A receptor with [3H]5-HT,,CHEMBL616424,D,9,,,Rattus norvegicus,10116.0,BAO_0000357,10576,,1101,,12280,B,,
Expert,,1,,,Binding affinity to the rat 5-hydroxytryptamine 1A receptor,,CHEMBL616425,H,8,,,,,BAO_0000357,10576,,1102,,17386,B,,
Expert,,1,,,Binding affinity was tested on 5-hydroxytryptamine 1A receptor using radioligand [3H]5-HT binding assay.,,CHEMBL616426,H,8,,,,,BAO_0000357,10576,,1103,,13654,B,,
Autocuration,,1,,,Binding affinity against 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as the radioligand.,,CHEMBL616427,H,8,,,,,BAO_0000221,10576,,1104,Hippocampus,14423,B,,10000000.0
Autocuration,,1,,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus tissue.,,CHEMBL616428,H,8,,,,,BAO_0000221,10576,,1105,Hippocampus,15412,B,,10000000.0
Autocuration,,1,,,Binding affinity by measuring displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,CHEMBL616290,H,8,,,,,BAO_0000221,10576,,1106,Hippocampus,12073,B,,10000000.0
Expert,,1,,,Displacement of [3H]8-OH-DPAT from rat striata 5-hydroxytryptamine 1A receptor,,CHEMBL616052,D,9,,,Rattus norvegicus,10116.0,BAO_0000357,10576,,1107,,4101,B,,
Autocuration,,1,,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1A receptor,,CHEMBL616053,H,8,,,,,BAO_0000357,10576,,1108,,10062,B,,
Autocuration,,1,,,Binding affinity towards 5-HT 1A receptor in rat cerebral cortex membranes using [3H]8-OH-DPAT as radioligand,,CHEMBL616054,H,8,,,,,BAO_0000249,10576,,1109,,6238,B,,
Autocuration,,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,,CHEMBL616055,H,8,,,,,BAO_0000357,10576,,1110,,16273,B,,
Autocuration,,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in competitive binding assay,,CHEMBL616056,H,8,,,,,BAO_0000357,10576,,1111,,11139,B,,
Expert,,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,,CHEMBL616057,H,8,,,,,BAO_0000019,10576,,1112,,16796,B,,
Expert,,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,,CHEMBL616058,D,9,,,Rattus norvegicus,10116.0,BAO_0000221,10576,,1113,Brain,9548,B,,955.0
Autocuration,,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,,CHEMBL616059,H,8,,,,,BAO_0000221,10576,,1114,Brain,10381,B,,955.0
Autocuration,,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hypocampus membrane using [3H]8-OH-DPAT as radioligand,,CHEMBL616060,H,8,,,,,BAO_0000249,10576,,1115,,13408,B,,
Expert,,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in the rat brain (hippocampus) using [3H]8-OH-DPAT,,CHEMBL616061,D,9,,,Rattus norvegicus,10116.0,BAO_0000221,10576,,1116,Hippocampus,13825,B,,10000000.0
Expert,,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]-8-hydroxy-2-(di-n-propylamine) tetralin (8-OH-DPAT) as a radioligand,,CHEMBL616062,H,8,,,,,BAO_0000221,10576,,1117,Hippocampus,11147,B,,10000000.0
Autocuration,,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor sites in cortical membranes using [3H]8-OH-DPAT as radioligand,,CHEMBL616063,H,8,,,,,BAO_0000249,10576,,1118,,10552,B,,
Autocuration,,1,,,"Binding affinity towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",,CHEMBL616064,H,8,,,,,BAO_0000249,10576,,1119,Striatum,10552,B,,2435.0
Expert,,1,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cortex membranes,Membranes,CHEMBL616065,D,9,,,Rattus norvegicus,10116.0,BAO_0000249,10576,,1120,,17136,B,,
Expert,,1,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cerebral cortex membranes,Membranes,CHEMBL616066,D,9,,,Rattus norvegicus,10116.0,BAO_0000249,10576,,1121,,5778,B,,
Autocuration,,1,,,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,CHEMBL616067,H,8,,,,,BAO_0000221,10576,,1122,Hippocampus,13481,B,,10000000.0
Autocuration,,1,,,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; Not tested,,CHEMBL616068,H,8,,,,,BAO_0000221,10576,,1123,Hippocampus,13481,B,,10000000.0
Intermediate,,1,,,Binding affinity against rat hippocampal 5-hydroxytryptamine 1A (5-HT1A) receptor determined using [3H]8-OH-DPAT as radioligand,,CHEMBL616069,H,8,,,,,BAO_0000221,10576,,1124,Hippocampus,13630,B,,10000000.0
Expert,,1,,,Binding was determined on 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,,CHEMBL616070,H,8,,,,,BAO_0000249,10576,,1125,,16245,B,,
Autocuration,,1,,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand,,CHEMBL616071,H,8,,,,,BAO_0000221,10576,,1126,Hippocampus,14509,B,,10000000.0
Expert,,1,,,Binding affinity against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.,,CHEMBL616072,H,8,,,,,BAO_0000221,10576,,1127,Hippocampus,14509,B,,10000000.0
Autocuration,,1,,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.; ND = Not determined,,CHEMBL616073,H,8,,,,,BAO_0000221,10576,,1128,Hippocampus,14509,B,,10000000.0
Autocuration,,1,,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand; ND = Not determined,,CHEMBL616074,H,8,,,,,BAO_0000221,10576,,1129,Hippocampus,14509,B,,10000000.0
Expert,,1,,,Binding affinity was evaluated by determining in vitro displacement of [3H]8-OH-DPAT from the central 5-hydroxytryptamine 1A receptor recognition site in rat frontal cortex homogenate.,,CHEMBL616075,H,8,,,,,BAO_0000019,10576,,1130,,14256,B,,
Autocuration,,1,,,Binding affinity was evaluated by using [3H]8-OH-DPAT radioligand by using competitive binding assay on 5-hydroxytryptamine 1A receptor,,CHEMBL616076,H,8,,,,,BAO_0000357,10576,,1131,,11139,B,,
Expert,,1,,,Binding affinity for 5-HT1A measured by displacing [3H]8-OH-DPAT from rat cortical membranes; Not determined,,CHEMBL616077,D,9,,,Rattus norvegicus,10116.0,BAO_0000019,10576,,1132,,11047,B,,
Expert,,1,,,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes,,CHEMBL616078,D,9,,,Rattus norvegicus,10116.0,BAO_0000019,10576,,1133,,11047,B,,
Expert,,1,,,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes;ND-Not determined,,CHEMBL616079,D,9,,,Rattus norvegicus,10116.0,BAO_0000019,10576,,1134,,11047,B,,
Expert,,1,CHO-K1,,Binding affinity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,,CHEMBL616080,D,9,,485.0,Rattus norvegicus,10116.0,BAO_0000219,10576,,1135,,2395,B,,
Autocuration,,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,,CHEMBL616081,H,8,,,,,BAO_0000357,10576,,1136,,9699,B,,
Expert,,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [125I]trans-8-OH-PIPAT in membrane homogenates of hippocampal tissue of rat brain,,CHEMBL616082,D,9,,,Rattus norvegicus,10116.0,BAO_0000221,10576,,1137,Hippocampus,12028,B,,10000000.0
Autocuration,,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in membrane homogenates of hippocampal tissue of rat brain,,CHEMBL616083,H,8,,,,,BAO_0000221,10576,,1138,Hippocampus,12028,B,,10000000.0
Autocuration,,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,CHEMBL616084,H,8,,,,,BAO_0000019,10576,,1139,,5815,B,,
Expert,,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates,,CHEMBL616085,H,8,,,,,BAO_0000019,10576,,1140,,16616,B,,
Autocuration,,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT,,CHEMBL616086,H,8,,,,,BAO_0000019,10576,,1141,,5815,B,,
Autocuration,,1,,,"Binding affinity towards 5-hydroxytryptamine 1A receptor using 0.1 nM [3H]-8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tet-ralin), from rat hippocampal homogenate",,CHEMBL616087,H,8,,,,,BAO_0000221,10576,,1142,Hippocampus,2761,B,,10000000.0
Expert,,1,,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor using [3H]WB-4101,,CHEMBL616088,H,8,,,,,BAO_0000357,10576,,1143,,13133,B,,
Autocuration,,1,,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor was determined in male Sprague-Dawley rat brain.,,CHEMBL616089,H,8,,,,,BAO_0000019,10576,,1144,,10444,B,,
Expert,,1,,,Binding affinity was measured against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT by lysergic acid amides,,CHEMBL616090,D,9,,,Rattus norvegicus,10116.0,BAO_0000357,10576,,1145,,13278,B,,
Autocuration,,1,,,Binding affinity was measured on cloned rat 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,CHEMBL616091,H,8,,,,,BAO_0000357,10576,,1146,,15874,B,,
Autocuration,,1,,,"Binding affinity of the compound towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",Membranes,CHEMBL616092,H,8,,,,,BAO_0000249,10576,,1147,Striatum,10552,B,,2435.0
Autocuration,,1,,,Binding constant against 5-hydroxytryptamine 1A receptor (in vitro),,CHEMBL616093,H,8,,,,,BAO_0000357,10576,,1148,,11130,B,,
Autocuration,,1,,,Binding constant against 5-hydroxytryptamine 1A receptor (in vivo),,CHEMBL616094,H,8,,,,,BAO_0000218,10576,,1149,,11130,B,In vivo,
Autocuration,,1,,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex,,CHEMBL616095,H,8,,,,,BAO_0000221,10576,,1150,Brain,14542,B,,955.0
Expert,,1,,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,CHEMBL616096,D,9,,,Rattus norvegicus,10116.0,BAO_0000357,10576,,1151,,13670,B,,
Expert,,1,,,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes,,CHEMBL616097,H,8,,,,,BAO_0000249,10576,,1152,,9888,B,,
Expert,,1,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus membranes,Membranes,CHEMBL616098,D,9,,,Rattus norvegicus,10116.0,BAO_0000249,10576,,1153,,3678,B,,
Autocuration,,1,,,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,,CHEMBL616099,H,8,,,,,BAO_0000221,10576,,1154,Hippocampus,11332,B,,10000000.0
Autocuration,,1,,,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 1A receptor receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,,CHEMBL616100,H,8,,,,,BAO_0000221,10576,,1155,Hippocampus,11332,B,,10000000.0
Expert,,1,,,Ability to displace [3H]-8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,,CHEMBL616101,H,8,,,,,BAO_0000357,10576,,1156,,1185,B,,
Expert,,1,,,Binding affinity at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes by [3H]8-OH-DPAT displacement.,,CHEMBL616102,H,8,,,,,BAO_0000249,10576,,1157,,2014,B,,
Autocuration,,1,,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,,CHEMBL616103,H,8,,,,,BAO_0000357,10576,,1158,,1185,B,,
Expert,,1,,,Compound was evaluated for its binding affinity against 5-hydroxytryptamine 1A receptor from rat cerebral cortex,,CHEMBL616104,H,8,,,,,BAO_0000019,10576,,1159,,14429,B,,
Expert,,1,,,"Binding affinity to 5-hydroxytryptamine 1A receptor (5-HT 1A receptor, serotonin receptor) from rat cortex using [3H]8-OH-DPAT as radioligand",,CHEMBL616105,H,8,,,,,BAO_0000019,10576,,1160,,16288,B,,
Expert,,1,,,Displacement of [3H]prazosin from rat cortex membrane 5-hydroxytryptamine 1A receptor,,CHEMBL616106,D,9,,,Rattus norvegicus,10116.0,BAO_0000019,10576,,1161,,5432,B,,
Autocuration,,1,,,Compound was evaluated for its binding affinity with 5-hydroxytryptamine 1A receptor using membranes prepared from rat cerebral cortex,,CHEMBL616107,H,8,,,,,BAO_0000019,10576,,1162,,14429,B,,
Expert,,1,,,Binding affinity towards rat 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand.,,CHEMBL616108,H,8,,,,,BAO_0000357,10576,,1163,,13672,B,,
Expert,,1,,,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,,CHEMBL616109,H,8,,,,,BAO_0000221,10576,,1164,Hippocampus,11296,B,,10000000.0
Autocuration,,1,,,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site.,,CHEMBL616110,H,8,,,,,BAO_0000357,10576,,1165,,11296,B,,
Expert,,1,CHO,,Binding affinity against rat 5-hydroxytryptamine 1A receptor in CHO cells.,,CHEMBL616111,H,8,,449.0,,,BAO_0000219,10576,,1166,,14749,B,,
Expert,,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat brain using [3H]-8-OH-DPAT as radioligand,,CHEMBL616112,H,8,,,,,BAO_0000019,10576,,1167,,15086,B,,
Autocuration,,1,,,Compound was tested for the Binding affinity against rat hippocampal 5-hydroxytryptamine 1A receptor by Radio ligand [3H]8-OH-DPAT binding assay.,,CHEMBL616113,H,8,,,,,BAO_0000221,10576,,1168,Hippocampus,13462,B,,10000000.0
Autocuration,,1,,,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,,CHEMBL616114,H,8,,,,,BAO_0000019,10576,,1169,,15363,B,,
Autocuration,,1,,,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,,CHEMBL616115,H,8,,,,,BAO_0000019,10576,,1170,,15363,B,,
Autocuration,,1,,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1A receptor,,CHEMBL616116,H,8,,,,,BAO_0000357,10576,,1171,,10796,B,,
Expert,,1,,,Binding affinity for 5-hydroxytryptamine 1A receptor in rat brain tissue using [3H]8-OH-DPAT as radioligand,,CHEMBL615844,H,8,,,,,BAO_0000221,10576,,1172,Brain,12816,B,,955.0
Expert,,1,,,In vitro displacement of [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,,CHEMBL615939,H,8,,,,,BAO_0000221,10576,,1173,Hippocampus,13542,B,,10000000.0
Expert,,1,,,In vitro ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor sites of rat brain cortex.,,CHEMBL615940,H,8,,,,,BAO_0000019,10576,,1174,,13308,B,,
Expert,,1,,,In vitro affinity at 5-hydroxytryptamine 1A receptor of rat hippocampus by [3H]8-OH-DPAT displacement.,,CHEMBL615941,H,8,,,,,BAO_0000221,10576,,1175,Hippocampus,13541,B,,10000000.0
Autocuration,,1,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-HT1A receptor of rat hippocampus and the value ranges from 9 - 12,,CHEMBL615942,H,8,,,,,BAO_0000221,10576,,1176,Hippocampus,10058,B,,10000000.0
Autocuration,,1,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,,CHEMBL615943,H,8,,,,,BAO_0000221,10576,,1177,Hippocampus,10058,B,,10000000.0
Autocuration,,1,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 12 to 17,,CHEMBL615944,H,8,,,,,BAO_0000221,10576,,1178,Hippocampus,10058,B,,10000000.0
Autocuration,,1,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 391-841,,CHEMBL615945,H,8,,,,,BAO_0000221,10576,,1179,Hippocampus,10058,B,,10000000.0
Autocuration,,1,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 17.,,CHEMBL615946,H,8,,,,,BAO_0000221,10576,,1180,Hippocampus,10058,B,,10000000.0
Autocuration,,1,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 20.,,CHEMBL615947,H,8,,,,,BAO_0000221,10576,,1181,Hippocampus,10058,B,,10000000.0
Autocuration,,1,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 245 to 736,,CHEMBL615948,H,8,,,,,BAO_0000221,10576,,1182,Hippocampus,10058,B,,10000000.0
Autocuration,,1,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 25 - 84,,CHEMBL615949,H,8,,,,,BAO_0000221,10576,,1183,Hippocampus,10058,B,,10000000.0
Autocuration,,1,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 48 to 59,,CHEMBL615950,H,8,,,,,BAO_0000221,10576,,1184,Hippocampus,10058,B,,10000000.0
Autocuration,,1,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 3 -5,,CHEMBL615951,H,8,,,,,BAO_0000221,10576,,1185,Hippocampus,10058,B,,10000000.0
Autocuration,,1,,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 15 - 31,,CHEMBL615952,H,8,,,,,BAO_0000221,10576,,1186,Hippocampus,10058,B,,10000000.0
Autocuration,,1,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 27 - 42,,CHEMBL615953,H,8,,,,,BAO_0000221,10576,,1187,Hippocampus,10058,B,,10000000.0
Autocuration,,1,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 6 - 13,,CHEMBL615954,H,8,,,,,BAO_0000221,10576,,1188,Hippocampus,10058,B,,10000000.0
Expert,,1,,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,,CHEMBL615955,D,9,,,Rattus norvegicus,10116.0,BAO_0000221,10576,,1189,Hippocampus,10058,B,,10000000.0
Autocuration,,1,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.; ND is No Data.,,CHEMBL615956,H,8,,,,,BAO_0000221,10576,,1190,Hippocampus,10058,B,,10000000.0
Autocuration,,1,,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus. and the value ranges from 16 - 27,,CHEMBL615957,H,8,,,,,BAO_0000221,10576,,1191,Hippocampus,10058,B,,10000000.0
Expert,,1,,,Displacement of [3H]2-(di-N-propylamino)-8-hydroxytetralin from central 5-hydroxytryptamine 1A receptor recognition sites in rat frontal cortex homogenates.,,CHEMBL615958,H,8,,,,,BAO_0000019,10576,,1192,,12879,B,,
Expert,,1,,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate,,CHEMBL615959,H,8,,,,,BAO_0000019,10576,,1193,,11964,B,,
Autocuration,,1,,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 1),,CHEMBL615960,H,8,,,,,BAO_0000019,10576,,1194,,11964,B,,
Autocuration,,1,,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 2),,CHEMBL615961,H,8,,,,,BAO_0000019,10576,,1195,,11964,B,,
Expert,,1,,,Evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,,CHEMBL615962,H,8,,,,,BAO_0000221,10576,,1196,Brain,9548,B,,955.0
Expert,,1,,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand.,,CHEMBL615963,H,8,,,,,BAO_0000019,10576,,1197,,9098,B,,
Autocuration,,1,,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand; ND is no data.,,CHEMBL615964,H,8,,,,,BAO_0000019,10576,,1198,,9098,B,,
Autocuration,,1,,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand;ND means no data,,CHEMBL615965,H,8,,,,,BAO_0000019,10576,,1199,,9098,B,,
Expert,,1,CHO,,In vitro displacement of radioactively labeled ligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor site in CHO cells,,CHEMBL615966,H,8,,449.0,,,BAO_0000219,10576,,1200,,13248,B,,
Expert,,1,,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat cortical membranes,,CHEMBL615967,H,8,,,,,BAO_0000249,10576,,1201,,3147,B,,
Expert,,1,,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor of rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,,CHEMBL615968,H,8,,,,,BAO_0000019,10576,,1202,,13949,B,,
Autocuration,,1,CHO,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),,CHEMBL615969,H,8,,449.0,,,BAO_0000218,10576,,1203,,11883,B,,
Autocuration,,1,,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (agonist) as radioligand (sc),,CHEMBL615970,H,8,,,,,BAO_0000218,10576,,1204,,11883,B,,
Expert,,1,,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT,,CHEMBL615971,D,9,,,Rattus norvegicus,10116.0,BAO_0000357,10576,,1205,,11883,B,,
Expert,,1,,,In vitro binding affinity at 5-HT1A receptors assayed by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,Membranes,CHEMBL615972,H,8,,,,,BAO_0000249,10576,,1206,,15535,B,,
Autocuration,,1,,,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes + cortex,,CHEMBL615973,H,8,,,,,BAO_0000249,10576,,1207,,15535,B,,
Autocuration,,1,,,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes+cortex,,CHEMBL615974,H,8,,,,,BAO_0000249,10576,,1208,,15535,B,,
Expert,,1,CHO,,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,,CHEMBL615975,D,9,,449.0,Homo sapiens,9606.0,BAO_0000219,51,,1209,,16372,B,,
Expert,,1,,,In vitro binding affinity for 5-hydroxytryptamine 1A receptor in rat hippocampal membranes by [125I]-labeled agonist displacement.,,CHEMBL615976,H,8,,,,,BAO_0000249,10576,,1210,,14608,B,,
Expert,,1,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus,,CHEMBL872106,D,9,,,Rattus norvegicus,10116.0,BAO_0000221,10576,,1211,Hippocampus,4795,B,,10000000.0
Autocuration,,1,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,CHEMBL615977,H,8,,,,,BAO_0000357,10576,,1212,,13863,B,,
Autocuration,,1,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=100-230,,CHEMBL615978,H,8,,,,,BAO_0000357,10576,,1213,,13863,B,,
Autocuration,,1,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=12-14,,CHEMBL616166,H,8,,,,,BAO_0000357,10576,,1214,,13863,B,,
Autocuration,,1,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=16-20,,CHEMBL616167,H,8,,,,,BAO_0000357,10576,,1215,,13863,B,,
Autocuration,,1,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=160-430,,CHEMBL616168,H,8,,,,,BAO_0000357,10576,,1216,,13863,B,,
Autocuration,,1,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=174-224,,CHEMBL616169,H,8,,,,,BAO_0000357,10576,,1217,,13863,B,,
Autocuration,,1,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=184-503,,CHEMBL616170,H,8,,,,,BAO_0000357,10576,,1218,,13863,B,,
Autocuration,,1,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=19-23,,CHEMBL616171,H,8,,,,,BAO_0000357,10576,,1219,,13863,B,,
Autocuration,,1,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=2.2-3.2,,CHEMBL616172,H,8,,,,,BAO_0000357,10576,,1220,,13863,B,,
Autocuration,,1,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=2.7-3.6,,CHEMBL616173,H,8,,,,,BAO_0000357,10576,,1221,,13863,B,,
Autocuration,,1,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=20-23,,CHEMBL616174,H,8,,,,,BAO_0000357,10576,,1222,,13863,B,,
Autocuration,,1,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=21-28,,CHEMBL616175,H,8,,,,,BAO_0000357,10576,,1223,,13863,B,,
Autocuration,,1,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=240-760,,CHEMBL616176,H,8,,,,,BAO_0000357,10576,,1224,,13863,B,,
Autocuration,,1,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=39-87,,CHEMBL616177,H,8,,,,,BAO_0000357,10576,,1225,,13863,B,,
Autocuration,,1,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=4.6-5.2,,CHEMBL616178,H,8,,,,,BAO_0000357,10576,,1226,,13863,B,,
Autocuration,,1,,,Inhibitory activity tested in vitro at 5-hydroxytryptamine 1A receptor binding site in rat,,CHEMBL616179,H,8,,,,,BAO_0000019,10576,,1227,,9742,B,,
Autocuration,,1,,,Inhibitory concentration against 5-hydroxytryptamine 1A receptor,,CHEMBL616180,H,8,,,,,BAO_0000357,10576,,1228,,12073,B,,
Autocuration,,1,,,Inhibitory concentration against binding of 5-hydroxytryptamine 1A receptor from striata of male Wistar rats by displacement of [3H]8-OH-DPAT,,CHEMBL616181,H,8,,,,,BAO_0000357,10576,,1229,,4101,B,,
Autocuration,,1,,,Inhibitory concentration against radioligand [3H]hydroxy-2-(di-n-propylamino)-tetralin binding to 5-hydroxytryptamine 1A receptor in rat,,CHEMBL616182,H,8,,,,,BAO_0000019,10576,,1230,,15360,B,,
Autocuration,,1,,,Inhibitory concentration against radioligand [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,,CHEMBL616183,H,8,,,,,BAO_0000221,10576,,1231,Hippocampus,11576,B,,10000000.0
Expert,,1,,,Inhibition of the 5-hydroxytryptamine 1A receptor in rat dorsal raphe,,CHEMBL615874,H,8,,,,,BAO_0000019,10576,,1232,,5834,B,,
Expert,,1,CHO-K1,,Inhibitory concentration against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,,CHEMBL615875,D,9,,485.0,Rattus norvegicus,10116.0,BAO_0000219,10576,,1233,,2395,B,,
Autocuration,,1,,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand,,CHEMBL615876,H,8,,,,,BAO_0000019,10576,,1234,,1375,B,,
Autocuration,,1,,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand; NT means not tested,,CHEMBL615877,H,8,,,,,BAO_0000019,10576,,1235,,1375,B,,
Autocuration,,1,,,The compound was evaluated for the ability to displace [3H]- 8-OH -DPAT from 5-hydroxytryptamine 1A receptor ( striata of male wistar rats),,CHEMBL615878,H,8,,,,,BAO_0000357,10576,,1236,,3967,B,,
Expert,,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor binding site using [3H]8-OH-DPAT. ,,CHEMBL615879,H,8,,,,,BAO_0000357,10576,,1237,,12884,B,,
Expert,,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using receptor binding assay,,CHEMBL615880,H,8,,,,,BAO_0000357,10576,,1238,,2343,B,,
Autocuration,,1,,,"The compound was tested in vitro for inhibitory activity against 5-HT1A receptor in rats, using [3H]8-OH-DPAT as radioligand",,CHEMBL615881,H,8,,,,,BAO_0000019,10576,,1239,,11511,B,,
Expert,,1,,,"Inhibitory activity against 5-hydroxytryptamine 1A receptor in rats, using [3H]8-OH-DPAT as radioligand",,CHEMBL615882,D,9,,,Rattus norvegicus,10116.0,BAO_0000019,10576,,1240,,11511,B,,
Autocuration,,1,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat,,CHEMBL615883,H,8,,,,,BAO_0000218,10576,,1241,,16394,F,In vivo,
Autocuration,,1,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.10-6.20),,CHEMBL615884,H,8,,,,,BAO_0000218,10576,,1242,,16394,F,In vivo,
Autocuration,,1,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.60),,CHEMBL615885,H,8,,,,,BAO_0000218,10576,,1243,,16394,F,In vivo,
Autocuration,,1,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.80),,CHEMBL615886,H,8,,,,,BAO_0000218,10576,,1244,,16394,F,In vivo,
Autocuration,,1,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.37-4.27),,CHEMBL615887,H,8,,,,,BAO_0000218,10576,,1245,,16394,F,In vivo,
Autocuration,,1,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-2.70),,CHEMBL615888,H,8,,,,,BAO_0000218,10576,,1246,,16394,F,In vivo,
Autocuration,,1,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-4),,CHEMBL615889,H,8,,,,,BAO_0000218,10576,,1247,,16394,F,In vivo,
Autocuration,,1,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.45-4.51),,CHEMBL615890,H,8,,,,,BAO_0000218,10576,,1248,,16394,F,In vivo,
Autocuration,,1,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.50-5.30),,CHEMBL615891,H,8,,,,,BAO_0000218,10576,,1249,,16394,F,In vivo,
Autocuration,,1,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.60-1.60),,CHEMBL615892,H,8,,,,,BAO_0000218,10576,,1250,,16394,F,In vivo,
Autocuration,,1,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.72-2.87),,CHEMBL615893,H,8,,,,,BAO_0000218,10576,,1251,,16394,F,In vivo,
Autocuration,,1,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.80-5.80),,CHEMBL615894,H,8,,,,,BAO_0000218,10576,,1252,,16394,F,In vivo,
Autocuration,,1,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (1.50-16.5),,CHEMBL615895,H,8,,,,,BAO_0000218,10576,,1253,,16394,F,In vivo,
Autocuration,,1,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (2.20-30.5),,CHEMBL615896,H,8,,,,,BAO_0000218,10576,,1254,,16394,F,In vivo,
Autocuration,,1,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges is not computable,,CHEMBL615897,H,8,,,,,BAO_0000218,10576,,1255,,16394,F,In vivo,
Expert,,1,,,"Percent increase of R(+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",Membranes,CHEMBL615898,D,9,,,Rattus norvegicus,10116.0,BAO_0000249,10576,,1256,,16616,F,,
Autocuration,,1,,,% inhibition towards 5-HT1A receptor from rat hippocampal membranes,,CHEMBL615899,H,8,,,,,BAO_0000019,10576,,1257,,16796,B,,
Autocuration,,1,,,% inhibition towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,,CHEMBL616291,H,8,,,,,BAO_0000019,10576,,1258,,16796,B,,
Autocuration,,1,,,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor.,,CHEMBL616292,H,8,,,,,BAO_0000357,10576,,1259,,15629,B,,
Autocuration,,1,,,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",,CHEMBL616293,H,8,,,,,BAO_0000249,10576,,1260,,13241,F,,
Expert,,1,,,Measurement of binding affinity by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,CHEMBL616294,H,8,,,,,BAO_0000221,10576,,1261,Hippocampus,12073,B,,10000000.0
Autocuration,,1,,,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane,,CHEMBL616295,H,8,,,,,BAO_0000249,10576,,1262,Hippocampus,14286,B,,10000000.0
Autocuration,,1,,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex at 10 uM,,CHEMBL616296,H,8,,,,,BAO_0000221,10576,,1263,Brain,14542,B,,955.0
Autocuration,,1,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,,CHEMBL616297,H,8,,,,,BAO_0000019,10576,,1264,,13630,F,,
Autocuration,,1,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0+ 1 uM 5-HT.,,CHEMBL616605,H,8,,,,,BAO_0000019,10576,,1265,,13630,F,,
Autocuration,,1,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.01 uM+ 1 uM 5-HT.,,CHEMBL616606,H,8,,,,,BAO_0000019,10576,,1266,,13630,F,,
Autocuration,,1,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,,CHEMBL616607,H,8,,,,,BAO_0000019,10576,,1267,,13630,F,,
Expert,,1,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,,CHEMBL616608,H,8,,,,,BAO_0000019,10576,,1268,,13630,F,,
Autocuration,,1,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM+ 1 uM 5-HT.,,CHEMBL616609,H,8,,,,,BAO_0000019,10576,,1269,,13630,F,,
Expert,,1,,,Effect against 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at 0.1 uM dose,,CHEMBL616610,D,9,,,Rattus norvegicus,10116.0,BAO_0000019,10576,,1270,,13630,F,,
Autocuration,,1,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,,CHEMBL616611,H,8,,,,,BAO_0000019,10576,,1271,,13630,F,,
Expert,,1,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 1 uM 5-HT.,,CHEMBL616612,H,8,,,,,BAO_0000019,10576,,1272,,13630,F,,
Autocuration,,1,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 0.1 uM 5-HT.,,CHEMBL616613,H,8,,,,,BAO_0000019,10576,,1273,,13630,F,,
Expert,,1,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM,,CHEMBL616614,H,8,,,,,BAO_0000019,10576,,1274,,13630,F,,
Autocuration,,1,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM+ 10 uM 5-HT.,,CHEMBL616615,H,8,,,,,BAO_0000019,10576,,1275,,13630,F,,
Expert,,1,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,,CHEMBL616616,H,8,,,,,BAO_0000019,10576,,1276,,13630,F,,
Autocuration,,1,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 0.1 uM 5-HT.,,CHEMBL616617,H,8,,,,,BAO_0000019,10576,,1277,,13630,F,,
Autocuration,,1,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,,CHEMBL616618,H,8,,,,,BAO_0000019,10576,,1278,,13630,F,,
Autocuration,,1,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 1 uM 5-HT.,,CHEMBL616619,H,8,,,,,BAO_0000019,10576,,1279,,13630,F,,
Expert,,1,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 3 uM 5-HT.,,CHEMBL616620,H,8,,,,,BAO_0000019,10576,,1280,,13630,F,,
Expert,,1,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,,CHEMBL616621,H,8,,,,,BAO_0000019,10576,,1281,,13630,F,,
Autocuration,,1,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 30 uM,,CHEMBL616622,H,8,,,,,BAO_0000019,10576,,1282,,13630,F,,
Expert,,1,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM,,CHEMBL616146,H,8,,,,,BAO_0000019,10576,,1283,,13630,F,,
Autocuration,,1,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM+ 50 uM 5-HT.,,CHEMBL832873,H,8,,,,,BAO_0000019,10576,,1284,,13630,F,,
Autocuration,,1,,,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM,,CHEMBL616147,H,8,,,,,BAO_0000019,10576,,1285,,13630,F,,
Autocuration,,1,,,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,,CHEMBL872872,H,8,,,,,BAO_0000019,10576,,1286,,13630,F,,
Autocuration,,1,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,,CHEMBL616148,H,8,,,,,BAO_0000019,10576,,1287,,13630,F,,
Autocuration,,1,,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue,,CHEMBL616149,H,8,,,,,BAO_0000221,10576,,1288,Hippocampus,9783,B,,10000000.0
Expert,,1,,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue at 1 uM,,CHEMBL616150,H,8,,,,,BAO_0000221,10576,,1289,Hippocampus,9783,B,,10000000.0
Expert,,1,,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membranes at 10e-7 M,Membranes,CHEMBL616151,D,9,,,Rattus norvegicus,10116.0,BAO_0000249,10576,,1290,,14331,B,,
Expert,,1,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue at 1 uM,,CHEMBL872873,H,8,,,,,BAO_0000221,10576,,1291,Hippocampus,15260,B,,10000000.0
Autocuration,,1,,,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 0.1 uM concentration,,CHEMBL616670,H,8,,,,,BAO_0000221,10576,,1292,Hippocampus,15260,B,,10000000.0
Autocuration,,1,,,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 1 uM concentration,,CHEMBL616671,H,8,,,,,BAO_0000221,10576,,1293,Hippocampus,15260,B,,10000000.0
Expert,,1,,,"Percent inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",,CHEMBL884861,D,9,,,Rattus norvegicus,10116.0,BAO_0000249,10576,,1294,,16616,F,,
Autocuration,,1,,,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor,,CHEMBL616672,H,8,,,,,BAO_0000357,10576,,1295,,15629,B,,
Autocuration,,1,,,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,,CHEMBL616673,H,8,,,,,BAO_0000019,10576,,1296,,15086,B,,
Expert,,1,,,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,,CHEMBL616674,H,8,,,,,BAO_0000019,10576,,1297,,5717,F,,
Autocuration,,1,,,Binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,,CHEMBL616675,H,8,,,,,BAO_0000357,10576,,1298,,12652,B,,
Autocuration,,1,,,In vitro binding affinity for 5-hydroxytryptamine 1A receptor was determined by measuring specific inhibition of [125I]-binding to rat hippocampal membrane preparations,,CHEMBL616676,H,8,,,,,BAO_0000221,10576,,1299,Hippocampus,14608,B,,10000000.0
Autocuration,,1,,,Inhibition of binding of [125I]-8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,CHEMBL616677,H,8,,,,,BAO_0000221,10576,,1300,Hippocampus,12306,B,,10000000.0
Autocuration,,1,,,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,CHEMBL616678,H,8,,,,,BAO_0000221,10576,,1301,Hippocampus,12306,B,,10000000.0
Expert,,1,,,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,CHEMBL616679,D,9,,,Rattus norvegicus,10116.0,BAO_0000357,10576,,1302,,15247,B,,
Expert,,1,,,Ability to bind to central serotonin 5-hydroxytryptamine 1A receptor in vitro in hippocampus of the rat brain using [3H]8-OH-DPAT radioligand,,CHEMBL616680,H,8,,,,,BAO_0000221,10576,,1303,Hippocampus,17529,B,,10000000.0
Autocuration,,1,,,Ability to displace [3H]- -OH-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,,CHEMBL616681,H,8,,,,,BAO_0000221,10576,,1304,Hippocampus,14826,B,,10000000.0
Autocuration,,1,,,Ability to displace [3H]- -(OH)-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,,CHEMBL616682,H,8,,,,,BAO_0000221,10576,,1305,Hippocampus,14826,B,,10000000.0
Autocuration,,1,,,Ability to displace [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,,CHEMBL616683,H,8,,,,,BAO_0000221,10576,,1306,Hippocampus,13241,B,,10000000.0
Autocuration,,1,,,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor,,CHEMBL616684,H,8,,,,,BAO_0000221,10576,,1307,Hippocampus,14093,B,,10000000.0
Autocuration,,1,,,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor; Not tested,,CHEMBL616685,H,8,,,,,BAO_0000221,10576,,1308,Hippocampus,14093,B,,10000000.0
Autocuration,,1,,,Affinity at [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in rat brain homogenate was determined,,CHEMBL616686,H,8,,,,,BAO_0000221,10576,,1309,Brain,14442,B,,955.0
Autocuration,,1,,,Affinity for 5-hydroxytryptamine 1A receptor site,,CHEMBL616687,H,8,,,,,BAO_0000357,10576,,1310,,9919,B,,
Autocuration,,1,,,Affinity for 5-hydroxytryptamine 1A receptor site,,CHEMBL616688,H,8,,,,,BAO_0000357,10576,,1311,,9919,B,,
Autocuration,,1,,,Affinity in displacing [3H]8-OH-DPAT from rat hippocampal 5-HT1A receptor.,,CHEMBL616689,H,8,,,,,BAO_0000221,10576,,1312,Hippocampus,11440,B,,10000000.0
Autocuration,,1,,,Affinity on 5-hydroxytryptamine 1A receptor labeled by [3H]8-OH-DPAT,,CHEMBL616690,H,8,,,,,BAO_0000357,10576,,1313,,11257,B,,
Expert,,1,,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand,,CHEMBL616691,H,8,,,,,BAO_0000357,10576,,1314,,10330,B,,
Expert,,1,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus mambranes,,CHEMBL616692,D,9,,,Rattus norvegicus,10116.0,BAO_0000221,10576,,1315,Hippocampus,17331,B,,10000000.0
Expert,,1,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane,,CHEMBL616693,H,8,,,,,BAO_0000249,10576,,1316,,16567,B,,
Expert,,1,,,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",,CHEMBL616694,D,9,,,Rattus norvegicus,10116.0,BAO_0000019,10576,,1317,,12058,B,,
Autocuration,,1,,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal tissue,,CHEMBL616695,H,8,,,,,BAO_0000221,10576,,1318,Hippocampus,9699,B,,10000000.0
Autocuration,,1,,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat was determined using [3H]8-OH-DPAT in binding assay,,CHEMBL616696,H,8,,,,,BAO_0000357,10576,,1319,,9547,B,,
Autocuration,,1,,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]DOB as radioligand,,CHEMBL616697,H,8,,,,,BAO_0000357,10576,,1320,,10330,B,,
Autocuration,,1,,,Binding affinity against rat 5-hydroxytryptamine 1A receptor,,CHEMBL616698,H,8,,,,,BAO_0000357,10576,,1321,,14331,B,,
Expert,,1,,,Binding affinity against rat brain 5-hydroxytryptamine 1A receptor,,CHEMBL616949,D,9,,,Rattus norvegicus,10116.0,BAO_0000019,10576,,1322,,14060,B,,
Autocuration,,1,,,Binding affinity against the 5-hydroxytryptamine 1A receptor labelled with [3H]8-OH-DPAT in rat hippocampal homogenates,,CHEMBL616950,H,8,,,,,BAO_0000221,10576,,1323,Hippocampus,14744,B,,10000000.0
Autocuration,,1,,,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,,CHEMBL832875,H,8,,,,,BAO_0000357,10576,,1324,,13506,B,,
Expert,,1,,,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,,CHEMBL616951,H,8,,,,,BAO_0000221,10576,,1325,Brain,10862,B,,955.0
Expert,,1,,,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,,CHEMBL616952,H,8,,,,,BAO_0000221,10576,,1326,Brain,10862,B,,955.0
Expert,,1,,,Binding affinity at rat 5-hydroxytryptamine 1A receptor by [3H]WB-4101 displacement.,,CHEMBL616953,H,8,,,,,BAO_0000357,10576,,1327,,10062,B,,
Autocuration,,1,,,Binding affinity for 5-hydroxytryptamine 1A receptor by use of [3H]8-OH-DPAT in male rat,,CHEMBL616954,H,8,,,,,BAO_0000357,10576,,1328,,12073,B,,
Autocuration,,1,,,GTPgammaS radioligand binding assay,,CHEMBL616955,H,8,,,,,BAO_0000357,106,,1329,,14875,B,,
Autocuration,,1,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,,CHEMBL616956,H,8,,,,,BAO_0000357,106,,1330,,2391,B,,
Autocuration,,1,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Partial agonist,,CHEMBL616957,H,8,,,,,BAO_0000019,106,,1331,,2391,F,,
Autocuration,,1,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Slient antagonist,,CHEMBL616958,H,8,,,,,BAO_0000019,106,,1332,,2391,F,,
Autocuration,,1,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,,CHEMBL616959,H,8,,,,,BAO_0000357,106,,1333,,2391,B,,
Autocuration,,1,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,,CHEMBL616960,H,8,,,,,BAO_0000357,106,,1334,,2391,B,,
Autocuration,,1,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; silent antagonist,,CHEMBL616961,H,8,,,,,BAO_0000019,106,,1335,,2391,F,,
Expert,,1,HeLa,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor,,CHEMBL616962,H,8,,308.0,,,BAO_0000219,106,,1336,,17211,B,,
Autocuration,,1,HeLa,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor receptor,,CHEMBL616963,H,8,,308.0,,,BAO_0000219,106,,1337,,17211,B,,
Expert,,1,,,Affinity towards human 5-hydroxytryptamine 1B serotonin receptor,,CHEMBL616524,D,9,,,Homo sapiens,9606.0,BAO_0000357,106,,1338,,6491,B,,
Autocuration,,1,CHO,,Binding affinity against 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,,CHEMBL616525,H,8,,449.0,,,BAO_0000219,106,,1339,,16190,B,,
Autocuration,,1,,,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]5-CT as radioligand,,CHEMBL872908,H,8,,,,,BAO_0000019,106,,1340,,14165,B,,
Autocuration,,1,,,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]GR-125743 as radioligand,,CHEMBL616526,H,8,,,,,BAO_0000019,106,,1341,,14165,B,,
Expert,,1,,,Binding affinity to cloned human 5-hydroxytryptamine 1B receptor,,CHEMBL616527,D,9,,,Homo sapiens,9606.0,BAO_0000357,106,,1342,,4234,B,,
Expert,,1,,,Binding affinity towards human 5-hydroxytryptamine 1B receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,,CHEMBL616528,H,8,,,,,BAO_0000219,106,,1343,,6328,B,,
Autocuration,,1,,,Binding affinity for recombinant human 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,CHEMBL616529,H,8,,,,,BAO_0000357,106,,1344,,14770,B,,
Autocuration,,1,,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1B receptor using [3H]5-CT as radioligand,,CHEMBL616530,H,8,,,,,BAO_0000357,106,,1345,,2598,B,,
Expert,,1,,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,,CHEMBL616531,H,8,,,,,BAO_0000357,106,,1346,,6897,B,,
Autocuration,,1,,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,,CHEMBL616532,H,8,,,,,BAO_0000357,106,,1347,,6897,B,,
Autocuration,,1,,,Binding affinity towards 5-hydroxytryptamine 1B receptor,,CHEMBL616533,H,8,,,,,BAO_0000357,106,,1348,,6013,B,,
Expert,,1,,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,,CHEMBL616534,H,8,,,,,BAO_0000357,106,,1349,,5843,B,,
Expert,,1,,,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT trifluoroacetate as radioligand,,CHEMBL616535,H,8,,,,,BAO_0000357,106,,1350,,14454,B,,
Autocuration,,1,,,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT radioligand,,CHEMBL616536,H,8,,,,,BAO_0000357,106,,1351,,16209,B,,
Autocuration,,1,,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1B receptor,,CHEMBL616537,H,8,,,,,BAO_0000357,106,,1352,,3935,B,,
Expert,,1,CHO-K1,,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1B receptor in CHO-K1 cells,,CHEMBL616538,H,8,,485.0,,,BAO_0000219,106,,1353,,13729,F,,
Expert,,1,,,Agonist activity to the human recombinant 5-hydroxytryptamine 1B receptor,,CHEMBL616539,H,8,,,,,BAO_0000019,106,,1354,,14251,F,,
Expert,,1,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor,,CHEMBL616540,H,8,,,,,BAO_0000019,106,,1355,,17085,B,,
Autocuration,,1,,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,,CHEMBL616429,H,8,,,,,BAO_0000357,106,,1356,,3025,B,,
Expert,,1,,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor,,CHEMBL616430,H,8,,,,,BAO_0000357,106,,1357,,15315,B,,
Expert,,1,,,Receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor in Cos-7 cells,,CHEMBL616431,D,9,,,Homo sapiens,9606.0,BAO_0000219,106,,1358,,14214,B,,
Expert,,1,,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,,CHEMBL616432,D,9,,,Homo sapiens,9606.0,BAO_0000357,106,,1359,,3804,B,,
Expert,,1,,,Affinity for 5-hydroxytryptamine 1B receptor subtype,,CHEMBL616433,D,9,,,Homo sapiens,9606.0,BAO_0000357,106,,1360,,2391,B,,
Expert,,1,,,Binding affinity for human 5-hydroxytryptamine 1B receptor,,CHEMBL616434,D,9,,,Homo sapiens,9606.0,BAO_0000357,106,,1361,,4175,B,,
Autocuration,,1,CHO,,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand; Not determined,,CHEMBL616435,H,8,,449.0,,,BAO_0000219,106,,1362,,17296,B,,
Expert,,1,,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor; ND means not determined,,CHEMBL616436,H,8,,,,,BAO_0000019,106,,1363,,17085,B,,
Autocuration,,1,HeLa,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,,CHEMBL616437,H,8,,308.0,,,BAO_0000219,106,,1364,,17211,B,,
Autocuration,,1,HeLa,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT=not tested,,CHEMBL616438,H,8,,308.0,,,BAO_0000219,106,,1365,,17211,B,,
Autocuration,,1,HeLa,,Ability to displace [3H]-5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,,CHEMBL616439,H,8,,308.0,,,BAO_0000219,106,,1366,,17211,B,,
Expert,,1,,,Binding activity against human 5-hydroxytryptamine 1B receptor; NT means not tested,,CHEMBL616440,D,9,,,Homo sapiens,9606.0,BAO_0000357,106,,1367,,15926,B,,
Autocuration,,1,CHO-K1,,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor; not tested,,CHEMBL616441,H,8,,485.0,,,BAO_0000219,106,,1368,,16312,B,,
Expert,,1,,,Selectivity ratio against cloned human 5-HT1B receptor to that of h5-HT1D receptor,,CHEMBL616442,H,8,,,,,BAO_0000357,106,,1369,,5843,B,,
Autocuration,,1,,,Selectivity ratio against cloned human 5-hydroxytryptamine 1B receptor to that of human 5-hydroxytryptamine 1D receptor,,CHEMBL616443,H,8,,,,,BAO_0000357,106,,1370,,5843,B,,
Expert,,1,CHO-K1,,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor,,CHEMBL616444,H,8,,485.0,,,BAO_0000219,106,,1371,,16312,B,,
Expert,,1,,,Binding activity against human 5-hydroxytryptamine 1B receptor,,CHEMBL616445,D,9,,,Homo sapiens,9606.0,BAO_0000357,106,,1372,,15926,B,,
Expert,,1,,,Binding activity against human 5-hydroxytryptamine 1B receptor,,CHEMBL616446,D,9,,,Homo sapiens,9606.0,BAO_0000357,106,,1373,,15926,B,,
Expert,,1,CHO,,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,,CHEMBL616447,D,9,,449.0,Homo sapiens,9606.0,BAO_0000219,106,,1374,,4540,B,,
Autocuration,,1,,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor was determined,,CHEMBL616448,H,8,,,,,BAO_0000357,106,,1375,,6166,B,,
Autocuration,,1,CHO,,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand,,CHEMBL616449,H,8,,449.0,,,BAO_0000219,106,,1376,,17296,B,,
Autocuration,,1,CHO,,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells,,CHEMBL616450,H,8,,449.0,,,BAO_0000219,106,,1377,,17296,B,,
Autocuration,,1,CHO,,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells using [3H]5-CT as radioligand,,CHEMBL857974,H,8,,449.0,,,BAO_0000219,106,,1378,,17296,B,,
Autocuration,,1,CHO,,Binding affinity towards 5-hydroxytryptamine 1B (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,,CHEMBL616451,H,8,,449.0,,,BAO_0000219,106,,1379,,15779,B,,
Autocuration,,1,CHO,,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,,CHEMBL616452,H,8,,449.0,,,BAO_0000219,106,,1380,,15779,B,,
Autocuration,,1,CHO,,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand;ND means no data.,,CHEMBL616453,H,8,,449.0,,,BAO_0000219,106,,1381,,15779,B,,
Autocuration,,1,CHO,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as the radioligand,,CHEMBL616454,H,8,,449.0,,,BAO_0000219,106,,1382,,4199,B,,
Expert,,1,,,Binding affinity for human 5-hydroxytryptamine 1B receptor,,CHEMBL616455,D,9,,,Homo sapiens,9606.0,BAO_0000357,106,,1383,,14875,B,,
Autocuration,,1,CHO,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,,CHEMBL616456,H,8,,449.0,,,BAO_0000219,106,,1384,,15146,B,,
Autocuration,,1,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1B receptor in CHO using [3H]5-HT as a radioligand,,CHEMBL616457,H,8,,,,,BAO_0000357,106,,1385,,5213,B,,
Autocuration,,1,CHO,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,,CHEMBL616458,H,8,,449.0,,,BAO_0000219,106,,1386,,14818,B,,
Autocuration,,1,CHO,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1B receptor in CHO cells, using [3H]5-HT as radioligand",,CHEMBL616459,H,8,,449.0,,,BAO_0000219,106,,1387,,4829,B,,
Expert,,1,,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 1 uM,,CHEMBL616460,H,8,,,,,BAO_0000019,106,,1388,,14454,F,,
Expert,,1,,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 10 uM,,CHEMBL616461,H,8,,,,,BAO_0000019,106,,1389,,14454,F,,
Autocuration,,1,CHO,,"Effect of compound on [35S]GTP-gamma-S, radioligand binding CHO cells expressing human 5-hydroxytryptamine 1B receptor",,CHEMBL616462,H,8,,449.0,,,BAO_0000219,106,,1390,,14875,F,,
Autocuration,,1,CHO,,"Effect of compound on [35S]GTP-gamma-S, radioligand binding in CHO cells expressing human 5-hydroxytryptamine 1B receptor",,CHEMBL616463,H,8,,449.0,,,BAO_0000219,106,,1391,,14875,F,,
Autocuration,,1,,,"Compound was tested for maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-HT.",,CHEMBL616464,H,8,,,,,BAO_0000019,105,,1392,,15250,F,,
Autocuration,,1,CHO,,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells.,,CHEMBL616465,H,8,,449.0,,,BAO_0000219,105,,1393,,15250,B,,
Autocuration,,1,,,The compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,,CHEMBL832874,H,8,,,,,BAO_0000357,17105,,1394,,15086,B,,
Autocuration,,1,,,5-hydroxytryptamine 1B receptor agonist potency determined in rabbit saphenous vein contraction model,,CHEMBL616184,H,8,,,Oryctolagus cuniculus,9986.0,BAO_0000019,106,,1395,,3025,F,,
Autocuration,,1,,,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein (RbSV).,,CHEMBL616185,H,8,,,Oryctolagus cuniculus,9986.0,BAO_0000019,106,,1396,,14998,B,,
Intermediate,,1,,,"Binding affinity against vascular 5-hydroxytryptamine 1B receptor, measured using ring preparations of rabbit saphenous vein (RbSV)",,CHEMBL616186,H,8,,,Oryctolagus cuniculus,9986.0,BAO_0000019,106,,1397,,14998,B,,
Autocuration,,1,,,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein(RbSV).,,CHEMBL616187,H,8,,,Oryctolagus cuniculus,9986.0,BAO_0000019,106,,1398,,14998,B,,
Expert,,1,,,Binding affinity towards 5-hydroxytryptamine 1B receptor was measured using [3H]5-HT as radioligand,,CHEMBL616188,H,8,,,,,BAO_0000357,10577,,1399,,13969,B,,
Intermediate,,1,,,Binding affinity for 5-hydroxytryptamine 1B receptor,,CHEMBL873475,D,9,,,,,BAO_0000357,10577,,1400,,13392,B,,
Expert,,1,,,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Less active,,CHEMBL616189,D,9,,,Rattus norvegicus,10116.0,BAO_0000019,10577,,1401,Striatum,3651,B,,2435.0
Expert,,1,,,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,,CHEMBL616190,H,8,,,,,BAO_0000357,10577,,1402,,10025,B,,
Autocuration,,1,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=48-77,,CHEMBL616191,H,8,,,,,BAO_0000357,10576,,1403,,13863,B,,
Autocuration,,1,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=63-95,,CHEMBL616192,H,8,,,,,BAO_0000357,10576,,1404,,13863,B,,
Autocuration,,1,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=710-980,,CHEMBL616193,H,8,,,,,BAO_0000357,10576,,1405,,13863,B,,
Autocuration,,1,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=78-140,,CHEMBL616194,H,8,,,,,BAO_0000357,10576,,1406,,13863,B,,
Autocuration,,1,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=85-130,,CHEMBL616195,H,8,,,,,BAO_0000357,10576,,1407,,13863,B,,
Autocuration,,1,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=89-280,,CHEMBL616196,H,8,,,,,BAO_0000357,10576,,1408,,13863,B,,
Autocuration,,1,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampus membrane.,,CHEMBL616197,H,8,,,,,BAO_0000249,10576,,1409,Hippocampus,4622,B,,10000000.0
Intermediate,,1,,,Binding affinity at 5-hydroxytryptamine 1A (5-HT1A) receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand,,CHEMBL616198,H,8,,,,,BAO_0000019,10576,,1410,,14911,B,,
Autocuration,,1,,,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,,CHEMBL616199,H,8,,,,,BAO_0000221,10576,,1411,Hippocampus,12678,B,,10000000.0
Expert,,1,,,In vitro binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampal homogenate by [125I](R)-(+)-trans-8-OH-PIPAT displacement.,,CHEMBL616200,H,8,,,,,BAO_0000221,10576,,1412,Hippocampus,12678,B,,10000000.0
Expert,,1,,,In vitro binding affinity to rat hippocampal 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,CHEMBL616201,H,8,,,,,BAO_0000221,10576,,1413,Hippocampus,14235,B,,10000000.0
Expert,,1,,,In vitro binding affinity towards 5-hydroxytryptamine 1A r receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,,CHEMBL616202,H,8,,,,,BAO_0000221,10576,,1414,Hippocampus,14949,B,,10000000.0
Expert,,1,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,,CHEMBL616203,H,8,,,,,BAO_0000221,10576,,1415,Hippocampus,14949,B,,10000000.0
Expert,,1,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; ND=not determined,,CHEMBL616204,H,8,,,,,BAO_0000221,10576,,1416,Hippocampus,14949,B,,10000000.0
Expert,,1,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; Not determined,,CHEMBL616205,H,8,,,,,BAO_0000221,10576,,1417,Hippocampus,14949,B,,10000000.0
Expert,,1,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; not determined,,CHEMBL616206,H,8,,,,,BAO_0000221,10576,,1418,Hippocampus,14949,B,,10000000.0
Expert,,1,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,,CHEMBL616207,H,8,,,,,BAO_0000249,10576,,1419,,16118,B,,
Autocuration,,1,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes,,CHEMBL616208,H,8,,,,,BAO_0000249,10576,,1420,,3268,B,,
Autocuration,,1,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes; Inactive,,CHEMBL616209,H,8,,,,,BAO_0000249,10576,,1421,,3268,B,,
Expert,,1,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using radioligand [3H]-8-OH-DPAT,,CHEMBL616210,H,8,,,,,BAO_0000357,10576,,1422,,16117,B,,
Expert,,1,,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue.,,CHEMBL616211,H,8,,,,,BAO_0000221,10576,,1423,Hippocampus,9783,B,,10000000.0
Autocuration,,1,,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue; NT=Not tested,,CHEMBL616504,H,8,,,,,BAO_0000221,10576,,1424,Hippocampus,9783,B,,10000000.0
Expert,,1,,,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,,CHEMBL616505,D,9,,,Rattus norvegicus,10116.0,BAO_0000221,10576,,1425,Hippocampus,14356,B,,10000000.0
Autocuration,,1,,,Inhibition constant of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,,CHEMBL616506,H,8,,,,,BAO_0000019,10576,,1426,,15740,F,,
Autocuration,,1,,,Inhibition of binding of [125I]8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,CHEMBL872107,H,8,,,,,BAO_0000221,10576,,1427,Hippocampus,12306,B,,10000000.0
Expert,,1,,,Displacement of [3H]5-HT from rat hippocampal 5-hydroxytryptamine 1A receptor with 10e-6 M ketanserin,,CHEMBL616507,D,9,,,Rattus norvegicus,10116.0,BAO_0000221,10576,,1428,Hippocampus,13348,B,,10000000.0
Autocuration,,1,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor in rat cortical membranes using [3H]8-OH-DPAT as a radioligand,,CHEMBL616303,H,8,,,,,BAO_0000249,10576,,1429,,10394,B,,
Autocuration,,1,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue,,CHEMBL616304,H,8,,,,,BAO_0000221,10576,,1430,Hippocampus,15260,B,,10000000.0
Expert,,1,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,,CHEMBL616305,H,8,,,,,BAO_0000221,10576,,1431,Hippocampus,10046,B,,10000000.0
Intermediate,,1,,,Antagonist activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor,,CHEMBL616306,H,8,,,,,BAO_0000221,10576,,1432,Hippocampus,15260,F,,10000000.0
Autocuration,,1,,,Inhibitory affinity constant against 5-hydroxytryptamine 1A receptor,,CHEMBL616307,H,8,,,,,BAO_0000357,10576,,1433,,12851,B,,
Expert,,1,,,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat brain hippocampus,,CHEMBL881829,D,9,,,Rattus norvegicus,10116.0,BAO_0000221,10576,,1434,Hippocampus,2148,B,,10000000.0
Expert,,1,,,Affinity against the 5-hydroxytryptamine receptor 1A using [3H]WB-4101.,,CHEMBL616308,H,8,,,,,BAO_0000357,10576,,1435,,13134,B,,
Autocuration,,1,,,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain,,CHEMBL616309,H,8,,,,,BAO_0000019,10576,,1436,,12462,B,,
Expert,,1,,,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain tissue,,CHEMBL616310,H,8,,,,,BAO_0000019,10576,,1437,,12462,B,,
Autocuration,,1,CHO,,Tested for affinity against 5-hydroxytryptamine 1A receptors using [3H]8-OH-DPAT in homogenized rat cloned CHO cells,,CHEMBL616311,H,8,,449.0,,,BAO_0000219,10576,,1438,,12462,B,,
Expert,,1,,,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand,,CHEMBL616312,H,8,,,,,BAO_0000357,10576,,1439,,11933,B,,
Autocuration,,1,,,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand; ND is Not Determined,,CHEMBL616313,H,8,,,,,BAO_0000357,10576,,1440,,11933,B,,
Expert,,1,,,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,,CHEMBL616314,D,9,,,Rattus norvegicus,10116.0,BAO_0000221,10576,,1441,Hippocampus,403,B,,10000000.0
Autocuration,,1,,,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus,,CHEMBL616315,H,8,,,,,BAO_0000221,10576,,1442,Hippocampus,15538,B,,10000000.0
Autocuration,,1,,,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; NA means Not Active,,CHEMBL616567,H,8,,,,,BAO_0000221,10576,,1443,Hippocampus,15538,B,,10000000.0
Autocuration,,1,,,Tested for binding affinity by measuring displacement of [3H]-8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; ND means Not Determined,,CHEMBL616568,H,8,,,,,BAO_0000221,10576,,1444,Hippocampus,15538,B,,10000000.0
Intermediate,,1,,,Binding affinity to displace [3H]2-(di-N-propylamino)-8-hydroxy-tetralin from 5-hydroxytryptamine 1A (5-HT1A) receptor in rat frontal cortex homogenates,,CHEMBL616569,H,8,,,,,BAO_0000019,10576,,1445,,12464,B,,
Expert,,1,,,Binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand assay.,,CHEMBL616570,H,8,,,,,BAO_0000357,10576,,1446,,1455,B,,
Autocuration,,1,,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,,CHEMBL616571,H,8,,,,,BAO_0000357,10576,,1447,,12652,B,,
Autocuration,,1,,,Tested for the inhibitory activity against 5-hydroxytryptamine 1A receptor in rat hippocampal,,CHEMBL616572,H,8,,,,,BAO_0000221,10576,,1448,Hippocampus,12639,B,,10000000.0
Expert,,1,,,Tested in vitro for binding affinity by measuring its ability to inhibit [3H]8-OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes.,,CHEMBL616573,H,8,,,,,BAO_0000249,10576,,1449,,13949,B,,
Expert,,1,,,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT,,CHEMBL616574,D,9,,,Rattus norvegicus,10116.0,BAO_0000357,10576,,1450,,12463,B,,
Expert,,1,,,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation,,CHEMBL616575,H,8,,,,,BAO_0000221,10576,,1451,Hippocampus,14829,B,,10000000.0
Autocuration,,1,,,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation; ND=not determined,,CHEMBL872108,H,8,,,,,BAO_0000221,10576,,1452,Hippocampus,14829,B,,10000000.0
Autocuration,,1,,,The binding affinity was measured on 5-hydroxytryptamine 1A receptor using [3H]- 8-OH-DPAT as radioligand.,,CHEMBL616576,H,8,,,,,BAO_0000357,10576,,1453,,12092,B,,
Autocuration,,1,,,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 1 mM of MnCl2,,CHEMBL616577,H,8,,,,,BAO_0000249,10576,,1454,,403,B,,
Autocuration,,1,,,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 3*10e-5 M GTP gamma S,,CHEMBL616578,H,8,,,,,BAO_0000249,10576,,1455,,403,B,,
Expert,,1,,,Binding affinity at 5-hydroxytryptamine 1A receptor from striata of wistar rats by [3H]- 8-OH -DPAT displacement.,,CHEMBL616579,H,8,,,,,BAO_0000357,10576,,1456,,3967,B,,
Expert,,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat brain synaptosomal preparations,,CHEMBL616580,D,9,,,Rattus norvegicus,10116.0,BAO_0000019,10576,,1457,,12771,B,,
Autocuration,,1,,,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,,CHEMBL616581,H,8,,,,,BAO_0000019,10576,,1458,,15086,B,,
Autocuration,,1,,,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,,CHEMBL616582,H,8,,,,,BAO_0000221,10576,,1459,Hippocampus,14909,B,,10000000.0
Expert,,1,,,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,,CHEMBL616583,H,8,,,,,BAO_0000221,10576,,1460,Hippocampus,14949,B,,10000000.0
Expert,,1,,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]8-OH-DPAT,,CHEMBL616584,D,9,,,Rattus norvegicus,10116.0,BAO_0000221,10576,,1461,Hippocampus,2309,B,,10000000.0
Expert,,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,,CHEMBL616585,H,8,,,,,BAO_0000357,10576,,1462,,4170,B,,
Expert,,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 from rat hippocampus,,CHEMBL616586,D,9,,,Rattus norvegicus,10116.0,BAO_0000221,10576,,1463,Hippocampus,11642,B,,10000000.0
Autocuration,,1,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 radioligand in rat hippocampus,,CHEMBL616587,H,8,,,,,BAO_0000221,10576,,1464,Hippocampus,11642,B,,10000000.0
Autocuration,,1,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]-8-OH-DPAT as radioligand,,CHEMBL616588,H,8,,,,,BAO_0000221,10576,,1465,Hippocampus,12953,B,,10000000.0
Autocuration,,1,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand.,,CHEMBL616589,H,8,,,,,BAO_0000221,10576,,1466,Hippocampus,12953,B,,10000000.0
Expert,,1,,,Binding affinity for 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand,,CHEMBL616590,H,8,,,,,BAO_0000221,10576,,1467,Hippocampus,12953,B,,10000000.0
Expert,,1,CHO,,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1A receptor expressed in CHO cells, by using [3H]8-OH-DPAT as radioligand.",,CHEMBL616591,H,8,,449.0,,,BAO_0000219,10576,,1468,,12903,B,,
Expert,,1,,,Displacement of the radioligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,CHEMBL616592,H,8,,,,,BAO_0000357,10576,,1469,,12536,B,,
Autocuration,,1,,,The inhibition activity of 5-HT1A at 1 uM,,CHEMBL616593,H,8,,,,,BAO_0000357,10576,,1470,,10058,B,,
Expert,,1,CHO-K1,,"Binding affinity against 5-hydroxytryptamine 1A receptor from CHO-K1 cells, using [3H]8-OH-DPAT as the radioligand.",,CHEMBL616594,H,8,,485.0,,,BAO_0000219,10576,,1471,,12902,B,,
Expert,,1,,,Binding affinities against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membrane,,CHEMBL616595,H,8,,,,,BAO_0000249,10576,,1472,,14057,B,,
Autocuration,,1,,,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-HT 1A receptor site.,,CHEMBL616596,H,8,,,,,BAO_0000357,10576,,1473,,11296,B,,
Autocuration,,1,,,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,,CHEMBL616597,H,8,,,,,BAO_0000221,10576,,1474,Hippocampus,11296,B,,10000000.0
Expert,,1,,,Ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,,CHEMBL616598,H,8,,,,,BAO_0000221,10576,,1475,Hippocampus,11296,B,,10000000.0
Expert,,1,,,Antagonist activity to stimulate binding of [35S]-GTP-gamma S binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes,Membranes,CHEMBL616599,D,9,,,Rattus norvegicus,10116.0,BAO_0000249,10576,,1476,,16616,F,,
Expert,,1,,,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",Membranes,CHEMBL616600,D,9,,,Rattus norvegicus,10116.0,BAO_0000249,10576,,1477,Hippocampus,16616,F,,10000000.0
Autocuration,,1,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not -determined.,,CHEMBL616601,H,8,,,,,BAO_0000019,10576,,1478,,16567,B,,
Autocuration,,1,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not defined.,,CHEMBL616602,H,8,,,,,BAO_0000019,10576,,1479,,16567,B,,
Autocuration,,1,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not determined.,,CHEMBL616603,H,8,,,,,BAO_0000019,10576,,1480,,16567,B,,
Autocuration,,1,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND means not determined.,,CHEMBL616604,H,8,,,,,BAO_0000019,10576,,1481,,16567,B,,
Autocuration,,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; No data,,CHEMBL616316,H,8,,,,,BAO_0000249,10576,,1482,,17136,B,,
Autocuration,,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; Not determined,,CHEMBL616317,H,8,,,,,BAO_0000249,10576,,1483,,17136,B,,
Expert,,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates; ND means No data,,CHEMBL616318,D,9,,,Rattus norvegicus,10116.0,BAO_0000019,10576,,1484,,16616,B,,
Autocuration,,1,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes,,CHEMBL616319,H,8,,,,,BAO_0000221,10576,,1485,Hippocampus,17331,B,,10000000.0
Autocuration,,1,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes; Not tested,,CHEMBL616320,H,8,,,,,BAO_0000221,10576,,1486,Hippocampus,17331,B,,10000000.0
Expert,,1,,,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding; Not tested,,CHEMBL616321,D,9,,,Rattus norvegicus,10116.0,BAO_0000221,10576,,1487,Hippocampus,17167,B,,10000000.0
Autocuration,,1,,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,,CHEMBL616322,H,8,,,,,BAO_0000019,10576,,1488,,15740,F,,
Autocuration,,1,,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; not tested,,CHEMBL616323,H,8,,,,,BAO_0000019,10576,,1489,,15740,F,,
Autocuration,,1,,,Ratio of binding affinity to 5-HT 1A and D2 receptor,,CHEMBL616324,H,8,,,,,BAO_0000357,10576,,1490,,4671,B,,
Autocuration,,1,,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,,CHEMBL616325,H,8,,,,,BAO_0000221,10576,,1491,Hippocampus,10058,B,,10000000.0
Autocuration,,1,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,,CHEMBL616326,H,8,,,,,BAO_0000221,10576,,1492,Hippocampus,10058,B,,10000000.0
Autocuration,,1,,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.,,CHEMBL616327,H,8,,,,,BAO_0000221,10576,,1493,Hippocampus,10058,B,,10000000.0
Autocuration,,1,,,Percentage inhibition against 5-hydroxytryptamine 1A receptor,,CHEMBL616328,H,8,,,,,BAO_0000357,10576,,1494,,12073,B,,
Autocuration,,1,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),,CHEMBL858110,H,8,,,,,BAO_0000249,10576,,1495,,2759,B,,
Autocuration,,1,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),,CHEMBL616329,H,8,,,,,BAO_0000249,10576,,1496,,2759,F,,
Autocuration,,1,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),,CHEMBL616330,H,8,,,,,BAO_0000249,10576,,1497,,2759,B,,
Autocuration,,1,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),,CHEMBL616331,H,8,,,,,BAO_0000249,10576,,1498,,2759,F,,
Autocuration,,1,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,,CHEMBL616332,H,8,,,,,BAO_0000249,10576,,1499,,2759,F,,
Autocuration,,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,CHEMBL857063,H,8,,,,,BAO_0000249,10576,,1500,Brain,9737,B,,955.0
Autocuration,,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [3H]8-OH-DPAT as a radioligand,,CHEMBL616333,H,8,,,,,BAO_0000019,10576,,1501,,9737,B,,
Expert,,1,,,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT as radioligand.,,CHEMBL616334,H,8,,,,,BAO_0000019,10576,,1502,,5717,F,,
Autocuration,,1,,,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,,CHEMBL616335,H,8,,,,,BAO_0000221,10576,,1503,Hippocampus,12253,B,,10000000.0
Autocuration,,1,,,Affinity pKi for 5-hydroxytryptamine 1A receptor was measured in rat cortex homogenates.,,CHEMBL616336,H,8,,,,,BAO_0000019,10576,,1504,,14025,B,,
Expert,,1,,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cerebral cortical membrane using [3H]-8-OH-DPAT as radioligand.,,CHEMBL616337,H,8,,,,,BAO_0000249,10576,,1505,,10425,B,,
Autocuration,,1,,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cortex homogenates.,,CHEMBL616338,H,8,,,,,BAO_0000019,10576,,1506,,14998,B,,
Autocuration,,1,,,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]- 8-hydri\oxy-2-(di-n-propylamino)tetraline) binding assay,,CHEMBL616339,H,8,,,,,BAO_0000221,10576,,1507,Hippocampus,13694,B,,10000000.0
Autocuration,,1,,,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]8-hydroxy-2-(di-n-propylamino)-tetraline) binding assay,,CHEMBL616340,H,8,,,,,BAO_0000221,10576,,1508,Hippocampus,13694,B,,10000000.0
Autocuration,,1,,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined,,CHEMBL616341,H,8,,,,,BAO_0000357,10576,,1509,,4342,B,,
Expert,,1,,,Binding affinity against rat 5-hydroxytryptamine 1A receptor,,CHEMBL616342,D,9,,,Rattus norvegicus,10116.0,BAO_0000357,10576,,1510,,12936,B,,
Expert,,1,,,Inhibition of [3H]2-(di-N-propylamino)-8-hydroxytetralin binding to 5-HT1A receptor of rat frontal cortex homogenates,,CHEMBL616343,D,9,,,Rattus norvegicus,10116.0,BAO_0000019,10576,,1511,,13144,B,,
Expert,,1,,,Binding affinity of a compound to rat brain 5-hydroxytryptamine 1A (serotonin) receptor assayed by radiolabeled [3H]-8-OH-DPAT ligand displacement,,CHEMBL616344,H,8,,,,,BAO_0000019,10576,,1512,,13343,B,,
Expert,,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,CHEMBL616345,H,8,,,,,BAO_0000357,10576,,1513,,12132,B,,
Expert,,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]8-OH-DPAT as a radioligand,,CHEMBL616346,H,8,,,,,BAO_0000019,10576,,1514,,15419,B,,
Autocuration,,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,,CHEMBL616347,H,8,,,,,BAO_0000221,10576,,1515,Hippocampus,1479,B,,10000000.0
Expert,,1,,,In vitro by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor on rat cortical membrane,,CHEMBL616348,H,8,,,,,BAO_0000019,10576,,1516,,14287,B,,
Expert,,1,,,Binding affinity at 5-hydroxytryptamine 1A receptor,,CHEMBL616349,H,8,,,,,BAO_0000357,10576,,1517,,13116,B,,
Expert,,1,,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat frontal cortex membranes,Membranes,CHEMBL616152,D,9,,,Rattus norvegicus,10116.0,BAO_0000249,10576,,1518,,2759,B,,
Autocuration,,1,,,Compound was tested for inhibition constant against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,,CHEMBL616153,H,8,,,,,BAO_0000249,10576,,1519,,2759,B,,
Expert,,1,,,"Binding affinity for rat cortex 5-hydroxytryptamine 1A receptor, by displacement of 0.2 nM [3H]8-OH-DPAT radioligand",,CHEMBL616154,H,8,,,,,BAO_0000019,10576,,1520,,14748,B,,
Autocuration,,1,,,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,CHEMBL616155,H,8,,,,,BAO_0000019,10576,,1521,,12304,B,,
Expert,,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT,,CHEMBL616156,D,9,,,Rattus norvegicus,10116.0,BAO_0000221,10576,,1522,Hippocampus,12409,B,,10000000.0
Expert,,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus with [3H]8-OH-DPAT,,CHEMBL616157,D,9,,,Rattus norvegicus,10116.0,BAO_0000221,10576,,1523,Hippocampus,12409,B,,10000000.0
Autocuration,,1,,,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]-SB 207710 as radioligand,,CHEMBL616158,H,8,,,,,BAO_0000221,10576,,1524,Hippocampus,13267,B,,10000000.0
Autocuration,,1,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,CHEMBL616159,H,8,,,,,BAO_0000357,10576,,1525,,15194,B,,
Expert,,1,,,pKi value against rat 5-hydroxytryptamine 1A receptor.,,CHEMBL616160,H,8,,,,,BAO_0000357,10576,,1526,,14256,B,,
Autocuration,,1,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is define as non-determined.,,CHEMBL616161,H,8,,,,,BAO_0000019,10576,,1527,,16567,B,,
Autocuration,,1,,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,,CHEMBL616162,H,8,,,,,BAO_0000019,10576,,1528,,15740,F,,
Expert,,1,,,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,,CHEMBL616163,D,9,,,Rattus norvegicus,10116.0,BAO_0000357,12687,,1529,,13278,B,,
Expert,,1,,,Inhibition of specific [3H]OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,Membranes,CHEMBL616164,H,8,,,,,BAO_0000249,10626,,1530,,1970,B,,
Autocuration,,1,,,Concentration of compound required to inhibit cortical 5-hydroxytryptamine 1A receptor binding sites in rat brain was evaluated,,CHEMBL616165,H,8,,,,,BAO_0000221,10576,,1531,Brain,10034,B,,955.0
Autocuration,,1,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor isolated from rat hippocampus membranes membrane using [3H]5-HT as radioligand in the presence of 10e-6 M ketanserin as 5-HT2 blocker,,CHEMBL616355,H,8,,,Rattus norvegicus,10116.0,BAO_0000019,51,,1532,,13348,B,,
Autocuration,,1,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,,CHEMBL616356,H,8,,,,,BAO_0000019,10576,,1533,,13630,F,,
Autocuration,,1,,,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,,CHEMBL616357,H,8,,,,,BAO_0000221,10576,,1534,Brain,10862,B,,955.0
Autocuration,,1,,,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",,CHEMBL616358,H,8,,,,,BAO_0000019,10576,,1535,,12058,B,,
Autocuration,,1,,,Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor,,CHEMBL616359,H,8,,,,,BAO_0000357,51,,1536,,4639,B,,
Expert,,1,,,Percent decrease in 5-hydroxytryptamine 1A receptor binding using 8-OH-DPAT,,CHEMBL616360,H,8,,,,,BAO_0000357,51,,1537,,15453,B,,
Expert,,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,,CHEMBL616361,H,8,,,,,BAO_0000357,51,,1538,,4820,B,,
Autocuration,,1,,,Tested for binding affinity for 5-hydroxytryptamine 1A receptor,,CHEMBL616362,H,8,,,,,BAO_0000357,51,,1539,,1089,B,,
Autocuration,,1,,,The compound was evaluated for its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in cellular brain membranes,Brain membranes,CHEMBL616363,H,8,,,,,BAO_0000249,51,,1540,,386,B,,
Autocuration,,1,,,Inhibition of binding towards 5-hydroxytryptamine 1A receptor at 100 nM concentration,,CHEMBL616364,H,8,,,,,BAO_0000357,51,,1541,,6011,B,,
Autocuration,,1,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1A receptor,,CHEMBL616365,H,8,,,,,BAO_0000357,51,,1542,,5014,B,,
Expert,,1,,,Binding affinity for 5-hydroxytryptamine 1A receptor determined using [3H]8-OH-DPAT as radioligand,,CHEMBL616366,H,8,,,,,BAO_0000357,51,,1543,,4402,B,,
Expert,,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,,CHEMBL872906,H,8,,,,,BAO_0000357,51,,1544,,17066,B,,
Autocuration,,1,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1A receptor; inactive at 10 uM,,CHEMBL616367,H,8,,,,,BAO_0000357,51,,1545,,17515,B,,
Autocuration,,1,,,Binding affinity against 5-hydroxytryptamine 1A receptor,,CHEMBL616368,H,8,,,,,BAO_0000357,51,,1546,,2474,B,,
Autocuration,,1,,,Binding affinity to 5-hydroxytryptamine 1A receptor was determined,,CHEMBL616369,H,8,,,,,BAO_0000357,51,,1547,,4775,B,,
Expert,,1,,,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H]-(+)-8-OH-DPAT.,,CHEMBL616370,D,9,,,Homo sapiens,9606.0,BAO_0000357,51,,1548,,14294,B,,
Expert,,1,,,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H](+)-8-OH-DPAT; inactive,,CHEMBL616371,D,9,,,Homo sapiens,9606.0,BAO_0000357,51,,1549,,14294,B,,
Autocuration,,1,CHO,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,CHEMBL616372,H,8,,449.0,,,BAO_0000219,51,,1550,,12249,B,,
Expert,,1,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor expressed in CHO cell membranes,,CHEMBL616373,H,8,,,,,BAO_0000219,51,,1551,,11376,B,,
Autocuration,,1,,,Compound was measured in vivo for its binding affinity at 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,CHEMBL616374,H,8,,,,,BAO_0000218,51,,1552,,2474,B,In vivo,
Autocuration,,1,,,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,,CHEMBL616375,H,8,,,,,BAO_0000221,51,,1553,Hippocampus,13311,B,,10000000.0
Autocuration,,1,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1A receptor was determined,,CHEMBL616376,H,8,,,,,BAO_0000357,51,,1554,,4373,B,,
Expert,,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT.,,CHEMBL857064,H,8,,,,,BAO_0000357,51,,1555,,1633,B,,
Autocuration,,1,,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,,CHEMBL616377,H,8,,,,,BAO_0000357,51,,1556,,11866,B,,
Autocuration,,1,,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,,CHEMBL616378,H,8,,,,,BAO_0000357,51,,1557,,4373,B,,
Autocuration,,1,,,Evaluated for the binding affinity to 5-hydroxytryptamine 1A receptor,,CHEMBL616379,H,8,,,,,BAO_0000357,51,,1558,,4687,B,,
Autocuration,,1,,,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,CHEMBL616380,H,8,,,,,BAO_0000357,11863,,1559,,16946,B,,
Autocuration,,1,,,Binding affinity against 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT radioligand,,CHEMBL616381,H,8,,,,,BAO_0000357,11863,,1560,,13291,B,,
Autocuration,,1,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1A receptor,,CHEMBL616382,H,8,,,,,BAO_0000357,11863,,1561,,14159,B,,
Autocuration,,1,,,Compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor by using [3H]DPAT as radioligand,,CHEMBL616383,H,8,,,,,BAO_0000357,11863,,1562,,10812,B,,
Expert,,1,CHO,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor in CHO cells,,CHEMBL616350,D,9,,449.0,Mus musculus,10090.0,BAO_0000219,11863,,1563,,3032,B,,
Autocuration,,1,,,Inhibition of 5-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,CHEMBL616351,H,8,,,,,BAO_0000357,11863,,1564,,16655,B,,
Autocuration,,1,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand at 10e-5 M concentration,,CHEMBL616352,H,8,,,,,BAO_0000357,11863,,1565,,14532,B,,
Autocuration,,1,,,Binding affinity against 5-hydroxytryptamine 1A receptor,,CHEMBL616353,H,8,,,,,BAO_0000357,11863,,1566,,13944,B,,
Autocuration,,1,,,Binding affinity against serotonergic 5-HT1a receptor,,CHEMBL616354,H,8,,,,,BAO_0000357,11863,,1567,,13033,B,,
Autocuration,,1,,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by using [3H]8-OH-DPAT as radioligand,,CHEMBL616508,H,8,,,,,BAO_0000357,11863,,1568,,10321,B,,
Expert,,1,,,Binding affinity for 5-hydroxytryptamine 1A receptor,,CHEMBL616559,D,9,,,Mus musculus,10090.0,BAO_0000357,11863,,1569,,2968,B,,
Autocuration,,1,,,Binding affinity at 5-hydroxytryptamine 1A receptor,,CHEMBL616560,H,8,,,,,BAO_0000357,11863,,1570,,13964,B,,
Autocuration,,1,,,"Binding affinity towards 5-hydroxytryptamine 1A receptor receptor, using [3H]5-HT as radioligand.",,CHEMBL616561,H,8,,,,,BAO_0000357,11863,,1571,,15527,B,,
Autocuration,,1,CHO,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,CHEMBL616562,H,8,,449.0,,,BAO_0000219,11863,,1572,,12248,B,,
Autocuration,,1,CHO,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,CHEMBL616563,H,8,,449.0,,,BAO_0000219,11863,,1573,,12249,B,,
Autocuration,,1,,,Compound was tested for binding affinity using [3H]8-OH-DPAT against 5-hydroxytryptamine 1A receptor,,CHEMBL616564,H,8,,,,,BAO_0000357,11863,,1574,,15120,B,,
Autocuration,,1,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by using [3H]-8-OH-DPAT as radioligand,,CHEMBL616565,H,8,,,,,BAO_0000357,11863,,1575,,13313,B,,
Autocuration,,1,,,In vivo binding affinity was evaluated against 5-hydroxytryptamine 1A receptor,,CHEMBL616566,H,8,,,,,BAO_0000218,11863,,1576,,2613,B,,
Autocuration,,1,,,The binding affinity towards 5-hydroxytryptamine 1A receptor; No affinity,,CHEMBL616989,H,8,,,,,BAO_0000357,11863,,1577,,16700,B,,
Autocuration,,1,,,Ability to displace [125I]iodosulpiride from 5-hydroxytryptamine 1A receptor,,CHEMBL857975,H,8,,,,,BAO_0000357,11863,,1578,,2201,B,,
Expert,,1,,,Binding affinity against 5-hydroxytryptamine 1A receptor,,CHEMBL616990,D,9,,,Mus musculus,10090.0,BAO_0000357,11863,,1579,,1274,B,,
Autocuration,,1,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor using radioligand binding assay,,CHEMBL616991,H,8,,,,,BAO_0000357,11863,,1580,,1317,B,,
Autocuration,,1,,,Tested against 5-hydroxytryptamine 1A receptor,,CHEMBL616992,H,8,,,,,BAO_0000357,11863,,1581,,12146,B,,
Autocuration,,1,,,The compound's binding affinity against 5-hydroxytryptamine 1A receptor,,CHEMBL616993,H,8,,,,,BAO_0000357,11863,,1582,,14059,B,,
Expert,,1,,,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein,,CHEMBL616994,H,8,,,Oryctolagus cuniculus,9986.0,BAO_0000019,106,,1583,,14025,B,,
Autocuration,,1,,,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein(RbSV); NS=non surmountable,,CHEMBL616995,H,8,,,Oryctolagus cuniculus,9986.0,BAO_0000019,106,,1584,,14025,B,,
Intermediate,,1,HEK293,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1B receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,,CHEMBL616996,D,9,,722.0,Gorilla gorilla,9593.0,BAO_0000219,105571,,1585,,14447,B,,
Autocuration,,1,,,5-HT1B agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,,CHEMBL616997,H,8,,,Cavia porcellus,10141.0,BAO_0000218,106,,1586,,3025,F,In vivo,
Autocuration,,1,,,5-hydroxytryptamine 1B receptor agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,,CHEMBL616998,H,8,,,Cavia porcellus,10141.0,BAO_0000218,106,,1587,,3025,F,In vivo,
Autocuration,,1,,,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery,,CHEMBL616999,H,8,,,Cavia porcellus,10141.0,BAO_0000019,106,,1588,,15329,F,,
Autocuration,,1,,,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery; n.d. indicates Not determined,,CHEMBL617000,H,8,,,Cavia porcellus,10141.0,BAO_0000019,106,,1589,,15329,F,,
Autocuration,,1,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig,,CHEMBL617001,H,8,,,Cavia porcellus,10141.0,BAO_0000019,106,,1590,,15847,F,,
Autocuration,,1,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig; ND means not done,,CHEMBL858111,H,8,,,Cavia porcellus,10141.0,BAO_0000019,106,,1591,,15847,F,,
Autocuration,,1,,,Intrinsic activity for Antagonism of 5-hydroxytryptamine 1B receptor-mediated stimulation of [35S]GTP gamma S binding,,CHEMBL617002,H,8,,,,,BAO_0000019,106,,1592,,14165,F,,
Autocuration,,1,,,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine (5-CT),,CHEMBL617003,H,8,,,,,BAO_0000019,106,,1593,,14214,F,,
Autocuration,,1,,,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine(5-CT),,CHEMBL617004,H,8,,,,,BAO_0000019,106,,1594,,14214,F,,
Expert,,1,,,Agonist activity at 5-hydroxytryptamine 1B receptor by measuring the inhibition of forskolin-stimulated cAMP formation,,CHEMBL617005,D,9,,,Homo sapiens,9606.0,BAO_0000019,106,,1595,,14214,F,,
Expert,,1,CHO-K1,,Inhibition of forskolin-stimulated c-AMP formation by human 5-hydroxytryptamine 1B receptor expressed in CHO-K1 cells,,CHEMBL616623,D,9,,485.0,Homo sapiens,9606.0,BAO_0000219,106,,1596,,13729,F,,
Autocuration,,1,CHO,,Effective concentration determined by measuring inhibition of forskolin-stimulated c-AMP formation at 5-hydroxytryptamine 1B receptor stably transfected in CHO cell lines,,CHEMBL616624,H,8,,449.0,,,BAO_0000219,106,,1597,,3025,F,,
Autocuration,,1,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,,CHEMBL883243,H,8,,,,,BAO_0000357,106,,1598,,2391,B,,
Autocuration,,1,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; full agonist,,CHEMBL616625,H,8,,,,,BAO_0000019,106,,1599,,2391,F,,
Expert,,1,CHO,,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1B receptor",,CHEMBL616626,H,8,,449.0,,,BAO_0000219,106,,1600,,14956,F,,
Autocuration,,1,CHO,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line,,CHEMBL616627,H,8,,449.0,,,BAO_0000219,106,,1601,,2598,F,,
Autocuration,,1,CHO,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Antagonist,,CHEMBL616628,H,8,,449.0,,,BAO_0000219,106,,1602,,2598,F,,
Autocuration,,1,CHO,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Full Agonist,,CHEMBL616629,H,8,,449.0,,,BAO_0000219,106,,1603,,2598,F,,
Autocuration,,1,CHO,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Partial Agonist,,CHEMBL616630,H,8,,449.0,,,BAO_0000219,106,,1604,,2598,F,,
Expert,,1,,,"Efficacy was evaluated relative to human 5-HT1B receptor using [35S]GTP-gamma-S, as radioligand",,CHEMBL616631,H,8,,,,,BAO_0000019,106,,1605,,14956,F,,
Autocuration,,1,,,"Efficacy of compound was evaluated relative to human 5-hydroxytryptamine 1B receptor using [35S]GTP-gamma-S, as radioligand",,CHEMBL616632,H,8,,,,,BAO_0000019,106,,1606,,14956,F,,
Expert,,1,,,Percentage Maximal inhibition obtained with 1 uM 5-HT against 5-hydroxytryptamine 1B receptor,,CHEMBL616633,D,9,,,Homo sapiens,9606.0,BAO_0000357,106,,1607,,14214,B,,
Expert,,1,CHO,,Ability to displace [3H]5-HT from recombinant human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells determined in vitro,,CHEMBL616634,H,8,,449.0,,,BAO_0000219,106,,1608,,3463,B,,
Autocuration,,1,,,Affinity of compound towards 5-hydroxytryptamine 1B receptor was evaluated using radioligand binding technique,,CHEMBL616635,H,8,,,,,BAO_0000357,106,,1609,,15331,B,,
Expert,,1,,,Binding affinity against 5-hydroxytryptamine 1B receptor,,CHEMBL885358,D,9,,,Homo sapiens,9606.0,BAO_0000357,106,,1610,,16146,B,,
Expert,,1,CHO,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1B receptor expressed in CHO cells,,CHEMBL616636,D,9,,449.0,Homo sapiens,9606.0,BAO_0000219,106,,1611,,14159,B,,
Expert,,1,CHO,,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells by [3H]5-HT binding displacement.,,CHEMBL616637,H,8,,449.0,,,BAO_0000219,106,,1612,,14158,B,,
Autocuration,,1,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1B receptor,,CHEMBL616638,H,8,,,,,BAO_0000357,106,,1613,,14159,B,,
Expert,,1,CHO,,Displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,,CHEMBL616639,H,8,,449.0,,,BAO_0000219,106,,1614,,15250,B,,
Expert,,1,CHO,,Binding affinity at cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells by [3H]5-HT displacement.,,CHEMBL616640,H,8,,449.0,,,BAO_0000219,106,,1615,,15250,B,,
Expert,,1,CHO,,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,,CHEMBL616641,H,8,,449.0,,,BAO_0000219,106,,1616,,15331,B,,
Expert,,1,CHO,,Displacement of [3H]5-HT binding from cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells.,,CHEMBL616642,H,8,,449.0,,,BAO_0000219,106,,1617,,15332,B,,
Expert,,1,CHO,,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1B receptor expressed in CHO cells,,CHEMBL616643,H,8,,449.0,,,BAO_0000219,106,,1618,,14956,B,,
Autocuration,,1,,,In vitro binding affinity against human 5-hydroxytryptamine 1B receptor at a concentration of 100 (nM),,CHEMBL616644,H,8,,,,,BAO_0000357,106,,1619,,3805,B,,
Autocuration,,1,,,Intrinsic activity for each compound is calculated as a percentage of the 5-hydroxytryptamine 1B receptor response,,CHEMBL616645,H,8,,,,,BAO_0000357,106,,1620,,14875,B,,
Autocuration,,1,,,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),,CHEMBL616646,H,8,,,Oryctolagus cuniculus,9986.0,BAO_0000019,105,,1621,,14454,F,,
Expert,,1,,,Tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),,CHEMBL616647,H,8,,,Oryctolagus cuniculus,9986.0,BAO_0000019,105,,1622,,14454,F,,
Autocuration,,1,,,Affinity at 5-hydroxytryptamine 1D receptor (For sumatriptan = Ki (nM)-12+/-1.9),,CHEMBL616509,H,8,,,,,BAO_0000357,105,,1623,,16288,B,,
Autocuration,,1,,,Affinity at 5-hydroxytryptamine 1D receptor from calf caudate using [3H]5-HT as radioligand (For sumatriptan = Ki(nM)-12+/-1.9),,CHEMBL616510,H,8,,,,,BAO_0000357,105,,1624,,16288,B,,
Autocuration,,1,,,Binding affinity against calf caudate 5-hydroxytryptamine 1D receptor,,CHEMBL616511,H,8,,,,,BAO_0000357,105,,1625,,16312,B,,
Expert,,1,,,Inhibitory activity against 5-hydroxytryptamine 1D receptor subtype,,CHEMBL616512,H,8,,,Bos taurus,9913.0,BAO_0000357,105,,1626,,1348,B,,
Autocuration,,1,,,Inhibitory concentration required against 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT,,CHEMBL616513,H,8,,,Bos taurus,9913.0,BAO_0000357,105,,1627,,5834,B,,
Autocuration,,1,,,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,,CHEMBL616514,H,8,,,Bos taurus,9913.0,BAO_0000019,105,,1628,Striatum,13366,B,,2435.0
Expert,,1,,,Ability to bind to 5-hydroxytryptamine 1D receptor of calf substantia nigra,,CHEMBL616515,H,8,,,Bos taurus,9913.0,BAO_0000357,105,,1629,,1414,B,,
Autocuration,,1,,,Binding affinity against 5-hydroxytryptamine 1D receptor in calf caudate homogenates.,,CHEMBL616516,H,8,,,Bos taurus,9913.0,BAO_0000019,105,,1630,,14998,B,,
Autocuration,,1,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,,CHEMBL616517,H,8,,,Bos taurus,9913.0,BAO_0000357,105,,1631,,11473,B,,
Autocuration,,1,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,,CHEMBL616518,H,8,,,Bos taurus,9913.0,BAO_0000357,105,,1632,,11473,B,,
Autocuration,,1,,,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,,CHEMBL616519,H,8,,,Bos taurus,9913.0,BAO_0000357,105,,1633,,10639,B,,
Autocuration,,1,,,Inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,,CHEMBL616520,H,8,,,Bos taurus,9913.0,BAO_0000357,105,,1634,,10639,B,,
Autocuration,,1,,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand,,CHEMBL616521,H,8,,,Bos taurus,9913.0,BAO_0000357,105,,1635,,1375,B,,
Autocuration,,1,,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand; NT means not tested,,CHEMBL616522,H,8,,,Bos taurus,9913.0,BAO_0000357,105,,1636,,1375,B,,
Autocuration,,1,,,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,,CHEMBL884531,H,8,,,Bos taurus,9913.0,BAO_0000357,105,,1637,,16532,B,,
Autocuration,,1,,,Binding affinity towards 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand,,CHEMBL616523,H,8,,,Bos taurus,9913.0,BAO_0000357,105,,1638,,11147,B,,
Autocuration,,1,,,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,,CHEMBL616731,H,8,,,Bos taurus,9913.0,BAO_0000019,105,,1639,Striatum,13366,B,,2435.0
Autocuration,,1,,,Binding affinity was determined against 5-hydroxytryptamine 1D receptor in bovine caudate homogenate,,CHEMBL616732,H,8,,,Bos taurus,9913.0,BAO_0000019,105,,1640,,10444,B,,
Autocuration,,1,,,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT,,CHEMBL616733,H,8,,,Bos taurus,9913.0,BAO_0000357,105,,1641,,16532,B,,
Autocuration,,1,,,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,,CHEMBL616734,H,8,,,Bos taurus,9913.0,BAO_0000357,105,,1642,,16532,B,,
Autocuration,,1,,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP,,CHEMBL616735,H,8,,,Bos taurus,9913.0,BAO_0000249,105,,1643,,12827,B,,
Autocuration,,1,,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP; Not determined,,CHEMBL616736,H,8,,,Bos taurus,9913.0,BAO_0000249,105,,1644,,12827,B,,
Expert,,1,,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,CHEMBL616737,H,8,,,Bos taurus,9913.0,BAO_0000019,105,,1645,,12919,F,,
Autocuration,,1,,,Affinity pKi for 5-hydroxytryptamine 1D receptor was measured in calf caudate homogenate,,CHEMBL616738,H,8,,,Bos taurus,9913.0,BAO_0000019,105,,1646,,14025,B,,
Expert,,1,,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,CHEMBL616739,H,8,,,Bos taurus,9913.0,BAO_0000019,105,,1647,,12919,F,,
Expert,,1,,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,CHEMBL616740,H,8,,,Bos taurus,9913.0,BAO_0000019,105,,1648,,12919,F,,
Expert,,1,,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,CHEMBL616741,H,8,,,Bos taurus,9913.0,BAO_0000019,105,,1649,,12919,F,,
Autocuration,,1,HEK293,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1D receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,,CHEMBL616742,H,8,,722.0,Gorilla gorilla,9593.0,BAO_0000219,105,,1650,,14447,B,,
Intermediate,,1,,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra,,CHEMBL616743,D,9,,,Cavia porcellus,10141.0,BAO_0000019,105570,,1651,,1375,B,,
Intermediate,,1,,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra; NT means not tested,,CHEMBL616744,D,9,,,Cavia porcellus,10141.0,BAO_0000019,105570,,1652,,1375,B,,
Intermediate,,1,,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptor by the agonist GR-46611,,CHEMBL616745,D,9,,,Cavia porcellus,10141.0,BAO_0000019,105570,,1653,,12409,F,,
Intermediate,,1,,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,CHEMBL616746,D,9,,,Cavia porcellus,10141.0,BAO_0000019,105570,,1654,,12409,F,,
Intermediate,,1,,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611; range is 2-9,,CHEMBL616747,D,9,,,Cavia porcellus,10141.0,BAO_0000019,105570,,1655,,12409,F,,
Intermediate,,1,,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-0.4,,CHEMBL616748,D,9,,,Cavia porcellus,10141.0,BAO_0000019,105570,,1656,,12409,F,,
Intermediate,,1,,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-1.2,,CHEMBL616648,D,9,,,Cavia porcellus,10141.0,BAO_0000019,105570,,1657,,12409,F,,
Intermediate,,1,,,Binding affinity against 5-hydroxytryptamine 1D receptor,,CHEMBL616649,D,9,,,Cavia porcellus,10141.0,BAO_0000357,105570,,1658,,11574,B,,
Intermediate,,1,,,Binding affinity towards guinea pig 5-hydroxytryptamine 1D receptor was determined,,CHEMBL616650,D,9,,,Cavia porcellus,10141.0,BAO_0000357,105570,,1659,,1558,B,,
Intermediate,,1,,,Compound at 3 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,CHEMBL616651,D,9,,,Cavia porcellus,10141.0,BAO_0000218,105570,,1660,,12409,F,,
Intermediate,,1,,,Compound at 45 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,CHEMBL616652,D,9,,,Cavia porcellus,10141.0,BAO_0000218,105570,,1661,,12409,F,,
Intermediate,,1,,,Compound at 50 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,CHEMBL616653,D,9,,,Cavia porcellus,10141.0,BAO_0000218,105570,,1662,,12409,F,,
Intermediate,,1,,,Compound at oral dose of 45 mg/kg was tested for percent inhibition against 5-hydroxytryptamine 1D receptor causes hypothermia in guinea pig,,CHEMBL616654,D,9,,,Cavia porcellus,10141.0,BAO_0000218,105570,,1663,,12409,F,,
Intermediate,,1,,,Binding affinity of 5-hydroxytryptamine 1D receptor using [3H]-8-HT in guinea pig cortex,,CHEMBL616655,D,9,,,Cavia porcellus,10141.0,BAO_0000019,105570,,1664,,12253,B,,
Intermediate,,1,,,Binding affinity against guinea pig 5-hydroxytryptamine 1D receptor,,CHEMBL616656,D,9,,,Cavia porcellus,10141.0,BAO_0000357,105570,,1665,,12936,B,,
Autocuration,,1,,,Binding affinity was determined against 5-hydroxytryptamine 4 receptor using [125I]SB 207710 as radioligand from piglet hippocampal membranes,,CHEMBL616657,H,8,,,Cavia porcellus,10141.0,BAO_0000019,105,,1666,,13181,B,,
Intermediate,,1,,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor in guinea-pig striatum in presence of BMY-7378 and mesulergine,,CHEMBL616658,D,9,,,Cavia porcellus,10141.0,BAO_0000357,105570,,1667,Striatum,12409,B,,2435.0
Intermediate,,1,,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of guinea pig substantia nigra,,CHEMBL616659,D,9,,,Cavia porcellus,10141.0,BAO_0000357,105570,,1668,,10639,B,,
Autocuration,,1,,,Binding affinity against 5-hydroxytryptamine 1D receptor,,CHEMBL616660,H,8,,,,,BAO_0000357,51,,1669,,5254,B,,
Autocuration,,1,,,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta,,CHEMBL616661,H,8,,,,,BAO_0000357,106,,1670,,13051,B,,
Expert,,1,,,Maximum stimulation of [35S]GTP gamma-S binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor,,CHEMBL616662,H,8,,,,,BAO_0000019,105,,1671,,3463,F,,
Autocuration,,1,,,Ability to inhibit forskolin-stimulated adenylate cyclase in a cell line expressing human 5-hydroxytryptamine 1D receptor,,CHEMBL616663,H,8,,,,,BAO_0000019,105,,1672,,15315,F,,
Autocuration,,1,,,Ability to inhibit forskolin-stimulated adenylate cyclase activity in Chinese hamster ovary (CHO) stable cell lines expressing human 5-hydroxytryptamine 1D receptor,,CHEMBL616664,H,8,,,,,BAO_0000019,105,,1673,,6011,F,,
Expert,,1,CHO,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing 5-hydroxytryptamine 1D receptor",,CHEMBL881820,D,9,,449.0,Homo sapiens,9606.0,BAO_0000219,105,,1674,,14159,F,,
Autocuration,,1,CHO,,"Compound was evaluated for the stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor.",,CHEMBL616665,H,8,,449.0,,,BAO_0000219,105,,1675,,14159,F,,
Expert,,1,CHO,,Agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,,CHEMBL616666,H,8,,449.0,,,BAO_0000219,105,,1676,,15250,B,,
Autocuration,,1,CHO,,Compound was tested for measuring agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor,,CHEMBL616667,H,8,,449.0,,,BAO_0000219,105,,1677,,15250,B,,
Expert,,1,CHO,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",,CHEMBL616668,H,8,,449.0,,,BAO_0000219,105,,1678,,15331,F,,
Expert,,1,CHO,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",,CHEMBL616669,D,9,,449.0,Homo sapiens,9606.0,BAO_0000219,105,,1679,,15332,F,,
Expert,,1,CHO,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the human 5-hydroxytryptamine 1D receptor.",,CHEMBL617040,H,8,,449.0,,,BAO_0000219,105,,1680,,15332,F,,
Autocuration,,1,CHO,,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor",,CHEMBL617041,H,8,,449.0,,,BAO_0000219,105,,1681,,3294,F,,
Expert,,1,CHO,,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor.",,CHEMBL617042,H,8,,449.0,,,BAO_0000219,105,,1682,,14158,F,,
Expert,,1,CHO,,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor",,CHEMBL617043,H,8,,449.0,,,BAO_0000219,105,,1683,,14956,F,,
Autocuration,,1,,,Compound was evaluated for its agonistic activity on 5-hydroxytryptamine 1D receptor,,CHEMBL617044,H,8,,,,,BAO_0000019,105,,1684,,12469,F,,
Expert,,1,CHO,,Measurement of agonist-induced [35S]-GTP gamma-S binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,,CHEMBL617045,H,8,,449.0,,,BAO_0000219,105,,1685,,3463,F,,
Expert,,1,CHO,,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",,CHEMBL617046,D,9,,449.0,Homo sapiens,9606.0,BAO_0000219,105,,1686,,15250,F,,
Expert,,1,CHO,,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",,CHEMBL617047,D,9,,449.0,Homo sapiens,9606.0,BAO_0000219,105,,1687,,15250,F,,
Expert,,1,,,"Efficacy was evaluated relative to human 5-hydroxytryptamine 1D receptor using [35S]GTP-gamma-S, as radioligand",,CHEMBL617048,H,8,,,,,BAO_0000019,105,,1688,,14956,F,,
Autocuration,,1,,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor.",,CHEMBL616897,H,8,,,,,BAO_0000019,105,,1689,,14159,F,,
Expert,,1,,,"Maximum stimulation of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1D receptor relative to 5-HT",,CHEMBL616898,D,9,,,Homo sapiens,9606.0,BAO_0000019,105,,1690,,14159,F,,
Expert,,1,CHO,,Percent efficacy relative to 5-HT treatment of CHO cells expressing 5-HT 1d receptor,,CHEMBL858201,D,9,,449.0,Homo sapiens,9606.0,BAO_0000219,105,,1691,,14499,F,,
Autocuration,,1,,,Intrinsic activity for 5-hydroxytryptamine 1D receptor,,CHEMBL616899,H,8,,,,,BAO_0000019,105,,1692,,15315,F,,
Autocuration,,1,,,Ability to displace [3H]- -5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in chinese hamster cells (CHO cells),,CHEMBL616900,H,8,,,,,BAO_0000219,105,,1693,,3294,B,In vitro,
Expert,,1,CHO,,Ability to displace [3H]-5-HT from recombinant human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells determined in vitro,,CHEMBL616901,H,8,,449.0,,,BAO_0000219,105,,1694,,3463,B,,
Autocuration,,1,,,Affinity of compound towards 5-hydroxytryptamine 1D receptor was evaluated using radioligand binding technique,,CHEMBL616902,H,8,,,,,BAO_0000357,105,,1695,,15331,B,,
Expert,,1,CHO,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,CHEMBL616903,D,9,,449.0,Homo sapiens,9606.0,BAO_0000219,105,,1696,,14159,B,,
Expert,,1,CHO,,Binding affinity by displacement to human cloned 5-hydroxytryptamine 1D receptor in CHO cells by [3H]5-HT displacement.,,CHEMBL616904,H,8,,449.0,,,BAO_0000219,105,,1697,,14158,B,,
Autocuration,,1,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1D receptor,,CHEMBL616905,H,8,,,,,BAO_0000357,105,,1698,,14159,B,,
Expert,,1,CHO,,Binding affinity at human cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells by [3H]5-HT displacement.,,CHEMBL616906,H,8,,449.0,,,BAO_0000219,105,,1699,,15250,B,,
Expert,,1,CHO,,Displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,,CHEMBL616907,H,8,,449.0,,,BAO_0000219,105,,1700,,15250,B,,
Expert,,1,CHO,,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,,CHEMBL616908,H,8,,449.0,,,BAO_0000219,105,,1701,,15331,B,,
Expert,,1,CHO,,Displacement of [3H]5-HT binding from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,CHEMBL616909,D,9,,449.0,Homo sapiens,9606.0,BAO_0000219,105,,1702,,15332,B,,
Expert,,1,CHO,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,CHEMBL616910,D,9,,449.0,Homo sapiens,9606.0,BAO_0000219,105,,1703,,14499,B,,
Expert,,1,CHO,,Displacement of [3H]5-HT binding to the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,,CHEMBL616911,H,8,,449.0,,,BAO_0000219,105,,1704,,15332,B,,
Expert,,1,CHO,,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,CHEMBL616912,H,8,,449.0,,,BAO_0000219,105,,1705,,14956,B,,
Autocuration,,1,,,In vitro binding affinity against human 5-hydroxytryptamine 1D receptor at a concentration of 100 (nM),,CHEMBL616913,H,8,,,,,BAO_0000357,105,,1706,,3805,B,,
Expert,,1,CHO,,Inhibition of [3H]5-HT binding to human 5-hydroxytryptamine 1D receptor expressed in CHO cells at 1 uM,,CHEMBL616914,D,9,,449.0,Homo sapiens,9606.0,BAO_0000219,105,,1707,,6011,B,,
Autocuration,,1,CHO,,Binding affinity against 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,,CHEMBL616915,H,8,,449.0,,,BAO_0000219,105,,1708,,16190,B,,
Autocuration,,1,,,Binding affinity for 5-hydroxytryptamine 1D receptor in Cos-7 transfected cell type using [3H]5-CT as radioligand,,CHEMBL616916,H,8,,,,,BAO_0000019,105,,1709,,14165,B,,
Expert,,1,,,Binding affinity to cloned human 5-hydroxytryptamine 1D receptor,,CHEMBL616917,D,9,,,Homo sapiens,9606.0,BAO_0000357,105,,1710,,4234,B,,
Autocuration,,1,,,"Binding affinity towards 5-HT1D receptor, using [3H]5-HT as radioligand.",,CHEMBL616918,H,8,,,,,BAO_0000357,105,,1711,,15527,B,,
Expert,,1,,,Binding affinity towards human 5-hydroxytryptamine 1D receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,,CHEMBL616919,H,8,,,,,BAO_0000219,105,,1712,,6328,B,,
Autocuration,,1,,,Binding affinity towards human 5-hydroxytryptamine 1D receptor was determined using [3H]5-HT as radioligand,,CHEMBL616920,H,8,,,,,BAO_0000357,105,,1713,,16209,B,,
Autocuration,,1,,,Binding affinity for recombinant human 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand.,,CHEMBL872914,H,8,,,,,BAO_0000357,105,,1714,,14770,B,,
Autocuration,,1,,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1D receptor using [3H]-5-CT as radioligand,,CHEMBL616921,H,8,,,,,BAO_0000357,105,,1715,,2598,B,,
Expert,,1,,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1D receptor,,CHEMBL616922,H,8,,,,,BAO_0000357,105,,1716,,6897,B,,
Autocuration,,1,,,Binding affinity towards 5-hydroxytryptamine 1D receptor,,CHEMBL616923,H,8,,,,,BAO_0000357,105,,1717,,6013,B,,
Expert,,1,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,,CHEMBL616924,H,8,,,,,BAO_0000357,105,,1718,,5843,B,,
Expert,,1,,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand,,CHEMBL875909,H,8,,,,,BAO_0000357,105,,1719,,14454,B,,
Autocuration,,1,,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; Not determined,,CHEMBL616925,H,8,,,,,BAO_0000357,105,,1720,,14454,B,,
Autocuration,,1,,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; not determined,,CHEMBL616926,H,8,,,,,BAO_0000357,105,,1721,,14454,B,,
Autocuration,,1,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1D receptor,,CHEMBL616927,H,8,,,,,BAO_0000357,105,,1722,,15818,B,,
Expert,,1,CHO-K1,,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1D receptor in CHO-K1 cells,,CHEMBL616928,H,8,,485.0,,,BAO_0000219,105,,1723,,13729,F,,
Expert,,1,,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in Chinese hamster ovary cells (CHO cells),,CHEMBL616929,D,9,,,Homo sapiens,9606.0,BAO_0000219,105,,1724,,6011,B,In vitro,
Expert,,1,,,In vitro binding affinity to human 5-hydroxytryptamine 1D receptor,,CHEMBL616930,D,9,,,Homo sapiens,9606.0,BAO_0000357,105,,1725,,4234,B,,
Expert,,1,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,,CHEMBL616931,H,8,,,,,BAO_0000019,105,,1726,,17085,B,,
Autocuration,,1,,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,,CHEMBL616932,H,8,,,,,BAO_0000357,105,,1727,,3025,B,,
Expert,,1,,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor,,CHEMBL616933,H,8,,,,,BAO_0000357,105,,1728,,15315,B,,
Expert,,1,,,Receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor in Cos-7 cells,,CHEMBL616934,D,9,,,Homo sapiens,9606.0,BAO_0000219,105,,1729,,14214,B,,
Expert,,1,,,Binding affinity for human 5-hydroxytryptamine 1D receptor,,CHEMBL616935,D,9,,,Homo sapiens,9606.0,BAO_0000357,105,,1730,,3804,B,,
Autocuration,,1,,,The binding affinity towards the 5-hydroxytryptamine 1D receptor; No affinity,,CHEMBL616936,H,8,,,,,BAO_0000357,105,,1731,,16700,B,,
Expert,,1,,,Affinity for 5-hydroxytryptamine 1D receptor subtype,,CHEMBL616937,D,9,,,Homo sapiens,9606.0,BAO_0000357,105,,1732,,2391,B,,
Expert,,1,,,Binding affinity for human 5-hydroxytryptamine 1D receptor,,CHEMBL616938,D,9,,,Homo sapiens,9606.0,BAO_0000357,105,,1733,,4175,B,,
Autocuration,,1,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,,CHEMBL616939,H,8,,,,,BAO_0000019,105,,1734,,17085,B,,
Expert,,1,,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor; ND means not determined,,CHEMBL616940,H,8,,,,,BAO_0000019,105,,1735,,17085,B,,
Expert,,1,,,Binding activity against human 5-hydroxytryptamine 1D receptor; NT means not tested,,CHEMBL616941,D,9,,,Homo sapiens,9606.0,BAO_0000357,105,,1736,,15926,B,,
Autocuration,,1,CHO-K1,,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; Not tested,,CHEMBL616942,H,8,,485.0,,,BAO_0000219,105,,1737,,16312,B,,
Autocuration,,1,CHO-K1,,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; not tested,,CHEMBL616943,H,8,,485.0,,,BAO_0000219,105,,1738,,16312,B,,
Autocuration,,1,CHO,,Selectivity towards 5-HT1D and to that of 5-HT1B in CHO cells,,CHEMBL616944,H,4,,449.0,,,BAO_0000219,104802,,1739,,14956,B,,
Autocuration,,1,,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by the 5-HT",,CHEMBL616945,H,8,,,,,BAO_0000019,105,,1740,,3294,F,,
Autocuration,,1,,,Binding activity radioligand.,,CHEMBL616946,H,8,,,,,BAO_0000357,105,,1741,,12861,B,,
Autocuration,,1,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,CHEMBL616947,H,8,,,,,BAO_0000019,105,,1742,,12861,B,,
Expert,,1,CHO-K1,,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor,,CHEMBL616948,H,8,,485.0,,,BAO_0000219,105,,1743,,16312,B,,
Autocuration,,1,,,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,,CHEMBL616851,H,8,,,,,BAO_0000357,105,,1744,,5104,B,,
Autocuration,,1,,,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,,CHEMBL616852,H,8,,,,,BAO_0000357,105,,1745,,5105,B,,
Autocuration,,1,,,Measured as -log Ka on 5-hydroxytryptamine 1D receptor,,CHEMBL616853,H,8,,,,,BAO_0000357,105,,1746,,14499,B,,
Expert,,1,,,Binding activity against human 5-hydroxytryptamine 1D receptor,,CHEMBL616854,D,9,,,Homo sapiens,9606.0,BAO_0000357,105,,1747,,15926,B,,
Expert,,1,CHO,,Binding affinity to human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,,CHEMBL616855,D,9,,449.0,Homo sapiens,9606.0,BAO_0000219,105,,1748,,4540,B,,
Autocuration,,1,CHO,,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]-5-HT as radioligand.,,CHEMBL616856,H,8,,449.0,,,BAO_0000219,105,,1749,,15779,B,,
Autocuration,,1,CHO,,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,CHEMBL616857,H,8,,449.0,,,BAO_0000219,105,,1750,,15779,B,,
Autocuration,,1,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,,CHEMBL616858,H,8,,,,,BAO_0000357,105,,1751,,6166,B,,
Autocuration,,1,CHO,,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand.,,CHEMBL616859,H,8,,449.0,,,BAO_0000219,105,,1752,,15779,B,,
Autocuration,,1,CHO,,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]-5-HT as radioligand.;ND means no data.,,CHEMBL616860,H,8,,449.0,,,BAO_0000219,105,,1753,,15779,B,,
Autocuration,,1,HEK293,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,,CHEMBL616861,H,8,,722.0,,,BAO_0000219,105,,1754,,17451,B,,
Autocuration,,1,HEK293,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,,CHEMBL616541,H,8,,722.0,,,BAO_0000219,105,,1755,,17451,B,,
Autocuration,,1,HEK293,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand; Not determined,,CHEMBL616542,H,8,,722.0,,,BAO_0000219,105,,1756,,17451,B,,
Autocuration,,1,CHO,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as the radioligand,,CHEMBL616543,H,8,,449.0,,,BAO_0000219,105,,1757,,4199,B,,
Expert,,1,,,Binding affinity for human 5-hydroxytryptamine 1D receptor,,CHEMBL616544,D,9,,,Homo sapiens,9606.0,BAO_0000357,105,,1758,,14875,B,,
Autocuration,,1,CHO,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT,,CHEMBL616545,H,8,,449.0,,,BAO_0000219,105,,1759,,15146,B,,
Autocuration,,1,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1D receptor in CHO using [3H]5-HT as a radioligand,,CHEMBL616546,H,8,,,,,BAO_0000357,105,,1760,,5213,B,,
Autocuration,,1,CHO,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT.,,CHEMBL616547,H,8,,449.0,,,BAO_0000219,105,,1761,,14818,B,,
Autocuration,,1,CHO,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells, using [3H]5-HT as radioligand",,CHEMBL616548,H,8,,449.0,,,BAO_0000219,105,,1762,,4829,B,,
Expert,,1,,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 1 uM,,CHEMBL616549,H,8,,,,,BAO_0000019,105,,1763,,14454,F,,
Expert,,1,,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 10 uM,,CHEMBL616550,H,8,,,,,BAO_0000019,105,,1764,,14454,F,,
Autocuration,,1,,,Binding affinity against 5-HT2C receptor,,CHEMBL857066,H,8,,,,,BAO_0000357,108,,1765,,5254,B,,
Autocuration,,1,,,Binding affinity against 5-hydroxytryptamine 1D receptor,,CHEMBL616551,H,8,,,,,BAO_0000357,108,,1766,,5254,B,,
Autocuration,,1,,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,,CHEMBL616552,H,8,,,,,BAO_0000357,10577,,1767,,10639,B,,
Autocuration,,1,,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,,CHEMBL832876,H,8,,,,,BAO_0000019,10577,,1768,,10639,F,,
Expert,,1,,,"Binding affinity for 5-hydroxytryptamine 1B receptor in rat cortex, striatum and globus pallidus",,CHEMBL616553,H,8,,,,,BAO_0000019,10577,,1769,,12352,B,,
Autocuration,,1,,,Binding affinity towards 5-HT1B was determined,,CHEMBL616554,H,8,,,,,BAO_0000357,10577,,1770,,9098,B,,
Expert,,1,,,Affinity towards 5-hydroxytryptamine 1B receptor in membranes from rat frontal cortex using [3H]5-HT,,CHEMBL616555,H,8,,,,,BAO_0000019,10577,,1771,,14430,B,,
Expert,,1,,,"Binding affinity to 5-HT1B receptors using rat cortex+striatum + globus pallidus,[3H]-5-OH-tryptamine, and serotonin for NSB",,CHEMBL616556,H,8,,,,,BAO_0000019,10577,,1772,,13657,B,,
Autocuration,,1,,,"Compound was evaluated for binding affinity on 5-HT1B receptors using rat cortex+striatum+ globus pallidus,[ 3H]-5-OH-tryptamine, and serotonin for NSB.",,CHEMBL616557,H,8,,,,,BAO_0000019,10577,,1773,,13657,B,,
Expert,,1,,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,CHEMBL616558,H,8,,,,,BAO_0000019,10577,,1774,,15854,B,,
Expert,,1,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT,,CHEMBL616749,D,9,,,Rattus norvegicus,10116.0,BAO_0000019,10577,,1775,,10639,B,,
Autocuration,,1,,,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,,CHEMBL616750,H,8,,,,,BAO_0000357,10577,,1776,,10025,B,,
Autocuration,,1,,,"Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol, binds to 5-hydroxytryptamine 1B receptor at 1 uM",,CHEMBL616751,H,8,,,,,BAO_0000357,10577,,1777,,10025,B,,
Autocuration,,1,,,In vitro inhibitory concentration against radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,,CHEMBL616752,H,8,,,,,BAO_0000249,10577,,1778,,14286,B,,
Autocuration,,1,,,Inhibition of [3H]-5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Residual radioligand binding higher than 50%,,CHEMBL616753,H,8,,,,,BAO_0000019,10577,,1779,Striatum,3651,B,,2435.0
Expert,,1,,,Inhibition of radiolabeled [3H]-5-HT ligand binding to 5-hydroxytryptamine 1B receptor,,CHEMBL616754,D,9,,,Rattus norvegicus,10116.0,BAO_0000357,10577,,1780,,14178,B,,
Autocuration,,1,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT as the radioligand.,,CHEMBL616755,H,8,,,,,BAO_0000019,10577,,1781,,10639,B,,
Autocuration,,1,,,Inhibitory activity against [3H]5-HT binding to 5-HT1B receptor in rat striatum,,CHEMBL616756,H,8,,,,,BAO_0000019,10577,,1782,Striatum,13605,B,,2435.0
Autocuration,,1,,,Inhibitory concentration required against 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT,,CHEMBL616757,H,8,,,,,BAO_0000019,10577,,1783,Striatum,5834,B,,2435.0
Autocuration,,1,,,compound was measured for affinity against 5-hydroxytryptamine 1B receptor labelled with [3H]5-HT radioligand in striatum tissue,,CHEMBL616758,H,8,,,,,BAO_0000357,10577,,1784,Striatum,10922,B,,2435.0
Autocuration,,1,,,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,,CHEMBL616759,H,8,,,,,BAO_0000249,10577,,1785,,14286,B,,
Autocuration,,1,,,In vitro binding affinity towards the 5-hydroxytryptamine 1B receptor at 10 e-6 M,,CHEMBL616760,H,8,,,,,BAO_0000357,10577,,1786,,11825,B,,
Autocuration,,1,,,Ability to displace [3H]5-HT bound to 5-hydroxytryptamine 1B receptor in rat striatum,,CHEMBL616761,H,8,,,,,BAO_0000019,10577,,1787,Striatum,14826,B,,2435.0
Autocuration,,1,,,Binding affinity against 5-HT1B serotonin receptor in rat striatum,,CHEMBL616762,H,8,,,,,BAO_0000019,10577,,1788,Striatum,9699,B,,2435.0
Autocuration,,1,,,Binding affinity against 5-hydroxytryptamine 1B receptor in membranes of Rat cerebral cortex,,CHEMBL616763,H,8,,,,,BAO_0000019,10577,,1789,,14423,B,,
Expert,,1,,,Binding affinity at rat 5-hydroxytryptamine 1B receptor by [3H]5-HT displacement.,,CHEMBL872909,H,8,,,,,BAO_0000357,10577,,1790,,10062,B,,
Autocuration,,1,,,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,,CHEMBL616764,H,8,,,,,BAO_0000357,10577,,1791,,10062,B,,
Expert,,1,,,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor,,CHEMBL616765,D,9,,,Rattus norvegicus,10116.0,BAO_0000357,10577,,1792,,12280,B,,
Autocuration,,1,,,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum,,CHEMBL616766,H,8,,,,,BAO_0000357,10577,,1793,Striatum,15412,B,,2435.0
Autocuration,,1,,,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum.,,CHEMBL616767,H,8,,,,,BAO_0000357,10577,,1794,Striatum,15412,B,,2435.0
Autocuration,,1,,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,,CHEMBL616768,H,8,,,,,BAO_0000357,10577,,1795,,10062,B,,
Autocuration,,1,,,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,,CHEMBL616769,H,8,,,,,BAO_0000357,10577,,1796,,11147,B,,
Autocuration,,1,,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat was determined using 50 uL of [125I]ICYP in binding assay,,CHEMBL616770,H,8,,,,,BAO_0000019,10577,,1797,,9547,B,,
Autocuration,,1,,,Binding affinity was determined against 5-hydroxytryptamine 1B receptor was determined in male Sprague-Dawley rat brain.,,CHEMBL616771,H,8,,,,,BAO_0000019,10577,,1798,,10444,B,,
Autocuration,,1,,,Binding affinity was measured on 5-hydroxytryptamine 1B receptor in rat striatum labeled with [3H]5-HT,,CHEMBL616772,H,8,,,,,BAO_0000019,10577,,1799,Striatum,12469,B,,2435.0
Expert,,1,,,Binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand.,,CHEMBL616773,H,8,,,,,BAO_0000019,10577,,1800,,9098,B,,
Autocuration,,1,,,Compound was evaluated for the binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand; ND is no data.,,CHEMBL616774,H,8,,,,,BAO_0000019,10577,,1801,,9098,B,,
Autocuration,,1,,,Evaluated for binding affinity towards 5-hydroxytryptamine 1B receptor,,CHEMBL616775,H,8,,,,,BAO_0000357,10577,,1802,,9699,B,,
Autocuration,,1,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor in rat cortical membranes using [3H]5-HT as a radioligand,,CHEMBL616776,H,8,,,,,BAO_0000249,10577,,1803,,10394,B,,
Autocuration,,1,,,The binding affinity was measured on 5-hydroxytryptamine 1B receptor using [3H]- serotonin as radioligand.,,CHEMBL616777,H,8,,,,,BAO_0000357,10577,,1804,,12092,B,,
Autocuration,,1,,,The binding affinity towards the receptor rat 5-hydroxytryptamine 1B receptor; No affinity,,CHEMBL616778,H,8,,,,,BAO_0000357,10577,,1805,,16700,B,,
Expert,,1,,,Binding affinity against 5-hydroxytryptamine 1B receptor in rat striatal membranes using [3H]5-HT as radioligand,,CHEMBL616779,D,9,,,Rattus norvegicus,10116.0,BAO_0000249,10577,,1806,,403,B,,
Expert,,1,,,Binding affinity towards 5-hydroxytryptamine 1B receptor,,CHEMBL616780,D,9,,,Rattus norvegicus,10116.0,BAO_0000357,10577,,1807,,12771,B,,
Autocuration,,1,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1B receptor by displacing [3H]serotonin radioligand in rat cerebral cortex,,CHEMBL616781,H,8,,,,,BAO_0000019,10577,,1808,,11642,B,,
Autocuration,,1,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand,,CHEMBL616782,H,8,,,,,BAO_0000357,10577,,1809,,12953,B,,
Autocuration,,1,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand.,,CHEMBL616783,H,8,,,,,BAO_0000357,10577,,1810,,12953,B,,
Expert,,1,,,Binding affinity for 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT as radioligand,,CHEMBL616784,H,8,,,,,BAO_0000019,10577,,1811,Striatum,12953,B,,2435.0
Autocuration,,1,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand; Nonactive at 10 uM,,CHEMBL616785,H,8,,,,,BAO_0000357,10577,,1812,,12953,B,,
Autocuration,,1,,,Binding affinity against 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,CHEMBL857067,H,8,,,,,BAO_0000249,10577,,1813,Brain,9737,B,,955.0
Autocuration,,1,,,Binding affinity against 5-HT1B receptor in rat frontal cortex using [3H]-5-HT in presence of 0.1 uM [3H]-8-OH-DPAT as a radioligand,,CHEMBL616786,H,8,,,,,BAO_0000019,10577,,1814,,9737,B,,
Autocuration,,1,,,Binding affinity towards 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,CHEMBL616787,H,8,,,,,BAO_0000249,10577,,1815,Brain,9737,B,,955.0
Autocuration,,1,,,Binding affinity towards 5-hydroxytryptamine 2C receptor of porcine choroid plexus using [3H]mesulergine,,CHEMBL616788,H,8,,,,,BAO_0000357,10577,,1816,,12827,B,,
Autocuration,,1,,,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-hydroxytryptamine 1B receptor,,CHEMBL616789,H,8,,,,,BAO_0000357,10577,,1817,,5033,B,,
Expert,,1,,,Displacement of [3H]5-HT from 5-HT1B receptor of rat frontal cortex homogenate,,CHEMBL616790,D,9,,,Rattus norvegicus,10116.0,BAO_0000019,10577,,1818,,9786,B,,
Expert,,1,,,Binding affinity at 5-hydroxytryptamine 1B receptor,,CHEMBL616791,H,8,,,,,BAO_0000357,10577,,1819,,13116,B,,
Autocuration,,1,,,In vitro binding affinity at 5-hydroxytryptamine 1B receptor in rat striatal muscles using [125I](-)-iodocyanopindolol as the radioligand,,CHEMBL616792,H,8,,,,,BAO_0000019,10577,,1820,,16429,B,,
Expert,,1,,,In vitro binding affinity towards 5-hydroxytryptamine 1B receptor in rat striatal membrane with [125I]- iodocyanopindolol,,CHEMBL616793,D,9,,,Rattus norvegicus,10116.0,BAO_0000249,10577,,1821,,12409,B,,
Autocuration,,1,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,,CHEMBL616794,H,8,,,,,BAO_0000357,10577,,1822,,15194,B,,
Autocuration,,1,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,CHEMBL616795,H,8,,,,,BAO_0000357,10577,,1823,,15194,B,,
Autocuration,,1,,,Binding affinity towards 5-HT2 receptor by the displacement of [3H]-ketanserin] in rat cerebral cortex,,CHEMBL616796,H,4,,,,,BAO_0000019,104686,,1824,,5486,B,,
Autocuration,,1,,,Compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,,CHEMBL616797,H,8,,,,,BAO_0000357,106,,1825,,4639,B,,
Autocuration,,1,,,The compound was evaluated for its ability to displace [3H]5-HT from 5-hydroxytryptamine 1B receptor in cellular brain membranes,Brain membranes,CHEMBL616798,H,8,,,,,BAO_0000249,106,,1826,,386,B,,
Autocuration,,1,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1B receptor at a concentration of 100 nM using [125I]CYP as radioligand,,CHEMBL616799,H,8,,,,,BAO_0000357,106,,1827,,2474,B,,
Autocuration,,1,,,Inhibition of binding towards 5-hydroxytryptamine 1B receptor at 100 nM concentration,,CHEMBL616800,H,8,,,,,BAO_0000357,106,,1828,,6011,B,,
Autocuration,,1,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1B receptor,,CHEMBL616801,H,8,,,,,BAO_0000357,106,,1829,,5014,B,,
Autocuration,,1,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1B receptor; inactive at 10 uM,,CHEMBL616802,H,8,,,,,BAO_0000357,106,,1830,,17515,B,,
Autocuration,,1,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1B receptor was determined,,CHEMBL616803,H,8,,,,,BAO_0000357,106,,1831,,4373,B,,
Expert,,1,,,Binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]5-HT.,,CHEMBL857068,H,8,,,,,BAO_0000357,106,,1832,,1633,B,,
Autocuration,,1,,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]ketanserin.,,CHEMBL616804,H,8,,,,,BAO_0000357,106,,1833,,1633,B,,
Autocuration,,1,,,Binding affinity for 5-hydroxytryptamine 1B receptor was determined,,CHEMBL616805,H,8,,,,,BAO_0000357,106,,1834,,4373,B,,
Autocuration,,1,,,Evaluated for the binding affinity to 5-hydroxytryptamine 1B receptor,,CHEMBL616806,H,8,,,,,BAO_0000357,106,,1835,,4687,B,,
Autocuration,,1,,,Binding affinity against 5-hydroxytryptamine 1B receptor,,CHEMBL616807,H,8,,,,,BAO_0000357,106,,1836,,11574,B,,
Autocuration,,1,,,Binding affinity for 5-hydroxytryptamine 1B receptor was determined by using [3H]5-HT as radioligand,,CHEMBL616808,H,8,,,,,BAO_0000357,106,,1837,,10321,B,,
Autocuration,,1,,,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,CHEMBL616809,H,8,,,,,BAO_0000357,106,,1838,,15527,B,,
Autocuration,,1,,,Inhibitory constant against 5-hydroxytryptamine 1B receptor using with [125I]- cyanopindolol radioligand,,CHEMBL616810,H,8,,,,,BAO_0000357,106,,1839,,17200,B,,
Autocuration,,1,,,Binding affinity against 5-hydroxytryptamine 1B receptor - 5-hydroxytryptamine 1D receptor using [3H]5-HT as the radioligand.,,CHEMBL616811,H,4,,,,,BAO_0000224,104802,,1840,,14423,B,,
Autocuration,,1,,,Inhibitory concentration required against 5-hydroxytryptamine 1C receptor in bovine choroid plexus using [3H]mesulergine,,CHEMBL616812,H,8,,,Bos taurus,9913.0,BAO_0000357,108,,1841,,5834,B,,
Autocuration,,1,,,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,,CHEMBL616813,H,8,,,Sus scrofa,9823.0,BAO_0000357,108,,1842,,11473,B,,
Autocuration,,1,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1C receptor in pig choroid plexus using [3H]mesulergine as radioligand,,CHEMBL616814,H,8,,,Sus scrofa,9823.0,BAO_0000357,108,,1843,,11473,B,,
Autocuration,,1,,,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,,CHEMBL616815,H,8,,,Sus scrofa,9823.0,BAO_0000357,108,,1844,,10639,B,,
Autocuration,,1,,,inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,,CHEMBL616816,H,8,,,Sus scrofa,9823.0,BAO_0000357,108,,1845,,10639,B,,
Autocuration,,1,,,Binding affinity of compound towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine (1.2 nM) ligand in choroid Plexus pig was determined,,CHEMBL616817,H,8,,,Sus scrofa,9823.0,BAO_0000357,108,,1846,,14331,B,,
Autocuration,,1,,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1C receptor,,CHEMBL616818,H,8,,,Sus scrofa,9823.0,BAO_0000357,108,,1847,,10796,B,,
Expert,,1,,,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 2C receptor binding site by using [3H]-MES as a radioligand.,,CHEMBL616819,H,8,,,Sus scrofa,9823.0,BAO_0000357,108,,1848,,9098,B,,
Expert,,1,,,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 1C receptor of pig choroid Plexus,,CHEMBL616820,H,8,,,Sus scrofa,9823.0,BAO_0000357,108,,1849,,14331,B,,
Expert,,1,,,Displacement of [3H]mesulergine from pig cortex 5-hydroxytryptamine 1C receptor,,CHEMBL616821,H,8,,,Sus scrofa,9823.0,BAO_0000019,108,,1850,,11828,B,,
Autocuration,,1,,,Binding affinity for 5-hydroxytryptamine 1C receptor in piglet choroid plexus using [3H]5-HT,,CHEMBL616822,H,8,,,Sus scrofa,9823.0,BAO_0000357,108,,1851,,11866,B,,
Autocuration,,1,,,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,,CHEMBL616823,H,8,,,Oryctolagus cuniculus,9986.0,BAO_0000019,108,,1852,,13047,B,,
Autocuration,,1,,,Tested for the effect on binding at 5-hydroxytryptamine 1C receptor; No activity,,CHEMBL616824,D,9,,,Rattus norvegicus,10116.0,BAO_0000357,12689,,1853,,188,B,,
Autocuration,,1,,,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,,CHEMBL616825,D,9,,,Rattus norvegicus,10116.0,BAO_0000357,12689,,1854,,11825,B,,
Autocuration,,1,,,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,,CHEMBL616826,D,9,,,Rattus norvegicus,10116.0,BAO_0000357,12689,,1855,,11825,B,,
Expert,,1,,,Binding affinity against 5-hydroxytryptamine 1C receptor in rat using [3H]mesulergine as radioligand,,CHEMBL616827,D,9,,,Rattus norvegicus,10116.0,BAO_0000019,12689,,1856,,11624,B,,
Autocuration,,1,,,Binding affinity towards 5-hydroxytryptamine 1C receptor using [125 I]-SCH23982 as radioligand in competitive binding assay,,CHEMBL616828,D,9,,,Rattus norvegicus,10116.0,BAO_0000357,12689,,1857,,11139,B,,
Autocuration,,1,,,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,,CHEMBL616829,D,9,,,Rattus norvegicus,10116.0,BAO_0000357,12689,,1858,,11147,B,,
Autocuration,,1,,,Binding affinity was determined against 5-hydroxytryptamine 1C receptor was determined in male Sprague-Dawley rat brain.,,CHEMBL616830,D,9,,,Rattus norvegicus,10116.0,BAO_0000019,12689,,1859,,10444,B,,
Expert,,1,,,Binding affinity against 5-hydroxytryptamine 1C receptor,,CHEMBL616831,D,9,,,Rattus norvegicus,10116.0,BAO_0000357,12689,,1860,,11624,B,,
Autocuration,,1,,,"Compound was tested for binding affinity towards 5-HT1C (5-HT1C) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,CHEMBL616832,D,9,,,Rattus norvegicus,10116.0,BAO_0000019,12689,,1861,,11662,B,,
Autocuration,,1,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,CHEMBL616833,D,9,,,Rattus norvegicus,10116.0,BAO_0000019,12689,,1862,,11662,B,,
Expert,,1,,,"Binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,CHEMBL616834,D,9,,,Rattus norvegicus,10116.0,BAO_0000019,12689,,1863,,11662,B,,
Autocuration,,1,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,CHEMBL829595,D,9,,,Rattus norvegicus,10116.0,BAO_0000019,12689,,1864,,11662,B,,
Autocuration,,1,,,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 1C receptor binding site by using [3H]- MES as a radioligand.,,CHEMBL616835,D,9,,,Rattus norvegicus,10116.0,BAO_0000357,12689,,1865,,9098,B,,
Autocuration,,1,,,Inhibitory activity against 5-hydroxytryptamine 1C receptor in rat cortical membranes using [3H]mesulergine as a radioligand,,CHEMBL872910,D,9,,,Rattus norvegicus,10116.0,BAO_0000249,12689,,1866,,10394,B,,
Expert,,1,,,Tested for binding affinity against 5-hydroxytryptamine 1C receptor from rat frontal cortical regions using [3H]mesulergine as radioligand,,CHEMBL616836,H,8,,,,,BAO_0000357,12689,,1867,,11933,B,,
Autocuration,,1,,,The binding affinity was measured on 5-hydroxytryptamine 1C receptor using [3H]- serotonin as radioligand.,,CHEMBL616837,D,9,,,Rattus norvegicus,10116.0,BAO_0000357,12689,,1868,,12092,B,,
Autocuration,,1,,,Binding affinity of 5-hydroxytryptamine 1C receptor using [3H]- ketanserin in rat frontal cortex,,CHEMBL616466,D,9,,,Rattus norvegicus,10116.0,BAO_0000019,12689,,1869,,12253,B,,
Autocuration,,1,HEK293,,Binding affinity towards rat 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand expressed in 293 cells,,CHEMBL616467,D,9,,722.0,Rattus norvegicus,10116.0,BAO_0000219,12689,,1870,,12253,B,,
Autocuration,,1,,,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,,CHEMBL616468,H,8,,,,,BAO_0000357,108,,1871,,1558,B,,
Autocuration,,1,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,,CHEMBL616469,H,8,,,,,BAO_0000357,108,,1872,,2474,B,,
Autocuration,,1,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,,CHEMBL616470,H,8,,,,,BAO_0000357,108,,1873,,2474,B,,
Autocuration,,1,,,Binding affinity against 5-hydroxytryptamine 1C receptor,,CHEMBL616471,H,8,,,,,BAO_0000357,12689,,1874,,11574,B,,
Autocuration,,1,,,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,,CHEMBL616472,H,8,,,,,BAO_0000357,12689,,1875,,1558,B,,
Autocuration,,1,,,Binding affinity against 5-hydroxytryptamine 1C receptor,,CHEMBL616473,H,8,,,,,BAO_0000357,12689,,1876,,13944,B,,
Autocuration,,1,,,Binding affinity against serotonergic 5-HT1c receptor,,CHEMBL616474,H,8,,,,,BAO_0000357,12689,,1877,,13033,B,,
Autocuration,,1,,,Binding affinity for 5-hydroxytryptamine 1C receptor was determined by using [3H]- mesulergine as radioligand,,CHEMBL616475,H,8,,,,,BAO_0000357,12689,,1878,,10321,B,,
Autocuration,,1,,,Binding affinity for 5-hydroxytryptamine 1C receptor was determined,,CHEMBL616476,H,8,,,,,BAO_0000357,12689,,1879,,11866,B,,
Autocuration,,1,,,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),,CHEMBL616477,H,8,,,Oryctolagus cuniculus,9986.0,BAO_0000019,105,,1880,,14454,B,,
Autocuration,,1,,,Binding affinity against 5-hydroxytryptamine 2 receptor using [125I]DOI as radioligand.,,CHEMBL616478,H,4,,,,,BAO_0000224,104686,,1881,,11574,B,,
Autocuration,,1,,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ket as radioligand.,,CHEMBL616479,H,4,,,,,BAO_0000224,104686,,1882,,11574,B,,
Autocuration,,1,,,Binding affinity towards serotonin 5-HT2 receptor was determined in rat cortex using [3H]spiperone as ligand,,CHEMBL616480,H,4,,,,,BAO_0000019,104686,,1883,,13631,B,,
Autocuration,,1,,,Binding affinity towards 5-hydroxytryptamine 2 receptor as antagonism of serotonin-induced contractions in rat jugular vein,,CHEMBL616481,D,5,,,Rattus norvegicus,10116.0,BAO_0000019,104686,,1884,,9630,B,,
Autocuration,,1,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain cortical membranes,,CHEMBL616482,D,5,,,Rattus norvegicus,10116.0,BAO_0000249,104686,,1885,,8822,B,,
Autocuration,,1,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain using [3H]spiroperidol,,CHEMBL884713,D,5,,,Rattus norvegicus,10116.0,BAO_0000221,104686,,1886,Brain,9064,B,,955.0
Autocuration,,1,,,Binding affinity towards 5-hydroxytryptamine 2 receptor measured using radioligand ([3H]spiperone) binding assay,,CHEMBL616483,H,4,,,,,BAO_0000224,104686,,1887,,8868,B,,
Autocuration,,1,,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- spiroperidol,,CHEMBL616484,H,4,,,,,BAO_0000224,104686,,1888,,9064,B,,
Autocuration,,1,,,Binding affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenates by [3H]-spiperone displacement.,,CHEMBL616485,H,4,,,,,BAO_0000019,104686,,1889,,9806,B,,
Autocuration,,1,,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,CHEMBL616486,H,4,,,,,BAO_0000224,104686,,1890,,9098,B,,
Autocuration,,1,,,Binding affinity towards 5-hydroxytryptamine 2 receptor was measured using radioligand ([3H]spiperone) binding assay,,CHEMBL616487,H,4,,,,,BAO_0000224,104686,,1891,,8868,B,,
Autocuration,,1,,,Binding affinity at serotonin 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,,CHEMBL616488,H,4,,,,,BAO_0000224,104686,,1892,,12765,B,,
Autocuration,,1,,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,CHEMBL616489,H,4,,,,,BAO_0000019,104686,,1893,,11049,B,,
Autocuration,,1,,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,CHEMBL616490,H,4,,,,,BAO_0000019,104686,,1894,,11049,B,,
Autocuration,,1,,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]-Ketanserin as radioligand; not determined,,CHEMBL616491,H,4,,,,,BAO_0000019,104686,,1895,,11049,B,,
Autocuration,,1,,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand; ND-Not determined,,CHEMBL616492,H,4,,,,,BAO_0000019,104686,,1896,,11049,B,,
Autocuration,,1,,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,CHEMBL616493,H,4,,,,,BAO_0000019,104686,,1897,,11049,B,,
Autocuration,,1,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [125I]DOI as radioligand,,CHEMBL616494,H,4,,,,,BAO_0000019,104686,,1898,,11473,B,,
Autocuration,,1,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [3H]ketanserin as radioligand,,CHEMBL616495,H,4,,,,,BAO_0000019,104686,,1899,,11473,B,,
Autocuration,,1,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat pre frontal cortex,,CHEMBL616496,H,4,,,,,BAO_0000019,104686,,1900,,3086,B,,
Autocuration,,1,,,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,CHEMBL616497,H,4,,,,,BAO_0000019,104686,,1901,,11049,B,,
Autocuration,,1,,,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,CHEMBL616498,H,4,,,,,BAO_0000019,104686,,1902,,11049,B,,
Autocuration,,1,,,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 2 receptor of rat anterior cortex using [3H]ketanserin as the radioligand,,CHEMBL616499,H,4,,,,,BAO_0000019,104686,,1903,,10639,B,,
Autocuration,,1,,,Compound was measured for affinity at 5-hydroxytryptamine 2 receptor in rat cortical by [3H]spiroperidol displacement.,,CHEMBL616500,H,4,,,,,BAO_0000019,104686,,1904,,10922,B,,
Autocuration,,1,,,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,,CHEMBL616501,D,5,,,Rattus norvegicus,10116.0,BAO_0000221,104686,,1905,Brain,9064,B,,955.0
Autocuration,,1,,,Compound was tested for its inhibitory effect on the binding profile in 5-hydroxytryptamine 2 receptor using [3H]spiroperidol in rat brain.,,CHEMBL616502,H,4,,,,,BAO_0000221,104686,,1906,Brain,10748,B,,955.0
Autocuration,,1,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor from rat cortical membranes.,Membranes,CHEMBL884529,H,4,,,,,BAO_0000249,104686,,1907,,11614,B,,
Autocuration,,1,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,Membranes,CHEMBL616503,H,4,,,,,BAO_0000249,104686,,1908,,11615,B,,
Autocuration,,1,,,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor,,CHEMBL616964,H,4,,,,,BAO_0000224,104686,,1909,,11615,B,,
Autocuration,,1,,,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor from rat cortical membranes.,Membranes,CHEMBL616965,H,4,,,,,BAO_0000249,104686,,1910,,11614,B,,
Autocuration,,1,,,Inhibition of [3H]ketanserin binding to rat 5-hydroxytryptamine 2 receptors.,,CHEMBL616966,H,4,,,,,BAO_0000224,104686,,1911,,11702,B,,
Autocuration,,1,,,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor; NT=Not tested,,CHEMBL616967,H,4,,,,,BAO_0000224,104686,,1912,,11702,B,,
Autocuration,,1,,,Inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor,,CHEMBL616968,D,5,,,Rattus norvegicus,10116.0,BAO_0000224,104686,,1913,,11702,B,,
Autocuration,,1,,,Compound was tested for the inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor; NT=Not tested,,CHEMBL616969,H,4,,,,,BAO_0000224,104686,,1914,,11702,B,,
Autocuration,,1,,,Inhibition of [3H]ketanserin binding at 5-hydroxytryptamine 2 receptor from rat frontal cortex.,,CHEMBL884530,H,4,,,,,BAO_0000019,104686,,1915,,13346,B,,
Autocuration,,1,,,Concentration necessary to achieve half maximal inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor,,CHEMBL616970,H,4,,,,,BAO_0000224,104686,,1916,,10025,B,,
Autocuration,,1,,,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,,CHEMBL616971,H,4,,,,,BAO_0000224,104686,,1917,,10025,B,,
Autocuration,,1,,,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",,CHEMBL616972,H,4,,,,,BAO_0000224,104686,,1918,,10025,B,,
Autocuration,,1,,,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]-spiperone,,CHEMBL616973,H,4,,,,,BAO_0000224,104686,,1919,,9036,B,,
Autocuration,,1,,,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]spiperone; IA=Inactive,,CHEMBL616974,H,4,,,,,BAO_0000224,104686,,1920,,9036,B,,
Autocuration,,1,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.,,CHEMBL616975,H,4,,,,,BAO_0000019,104686,,1921,,9161,B,,
Autocuration,,1,,,Inhibition of binding of radioligand [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cerebral cortex,,CHEMBL616976,H,4,,,,,BAO_0000019,104686,,1922,,12304,B,,
Autocuration,,1,,,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand.,,CHEMBL616977,H,4,,,,,BAO_0000224,104686,,1923,,13276,B,,
Autocuration,,1,,,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,,CHEMBL616978,H,4,,,,,BAO_0000224,104686,,1924,,11825,B,,
Autocuration,,1,,,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 2 receptor by displacement of [3H]- ketanserin,,CHEMBL616979,H,4,,,,,BAO_0000224,104686,,1925,,12443,B,,
Autocuration,,1,,,In vitro inhibitory activity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor,,CHEMBL616980,H,4,,,,,BAO_0000224,104686,,1926,,13830,B,,
Autocuration,,1,,,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes,Membranes,CHEMBL616981,H,4,,,,,BAO_0000249,104686,,1927,,9592,B,,
Autocuration,,1,,,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes; Not tested,Membranes,CHEMBL616982,H,4,,,,,BAO_0000249,104686,,1928,,9592,B,,
Autocuration,,1,,,Inhibitory activity against 5-hydroxytryptamine 2 receptor by 3H ligand binding experiments.,,CHEMBL616983,H,4,,,,,BAO_0000224,104686,,1929,,10881,B,,
Autocuration,,1,,,Inhibitory activity against [3H]spiroperidol binding to 5-HT2 receptor in rat cortex,,CHEMBL616984,H,4,,,,,BAO_0000019,104686,,1930,,13605,B,,
Autocuration,,1,,,Inhibitory activity against 5-hydroxytryptamine 2 receptor,,CHEMBL616985,D,5,,,Rattus norvegicus,10116.0,BAO_0000224,104686,,1931,,11624,B,,
Autocuration,,1,,,Inhibitory concentration against 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,,CHEMBL616986,H,4,,,,,BAO_0000224,104686,,1932,,4101,B,,
Autocuration,,1,,,Inhibitory concentration against binding of 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,,CHEMBL616987,H,4,,,,,BAO_0000224,104686,,1933,,4101,B,,
Autocuration,,1,,,Inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat,,CHEMBL616988,H,4,,,,,BAO_0000019,104686,,1934,,15360,B,,
Autocuration,,1,,,Inhibitory concentration against radioligand [3H]spiperone binding to 5-hydroxytryptamine 2 receptor in rat cortex,,CHEMBL617243,H,4,,,,,BAO_0000019,104686,,1935,,11576,B,,
Autocuration,,1,,,Inhibitory concentration required against 5-hydroxytryptamine 2 receptor in rat cortex using [3H]spiperone,,CHEMBL617244,H,4,,,,,BAO_0000019,104686,,1936,,5834,B,,
Autocuration,,1,CHO-K1,,Inhibitory concentration against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,,CHEMBL617245,D,5,,485.0,Rattus norvegicus,10116.0,BAO_0000219,104686,,1937,,2395,B,,
Autocuration,,1,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,Membranes,CHEMBL617246,H,4,,,,,BAO_0000249,104686,,1938,,11965,B,,
Autocuration,,1,,,The compound was evaluated for the ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor ( striata of male wistar rats),,CHEMBL617546,H,4,,,,,BAO_0000224,104686,,1939,,3967,B,,
Autocuration,,1,,,The concentration required to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat brain membranes (in vitro),Brain membranes,CHEMBL617547,H,4,,,,,BAO_0000249,104686,,1940,,11130,B,,
Autocuration,,1,,,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,,CHEMBL617548,H,4,,,,,BAO_0000219,104686,,1941,,13427,B,In vitro,
Autocuration,,1,,,Binding affinity towards 5-hydroxytryptamine 2 receptor,,CHEMBL617549,H,4,,,,,BAO_0000224,104686,,1942,,9443,B,,
Autocuration,,1,,,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,,CHEMBL617550,H,4,,,,,BAO_0000224,104686,,1943,,9443,B,,
Autocuration,,1,,,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,,CHEMBL617551,H,4,,,,,BAO_0000224,104686,,1944,,11825,B,,
Autocuration,,1,,,Percent inhibition of binding of 1.0 nM [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e -5 M,Membranes,CHEMBL617552,H,4,,,,,BAO_0000249,104686,,1945,,12120,B,,
Autocuration,,1,,,Percent inhibition of binding of 1.0 nM [3H]-ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e-5 M.,Membranes,CHEMBL617553,H,4,,,,,BAO_0000249,104686,,1946,,12120,B,,
Autocuration,,1,,,Tested for antagonistic activity against 5-hydroxytryptamine 2 receptor from rat thoracic aorta,,CHEMBL617554,H,4,,,,,BAO_0000019,104686,,1947,Thoracic aorta,11963,F,,1515.0
Autocuration,,1,,,Binding affinity for membrane-bound 5-hydroxytryptamine 2 receptor,,CHEMBL617555,H,4,,,,,BAO_0000019,104686,,1948,,9069,B,,
Autocuration,,1,,,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,,CHEMBL617556,H,4,,,,,BAO_0000224,104686,,1949,,8868,B,,
Autocuration,,1,,,Inhibitory constant against human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,,CHEMBL617557,H,8,,,,,BAO_0000357,10624,,1950,,17200,B,,
Autocuration,,1,,,Inhibitory constant against human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,,CHEMBL617558,H,8,,,,,BAO_0000357,10624,,1951,,17200,B,,
Expert,,1,,,Binding affinity against 5-hydroxytryptamine 1D receptor was measured using [3H]5-HT as radioligand,,CHEMBL617559,H,8,,,,,BAO_0000357,17106,,1952,,13969,B,,
Expert,,1,,,Binding affinity for 5-hydroxytryptamine 1D receptor,,CHEMBL617560,D,9,,,,,BAO_0000357,17106,,1953,,13392,B,,
Autocuration,,1,,,Compound was tested for its ability to displace [125I]GTI binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,CHEMBL617561,H,8,,,,,BAO_0000249,17106,,1954,,1742,B,,
Autocuration,,1,,,Compound was tested for its ability to displace [3H]-5-HT binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,CHEMBL617562,H,8,,,,,BAO_0000249,17106,,1955,,1742,B,,
Autocuration,,1,,,Binding affinity against 5-hydroxytryptamine 1D receptor using [3H]5-HT in pig striatum + frontalCortex,,CHEMBL617563,H,8,,,,,BAO_0000357,17106,,1956,Striatum,14331,B,,2435.0
Autocuration,,1,,,Relative agonist efficacy against 1 uM 5-hydroxytryptamine 1D receptor,,CHEMBL617564,H,8,,,,,BAO_0000019,17106,,1957,,12861,F,,
Expert,,1,,,Binding activity against 5-hydroxytryptamine 1D receptor from pig caudate membrane using [3H]5-HT as radioligand,,CHEMBL617565,H,8,,,,,BAO_0000019,17106,,1958,,12861,B,,
Autocuration,,1,,,Binding activity radioligand.,,CHEMBL856076,H,8,,,,,BAO_0000357,17106,,1959,,12861,B,,
Autocuration,,1,,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,CHEMBL617566,H,8,,,,,BAO_0000019,17106,,1960,,12861,B,,
Expert,,1,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,CHEMBL875911,H,8,,,,,BAO_0000019,17106,,1961,,12861,B,,
Autocuration,,1,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,,CHEMBL617567,H,8,,,,,BAO_0000019,17106,,1962,,12861,B,,
Autocuration,,1,,,Compound was tested for the displacement of [3H]-5-HT to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,CHEMBL617568,H,8,,,,,BAO_0000249,17106,,1963,,675,B,,
Expert,,1,,,Displacement of [3H]5-HT binding to 5-hydroxytryptamine 1D receptor from pig caudate membrane,,CHEMBL617569,H,8,,,,,BAO_0000019,17106,,1964,,12490,B,,
Expert,,1,,,Displacement of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1D receptor in pig caudate membrane,,CHEMBL617570,H,8,,,,,BAO_0000249,17106,,1965,,11828,B,,
Autocuration,,1,,,Binding affinity for 5-hydroxytryptamine 1D receptor in piglet caudate using [3H]5-HT,,CHEMBL617571,H,8,,,,,BAO_0000357,17106,,1966,,11866,B,,
Autocuration,,1,,,In Vitro Binding affinity againist 5-hydroxytryptamine 1D receptor by displacing [125I]GTI from pig caudate,,CHEMBL617572,H,8,,,Sus scrofa,9823.0,BAO_0000357,105,,1967,,773,B,,
Expert,,1,,,The compound was tested for intrinsic activity against 5-HT1D receptor,,CHEMBL617573,H,8,,,Oryctolagus cuniculus,9986.0,BAO_0000357,105,,1968,,13047,B,,
Autocuration,,1,,,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,,CHEMBL617574,H,8,,,Oryctolagus cuniculus,9986.0,BAO_0000019,105,,1969,,13047,B,,
Expert,,1,,,The compound was tested for binding affinity against 5-HT1D receptor,,CHEMBL617575,H,8,,,Oryctolagus cuniculus,9986.0,BAO_0000357,105,,1970,,13047,B,,
Autocuration,,1,,,Tested for the effect on binding at 5-hydroxytryptamine 1D receptor; No activity,,CHEMBL617576,H,8,,,,,BAO_0000357,10578,,1971,,188,B,,
Autocuration,,1,,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of rat substantia nigra,,CHEMBL617577,H,8,,,,,BAO_0000019,10578,,1972,,10639,F,,
Autocuration,,1,,,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor,,CHEMBL617578,H,8,,,,,BAO_0000019,10578,,1973,,12438,F,,
Autocuration,,1,,,Binding affinity was measured against serotonin 5-hydroxytryptamine 1D receptor,,CHEMBL617579,H,8,,,,,BAO_0000357,10578,,1974,,12438,B,,
Expert,,1,,,Binding affinity towards 5-hydroxytryptamine 1D receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,CHEMBL617580,H,8,,,,,BAO_0000019,10578,,1975,,15854,B,,
Autocuration,,1,,,Inhibitory activity against 5-hydroxytryptamine 1D receptor in rat cortical membranes using [3H]5-HT as a radioligand,,CHEMBL617581,H,8,,,,,BAO_0000249,10578,,1976,,10394,B,,
Autocuration,,1,,,The binding affinity was measured on 5-hydroxytryptamine 1D receptor using [3H]- serotonin as radioligand.,,CHEMBL617582,H,8,,,,,BAO_0000357,10578,,1977,,12092,B,,
Expert,,1,,,Binding affinity to 5-hydroxytryptamine 1D receptor in the rat forebrain by [3H]- SB-204269 displacement.,,CHEMBL617583,H,8,,,,,BAO_0000019,10578,,1978,,3389,B,,
Autocuration,,1,,,Inhibition of binding towards 5-hydroxytryptamine 1D receptor at 100 nM concentration,,CHEMBL617584,H,8,,,,,BAO_0000357,105,,1979,,6011,B,,
Autocuration,,1,,,Compound was tested for binding affinity against 5-hydroxytryptamine 1D receptor,,CHEMBL617585,H,8,,,,,BAO_0000357,105,,1980,,4639,B,,
Autocuration,,1,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1D receptor at a concentration of 10 uM using [3H]5-HT as radioligand,,CHEMBL875912,H,8,,,,,BAO_0000357,105,,1981,,2474,B,,
Autocuration,,1,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1D receptor,,CHEMBL617586,H,8,,,,,BAO_0000357,105,,1982,,5014,B,,
Autocuration,,1,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1D receptor; inactive at 10 uM,,CHEMBL617587,H,8,,,,,BAO_0000357,105,,1983,,17515,B,,
Autocuration,,1,,,Binding affinity for 5-hydroxytryptamine 1D receptor was determined,,CHEMBL617588,H,8,,,,,BAO_0000357,105,,1984,,11866,B,,
Autocuration,,1,,,Evaluated for the binding affinity against 5-hydroxytryptamine 1D receptor,,CHEMBL857980,H,8,,,,,BAO_0000357,105,,1985,,4687,B,,
Autocuration,,1,,,Tested against 5-hydroxytryptamine 1D receptor,,CHEMBL617589,H,8,,,,,BAO_0000357,105,,1986,,12146,B,,
Autocuration,,1,,,Binding affinity for 5-hydroxytryptamine 1D receptor was determined by using [3H]5-HT as radioligand,,CHEMBL617590,H,8,,,,,BAO_0000357,105,,1987,,10321,B,,
Autocuration,,1,HEK293,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,,CHEMBL617591,H,8,,722.0,,,BAO_0000219,105,,1988,,13267,B,,
Expert,,1,,,Binding affinity against 5-Hydroxytryptamine 1D receptor,,CHEMBL617592,D,9,,,Homo sapiens,9606.0,BAO_0000357,105,,1989,,1274,B,,
Autocuration,,1,,,,,CHEMBL617593,H,8,,,,,BAO_0000357,105,,1990,,15250,B,,
Autocuration,,1,CHO-K1,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,,CHEMBL617594,H,8,,485.0,,,BAO_0000219,106,,1991,,13706,B,,
Autocuration,,1,CHO-K1,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,,CHEMBL617595,H,8,,485.0,,,BAO_0000219,105,,1992,,13706,B,,
Autocuration,,1,HEK293,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line.,,CHEMBL617596,H,8,,722.0,,,BAO_0000219,105,,1993,,13706,B,,
Autocuration,,1,HEK293,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,,CHEMBL617597,H,8,,722.0,,,BAO_0000219,105,,1994,,13706,B,,
Autocuration,,1,,,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,,CHEMBL617598,H,8,,,,,BAO_0000019,105,,1995,,13047,B,,
Autocuration,,1,,,Binding affinity of compound against 5-HT1Dalpha Binding affinity of compound against 5-HT1D alpha receptors in human,,CHEMBL872916,H,8,,,,,BAO_0000357,105,,1996,,13366,B,,
Expert,,1,,,In vitro affinity human cloned 5-hydroxytryptamine 1D receptor alpha by [3H]5-HT displacement.,,CHEMBL617599,H,8,,,,,BAO_0000357,105,,1997,,13366,B,,
Autocuration,,1,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor alpha was determined,,CHEMBL617091,H,8,,,,,BAO_0000357,105,,1998,,1558,B,,
Expert,,1,CHO-K1,,"Binding affinity against 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells, using [3H]-5-HT as the radioligand.",,CHEMBL617092,H,8,,485.0,,,BAO_0000219,105,,1999,,12902,B,,
Autocuration,,1,CHO-K1,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,,CHEMBL617093,H,8,,485.0,,,BAO_0000219,105,,2000,,13706,B,,
Autocuration,,1,,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor alpha measured as the reduction of forskolin-stimulated cAMP.,,CHEMBL617094,H,8,,,,,BAO_0000019,105,,2001,,13706,F,,
Autocuration,,1,,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,CHEMBL617095,H,8,,,,,BAO_0000019,105,,2002,,13706,F,,
Autocuration,,1,,,Compound was tested for its agonist activity against human 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,CHEMBL617096,H,8,,,,,BAO_0000019,105,,2003,,14251,F,,
Autocuration,,1,,,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,CHEMBL617097,H,8,,,,,BAO_0000019,105,,2004,,14251,F,,
Autocuration,,1,,,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,CHEMBL617098,H,8,,,,,BAO_0000019,105,,2005,,14251,F,,
Autocuration,,1,,,In vitro binding affinity towards 5-HT1D alpha receptor by using [3H]5-HT as radioligand,,CHEMBL617301,H,8,,,,,BAO_0000357,105,,2006,,13313,B,,
Autocuration,,1,,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]5-HT as radioligand,,CHEMBL617302,H,8,,,,,BAO_0000357,105,,2007,,13313,B,,
Autocuration,,1,,,Selectivity towards 5-hydroxytryptamine 1D receptor beta to that of 5-hydroxytryptamine 1D receptor alpha,,CHEMBL617303,H,8,,,,,BAO_0000357,105,,2008,,13366,B,,
Expert,,1,,,Binding affinity to recombinant human 5-hydroxytryptamine 1D receptor alpha,,CHEMBL617304,H,8,,,,,BAO_0000357,105,,2009,,13051,B,,
Expert,,1,CHO,,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor alpha expressed in CHO cells, by using [3H]5-HT as radioligand",,CHEMBL617305,H,8,,449.0,,,BAO_0000219,105,,2010,,12903,B,,
Autocuration,,1,,,Binding affinity was measured on 5-hydroxytryptamine 1D receptor alpha in COS cells transfected with human 5-HT1D alpha gene labeled with [3H]5-HT,,CHEMBL617306,D,9,,,Homo sapiens,9606.0,BAO_0000219,105,,2011,,12469,B,,
Autocuration,,1,,,Binding affinity (in vitro) against 5-hydroxytryptamine 1D receptor alpha using radio-ligand binding assay,,CHEMBL617307,H,8,,,,,BAO_0000357,17106,,2012,,5619,B,,
Autocuration,,1,,,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,,CHEMBL617308,H,8,,,Oryctolagus cuniculus,9986.0,BAO_0000019,105,,2013,,13047,B,,
Autocuration,,1,,,Binding affinities against 5-hydroxytryptamine 1D receptor alpha,,CHEMBL617309,H,8,,,,,BAO_0000357,105,,2014,,16633,B,,
Autocuration,,1,,,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,,CHEMBL617310,H,8,,,,,BAO_0000357,105,,2015,,16633,B,,
Autocuration,,1,,,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,,CHEMBL617311,H,8,,,,,BAO_0000357,105,,2016,,16633,B,,
Autocuration,,1,,,Binding affinity towards 5-hydroxytryptamine 1D receptor alpha using [3H]8-OH-DPAT as radioligand,,CHEMBL617312,H,8,,,,,BAO_0000357,105,,2017,,16633,B,,
Autocuration,,1,,,Affinity against 5-hydroxytryptamine 1D receptor alpha,,CHEMBL617313,H,8,,,,,BAO_0000357,105,,2018,,3269,B,,
Expert,,1,,,Binding affinity against 5-hydroxytryptamine 1D receptor alpha,,CHEMBL617314,H,8,,,,,BAO_0000357,105,,2019,,12409,B,,
Autocuration,,1,,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,CHEMBL617315,H,8,,,,,BAO_0000019,106,,2020,,13706,F,,
Autocuration,,1,HEK293,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line.,,CHEMBL617316,H,8,,722.0,,,BAO_0000219,106,,2021,,13706,B,,
Autocuration,,1,HEK293,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,,CHEMBL617317,H,8,,722.0,,,BAO_0000219,106,,2022,,13706,B,,
Autocuration,,1,CHO,,"The compound was tested in vitro for binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",,CHEMBL617318,H,8,,449.0,,,BAO_0000219,106,,2023,,12903,B,,
Autocuration,,1,,,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,,CHEMBL617319,H,8,,,,,BAO_0000019,106,,2024,,13047,B,,
Expert,,1,,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,CHEMBL617320,D,9,,,,,BAO_0000357,106,,2025,,13366,B,,
Expert,,1,,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,CHEMBL617321,D,9,,,,,BAO_0000357,106,,2026,,13366,B,,
Expert,,1,,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,CHEMBL617322,D,9,,,,,BAO_0000357,106,,2027,,13366,B,,
Autocuration,,1,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined using [3H]8-OH-DPAT as radioligand,,CHEMBL616862,H,8,,,,,BAO_0000357,106,,2028,,13366,B,,
Autocuration,,1,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor was determined using [3H]8-OH-DPAT as radioligand,,CHEMBL616863,H,8,,,,,BAO_0000357,106,,2029,,13366,B,,
Autocuration,,1,CHO,,Binding affinity was measured on 5-hydroxytryptamine 1D receptor beta in CHO cells transfected with human 5-HT1D beta gene labeled with [3H]5-HT,,CHEMBL616864,H,8,,449.0,,,BAO_0000219,106,,2030,,12469,B,,
Autocuration,,1,CHO-K1,,Compound was tested for binding affinity against cloned human 5-HT1D beta receptor expressed in CHO-K1 cells.,,CHEMBL616865,H,8,,485.0,,,BAO_0000219,106,,2031,,13706,B,,
Autocuration,,1,CHO-K1,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells.,,CHEMBL616866,H,8,,485.0,,,BAO_0000219,106,,2032,,13706,B,,
Autocuration,,1,,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,CHEMBL616867,H,8,,,,,BAO_0000019,106,,2033,,13706,F,,
Expert,,1,CHO-K1,,"Binding affinity against 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells, using [3H]5-HT as the radioligand.",,CHEMBL616868,H,8,,485.0,,,BAO_0000219,106,,2034,,12902,B,,
Expert,,1,,,Binding affinity for cloned human 5-hydroxytryptamine 1D receptor beta,,CHEMBL616869,H,8,,,,,BAO_0000357,105,,2035,,13051,B,,
Expert,,1,CHO,,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",,CHEMBL616870,H,8,,449.0,,,BAO_0000219,106,,2036,,12903,B,,
Autocuration,,1,CHO-K1,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.24-0.55,,CHEMBL616871,H,8,,485.0,,,BAO_0000219,105,,2037,,1558,F,,
Autocuration,,1,CHO-K1,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.6-2.0,,CHEMBL616872,H,8,,485.0,,,BAO_0000219,105,,2038,,1558,F,,
Autocuration,,1,CHO-K1,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 2.8-6.5,,CHEMBL616873,H,8,,485.0,,,BAO_0000219,105,,2039,,1558,F,,
Autocuration,,1,CHO-K1,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 30-70,,CHEMBL616838,H,8,,485.0,,,BAO_0000219,105,,2040,,1558,F,,
Autocuration,,1,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined,,CHEMBL616839,H,8,,,,,BAO_0000357,105,,2041,,1558,B,,
Autocuration,,1,,,Binding affinity against 5-hydroxytryptamine 3 receptor using rabbit saphenous vein assay.,,CHEMBL616840,H,8,,,Oryctolagus cuniculus,9986.0,BAO_0000019,106,,2042,,13047,B,,
Autocuration,,1,,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]-5-HT as radioligand,,CHEMBL616841,H,8,,,,,BAO_0000357,105,,2043,,13313,B,,
Autocuration,,1,,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor beta by using [3H]5-HT as radioligand,,CHEMBL616842,H,8,,,,,BAO_0000357,105,,2044,,13313,B,,
Expert,,1,,,Binding affinity against 5-hydroxytryptamine 1D receptor beta,,CHEMBL857976,H,8,,,,,BAO_0000357,105,,2045,,12409,B,,
Autocuration,,1,CHO,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1E receptor stably expressed in CHO cells,,CHEMBL616843,H,8,,449.0,,,BAO_0000219,10618,,2046,,15250,B,,
Expert,,1,,,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype,,CHEMBL616844,D,9,,,Homo sapiens,9606.0,BAO_0000357,10618,,2047,,1348,B,,
Autocuration,,1,,,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype; NA denotes data not available,,CHEMBL616845,H,8,,,,,BAO_0000357,10618,,2048,,1348,B,,
Expert,,1,,,Binding affinity to cloned human 5-hydroxytryptamine 1E receptor,,CHEMBL616846,D,9,,,Homo sapiens,9606.0,BAO_0000357,10618,,2049,,4234,B,,
Autocuration,,1,,,Binding affinity towards human 5-hydroxytryptamine 1E receptor was determined using [3H]5-HT as radioligand,,CHEMBL616847,H,8,,,,,BAO_0000357,10618,,2050,,16209,B,,
Autocuration,,1,,,Binding affinity was determined against 5-hydroxytryptamine 1E receptor in human cortical homogenate,,CHEMBL616848,H,8,,,,,BAO_0000019,10618,,2051,,10444,B,,
Autocuration,,1,,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1E receptor,,CHEMBL616849,H,8,,,,,BAO_0000357,10618,,2052,,3935,B,,
Autocuration,,1,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1E receptor,,CHEMBL872911,H,8,,,,,BAO_0000357,10618,,2053,,15818,B,,
Autocuration,,1,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1E receptor,,CHEMBL616850,H,8,,,,,BAO_0000019,10618,,2054,,17085,B,,
Expert,,1,CHO,,Binding affinity against human 5-hydroxytryptamine 1E receptor expressed in CHO cells,,CHEMBL616699,D,9,,449.0,Homo sapiens,9606.0,BAO_0000219,10618,,2055,,12936,B,,
Autocuration,,1,,,Binding affinity towards cloned human 5-hydroxytryptamine 1E receptor was determined,,CHEMBL616700,H,8,,,,,BAO_0000357,10618,,2056,,6166,B,,
Autocuration,,1,CHO,,Binding affinity towards 5-hydroxytryptamine 1E receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,CHEMBL616701,H,8,,449.0,,,BAO_0000219,10618,,2057,,15779,B,,
Autocuration,,1,CHO,,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand.,,CHEMBL616702,H,8,,449.0,,,BAO_0000219,10618,,2058,,15779,B,,
Autocuration,,1,CHO,,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand;ND means no data.,,CHEMBL616703,H,8,,449.0,,,BAO_0000219,10618,,2059,,15779,B,,
Autocuration,,1,,,Binding affinity was determined against 5-hydroxytryptamine 1D receptor,,CHEMBL616704,H,8,,,,,BAO_0000357,10618,,2060,,13181,B,,
Autocuration,,1,CHO,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as the radioligand,,CHEMBL616705,H,8,,449.0,,,BAO_0000219,10618,,2061,,4199,B,,
Autocuration,,1,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1E receptor,,CHEMBL616706,H,8,,,,,BAO_0000357,10618,,2062,,14875,B,,
Autocuration,,1,CHO,,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]-5-HT,,CHEMBL616707,H,8,,449.0,,,BAO_0000219,10618,,2063,,15146,B,,
Autocuration,,1,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1E receptor in CHO using [3H]5-HT as a radioligand,,CHEMBL616708,H,8,,,,,BAO_0000357,10618,,2064,,5213,B,,
Autocuration,,1,,,Tested for binding affinity towards cloned human 5-hydroxytryptamine 1E receptor using [3H]5-HT as radioligand,,CHEMBL616709,H,8,,,,,BAO_0000357,10618,,2065,,12146,B,,
Autocuration,,1,CHO,,The binding affinity (pKi) measured against 5-hydroxytryptamine 1E receptor (cloned human receptors in CHO cells) using [3H]5-HT1E as radioligand,,CHEMBL616710,H,8,,449.0,,,BAO_0000219,10618,,2066,,13267,B,,
Autocuration,,1,CHO,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT.,,CHEMBL616711,H,8,,449.0,,,BAO_0000219,10618,,2067,,14818,B,,
Autocuration,,1,CHO,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells, using [3H]5-HT as radioligand",,CHEMBL616712,H,8,,449.0,,,BAO_0000219,10618,,2068,,4829,B,,
Autocuration,,1,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1E receptor was determined,,CHEMBL616713,H,8,,,,,BAO_0000357,10618,,2069,,4373,B,,
Autocuration,,1,,,Binding affinity for 5-hydroxytryptamine 1E receptor was determined,,CHEMBL616714,H,8,,,,,BAO_0000357,10618,,2070,,4373,B,,
Autocuration,,1,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1E receptor,,CHEMBL616715,H,8,,,,,BAO_0000357,10618,,2071,,14159,B,,
Autocuration,,1,,,Binding affinity towards 5-hydroxytryptamine 1E receptor,,CHEMBL616716,H,8,,,,,BAO_0000357,10618,,2072,,16633,B,,
Autocuration,,1,,,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-HT1F receptor",,CHEMBL616717,H,8,,,,,BAO_0000019,279,,2073,,17085,F,,
Expert,,1,,,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-hydroxytryptamine 1F receptor",,CHEMBL616718,H,8,,,,,BAO_0000019,279,,2074,,17085,F,,
Autocuration,,1,,,In vitro effective concentration for inhibition of skolin-stimulated adenylate cyclase in cell line expressing human 5-hydroxytryptamine 1F receptor,,CHEMBL875905,H,8,,,,,BAO_0000019,279,,2075,,16209,F,,
Autocuration,,1,,,In vitro agonist potency against human 5-hydroxytryptamine 1F receptor,,CHEMBL616719,H,8,,,,,BAO_0000019,279,,2076,,16209,F,,
Expert,,1,,,"Maximum stimulation of of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine 1F receptor",,CHEMBL616720,H,8,,,,,BAO_0000019,279,,2077,,17085,F,,
Autocuration,,1,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1F receptor,,CHEMBL616721,H,8,,,,,BAO_0000357,279,,2078,,14159,B,,
Autocuration,,1,CHO,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1F receptor stably expressed in CHO cells,,CHEMBL616722,H,8,,449.0,,,BAO_0000219,279,,2079,,15250,B,,
Autocuration,,1,,,In vitro binding affinity against human 5-hydroxytryptamine 1F receptor at a concentration of 100 (nM),,CHEMBL616723,H,8,,,,,BAO_0000357,279,,2080,,3805,B,,
Autocuration,,1,CHO,,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT radioligand,,CHEMBL616724,H,8,,449.0,,,BAO_0000219,279,,2081,,16190,B,,
Autocuration,,1,,,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT radioligand,,CHEMBL616725,H,8,,,,,BAO_0000357,279,,2082,,16190,B,,
Autocuration,,1,,,Binding affinity towards human 5-hydroxytryptamine 1F receptor,,CHEMBL616726,H,8,,,,,BAO_0000357,279,,2083,,16209,B,,
Autocuration,,1,,,Binding affinity towards human 5-hydroxytryptamine 1F receptor was determined,,CHEMBL616727,H,8,,,,,BAO_0000357,279,,2084,,16209,B,,
Autocuration,,1,,,Binding affinity towards human 5-hydroxytryptamine 1F receptor using [3H]-5-HT radioligand,,CHEMBL616728,H,8,,,,,BAO_0000357,279,,2085,,16209,B,,
Autocuration,,1,,,In vitro binding affinity for human 5-hydroxytryptamine 1F receptor,,CHEMBL616729,H,8,,,,,BAO_0000357,279,,2086,,6866,B,,
Expert,,1,,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1F receptor,,CHEMBL616730,H,8,,,,,BAO_0000019,279,,2087,,17085,B,,
Autocuration,,1,,,Binding affinity towards human recombinant 5-hydroxytryptamine 1F receptor,,CHEMBL617125,H,8,,,,,BAO_0000357,279,,2088,,16312,B,,
Autocuration,,1,,,Binding affinity towards cloned human 5-hydroxytryptamine 1F receptor was determined,,CHEMBL857977,H,8,,,,,BAO_0000357,279,,2089,,6166,B,,
Autocuration,,1,CHO,,Binding affinity towards 5-hydroxytryptamine 1F receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,CHEMBL617126,H,8,,449.0,,,BAO_0000219,279,,2090,,15779,B,,
Autocuration,,1,CHO,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1F receptor in CHO cells using [3H]-5-HT as the radioligand,,CHEMBL617127,H,8,,449.0,,,BAO_0000219,279,,2091,,4199,B,,
Autocuration,,1,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1F receptor,,CHEMBL617128,H,8,,,,,BAO_0000357,279,,2092,,14875,B,,
Autocuration,,1,CHO,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1F receptor in human cloned receptors in CHO cells using [3H]5-HT,,CHEMBL617129,H,8,,449.0,,,BAO_0000219,279,,2093,,15146,B,,
Autocuration,,1,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT as a radioligand,,CHEMBL617130,H,8,,,,,BAO_0000357,279,,2094,,5213,B,,
Autocuration,,1,CHO,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT.,,CHEMBL617131,H,8,,449.0,,,BAO_0000219,279,,2095,,14818,B,,
Autocuration,,1,CHO,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",,CHEMBL617132,H,8,,449.0,,,BAO_0000219,279,,2096,,4829,B,,
Autocuration,,1,CHO,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",,CHEMBL617133,H,8,,449.0,,,BAO_0000219,279,,2097,,4829,B,,
Autocuration,,1,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1F receptor was determined,,CHEMBL617134,H,8,,,,,BAO_0000357,279,,2098,,4373,B,,
Autocuration,,1,,,Binding affinity for 5-hydroxytryptamine 1F receptor was determined,,CHEMBL617135,H,8,,,,,BAO_0000357,279,,2099,,4373,B,,
Autocuration,,1,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1F receptor,,CHEMBL617136,H,8,,,,,BAO_0000357,279,,2100,,5014,B,,
Autocuration,,1,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]-ketanserin as radioligand",,CHEMBL617137,H,4,,,,,BAO_0000019,104686,,2101,,11662,B,,
Autocuration,,1,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",,CHEMBL617138,H,4,,,,,BAO_0000019,104686,,2102,,11662,B,,
Autocuration,,1,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,CHEMBL617139,H,4,,,,,BAO_0000019,104686,,2103,,11662,B,,
Autocuration,,1,,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,,CHEMBL617140,H,8,,,,,BAO_0000019,12687,,2104,,14093,B,,
Autocuration,,1,,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-HT2 receptor 1 hr after oral administration",,CHEMBL617141,H,4,,,,,BAO_0000218,104686,,2105,,11200,F,In vivo,
Autocuration,,1,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,CHEMBL858112,H,4,,,,,BAO_0000019,104686,,2106,,11200,F,,
Intermediate,,1,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in calf frontal cortex,,CHEMBL617142,H,8,,,,,BAO_0000019,17005,,2107,,12352,B,,
Autocuration,,1,,,"Binding affinity to 5-hydroxytryptamine 2 receptor using calf frontal cortex, [3H]- ketanserin, and spiperone for NSB",,CHEMBL617143,U,0,,,Bos taurus,9913.0,BAO_0000019,22226,,2108,,13657,B,,
Autocuration,,1,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex at 10e-7 M,,CHEMBL617144,U,0,,,Bos taurus,9913.0,BAO_0000019,22226,,2109,,14331,B,,
Autocuration,,1,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex,,CHEMBL617145,U,0,,,Bos taurus,9913.0,BAO_0000019,22226,,2110,,14331,B,,
Autocuration,,1,,,Binding affinity of compound towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin (0.8 nM) ligand in frontal cortex bovine was determined,,CHEMBL617146,U,0,,,,,BAO_0000019,22226,,2111,,14331,B,,
Autocuration,,1,,,Binding affinity for serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin in guinea pig frontal cortex,,CHEMBL617147,H,4,,,Cavia porcellus,10141.0,BAO_0000019,104784,,2112,,12685,B,,
Autocuration,,1,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of guinea pig frontal cortex membranes,,CHEMBL617148,H,4,,,Cavia porcellus,10141.0,BAO_0000019,104784,,2113,,14389,B,,
Autocuration,,1,,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin from guinea pig frontal cortex,,CHEMBL617149,H,4,,,Cavia porcellus,10141.0,BAO_0000019,104784,,2114,,14386,B,,
Autocuration,,1,,,Binding affinity towards cloned human 5-hydroxytryptamine 2 receptor was determined,,CHEMBL617150,H,4,,,,,BAO_0000224,104784,,2115,,5732,B,,
Autocuration,,1,,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,CHEMBL617151,H,4,,,,,BAO_0000224,104784,,2116,,16293,B,,
Autocuration,,1,,,In vitro binding affinity of compound against neuronal 5-hydroxytryptamine 2 receptor,,CHEMBL617201,H,4,,,,,BAO_0000224,104784,,2117,,2078,B,,
Autocuration,,1,,,Binding affinity towards 5-HT7 receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,,CHEMBL617202,H,8,,,,,BAO_0000357,10209,,2118,,5486,B,,
Autocuration,,1,,,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,,CHEMBL617203,H,4,,,,,BAO_0000218,104826,,2119,,11820,B,In vivo,
Autocuration,,1,,,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,,CHEMBL617204,H,4,,,,,BAO_0000019,104826,,2120,,10297,B,,
Autocuration,,1,,,Inhibitory activity against serotonin 5-hydroxytryptamine 2 receptor from mice.,,CHEMBL617205,H,4,,,,,BAO_0000224,104826,,2121,,13704,B,,
Autocuration,,1,,,Inhibitory activity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in mouse cerebral cortex,,CHEMBL617206,D,5,,,Mus musculus,10090.0,BAO_0000019,104826,,2122,,10297,B,,
Autocuration,,1,,,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,,CHEMBL617207,H,4,,,,,BAO_0000218,104826,,2123,,11820,B,In vivo,
Autocuration,,1,,,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]-ketanserin in mouse cerebral cortex,,CHEMBL617208,D,5,,,Mus musculus,10090.0,BAO_0000019,104826,,2124,,10297,B,,
Autocuration,,1,,,The compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2 receptor,,CHEMBL617209,H,4,,,,,BAO_0000224,104826,,2125,,11555,B,,
Autocuration,,1,,,In vitro binding affinity for serotonin 5-hydroxytryptamine (5-HT) 2 receptors,,CHEMBL617210,H,4,,,,,BAO_0000224,104826,,2126,,11555,B,,
Autocuration,,1,,,The compound was tested in vitro for its binding affinity towards serotonin 5-hydroxytryptamine 2 receptor; nd = no data,,CHEMBL617211,H,4,,,,,BAO_0000224,104826,,2127,,11555,B,,
Autocuration,,1,,,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,,CHEMBL617212,D,5,,,Mus musculus,10090.0,BAO_0000019,104826,,2128,,10297,B,,
Autocuration,,1,,,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin,,CHEMBL617213,H,4,,,Sus scrofa,9823.0,BAO_0000224,104784,,2129,,16688,B,,
Autocuration,,1,,,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin with 10 uM prazosin,,CHEMBL617214,H,4,,,Sus scrofa,9823.0,BAO_0000224,104784,,2130,,16688,B,,
Autocuration,,1,,,Compound was tested in vitro for its ability to compete with [3H]-ketanserin at 5-hydroxytryptamine 2 receptor in porcine brain homogenate,,CHEMBL617215,U,0,,,,,BAO_0000221,22226,,2131,,5333,B,,
Autocuration,,1,,,In vitro for its ability to displace [3H]- ketanserin from 5-hydroxytryptamine 2 receptor in porcine brain homogenate,,CHEMBL617216,U,0,,,,,BAO_0000221,22226,,2132,,4437,B,,
Autocuration,,1,,,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2 receptor,,CHEMBL617217,H,8,,,Sus scrofa,9823.0,BAO_0000357,17005,,2133,,5033,B,,
Autocuration,,1,,,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,,CHEMBL617218,H,4,,,,,BAO_0000019,104686,,2134,,15267,B,,
Autocuration,,1,,,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,,CHEMBL872913,H,4,,,,,BAO_0000019,104686,,2135,,15267,B,,
Autocuration,,1,,,Binding affinity against 5-hydroxytryptamine 2 receptor from rat cortical synaptosomal membrane using radioligand [3H]ketanserin.,,CHEMBL617219,H,4,,,,,BAO_0000019,104826,,2136,,11820,B,,
Autocuration,,1,,,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,,CHEMBL873482,H,4,,,,,BAO_0000224,104686,,2137,,9069,B,,
Autocuration,,1,,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; ND means no data,,CHEMBL617220,D,5,,,Rattus norvegicus,10116.0,BAO_0000019,104686,,2138,,9162,B,,
Autocuration,,1,,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein.,,CHEMBL617221,H,4,,,,,BAO_0000019,104686,,2139,,9162,B,,
Autocuration,,1,,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; no appreciable 5-HT2 receptor affinity,,CHEMBL617222,H,4,,,,,BAO_0000019,104686,,2140,,9162,B,,
Autocuration,,1,,,Antagonistic activity against (5-hydroxytryptamine 2 receptor) serotonin-induced contractions in the rat jugular vein,,CHEMBL875906,H,4,,,,,BAO_0000019,104686,,2141,,10428,F,,
Autocuration,,1,,,Binding affinity to the 5-hydroxytryptamine 2 receptor assayed by antagonism of serotonin-induced contractions in the rat jugular vein,,CHEMBL617223,H,4,,,,,BAO_0000019,104686,,2142,,9628,B,,
Autocuration,,1,,,Binding affinity against serotonin 5-hydroxytryptamine 2 receptor,,CHEMBL617224,H,4,,,,,BAO_0000224,104686,,2143,,12704,B,,
Autocuration,,1,,,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,,CHEMBL617225,D,5,,,Rattus norvegicus,10116.0,BAO_0000224,104686,,2144,,15453,B,,
Autocuration,,1,,,Tested for the effect on binding at 5-hydroxytryptamine 2 receptor; No activity,,CHEMBL617226,H,4,,,,,BAO_0000224,104686,,2145,,188,B,,
Autocuration,,1,,,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.4 nM dose of [3H]- spiperone as a radioligand.,,CHEMBL617227,H,4,,,,,BAO_0000224,104686,,2146,,10349,B,,
Autocuration,,1,,,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.6 nM dose of [3H]- spiperone as a radioligand.,,CHEMBL617228,H,4,,,,,BAO_0000224,104686,,2147,,10349,B,,
Autocuration,,1,,,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,,CHEMBL617229,H,4,,,,,BAO_0000224,104686,,2148,,8868,B,,
Autocuration,,1,,,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,,CHEMBL617230,H,4,,,,,BAO_0000224,104686,,2149,,10025,B,,
Autocuration,,1,,,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",,CHEMBL617231,H,4,,,,,BAO_0000224,104686,,2150,,10025,B,,
Autocuration,,1,,,Compound was tested for the inhibition of quipazine binding at 5-HT2 receptor,,CHEMBL617232,H,4,,,,,BAO_0000224,104686,,2151,,11702,B,,
Autocuration,,1,,,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor,,CHEMBL617233,H,4,,,,,BAO_0000224,104686,,2152,,11702,B,,
Autocuration,,1,,,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor; NT=Not tested,,CHEMBL617234,H,4,,,,,BAO_0000224,104686,,2153,,11702,B,,
Autocuration,,1,,,Compound was tested for the inhibition of quipazine induced head twitches in rats,,CHEMBL617235,H,4,,,,,BAO_0000019,104686,,2154,,11702,F,,
Autocuration,,1,,,Compound was tested for the inhibition of quipazine induced head twitches in rats; NT=Not tested,,CHEMBL617236,H,4,,,,,BAO_0000019,104686,,2155,,11702,F,,
Autocuration,,1,,,Ability to bind at 5-hydroxytryptamine 2 receptor of rat hippocampus by displacing [3H]spiperone,,CHEMBL617237,H,4,,,,,BAO_0000221,104686,,2156,Hippocampus,10085,B,,10000000.0
Autocuration,,1,,,Ability to bind at serotonin 5-hydroxytryptamine 2 receptors of rat hippocampus by displacing [3H]spiperone,,CHEMBL617238,H,4,,,,,BAO_0000221,104686,,2157,Hippocampus,10085,B,,10000000.0
Autocuration,,1,,,Displacement of [3H]spiroperidol from 5-hydroxytryptamine 2 receptor in rat brain,,CHEMBL617239,D,5,,,Rattus norvegicus,10116.0,BAO_0000221,104686,,2158,Brain,9630,B,,955.0
Autocuration,,1,,,Ability to inhibit binding of [3H]KET to 5-hydroxytryptamine 2 receptor in rat cortex,,CHEMBL617240,H,4,,,,,BAO_0000019,104686,,2159,,11070,B,,
Autocuration,,1,,,Ability to inhibit binding of titreated spiperone to 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,Membranes,CHEMBL617241,H,4,,,,,BAO_0000249,104686,,2160,,9841,B,,
Autocuration,,1,,,Ability to inhibit binding of titreated spiperone to the 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,Membranes,CHEMBL875907,H,4,,,,,BAO_0000249,104686,,2161,,9841,B,,
Autocuration,,1,,,Affinity for 5-hydroxytryptamine 2 receptor binding sites by its ability to displace [3H]spiperone from rat frontal cortex.,,CHEMBL617242,H,4,,,,,BAO_0000019,104686,,2162,,13291,B,,
Autocuration,,1,,,Antagonistic activity against 5-hydroxytryptamine 2 receptor on rat frontal cortex membrane.,,CHEMBL617152,H,4,,,,,BAO_0000019,104686,,2163,,10590,F,,
Autocuration,,1,,,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,,CHEMBL617153,D,5,,,Rattus norvegicus,10116.0,BAO_0000221,104686,,2164,Brain,9064,B,,955.0
Autocuration,,1,,,Binding affinity at 5-hydroxytryptamine 2 receptor by the inhibition of binding to [3H]ketanserin in rat cortical membranes,Membranes,CHEMBL617154,D,5,,,Rattus norvegicus,10116.0,BAO_0000249,104686,,2165,,12268,B,,
Autocuration,,1,,,Binding affinity against 5-hydroxytryptamine 2 receptor in rat brain using [3H]ketanserin as radioligand,,CHEMBL617155,H,4,,,,,BAO_0000221,104686,,2166,Brain,13508,B,,955.0
Autocuration,,1,,,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,,CHEMBL617156,H,4,,,,,BAO_0000019,104686,,2167,,11279,F,,
Autocuration,,1,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-HT2 receptor in rat thoracic aortic strips,,CHEMBL617157,H,4,,,,,BAO_0000019,104686,,2168,,11200,F,,
Autocuration,,1,,,In vitro antagonistic activity tested against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,CHEMBL617158,H,4,,,,,BAO_0000019,104686,,2169,,11200,F,,
Autocuration,,1,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,,CHEMBL617159,H,4,,,,,BAO_0000019,104686,,2170,,11200,F,,
Autocuration,,1,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,,CHEMBL617160,H,4,,,,,BAO_0000019,104686,,2171,,11200,F,,
Autocuration,,1,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,CHEMBL858113,H,4,,,,,BAO_0000019,104686,,2172,,11200,F,,
Autocuration,,1,,,Tested for 5-hydroxytryptamine 2 receptor binding ability by displacement of [3H]spiperone from rat brain frontal cortex synaptosomes,,CHEMBL617247,H,4,,,,,BAO_0000220,104686,,2173,Brain,9231,B,,955.0
Autocuration,,1,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,,CHEMBL617248,H,4,,,,,BAO_0000019,104686,,2174,,9737,B,,
Autocuration,,1,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,CHEMBL617249,H,4,,,,,BAO_0000249,104686,,2175,Brain,9737,B,,955.0
Autocuration,,1,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex,,CHEMBL617250,H,4,,,,,BAO_0000019,104686,,2176,,9737,B,,
Autocuration,,1,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,,CHEMBL617251,H,4,,,,,BAO_0000019,104686,,2177,,9737,B,,
Autocuration,,1,,,isplacement of [3H]DOB from rat cortex homogenate 5-hydroxytryptamine 2 receptor,,CHEMBL617252,D,5,,,Rattus norvegicus,10116.0,BAO_0000019,104686,,2178,,11828,B,,
Autocuration,,1,,,Binding affinity of 5-hydroxytryptamine 2 receptor using [3H]- ketanserin in rat frontal cortex,,CHEMBL617006,H,4,,,,,BAO_0000019,104686,,2179,,12253,B,,
Autocuration,,1,,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat frontal cortex,,CHEMBL617007,H,4,,,,,BAO_0000019,104686,,2180,,12253,B,,
Autocuration,,1,,,"5-hydroxytryptamine 2 receptor antagonistic activity at concentrations of<br>3,10 and 30 uM on the rat tail artery.",,CHEMBL617008,H,4,,,,,BAO_0000019,104686,,2181,,11279,F,,
Autocuration,,1,,,Binding affinity for 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- ketanserin,,CHEMBL617009,H,4,,,,,BAO_0000019,104686,,2182,,11866,B,,
Autocuration,,1,,,Binding affinity against 5-hydroxytryptamine 2 receptor in serotonin-induced contraction of the rat aorta,,CHEMBL617010,D,5,,,Rattus norvegicus,10116.0,BAO_0000224,104686,,2183,,14424,B,,
Autocuration,,1,,,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,,CHEMBL857978,D,5,,,Rattus norvegicus,10116.0,BAO_0000019,104686,,2184,,15180,B,,
Autocuration,,1,,,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,,CHEMBL617011,D,5,,,Rattus norvegicus,10116.0,BAO_0000019,104686,,2185,,15180,B,,
Autocuration,,1,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat frontal cortex homogenate,,CHEMBL617012,D,5,,,Rattus norvegicus,10116.0,BAO_0000019,104686,,2186,,9786,B,,
Autocuration,,1,,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand.,,CHEMBL617013,H,4,,,,,BAO_0000224,104686,,2187,,12132,B,,
Autocuration,,1,,,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in rat cerebral cortex membrane,,CHEMBL617014,H,4,,,,,BAO_0000249,104686,,2188,,5486,B,,
Autocuration,,1,,,Compound was evaluated for its ability to displace [3H]ketanserin binding from cloned rat cerebral cortex membranes 5-hydroxytryptamine 2 receptor,,CHEMBL617015,H,4,,,,,BAO_0000019,104686,,2189,,15316,B,,
Autocuration,,1,,,In vitro binding affinity to 5-hydroxytryptamine 2 receptor of rat cerebral cortex membranes using [3H]ketanserin as the radioligand,,CHEMBL617016,H,4,,,,,BAO_0000019,104686,,2190,,16429,B,,
Autocuration,,1,,,pKi value for 5-hydroxytryptamine 2 receptor binding site,,CHEMBL617017,H,4,,,,,BAO_0000224,104686,,2191,,14617,B,,
Autocuration,,1,,,Inhibitory constant (1 uM) was measured on 5-hydroxytryptamine 2 receptor/uptake using [3H]- ketanserin as radioligand in rat brain cortex.,,CHEMBL617018,H,4,,,,,BAO_0000221,104686,,2192,Brain,11351,B,,955.0
Autocuration,,1,,,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,,CHEMBL617019,H,4,,,,,BAO_0000019,104686,,2193,,11279,F,,
Autocuration,,1,,,Binding affinity at 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,CHEMBL617020,H,4,,,,,BAO_0000019,105075,,2194,,9523,B,,
Autocuration,,1,,,Binding affinity at 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,CHEMBL617021,H,4,,,,,BAO_0000019,105075,,2195,,9523,B,,
Autocuration,,1,,,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,CHEMBL617022,H,4,,,,,BAO_0000019,105075,,2196,,9523,B,,
Autocuration,,1,,,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,CHEMBL617023,H,4,,,,,BAO_0000019,105075,,2197,,9523,B,,
Autocuration,,1,,,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,CHEMBL617024,H,4,,,,,BAO_0000019,105075,,2198,,9523,B,,
Autocuration,,1,,,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,CHEMBL617025,H,4,,,,,BAO_0000019,105075,,2199,,9523,B,,
Autocuration,,1,,,Hill coefficient of compound was determined,,CHEMBL617026,H,4,,,,,BAO_0000224,105075,,2200,,9523,B,,
Autocuration,,1,,,Ancillary Binding affinity towards rat 5-hydroxytryptamine 2 receptor,,CHEMBL617027,U,0,,,,,BAO_0000019,22226,,2201,,4771,B,,
Autocuration,,1,,,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-ketanserin) from 5-hydroxytryptamine 2 receptor of rat cerebral cortex membrane,,CHEMBL617028,D,5,,,Rattus norvegicus,10116.0,BAO_0000019,104686,,2202,,5033,B,,
Expert,,1,,,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand,,CHEMBL617029,H,8,,,,,BAO_0000019,12687,,2203,,10845,B,,
Expert,,1,,,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand; IA-Inactive,,CHEMBL875908,H,8,,,,,BAO_0000019,12687,,2204,,10845,B,,
Autocuration,,1,,,Affinity at 5-hydroxytryptamine 2 receptor (For ketanserin = Ki(nM)= 0.7+/-0.09),,CHEMBL617030,H,8,,,,,BAO_0000357,12687,,2205,,16288,B,,
Autocuration,,1,,,Affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex using [3H]ketanserin as radioligand (For ketanserin = Ki(nM)=0.7+/-0.09),,CHEMBL617031,H,8,,,,,BAO_0000019,12687,,2206,,16288,B,,
Autocuration,,1,,,Binding affinity for 5-hydroxytryptamine 2 receptor of rat cortical membrane using [3H]DOB radioligand,,CHEMBL617032,H,8,,,,,BAO_0000019,12687,,2207,,16190,B,,
Autocuration,,1,,,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 2 receptor using radioligand [3H]ketanserin,,CHEMBL617033,D,5,,,Rattus norvegicus,10116.0,BAO_0000224,104686,,2208,,12463,B,,
Autocuration,,1,,,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand",,CHEMBL617034,H,4,,,,,BAO_0000224,104686,,2209,,9699,B,,
Autocuration,,1,,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand,,CHEMBL617035,H,4,,,,,BAO_0000224,104686,,2210,,9699,B,,
Autocuration,,1,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,CHEMBL617036,H,4,,,,,BAO_0000019,104686,,2211,,11662,B,,
Autocuration,,1,,,Inhibitory concentration against 5-hydroxytryptamine 2 receptor,,CHEMBL617037,H,4,,,,,BAO_0000224,104784,,2212,,1205,B,,
Autocuration,,1,,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2 receptor from mammalian clones expressed in CHO cell membranes using [3H]-ketanserin as radioligand,,CHEMBL617038,U,0,,,,,BAO_0000219,22226,,2213,,11376,B,,
Autocuration,,1,,,"Binding affinity towards 5-hydroxytryptamine 2 receptor expressed in CHO cell membranes using [3H]ketanserin (60 Ci/mmol, 1 nM)",,CHEMBL617039,H,4,,,,,BAO_0000219,104784,,2214,,11376,B,,
Autocuration,,1,,,Compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor,,CHEMBL617161,H,4,,,,,BAO_0000224,104784,,2215,,4639,B,,
Autocuration,,1,,,Compound was tested for inhibitory activity against 5-hydroxytryptamine 2 receptor,,CHEMBL617162,H,4,,,,,BAO_0000224,104784,,2216,,2222,B,,
Autocuration,,1,,,Compound was tested for its affinity towards 5-hydroxytryptamine 2 receptor,,CHEMBL617163,H,4,,,,,BAO_0000224,104784,,2217,,1558,B,,
Autocuration,,1,,,Tested for binding affinity for 5-hydroxytryptamine 2 receptor,,CHEMBL617164,H,4,,,,,BAO_0000224,104784,,2218,,1089,B,,
Autocuration,,1,,,The compound was evaluated for its ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor in cellular brain membranes,Brain membranes,CHEMBL617165,H,4,,,,,BAO_0000249,104784,,2219,,386,B,,
Autocuration,,1,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 2 receptor at a concentration of 10 uM using [3H]ketanserin as radioligand,,CHEMBL617166,H,4,,,,,BAO_0000224,104784,,2220,,2474,B,,
Autocuration,,1,,,Binding affinity towards 5-HT2 receptor,,CHEMBL617167,H,4,,,,,BAO_0000224,104784,,2221,,17066,B,,
Autocuration,,1,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,CHEMBL872912,H,4,,,,,BAO_0000224,104784,,2222,,959,B,,
Autocuration,,1,,,Compound was evaluated for 5-hydroxytryptamine 2 receptor binding,,CHEMBL617168,H,4,,,,,BAO_0000224,104784,,2223,,6398,B,,
Autocuration,,1,,,In vitro binding affinity against rat 5-hydroxytryptamine 2 receptor.,,CHEMBL617169,H,4,,,,,BAO_0000224,104686,,2224,,11889,B,,
Autocuration,,1,,,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,,CHEMBL617170,H,4,,,,,BAO_0000224,104784,,2225,,4221,B,,
Autocuration,,1,,,The compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor using ketanserin as radioligand,,CHEMBL617171,H,4,,,,,BAO_0000224,104784,,2226,,11026,B,,
Autocuration,,1,,,Binding affinity for 5-hydroxytryptamine 2 receptor was determined,,CHEMBL617172,H,4,,,,,BAO_0000224,104784,,2227,,11866,B,,
Autocuration,,1,,,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,,CHEMBL617173,H,4,,,,,BAO_0000224,104784,,2228,,4221,B,,
Autocuration,,1,,,In Vitro binding affinity for 5-hydroxytryptamine 2 receptor,,CHEMBL617174,U,0,,,,,BAO_0000019,22226,,2229,,13950,B,,
Autocuration,,1,,,5-hydroxytryptamine 2 receptor binding affinity,,CHEMBL617175,H,4,,,,,BAO_0000224,104784,,2230,,1263,B,,
Autocuration,,1,,,Binding affinity against 5-hydroxytryptamine 2 receptor was determined using [ [3H]spiperone radioligand,,CHEMBL617176,H,8,,,,,BAO_0000357,17005,,2231,,13291,B,,
Autocuration,,1,,,Compound was tested for the binding affinity against 5-hydroxytryptamine 2 receptor by using [3H]ketanserin as radioligand,,CHEMBL617177,H,8,,,,,BAO_0000357,17005,,2232,,10812,B,,
Autocuration,,1,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,,CHEMBL617178,H,4,,,,,BAO_0000224,104784,,2233,,13020,B,,
Autocuration,,1,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of central nervous system,,CHEMBL617179,H,4,,,,,BAO_0000224,104784,,2234,,13021,B,,
Autocuration,,1,,,Ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,,CHEMBL617180,H,4,,,,,BAO_0000224,104784,,2235,,13020,B,,
Autocuration,,1,,,Inhibitory activity against 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand at 10e-5 M concentration,,CHEMBL617181,H,8,,,,,BAO_0000357,17005,,2236,,14532,B,,
Autocuration,,1,,,Binding affinity against 5-hydroxytryptamine 2 receptor,,CHEMBL617182,H,8,,,,,BAO_0000357,17005,,2237,,13944,B,,
Autocuration,,1,,,Binding affinity against 5-hydroxytryptamine 2 receptor,,CHEMBL617183,H,8,,,,,BAO_0000357,17005,,2238,,14331,B,,
Autocuration,,1,,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,,CHEMBL617184,H,8,,,,,BAO_0000357,17005,,2239,,14118,B,,
Autocuration,,1,,,Binding affinity against serotonergic 5-HT2 receptor,,CHEMBL617185,H,8,,,,,BAO_0000357,17005,,2240,,13033,B,,
Autocuration,,1,,,Binding affinity for 5-hydroxytryptamine 2 receptor was determined by using [3H]ketanserin as radioligand,,CHEMBL617186,H,8,,,,,BAO_0000357,17005,,2241,,10321,B,,
Autocuration,,1,,,Compound was evaluated for the binding affinity at 5- HT2 receptor,,CHEMBL617187,H,8,,,,,BAO_0000357,17005,,2242,,12918,B,,
Autocuration,,1,,,Compound was tested for binding affinity using [3H]ketanserin against 5-hydroxytryptamine 2 receptor,,CHEMBL617188,H,8,,,,,BAO_0000357,17005,,2243,,15120,B,,
Autocuration,,1,,,In vivo binding affinity was evaluated against 5-hydroxytryptamine 2 receptor,,CHEMBL617189,H,8,,,,,BAO_0000218,17005,,2244,,2613,B,,
Autocuration,,1,,,Inhibitory activity against cloned human 5-HT2 receptor,,CHEMBL617190,D,5,,,Homo sapiens,9606.0,BAO_0000224,104784,,2245,,13378,B,,
Autocuration,,1,CHO,,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells",,CHEMBL617191,D,5,,449.0,Homo sapiens,9606.0,BAO_0000219,104784,,2246,,2331,B,,
Autocuration,,1,CHO,,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells.",,CHEMBL617192,D,5,,449.0,Homo sapiens,9606.0,BAO_0000219,104784,,2247,,2331,B,,
Autocuration,,1,CHO,,"Tested in vitro for the inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; Inactive",,CHEMBL617193,D,5,,449.0,Homo sapiens,9606.0,BAO_0000219,104784,,2248,,2331,B,,
Autocuration,,1,CHO,,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; not tested",,CHEMBL617194,D,5,,449.0,Homo sapiens,9606.0,BAO_0000219,104784,,2249,,2331,B,,
Autocuration,,1,,,Binding affinity towards 5-hydroxytryptamine 2 receptor,,CHEMBL617195,H,4,,,,,BAO_0000224,104784,,2250,,4170,B,,
Autocuration,,1,,,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,,CHEMBL881830,H,4,,,,,BAO_0000224,104784,,2251,,15453,B,,
Autocuration,,1,,,Binding affinity towards 5-hydroxytryptamine 2 receptor,,CHEMBL617196,H,8,,,,,BAO_0000357,17005,,2252,,1479,B,,
Autocuration,,1,,,Binding affinity towards 5-hydroxytryptamine 2- receptor using [3H]ketanserin as radioligand in competitive binding assay,,CHEMBL617197,H,4,,,,,BAO_0000224,104686,,2253,,11139,B,,
Expert,,1,,,Binding affinity against 5-hydroxytryptamine 2A receptor was measured using [3H]ketanserin as radioligand,,CHEMBL617198,H,8,,,,,BAO_0000357,17005,,2254,,13969,B,,
Expert,,1,,,Binding affinity towards 5-hydroxytryptamine 2A receptor,,CHEMBL873476,H,8,,,,,BAO_0000357,17005,,2255,,13392,B,,
Expert,,1,,,Affinity towards 5-hydroxytryptamine 2A receptor in membranes from bovine frontal cortex using [3H]ketanserin,,CHEMBL617199,H,8,,,,,BAO_0000019,17005,,2256,,14430,B,,
Autocuration,,1,,,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,,CHEMBL617200,H,8,,,Cavia porcellus,10141.0,BAO_0000357,107,,2257,,13181,B,,
Autocuration,,1,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,CHEMBL617484,H,8,,,,,BAO_0000357,51,,2258,,17200,B,,
Autocuration,,1,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,CHEMBL617485,H,8,,,,,BAO_0000357,107,,2259,,17200,B,,
Autocuration,,1,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,CHEMBL617486,H,8,,,,,BAO_0000357,51,,2260,,17200,B,,
Autocuration,,1,,,Binding affinity analysed on 5-HT 2A human clone using [3H]ketanserin as radioligand,,CHEMBL858022,H,8,,,,,BAO_0000357,107,,2261,,13463,B,,
Autocuration,,1,CHO,,Effective concentration against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,,CHEMBL617049,H,8,,449.0,,,BAO_0000219,107,,2262,,6347,B,,
Expert,,1,CHO,,Functional activity against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader,,CHEMBL617050,D,9,,449.0,Homo sapiens,9606.0,BAO_0000219,107,,2263,,6857,F,,
Autocuration,,1,,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,,CHEMBL617051,H,8,,,,,BAO_0000219,107,,2264,,4176,F,,
Autocuration,,1,,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line; no data,,CHEMBL617052,H,8,,,,,BAO_0000219,107,,2265,,4176,F,,
Autocuration,,1,,,Functional antagonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,,CHEMBL617053,H,8,,,,,BAO_0000219,107,,2266,,4176,F,,
Autocuration,,1,CHO,,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand, expressed as Emax",,CHEMBL617054,H,8,,449.0,,,BAO_0000219,107,,2267,,6347,B,,
Autocuration,,1,CHO,,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells, expressed as Emax",,CHEMBL617055,H,8,,449.0,,,BAO_0000219,107,,2268,,6347,B,,
Autocuration,,1,,,Affinity of compound towards human 5-hydroxytryptamine 2A receptor was evaluated using radioligand binding technique,,CHEMBL882924,H,8,,,,,BAO_0000357,107,,2269,,15331,B,,
Expert,,1,,,Inhibition of human 5-hydroxytryptamine 2A receptor,,CHEMBL617056,D,9,,,Homo sapiens,9606.0,BAO_0000357,107,,2270,,16146,B,,
Autocuration,,1,CHO,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,CHEMBL617057,H,8,,449.0,,,BAO_0000219,107,,2271,,15250,B,,
Expert,,1,,,Inhibitory concentration against human 5-HT2A receptor in BEK cells,,CHEMBL617058,H,8,,,,,BAO_0000219,107,,2272,,13631,B,,
Autocuration,,1,,,In vitro binding affinity against human 5-hydroxytryptamine 2A receptor at a concentration of 100 (nM),,CHEMBL617059,H,8,,,,,BAO_0000357,107,,2273,,3805,B,,
Autocuration,,1,CHO,,Ability to displace [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor was determined,,CHEMBL617060,H,8,,449.0,,,BAO_0000219,107,,2274,,4011,B,,
Expert,,1,CHO,,Displacement of [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor.,,CHEMBL617061,H,8,,449.0,,,BAO_0000219,107,,2275,,4012,B,,
Expert,,1,L929,,Ability to displace [125I]R91150 from human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells,,CHEMBL617062,H,8,,307.0,,,BAO_0000219,107,,2276,,6366,B,,
Expert,,1,CHO,,Ability to displace [3H]ketanserin binding to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,CHEMBL617063,H,8,,449.0,,,BAO_0000219,107,,2277,,15949,B,,
Autocuration,,1,,,Agonist activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand,,CHEMBL617064,H,8,,,,,BAO_0000019,107,,2278,,14093,F,,
Autocuration,,1,,,Agonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,CHEMBL617065,H,8,,,,,BAO_0000019,107,,2279,,13481,F,,
Autocuration,,1,CHO,,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,,CHEMBL617066,H,8,,449.0,,,BAO_0000219,107,,2280,,6347,B,,
Autocuration,,1,CHO,,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand; Nd means not done,,CHEMBL617067,H,8,,449.0,,,BAO_0000219,107,,2281,,6347,B,,
Autocuration,,1,,,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]-Ketanserin radioligand,,CHEMBL617068,H,8,,,,,BAO_0000019,107,,2282,,14093,F,,
Autocuration,,1,,,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand; Not tested,,CHEMBL617069,H,8,,,,,BAO_0000019,107,,2283,,14093,F,,
Autocuration,,1,,,Antagonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,CHEMBL617070,H,8,,,,,BAO_0000019,107,,2284,,13481,F,,
Autocuration,,1,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [125 I]DOI as radioligand,,CHEMBL617071,H,8,,,,,BAO_0000357,107,,2285,,14442,B,,
Autocuration,,1,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,CHEMBL872915,H,8,,,,,BAO_0000357,107,,2286,,14442,B,,
Autocuration,,1,,,Binding activity against cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand.,,CHEMBL617072,H,8,,,,,BAO_0000357,107,,2287,,14755,B,,
Autocuration,,1,,,Binding affinity against 5-hydroxytryptamine 2A receptor in humans,,CHEMBL617073,H,8,,,,,BAO_0000357,107,,2288,,16441,B,,
Autocuration,,1,,,Binding affinity against the cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand,,CHEMBL617074,H,8,,,,,BAO_0000357,107,,2289,,14744,B,,
Expert,,1,CHO,,Binding affinity for displacement of [3H]ketanserin to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,CHEMBL617075,H,8,,449.0,,,BAO_0000219,107,,2290,,16659,B,,
Autocuration,,1,,,Binding affinity of compound to human 5-hydroxytryptamine 2A receptor,,CHEMBL617076,H,8,,,,,BAO_0000357,107,,2291,,3307,B,,
Expert,,1,,,Affinity for human 5-hydroxytryptamine 2A receptor expressed in mammalian cell line,,CHEMBL617077,D,9,,,Homo sapiens,9606.0,BAO_0000019,107,,2292,,6857,B,,
Expert,,1,,,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand.,,CHEMBL617078,H,8,,,,,BAO_0000357,107,,2293,,5635,B,,
Expert,,1,,,Binding affinity to cloned human 5-hydroxytryptamine 2A receptor,,CHEMBL617079,D,9,,,Homo sapiens,9606.0,BAO_0000357,107,,2294,,4234,B,,
Autocuration,,1,,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,,CHEMBL617080,H,8,,,,,BAO_0000357,107,,2295,,15527,B,,
Expert,,1,CHO,,Binding affinity towards human 5-hydroxytryptamine 2A receptor by the displacement of [3H]ketanserin radioligand from the cloned receptor expressed in CHO cells,,CHEMBL617081,H,8,,449.0,,,BAO_0000219,107,,2296,,6588,B,,
Expert,,1,,,Binding affinity towards human 5-HT2A receptor in BEK cells,,CHEMBL617082,H,8,,,,,BAO_0000219,107,,2297,,13631,B,,
Autocuration,,1,,,Binding affinity towards human serotonin 5-hydroxytryptamine 2A receptor,,CHEMBL617083,H,8,,,,,BAO_0000357,107,,2298,,17723,B,,
Autocuration,,1,,,Binding affinity for recombinant human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,,CHEMBL617084,H,8,,,,,BAO_0000357,107,,2299,,14770,B,,
Expert,,1,,,Binding affinity for human 5-hydroxytryptamine 2A receptor,,CHEMBL617085,D,9,,,Homo sapiens,9606.0,BAO_0000357,107,,2300,,16293,B,,
Autocuration,,1,,,Binding affinity towards human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,CHEMBL617086,H,8,,,,,BAO_0000357,107,,2301,,16209,B,,
Autocuration,,1,,,Binding affinity was measured on 5-hydroxytryptamine 2A receptor in GF6 cells transfected with human 5-HT2A gene labeled with [3H]ketanserin,,CHEMBL617087,H,8,,,,,BAO_0000219,107,,2302,,12469,B,,
Autocuration,,1,,,Compound was tested for the displacement of [125I]-DOI from clone human 5-hydroxytryptamine 2A receptor,,CHEMBL617088,H,8,,,,,BAO_0000357,107,,2303,,15363,B,,
Autocuration,,1,,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2A receptor,,CHEMBL617089,H,8,,,,,BAO_0000357,107,,2304,,15363,B,,
Expert,,1,,,"Tested on genetically transfected COS7 cell membranes selectively expressing human 5-hydroxytryptamine 2A receptor, using [3H]ketanserin as radioligand",,CHEMBL617090,H,8,,,,,BAO_0000019,107,,2305,,16441,B,,
Autocuration,,1,,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in human using [3H]ketanserin as radioligand,,CHEMBL617513,H,8,,,,,BAO_0000357,107,,2306,,8,B,,
Autocuration,,1,HEK293,,In vitro binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells was determined using [3H]ketanserin as radioligand,,CHEMBL617514,H,8,,722.0,,,BAO_0000219,107,,2307,,4176,B,,
Autocuration,,1,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2A receptor,,CHEMBL617515,H,8,,,,,BAO_0000019,107,,2308,,17085,B,,
Autocuration,,1,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,CHEMBL617516,H,8,,,,,BAO_0000357,107,,2309,,17200,B,,
Expert,,1,,,Inhibitory constant determined against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,CHEMBL617517,D,9,,,Homo sapiens,9606.0,BAO_0000357,107,,2310,,17200,B,,
Expert,,1,CHO,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in CHO cells,,CHEMBL617518,D,9,,449.0,Homo sapiens,9606.0,BAO_0000219,107,,2311,,4013,B,,
Autocuration,,1,,,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor,,CHEMBL617519,H,8,,,,,BAO_0000357,107,,2312,,5088,B,,
Expert,,1,,,Displacement of [3H]DOB from human 5-hydroxytryptamine 2A receptor,,CHEMBL617520,D,9,,,Homo sapiens,9606.0,BAO_0000357,107,,2313,,5088,B,,
Autocuration,,1,,,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]DOB as labeled ligand; binding data not obtained,,CHEMBL617521,H,8,,,,,BAO_0000357,107,,2314,,5088,B,,
Expert,,1,,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor,,CHEMBL617522,D,9,,,Homo sapiens,9606.0,BAO_0000357,107,,2315,,5088,B,,
Autocuration,,1,,,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand,,CHEMBL617523,H,8,,,,,BAO_0000357,107,,2316,,5088,B,,
Autocuration,,1,,,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,CHEMBL617524,H,8,,,,,BAO_0000357,107,,2317,,5088,B,,
Autocuration,,1,,,Ability to displace 0.75 nM [3H]ketanserin in 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenate,,CHEMBL617525,H,4,,,,,BAO_0000019,104686,,2318,,9786,B,,
Autocuration,,1,,,Ability to inhibit [3H]spiperone binding to 5-hydroxytryptamine 2 receptor determined in rat,,CHEMBL617526,D,5,,,Rattus norvegicus,10116.0,BAO_0000019,104686,,2319,,9205,B,,
Autocuration,,1,,,Affinity on 5-hydroxytryptamine 2 receptor labeled by [125I]DOI,,CHEMBL617527,H,4,,,,,BAO_0000224,104686,,2320,,11257,B,,
Autocuration,,1,,,Affinity towards [3H]- DOB -labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,,CHEMBL617528,H,4,,,,,BAO_0000019,104686,,2321,,9362,B,,
Autocuration,,1,,,Affinity towards [3H]- ketanserin-labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,,CHEMBL617529,H,4,,,,,BAO_0000019,104686,,2322,,9362,B,,
Autocuration,,1,,,Inhibition of 5-hydroxytryptamine 2 induced vasoconstriction of rat caudal artery.,,CHEMBL617530,H,4,,,,,BAO_0000224,104686,,2323,,10590,B,,
Autocuration,,1,,,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,,CHEMBL617531,H,4,,,,,BAO_0000019,104686,,2324,,10468,B,,
Autocuration,,1,,,Binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortex using [125]-(R)-DOI as radioligand,,CHEMBL617532,H,4,,,,,BAO_0000019,104686,,2325,,13050,B,,
Autocuration,,1,,,Binding affinity against 5-hydroxytryptamine 2 receptor in rat using [3H]ketanserin as radioligand,,CHEMBL617533,H,4,,,,,BAO_0000019,104686,,2326,,11624,B,,
Autocuration,,1,,,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,,CHEMBL617534,H,4,,,,,BAO_0000019,104686,,2327,,10468,B,,
Autocuration,,1,,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,,CHEMBL617535,H,4,,,,,BAO_0000224,104686,,2328,,10330,B,,
Autocuration,,1,,,Binding affinity at rat 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,,CHEMBL617536,H,4,,,,,BAO_0000224,104686,,2329,,10062,B,,
Autocuration,,1,,,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,,CHEMBL617537,H,4,,,,,BAO_0000224,104686,,2330,,11642,B,,
Autocuration,,1,,,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,,CHEMBL617538,H,4,,,,,BAO_0000224,104686,,2331,,10062,B,,
Autocuration,,1,,,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,,CHEMBL617539,H,4,,,,,BAO_0000219,104686,,2332,,13427,B,In vitro,
Autocuration,,1,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,CHEMBL617540,D,5,,,Rattus norvegicus,10116.0,BAO_0000224,104686,,2333,,12280,B,,
Autocuration,,1,,,Binding affinity for 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]ketanserin,,CHEMBL617541,D,5,,,Rattus norvegicus,10116.0,BAO_0000224,104686,,2334,,4101,B,,
Autocuration,,1,,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 2 receptor,,CHEMBL617542,H,4,,,,,BAO_0000224,104686,,2335,,10062,B,,
Autocuration,,1,,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]DOB as,,CHEMBL617543,H,4,,,,,BAO_0000224,104686,,2336,,11147,B,,
Autocuration,,1,CHO-K1,,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,,CHEMBL617544,D,5,,485.0,Rattus norvegicus,10116.0,BAO_0000219,104686,,2337,,2395,B,,
Autocuration,,1,CHO-K1,,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,,CHEMBL617545,D,5,,485.0,Rattus norvegicus,10116.0,BAO_0000219,104686,,2338,,2395,B,,
Autocuration,,1,,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand,,CHEMBL617413,D,5,,,Rattus norvegicus,10116.0,BAO_0000019,104686,,2339,,9098,B,,
Autocuration,,1,,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand.,,CHEMBL617414,H,4,,,,,BAO_0000019,104686,,2340,,9098,B,,
Autocuration,,1,,,Binding affinity to 5-hydroxytryptamine 2 receptor of rat cortical membranes using [3H]- DOB; ND means no data.,,CHEMBL617415,D,5,,,Rattus norvegicus,10116.0,BAO_0000019,104686,,2341,,9098,B,,
Autocuration,,1,,,Binding affinity towards 5-hydroxytryptamine 2 receptor,,CHEMBL617416,H,4,,,,,BAO_0000224,104686,,2342,,9443,B,,
Autocuration,,1,,,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,,CHEMBL617417,H,4,,,,,BAO_0000224,104686,,2343,,9443,B,,
Autocuration,,1,,,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand in rat frontal cortex",,CHEMBL617418,H,4,,,,,BAO_0000019,104686,,2344,,9699,B,,
Autocuration,,1,,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand in rat frontal cortex,,CHEMBL617419,H,4,,,,,BAO_0000019,104686,,2345,,9699,B,,
Autocuration,,1,,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,CHEMBL617420,H,4,,,,,BAO_0000224,104686,,2346,,9098,B,,
Autocuration,,1,,,Affinity for 5-hydroxytryptamine 2 receptor,,CHEMBL617421,D,5,,,Rattus norvegicus,10116.0,BAO_0000224,104686,,2347,,3070,B,,
Autocuration,,1,,,Binding affinity towards serotonin 5-hydroxytryptamine 2 receptor of rat determined using 0.5 nM of [3H]ketanserin in binding assay,,CHEMBL617422,H,4,,,,,BAO_0000224,104686,,2348,,9547,B,,
Autocuration,,1,,,Binding affinity was determined against 5-hydroxytryptamine 2 receptor from male Sprague-Dawley rat brain.,,CHEMBL617423,H,4,,,,,BAO_0000019,104686,,2349,,10444,B,,
Autocuration,,1,,,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor from rat tissue homogenate,,CHEMBL617424,H,4,,,,,BAO_0000019,104686,,2350,,14617,B,,
Autocuration,,1,,,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor rat tissue homogenate,,CHEMBL617425,H,4,,,,,BAO_0000019,104686,,2351,,14617,B,,
Autocuration,,1,,,Binding constant against 5-hydroxytryptamine 2 receptor (in vitro),,CHEMBL617426,H,4,,,,,BAO_0000224,104686,,2352,,11130,B,,
Autocuration,,1,,,Binding constant against 5-hydroxytryptamine 2 receptor (in vivo),,CHEMBL617427,H,4,,,,,BAO_0000218,104686,,2353,,11130,B,In vivo,
Autocuration,,1,,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat brain,,CHEMBL617428,H,4,,,,,BAO_0000221,104686,,2354,Brain,14542,B,,955.0
Autocuration,,1,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2 receptor from rat,,CHEMBL617429,H,4,,,,,BAO_0000224,104686,,2355,,2797,B,,
Autocuration,,1,,,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,,CHEMBL617430,H,4,,,,,BAO_0000019,104686,,2356,,11332,B,,
Autocuration,,1,,,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,,CHEMBL617431,H,4,,,,,BAO_0000019,104686,,2357,,11332,B,,
Autocuration,,1,,,Compound was evaluated for its ability to displace 0.25 nM [125I](R)-DOI from binding sites in rat frontal cortex.,,CHEMBL617432,H,4,,,,,BAO_0000019,104686,,2358,Frontal cortex,10752,B,,1870.0
Autocuration,,1,,,Ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,,CHEMBL617433,H,4,,,,,BAO_0000224,104686,,2359,,1185,B,,
Autocuration,,1,,,Compound was evaluated for its ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,,CHEMBL617434,H,4,,,,,BAO_0000224,104686,,2360,,1185,B,,
Autocuration,,1,,,Binding affinity against 5-Hydroxy tryptamine 2 (5-hydroxytryptamine 2)receptor,,CHEMBL617435,D,5,,,Rattus norvegicus,10116.0,BAO_0000224,104686,,2361,,11624,B,,
Autocuration,,1,,,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 2 receptor in rat cortex using [3H]ketanserin radioligand assay,,CHEMBL617436,H,4,,,,,BAO_0000019,104686,,2362,,1344,B,,
Autocuration,,1,,,Binding affinity against 5-hydroxytryptamine 2 receptor in rat striatum using [3H]-RP62203,,CHEMBL617437,D,5,,,Rattus norvegicus,10116.0,BAO_0000019,104686,,2363,Striatum,15453,B,,2435.0
Autocuration,,1,,,"Binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",,CHEMBL617438,H,4,,,,,BAO_0000019,104686,,2364,,11662,B,,
Autocuration,,1,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,CHEMBL617439,H,4,,,,,BAO_0000019,104686,,2365,,11662,B,,
Autocuration,,1,,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 2 receptor,,CHEMBL617440,H,4,,,,,BAO_0000224,104686,,2366,,10796,B,,
Autocuration,,1,,,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,,CHEMBL617441,H,4,,,,,BAO_0000224,104686,,2367,,9069,B,,
Autocuration,,1,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortical membrane homogenates,,CHEMBL872918,D,5,,,Rattus norvegicus,10116.0,BAO_0000019,104686,,2368,,8814,B,,
Autocuration,,1,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortex,,CHEMBL617442,D,5,,,Rattus norvegicus,10116.0,BAO_0000019,104686,,2369,,8908,B,,
Autocuration,,1,,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,,CHEMBL617443,H,4,,,,,BAO_0000019,104686,,2370,,9098,B,,
Autocuration,,1,,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 (5-HT2) receptor using [3H]KET as a radioligand,,CHEMBL617444,H,4,,,,,BAO_0000019,104686,,2371,,9098,B,,
Autocuration,,1,,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,,CHEMBL617445,H,4,,,,,BAO_0000019,104686,,2372,,9098,B,,
Autocuration,,1,,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.,,CHEMBL617446,H,4,,,,,BAO_0000019,104686,,2373,,9098,B,,
Autocuration,,1,,,Binding affinity to 5-hydroxytryptamine 2 receptor in rat frontal cortical membranes by [3H]- KET displacement.,,CHEMBL617447,H,4,,,,,BAO_0000249,104686,,2374,,9098,B,,
Autocuration,,1,,,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.;ND is not determined,,CHEMBL617448,H,4,,,,,BAO_0000019,104686,,2375,,9098,B,,
Autocuration,,1,,,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand;ND means no data,,CHEMBL617449,H,4,,,,,BAO_0000019,104686,,2376,,9098,B,,
Autocuration,,1,,,In vitro binding affinity at 5-hydroxytryptamine 2 receptor in rat cortical tissue by [3H]spiperone displacement; No data.,,CHEMBL617450,H,4,,,,,BAO_0000019,104686,,2377,,9161,B,,
Autocuration,,1,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 165 to 263,,CHEMBL617451,H,4,,,,,BAO_0000019,104686,,2378,,9161,B,,
Autocuration,,1,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 2.4 to 5.3,,CHEMBL617452,H,4,,,,,BAO_0000019,104686,,2379,,9161,B,,
Autocuration,,1,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue.,,CHEMBL617453,H,4,,,,,BAO_0000019,104686,,2380,,9161,B,,
Autocuration,,1,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 140 to 980,,CHEMBL617660,H,4,,,,,BAO_0000019,104686,,2381,,9161,B,,
Autocuration,,1,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 76 to 299,,CHEMBL617661,H,4,,,,,BAO_0000019,104686,,2382,,9161,B,,
Autocuration,,1,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue; value may range from 12 to 66,,CHEMBL617662,H,4,,,,,BAO_0000019,104686,,2383,,9161,B,,
Autocuration,,1,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 136 to 220,,CHEMBL872919,H,4,,,,,BAO_0000019,104686,,2384,,9161,B,,
Autocuration,,1,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 197 to 341,,CHEMBL617663,H,4,,,,,BAO_0000019,104686,,2385,,9161,B,,
Autocuration,,1,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 23 to 187,,CHEMBL617664,H,4,,,,,BAO_0000019,104686,,2386,,9161,B,,
Autocuration,,1,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 29 to 132,,CHEMBL617665,H,4,,,,,BAO_0000019,104686,,2387,,9161,B,,
Autocuration,,1,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 6 to 75,,CHEMBL617666,H,4,,,,,BAO_0000019,104686,,2388,,9161,B,,
Autocuration,,1,,,In vitro binding affinity on 5-hydroxytryptamine 2 receptor is inhibition of binding of [125I]- I-LSD to P11 cells,,CHEMBL617667,H,4,,,,,BAO_0000019,104686,,2389,,12094,B,,
Autocuration,,1,,,In vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat striatal membranes by [3H]ketanserin displacement.,,CHEMBL617668,H,4,,,,,BAO_0000249,104686,,2390,,12018,B,,
Autocuration,,1,,,Inhibitory activity against 5-hydroxytryptamine 2 receptor in rat cortical membranes using [3H]ketanserin as a radioligand,,CHEMBL617669,H,4,,,,,BAO_0000249,104686,,2391,,10394,B,,
Autocuration,,1,,,Inhibitory activity against rat cortical 5-hydroxytryptamine 2 receptor,,CHEMBL617670,H,4,,,,,BAO_0000224,104686,,2392,,15260,B,,
Autocuration,,1,,,Inhibitory constant against 5-hydroxytryptamine 2 receptor,,CHEMBL617671,D,5,,,Rattus norvegicus,10116.0,BAO_0000224,104686,,2393,,11624,B,,
Autocuration,,1,,,Percentage specific displacement of radioligand [3H]-ketanserin from 5-hydroxytryptamine 2 receptor,,CHEMBL617672,H,4,,,,,BAO_0000224,104686,,2394,,13654,B,,
Autocuration,,1,,,Potency to displace [3H]- Spiperone from 5-hydroxytryptamine 2 receptor in rat striatum,,CHEMBL617673,H,4,,,,,BAO_0000019,104686,,2395,,9541,B,,
Autocuration,,1,,,Tested for binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortical regions using [3H]ketanserin as radioligand,,CHEMBL617674,H,4,,,,,BAO_0000224,104686,,2396,,11933,B,,
Autocuration,,1,,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex,,CHEMBL617675,H,4,,,,,BAO_0000019,104686,,2397,,15538,B,,
Autocuration,,1,,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; NA means Not Active,,CHEMBL617676,H,4,,,,,BAO_0000019,104686,,2398,,15538,B,,
Autocuration,,1,,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; not determined,,CHEMBL617677,H,4,,,,,BAO_0000019,104686,,2399,,15538,B,,
Autocuration,,1,,,Displacement of [3H]ketanserin from rat prefrontal cortex 5-hydroxytryptamine 2 receptor,,CHEMBL617678,D,5,,,,,BAO_0000019,104686,,2400,,8841,B,,
Autocuration,,1,,,Binding affinity to 5-hydroxytryptamine 2 receptor using [3H]ketanserin radioligand assay.,,CHEMBL617679,H,4,,,,,BAO_0000224,104686,,2401,,1455,B,,
Autocuration,,1,,,Tested for its binding affinity to Tested for its binding affinity to 5-hydroxytryptamine 2 receptor using [3H]-ketanserin radioligand assay using [3H]-ketanserin radioligand assay,,CHEMBL617680,H,4,,,,,BAO_0000224,104686,,2402,,1455,B,,
Autocuration,,1,,,The ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat whole brain,,CHEMBL617681,H,4,,,,,BAO_0000019,104686,,2403,,11752,B,,
Autocuration,,1,,,The binding affinity was measured on 5-hydroxytryptamine 2 receptor in rat brain tissue,,CHEMBL617682,H,4,,,,,BAO_0000221,104686,,2404,Brain,11642,B,,955.0
Autocuration,,1,,,The binding affinity was measured on 5-hydroxytryptamine 2 receptor using [3H]- spiperone as radioligand.,,CHEMBL617683,H,4,,,,,BAO_0000224,104686,,2405,,12092,B,,
Autocuration,,1,,,Binding affinity at 5-hydroxytryptamine 2 receptor from striata wistar rats by [3H]ketanserin displacement.,,CHEMBL617684,H,4,,,,,BAO_0000224,104686,,2406,,3967,B,,
Autocuration,,1,,,Binding affinity towards 5-hydroxytryptamine 2 receptor,,CHEMBL617685,D,5,,,Rattus norvegicus,10116.0,BAO_0000224,104686,,2407,,12771,B,,
Autocuration,,1,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [3H]ketanserin radioligand in rat cerebral cortex,,CHEMBL617686,H,4,,,,,BAO_0000019,104686,,2408,,11642,B,,
Autocuration,,1,,,The compound was tested in vitro for binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [125]I-LSD radioligand,,CHEMBL617687,H,4,,,,,BAO_0000224,104686,,2409,,11628,B,,
Autocuration,,1,,,Percentage specific displacement of radioligand [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,CHEMBL617688,H,4,,,,,BAO_0000224,104686,,2410,,13654,B,,
Autocuration,,1,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,CHEMBL617689,H,4,,,,,BAO_0000019,104686,,2411,,11200,F,,
Autocuration,,1,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,CHEMBL617690,H,4,,,,,BAO_0000019,104686,,2412,,11200,F,,
Autocuration,,1,,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",,CHEMBL617691,H,4,,,,,BAO_0000218,104686,,2413,,11200,F,In vivo,
Autocuration,,1,,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",,CHEMBL617692,H,4,,,,,BAO_0000218,104686,,2414,,11200,F,In vivo,
Autocuration,,1,,,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",,CHEMBL617693,H,4,,,,,BAO_0000218,104686,,2415,,11200,F,In vivo,
Autocuration,,1,,,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",,CHEMBL617694,H,4,,,,,BAO_0000218,104686,,2416,,11200,F,In vivo,
Expert,,1,,,Affinity for 5-hydroxytryptamine 2A receptor in rat brain cortex by ability to displace [3H]ketanserin,,CHEMBL857985,H,8,,,,,BAO_0000221,12687,,2417,Brain,15436,B,,955.0
Expert,,1,,,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,,CHEMBL617695,D,9,,,Rattus norvegicus,10116.0,BAO_0000019,12687,,2418,,15436,B,,
Autocuration,,1,,,Affinity pKi for 5-hydroxytryptamine 2A receptor was measured in rat cortex homogenates,,CHEMBL617696,H,8,,,,,BAO_0000019,12687,,2419,,14025,B,,
Autocuration,,1,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor was determined,,CHEMBL617697,H,8,,,,,BAO_0000357,12687,,2420,,4342,B,,
Expert,,1,,,Displacement of [3H]ketanserin from 5-HT2A receptor of rat frontal cortex,,CHEMBL617257,D,9,,,Rattus norvegicus,10116.0,BAO_0000019,12687,,2421,,13735,B,,
Expert,,1,,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,,CHEMBL617258,D,9,,,Rattus norvegicus,10116.0,BAO_0000357,12687,,2422,,5816,B,,
Expert,,1,,,Binding affinity was evaluated in vitro by displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor on rat cortical membrane,,CHEMBL617259,H,8,,,,,BAO_0000019,12687,,2423,,14287,B,,
Autocuration,,1,,,In vitro affinity against serotonin ( 5-hydroxytryptamine 2A receptor ) receptor,,CHEMBL617260,H,8,,,,,BAO_0000357,12687,,2424,,15738,B,,
Expert,,1,,,In vitro affinity against serotonin 5-hydroxytryptamine 2A receptor,,CHEMBL617261,D,9,,,Rattus norvegicus,10116.0,BAO_0000357,12687,,2425,,15738,B,,
Autocuration,,1,,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]-ketanserin as radioligand,,CHEMBL617262,H,8,,,,,BAO_0000019,12687,,2426,,15026,B,,
Expert,,1,,,Half-maximal inhibition of [3H]- Ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,,CHEMBL617263,H,8,,,,,BAO_0000019,12687,,2427,,16647,B,,
Autocuration,,1,,,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat tissue homogenate,,CHEMBL617264,H,8,,,,,BAO_0000019,12687,,2428,,16647,B,,
Expert,,1,,,Displacement of [3H]-ketanserin from rat brain 5-hydroxytryptamine 2A receptor,,CHEMBL617265,D,9,,,Rattus norvegicus,10116.0,BAO_0000019,12687,,2429,,13345,B,,
Autocuration,,1,,,Inhibition constant for in vitro inhibition of [3H]ketanserin binding to rat frontal cortex membranes 5-hydroxytryptamine 2A receptor,Membranes,CHEMBL617266,H,8,,,,,BAO_0000249,12687,,2430,,1543,B,,
Autocuration,,1,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor rat frontal cortex membrane,,CHEMBL617267,H,8,,,,,BAO_0000019,12687,,2431,,12444,B,,
Expert,,1,,,Inhibitory constant on 5-hydroxytryptamine 2A receptor of Rat frontal cortex,,CHEMBL617268,H,8,,,,,BAO_0000019,12687,,2432,,16404,B,,
Autocuration,,1,CHO,,Inhibitory constant on human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,,CHEMBL617269,H,8,,449.0,,,BAO_0000219,12687,,2433,,16404,B,,
Expert,,1,,,Kinetic inhibition constant evaluated by measuring serotonergic activity,,CHEMBL617323,H,8,,,,,BAO_0000357,12687,,2434,,15577,B,,
Autocuration,,1,,,Serotonergic activity of the compound.,,CHEMBL617324,H,8,,,,,BAO_0000357,12687,,2435,,15577,B,,
Autocuration,,1,,,Tested in vitro for its ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat frontal cortex membranes,,CHEMBL617325,H,8,,,,,BAO_0000249,12687,,2436,,2495,B,,
Expert,,1,,,The binding affinity was evaluated on 5-hydroxytryptamine 2A receptor expressed in rat cortex by using [3H]ketanserin as radioligand.,,CHEMBL617326,D,9,,,Rattus norvegicus,10116.0,BAO_0000019,12687,,2437,,15042,B,,
Expert,,1,,,In vitro ability to displace [3H]ketanserin binding from 5-hydroxytryptamine 2A receptor in rat striatal membrane.,,CHEMBL617327,H,8,,,,,BAO_0000249,12687,,2438,,15026,B,,
Expert,,1,,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,CHEMBL617328,D,9,,,Rattus norvegicus,10116.0,BAO_0000019,12687,,2439,,12919,F,,
Expert,,1,,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,CHEMBL617329,D,9,,,Rattus norvegicus,10116.0,BAO_0000019,12687,,2440,,12919,F,,
Expert,,1,,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,CHEMBL617330,D,9,,,Rattus norvegicus,10116.0,BAO_0000019,12687,,2441,,12919,F,,
Autocuration,,1,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,CHEMBL617331,H,8,,,,,BAO_0000357,12687,,2442,,15194,B,,
Autocuration,,1,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand.,,CHEMBL617332,H,8,,,,,BAO_0000357,12687,,2443,,15194,B,,
Expert,,1,,,Binding affinity towards 5-hydroxytryptamine 2A receptor,,CHEMBL617333,H,8,,,,,BAO_0000357,107,,2444,,4820,B,,
Autocuration,,1,,,Binding affinity against serotonin 5-hydroxytryptamine 2A receptor was determined using human [125I]-eotaxin,,CHEMBL617334,H,8,,,,,BAO_0000357,107,,2445,,6736,B,,
Autocuration,,1,,,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.000001 mol/L,,CHEMBL617335,H,8,,,,,BAO_0000357,107,,2446,,5163,B,,
Autocuration,,1,,,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.00001 mol/L,,CHEMBL617336,H,8,,,,,BAO_0000357,107,,2447,,5163,B,,
Autocuration,,1,,,Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration,,CHEMBL617337,H,8,,,,,BAO_0000357,107,,2448,,6011,B,,
Expert,,1,,,Percent inhibition against 5-hydroxytryptamine 2A receptor using [3H]ketanserin at 1 uM,,CHEMBL617338,D,9,,,Homo sapiens,9606.0,BAO_0000357,107,,2449,,14294,B,,
Autocuration,,1,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2A receptor,,CHEMBL617339,H,8,,,,,BAO_0000357,107,,2450,,5014,B,,
Expert,,1,,,Binding affinity towards 5-hydroxytryptamine 2A receptor,,CHEMBL617340,H,8,,,,,BAO_0000357,107,,2451,,17066,B,,
Autocuration,,1,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor; inactive at 10 uM,,CHEMBL617341,H,8,,,,,BAO_0000357,107,,2452,,17515,B,,
Expert,,1,,,Inhibition of [125I]-eotaxin binding to serotonin 5-hydroxytryptamine 2A receptor,,CHEMBL617342,H,8,,,,,BAO_0000357,107,,2453,,6736,B,,
Expert,,1,,,Affinity for 5-hydroxytryptamine 2A receptor,,CHEMBL617343,H,8,,,,,BAO_0000357,107,,2454,,5163,B,,
Expert,,1,NIH3T3,,Binding affinity was performed using [3H]ketanserin as the radioligand and stably transfected NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor (GF-62 cells).,,CHEMBL617344,H,8,,723.0,,,BAO_0000219,107,,2455,,16911,B,,
Expert,,1,,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,,CHEMBL617345,H,8,,,,,BAO_0000357,107,,2456,,6841,B,,
Expert,,1,,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand.,,CHEMBL617346,H,8,,,,,BAO_0000357,107,,2457,,6119,B,,
Autocuration,,1,,,Compound was evaluated for its binding against 5-hydroxytryptamine 2A receptor,,CHEMBL617347,H,8,,,,,BAO_0000357,107,,2458,,3962,B,,
Autocuration,,1,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2A receptor was determined,,CHEMBL617348,H,8,,,,,BAO_0000357,107,,2459,,4373,B,,
Autocuration,,1,,,Binding affinity relative to indolopiperidine (compound 1)for 5-hydroxytryptamine 2A receptor was determined,,CHEMBL617349,H,8,,,,,BAO_0000357,107,,2460,,4373,B,,
Autocuration,,1,,,Compound was evaluated for its inverse agonist activity against 5-hydroxytryptamine 2A receptor,,CHEMBL617350,H,8,,,,,BAO_0000019,107,,2461,,3962,F,,
Expert,,1,,,Binding affinity towards 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin,,CHEMBL872339,H,8,,,,,BAO_0000357,107,,2462,,1633,B,,
Autocuration,,1,,,Binding affinity for 5-hydroxytryptamine 2A receptor was determined,,CHEMBL617351,H,8,,,,,BAO_0000357,107,,2463,,4373,B,,
Expert,,1,,,Binding affinity towards serotonin 5-hydroxytryptamine 2A receptor,,CHEMBL617352,H,8,,,,,BAO_0000357,107,,2464,,6576,B,,
Autocuration,,1,,,Evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor,,CHEMBL617353,H,8,,,,,BAO_0000357,107,,2465,,4687,B,,
Autocuration,,1,,,Ability to displace [3H]-ketanserin from 5-hydroxytryptamine 2A receptor,,CHEMBL617354,H,8,,,,,BAO_0000357,107,,2466,,16946,B,,
Autocuration,,1,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 2A receptor,,CHEMBL617355,H,8,,,,,BAO_0000357,107,,2467,,14159,B,,
Expert,,1,CHO,,In vitro binding affinity against 5-hydroxytryptamine 2A receptor in CHO cells,,CHEMBL617356,H,8,,449.0,Mus musculus,10090.0,BAO_0000219,107,,2468,,3032,B,,
Autocuration,,1,,,Inhibition of ketanserin binding to 5-hydroxytryptamine 2A receptor,,CHEMBL617357,H,8,,,,,BAO_0000357,107,,2469,,16655,B,,
Autocuration,,1,,,Binding affinity at 5-hydroxytryptamine 2A receptor,,CHEMBL617358,H,8,,,,,BAO_0000357,107,,2470,,13964,B,,
Expert,,1,,,Binding affinity towards Serotonin 5-hydroxytryptamine 2A receptor,,CHEMBL617359,H,8,,,,,BAO_0000357,107,,2471,,16989,B,,
Autocuration,,1,,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor was determined,,CHEMBL617360,H,8,,,,,BAO_0000357,107,,2472,,16117,B,,
Autocuration,,1,,,The binding affinity towards 5-hydroxytryptamine 2A receptor; No affinity,,CHEMBL875913,H,8,,,,,BAO_0000357,107,,2473,,16700,B,,
Autocuration,,1,,,Affinity against 5-hydroxytryptamine 2A receptor,,CHEMBL617361,H,8,,,,,BAO_0000357,107,,2474,,3269,B,,
Expert,,1,,,Binding affinity against 5-Hydroxytryptamine 2A receptor,,CHEMBL617362,D,9,,,Homo sapiens,9606.0,BAO_0000357,107,,2475,,1274,B,,
Autocuration,,1,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using radioligand binding assay,,CHEMBL617363,H,8,,,,,BAO_0000357,107,,2476,,1317,B,,
Autocuration,,1,,,Tested against 5-hydroxytryptamine 2A receptor,,CHEMBL617364,H,8,,,,,BAO_0000357,107,,2477,,12146,B,,
Autocuration,,1,,,Binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,,CHEMBL617365,H,4,,,,,BAO_0000224,105075,,2478,,12652,B,,
Autocuration,,1,,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H] ketanserin,,CHEMBL617366,H,4,,,,,BAO_0000224,105075,,2479,,12652,B,,
Autocuration,,1,,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor agonist [125I]- - (+/-)DOI,,CHEMBL617367,H,4,,,,,BAO_0000224,105075,,2480,,12652,B,,
Autocuration,,1,,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,,CHEMBL617368,H,4,,,,,BAO_0000224,105075,,2481,,12652,B,,
Autocuration,,1,,,Selectivity ratio towards 5-hydroxytryptamine 2A receptor to Dopamine receptor D2 (5-HT2A/D2 ),,CHEMBL617369,H,8,,,,,BAO_0000357,107,,2482,,16647,B,,
Expert,,1,HEK293,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND means no data,,CHEMBL617370,D,9,,722.0,Homo sapiens,9606.0,BAO_0000219,227,,2483,,15851,B,,
Expert,,1,CHO,,Functional activity against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader,,CHEMBL617371,D,9,,449.0,Homo sapiens,9606.0,BAO_0000219,227,,2484,,6857,F,,
Autocuration,,1,,,In vitro binding affinity against human 5-HT2B receptor at a concentration of 100 (nM),,CHEMBL617372,H,8,,,,,BAO_0000357,227,,2485,,3805,B,,
Expert,,1,,,Affinity towards human 5-hydroxytryptamine 2B serotonin receptor,,CHEMBL617373,D,9,,,Homo sapiens,9606.0,BAO_0000357,227,,2486,,6491,B,,
Autocuration,,1,,,Agonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT radioligand,,CHEMBL617374,H,8,,,,,BAO_0000019,227,,2487,,14093,F,,
Autocuration,,1,,,Agonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]-5-HT as radioligand,,CHEMBL617375,H,8,,,,,BAO_0000019,227,,2488,,13481,F,,
Autocuration,,1,,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand,,CHEMBL617376,H,8,,,,,BAO_0000019,227,,2489,,14093,F,,
Autocuration,,1,,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand; Not tested,,CHEMBL617377,H,8,,,,,BAO_0000019,227,,2490,,14093,F,,
Autocuration,,1,,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine radioligand,,CHEMBL617378,H,8,,,,,BAO_0000019,227,,2491,,14093,F,,
Autocuration,,1,,,Antagonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,,CHEMBL617379,H,8,,,,,BAO_0000019,227,,2492,,13481,F,,
Autocuration,,1,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine as radioligand,,CHEMBL617380,H,8,,,,,BAO_0000357,227,,2493,,14442,B,,
Autocuration,,1,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT 2B as radioligand,,CHEMBL617381,H,8,,,,,BAO_0000357,227,,2494,,14442,B,,
Autocuration,,1,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,,CHEMBL617382,H,8,,,,,BAO_0000357,227,,2495,,14442,B,,
Autocuration,,1,,,The compound evaluated for its affinity against 5-hydroxytryptamine 2A receptor,,CHEMBL617383,H,8,,,,,BAO_0000357,107,,2496,,12369,B,,
Expert,,1,,,Affinity against 5-hydroxytryptamine 2A receptor (D) labeled with [125I]DOI.,,CHEMBL617384,H,8,,,,,BAO_0000357,107,,2497,,12369,B,,
Expert,,1,,,Affinity against 5-hydroxytryptamine 2A receptor (K) labeled with [3H]ketanserin.,,CHEMBL617385,H,8,,,,,BAO_0000357,107,,2498,,12369,B,,
Autocuration,,1,,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes,,CHEMBL617386,H,8,,,,,BAO_0000019,107,,2499,,14447,B,,
Autocuration,,1,,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes.,,CHEMBL617387,H,8,,,,,BAO_0000019,107,,2500,,14447,B,,
Autocuration,,1,NIH3T3,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,CHEMBL617388,H,8,,723.0,,,BAO_0000219,107,,2501,,17451,B,,
Autocuration,,1,CHO,,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,CHEMBL617389,H,8,,449.0,,,BAO_0000219,107,,2502,,6857,F,,
Expert,,1,CHO,,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,CHEMBL617390,D,9,,449.0,Homo sapiens,9606.0,BAO_0000219,107,,2503,,6857,F,,
Autocuration,,1,,,Selectivity ratio of binding affinity of 5-hydroxytryptamine 2A receptor to that of 5-hydroxytryptamine 2C receptor.,,CHEMBL617391,H,4,,,,,BAO_0000224,104817,,2504,,5635,B,,
Autocuration,,1,,,Binding activity radioligand.,,CHEMBL617392,H,8,,,,,BAO_0000357,107,,2505,,12861,B,,
Autocuration,,1,,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,CHEMBL617393,H,8,,,,,BAO_0000019,107,,2506,,12861,B,,
Autocuration,,1,L929,,Binding affinity for human cloned 5-HT2A receptor expressed in L929 cells using [125I]R91150 as radioligand,,CHEMBL617394,H,8,,307.0,,,BAO_0000219,107,,2507,,5105,B,,
Expert,,1,L929,,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand,,CHEMBL617395,H,8,,307.0,,,BAO_0000219,107,,2508,,5104,B,,
Expert,,1,L929,,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells by [125I]R91150 displacement.,,CHEMBL617396,H,8,,307.0,,,BAO_0000219,107,,2509,,5105,B,,
Autocuration,,1,L929,,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand; Not tested,,CHEMBL617397,H,8,,307.0,,,BAO_0000219,107,,2510,,5105,B,,
Autocuration,,1,,,Binding affinity against 5-HT2A receptor,,CHEMBL617398,H,8,,,,,BAO_0000357,107,,2511,,5254,B,,
Autocuration,,1,,,Binding affinity against 5-hydroxytryptamine 2A receptor,,CHEMBL617399,H,8,,,,,BAO_0000357,107,,2512,,5254,B,,
Autocuration,,1,HEK293,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,,CHEMBL617400,H,8,,722.0,,,BAO_0000219,107,,2513,,13267,B,,
Autocuration,,1,HEK293,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,,CHEMBL617401,H,8,,722.0,,,BAO_0000219,107,,2514,,13267,B,,
Expert,,1,HEK293,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells,,CHEMBL617402,D,9,,722.0,Homo sapiens,9606.0,BAO_0000219,107,,2515,,14157,B,,
Expert,,1,HEK293,,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,CHEMBL617403,D,9,,722.0,Homo sapiens,9606.0,BAO_0000219,107,,2516,,12936,B,,
Expert,,1,,,Binding affinity against human 5-hydroxytryptamine 2A receptor using displacement of [3H]5-HT,,CHEMBL617404,H,8,,,,,BAO_0000357,107,,2517,,14068,B,,
Expert,,1,HEK293,,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,CHEMBL857981,D,9,,722.0,Homo sapiens,9606.0,BAO_0000219,107,,2518,,12936,B,,
Expert,,1,HEK293,,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,CHEMBL617405,D,9,,722.0,Homo sapiens,9606.0,BAO_0000219,107,,2519,,12936,B,,
Expert,,1,HEK293,,Binding affinity to human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]- ketanserin as radioligand,,CHEMBL617253,D,9,,722.0,Homo sapiens,9606.0,BAO_0000219,107,,2520,,4540,B,,
Expert,,1,,,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor.,,CHEMBL617254,H,8,,,,,BAO_0000357,107,,2521,,6166,B,,
Autocuration,,1,HEK293,,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,,CHEMBL617255,H,8,,722.0,,,BAO_0000219,107,,2522,,17296,B,,
Autocuration,,1,HEK293,,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,,CHEMBL617256,H,8,,722.0,,,BAO_0000219,107,,2523,,17296,B,,
Autocuration,,1,HEK293,,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]ketanserin as radioligand,,CHEMBL616874,H,8,,722.0,,,BAO_0000219,107,,2524,,17296,B,,
Expert,,1,HEK293,,Binding affinity towards 5-hydroxytryptamine 2A receptor (human cloned receptor) in HEK 293 cells using [3H]ketanserin as radioligand.,,CHEMBL616875,D,9,,722.0,Homo sapiens,9606.0,BAO_0000219,107,,2525,,15779,B,,
Expert,,1,HEK293,,Binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells using [3H]ketanserin as radioligand,,CHEMBL616876,H,8,,722.0,,,BAO_0000219,107,,2526,,14391,B,,
Expert,,1,HEK293,,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2A in HEK293 cells, using [3H]ketanserin as radioligand.",,CHEMBL616877,H,8,,722.0,,,BAO_0000219,107,,2527,,15851,B,,
Expert,,1,HEK293,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells; compound is insoluble,,CHEMBL616878,D,9,,722.0,Homo sapiens,9606.0,BAO_0000219,107,,2528,,15851,B,,
Expert,,1,HEK293,,Binding affinity towards human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by displacement of [3H]ketanserin,,CHEMBL616879,H,8,,722.0,,,BAO_0000219,107,,2529,,3832,B,,
Expert,,1,HEK293,,In vitro binding affinity at human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by [3H]ketanserin displacement.,,CHEMBL616880,H,8,,722.0,,,BAO_0000219,107,,2530,,3833,B,,
Expert,,1,HEK293,,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,CHEMBL616881,D,9,,722.0,Homo sapiens,9606.0,BAO_0000219,107,,2531,,12936,B,,
Autocuration,,1,NIH3T3,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand,,CHEMBL616882,H,8,,723.0,,,BAO_0000219,107,,2532,,17451,B,,
Autocuration,,1,NIH3T3,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,CHEMBL616883,H,8,,723.0,,,BAO_0000219,107,,2533,,17451,B,,
Autocuration,,1,NIH3T3,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,CHEMBL616884,H,8,,723.0,,,BAO_0000219,107,,2534,,17451,B,,
Autocuration,,1,HEK293,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]ketanserin as the radioligand,,CHEMBL616885,H,8,,722.0,,,BAO_0000219,107,,2535,,4199,B,,
Autocuration,,1,CHO-K1,,Compound was evaluated for displacement of [3H]ketanserin from human cloned 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells,,CHEMBL616886,H,8,,485.0,,,BAO_0000219,107,,2536,,1883,B,,
Expert,,1,CHO-K1,,Displacement of [3H]-ketanserin from human cloned 5-hydroxytryptamine 2A receptor expressed in CHO-K1 cells.,,CHEMBL616887,H,8,,485.0,,,BAO_0000219,107,,2537,,1883,B,,
Expert,,1,,,Binding affinity for human 5-hydroxytryptamine 2A receptor,,CHEMBL616888,D,9,,,Homo sapiens,9606.0,BAO_0000357,107,,2538,,14875,B,,
Autocuration,,1,HEK293,,Compound was tested for its binding affinity against 5-hydroxytryptamine 2A receptor in human cloned receptors in HEK 293 cells using [3H]ketanserin,,CHEMBL616889,H,8,,722.0,,,BAO_0000219,107,,2539,,15146,B,,
Autocuration,,1,HEK293,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2A receptor in HEK 293 using [3H]ketanserin as a radioligand,,CHEMBL616890,H,8,,722.0,,,BAO_0000219,107,,2540,,5213,B,,
Expert,,1,CHO,,Inhibitory constant for human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,,CHEMBL616891,D,9,,449.0,Homo sapiens,9606.0,BAO_0000219,107,,2541,,16404,B,,
Autocuration,,1,HEK293,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2A receptor in HEK293 cells using [3H]-ketanserin.,,CHEMBL616892,H,8,,722.0,,,BAO_0000219,107,,2542,,14818,B,,
Autocuration,,1,HEK293,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2A receptor in HEK293 cells, using [3H]ketanserin as radioligand",,CHEMBL616893,H,8,,722.0,,,BAO_0000219,107,,2543,,4829,B,,
Autocuration,,1,NIH3T3,,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2A receptor in 3T3 cells,,CHEMBL616894,H,8,,723.0,,,BAO_0000219,10620,,2544,,12652,F,,
Expert,,1,NIH3T3,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells,,CHEMBL616895,H,8,,723.0,,,BAO_0000219,107,,2545,,4682,B,,
Autocuration,,1,,,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2A receptor,,CHEMBL616896,H,8,,,,,BAO_0000019,10620,,2546,,12652,F,,
Autocuration,,1,,,Ability to displace [3H]-Ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor,,CHEMBL617099,H,8,,,,,BAO_0000357,10621,,2547,,4921,B,,
Autocuration,,1,,,Ability to displace [3H]ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor; ND denotes not determined,,CHEMBL617100,H,8,,,,,BAO_0000357,10621,,2548,,4921,B,,
Autocuration,,1,,,Binding affinity against rabbit aorta 5-HT2A receptor,,CHEMBL884532,H,8,,,Oryctolagus cuniculus,9986.0,BAO_0000357,107,,2549,,16312,B,,
Expert,,1,,,Binding affinity for 5-hydroxytryptamine 2A receptor of rabbit aorta ring preparations,,CHEMBL617101,H,8,,,Oryctolagus cuniculus,9986.0,BAO_0000357,107,,2550,,14998,B,,
Expert,,1,,,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 2A receptor in the rabbit saphenous aorta,,CHEMBL617102,H,8,,,Oryctolagus cuniculus,9986.0,BAO_0000357,107,,2551,,14025,B,,
Autocuration,,1,,,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,,CHEMBL617103,H,8,,,Oryctolagus cuniculus,9986.0,BAO_0000019,107,,2552,,13047,B,,
Expert,,1,,,The compound was tested for binding affinity against 5-HT2A receptor,,CHEMBL617104,H,8,,,Oryctolagus cuniculus,9986.0,BAO_0000357,107,,2553,,13047,B,,
Autocuration,,1,CHO-K1,,Compound was evaluated for displacement of [3H]ketanserin from cloned rat 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells.,,CHEMBL857979,H,8,,485.0,,,BAO_0000219,10576,,2554,,1883,B,,
Autocuration,,1,,,Binding affinity analysed towards 5-HT 2A in rat jugular vein,,CHEMBL857502,H,8,,,,,BAO_0000019,12687,,2555,,13463,B,,
Autocuration,,1,,,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,,CHEMBL617105,H,8,,,,,BAO_0000019,12687,,2556,,13463,B,,
Autocuration,,1,,,Binding affinity analysed on 5-HT 2A in rat stomach fundus.,,CHEMBL858021,H,8,,,,,BAO_0000019,12687,,2557,Stomach,13463,B,,945.0
Expert,,1,,,Binding affinity for 5-HT 2A in rat stomach fundus,,CHEMBL875910,D,9,,,Rattus norvegicus,10116.0,BAO_0000019,12687,,2558,Stomach,13463,B,,945.0
Autocuration,,1,,,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,,CHEMBL617106,H,8,,,,,BAO_0000019,12687,,2559,,13463,B,,
Expert,,1,NIH3T3,,Ability to stimulate phosphoinositide hydrolysis in NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor,,CHEMBL617107,H,8,,723.0,,,BAO_0000219,12687,,2560,,16326,B,,
Autocuration,,1,,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2A receptor,,CHEMBL617108,H,8,,,,,BAO_0000019,12687,,2561,,14093,F,,
Autocuration,,1,,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast expressing 5-hydroxytryptamine 2A receptor,,CHEMBL617109,H,8,,,,,BAO_0000019,12687,,2562,,14093,F,,
Autocuration,,1,,,Evaluated for the effective concentration at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,,CHEMBL617110,H,8,,,,,BAO_0000357,12687,,2563,,15740,B,,
Autocuration,,1,,,Functional potency at the rat 5-hydroxytryptamine 2A receptor as effective concentration EC50 for stimulating Phosphoinositide accumulation,,CHEMBL617111,H,8,,,,,BAO_0000357,12687,,2564,,16633,B,,
Expert,,1,,,In vitro relative agonist activity against 5-hydroxytryptamine 2A using PI assay in rat vascular smooth muscle cells,,CHEMBL617112,D,9,,,Rattus norvegicus,10116.0,BAO_0000019,12687,,2565,,17200,F,,
Autocuration,,1,,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,CHEMBL617113,H,8,,,,,BAO_0000357,12687,,2566,,17133,B,,
Autocuration,,1,,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,CHEMBL617114,H,8,,,,,BAO_0000357,12687,,2567,,17133,B,,
Autocuration,,1,,,Tested for its ability to activate phospholipase c by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,CHEMBL617115,H,8,,,,,BAO_0000357,12687,,2568,,17133,B,,
Autocuration,,1,,,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,CHEMBL617116,H,8,,,,,BAO_0000219,12687,,2569,,17200,F,,
Autocuration,,1,,,Efficacy at 5-hydroxytryptamine 2A receptor,,CHEMBL617117,H,8,,,,,BAO_0000019,12687,,2570,,15363,F,,
Autocuration,,1,,,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),,CHEMBL617118,H,8,,,,,BAO_0000357,12687,,2571,,17200,B,,
Expert,,1,,,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),,CHEMBL617119,D,9,,,Rattus norvegicus,10116.0,BAO_0000357,12687,,2572,,17200,B,,
Expert,,1,,,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor determined by using PI assay (Emax),,CHEMBL617120,D,9,,,Rattus norvegicus,10116.0,BAO_0000357,12687,,2573,,17200,B,,
Expert,,1,,,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,CHEMBL617121,D,9,,,Rattus norvegicus,10116.0,BAO_0000219,12687,,2574,,17200,F,,
Autocuration,,1,,,The receptor (5-hydroxytryptamine 2A) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,CHEMBL617122,H,8,,,,,BAO_0000219,12687,,2575,,17200,F,,
Autocuration,,1,,,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor,,CHEMBL617123,H,8,,,,,BAO_0000019,12687,,2576,,17211,B,,
Expert,,1,,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes,,CHEMBL617124,H,8,,,,,BAO_0000019,12687,,2577,,17331,B,,
Expert,,1,,,Binding affinity to serotonin 5-hydroxytryptamine 2A receptors using a radioligand [3H]ketanserin binding assay in rat cortical membranes,,CHEMBL617600,H,8,,,,,BAO_0000249,12687,,2578,,13565,B,,
Expert,,1,,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was evaluated using [3H]- ketanserin as radioligand,,CHEMBL617601,H,8,,,,,BAO_0000357,12687,,2579,,13730,B,,
Expert,,1,,,In vitro affinity towards 5-hydroxytryptamine 2A receptor using [3H]spiroperidol as radioligand in cortex,,CHEMBL882923,H,8,,,,,BAO_0000019,12687,,2580,,12416,B,,
Autocuration,,1,,,Compound was tested for it's binding affinity towards 5-hydroxytryptamine 2A receptor,,CHEMBL617602,H,8,,,,,BAO_0000357,12687,,2581,,15295,B,,
Autocuration,,1,,,Compound was tested for its ability to displace [3H]DOB from 5-hydroxytryptamine 2A receptor in rat cortex homogenates,,CHEMBL617603,H,8,,,,,BAO_0000019,12687,,2582,,1742,B,,
Autocuration,,1,,,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor,,CHEMBL617604,H,8,,,,,BAO_0000357,12687,,2583,,15295,B,,
Expert,,1,,,Binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]ketanserin as radioligand,,CHEMBL617605,H,8,,,,,BAO_0000019,12687,,2584,,14970,B,,
Expert,,1,,,In vitro binding affinity for serotonin 5-hydroxytryptamine 2A receptor of rat cerebral cortex using [3H]ketanserin as radioligand,,CHEMBL617606,H,8,,,,,BAO_0000019,12687,,2585,,16693,B,,
Expert,,1,,,Inhibition of [3H]ketanserin binding to rat frontal cortex membrane 5-hydroxytryptamine 2A receptor,,CHEMBL617607,D,9,,,Rattus norvegicus,10116.0,BAO_0000019,12687,,2586,,14776,B,,
Autocuration,,1,,,In vitro inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cortical membrane,,CHEMBL617455,H,8,,,,,BAO_0000249,12687,,2587,,14286,B,,
Expert,,1,,,In vitro inhibition of [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,,CHEMBL617456,D,9,,,Rattus norvegicus,10116.0,BAO_0000019,12687,,2588,,17200,B,,
Expert,,1,,,Inhibitory concentration against 5-hydroxytryptamine 2A receptor (Inactive at >1000 nM concentration),,CHEMBL617457,H,8,,,,,BAO_0000357,12687,,2589,,15306,B,,
Expert,,1,,,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2A receptor,,CHEMBL617458,D,9,,,Rattus norvegicus,10116.0,BAO_0000357,12687,,2590,,14178,B,,
Expert,,1,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor from rat brain,,CHEMBL617459,D,9,,,Rattus norvegicus,10116.0,BAO_0000019,12687,,2591,,14229,B,,
Expert,,1,,,Binding affinity towards 5-hydroxytryptamine 2A receptor binding site using [3H]ketanserin. ,,CHEMBL617460,H,8,,,,,BAO_0000357,12687,,2592,,12884,B,,
Expert,,1,,,"Binding affinity for 5-hydroxytryptamine 2A receptor, activity is expressed as IC50 values.",,CHEMBL617461,H,8,,,,,BAO_0000357,12687,,2593,,13149,B,,
Expert,,1,,,Displacement of [3H]ketanserin from rat cortical membrane 5-hydroxytryptamine 2A receptor at 10e-7 M,,CHEMBL617462,D,9,,,Rattus norvegicus,10116.0,BAO_0000019,12687,,2594,,15295,B,,
Autocuration,,1,,,Intrinsic activity was determined at 5-hydroxytryptamine 2A receptor which is percentage response given compared with the response produced by 10 uM serotonin.,,CHEMBL617463,H,8,,,,,BAO_0000357,12687,,2595,,15740,B,,
Autocuration,,1,,,"Compound was tested for binding affinity at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate using [125I]-2,5-Dimethoxy -4-iodoamphetamine (DOI).",,CHEMBL617464,H,8,,,,,BAO_0000019,12687,,2596,,15185,B,,
Autocuration,,1,,,"Compound was tested for binding affinity using [3H]MDL-100,907 at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate.",,CHEMBL617465,H,8,,,,,BAO_0000019,12687,,2597,,15185,B,,
Expert,,1,,,Ability to bind to central serotonin 5-hydroxytryptamine 2A receptor in vitro in cortex of the rat brain using [3H]ketanserin radioligand,,CHEMBL617466,H,8,,,,,BAO_0000019,12687,,2598,,17529,B,,
Autocuration,,1,,,Ability to displace [3H]- ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,,CHEMBL617467,H,8,,,,,BAO_0000019,12687,,2599,,14826,B,,
Expert,,1,,,Displacement of [3H]ketanserin (0.5 nM) from rat cerebral cortex 5-hydroxytryptamine 2A receptors,,CHEMBL617468,H,8,,,,,BAO_0000019,12687,,2600,,17211,B,,
Autocuration,,1,,,Ability to displace [3H]ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,,CHEMBL617469,H,8,,,,,BAO_0000019,12687,,2601,,14826,B,,
Autocuration,,1,,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,,CHEMBL617470,H,8,,,,,BAO_0000019,12687,,2602,,14093,B,,
Autocuration,,1,,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor; Not tested,,CHEMBL617471,H,8,,,,,BAO_0000019,12687,,2603,,14093,B,,
Expert,,1,NIH3T3,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor in NIH3T3 cell line membranes,,CHEMBL617472,H,8,,723.0,,,BAO_0000219,12687,,2604,,13246,B,,
Expert,,1,,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor.,,CHEMBL617473,H,8,,,,,BAO_0000357,12687,,2605,,13246,B,,
Expert,,1,,,Affinity 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,,CHEMBL617474,D,9,,,Rattus norvegicus,10116.0,BAO_0000019,12687,,2606,,15436,B,,
Expert,,1,,,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,,CHEMBL617475,D,9,,,Rattus norvegicus,10116.0,BAO_0000019,12687,,2607,,15436,B,,
Autocuration,,1,,,Affinity at [3H]ketanserin-labeled 5-hydroxytryptamine 2A receptor in rat brain homogenate was determined,,CHEMBL617476,H,8,,,,,BAO_0000221,12687,,2608,Brain,14442,B,,955.0
Expert,,1,,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2A receptor,,CHEMBL617477,H,8,,,,,BAO_0000357,12687,,2609,,12457,B,,
Expert,,1,NIH3T3,,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2A receptor,,CHEMBL617478,H,8,,723.0,,,BAO_0000219,12687,,2610,,12457,B,,
Autocuration,,1,,,"Antagonistic activity measured for 5-hydroxytryptamine 2A receptor using [3H]-MDL- 100,907 as radioligand in rat cortical homogenates.",,CHEMBL617479,H,8,,,,,BAO_0000221,12687,,2611,,14755,F,,
Autocuration,,1,,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was determined using [125I]- DOI as radioligand,,CHEMBL617480,H,8,,,,,BAO_0000357,12687,,2612,,4707,B,,
Expert,,1,,,Binding affinity against 5-hydroxytryptamine 2A receptor,,CHEMBL617481,H,8,,,,,BAO_0000357,12687,,2613,,13297,B,,
Expert,,1,,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat prefrontal cerebral cortex mambranes,,CHEMBL617482,H,8,,,,,BAO_0000019,12687,,2614,,17331,B,,
Autocuration,,1,,,Binding affinity against 5-hydroxytryptamine 2A receptor from rat forebrain using [3H]ketanserin as radioligand,,CHEMBL617483,H,8,,,,,BAO_0000019,12687,,2615,,4664,B,,
Autocuration,,1,,,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,CHEMBL621528,H,8,,,,,BAO_0000357,12687,,2616,,16633,B,,
Expert,,1,NIH3T3,,Binding affinity against 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells using [3H]ketanserin,,CHEMBL621529,D,9,,723.0,Rattus norvegicus,10116.0,BAO_0000219,12687,,2617,,4664,B,,
Expert,,1,,,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,CHEMBL621530,H,8,,,,,BAO_0000357,12687,,2618,,16133,B,,
Expert,,1,,,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,CHEMBL621531,H,8,,,,,BAO_0000357,12687,,2619,,16133,B,,
Expert,,1,,,Binding affinity against rat brain 5-hydroxytryptamine 2A receptor,,CHEMBL621532,D,9,,,Rattus norvegicus,10116.0,BAO_0000019,12687,,2620,,14060,B,,
Expert,,1,,,Binding affinity at cloned rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,CHEMBL621533,H,8,,,,,BAO_0000357,12687,,2621,,16326,B,,
Expert,,1,CHO,,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,CHEMBL621534,H,8,,449.0,,,BAO_0000219,12687,,2622,,16659,B,,
Autocuration,,1,,,Binding affinity measured at the 5-hydroxytryptamine 2A receptor by the inhibition of [3H]ketanserin binding to rat cortex using unlabeled mianserin for nonspecific binding.,,CHEMBL621535,H,8,,,,,BAO_0000019,12687,,2623,,14776,B,,
Autocuration,,1,,,Binding affinity of [3H]- ketanserin labelled towards Rat cortical 5-hydroxytryptamine 2A receptor using radioligand binding assay,,CHEMBL621536,H,8,,,,,BAO_0000357,12687,,2624,,13481,B,,
Autocuration,,1,,,Binding affinity of compound was tested for 5-hydroxytryptamine 2A receptor,,CHEMBL621537,H,8,,,,,BAO_0000357,12687,,2625,,17386,B,,
Expert,,1,,,Binding affinity for 5-hydroxytryptamine 2A receptor,,CHEMBL621538,D,9,,,Rattus norvegicus,10116.0,BAO_0000357,12687,,2626,,6611,B,,
Autocuration,,1,,,Binding affinity against 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as the radioligand.,,CHEMBL621539,H,8,,,,,BAO_0000019,12687,,2627,,14423,B,,
Autocuration,,1,,,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex,,CHEMBL621540,H,8,,,,,BAO_0000019,12687,,2628,,15412,B,,
Autocuration,,1,,,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex.,,CHEMBL621541,H,8,,,,,BAO_0000019,12687,,2629,,15412,B,,
Autocuration,,1,,,Binding affinity towards 5-HT 2A receptor in rat cerebral frontal cortex membranes using [3H]ketanserin as radioligand,,CHEMBL621542,H,8,,,,,BAO_0000019,12687,,2630,,6238,B,,
Expert,,1,,,Binding affinity at 5-hydroxytryptamine 2A receptor of rat.,,CHEMBL621543,H,8,,,,,BAO_0000357,12687,,2631,,6648,B,,
Expert,,1,,,Binding affinity towards 5-hydroxytryptamine 2A receptor sites by using [3H]ketanserin as radioligand,,CHEMBL621544,H,8,,,,,BAO_0000357,12687,,2632,,5667,B,,
Expert,,1,,,Binding affinity for 5-hydroxytryptamine 2A serotonin receptor,,CHEMBL621545,D,9,,,Rattus norvegicus,10116.0,BAO_0000357,12687,,2633,,6611,B,,
Autocuration,,1,,,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,CHEMBL621546,H,8,,,,,BAO_0000357,12687,,2634,,13481,B,,
Autocuration,,1,,,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand; Not tested,,CHEMBL621547,H,8,,,,,BAO_0000357,12687,,2635,,13481,B,,
Expert,,1,NIH3T3,,Displacement of [3H]ketanserin from NIH3T3 cells stably expressing rat 5-hydroxytryptamine 2A receptor,,CHEMBL618692,H,8,,723.0,,,BAO_0000219,12687,,2636,,15558,B,,
Autocuration,,1,,,Binding affinity towards 5-hydroxytryptamine 2A receptor,,CHEMBL618693,H,8,,,,,BAO_0000357,12687,,2637,,6013,B,,
Autocuration,,1,,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,CHEMBL872922,H,8,,,,,BAO_0000357,12687,,2638,,16633,B,,
Autocuration,,1,,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor from fundus tissue was determined using [3H]mesulergine as radioligand,,CHEMBL618694,H,8,,,,,BAO_0000357,12687,,2639,,6013,B,,
Expert,,1,,,Binding affinity for rat 5-hydroxytryptamine 2A receptor using [3H]DOB,,CHEMBL618695,D,9,,,Rattus norvegicus,10116.0,BAO_0000357,12687,,2640,,6013,B,,
Autocuration,,1,,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor was determined using [3H]DOB as radioligand; ND=No data,,CHEMBL618696,H,8,,,,,BAO_0000357,12687,,2641,,6013,B,,
Expert,,1,,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor by [3H]ketanserin displacement.,,CHEMBL618697,H,8,,,,,BAO_0000357,12687,,2642,,6013,B,,
Autocuration,,1,,,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]DOB as radioligand,,CHEMBL618892,H,8,,,,,BAO_0000357,12687,,2643,,6013,B,,
Autocuration,,1,,,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]ketanserin as radioligand,,CHEMBL618893,H,8,,,,,BAO_0000357,12687,,2644,,6013,B,,
Autocuration,,1,,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor,,CHEMBL618894,H,8,,,,,BAO_0000357,12687,,2645,,16293,B,,
Expert,,1,NIH3T3,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor expressed in NIH3T3 cells using [3H]ketanserin as radioligand,,CHEMBL618895,H,8,,723.0,,,BAO_0000219,12687,,2646,,17175,B,,
Expert,,1,,,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,,CHEMBL618896,D,9,,,Rattus norvegicus,10116.0,BAO_0000357,12687,,2647,,13278,B,,
Autocuration,,1,,,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2A receptor in homogenate of caudate putamen tissue from rat brain,,CHEMBL618897,H,8,,,,,BAO_0000019,12687,,2648,Caudate-putamen,3682,B,,5383.0
Autocuration,,1,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand,,CHEMBL618898,H,8,,,,,BAO_0000357,12687,,2649,,2014,B,,
Autocuration,,1,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand; Not determined,,CHEMBL618899,H,8,,,,,BAO_0000357,12687,,2650,,2014,B,,
Autocuration,,1,,,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2A receptor in cloned rat cell culture,,CHEMBL618900,H,8,,,,,BAO_0000357,12687,,2651,,4932,B,,
Autocuration,,1,,,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2A receptor in cloned rat prefrontal cortex homogenate,,CHEMBL618901,H,8,,,,,BAO_0000019,12687,,2652,,4932,B,,
Autocuration,,1,,,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2A receptor,,CHEMBL618902,H,8,,,,,BAO_0000357,12687,,2653,,3935,B,,
Expert,,1,,,Displacement of [3H]8-OH-DPAT from rat hippocampus membrane 5-hydroxytryptamine 2A receptor,,CHEMBL618903,D,9,,,Rattus norvegicus,10116.0,BAO_0000221,12687,,2654,Hippocampus,5432,B,,10000000.0
Autocuration,,1,,,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2A receptor,,CHEMBL618904,H,8,,,,,BAO_0000357,12687,,2655,,15818,B,,
Autocuration,,1,,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand.,,CHEMBL618905,H,8,,,,,BAO_0000357,12687,,2656,,13672,B,,
Autocuration,,1,,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]-ketanserin radioligand.,,CHEMBL618906,H,8,,,,,BAO_0000357,12687,,2657,,13672,B,,
Expert,,1,NIH3T3,,Binding affinity against rat 5-hydroxytryptamine 2A receptor in NIH3T3 cells.,,CHEMBL618907,H,8,,723.0,,,BAO_0000219,12687,,2658,,14749,B,,
Autocuration,,1,,,Compound was tested for the Binding affinity against rat frontal cortex 5-hydroxytryptamine 2A receptor by Radio ligand [3H]ketanserin binding assay.,,CHEMBL618908,H,8,,,,,BAO_0000019,12687,,2659,,13462,B,,
Autocuration,,1,,,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,,CHEMBL617909,H,8,,,,,BAO_0000357,12687,,2660,,15740,B,,
Expert,,1,,,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,,CHEMBL617910,H,8,,,,,BAO_0000019,12687,,2661,,16647,B,,
Autocuration,,1,,,In vitro ability to displace [3H]ketanserin from 5-hydroxytryptamine 2A receptor in rat brain.,,CHEMBL617911,H,8,,,,,BAO_0000221,12687,,2662,Brain,13345,B,,955.0
Autocuration,,1,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,CHEMBL872923,H,8,,,,,BAO_0000249,12687,,2663,,16740,B,,
Autocuration,,1,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,CHEMBL617912,H,8,,,,,BAO_0000249,12687,,2664,,16740,B,,
Expert,,1,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat cortex,,CHEMBL617913,D,9,,,Rattus norvegicus,10116.0,BAO_0000019,12687,,2665,,15535,B,,
Expert,,1,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,CHEMBL617914,H,8,,,,,BAO_0000249,12687,,2666,,16740,B,,
Autocuration,,1,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,CHEMBL617915,H,8,,,,,BAO_0000249,12687,,2667,,16740,B,,
Autocuration,,1,,,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane,,CHEMBL617916,H,8,,,,,BAO_0000249,12687,,2668,,16740,B,,
Expert,,1,,,Displacement of [3H]- Ketanserin from rat cortex 5-hydroxytryptamine 2A receptor,,CHEMBL617917,D,9,,,Rattus norvegicus,10116.0,BAO_0000019,12687,,2669,,4795,B,,
Expert,,1,,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand,,CHEMBL617918,H,8,,,,,BAO_0000019,12687,,2670,,8,B,,
Autocuration,,1,,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand; Not active at 10-5 M,,CHEMBL617919,H,8,,,,,BAO_0000019,12687,,2671,,8,B,,
Expert,,1,,,In vitro inhibitory constant against [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,,CHEMBL617920,D,9,,,Rattus norvegicus,10116.0,BAO_0000019,12687,,2672,,17200,B,,
Expert,,1,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor of rat brain cortex,,CHEMBL617921,D,9,,,Rattus norvegicus,10116.0,BAO_0000019,12687,,2673,,2148,B,,
Expert,,1,,,"Relative binding affinity for D2 receptor and 5-hydroxytryptamine 2A receptor, ratio of Ki",,CHEMBL617922,D,5,,,Rattus norvegicus,10116.0,BAO_0000224,105102,,2674,,13345,B,,
Autocuration,,1,,,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,CHEMBL617923,H,8,,,,,BAO_0000357,12687,,2675,,5088,B,,
Autocuration,,1,,,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,CHEMBL617924,H,8,,,,,BAO_0000357,12687,,2676,,5088,B,,
Autocuration,,1,,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2A receptor using [125 I]-DOI as radioligand,,CHEMBL617925,H,8,,,,,BAO_0000357,12687,,2677,,17133,B,,
Expert,,1,,,In vitro binding to 5-hydroxytryptamine 2A receptor using [125 I]-DOI,,CHEMBL617926,D,9,,,Rattus norvegicus,10116.0,BAO_0000357,12687,,2678,,17133,B,,
Autocuration,,1,,,The binding affinity at 5-hydroxytryptamine 2A receptor was determined using [3H]ketanserin,,CHEMBL617927,H,8,,,,,BAO_0000357,12687,,2679,,16532,B,,
Autocuration,,1,,,The compound was tested for binding affinity against 5-hydroxytryptamine 2A receptor,,CHEMBL617928,H,8,,,,,BAO_0000357,12687,,2680,,15086,B,,
Expert,,1,,,Binding affinity for 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,CHEMBL617929,D,9,,,Rattus norvegicus,10116.0,BAO_0000019,12687,,2681,,2309,B,,
Expert,,1,,,Binding affinity to 5-hydroxytryptamine 2A receptor from rat cortex assayed using [3H]ketanserin as radioligand.,,CHEMBL617930,H,8,,,,,BAO_0000019,12687,,2682,,12953,B,,
Autocuration,,1,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as radioligand.; Nonactive at 10 uM,,CHEMBL617931,H,8,,,,,BAO_0000019,12687,,2683,,12953,B,,
Autocuration,,1,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]-ketanserin as radioligand; Nonactive at 10 uM,,CHEMBL617932,H,8,,,,,BAO_0000019,12687,,2684,,12953,B,,
Autocuration,,1,CHO,,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells; ND is No Data,,CHEMBL617933,H,8,,449.0,,,BAO_0000219,12687,,2685,,16659,B,,
Autocuration,,1,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,,CHEMBL617934,H,8,,,,,BAO_0000019,12687,,2686,,16740,B,,
Autocuration,,1,,,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,,CHEMBL617935,H,8,,,,,BAO_0000019,12687,,2687,,16740,B,,
Autocuration,,1,,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor; Not determined,,CHEMBL617936,H,8,,,,,BAO_0000357,12687,,2688,,17133,B,,
Autocuration,,1,,,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor; NT=not tested,,CHEMBL617937,H,8,,,,,BAO_0000019,12687,,2689,,17211,B,,
Autocuration,,1,,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes; Not tested,,CHEMBL617938,H,8,,,,,BAO_0000019,12687,,2690,,17331,B,,
Autocuration,,1,,,Compound was evaluated for effective dose measured in nmol/kg following a dose of 0.04 mg/kg and 0.093 uM/kg (95%CI); range 32-63,,CHEMBL617939,H,8,,,,,BAO_0000218,12687,,2691,,16633,B,,
Autocuration,,1,,,Compound was evaluated for the percentage of rats disrupted following a dose of 0.04 mg/kg and 0.097 uM/kg,,CHEMBL617940,H,8,,,,,BAO_0000218,12687,,2692,,16633,B,,
Autocuration,,1,,,Compound was evaluated for the percentage of rats disrupted following a dose of 0.08 mg/kg and 0.194 uM/kg,,CHEMBL617941,H,8,,,,,BAO_0000218,12687,,2693,,16633,B,,
Expert,,1,,,Ratio of pKi of 5-HT2A to that of 5-HT2C receptor,,CHEMBL617942,H,8,,,,,BAO_0000357,12687,,2694,,15026,B,,
Expert,,1,,,Ratio of pKi of 5-HT2A to that of D2 receptor,,CHEMBL617943,H,8,,,,,BAO_0000357,12687,,2695,,15026,B,,
Expert,,1,,,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,,CHEMBL617944,H,4,,,,,BAO_0000224,105093,,2696,,16404,B,,
Expert,,1,,,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,,CHEMBL617945,H,4,,,,,BAO_0000224,105093,,2697,,16404,B,,
Expert,,1,,,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor,,CHEMBL617946,H,4,,,,,BAO_0000224,105075,,2698,,16404,B,,
Autocuration,,1,,,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor; ND is no data,,CHEMBL617947,H,8,,,,,BAO_0000357,12687,,2699,,16404,B,,
Expert,,1,,,Percent maximal 5-HT stimulation at cloned rat 5-hydroxytryptamine 2A receptor (phosphoinositide hydrolysis study) at a conc of 100 uM,,CHEMBL617948,H,8,,,,,BAO_0000357,12687,,2700,,16326,B,,
Autocuration,,1,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat,,CHEMBL858116,H,8,,,,,BAO_0000019,12687,,2701,,15847,F,,
Autocuration,,1,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat; ND means not done,,CHEMBL617949,H,8,,,,,BAO_0000019,12687,,2702,,15847,F,,
Autocuration,,1,,,Effectiveness of compound in blocking 5-hydroxytryptamine 2A receptor-mediated contractions of rat tail artery,,CHEMBL617950,H,8,,,,,BAO_0000019,12687,,2703,,15329,F,,
Expert,,1,,,Negative log concentration of antagonist on 5-hydroxytryptamine 2A receptor in rat thoracic aorta,,CHEMBL617951,H,8,,,,,BAO_0000019,12687,,2704,Thoracic aorta,16404,F,,1515.0
Expert,,1,,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta,,CHEMBL617952,H,8,,,,,BAO_0000019,12687,,2705,Thoracic aorta,16404,F,,1515.0
Autocuration,,1,,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta; ND is not determined.,,CHEMBL617953,H,8,,,,,BAO_0000019,12687,,2706,Thoracic aorta,16404,F,,1515.0
Autocuration,,1,,,Binding activity radioligand.,,CHEMBL617954,H,8,,,,,BAO_0000357,12687,,2707,,12861,B,,
Expert,,1,,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,CHEMBL617955,H,8,,,,,BAO_0000019,12687,,2708,,12861,B,,
Autocuration,,1,,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,,CHEMBL857071,H,8,,,,,BAO_0000019,12687,,2709,,12861,B,,
Expert,,1,,,Displacement of [3H]DOB binding to 5-hydroxytryptamine 2A receptor from rat cortex homogenate,,CHEMBL617270,H,8,,,,,BAO_0000019,12687,,2710,,12490,B,,
Autocuration,,1,N1E-115,,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930,,CHEMBL617271,H,8,,339.0,,,BAO_0000219,12687,,2711,,12827,B,,
Autocuration,,1,N1E-115,,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930; Not determined,,CHEMBL617272,H,8,,339.0,,,BAO_0000219,12687,,2712,,12827,B,,
Autocuration,,1,,,Binding affinity was evaluated by 5-hydroxytryptamine 2A receptor agonism in the rat cortex by displacing ketanserin,,CHEMBL617273,H,8,,,,,BAO_0000019,12687,,2713,,12918,B,,
Expert,,1,,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]-ketanserin,,CHEMBL617274,D,9,,,Rattus norvegicus,10116.0,BAO_0000019,12687,,2714,,12919,F,,
Autocuration,,1,,,Binding affinity towards human serotonin 5-hydroxytryptamine 2C receptor,,CHEMBL617275,H,8,,,,,BAO_0000357,108,,2715,,17723,B,,
Autocuration,,1,,,Binding affinity towards 5-hydroxytryptamine 2C receptor,,CHEMBL617276,H,8,,,,,BAO_0000357,108,,2716,,6013,B,,
Autocuration,,1,,,Binding affinity towards human 5-hydroxytryptamine 2C receptor,,CHEMBL617277,H,8,,,,,BAO_0000357,108,,2717,,16293,B,,
Expert,,1,,,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,,CHEMBL617278,H,8,,,,,BAO_0000019,108,,2718,,3857,B,,
Expert,,1,,,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor; Not determined,,CHEMBL617279,H,8,,,,,BAO_0000019,108,,2719,,3857,B,,
Expert,,1,,,Binding affinity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,,CHEMBL617280,H,8,,,,,BAO_0000019,108,,2720,,3857,B,,
Autocuration,,1,,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,,CHEMBL617281,H,8,,,,,BAO_0000357,108,,2721,,15363,B,,
Autocuration,,1,,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,,CHEMBL617282,H,8,,,,,BAO_0000357,108,,2722,,15363,B,,
Expert,,1,,,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]mesulergine,,CHEMBL617283,H,8,,,,,BAO_0000019,108,,2723,,16441,B,,
Expert,,1,,,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]-mesulergine; ND is No Data.,,CHEMBL617284,H,8,,,,,BAO_0000019,108,,2724,,16441,B,,
Autocuration,,1,HEK293,,In vitro binding affinity towards human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells was determined using [3H]mesulergine as radioligand,,CHEMBL617285,H,8,,722.0,,,BAO_0000219,108,,2725,,4176,B,,
Autocuration,,1,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2C receptor,,CHEMBL617286,H,8,,,,,BAO_0000019,108,,2726,,17085,B,,
Expert,,1,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2C receptor using with [125I]- DOI radioligand,,CHEMBL617287,D,9,,,Homo sapiens,9606.0,BAO_0000357,108,,2727,,17200,B,,
Expert,,1,,,Binding affinity towards human 5-hydroxytryptamine 2C receptor.,,CHEMBL617288,H,8,,,,,BAO_0000357,108,,2728,,5088,B,,
Autocuration,,1,,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]DOB as radioligand,,CHEMBL617289,H,8,,,,,BAO_0000357,108,,2729,,5088,B,,
Autocuration,,1,,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,CHEMBL872917,H,8,,,,,BAO_0000357,108,,2730,,5088,B,,
Autocuration,,1,,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,,CHEMBL617290,H,8,,,,,BAO_0000357,108,,2731,,5088,B,,
Autocuration,,1,CHO,,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,,CHEMBL617291,H,8,,449.0,,,BAO_0000219,108,,2732,,16659,B,,
Autocuration,,1,CHO,,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells; ND is no data,,CHEMBL617292,H,8,,449.0,,,BAO_0000219,108,,2733,,16659,B,,
Autocuration,,1,NIH3T3,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,CHEMBL617293,H,8,,723.0,,,BAO_0000219,108,,2734,,17451,B,,
Expert,,1,CHO,,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,CHEMBL617294,D,9,,449.0,Homo sapiens,9606.0,BAO_0000219,108,,2735,,6857,F,,
Expert,,1,,,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,,CHEMBL617295,H,8,,,,,BAO_0000019,108,,2736,,3857,B,,
Autocuration,,1,,,Binding activity radioligand.,,CHEMBL617296,H,8,,,,,BAO_0000357,108,,2737,,12861,B,,
Autocuration,,1,,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,CHEMBL617297,H,8,,,,,BAO_0000019,108,,2738,,12861,B,,
Expert,,1,CHO,,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand,,CHEMBL617298,H,8,,449.0,,,BAO_0000219,108,,2739,,5104,B,,
Expert,,1,CHO,,Binding affinity at human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells by [3H]mesulergine displacement.,,CHEMBL617299,H,8,,449.0,,,BAO_0000219,108,,2740,,5105,B,,
Autocuration,,1,CHO,,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand; NT means not tested,,CHEMBL617300,H,8,,449.0,,,BAO_0000219,108,,2741,,5105,B,,
Autocuration,,1,,,Binding affinity against 5-HT2C receptor,,CHEMBL617454,H,8,,,,,BAO_0000357,108,,2742,,5254,B,,
Autocuration,,1,HEK293,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,,CHEMBL617505,H,8,,722.0,,,BAO_0000219,108,,2743,,13267,B,,
Expert,,1,HEK293,,Displacement of [3H]mesulergine from 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells,,CHEMBL617506,D,9,,722.0,Homo sapiens,9606.0,BAO_0000219,108,,2744,,14157,B,,
Expert,,1,HEK293,,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,,CHEMBL617507,D,9,,722.0,Homo sapiens,9606.0,BAO_0000219,108,,2745,,12936,B,,
Expert,,1,,,Binding affinity against human 5-hydroxytryptamine 2C receptor using displacement of [3H]DOB,,CHEMBL617508,H,8,,,,,BAO_0000357,108,,2746,,14068,B,,
Expert,,1,HEK293,,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,,CHEMBL857982,D,9,,722.0,Homo sapiens,9606.0,BAO_0000219,108,,2747,,12936,B,,
Expert,,1,HEK293,,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand,,CHEMBL617509,D,9,,722.0,Homo sapiens,9606.0,BAO_0000219,108,,2748,,4540,B,,
Expert,,1,HEK293,,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand; Nd means not determined,,CHEMBL617510,D,9,,722.0,Homo sapiens,9606.0,BAO_0000219,108,,2749,,4540,B,,
Autocuration,,1,,,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor was determined,,CHEMBL617511,H,8,,,,,BAO_0000357,108,,2750,,6166,B,,
Autocuration,,1,HEK293,,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptors in HEK 293 cells using [3H]mesulergine as radioligand,,CHEMBL617512,H,8,,722.0,,,BAO_0000219,108,,2751,,17296,B,,
Autocuration,,1,HEK293,,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]mesulergine as radioligand,,CHEMBL617749,H,8,,722.0,,,BAO_0000219,108,,2752,,17296,B,,
Autocuration,,1,HEK293,,Binding affinity towards 5-HT2C (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,CHEMBL617750,H,8,,722.0,,,BAO_0000219,108,,2753,,15779,B,,
Autocuration,,1,HEK293,,Binding affinity towards 5-hydroxytryptamine 2C receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,CHEMBL617751,H,8,,722.0,,,BAO_0000219,108,,2754,,15779,B,,
Expert,,1,HEK293,,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells using [3H]mesulergine as radioligand,,CHEMBL617752,H,8,,722.0,,,BAO_0000219,108,,2755,,14391,B,,
Autocuration,,1,HEK293,,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand",,CHEMBL617753,H,8,,722.0,,,BAO_0000219,108,,2756,,15779,B,,
Expert,,1,HEK293,,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2C in HEK293 cells, using [3H]mesulergine as radioligand.",,CHEMBL617754,H,8,,722.0,,,BAO_0000219,108,,2757,,15851,B,,
Expert,,1,HEK293,,Displacement of [3H]mesulergine from human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells; compound insoluble,,CHEMBL617755,D,9,,722.0,Homo sapiens,9606.0,BAO_0000219,108,,2758,,15851,B,,
Autocuration,,1,HEK293,,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand; no data",,CHEMBL617756,H,8,,722.0,,,BAO_0000219,108,,2759,,15779,B,,
Expert,,1,HEK293,,Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by displacement of [3H]mesulergine,,CHEMBL617757,H,8,,722.0,,,BAO_0000219,108,,2760,,3832,B,,
Expert,,1,HEK293,,In vitro binding affinity at human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by [3H]mesulergine displacement.,,CHEMBL617758,H,8,,722.0,,,BAO_0000219,108,,2761,,3833,B,,
Autocuration,,1,NIH3T3,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand,,CHEMBL617759,H,8,,723.0,,,BAO_0000219,108,,2762,,17451,B,,
Autocuration,,1,HEK293,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine as the radioligand,,CHEMBL617760,H,8,,722.0,,,BAO_0000219,108,,2763,,4199,B,,
Expert,,1,CHO-K1,,Displacement of [3H]mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO-K1 cells,,CHEMBL617761,H,8,,485.0,,,BAO_0000219,108,,2764,,1883,B,,
Expert,,1,,,Binding affinity against 5-hydroxytryptamine 2C receptor,,CHEMBL617762,D,9,,,Homo sapiens,9606.0,BAO_0000357,108,,2765,,4321,B,,
Autocuration,,1,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 2C receptor,,CHEMBL617763,H,8,,,,,BAO_0000357,108,,2766,,14875,B,,
Autocuration,,1,HEK293,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine,,CHEMBL857983,H,8,,722.0,,,BAO_0000219,108,,2767,,15146,B,,
Autocuration,,1,HEK293,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2C receptor in HEK 293 using [3H]mesulergine as a radioligand,,CHEMBL617764,H,8,,722.0,,,BAO_0000219,108,,2768,,5213,B,,
Autocuration,,1,HeLa,,Inhibitory constant on human 5-hydroxytryptamine 2C receptor transfected in to HeLa cells,,CHEMBL617765,H,8,,308.0,,,BAO_0000219,108,,2769,,16404,B,,
Autocuration,,1,,,Selectivity as the ratio of Ki value towards 5-hydroxytryptamine 2C receptor to that of pA2 value towards 5-hydroxytryptamine 2B receptor,,CHEMBL617766,H,8,,,,,BAO_0000019,108,,2770,,13267,F,,
Autocuration,,1,,,The binding affinity (pKi) measured against 5-hydroxytryptamine 3 receptor of rat hippocampus and entorhinal cortex using [3H]granisetron as radioligand,,CHEMBL617767,H,8,,,,,BAO_0000221,108,,2771,Hippocampus,13267,F,,10000000.0
Autocuration,,1,HEK293,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2C receptor in HEK293 cells using [3H]mesulergine.,,CHEMBL617768,H,8,,722.0,,,BAO_0000219,108,,2772,,14818,B,,
Autocuration,,1,HEK293,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]5-mesulergine as radioligand",,CHEMBL617769,H,8,,722.0,,,BAO_0000219,108,,2773,,4829,B,,
Autocuration,,1,,,Binding affinity analysed on 5-HT 2C in human clone using [3H]mesulergine as radioligand,,CHEMBL858023,H,8,,,,,BAO_0000357,11864,,2774,,13463,B,,
Autocuration,,1,,,Binding affinity analysed on 5-HT 2C in rat stomach fundus,,CHEMBL617770,H,8,,,,,BAO_0000019,11864,,2775,Stomach,13463,B,,945.0
Autocuration,,1,,,Binding affinity analysed towards 5-HT 2C in rat stomach fundus,,CHEMBL617771,H,8,,,,,BAO_0000019,11864,,2776,Stomach,13463,B,,945.0
Autocuration,,1,A9,,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2C receptor in A9 cells,,CHEMBL617772,H,8,,625.0,,,BAO_0000219,11864,,2777,,12652,F,,
Autocuration,,1,NIH3T3,,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,,CHEMBL617773,H,8,,723.0,,,BAO_0000219,11864,,2778,,4682,B,,
Autocuration,,1,NIH3T3,,Binding affinity to 5-hydroxytryptamine 2C receptor measured using radioligand [3H]Mesulergine in stably transfected NIH3T3 cells,,CHEMBL617850,H,8,,723.0,,,BAO_0000219,11864,,2779,,4682,B,,
Autocuration,,1,NIH3T3,,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,,CHEMBL617851,H,8,,723.0,,,BAO_0000219,11864,,2780,,4682,B,,
Autocuration,,1,,,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2C receptor,,CHEMBL617852,H,8,,,,,BAO_0000019,11864,,2781,,12652,F,,
Autocuration,,1,,,Binding affinity analysed on 5-HT 2C in rat stomach fundus.,,CHEMBL858024,H,8,,,Mus musculus,10090.0,BAO_0000019,12689,,2782,Stomach,13463,B,,945.0
Expert,,1,,,Binding affinity towards 5-HT 2C receptor in rat stomach fundus,,CHEMBL617853,D,9,,,Rattus norvegicus,10116.0,BAO_0000019,12689,,2783,Stomach,13463,B,,945.0
Expert,,1,,,Binding affinity against 5-Hydroxytryptamine 2C Receptor was measured using [3H]N-methyl-mesulergine as radioligand,,CHEMBL617854,H,8,,,,,BAO_0000357,108,,2784,,13969,B,,
Expert,,1,,,Binding affinity for 5-hydroxytryptamine 2C receptor,,CHEMBL873477,H,8,,,Sus scrofa,9823.0,BAO_0000357,108,,2785,,13392,B,,
Expert,,1,,,Binding affinity towards 5-hydroxytryptamine 2C receptor,,CHEMBL617855,H,8,,,,,BAO_0000357,108,,2786,,13392,B,,
Expert,,1,,,Affinity towards 5-hydroxytryptamine 2C receptor in membranes from pig choroid plexus using [3H]N-methyl-mesulergine,,CHEMBL617856,H,8,,,,,BAO_0000019,108,,2787,,14430,B,,
Autocuration,,1,,,Compound was tested for its ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor in pig cortex,,CHEMBL617857,H,8,,,,,BAO_0000019,108,,2788,,1742,B,,
Autocuration,,1,,,In vitro inhibitory concentration against radioligand [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in pig cortical membrane,,CHEMBL617858,H,8,,,,,BAO_0000249,108,,2789,,14286,B,,
Autocuration,,1,,,Binding affinity towards pig 5-hydroxytryptamine 2C receptor,,CHEMBL617859,H,8,,,,,BAO_0000357,108,,2790,,5619,B,,
Autocuration,,1,,,The compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,,CHEMBL617860,H,8,,,,,BAO_0000357,108,,2791,,15086,B,,
Autocuration,,1,,,Binding activity radioligand.,,CHEMBL617861,H,8,,,,,BAO_0000357,108,,2792,,12861,B,,
Expert,,1,,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,CHEMBL617862,H,8,,,,,BAO_0000019,108,,2793,,12861,B,,
Autocuration,,1,,,Binding activity against 5-hydroxytryptamine 3 receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,,CHEMBL617863,H,8,,,,,BAO_0000019,108,,2794,,12861,B,,
Autocuration,,1,,,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT,,CHEMBL617864,H,8,,,,,BAO_0000249,108,,2795,,12827,B,,
Autocuration,,1,,,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT; Not determined,,CHEMBL617649,H,8,,,,,BAO_0000249,108,,2796,,12827,B,,
Expert,,1,,,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,,CHEMBL617650,H,8,,,Sus scrofa,9823.0,BAO_0000019,108,,2797,,12919,F,,
Expert,,1,,,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,,CHEMBL617651,H,8,,,Sus scrofa,9823.0,BAO_0000019,108,,2798,,12919,F,,
Autocuration,,1,,,In vitro binding affinity at 5-hydroxytryptamine 2C receptor in pig choroid plexus using 3[H]mesulergine as the radioligand,,CHEMBL617652,H,8,,,Sus scrofa,9823.0,BAO_0000357,108,,2799,,16429,B,,
Autocuration,,1,,,In Vitro Binding affinity againist 5-hydroxytryptamine 2C receptor by displacing [3H]mesulergine from pig cortex,,CHEMBL857072,H,8,,,Sus scrofa,9823.0,BAO_0000019,108,,2800,,773,B,,
Autocuration,,1,,,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2C receptor,,CHEMBL617653,H,8,,,Sus scrofa,9823.0,BAO_0000357,108,,2801,,5033,B,,
Autocuration,,1,,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,CHEMBL617654,H,8,,,,,BAO_0000019,12687,,2802,,12861,B,,
Autocuration,,1,,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2C receptor,,CHEMBL617655,H,8,,,,,BAO_0000019,12689,,2803,,14093,F,,
Expert,,1,,,Binding affinity towards 5-HT2C receptor from rat using [3H]mesulergine as radioligand,,CHEMBL617656,H,8,,,,,BAO_0000357,12689,,2804,,14970,B,,
Autocuration,,1,,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand,,CHEMBL617657,H,8,,,,,BAO_0000357,12689,,2805,,14970,B,,
Autocuration,,1,,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand; Not tested,,CHEMBL617658,H,8,,,,,BAO_0000357,12689,,2806,,14970,B,,
Expert,,1,,,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2C receptor,,CHEMBL617659,D,9,,,Rattus norvegicus,10116.0,BAO_0000357,12689,,2807,,14178,B,,
Expert,,1,,,Inhibition of radiolabeled [3H]mesulergine ligand binding to 5-hydroxytryptamine 2C receptor,,CHEMBL617838,D,9,,,Rattus norvegicus,10116.0,BAO_0000357,12689,,2808,,14178,B,,
Expert,,1,,,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in rat brain membranes,Brain membranes,CHEMBL617839,D,9,,,Rattus norvegicus,10116.0,BAO_0000249,12689,,2809,,14229,B,,
Autocuration,,1,,,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine; Not tested,,CHEMBL617840,H,8,,,,,BAO_0000357,12689,,2810,,16532,B,,
Autocuration,,1,,,Ability to displace [3H]mesulergine bound to 5-hydroxytryptamine 2C receptor in rat cortex,,CHEMBL617841,H,8,,,,,BAO_0000019,12689,,2811,,14826,B,,
Autocuration,,1,,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-HT2C receptor,,CHEMBL875915,H,8,,,,,BAO_0000019,12689,,2812,,17211,B,,
Expert,,1,,,Displacement of [3H]mesulergine (0.5 nM) from rat 5-hydroxytryptamine 2C receptor expressed in SR-3T3 cells,,CHEMBL617842,H,8,,,,,BAO_0000219,12689,,2813,,17211,B,In vitro,
Expert,,1,NIH3T3,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor in NIH3T3 cell line membranes,,CHEMBL617843,H,8,,723.0,,,BAO_0000219,12689,,2814,,13246,B,,
Expert,,1,,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor.,,CHEMBL617844,H,8,,,,,BAO_0000357,12689,,2815,,13246,B,,
Expert,,1,,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2C receptor,,CHEMBL617845,H,8,,,,,BAO_0000357,12689,,2816,,12457,B,,
Expert,,1,NIH3T3,,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2C receptor,,CHEMBL617846,H,8,,723.0,,,BAO_0000219,12689,,2817,,12457,B,,
Autocuration,,1,,,Binding affinity towards rat 5-hydroxytryptamine 2C receptor was determined using [125I]- DOI as radioligand,,CHEMBL617847,H,8,,,,,BAO_0000357,12689,,2818,,4707,B,,
Expert,,1,,,Binding affinity against 5-hydroxytryptamine 2C receptor,,CHEMBL617848,H,8,,,,,BAO_0000357,12689,,2819,,13297,B,,
Autocuration,,1,,,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,CHEMBL617849,H,8,,,,,BAO_0000357,12689,,2820,,16633,B,,
Expert,,1,,,Binding affinity against rat 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,CHEMBL621507,H,8,,,,,BAO_0000357,12689,,2821,,16133,B,,
Expert,,1,,,Binding affinity at cloned rat 5-hydroxytryptamine 2C receptor using [3H]DOI as radioligand,,CHEMBL621508,H,8,,,,,BAO_0000357,12689,,2822,,16326,B,,
Autocuration,,1,,,Binding affinity against 5-hydroxytryptamine 2C receptor from rat cortex using [3H]mesulergine as the radioligand.,,CHEMBL621509,H,8,,,,,BAO_0000019,12689,,2823,,14423,B,,
Autocuration,,1,,,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex,,CHEMBL621510,H,8,,,,,BAO_0000019,12689,,2824,,15412,B,,
Autocuration,,1,,,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex.,,CHEMBL621511,H,8,,,,,BAO_0000019,12689,,2825,,15412,B,,
Expert,,1,A9,,Displacement of [3H]mesulergine from A9 cells stably expressing rat 5-hydroxytryptamine 2C receptor,,CHEMBL621512,H,8,,625.0,,,BAO_0000219,12689,,2826,,15558,B,,
Autocuration,,1,,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,CHEMBL621513,H,8,,,,,BAO_0000357,12689,,2827,,16633,B,,
Expert,,1,,,Binding affinity towards cloned rat 5-hydroxytryptamine 2C receptor from fundus tissue by [3H]mesulergine displacement.,,CHEMBL621514,H,8,,,,,BAO_0000357,12689,,2828,,6013,B,,
Expert,,1,,,Binding affinity towards rat 5-hydroxytryptamine 2C receptor expressed in A-9 cells using [3H]mesulergine as radioligand,,CHEMBL621515,H,8,,,,,BAO_0000219,12689,,2829,,17175,B,In vitro,
Autocuration,,1,,,Binding affinity was measured on 5-hydroxytryptamine 2C receptor in J1 cells transfected with rat 5-HT2C gene labeled with [3H]mesulergine,,CHEMBL621516,H,8,,,,,BAO_0000219,12689,,2830,,12469,B,,
Autocuration,,1,,,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2C receptor in homogenate of caudate putamen tissue from rat brain,,CHEMBL621517,H,8,,,,,BAO_0000019,12689,,2831,Caudate-putamen,3682,B,,5383.0
Autocuration,,1,,,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2C receptor in cloned rat cell culture,,CHEMBL621518,H,8,,,,,BAO_0000357,12689,,2832,,4932,B,,
Autocuration,,1,,,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2C receptor in cloned rat prefrontal cortex homogenate; ND denotes no data,,CHEMBL621519,H,8,,,,,BAO_0000019,12689,,2833,,4932,B,,
Autocuration,,1,,,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2C receptor,,CHEMBL621520,H,8,,,,,BAO_0000357,12689,,2834,,3935,B,,
Autocuration,,1,,,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2C receptor,,CHEMBL621521,H,8,,,,,BAO_0000357,12689,,2835,,15818,B,,
Autocuration,,1,,,Compound was evaluated for its binding affinity towards rat r5-hydroxytryptamine 2C receptor,,CHEMBL621522,H,8,,,,,BAO_0000357,12689,,2836,,15818,B,,
Expert,,1,,,Binding affinity against rat 5-hydroxytryptamine 2C receptor in A-9 cells.,,CHEMBL621523,H,8,,,,,BAO_0000219,12689,,2837,,14749,B,,
Autocuration,,1,,,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2C receptor,,CHEMBL621524,H,8,,,,,BAO_0000357,12689,,2838,,15740,B,,
Expert,,1,,,In vitro binding to 5-hydroxytryptamine 2C receptor using [125 I]-DOI,,CHEMBL621525,D,9,,,Rattus norvegicus,10116.0,BAO_0000357,12689,,2839,,17133,B,,
Autocuration,,1,,,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine,,CHEMBL872921,H,8,,,,,BAO_0000357,12689,,2840,,16532,B,,
Autocuration,,1,,,The compound evaluated for its affinity against 5-hydroxytryptamine 2C receptor,,CHEMBL621526,H,8,,,,,BAO_0000357,12689,,2841,,12369,B,,
Expert,,1,,,Affinity against 5-hydroxytryptamine 2C receptor in J1 cells transfected with the rat 5-HT2C gene labeled with [3H]mesulergine.,,CHEMBL621527,H,8,,,,,BAO_0000219,12689,,2842,,12369,B,,
Expert,,1,,,Binding affinity against 5-hydroxytryptamine 2C receptor in rat choroid plexus using [3H]N-methyl-mesulergine,,CHEMBL617865,D,9,,,Rattus norvegicus,10116.0,BAO_0000019,12689,,2843,,2309,B,,
Autocuration,,1,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor,,CHEMBL617866,H,8,,,,,BAO_0000357,12689,,2844,,12953,B,,
Autocuration,,1,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor from rat cortex using [3H]-citalopram as radioligand; Nonactive at 10 uM,,CHEMBL617867,H,8,,,,,BAO_0000019,12689,,2845,,12953,B,,
Autocuration,,1,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand; Nonactive at 10 uM,,CHEMBL617487,H,8,,,,,BAO_0000357,12689,,2846,,12953,B,,
Expert,,1,,,Binding affinity for 5-hydroxytryptamine 2C receptor,,CHEMBL617488,H,8,,,,,BAO_0000357,12689,,2847,,12953,B,,
Autocuration,,1,,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2C receptor using [125 I]-DOI as radioligand; Not determined,,CHEMBL617489,H,8,,,,,BAO_0000357,12689,,2848,,17133,B,,
Autocuration,,1,,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT denotes not tested,,CHEMBL617490,H,8,,,,,BAO_0000019,12689,,2849,,17211,B,,
Autocuration,,1,,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT=not tested,,CHEMBL617491,H,8,,,,,BAO_0000019,12689,,2850,,17211,B,,
Autocuration,,1,,,Affinity pKi for 5-hydroxytryptamine 2C receptor was measured in rat cortex homogenates.,,CHEMBL617492,H,8,,,,,BAO_0000019,12689,,2851,,14025,B,,
Autocuration,,1,,,Binding affinity against 5-hydroxytryptamine 2C receptor in rat cortex homogenates.,,CHEMBL617493,H,8,,,,,BAO_0000019,12689,,2852,,14998,B,,
Autocuration,,1,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2C receptor was determined,,CHEMBL617494,H,8,,,,,BAO_0000357,12689,,2853,,4342,B,,
Expert,,1,,,Displacement of [3H]mesulergine from rat 5-HT2C receptor expressed in HEK293,,CHEMBL617495,D,9,,,Rattus norvegicus,10116.0,BAO_0000019,12689,,2854,,13735,B,,
Autocuration,,1,,,Binding affinity was determined against cloned human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,,CHEMBL617496,H,8,,,,,BAO_0000357,12689,,2855,,13181,B,,
Autocuration,,1,CHO-K1,,Compound was evaluated for displacement of [3H]mesulergine from cloned rat 5-hydroxytryptamine 2C receptor in transfected CHO-K1 cells.,,CHEMBL617497,H,8,,485.0,,,BAO_0000219,12689,,2856,,1883,B,,
Autocuration,,1,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,CHEMBL617498,H,8,,,,,BAO_0000357,12689,,2857,,15194,B,,
Autocuration,,1,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand.,,CHEMBL617499,H,8,,,,,BAO_0000357,12689,,2858,,15194,B,,
Autocuration,,1,,,Compound tested for relative response using 0.1 uM 5-HT as agonist against 5-hydroxytryptamine 2C receptor,,CHEMBL617500,H,8,,,,,BAO_0000019,12689,,2859,,14579,F,,
Autocuration,,1,,,Compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,,CHEMBL617501,H,8,,,,,BAO_0000357,108,,2860,,4639,B,,
Expert,,1,,,Binding affinity towards 5-hydroxytryptamine 2C receptor,,CHEMBL617502,H,8,,,,,BAO_0000357,108,,2861,,4820,B,,
Autocuration,,1,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand; Not Tested,,CHEMBL617503,H,8,,,,,BAO_0000357,227,,2862,,14442,B,,
Autocuration,,1,,,Binding activity against cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand.,,CHEMBL617504,H,8,,,,,BAO_0000357,227,,2863,,14755,B,,
Autocuration,,1,,,Binding affinity against the cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand,,CHEMBL617406,H,8,,,,,BAO_0000357,227,,2864,,14744,B,,
Expert,,1,,,Affinity for human 5-hydroxytryptamine 2B receptor expressed in mammalian cell line,,CHEMBL617407,D,9,,,Homo sapiens,9606.0,BAO_0000019,227,,2865,,6857,B,,
Autocuration,,1,,,Binding affinity towards human 5-hydroxytryptamine 2B receptor using [3H]5-HT as radioligand,,CHEMBL617408,H,8,,,,,BAO_0000357,227,,2866,,16209,B,,
Autocuration,,1,,,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,,CHEMBL617409,H,8,,,,,BAO_0000357,227,,2867,,15363,B,,
Autocuration,,1,,,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,,CHEMBL617410,H,8,,,,,BAO_0000357,227,,2868,,15363,B,,
Autocuration,,1,,,Compound was tested for the displacement of [3H]5-HT from cloned human 5-hydroxytryptamine 2B receptor,,CHEMBL617411,H,8,,,,,BAO_0000357,227,,2869,,15363,B,,
Autocuration,,1,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2B receptor,,CHEMBL617412,H,8,,,,,BAO_0000019,227,,2870,,17085,B,,
Expert,,1,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2B receptor using with [125I]- DOI radioligand,,CHEMBL617774,D,9,,,Homo sapiens,9606.0,BAO_0000357,227,,2871,,17200,B,,
Expert,,1,HEK293,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,,CHEMBL617775,D,9,,722.0,Homo sapiens,9606.0,BAO_0000219,227,,2872,,15851,B,,
Expert,,1,HEK293,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,,CHEMBL617776,D,9,,722.0,Homo sapiens,9606.0,BAO_0000219,227,,2873,,15851,B,,
Expert,,1,CHO,,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,CHEMBL617777,D,9,,449.0,Homo sapiens,9606.0,BAO_0000219,227,,2874,,6857,F,,
Expert,,1,CHO,,Rleative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,CHEMBL617778,D,9,,449.0,Homo sapiens,9606.0,BAO_0000219,227,,2875,,6857,F,,
Autocuration,,1,HEK293,,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",,CHEMBL617779,H,8,,722.0,,,BAO_0000219,227,,2876,,15779,B,,
Expert,,1,HEK293,,Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells using [3H]5-HT as radioligand.,,CHEMBL617780,H,8,,722.0,,,BAO_0000219,227,,2877,,15851,B,,
Autocuration,,1,HEK293,,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand; no data",,CHEMBL617781,H,8,,722.0,,,BAO_0000219,227,,2878,,15779,B,,
Expert,,1,HEK293,,Displacement of [3H]5-HT from 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells,,CHEMBL617782,D,9,,722.0,Homo sapiens,9606.0,BAO_0000219,227,,2879,,14157,B,,
Expert,,1,HEK293,,Binding affinity to human cloned 5-HT2B receptor in HEK 293 cells using [3H]- -5-HT as radioligand,,CHEMBL617783,D,9,,722.0,Homo sapiens,9606.0,BAO_0000219,227,,2880,,4540,B,,
Autocuration,,1,,,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor was determined,,CHEMBL617784,H,8,,,,,BAO_0000357,227,,2881,,6166,B,,
Autocuration,,1,HEK293,,Binding affinity towards 5-hydroxytryptamine 2B receptor (human cloned receptor) in HEK 293 cells using [3H]5-HT as radioligand.,,CHEMBL617785,H,8,,722.0,,,BAO_0000219,227,,2882,,15779,B,,
Expert,,1,HEK293,,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells using [3H]5-HT as radioligand,,CHEMBL857984,H,8,,722.0,,,BAO_0000219,227,,2883,,14391,B,,
Expert,,1,HEK293,,Binding affinity towards human cloned 5-HT2B receptor of HEK293 cells by displacement of [3H]5-HT,,CHEMBL617786,H,8,,722.0,,,BAO_0000219,227,,2884,,3832,B,,
Expert,,1,HEK293,,In vitro binding affinity at human cloned 5-hydroxytryptamine 2B receptor of HEK293 cells by [3H]5-HT displacement.,,CHEMBL617787,H,8,,722.0,,,BAO_0000219,227,,2885,,3833,B,,
Expert,,1,HEK293,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells,,CHEMBL617788,D,9,,722.0,Homo sapiens,9606.0,BAO_0000219,227,,2886,,15851,B,,
Expert,,1,HEK293,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; compound is insoluble,,CHEMBL617789,D,9,,722.0,Homo sapiens,9606.0,BAO_0000219,227,,2887,,15851,B,,
Autocuration,,1,HEK293,,Compound was evaluated for binding affinity against human cloned 5-HT2B receptor in HEK 293 cells using [3H]5-HT as the radioligand,,CHEMBL617790,H,8,,722.0,,,BAO_0000219,227,,2888,,4199,B,,
Expert,,1,CHO-K1,,Displacement of [3H]-5-5HT from human cloned 5-hydroxytryptamine 2B receptor expressed in CHO-K1 cells,,CHEMBL617791,H,8,,485.0,,,BAO_0000219,227,,2889,,1883,B,,
Expert,,1,,,Binding affinity against 5-hydroxytryptamine 2B receptor,,CHEMBL617608,H,8,,,,,BAO_0000357,227,,2890,,4321,B,,
Autocuration,,1,HEK293,,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 2B receptor in HEK 293 cells using [3H]5-HT,,CHEMBL617609,H,8,,722.0,,,BAO_0000219,227,,2891,,15146,B,,
Autocuration,,1,HEK293,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2B receptor in HEK 293 using [3H]ketanserin as a radioligand,,CHEMBL617610,H,8,,722.0,,,BAO_0000219,227,,2892,,5213,B,,
Autocuration,,1,HEK293,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2B receptors in HEK293 cells using [3H]5-HT.,,CHEMBL617611,H,8,,722.0,,,BAO_0000219,227,,2893,,14818,B,,
Autocuration,,1,HEK293,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",,CHEMBL617612,H,8,,722.0,,,BAO_0000219,227,,2894,,4829,B,,
Autocuration,,1,HEK293,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",,CHEMBL617613,H,8,,722.0,,,BAO_0000219,227,,2895,,4829,B,,
Autocuration,,1,,,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 2B receptor in the endothelium intact rabbit jugular vein.,,CHEMBL617614,H,8,,,Oryctolagus cuniculus,9986.0,BAO_0000019,227,,2896,,14025,B,,
Expert,,1,,,Binding affinity analysed for 5-HT 2B receptor in rat stomach fundus,,CHEMBL617615,H,8,,,,,BAO_0000019,12688,,2897,Stomach,13463,B,,945.0
Expert,,1,,,Affinity against 5-hydroxytryptamine 2B receptor in the isolated rat stomach fundus,,CHEMBL858114,H,8,,,,,BAO_0000357,12688,,2898,Stomach,7259,B,,945.0
Autocuration,,1,,,Affinity against serotonergic receptor in the isolated rat stomach fundus,,CHEMBL617616,H,8,,,,,BAO_0000357,12688,,2899,Stomach,7259,B,,945.0
Expert,,1,,,Antagonistic activity against 5-hydroxytryptamine 2B receptor obtained from rat stomach fundus preparation,,CHEMBL617617,D,9,,,Rattus norvegicus,10116.0,BAO_0000019,12688,,2900,Stomach,7185,F,,945.0
Expert,,1,,,Antagonistic against 5-hydroxytryptamine 2B receptor,,CHEMBL875914,D,9,,,Rattus norvegicus,10116.0,BAO_0000019,12688,,2901,,7185,F,,
Autocuration,,1,,,Antagonistic affinity measured as pA2 value on 5-hydroxytryptamine 2B receptor of the rat stomach fundus,,CHEMBL617618,H,8,,,,,BAO_0000019,12688,,2902,Stomach,13267,F,,945.0
Expert,,1,,,Inhibition of 5-HT binding to 5-HT2B receptor of Rat stomach fundus,,CHEMBL617619,D,9,,,Rattus norvegicus,10116.0,BAO_0000357,12688,,2903,Stomach,13735,B,,945.0
Autocuration,,1,,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor,,CHEMBL617620,H,8,,,,,BAO_0000019,12688,,2904,,15738,F,,
Autocuration,,1,,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor; No data,,CHEMBL617621,H,8,,,,,BAO_0000019,12688,,2905,,15738,F,,
Autocuration,,1,,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B) receptor,,CHEMBL617622,H,8,,,,,BAO_0000019,12688,,2906,,15738,F,,
Expert,,1,,,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,,CHEMBL617623,D,9,,,Rattus norvegicus,10116.0,BAO_0000357,12688,,2907,Stomach,12936,B,,945.0
Expert,,1,,,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,,CHEMBL617624,D,9,,,Rattus norvegicus,10116.0,BAO_0000357,12688,,2908,Stomach,12936,B,,945.0
Expert,,1,,,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,,CHEMBL617625,D,9,,,Rattus norvegicus,10116.0,BAO_0000357,12688,,2909,Stomach,12936,B,,945.0
Expert,,1,,,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,,CHEMBL617626,D,9,,,Rattus norvegicus,10116.0,BAO_0000357,12688,,2910,Stomach,12936,B,,945.0
Autocuration,,1,,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,,CHEMBL617627,H,8,,,,,BAO_0000019,12688,,2911,Stomach,16404,F,,945.0
Expert,,1,,,Negative log concentration of antagonist was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,,CHEMBL617628,H,8,,,,,BAO_0000019,12688,,2912,Stomach,16404,F,,945.0
Autocuration,,1,,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is No Data.,,CHEMBL617629,H,8,,,,,BAO_0000019,12688,,2913,Stomach,16404,F,,945.0
Autocuration,,1,,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is not determined.,,CHEMBL858115,H,8,,,,,BAO_0000019,12688,,2914,Stomach,16404,F,,945.0
Expert,,1,,,Antagonistic activity on 5-hydroxytryptamine 2B receptor of Rat stomach fundus;ND is not determined,,CHEMBL617630,D,9,,,Rattus norvegicus,10116.0,BAO_0000019,12688,,2915,Stomach,16404,F,,945.0
Autocuration,,1,,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat thoracic aorta; ND is not determined,,CHEMBL617631,H,8,,,,,BAO_0000019,12688,,2916,Thoracic aorta,16404,F,,1515.0
Autocuration,,1,,,The binding affinity of compound to 5-HT receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,,CHEMBL617632,H,8,,,,,BAO_0000357,12688,,2917,,7483,B,,
Expert,,1,,,The binding affinity to 5-hydroxytryptamine 2B receptor of rat fundus,,CHEMBL617633,H,8,,,,,BAO_0000357,12688,,2918,,7483,B,,
Autocuration,,1,,,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,,CHEMBL617634,H,8,,,,,BAO_0000357,12688,,2919,,7483,B,,
Autocuration,,1,,,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus; Unable to determine valid PA2 value due to slope of Schild plot,,CHEMBL617635,H,8,,,,,BAO_0000357,12688,,2920,,7483,B,,
Autocuration,,1,,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,,CHEMBL617637,D,9,,,Rattus norvegicus,10116.0,BAO_0000019,12688,,2922,Stomach,16404,F,,945.0
Autocuration,,1,,,Binding affinity against 5-hydroxytryptamine 1A receptor,,CHEMBL617638,H,8,,,,,BAO_0000357,227,,2923,,6347,B,,
Autocuration,,1,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2B receptor was determined,,CHEMBL617639,H,8,,,,,BAO_0000357,227,,2924,,4373,B,,
Autocuration,,1,,,Binding affinity for 5-hydroxytryptamine 2B receptor was determined,,CHEMBL617640,H,8,,,,,BAO_0000357,227,,2925,,4373,B,,
Autocuration,,1,,,Evaluated for the binding affinity to 5-HT 2B receptor,,CHEMBL617641,H,8,,,,,BAO_0000357,227,,2926,,4687,B,,
Autocuration,,1,,,Ability to displace [3H]5-HT from 5-hydroxytryptamine 2B receptor,,CHEMBL617642,H,8,,,,,BAO_0000357,227,,2927,,16946,B,,
Autocuration,,1,,,Binding affinities against 5-hydroxytryptamine 2B receptor,,CHEMBL617643,H,8,,,,,BAO_0000357,227,,2928,,16633,B,,
Autocuration,,1,,,Binding affinities towards 5-hydroxytryptamine 2B receptor,,CHEMBL617644,H,8,,,,,BAO_0000357,227,,2929,,16633,B,,
Autocuration,,1,,,Binding affinity towards 5-hydroxytryptamine 2B receptor using [125I]DOI as radioligand,,CHEMBL617645,H,8,,,,,BAO_0000357,227,,2930,,16633,B,,
Expert,,1,,,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,,CHEMBL617646,H,8,,,,,BAO_0000357,108,,2931,,15026,B,,
Autocuration,,1,,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,,CHEMBL617647,H,8,,,Bos taurus,9913.0,BAO_0000357,108,,2932,,15738,B,,
Autocuration,,1,,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10E-6 M,,CHEMBL617648,H,8,,,Bos taurus,9913.0,BAO_0000357,108,,2933,,15738,B,,
Autocuration,,1,,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10e-6 M,,CHEMBL617875,H,8,,,Bos taurus,9913.0,BAO_0000357,108,,2934,,15738,B,,
Autocuration,,1,,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at concentration of 10e-6 M,,CHEMBL617876,H,8,,,Bos taurus,9913.0,BAO_0000357,108,,2935,,15738,B,,
Expert,,1,,,Inhibitory constant was determined on 5-hydroxytryptamine 2C receptor of Bovine choroid plexus,,CHEMBL617877,H,8,,,Bos taurus,9913.0,BAO_0000357,108,,2936,,16404,B,,
Expert,,1,,,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,,CHEMBL617878,H,8,,,Bos taurus,9913.0,BAO_0000357,108,,2937,,15026,B,,
Autocuration,,1,,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,,CHEMBL617879,H,8,,,Bos taurus,9913.0,BAO_0000357,108,,2938,,15738,B,,
Autocuration,,1,,,Binding affinity against guinea pig cortex 5-HT2C receptor in the presence of [3H]mesulergine,,CHEMBL617880,H,8,,,Cavia porcellus,10141.0,BAO_0000019,108,,2939,,16312,B,,
Intermediate,,1,,,Binding affinity towards 5-HT4 receptor by the displacement of [3H]GR-113808 in guinea-pig striatum,,CHEMBL617881,D,9,,,Cavia porcellus,10141.0,BAO_0000357,20033,,2940,Striatum,5486,B,,2435.0
Autocuration,,1,,,Binding affinity against 5-HT1A receptor,,CHEMBL857073,H,8,,,,,BAO_0000357,51,,2941,,5254,B,,
Expert,,1,CHO,,Agonistic activity for 5-HT2c (5-HT2C) by measuring [3H]inositol monophosphate fromation in CHO cells in which the human 5-HT2C receptor subtype was stably expressed,,CHEMBL617882,H,8,,449.0,,,BAO_0000219,108,,2942,,3857,F,,
Expert,,1,CHO,,Functional activity against human 5-hydroxytryptamine 2C receptor expressed in CHO cells using fluorometric imaging plate reader,,CHEMBL617883,D,9,,449.0,Homo sapiens,9606.0,BAO_0000219,108,,2943,,6857,F,,
Autocuration,,1,,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2c receptor cell line,,CHEMBL617884,H,8,,,,,BAO_0000219,108,,2944,,4176,F,,
Autocuration,,1,CHO,,Agonistic binding efficacy against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand,,CHEMBL617885,H,8,,449.0,,,BAO_0000219,108,,2945,,6347,B,,
Autocuration,,1,CHO,,"Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand, expressed as Emax",,CHEMBL617886,H,8,,449.0,,,BAO_0000219,108,,2946,,6347,B,,
Expert,,1,,,Inhibition of human 5-hydroxytryptamine 2C receptor,,CHEMBL617887,D,9,,,Homo sapiens,9606.0,BAO_0000357,108,,2947,,16146,B,,
Autocuration,,1,,,In vitro binding affinity against human 5-hydroxytryptamine 2C receptor at a concentration of 100 (nM),,CHEMBL617888,H,8,,,,,BAO_0000357,108,,2948,,3805,B,,
Autocuration,,1,,,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,,CHEMBL617889,H,8,,,,,BAO_0000019,108,,2949,,3857,B,,
Autocuration,,1,,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor,,CHEMBL617890,H,8,,,,,BAO_0000357,108,,2950,,5635,B,,
Autocuration,,1,,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,,CHEMBL617891,H,8,,,,,BAO_0000357,108,,2951,,5635,B,,
Autocuration,,1,,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,,CHEMBL617892,H,8,,,,,BAO_0000357,108,,2952,,5635,B,,
Expert,,1,CHO,,Displacement of [H]-mesulergine from CHO cells expressing human 5-hydroxytryptamine 2C receptor.,,CHEMBL617893,H,8,,449.0,,,BAO_0000219,108,,2953,,4012,B,,
Expert,,1,CHO,,Ability to displace [3H]- mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells,,CHEMBL617894,H,8,,449.0,,,BAO_0000219,108,,2954,,6366,B,,
Expert,,1,CHO,,Ability to displace [3H]mesulergine binding to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,,CHEMBL617895,H,8,,449.0,,,BAO_0000219,108,,2955,,15949,B,,
Autocuration,,1,CHO,,Ability to displace [3H]mesulergine (0.5 nM) from CHO cells of human 5-hydroxytryptamine 2C receptor,,CHEMBL617896,H,8,,449.0,,,BAO_0000219,108,,2956,,17211,B,,
Expert,,1,,,Affinity towards human 5-hydroxytryptamine 2C serotonin receptor,,CHEMBL617897,D,9,,,Homo sapiens,9606.0,BAO_0000357,108,,2957,,6491,B,,
Autocuration,,1,,,Agonist activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand,,CHEMBL617898,H,8,,,,,BAO_0000019,108,,2958,,14093,F,,
Autocuration,,1,,,Agonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,CHEMBL617899,H,8,,,,,BAO_0000019,108,,2959,,13481,F,,
Expert,,1,CHO,,Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI ,,CHEMBL617900,H,8,,449.0,Rattus norvegicus,10116.0,BAO_0000219,108,,2960,,6347,B,,
Autocuration,,1,,,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand,,CHEMBL617901,H,8,,,,,BAO_0000019,108,,2961,,14093,F,,
Autocuration,,1,,,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand; Not tested,,CHEMBL617902,H,8,,,,,BAO_0000019,108,,2962,,14093,F,,
Autocuration,,1,,,Antagonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,CHEMBL617903,H,8,,,,,BAO_0000019,108,,2963,,13481,F,,
Autocuration,,1,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [125 I]DOI as radioligand,,CHEMBL617904,H,8,,,,,BAO_0000357,108,,2964,,14442,B,,
Autocuration,,1,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand,,CHEMBL617905,H,8,,,,,BAO_0000357,108,,2965,,14442,B,,
Autocuration,,1,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand;not tested,,CHEMBL617906,H,8,,,,,BAO_0000357,108,,2966,,14442,B,,
Autocuration,,1,,,Binding activity against cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand.,,CHEMBL617907,H,8,,,,,BAO_0000357,108,,2967,,14755,B,,
Autocuration,,1,,,Binding affinity against the cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand,,CHEMBL617908,H,8,,,,,BAO_0000357,108,,2968,,14744,B,,
Expert,,1,CHO,,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,,CHEMBL620617,H,8,,449.0,,,BAO_0000219,108,,2969,,16659,B,,
Expert,,1,,,Affinity for human 5-hydroxytryptamine 2C receptor expressed in mammalian cell line,,CHEMBL620618,D,9,,,Homo sapiens,9606.0,BAO_0000019,108,,2970,,6857,B,,
Expert,,1,,,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand.,,CHEMBL620619,H,8,,,,,BAO_0000357,108,,2971,,5635,B,,
Expert,,1,,,Binding affinity to cloned human 5-hydroxytryptamine 2C receptor,,CHEMBL620620,D,9,,,Homo sapiens,9606.0,BAO_0000357,108,,2972,,4234,B,,
Autocuration,,1,,,Binding affinity towards human 5-HT2C receptor was determined using [125I]- DOI as radioligand,,CHEMBL620621,H,8,,,,,BAO_0000357,108,,2973,,16209,B,,
Autocuration,,1,,,Binding affinity for 5-HT3 receptor by displacement of [3H]-LY 278584 in rat cerebral cortex membranes,Membranes,CHEMBL872920,D,7,,,Rattus norvegicus,10116.0,BAO_0000249,104698,,2974,,5778,B,,
Autocuration,,1,,,Binding affinity towards rat 5-hydroxytryptamine 3 receptor was evaluated,,CHEMBL620622,H,6,,,,,BAO_0000223,104698,,2975,,5094,B,,
Autocuration,,1,,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 in rat posterior cortex,,CHEMBL620623,D,7,,,Rattus norvegicus,10116.0,BAO_0000019,104698,,2976,,809,B,,
Autocuration,,1,,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex,,CHEMBL620624,H,6,,,,,BAO_0000019,104698,,2977,,1578,B,,
Autocuration,,1,,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex; Not tested,,CHEMBL620625,H,6,,,,,BAO_0000019,104698,,2978,,809,B,,
Autocuration,,1,,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor in NG-108 cells labeled with [3H]GR-65630,,CHEMBL620626,H,6,,,,,BAO_0000219,104698,,2979,,12469,B,,
Autocuration,,1,,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex,,CHEMBL621307,H,6,,,,,BAO_0000019,104698,,2980,,14290,B,,
Autocuration,,1,,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex.,,CHEMBL621308,H,6,,,,,BAO_0000019,104698,,2981,,14290,B,,
Autocuration,,1,,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-5-HT,,CHEMBL621309,H,6,,,,,BAO_0000223,104698,,2982,,10609,B,,
Autocuration,,1,,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]GR-65630,,CHEMBL621310,H,6,,,,,BAO_0000223,104698,,2983,,10609,B,,
Autocuration,,1,,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-ketanserin,,CHEMBL621311,H,6,,,,,BAO_0000223,104698,,2984,,10609,B,,
Autocuration,,1,,,"Compound was evaluated for its in vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",,CHEMBL621502,H,6,,,,,BAO_0000249,104698,,2985,,15253,B,,
Autocuration,,1,,,"In vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",,CHEMBL621503,H,6,,,,,BAO_0000249,104698,,2986,,15253,B,,
Autocuration,,1,,,Displacement of the 5-hydroxytryptamine 3 receptor ligand [3H]GR-65630 from rat brain cortical membranes.,Membranes,CHEMBL621504,H,6,,,,,BAO_0000249,104698,,2987,,11683,B,,
Autocuration,,1,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor,,CHEMBL621505,H,6,,,,,BAO_0000223,104698,,2988,,12092,B,,
Autocuration,,1,,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,,CHEMBL621506,H,6,,,,,BAO_0000019,104698,,2989,,1946,B,,
Autocuration,,1,,,Ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15.,,CHEMBL619781,H,6,,,,,BAO_0000223,104698,,2990,,11623,B,,
Autocuration,,1,,,Compound was evaluated for its ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15. ,,CHEMBL619782,H,6,,,,,BAO_0000223,104698,,2991,,11623,B,,
Autocuration,,1,,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex,,CHEMBL619783,H,6,,,,,BAO_0000019,104698,,2992,,14788,B,,
Autocuration,,1,,,Displacement of [3H]ketanserin from rat cortex 5-HT3 receptor,,CHEMBL619784,D,7,,,Rattus norvegicus,10116.0,BAO_0000019,104698,,2993,,5432,B,,
Autocuration,,1,,,Ability to displace [3H]granisetron specifically bound to 5-hydroxytryptamine 3 receptor in rat cortical membrane,,CHEMBL619785,H,6,,,,,BAO_0000249,104698,,2994,,14826,B,,
Autocuration,,1,,,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,,CHEMBL619786,H,6,,,,,BAO_0000223,104698,,2995,,2222,B,,
Autocuration,,1,,,Displacement of binding of [3H]-BRL 43694 to 5-hydroxytryptamine 3 receptor in rat cerebral cortex,,CHEMBL619787,H,6,,,,,BAO_0000019,104698,,2996,,11963,B,,
Autocuration,,1,,,In vitro affinity for 5-hydroxytryptamine 3 (5-HT3) receptor by displacement of [3H]BRL-43694 from rat entorhinal cortex,,CHEMBL872925,H,6,,,,,BAO_0000019,104698,,2997,,14145,B,,
Autocuration,,1,,,In vitro binding affinity at serotonin 5-hydroxytryptamine 3 receptor in rat cortex by [3H]granisetron displacement.,,CHEMBL619788,H,6,,,,,BAO_0000019,104698,,2998,,17819,B,,
Autocuration,,1,,,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]- 1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,,CHEMBL619789,H,6,,,,,BAO_0000249,104698,,2999,,10394,B,,
Autocuration,,1,,,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]-1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,,CHEMBL619790,H,6,,,,,BAO_0000249,104698,,3000,,10394,B,,
Autocuration,,1,,,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,,CHEMBL619791,H,6,,,,,BAO_0000019,104698,,3001,,15034,B,,
Autocuration,,1,,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,,CHEMBL619792,H,6,,,,,BAO_0000019,104698,,3002,,691,B,,
Autocuration,,1,,,Displacement of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortical membranes,Membranes,CHEMBL619793,H,6,,,,,BAO_0000249,104698,,3003,,12092,B,,
Autocuration,,1,,,Inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor,,CHEMBL619794,D,7,,,Rattus norvegicus,10116.0,BAO_0000223,104698,,3004,,11752,B,,
Autocuration,,1,,,The ability to inhibit [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortices,,CHEMBL619795,H,6,,,,,BAO_0000221,104698,,3005,Brain,11752,B,,955.0
Autocuration,,1,,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat posterior cortex by [3H]-BRL 43694 displacement.,,CHEMBL619796,H,6,,,,,BAO_0000019,104698,,3006,,301,B,,
Autocuration,,1,,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584,,CHEMBL620448,H,6,,,,,BAO_0000223,104698,,3007,,16532,B,,
Autocuration,,1,,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,,CHEMBL620449,H,6,,,,,BAO_0000223,104698,,3008,,16532,B,,
Autocuration,,1,,,The binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand.,,CHEMBL620450,H,6,,,,,BAO_0000223,104698,,3009,,12092,B,,
Autocuration,,1,,,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630,,CHEMBL620451,H,6,,,,,BAO_0000223,104698,,3010,,11684,B,,
Autocuration,,1,,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630.,,CHEMBL620631,H,6,,,,,BAO_0000223,104698,,3011,,11684,B,,
Autocuration,,1,,,Binding affinity for 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand,,CHEMBL620632,H,6,,,,,BAO_0000019,104698,,3012,,12953,B,,
Autocuration,,1,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand; NA means Not active,,CHEMBL620633,H,6,,,,,BAO_0000019,104698,,3013,,12953,B,,
Autocuration,,1,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 3 receptor; Nonactive at 10 uM,,CHEMBL620634,H,6,,,,,BAO_0000223,104698,,3014,,12953,B,,
Autocuration,,1,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,,CHEMBL620635,H,6,,,,,BAO_0000019,104698,,3015,,12861,B,,
Autocuration,,1,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 0.5 hours in urethane-anesthetized rats,,CHEMBL620636,H,6,,,,,BAO_0000218,104698,,3016,,11454,F,In vivo,
Autocuration,,1,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 1 hour in urethane-anesthetized rats,,CHEMBL620637,H,6,,,,,BAO_0000218,104698,,3017,,11454,F,In vivo,
Autocuration,,1,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 3 hours in urethane-anesthetized rats,,CHEMBL620638,H,6,,,,,BAO_0000218,104698,,3018,,11454,F,In vivo,
Autocuration,,1,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 6 hours in urethane-anesthetized rats,,CHEMBL620639,H,6,,,,,BAO_0000218,104698,,3019,,11454,F,In vivo,
Autocuration,,1,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 0.5 hours in urethane-anesthetized rats,,CHEMBL620640,H,6,,,,,BAO_0000218,104698,,3020,,11454,F,In vivo,
Autocuration,,1,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 1 hour in urethane-anesthetized rats,,CHEMBL620641,H,6,,,,,BAO_0000218,104698,,3021,,11454,F,In vivo,
Autocuration,,1,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 16 hours in urethane-anesthetized rats,,CHEMBL620642,H,6,,,,,BAO_0000218,104698,,3022,,11454,F,In vivo,
Autocuration,,1,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 3 hours in urethane-anesthetized rats,,CHEMBL620643,H,6,,,,,BAO_0000218,104698,,3023,,11454,F,In vivo,
Autocuration,,1,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 6 hours in urethane-anesthetized rats,,CHEMBL620644,H,6,,,,,BAO_0000218,104698,,3024,,11454,F,In vivo,
Autocuration,,1,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 0.5 hours in urethane-anesthetized rats,,CHEMBL620645,H,6,,,,,BAO_0000218,104698,,3025,,11454,F,In vivo,
Autocuration,,1,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 1 hour in urethane-anesthetized rats,,CHEMBL620646,H,6,,,,,BAO_0000218,104698,,3026,,11454,F,In vivo,
Autocuration,,1,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 3 hours in urethane-anesthetized rats,,CHEMBL620647,H,6,,,,,BAO_0000218,104698,,3027,,11454,F,In vivo,
Autocuration,,1,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 6 hours in urethane-anesthetized rats,,CHEMBL620648,H,6,,,,,BAO_0000218,104698,,3028,,11454,F,In vivo,
Autocuration,,1,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 0.5 hours in urethane-anesthetized rats,,CHEMBL620649,H,6,,,,,BAO_0000218,104698,,3029,,11454,F,In vivo,
Autocuration,,1,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 3 hours in urethane-anesthetized rats,,CHEMBL620650,H,6,,,,,BAO_0000218,104698,,3030,,11454,F,In vivo,
Autocuration,,1,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 1 hour in urethane-anesthetized rats,,CHEMBL620651,H,6,,,,,BAO_0000218,104698,,3031,,11454,F,In vivo,
Autocuration,,1,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 3 hours in urethane-anesthetized rats,,CHEMBL872875,H,6,,,,,BAO_0000218,104698,,3032,,11454,F,In vivo,
Autocuration,,1,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 1 hour in urethane-anesthetized rats,,CHEMBL620652,H,6,,,,,BAO_0000218,104698,,3033,,11454,F,In vivo,
Autocuration,,1,,,5-hydroxytryptamine 3 receptor antagonist activity was confirmed by its ability to antagonize 5-HT evoked tachycardia of rabbit isolated heart,,CHEMBL620653,H,6,,,,,BAO_0000019,104698,,3034,,10609,F,,
Autocuration,,1,,,Binding activity against 5-hydroxytryptamine 2A receptor from rat cortex homogenates using [3H]DOB as radioligand.,,CHEMBL857076,H,6,,,,,BAO_0000019,104698,,3035,,12861,B,,
Autocuration,,1,,,Inhibition of [3H]-Q-ICS 205-930 binding to rat cortex homogenate 5-hydroxytryptamine 3 receptor,,CHEMBL620654,D,7,,,Rattus norvegicus,10116.0,BAO_0000019,104698,,3036,,12861,B,,
Autocuration,,1,,,Binding activity radioligand.,,CHEMBL620655,H,6,,,,,BAO_0000223,104698,,3037,,12861,B,,
Autocuration,,1,,,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor in rat brain membranes,Brain membranes,CHEMBL620656,H,6,,,,,BAO_0000249,104698,,3038,,10728,B,,
Autocuration,,1,,,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes.,Brain membranes,CHEMBL620657,H,6,,,,,BAO_0000249,104698,,3039,,10728,B,,
Autocuration,,1,,,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.000001 mol/L,,CHEMBL620658,H,8,,,,,BAO_0000357,108,,3040,,5163,B,,
Autocuration,,1,,,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.00001 mol/L,,CHEMBL620659,H,8,,,,,BAO_0000357,108,,3041,,5163,B,,
Autocuration,,1,,,Inhibition of binding towards 5-hydroxytryptamine 2C receptor at 100 nM concentration,,CHEMBL620660,H,8,,,,,BAO_0000357,108,,3042,,6011,B,,
Autocuration,,1,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2C receptor,,CHEMBL620661,H,8,,,,,BAO_0000357,108,,3043,,5014,B,,
Autocuration,,1,,,Binding affinity of compound towards 5-hydroxytryptamine 2C receptor,,CHEMBL620662,H,8,,,,,BAO_0000357,108,,3044,,5635,B,,
Expert,,1,,,Affinity for 5-hydroxytryptamine 2C receptor,,CHEMBL620663,H,8,,,,,BAO_0000357,108,,3045,,5163,B,,
Autocuration,,1,,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,CHEMBL620664,H,8,,,,,BAO_0000357,108,,3046,,6841,B,,
Expert,,1,,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand.,,CHEMBL620665,H,8,,,,,BAO_0000357,108,,3047,,6119,B,,
Autocuration,,1,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2C receptor was determined,,CHEMBL620666,H,8,,,,,BAO_0000357,108,,3048,,4373,B,,
Autocuration,,1,,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]-Ketanserin,,CHEMBL620667,H,8,,,,,BAO_0000357,108,,3049,,1633,B,,
Expert,,1,,,Binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]N-methyl-mesulergine,,CHEMBL620668,H,8,,,,,BAO_0000357,108,,3050,,1633,B,,
Autocuration,,1,,,Binding affinity for 5-hydroxytryptamine 2C receptor was determined,,CHEMBL620669,H,8,,,,,BAO_0000357,108,,3051,,4373,B,,
Expert,,1,,,Binding affinity towards serotonin 5-hydroxytryptamine 2C receptor,,CHEMBL620670,H,8,,,,,BAO_0000357,108,,3052,,6576,B,,
Autocuration,,1,,,Evaluated for the binding affinity to 5-hydroxytryptamine 2C receptor,,CHEMBL620671,H,8,,,,,BAO_0000357,108,,3053,,4687,B,,
Autocuration,,1,,,Tested agains t5-hydroxytryptamine 2C receptor in experiment 1,,CHEMBL620672,H,8,,,,,BAO_0000357,108,,3054,,12146,B,,
Autocuration,,1,,,Tested against 5-hydroxytryptamine 2C receptor in experiment 2,,CHEMBL620673,H,8,,,,,BAO_0000357,108,,3055,,12146,B,,
Autocuration,,1,,,Ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor,,CHEMBL620674,H,8,,,,,BAO_0000357,108,,3056,,16946,B,,
Autocuration,,1,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 2C receptor,,CHEMBL620675,H,8,,,,,BAO_0000357,108,,3057,,14159,B,,
Autocuration,,1,,,The binding affinity towards 5-hydroxytryptamine 2C receptor; No affinity,,CHEMBL620676,H,8,,,,,BAO_0000357,108,,3058,,16700,B,,
Autocuration,,1,,,Affinity against 5-hydroxytryptamine 2C receptor,,CHEMBL621382,H,8,,,,,BAO_0000357,108,,3059,,3269,B,,
Expert,,1,,,Binding affinity against 5-hydroxytryptamine 2C receptor,,CHEMBL621383,D,9,,,Homo sapiens,9606.0,BAO_0000357,108,,3060,,1274,B,,
Autocuration,,1,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2C receptor using radioligand binding assay,,CHEMBL621384,H,8,,,,,BAO_0000357,108,,3061,,1317,B,,
Autocuration,,1,,,Inhibitory concentration required against 5-HT3 receptor in bovine area postrema using [3H]GR-65630,,CHEMBL621385,H,8,,,Bos taurus,9913.0,BAO_0000357,144,,3062,,5834,B,,
Autocuration,,1,,,Binding affinity towards 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand,,CHEMBL617989,H,8,,,Bos taurus,9913.0,BAO_0000357,144,,3063,,11147,B,,
Expert,,1,,,Antagonistic potency against serotonin 5-hydroxytryptamine 3 receptor in GPI assay,,CHEMBL617990,H,4,,,Cavia porcellus,10141.0,BAO_0000019,104714,,3064,,14145,F,,
Autocuration,,1,,,Binding affinity to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,,CHEMBL875085,H,4,,,Cavia porcellus,10141.0,BAO_0000221,104714,,3065,Ileum,10561,B,,2116.0
Autocuration,,1,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig,,CHEMBL617991,H,4,,,Cavia porcellus,10141.0,BAO_0000019,104714,,3066,,15847,F,,
Autocuration,,1,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig; ND means not done,,CHEMBL617992,H,4,,,Cavia porcellus,10141.0,BAO_0000019,104714,,3067,,15847,F,,
Autocuration,,1,,,Potency to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,,CHEMBL617993,H,4,,,Cavia porcellus,10141.0,BAO_0000221,104714,,3068,Ileum,10561,B,,2116.0
Autocuration,,1,,,In vitro binding affinity was measured for 5-hydroxytryptamine 3 receptor in the guinea pig ileum.,,CHEMBL617994,H,4,,,Cavia porcellus,10141.0,BAO_0000221,104714,,3069,Ileum,11454,B,,2116.0
Autocuration,,1,,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea colon at a concentration 0.01 uM,,CHEMBL617995,H,4,,,Cavia porcellus,10141.0,BAO_0000019,104714,,3070,,4639,F,,
Autocuration,,1,,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.1 uM,,CHEMBL617996,H,4,,,Cavia porcellus,10141.0,BAO_0000019,104714,,3071,,4639,F,,
Autocuration,,1,,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM,,CHEMBL617997,H,4,,,Cavia porcellus,10141.0,BAO_0000019,104714,,3072,,4639,F,,
Autocuration,,1,,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM in the presence of 30 uM MDL 72222,,CHEMBL617998,H,4,,,Cavia porcellus,10141.0,BAO_0000019,104714,,3073,,4639,F,,
Autocuration,,1,,,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 0.01 uM,,CHEMBL617999,H,4,,,Cavia porcellus,10141.0,BAO_0000019,104714,,3074,,4639,F,,
Autocuration,,1,,,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 1 uM,,CHEMBL618000,H,4,,,Cavia porcellus,10141.0,BAO_0000019,104714,,3075,,4639,F,,
Autocuration,,1,,,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum",,CHEMBL617815,H,4,,,Cavia porcellus,10141.0,BAO_0000221,104714,,3076,Ileum,15253,F,,2116.0
Autocuration,,1,,,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum.",,CHEMBL617816,H,4,,,Cavia porcellus,10141.0,BAO_0000221,104714,,3077,Ileum,15253,F,,2116.0
Autocuration,,1,,,Tested for the antagonistic activity against 5-hydroxytryptamine 3 receptor from guinea pig ileum,,CHEMBL617817,H,4,,,Cavia porcellus,10141.0,BAO_0000221,104714,,3078,Ileum,11963,F,,2116.0
Autocuration,,1,,,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum,,CHEMBL617818,H,4,,,Cavia porcellus,10141.0,BAO_0000221,104714,,3079,Ileum,1946,B,,2116.0
Autocuration,,1,,,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum; Not tested,,CHEMBL617819,H,4,,,Cavia porcellus,10141.0,BAO_0000221,104714,,3080,Ileum,1946,B,,2116.0
Autocuration,,1,,,Binding affinity towards [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in HG108-15,,CHEMBL617820,H,4,,,Cavia porcellus,10141.0,BAO_0000223,104714,,3081,,12045,B,,
Autocuration,,1,,,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,,CHEMBL617821,H,4,,,Cavia porcellus,10141.0,BAO_0000221,104714,,3082,Ileum,1559,B,,2116.0
Autocuration,,1,,,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),,CHEMBL617822,H,4,,,Cavia porcellus,10141.0,BAO_0000221,104714,,3083,Ileum,273,F,,2116.0
Autocuration,,1,,,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor of isolated guinea pig ileum (GPI),,CHEMBL617823,H,4,,,Cavia porcellus,10141.0,BAO_0000221,104714,,3084,Ileum,273,F,,2116.0
Autocuration,,1,,,Tested for antagonistic activity on 5-hydroxytryptamine 3 receptor mediated effects of 5-HT in guinea pig isolated ileum,,CHEMBL617824,H,4,,,Cavia porcellus,10141.0,BAO_0000221,104714,,3085,Ileum,188,F,,2116.0
Autocuration,,1,,,Agonistic activity against 5-hydroxytryptamine 3 receptor in guinea pig ileum assay,,CHEMBL617825,H,4,,,Cavia porcellus,10141.0,BAO_0000221,104714,,3086,Ileum,12919,F,,2116.0
Autocuration,,1,,,5-hydroxytryptamine 3 receptor agonism in the guinea pig ileum by functional 5-HT3 receptor assay,,CHEMBL617826,H,4,,,Cavia porcellus,10141.0,BAO_0000221,104714,,3087,Ileum,12918,F,,2116.0
Autocuration,,1,,,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,,CHEMBL617827,H,4,,,Cavia porcellus,10141.0,BAO_0000221,104714,,3088,Ileum,1559,B,,2116.0
Autocuration,,1,,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),,CHEMBL617828,H,4,,,Cavia porcellus,10141.0,BAO_0000221,104714,,3089,Ileum,273,F,,2116.0
Autocuration,,1,,,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,,CHEMBL617829,H,4,,,Cavia porcellus,10141.0,BAO_0000221,104714,,3090,Ileum,1559,B,,2116.0
Autocuration,,1,,,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum; Not determined,,CHEMBL617830,H,4,,,Cavia porcellus,10141.0,BAO_0000221,104714,,3091,Ileum,1559,B,,2116.0
Autocuration,,1,,,Binding affinity towards 5-hydroxytryptamine 3 receptor of guinea pig ileum; not determined,,CHEMBL617831,H,4,,,Cavia porcellus,10141.0,BAO_0000221,104714,,3092,Ileum,1559,B,,2116.0
Autocuration,,1,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor in guinea pig ileum.,,CHEMBL617832,H,4,,,Cavia porcellus,10141.0,BAO_0000221,104714,,3093,Ileum,14424,B,,2116.0
Autocuration,,1,,,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,,CHEMBL617833,U,0,,,Cavia porcellus,10141.0,BAO_0000019,22226,,3094,,13181,B,,
Autocuration,,1,,,Binding affinity towards 5-HT1A receptor by the displacement of [3H]-8-OH-DPAT] in human recombinant receptors in mammalian cell,,CHEMBL617834,H,8,,,,,BAO_0000357,51,,3095,,5486,B,,
Expert,,1,,,Affinity towards human 5-hydroxytryptamine 3 serotonin receptor,,CHEMBL617835,D,5,,,Homo sapiens,9606.0,BAO_0000223,104714,,3096,,6491,B,,
Autocuration,,1,,,Binding affinity towards 5-HT3 receptor,,CHEMBL617836,H,4,,,,,BAO_0000223,104714,,3097,,6013,B,,
Autocuration,,1,,,Binding activity radioligand.,,CHEMBL617837,H,4,,,,,BAO_0000223,104714,,3098,,12861,B,,
Autocuration,,1,,,Binding activity against 5-hydroxytryptamine 1A receptor from human brain cortex using [3H]8-OH-DPAT-HT as radioligand.,,CHEMBL620392,H,4,,,,,BAO_0000019,104714,,3099,,12861,B,,
Autocuration,,1,,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,,CHEMBL620393,H,4,,,,,BAO_0000223,104714,,3100,,5104,B,,
Autocuration,,1,,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,,CHEMBL620394,H,4,,,,,BAO_0000223,104714,,3101,,5105,B,,
Autocuration,,1,,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor; NT means Not tested,,CHEMBL620395,H,4,,,,,BAO_0000223,104714,,3102,,5104,B,,
Autocuration,,1,,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 3 receptor,,CHEMBL620396,U,0,,,,,BAO_0000019,22226,,3103,,3935,B,,
Expert,,1,NG108-15,,Displacement of [3H]-BRC 36694 from 5-hydroxytryptamine 3 receptor in NG108-15 cells,,CHEMBL620582,H,4,,433.0,,,BAO_0000219,105030,,3104,,13657,B,,
Autocuration,,1,,,"Percent inhibition of [3H]5 binding to 5-hydroxytryptamine 3 receptor was evaluated by injection of compound (75 microCi/kg, 1.32 ug/kg) into the tail vein of mice (in vivo)",,CHEMBL620583,H,4,,,,,BAO_0000218,105030,,3105,,10369,B,In vivo,
Autocuration,,1,,,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),,CHEMBL620584,H,4,,,,,BAO_0000019,105030,,3106,,10369,B,,
Autocuration,,1,,,Compound was evaluated for the binding affinity at 5- HT3 receptor subtype,,CHEMBL620585,H,4,,,,,BAO_0000224,105030,,3107,,12918,B,,
Autocuration,,1,,,Compound was evaluated for the binding affinity at 5- HT3 receptor,,CHEMBL620586,H,4,,,,,BAO_0000224,105030,,3108,,12918,B,,
Autocuration,,1,,,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),,CHEMBL620587,H,4,,,,,BAO_0000019,105030,,3109,,10369,B,,
Autocuration,,1,,,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,,CHEMBL620588,H,4,,,,,BAO_0000019,105030,,3110,,773,B,,
Autocuration,,1,,,5-hydroxytryptamine 3 receptor agonism in mouse,,CHEMBL620589,H,4,,,,,BAO_0000218,105030,,3111,,12918,F,,
Autocuration,,1,,,Binding affinity towards 5-hydroxytryptamine 3 receptor was determined by using [3H]-ICS 205-930 as radioligand in mouse N1E 115 cells,,CHEMBL620590,H,4,,,,,BAO_0000219,105030,,3112,,10561,B,,
Autocuration,,1,,,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,,CHEMBL617956,H,4,,,,,BAO_0000019,105030,,3113,,12827,B,,
Autocuration,,1,,,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,,CHEMBL617957,H,4,,,,,BAO_0000019,105030,,3114,,12827,B,,
Autocuration,,1,,,Binding affinity was evaluated by 5-hydroxytryptamine 3 receptor agonism in the mouse NIE-115 by displacing tropisetron,,CHEMBL617958,H,4,,,,,BAO_0000224,105030,,3115,,12918,B,,
Autocuration,,1,,,Compound was evaluated for binding to 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,,CHEMBL617959,H,4,,,,,BAO_0000219,105030,,3116,,273,B,,
Autocuration,,1,,,Compound was evaluated for binding to Serotonin 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,,CHEMBL617960,H,4,,,,,BAO_0000219,105030,,3117,,273,B,,
Autocuration,,1,,,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,,CHEMBL617961,H,4,,,,,BAO_0000224,105030,,3118,,10561,B,,
Autocuration,,1,,,Ability to displace the radioligand [3H]GR-65630 from 5-hydroxytryptamine 3 receptor expressed in NIE-115 cells,,CHEMBL617962,H,4,,,,,BAO_0000219,105030,,3119,,5033,B,In vitro,
Autocuration,,1,N1E-115,,In vitro binding affinity at 5-hydroxytryptamine 3 receptor in N1E-115 cells using 3[H]GR-65630 as the radioligand,,CHEMBL617963,H,4,,339.0,,,BAO_0000219,105030,,3120,,16429,B,,
Autocuration,,1,,,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,,CHEMBL617964,H,8,,,,,BAO_0000019,11765,,3121,,10322,B,,
Autocuration,,1,,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in NG cells 108-15,,CHEMBL617965,H,8,,,,,BAO_0000219,11765,,3122,,14331,B,,
Autocuration,,1,,,Compound was tested for the Binding affinity against N1e-115 neuroblastoma 5-hydroxytryptamine 3 receptor by Radio ligand [3H]GR-65630 binding assay.,,CHEMBL617966,D,9,,,Mus musculus,10090.0,BAO_0000357,10630,,3123,,13462,B,,
Autocuration,,1,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,CHEMBL857074,H,8,,,,,BAO_0000019,17106,,3124,,12861,B,,
Autocuration,,1,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor,,CHEMBL617967,H,8,,,Sus scrofa,9823.0,BAO_0000357,144,,3125,,15086,B,,
Autocuration,,1,,,Binding activity radioligand.,,CHEMBL617968,H,8,,,Sus scrofa,9823.0,BAO_0000357,144,,3126,,12861,B,,
Autocuration,,1,,,Binding affinity to 5-hydroxytryptamine 3 receptor of neuronal in the afferent rabbit vagus,,CHEMBL617969,H,4,,,Oryctolagus cuniculus,9986.0,BAO_0000223,104714,,3127,,10561,B,,
Autocuration,,1,,,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,,CHEMBL617970,H,4,,,Oryctolagus cuniculus,9986.0,BAO_0000223,104714,,3128,,10561,B,,
Autocuration,,1,,,Potency at neuronal 5-hydroxytryptamine 3 receptors in the rabbit heart,,CHEMBL617971,H,4,,,Oryctolagus cuniculus,9986.0,BAO_0000223,104714,,3129,,10561,B,,
Autocuration,,1,,,Potency to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,,CHEMBL617972,H,4,,,Oryctolagus cuniculus,9986.0,BAO_0000019,104714,,3130,,10561,B,,
Autocuration,,1,,,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),,CHEMBL617973,H,4,,,Oryctolagus cuniculus,9986.0,BAO_0000019,104714,,3131,,273,F,,
Autocuration,,1,,,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),,CHEMBL617974,H,4,,,Oryctolagus cuniculus,9986.0,BAO_0000019,104714,,3132,,273,F,,
Autocuration,,1,,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),,CHEMBL617975,H,4,,,Oryctolagus cuniculus,9986.0,BAO_0000221,104714,,3133,Ileum,273,F,,2116.0
Autocuration,,1,,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),,CHEMBL617976,H,4,,,Oryctolagus cuniculus,9986.0,BAO_0000019,104714,,3134,,273,F,,
Autocuration,,1,,,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),,CHEMBL617977,H,4,,,Oryctolagus cuniculus,9986.0,BAO_0000019,104714,,3135,,273,F,,
Autocuration,,1,,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),,CHEMBL617978,H,4,,,Oryctolagus cuniculus,9986.0,BAO_0000019,104714,,3136,,273,F,,
Autocuration,,1,,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),,CHEMBL617979,H,4,,,Oryctolagus cuniculus,9986.0,BAO_0000019,104714,,3137,,273,F,,
Autocuration,,1,CHO,,Binding affinity against 5-hydroxytryptamine 3 receptor in CHO cells using [3H]5-HT as radioligand,,CHEMBL617980,H,4,,449.0,Oryctolagus cuniculus,9986.0,BAO_0000219,104714,,3138,,13047,B,,
Autocuration,,1,,,In vitro displacement of [3H]-LY 278584 from rat cerebral cortex 5-hydroxytryptamine 3 receptor,,CHEMBL617981,D,7,,,Rattus norvegicus,10116.0,BAO_0000019,104698,,3139,,1650,B,,
Autocuration,,1,,,Affinity at 5-hydroxytryptamine 3 receptor from rat frontal cortex using [3H]granisetron as radioligand (For granisetron = Ki(nM)=0.3+/-0.01),,CHEMBL617982,H,8,,,,,BAO_0000019,12020,,3140,,16288,B,,
Autocuration,,1,,,Affinity at 5-hydroxytryptamine 3 receptor (For granisetron = Ki (nM)=0.3+/-0.01),,CHEMBL617983,H,8,,,,,BAO_0000357,12020,,3141,,16288,B,,
Autocuration,,1,,,In vitro displacement of [3H]ICS-205-930 from 5-hydroxytryptamine 3 receptor in cultured NG-108-15 rat glioma cells,,CHEMBL617984,D,7,,,Rattus norvegicus,10116.0,BAO_0000019,104698,,3142,,10254,B,,
Autocuration,,1,,,"Binding affinity for 5-hydroxytryptamine 3 receptor in rat cerebral cortex, determined by displacement of [3H]GR-65630",,CHEMBL617985,H,6,,,,,BAO_0000019,104698,,3143,,14532,B,,
Autocuration,,1,,,"5-Hydroxy tryptamine 3 receptor showing agonist activity (in vivo) in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",,CHEMBL617986,H,6,,,,,BAO_0000218,104698,,3144,Heart,13392,F,In vivo,948.0
Autocuration,,1,,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",,CHEMBL617987,H,6,,,,,BAO_0000019,104698,,3145,Heart,13392,F,,948.0
Autocuration,,1,,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",,CHEMBL617988,H,6,,,,,BAO_0000019,104698,,3146,Heart,13392,F,,948.0
Autocuration,,1,,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as change in heart rate",,CHEMBL617792,H,6,,,,,BAO_0000019,104698,,3147,Heart,13392,F,,948.0
Autocuration,,1,,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptorr in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",,CHEMBL617793,H,6,,,,,BAO_0000019,104698,,3148,Heart,13392,F,,948.0
Autocuration,,1,,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100(ug/kg), evaluated as percent inhibition of bradycardia",,CHEMBL617794,H,6,,,,,BAO_0000019,104698,,3149,,13392,F,,
Autocuration,,1,,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",,CHEMBL617795,H,6,,,,,BAO_0000019,104698,,3150,,13392,F,,
Autocuration,,1,,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",,CHEMBL617796,H,6,,,,,BAO_0000019,104698,,3151,,13392,F,,
Autocuration,,1,,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60(ug/kg), evaluated as percent inhibition of bradycardia",,CHEMBL617797,H,6,,,,,BAO_0000019,104698,,3152,,13392,F,,
Autocuration,,1,,,Antagonism of 5-HT-induced Von Bezold-Jarisch reflex in rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor antagonism),,CHEMBL617798,D,7,,,Rattus norvegicus,10116.0,BAO_0000218,104698,,3153,,1089,F,In vivo,
Autocuration,,1,,,Ability to antagonise the 5-HT- induced Von Bezold-Jarisch reflex in the rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor),,CHEMBL617799,H,6,,,,,BAO_0000218,104698,,3154,,1089,F,In vivo,
Autocuration,,1,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,,CHEMBL617800,D,7,,,Rattus norvegicus,10116.0,BAO_0000218,104698,,3155,,11454,F,In vivo,
Autocuration,,1,,,Inhibition of 5-HT-induced bradycardia by 5-hydroxytryptamine 3+,,CHEMBL617801,D,7,,,Rattus norvegicus,10116.0,BAO_0000019,104698,,3156,,11454,F,,
Autocuration,,1,,,In vivo inhibitory concentration after 5 minutes against 5-hydroxytryptamine 3 receptor induced bradycardia [bezold-jarisch (B-J) reflex test] in rat by intravenous administration,,CHEMBL617802,D,7,,,Rattus norvegicus,10116.0,BAO_0000218,104698,,3157,,12205,F,In vivo,
Autocuration,,1,,,Inhibition of 5-HT (1 ug/mL) induced depolarization in rat vagus nerve (5-hydroxytryptamine 3 receptor antagonism),,CHEMBL617803,D,7,,,Rattus norvegicus,10116.0,BAO_0000019,104698,,3158,,1089,F,,
Autocuration,,1,,,Binding affinity towards 5-HT3 receptor in rat was evaluated,,CHEMBL617804,H,6,,,,,BAO_0000019,104698,,3159,,5094,B,,
Autocuration,,1,,,Inhibition of [3H]GR-65630 binding to rat cortical membrane 5-hydroxytryptamine 3 receptor,,CHEMBL617805,D,7,,,Rattus norvegicus,10116.0,BAO_0000019,104698,,3160,,2622,B,,
Autocuration,,1,,,Binding affinity was evaluated in vitro by displacement of [3H]zacopride radioligand from 5-hydroxytryptamine 3 receptor,,CHEMBL617806,H,6,,,,,BAO_0000223,104698,,3161,,245,B,,
Autocuration,,1,,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex.,,CHEMBL617807,H,6,,,,,BAO_0000019,104698,,3162,,14788,B,,
Autocuration,,1,,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement of [3H]granisetron from rat cerebral cortex,,CHEMBL617808,H,6,,,,,BAO_0000019,104698,,3163,,14788,B,,
Autocuration,,1,,,Binding affinity against 5-hydroxytryptamine 3 receptor in rat cortical membrane using [3H]GR-65630 as radioligand,,CHEMBL617809,H,6,,,,,BAO_0000249,104698,,3164,,3020,B,,
Autocuration,,1,,,Compound was tested for its ability to displace [3H]-Q-ICS 205-930 from 5-hydroxytryptamine 3 receptor in rat cortex homogenates,,CHEMBL617810,H,6,,,,,BAO_0000019,104698,,3165,,1742,B,,
Autocuration,,1,,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to 5-hydroxytryptamine 3 receptor in rat brain cortical membrane,,CHEMBL617811,H,6,,,,,BAO_0000249,104698,,3166,Brain,17394,B,,955.0
Autocuration,,1,,,Concentration required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine-3 receptor (5-HT 3 receptor)in rat brain cortical membrane,,CHEMBL617812,H,6,,,,,BAO_0000221,104698,,3167,Brain,17394,B,,955.0
Autocuration,,1,,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine 3 receptor in rat cortical membrane,,CHEMBL617813,H,6,,,,,BAO_0000249,104698,,3168,,17394,B,,
Autocuration,,1,,,In vitro inhibitory concentration against radioligand [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in rat cortical membrane,,CHEMBL617814,H,6,,,,,BAO_0000249,104698,,3169,,14286,B,,
Autocuration,,1,,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate.,,CHEMBL617698,H,6,,,,,BAO_0000019,104698,,3170,,14178,B,,
Autocuration,,1,,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; Not active at 10000 nm,,CHEMBL617699,D,7,,,Rattus norvegicus,10116.0,BAO_0000019,104698,,3171,,14178,B,,
Autocuration,,1,,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; not active at 10000 nM,,CHEMBL617700,D,7,,,Rattus norvegicus,10116.0,BAO_0000019,104698,,3172,,14178,B,,
Autocuration,,1,,,Inhibition of radiolabeled [3H]-Zacopride ligand binding to 5-hydroxytryptamine 3 receptor,,CHEMBL617701,D,7,,,Rattus norvegicus,10116.0,BAO_0000223,104698,,3173,,14178,B,,
Autocuration,,1,,,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,,CHEMBL617702,H,6,,,,,BAO_0000019,104698,,3174,,15034,B,,
Autocuration,,1,,,"Tested for inhibition of binding of [3H]GR-65630 to rat cortical membranes, expressed as IC50",Membranes,CHEMBL617703,H,6,,,,,BAO_0000249,104698,,3175,,1089,B,,
Autocuration,,1,,,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 3 receptor,,CHEMBL617704,D,7,,,Rattus norvegicus,10116.0,BAO_0000019,104698,,3176,,1089,B,,
Autocuration,,1,,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,,CHEMBL617705,H,6,,,,,BAO_0000223,104698,,3177,,16532,B,,
Autocuration,,1,,,Inhibition of [3H]BRL-43694 binding to rat 5-hydroxytryptamine 3 receptor,,CHEMBL617706,D,7,,,Rattus norvegicus,10116.0,BAO_0000223,104698,,3178,,12801,B,,
Autocuration,,1,NG108-15,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells (using [3H]zacopride as radioligand),,CHEMBL617707,H,6,,433.0,,,BAO_0000219,104698,,3179,,15194,B,,
Autocuration,,1,NG108-15,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells using [3H]zacopride as radioligand,,CHEMBL617708,H,6,,433.0,,,BAO_0000219,104698,,3180,,15194,B,,
Autocuration,,1,,,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor from rat cortical homogenate using [3H]zacopride as radioligand,,CHEMBL617709,H,6,,,,,BAO_0000019,104698,,3181,,15194,B,,
Autocuration,,1,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA= Not active,,CHEMBL617710,H,6,,,,,BAO_0000019,104698,,3182,,15194,B,,
Autocuration,,1,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA=Not active,,CHEMBL882925,H,6,,,,,BAO_0000019,104698,,3183,,15194,B,,
Autocuration,,1,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; not active,,CHEMBL617711,H,6,,,,,BAO_0000019,104698,,3184,,15194,B,,
Autocuration,,1,,,Antagonist potency to 5-hydroxytryptamine 3 receptor was assayed by antagonism of the 5-HT-evoked reflex bradycardia [Bezold-Jarisch(BJ) reflex] in rats,,CHEMBL617712,H,6,,,,,BAO_0000019,104698,,3185,,10610,F,,
Autocuration,,1,,,Antagonistic activity against 5-hydroxytryptamine 3 receptor as inhibition of 5-HT-induced bradycardia (von Bezold-jarisch reflex) in anesthetized rat,,CHEMBL617713,D,7,,,Rattus norvegicus,10116.0,BAO_0000019,104698,,3186,,10355,F,,
Autocuration,,1,,,"Compound was tested as a 5-hydroxytryptamine 3 receptor antagonist in the rat by assessment of the inhibition of the Bezold-Jarisch effect, when administered intravenously",,CHEMBL617714,H,6,,,,,BAO_0000019,104698,,3187,,691,F,,
Autocuration,,1,,,In vivo 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) antagonistic activity expressed as ability to inhibit Bezold-Jarich reflex evoked by 5-HT in rats,,CHEMBL617715,H,6,,,,,BAO_0000218,104698,,3188,,10611,F,,
Autocuration,,1,,,Inhibition dose for 50 percent antagonism for 5-hydroxytryptamine 3 receptor in vivo in rats,,CHEMBL617716,H,6,,,,,BAO_0000218,104698,,3189,,12801,F,In vivo,
Autocuration,,1,,,Inhibition of 5-HT evoked reflex bradycardia in rat.,,CHEMBL617717,H,6,,,,,BAO_0000218,104698,,3190,,10609,F,,
Autocuration,,1,,,5-HT3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,,CHEMBL617718,H,6,,,,,BAO_0000218,104698,,3191,,11454,F,In vivo,
Autocuration,,1,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1 ug/kg dose in urethane-anesthetized rats,,CHEMBL617719,H,6,,,,,BAO_0000218,104698,,3192,,11454,F,In vivo,
Autocuration,,1,,,5-hydroxytryptamine 3 receptor antagonistic activity measured by inhibition of 5-HT-induced bradycardia (iv administration 10 ug/kg dose in urethane-anesthetized rats),,CHEMBL617720,H,6,,,,,BAO_0000218,104698,,3193,,11454,F,In vivo,
Autocuration,,1,,,5-hydroxytryptamine 3 receptor antagonistic activity as inhibition of 5-HT-induced bradycardia after iv administration of 100 ug/kg dose in urethane-anesthetized rats,,CHEMBL617721,D,7,,,Rattus norvegicus,10116.0,BAO_0000218,104698,,3194,,11454,F,In vivo,
Autocuration,,1,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,,CHEMBL617722,H,6,,,,,BAO_0000218,104698,,3195,,11454,F,In vivo,
Autocuration,,1,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kgetized rats,,CHEMBL617723,H,6,,,,,BAO_0000218,104698,,3196,,11454,F,In vivo,
Autocuration,,1,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 3 ug/kg dose in urethane-anesthetized rats,,CHEMBL617724,H,6,,,,,BAO_0000218,104698,,3197,,11454,F,In vivo,
Autocuration,,1,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 10 ug/kg dose in urethane-anesthetized rats,,CHEMBL617725,H,6,,,,,BAO_0000218,104698,,3198,,11454,F,In vivo,
Autocuration,,1,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 100 ug/kg dose in urethane-anesthetized rats,,CHEMBL617726,H,6,,,,,BAO_0000218,104698,,3199,,11454,F,In vivo,
Autocuration,,1,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 1000 ug/kg dose in urethane-anesthetized rats,,CHEMBL617727,H,6,,,,,BAO_0000218,104698,,3200,,11454,F,In vivo,
Autocuration,,1,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 30 ug/kg dose in urethane-anesthetized rats,,CHEMBL617728,H,6,,,,,BAO_0000218,104698,,3201,,11454,F,In vivo,
Autocuration,,1,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 300 ug/kg dose in urethane-anesthetized rats,,CHEMBL617729,H,6,,,,,BAO_0000218,104698,,3202,,11454,F,In vivo,
Autocuration,,1,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 3ug/kg dose in urethane-anesthetized rats,,CHEMBL617730,H,6,,,,,BAO_0000218,104698,,3203,,11454,F,In vivo,
Autocuration,,1,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,,CHEMBL617731,H,6,,,,,BAO_0000218,104698,,3204,,11454,F,In vivo,
Autocuration,,1,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 0.3 ug/kg dose in urethane-anesthetized rats,,CHEMBL617732,H,6,,,,,BAO_0000218,104698,,3205,,11454,F,In vivo,
Autocuration,,1,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 1 ug/kg dose in urethane-anesthetized rats,,CHEMBL617733,H,6,,,,,BAO_0000218,104698,,3206,,11454,F,In vivo,
Autocuration,,1,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 30 ug/kg dose in urethane-anesthetized rats,,CHEMBL617734,H,6,,,,,BAO_0000218,104698,,3207,,11454,F,In vivo,
Autocuration,,1,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 0.05 hour,,CHEMBL872874,H,6,,,,,BAO_0000218,104698,,3208,,11454,F,In vivo,
Autocuration,,1,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 1 hour,,CHEMBL617735,H,6,,,,,BAO_0000218,104698,,3209,,11454,F,In vivo,
Autocuration,,1,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 16 hour,,CHEMBL617736,H,6,,,,,BAO_0000218,104698,,3210,,11454,F,In vivo,
Autocuration,,1,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 3 hour,,CHEMBL617737,H,6,,,,,BAO_0000218,104698,,3211,,11454,F,In vivo,
Autocuration,,1,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 6 hour,,CHEMBL617738,H,6,,,,,BAO_0000218,104698,,3212,,11454,F,In vivo,
Autocuration,,1,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,,CHEMBL617739,H,6,,,,,BAO_0000218,104698,,3213,,11454,F,In vivo,
Autocuration,,1,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 100 ug/kg dose in urethane-anesthetized rats,,CHEMBL617740,H,6,,,,,BAO_0000218,104698,,3214,,11454,F,In vivo,
Autocuration,,1,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,,CHEMBL617741,H,6,,,,,BAO_0000218,104698,,3215,,11454,F,In vivo,
Autocuration,,1,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,,CHEMBL617742,H,6,,,,,BAO_0000218,104698,,3216,,11454,F,In vivo,
Autocuration,,1,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 3 ug/kg dose in urethane-anesthetized rats,,CHEMBL617743,H,6,,,,,BAO_0000218,104698,,3217,,11454,F,In vivo,
Autocuration,,1,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 30 ug/kg dose in urethane-anesthetized rats,,CHEMBL617744,H,6,,,,,BAO_0000218,104698,,3218,,11454,F,In vivo,
Autocuration,,1,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 300 ug/kg dose in urethane-anesthetized rats,,CHEMBL617745,H,6,,,,,BAO_0000218,104698,,3219,,11454,F,In vivo,
Autocuration,,1,,,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.)",,CHEMBL617746,H,6,,,,,BAO_0000218,104698,,3220,,670,F,,
Autocuration,,1,,,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.); Not tested",,CHEMBL617747,H,6,,,,,BAO_0000218,104698,,3221,,670,F,,
Autocuration,,1,,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 10 ug/Kg,,CHEMBL617748,H,6,,,,,BAO_0000218,104698,,3222,,10321,F,In vivo,
Autocuration,,1,,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 100 ug/Kg,,CHEMBL618909,H,6,,,,,BAO_0000218,104698,,3223,,10321,F,In vivo,
Autocuration,,1,,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 2 ug/Kg,,CHEMBL618910,H,6,,,,,BAO_0000218,104698,,3224,,10321,F,In vivo,
Autocuration,,1,,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 20 ug/Kg,,CHEMBL618911,H,6,,,,,BAO_0000218,104698,,3225,,10321,F,In vivo,
Autocuration,,1,,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 5 ug/Kg,,CHEMBL618912,H,6,,,,,BAO_0000218,104698,,3226,,10321,F,In vivo,
Autocuration,,1,,,Tested for inhibition of Bezold-Jarisch (B-J) reflex mediated by 5-hydroxytryptamine 3 receptor in rats after intravenous administration (2.0 ug/kg),,CHEMBL618913,H,6,,,,,BAO_0000218,104698,,3227,,10322,F,In vivo,
Autocuration,,1,,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,,CHEMBL618914,H,6,,,,,BAO_0000019,104698,,3228,,15412,F,,
Autocuration,,1,,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,,CHEMBL618915,H,6,,,,,BAO_0000019,104698,,3229,,15412,F,,
Autocuration,,1,,,Intrinsic efficacy for rat 5-hydroxytryptamine 3 receptor,,CHEMBL618916,D,7,,,Rattus norvegicus,10116.0,BAO_0000223,104698,,3230,,15412,B,,
Autocuration,,1,,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; PA means partial agonist,,CHEMBL618917,H,6,,,,,BAO_0000019,104698,,3231,,15412,F,,
Intermediate,,1,,,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) of rat cortex and hippocampus tissue,,CHEMBL618918,D,7,,,,,BAO_0000221,104698,,3232,Hippocampus,15412,B,,10000000.0
Autocuration,,1,,,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor of rat cortical membrane,,CHEMBL618919,D,7,,,Rattus norvegicus,10116.0,BAO_0000019,104698,,3233,,15412,B,,
Autocuration,,1,,,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 5-hydroxytryptamine 3 receptor,,CHEMBL618920,D,7,,,Rattus norvegicus,10116.0,BAO_0000019,104698,,3234,,17394,B,,
Autocuration,,1,,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 3 receptor,,CHEMBL618921,H,6,,,,,BAO_0000223,104698,,3235,,12457,B,,
Autocuration,,1,,,Affinity was evaluated by inhibition of [3H]GR-65630 binding to NG108-15 cell transfected with cloned rat 5-hydroxytryptamine 3 receptor,,CHEMBL618922,H,6,,,,,BAO_0000019,104698,,3236,,12457,B,,
Autocuration,,1,,,Binding affinity against radioligand [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in neuroblastoma-glioma (NG108-15) cells.,,CHEMBL618923,H,6,,,,,BAO_0000019,104698,,3237,,12205,B,,
Autocuration,,1,,,Binding affinity for 5-hydroxytryptamine 3 receptor was determined by measuring displacement of [3H]GR-65630 from rat brain cortices,,CHEMBL618924,H,6,,,,,BAO_0000019,104698,,3238,,14532,B,,
Autocuration,,1,,,Binding affinity to 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-BRL 43694 as radioligand,,CHEMBL618925,H,6,,,,,BAO_0000019,104698,,3239,,1122,B,,
Autocuration,,1,,,Binding affinity towards 5-HT3 receptor in rat was evaluated,,CHEMBL618926,H,6,,,,,BAO_0000019,104698,,3240,,5094,B,,
Intermediate,,1,,,5-hydroxytryptamine 4 receptor agonist activity as increased response to electrical stimulation in guinea pig ileum,,CHEMBL618927,D,9,,,Cavia porcellus,10141.0,BAO_0000221,20033,,3241,Ileum,809,F,,2116.0
Intermediate,,1,,,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum; Not tested,,CHEMBL618928,D,9,,,Cavia porcellus,10141.0,BAO_0000221,20033,,3242,Ileum,809,F,,2116.0
Intermediate,,1,,,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum",,CHEMBL618929,D,9,,,Cavia porcellus,10141.0,BAO_0000221,20033,,3243,Ileum,14290,F,,2116.0
Intermediate,,1,,,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Inactive up to 10E-5 M",,CHEMBL618930,D,9,,,Cavia porcellus,10141.0,BAO_0000221,20033,,3244,Ileum,14290,F,,2116.0
Intermediate,,1,,,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",,CHEMBL618931,D,9,,,Cavia porcellus,10141.0,BAO_0000221,20033,,3245,Ileum,14290,F,,2116.0
Intermediate,,1,,,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",,CHEMBL619594,D,9,,,Cavia porcellus,10141.0,BAO_0000221,20033,,3246,Ileum,14290,F,,2116.0
Intermediate,,1,,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not capable of evaluation",,CHEMBL619595,D,9,,,Cavia porcellus,10141.0,BAO_0000221,20033,,3247,Ileum,14290,F,,2116.0
Intermediate,,1,,,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum.,,CHEMBL619596,D,9,,,Cavia porcellus,10141.0,BAO_0000221,20033,,3248,Ileum,13961,F,,2116.0
Intermediate,,1,,,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum. Activity expressed as percent of the maximum 5-HT response given in brackets.,,CHEMBL619755,D,9,,,Cavia porcellus,10141.0,BAO_0000221,20033,,3249,Ileum,13961,F,,2116.0
Intermediate,,1,,,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum,,CHEMBL619756,D,9,,,Cavia porcellus,10141.0,BAO_0000221,20033,,3250,Ileum,809,F,,2116.0
Intermediate,,1,,,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not evaluable,,CHEMBL619757,D,9,,,Cavia porcellus,10141.0,BAO_0000221,20033,,3251,Ileum,809,F,,2116.0
Intermediate,,1,,,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not tested,,CHEMBL619758,D,9,,,Cavia porcellus,10141.0,BAO_0000221,20033,,3252,Ileum,809,F,,2116.0
Intermediate,,1,,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum",,CHEMBL619759,D,9,,,Cavia porcellus,10141.0,BAO_0000221,20033,,3253,Ileum,14290,F,,2116.0
Intermediate,,1,,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10-5 M",,CHEMBL619760,D,9,,,Cavia porcellus,10141.0,BAO_0000221,20033,,3254,Ileum,14290,F,,2116.0
Intermediate,,1,,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10E-5 M",,CHEMBL619761,D,9,,,Cavia porcellus,10141.0,BAO_0000221,20033,,3255,Ileum,14290,F,,2116.0
Intermediate,,1,,,5-hydroxytryptamine 4 receptor antagonist activity as inhibition of 5-HT-induced contractions in guinea pig ileum; Not capable of evaluation.,,CHEMBL619762,D,9,,,Cavia porcellus,10141.0,BAO_0000221,20033,,3256,Ileum,14290,F,,2116.0
Intermediate,,1,,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",,CHEMBL619763,D,9,,,Cavia porcellus,10141.0,BAO_0000221,20033,,3257,Ileum,14290,F,,2116.0
Intermediate,,1,,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",,CHEMBL617868,D,9,,,Cavia porcellus,10141.0,BAO_0000221,20033,,3258,Ileum,14290,F,,2116.0
Intermediate,,1,,,Displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor in guinea pig striatum,,CHEMBL617869,D,9,,,Cavia porcellus,10141.0,BAO_0000357,20033,,3259,,15034,B,,
Intermediate,,1,,,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,,CHEMBL882926,D,9,,,Cavia porcellus,10141.0,BAO_0000249,20033,,3260,Striatum,5094,B,,2435.0
Intermediate,,1,,,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,,CHEMBL617870,D,9,,,Cavia porcellus,10141.0,BAO_0000249,20033,,3261,Striatum,5094,B,,2435.0
Intermediate,,1,,,Inhibitory activity against 5-hydroxytryptamine 4 receptor of guinea pig striatum using [3H]GR-113808 as radioligand,,CHEMBL617871,D,9,,,Cavia porcellus,10141.0,BAO_0000357,20033,,3262,Striatum,5399,B,,2435.0
Intermediate,,1,,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea pig striatum,,CHEMBL617872,D,9,,,Cavia porcellus,10141.0,BAO_0000357,20033,,3263,Striatum,17394,B,,2435.0
Intermediate,,1,,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea-pig striatum,,CHEMBL617873,D,9,,,Cavia porcellus,10141.0,BAO_0000357,20033,,3264,Striatum,17394,B,,2435.0
Intermediate,,1,,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to serotonin 5-hydroxytryptamine 4 receptor in guinea-pig striatum,,CHEMBL617874,D,9,,,Cavia porcellus,10141.0,BAO_0000357,20033,,3265,Striatum,17394,B,,2435.0
Intermediate,,1,,,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum.,,CHEMBL619067,D,9,,,Cavia porcellus,10141.0,BAO_0000221,20033,,3266,Ileum,13961,F,,2116.0
Intermediate,,1,,,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum. 95% confidence limits are in brackets.,,CHEMBL619068,D,9,,,Cavia porcellus,10141.0,BAO_0000221,20033,,3267,Ileum,13961,F,,2116.0
Intermediate,,1,,,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,,CHEMBL619069,D,9,,,Cavia porcellus,10141.0,BAO_0000221,20033,,3268,Ileum,13961,F,,2116.0
Intermediate,,1,,,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-6 M in guinea pig,,CHEMBL619070,D,9,,,Cavia porcellus,10141.0,BAO_0000357,20033,,3269,,16946,B,,
Intermediate,,1,,,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-8 M in guinea pig,,CHEMBL619071,D,9,,,Cavia porcellus,10141.0,BAO_0000357,20033,,3270,,16946,B,,
Intermediate,,1,,,Agonistic activity against 5-hydroxytryptamine 4 receptor,,CHEMBL619072,D,9,,,Cavia porcellus,10141.0,BAO_0000019,20033,,3271,,15034,F,,
Intermediate,,1,,,Agonistic activity against 5-hydroxytryptamine 4 receptor; not tested,,CHEMBL619073,D,9,,,Cavia porcellus,10141.0,BAO_0000019,20033,,3272,,15034,F,,
Intermediate,,1,,,Compound was evaluated for the relative potency with respect to serotonin against 5-hydroxytryptamine 4 receptor,,CHEMBL619074,D,9,,,Cavia porcellus,10141.0,BAO_0000019,20033,,3273,,12918,F,,
Intermediate,,1,,,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor,,CHEMBL619075,D,9,,,Cavia porcellus,10141.0,BAO_0000357,20033,,3274,,16946,B,,
Intermediate,,1,,,Inhibition of [3H]GR-113808 binding to guinea pig striatum 5-hydroxytryptamine 4 receptor,,CHEMBL619076,D,9,,,Cavia porcellus,10141.0,BAO_0000357,20033,,3275,Striatum,17394,B,,2435.0
Intermediate,,1,,,Binding affinity against 5-hydroxytryptamine 4 receptor in guinea pig striatum using [3H]GR-113808 as radioligand,,CHEMBL619077,D,9,,,Cavia porcellus,10141.0,BAO_0000357,20033,,3276,Striatum,15034,B,,2435.0
Intermediate,,1,,,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,,CHEMBL619078,D,9,,,Cavia porcellus,10141.0,BAO_0000249,20033,,3277,Striatum,5094,B,,2435.0
Intermediate,,1,,,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,,CHEMBL619079,D,9,,,Cavia porcellus,10141.0,BAO_0000249,20033,,3278,Striatum,5094,B,,2435.0
Intermediate,,1,,,Tested for affinity against 5-hydroxytryptamine 4 receptor in the myenteric plexus of the guinea pig ileum.,,CHEMBL619080,D,9,,,Cavia porcellus,10141.0,BAO_0000221,20033,,3279,Ileum,17358,B,,2116.0
Expert,,1,,,Displacement of [3H]-GR113808 from 5-HT4 receptor of guinea pig striatum,,CHEMBL619081,D,9,,,Cavia porcellus,10141.0,BAO_0000357,20033,,3280,,12953,B,,
Intermediate,,1,,,The compound was tested for their binding affinity towards 5-HT4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,,CHEMBL619082,D,9,,,Cavia porcellus,10141.0,BAO_0000357,20033,,3281,,12953,B,,
Intermediate,,1,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand.,,CHEMBL619083,D,9,,,Cavia porcellus,10141.0,BAO_0000357,20033,,3282,,12953,B,,
Intermediate,,1,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,,CHEMBL619084,D,9,,,Cavia porcellus,10141.0,BAO_0000357,20033,,3283,,12953,B,,
Intermediate,,1,,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,,CHEMBL859397,D,9,,,Cavia porcellus,10141.0,BAO_0000221,20033,,3284,Ileum,273,F,,2116.0
Intermediate,,1,,,5-hydroxytryptamine 4 receptor agonist activity in the guinea pig ileum assay,,CHEMBL619085,D,9,,,Cavia porcellus,10141.0,BAO_0000221,20033,,3285,Ileum,12918,F,,2116.0
Intermediate,,1,,,5-hydroxytryptamine 4 receptor agonistic activity was measured by twitch response enhancing activity in electrically stimulated guinea pig ileum preparation,,CHEMBL619086,D,9,,,Cavia porcellus,10141.0,BAO_0000221,20033,,3286,Ileum,12919,F,,2116.0
Intermediate,,1,,,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI).,,CHEMBL619087,D,9,,,Cavia porcellus,10141.0,BAO_0000221,20033,,3287,Ileum,273,F,,2116.0
Intermediate,,1,,,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,,CHEMBL619088,D,9,,,Cavia porcellus,10141.0,BAO_0000221,20033,,3288,Ileum,273,F,,2116.0
Intermediate,,1,,,Ability to antagonize 5-HT-evoked contractions mediated through 5-hydroxytryptamine 4 receptor activation in the guinea pig distal colon LMMP,,CHEMBL619089,D,9,,,Cavia porcellus,10141.0,BAO_0000357,20033,,3289,,13181,B,,
Autocuration,,1,,,Binding affinity was determined against 5-hydroxytryptamine 3 receptor,,CHEMBL619090,H,8,,,Cavia porcellus,10141.0,BAO_0000357,168,,3290,,13181,B,,
Intermediate,,1,,,Antagonistic activity against 5-hydroxytryptamine 4 receptor,,CHEMBL619091,D,9,,,Cavia porcellus,10141.0,BAO_0000019,20033,,3291,,15034,F,,
Intermediate,,1,,,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-hydroxytryptamine 4 receptor,,CHEMBL619092,D,9,,,Cavia porcellus,10141.0,BAO_0000357,20033,,3292,,5033,B,,
Intermediate,,1,,,Binding affinity for 5-hydroxytryptamine 4 receptor by displacement of [3H]GR-113808 from guinea pig brain striatum.,,CHEMBL619093,D,9,,,Cavia porcellus,10141.0,BAO_0000019,20033,,3293,,1980,B,,
Autocuration,,1,HEK293,,Binding affinity was determined against 5-hydroxytryptamine 2C receptor using cloned rat receptors expressed in 293 cells radiolabeled with [3H]mesulergine,,CHEMBL619094,H,8,,722.0,Cavia porcellus,10141.0,BAO_0000219,168,,3294,,13181,B,,
Intermediate,,1,,,In vitro by displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor on guinea pig striatal membrane,,CHEMBL619095,D,9,,,Cavia porcellus,10141.0,BAO_0000019,20033,,3295,,14287,B,,
Intermediate,,1,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 4 receptor using radioligand binding assay using [3H]GR as radioligand,,CHEMBL857988,D,9,,,Cavia porcellus,10141.0,BAO_0000357,20033,,3296,,1317,B,,
Intermediate,,1,,,Compound was evaluated for its ability to displace [3H]GR-113808 binding from 5-hydroxytryptamine 4 receptor in guinea pig striatum.,,CHEMBL619096,D,9,,,Cavia porcellus,10141.0,BAO_0000357,20033,,3297,,15316,B,,
Intermediate,,1,,,In vitro binding affinity at 5-hydroxytryptamine 4 receptor in guinea pig striatum using 3[H]GR-113808 as the radioligand,,CHEMBL619097,D,9,,,Cavia porcellus,10141.0,BAO_0000357,20033,,3298,Striatum,16429,B,,2435.0
Intermediate,,1,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 4 receptor in guinea pig hippocampus using [125I]SB-207710.,,CHEMBL619098,D,9,,,Cavia porcellus,10141.0,BAO_0000221,20033,,3299,Hippocampus,14818,B,,10000000.0
Intermediate,,1,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand,,CHEMBL619751,D,9,,,Cavia porcellus,10141.0,BAO_0000357,20033,,3300,,15194,B,,
Intermediate,,1,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand.,,CHEMBL619752,D,9,,,Cavia porcellus,10141.0,BAO_0000357,20033,,3301,,15194,B,,
Intermediate,,1,,,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,,CHEMBL875096,D,9,,,Cavia porcellus,10141.0,BAO_0000221,20033,,3302,Ileum,13961,F,,2116.0
Autocuration,,1,,,Binding affinity towards 5-HT2C receptor by the displacement of [3H]mesulergine] in human recombinant receptors in mammalian cell,,CHEMBL619004,H,8,,,,,BAO_0000357,108,,3303,,5486,B,,
Autocuration,,1,,,Binding affinity towards human 5-hydroxytryptamine 4 receptor using [3H]5-HT as radioligand,,CHEMBL619005,H,8,,,,,BAO_0000357,168,,3304,,16209,B,,
Autocuration,,1,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 4 receptor,,CHEMBL619006,H,8,,,,,BAO_0000019,168,,3305,,17085,B,,
Autocuration,,1,HeLa,,Compound was evaluated for the binding affinity against human cloned 5-hydroxytryptamine 4 receptor in HeLa cells using [3H]-LSD as the radioligand,,CHEMBL619007,H,8,,308.0,,,BAO_0000219,168,,3306,,4199,B,,
Autocuration,,1,,,Compound was tested for its binding affinity against 5-hydroxytryptamine 4 receptor,,CHEMBL619008,H,8,,,,,BAO_0000357,168,,3307,,15146,B,,
Autocuration,,1,,,Compound was tested for its binding affinity for 5-hydroxytryptamine 4 receptor,,CHEMBL619009,H,8,,,,,BAO_0000357,168,,3308,,5213,B,,
Autocuration,,1,HeLa,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 4 receptor in HeLa cells, using [3H]LSD as radioligand",,CHEMBL619010,H,8,,308.0,,,BAO_0000219,168,,3309,,4829,B,,
Autocuration,,1,,,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons,,CHEMBL619011,H,8,,,,,BAO_0000357,10622,,3310,,17358,B,,
Autocuration,,1,,,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons; IA means inactive,,CHEMBL619012,H,8,,,,,BAO_0000357,10622,,3311,,17358,B,,
Autocuration,,1,,,Ability to displace [3H]GR-113808 from mouse 5-hydroxytryptamine 4 receptor in COS7 cells,,CHEMBL619013,H,8,,,,,BAO_0000219,10622,,3312,,16946,B,,
Autocuration,,1,,,Tested for ability to stimulate 5-hydroxytryptamine 4 receptors in mouse Coliculi neurons,,CHEMBL619014,H,8,,,,,BAO_0000357,10622,,3313,,17358,B,,
Autocuration,,1,,,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model,,CHEMBL857503,H,8,,,,,BAO_0000019,11249,,3314,Cardiac atrium,268,F,,2081.0
Autocuration,,1,,,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model; compound found inactive at 1 uM,,CHEMBL619015,H,8,,,,,BAO_0000019,11249,,3315,Cardiac atrium,268,F,,2081.0
Autocuration,,1,,,The compound was tested for binding affinity against 5-hydroxytryptamine 4 receptor,,CHEMBL619016,H,8,,,,,BAO_0000357,11249,,3316,,15086,B,,
Autocuration,,1,,,Compound was tested for binding affinity against piglet hippocampus 5-hydroxytryptamine 4 receptor,,CHEMBL619017,H,8,,,,,BAO_0000221,11249,,3317,Hippocampus,14875,B,,10000000.0
Autocuration,,1,,,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]SB 207710 as radioligand,,CHEMBL619018,H,8,,,Sus scrofa,9823.0,BAO_0000221,168,,3318,Hippocampus,13267,B,,10000000.0
Autocuration,,1,,,Binding affinity against 5-hydroxytryptamine 2A receptor using rabbit saphenous vein assay.,,CHEMBL619019,H,8,,,Oryctolagus cuniculus,9986.0,BAO_0000019,168,,3319,,13047,B,,
Expert,,1,,,Displacement of [3H]GR-113808 from rat striatum 5-hydroxytryptamine 4 receptor,,CHEMBL619020,D,9,,,Rattus norvegicus,10116.0,BAO_0000357,10623,,3320,,1650,B,,
Autocuration,,1,,,Tested for its agonist potency against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,,CHEMBL619021,H,8,,,,,BAO_0000019,10623,,3321,,567,F,,
Autocuration,,1,,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in relaxation of rat oesophagus,,CHEMBL619022,H,8,,,,,BAO_0000357,10623,,3322,,17358,B,,
Autocuration,,1,,,Tested for the effect on binding at 5-hydroxytryptamine 4 receptor; No activity,,CHEMBL619023,H,8,,,,,BAO_0000357,10623,,3323,,188,B,,
Autocuration,,1,,,lntrinsic activity relative to 5-HT receptor,,CHEMBL619024,H,8,,,,,BAO_0000019,10623,,3324,,670,F,,
Autocuration,,1,,,Compound was evaluated for the agonistic activity towards 5-hydroxytryptamine 4 receptor using the rat tunica muscularis mucosae (TMM) esophagus strip assay,,CHEMBL619025,H,8,,,,,BAO_0000019,10623,,3325,,204,F,,
Expert,,1,,,In vitro relaxation of carbachol pre-contracted rat oesophageal TMM.,,CHEMBL619026,H,8,,,,,BAO_0000019,10623,,3326,,1946,F,,
Autocuration,,1,,,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay,,CHEMBL619027,H,8,,,,,BAO_0000019,10623,,3327,,6398,F,,
Autocuration,,1,,,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay; IN = Inactive,,CHEMBL619028,H,8,,,,,BAO_0000019,10623,,3328,,6398,F,,
Autocuration,,1,,,Efficient 5-hydroxytryptamine 4 agonist in the rat tunica muscularis mucosae,,CHEMBL619029,H,8,,,,,BAO_0000019,10623,,3329,,17358,F,,
Autocuration,,1,,,Tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay of racemate mixture,,CHEMBL619030,H,8,,,,,BAO_0000019,10623,,3330,,6398,F,,
Expert,,1,,,Relaxation of carbachol induced contractions of rat tunica muscularis mucosae,,CHEMBL619031,H,8,,,,,BAO_0000357,10623,,3331,,11752,B,,
Autocuration,,1,,,5-hydroxytryptamine 4 receptor agonist activity was determined by the relaxation of the carbachol-contracted rat esophageal tunica muscularis mucosae,,CHEMBL619032,H,8,,,,,BAO_0000019,10623,,3332,,809,F,,
Expert,,1,,,Inhibition of radiolabeled [3H]GR-113808 ligand binding to 5-hydroxytryptamine 4 receptor,,CHEMBL619033,D,9,,,Rattus norvegicus,10116.0,BAO_0000357,10623,,3333,,14178,B,,
Autocuration,,1,,,Tested for its efficacy against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,,CHEMBL619034,H,8,,,,,BAO_0000357,10623,,3334,,567,B,,
Autocuration,,1,,,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae.,,CHEMBL619035,H,8,,,,,BAO_0000357,10623,,3335,,1946,B,,
Autocuration,,1,,,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae; No activity up to 104M concentration,,CHEMBL619036,H,8,,,,,BAO_0000357,10623,,3336,,1946,B,,
Expert,,1,,,Binding affinity (Ki+/-SEM) against 5-hydroxytryptamine 4 receptor from cheng Prusoff equation by using [3H]GR-113808 in rat striatum,,CHEMBL619037,D,9,,,Rattus norvegicus,10116.0,BAO_0000019,10623,,3337,,13961,B,,
Autocuration,,1,,,Binding affinity towards 5-HT 4 receptor in rat striatum membranes using [3H]GR-113808 as radioligand,,CHEMBL619038,H,8,,,,,BAO_0000249,10623,,3338,Striatum,6238,B,,2435.0
Autocuration,,1,,,Binding affinity towards 5-HT4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand; Not tested,,CHEMBL619039,H,8,,,,,BAO_0000249,10623,,3339,,14290,B,,
Expert,,1,,,Binding affinity towards 5-hydroxytryptamine 4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand,,CHEMBL619040,H,8,,,,,BAO_0000249,10623,,3340,,14290,B,,
Expert,,1,,,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,,CHEMBL619041,D,9,,,Rattus norvegicus,10116.0,BAO_0000019,10623,,3341,Striatum,809,B,,2435.0
Autocuration,,1,,,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,,CHEMBL619042,H,8,,,,,BAO_0000019,10623,,3342,Striatum,1578,B,,2435.0
Expert,,1,,,Binding affinity to 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum membrane,,CHEMBL619043,H,8,,,,,BAO_0000249,10623,,3343,Striatum,16709,B,,2435.0
Expert,,1,,,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatum by [3H]GR-113808 displacement.,,CHEMBL619044,H,8,,,,,BAO_0000019,10623,,3344,Striatum,1946,B,,2435.0
Expert,,1,,,In vitro affinity at serotonergic 5-hydroxytryptamine 4 receptor by radioligand binding assay using [3H]GR-113808 in rat striatum membranes.,,CHEMBL619045,H,8,,,,,BAO_0000249,10623,,3345,Striatum,15253,B,,2435.0
Expert,,1,,,In vitro binding affinity to 5-hydroxytryptamine 4 receptor in rat striatum membrane,,CHEMBL619046,H,8,,,,,BAO_0000249,10623,,3346,Striatum,4535,B,,2435.0
Expert,,1,,,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatal membranes by [3H]GR-113808 displacement.,,CHEMBL619047,H,8,,,,,BAO_0000249,10623,,3347,,13961,B,,
Autocuration,,1,,,Tested for potency against 5-hydroxytryptamine 4 receptor agonist in rat brain,,CHEMBL619048,H,8,,,,,BAO_0000221,10623,,3348,Brain,17358,F,,955.0
Autocuration,,1,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat,,CHEMBL859398,H,8,,,,,BAO_0000019,10623,,3349,,15847,F,,
Autocuration,,1,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat; ND means not done,,CHEMBL619049,H,8,,,,,BAO_0000019,10623,,3350,,15847,F,,
Autocuration,,1,,,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae,,CHEMBL857886,H,8,,,,,BAO_0000019,10623,,3351,,670,F,,
Autocuration,,1,,,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae; Not tested,,CHEMBL619050,H,8,,,,,BAO_0000019,10623,,3352,,670,F,,
Autocuration,,1,,,Antagonist activity against 5-hydroxytryptamine 4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,,CHEMBL620591,H,8,,,,,BAO_0000019,10623,,3353,,1317,F,,
Expert,,1,,,Binding affinity against rat 5-hydroxytryptamine 4 receptor,,CHEMBL620592,D,9,,,Rattus norvegicus,10116.0,BAO_0000357,10623,,3354,,12936,B,,
Expert,,1,,,pKi against 5-hydroxytryptamine 4 receptor in rat striatum membrane,,CHEMBL620593,H,8,,,,,BAO_0000249,10623,,3355,Striatum,4535,B,,2435.0
Expert,,1,,,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-5 M.,,CHEMBL620594,D,9,,,Rattus norvegicus,10116.0,BAO_0000019,10623,,3356,,14424,F,,
Expert,,1,,,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-6 M.,,CHEMBL875079,H,8,,,,,BAO_0000019,10623,,3357,,14424,F,,
Expert,,1,,,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,,CHEMBL620595,H,8,,,,,BAO_0000019,10623,,3358,,14424,F,,
Expert,,1,,,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-8 M.,,CHEMBL620596,D,9,,,Rattus norvegicus,10116.0,BAO_0000019,10623,,3359,,14424,F,,
Autocuration,,1,,,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-7 M.,,CHEMBL620597,H,8,,,,,BAO_0000019,10623,,3360,,14424,F,,
Expert,,1,,,Antagonistic activity evaluated by ability to block serotonin induced relaxation (via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-8 M.,,CHEMBL620598,H,8,,,,,BAO_0000019,10623,,3361,,14424,F,,
Expert,,1,,,Antagonistic activity evaluated by ability to block serotonin induced relaxation via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 0.1 mg/kg (p.o.),,CHEMBL620599,H,8,,,,,BAO_0000218,10623,,3362,,14424,F,,
Autocuration,,1,,,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,,CHEMBL620600,H,8,,,,,BAO_0000019,10623,,3363,,14424,F,,
Autocuration,,1,,,Estimate from relaxation of carbachol-contracted rat esophageal muscularis mucosae,,CHEMBL620601,H,8,,,Rattus norvegicus,10116.0,BAO_0000019,168,,3364,,1980,F,,
Autocuration,,1,,,Compound was tested for agonistic activity against 5-hydroxytryptamine 4 receptor on guinea colon at a concentration 0.1 uM,,CHEMBL620602,H,8,,,,,BAO_0000019,168,,3365,,4639,F,,
Autocuration,,1,,,Tested for affinity towards 5-hydroxytryptamine 4 receptor,,CHEMBL620603,H,8,,,,,BAO_0000357,168,,3366,,17358,B,,
Autocuration,,1,,,Tested for affinity towards 5-hydroxytryptamine 4 receptor.,,CHEMBL620604,H,8,,,,,BAO_0000357,168,,3367,,17358,B,,
Autocuration,,1,,,Compound was tested for 5-hydroxytryptamine 4 binding affinity,,CHEMBL620605,H,8,,,,,BAO_0000357,168,,3368,,17358,B,,
Autocuration,,1,,,Compound was tested for its affinity towards 5-hydroxytryptamine 4 receptor,,CHEMBL620606,H,8,,,,,BAO_0000357,168,,3369,,1558,B,,
Autocuration,,1,,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,CHEMBL620607,H,8,,,,,BAO_0000019,168,,3370,,17358,F,,
Autocuration,,1,,,In vitro binding affinity towards 5-HT4 receptor was determined,,CHEMBL620608,H,8,,,,,BAO_0000357,168,,3371,,16117,B,,
Autocuration,,1,,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,CHEMBL620609,H,8,,,,,BAO_0000019,168,,3372,,17358,F,,
Autocuration,,1,,,Tested for agonist activity against 5-hydroxytryptamine 4 receptor,,CHEMBL620610,H,8,,,,,BAO_0000019,168,,3373,,17358,F,,
Autocuration,,1,,,Tested for selectivity for 5-hydroxytryptamine 4 receptor,,CHEMBL620611,H,8,,,,,BAO_0000357,168,,3374,,17358,B,,
Autocuration,,1,,,Tested for 5-hydroxytryptamine 4 binding affinity against cisapride,,CHEMBL620612,H,8,,,,,BAO_0000357,168,,3375,,17358,B,,
Autocuration,,1,,,Tested for 5-hydroxytryptamine 4 binding affinity against renzapride,,CHEMBL620613,H,8,,,,,BAO_0000357,168,,3376,,17358,B,,
Autocuration,,1,,,Tested for 5-hydroxytryptamine 4 binding affinity against zacopride,,CHEMBL620614,H,8,,,,,BAO_0000357,168,,3377,,17358,B,,
Expert,,1,,,Binding affinity against 5-Hydroxytryptamine 4 receptor,,CHEMBL620615,H,8,,,,,BAO_0000357,168,,3378,,1274,B,,
Autocuration,,1,,,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 recognition sites in rat brain membranes,Brain membranes,CHEMBL857075,H,6,,,,,BAO_0000249,104698,,3379,,10728,B,,
Autocuration,,1,,,Compound was evaluated for the displacement of [3H]Q-ICS-205-930 from 5-HT3 recognition sites in rat brain membranes,Brain membranes,CHEMBL620616,H,6,,,,,BAO_0000249,104698,,3380,,11695,B,,
Autocuration,,1,,,Displacement of [3H]Q-ICS-205-930 from 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes,Brain membranes,CHEMBL619411,H,6,,,,,BAO_0000249,104698,,3381,,11695,B,,
Autocuration,,1,,,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor from rat cortex homogenate,,CHEMBL619412,H,6,,,,,BAO_0000019,104698,,3382,,12490,B,,
Autocuration,,1,,,Displacement of [3H]-Q-ICS 205-930 from rat cortex homogenate 5-hydroxytryptamine 3 receptor,,CHEMBL619413,D,7,,,Rattus norvegicus,10116.0,BAO_0000019,104698,,3383,,11828,B,,
Autocuration,,1,,,Binding affinity of 5-hydroxytryptamine 3 receptor using [3H]granisetron in rat hippocampus and entorhinal cortex,,CHEMBL619414,H,6,,,,,BAO_0000221,104698,,3384,Hippocampus,12253,B,,10000000.0
Autocuration,,1,,,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,,CHEMBL619415,H,6,,,,,BAO_0000019,104698,,3385,,10561,B,,
Autocuration,,1,,,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]quipazine as radioligand in rat cortex,,CHEMBL619416,H,6,,,,,BAO_0000019,104698,,3386,,10561,B,,
Autocuration,,1,,,Rat 5-hydroxytryptamine 3 receptor (5-HT3) antagonist,,CHEMBL619417,H,6,,,,,BAO_0000019,104698,,3387,,14432,F,,
Autocuration,,1,,,Binding affinity against rat 5-hydroxytryptamine 3 receptor,,CHEMBL619418,D,7,,,Rattus norvegicus,10116.0,BAO_0000223,104698,,3388,,12936,B,,
Autocuration,,1,,,Binding affinity against 5-Hydroxytryptamine 3 receptor,,CHEMBL619419,D,7,,,Rattus norvegicus,10116.0,BAO_0000223,104698,,3389,,1274,B,,
Autocuration,,1,,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of racemic [3H]zacopride from rat cortex,,CHEMBL619420,H,6,,,,,BAO_0000019,104698,,3390,,1980,B,,
Autocuration,,1,,,Binding affinity to 5-hydroxytryptamine 3 receptor was determined in rat cerebro cortical membranes using [3H]quipazine.,,CHEMBL619421,H,6,,,,,BAO_0000249,104698,,3391,,670,B,,
Autocuration,,1,,,Displacement of [3H]granisetron from 5-hydroxytryptamine 3 receptor of rat cortex,,CHEMBL619422,D,7,,,Rattus norvegicus,10116.0,BAO_0000019,104698,,3392,,968,B,,
Autocuration,,1,,,In vitro by displacement of [3H]LY-278584 from 5-hydroxytryptamine 3 receptor on rat entorhinal cortex,,CHEMBL619423,H,6,,,,,BAO_0000019,104698,,3393,,14287,B,,
Autocuration,,1,,,Tested for its binding affinity by measuring its ability to displace [3H]granisetron from 5-hydroxytryptamine 3 receptor in rat cortex,,CHEMBL875080,H,6,,,,,BAO_0000019,104698,,3394,,567,B,,
Autocuration,,1,,,The binding affinity (pKi) measured against 5-hydroxytryptamine 1A receptor of rat cortex using [3H]8-OH-DPAT as radioligand,,CHEMBL619424,H,6,,,,,BAO_0000019,104698,,3395,,13267,B,,
Autocuration,,1,,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat cortical membrane by [3H]graniestron displacement.,,CHEMBL619425,H,6,,,,,BAO_0000249,104698,,3396,,14826,B,,
Autocuration,,1,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand,,CHEMBL619426,H,6,,,,,BAO_0000223,104698,,3397,,15194,B,,
Autocuration,,1,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand.,,CHEMBL619427,H,6,,,,,BAO_0000223,104698,,3398,,15194,B,,
Autocuration,,1,,,pKi value for inhibition of [3H]LY-278584 binding to 5-hydroxytryptamine 3 receptor,,CHEMBL619645,D,7,,,Rattus norvegicus,10116.0,BAO_0000223,104698,,3399,,10394,B,,
Expert,,1,,,"Compound was evaluated for binding affinity on 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding",,CHEMBL619646,D,9,,,,,BAO_0000249,10576,,3400,,13657,B,,
Autocuration,,1,,,Compound was tested for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat brain using [3H]zacopride as the radioligand.,,CHEMBL619647,H,8,,,,,BAO_0000221,12020,,3401,Brain,1879,F,,955.0
Autocuration,,1,,,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor,,CHEMBL619648,H,8,,,,,BAO_0000019,12020,,3402,,1879,F,,
Autocuration,,1,,,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat CNS.,,CHEMBL619165,H,8,,,,,BAO_0000019,12020,,3403,,1879,F,,
Autocuration,,1,,,Compound was evaluated in vivo for the antagonistic activity towards 5-hydroxytryptamine 3 receptor,,CHEMBL620719,H,8,,,,,BAO_0000218,12020,,3404,,204,F,In vivo,
Autocuration,,1,,,Compound was tested for its binding affinity towards 5-HT-3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,,CHEMBL872924,H,8,,,,,BAO_0000019,12020,,3405,,1879,B,,
Autocuration,,1,,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor,,CHEMBL620720,H,8,,,,,BAO_0000357,12020,,3406,,1879,B,,
Autocuration,,1,,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,,CHEMBL620721,H,8,,,,,BAO_0000019,12020,,3407,,1879,B,,
Autocuration,,1,,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using [125I]DAIZAC as the radioligand.,,CHEMBL620722,H,8,,,,,BAO_0000019,12020,,3408,,1879,B,,
Autocuration,,1,,,"Concentration that inhibits the binding of radioligand, [3H]-ICS 205930, to 5-hydroxytryptamine 3 receptor from rat cortex",,CHEMBL620723,H,6,,,,,BAO_0000019,104698,,3409,,10641,B,,
Autocuration,,1,,,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,,CHEMBL620724,H,8,,,,,BAO_0000019,12020,,3410,,773,B,,
Autocuration,,1,,,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor in rat brain cortical membranes using radioligand [3H]quipazine,,CHEMBL620725,H,6,,,,,BAO_0000249,104698,,3411,,11952,B,,
Autocuration,,1,,,Antagonist activity (100 ug/kg) for the Bezold Jarisch reflex evoked by 30 (ug/Kg) of 5-hydroxytryptamine 3 receptor in ethylurethane anesthetized rats i.v.,,CHEMBL620726,D,9,,,Rattus norvegicus,10116.0,BAO_0000019,12020,,3412,,14145,F,,
Expert,,1,,,Binding affinity towards 5-hydroxytryptamine 3 receptor,,CHEMBL620727,H,8,,,,,BAO_0000357,144,,3413,,17066,B,,
Autocuration,,1,,,Compound was evaluated for 5-hydroxytryptamine 3 receptor binding,,CHEMBL620728,H,4,,,,,BAO_0000223,104714,,3414,,6398,B,,
Autocuration,,1,,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,,CHEMBL620729,U,0,,,,,BAO_0000019,22226,,3415,,10321,B,,
Autocuration,,1,,,Tested for 5-hydroxytryptamine 3 receptor antagonist activity by inhibiting the 5-HT evoked Bezold-Jarisch reflex,,CHEMBL858288,H,4,,,,,BAO_0000019,104714,,3416,,511,F,,
Autocuration,,1,,,Compound was tested for binding affinity towards 5-hydroxytryptamine 3 receptor,,CHEMBL620730,H,4,,,,,BAO_0000223,104714,,3417,,4639,B,,
Autocuration,,1,,,Binding affinity towards 5-hydroxytryptamine 3 receptor,,CHEMBL620731,H,4,,,,,BAO_0000223,104714,,3418,,4639,B,,
Autocuration,,1,,,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 0.3 uM,,CHEMBL620732,H,4,,,Cavia porcellus,10141.0,BAO_0000019,104714,,3419,,4639,F,,
Autocuration,,1,,,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,,CHEMBL618042,H,4,,,Cavia porcellus,10141.0,BAO_0000019,104714,,3420,,4639,F,,
Autocuration,,1,,,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 30 uM,,CHEMBL618043,H,4,,,Cavia porcellus,10141.0,BAO_0000019,104714,,3421,,4639,F,,
Autocuration,,1,,,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,,CHEMBL618044,H,4,,,,,BAO_0000223,104714,,3422,,1558,B,,
Autocuration,,1,,,Evaluated for the 5-hydroxytryptamine 3 receptor antagonistic activity in Bezold-Jarisch model expressed as inhibition of the reflex bradycardia induced by an intravenous injection,,CHEMBL618045,H,4,,,,,BAO_0000019,104714,,3423,,268,F,,
Autocuration,,1,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 3 receptor at a concentration of 10 uM using [3H]BRL-43694 as radioligand,,CHEMBL618046,H,4,,,,,BAO_0000223,104714,,3424,,2474,B,,
Autocuration,,1,,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); A: agonist,,CHEMBL618047,H,4,,,,,BAO_0000019,104714,,3425,,5067,F,,
Autocuration,,1,,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: agonist,,CHEMBL875084,H,4,,,,,BAO_0000019,104714,,3426,,5067,F,,
Autocuration,,1,,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: antagonist,,CHEMBL618048,H,4,,,,,BAO_0000019,104714,,3427,,5067,F,,
Autocuration,,1,,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); NA means data not available,,CHEMBL618049,H,4,,,,,BAO_0000223,104714,,3428,,5067,B,,
Autocuration,,1,,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); PA: Partial agonist,,CHEMBL619764,H,4,,,,,BAO_0000019,104714,,3429,,5067,F,,
Autocuration,,1,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; A: agonist,,CHEMBL619765,H,4,,,,,BAO_0000019,104714,,3430,,5067,F,,
Autocuration,,1,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; ANT: Antagonist,,CHEMBL619766,H,4,,,,,BAO_0000019,104714,,3431,,5067,F,,
Autocuration,,1,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA: not active,,CHEMBL619767,H,4,,,,,BAO_0000223,104714,,3432,,5067,B,,
Autocuration,,1,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA means data not available,,CHEMBL619768,H,4,,,,,BAO_0000223,104714,,3433,,5067,B,,
Autocuration,,1,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; PA: Partial agonist,,CHEMBL619769,H,4,,,,,BAO_0000019,104714,,3434,,5067,F,,
Autocuration,,1,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; na means data not available,,CHEMBL619770,H,4,,,,,BAO_0000223,104714,,3435,,5067,B,,
Autocuration,,1,,,Binding affinity towards 5-hydroxytryptamine 3 receptor,,CHEMBL619771,H,4,,,,,BAO_0000223,104714,,3436,,5067,B,,
Autocuration,,1,,,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor using [3H]-BRL-43694 (1 nM) ligand in NG cells 108-15 was determined,,CHEMBL619772,H,4,,,,,BAO_0000219,104714,,3437,,14331,B,,
Autocuration,,1,,,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor; NA: not active,,CHEMBL619773,H,4,,,,,BAO_0000223,104714,,3438,,5067,B,,
Autocuration,,1,NG108-15,,Binding affinity for 5-HT3 receptor of NG108-15 cells using [3H]GR-65630,,CHEMBL619774,H,4,,433.0,,,BAO_0000219,104714,,3439,,6179,B,,
Autocuration,,1,,,Binding affinity to 5-HT3 serotonin receptor in NG 108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand.,,CHEMBL875083,H,4,,,,,BAO_0000019,104714,,3440,,4265,B,,
Autocuration,,1,NG108-15,,Binding affinity to 5-HT3 serotonin receptor in NG108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand,,CHEMBL620718,H,4,,433.0,,,BAO_0000219,104714,,3441,,4265,B,,
Autocuration,,1,,,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,,CHEMBL618127,H,4,,,,,BAO_0000223,104714,,3442,,17358,B,,
Autocuration,,1,,,Compound was tested for selectivity against 5-hydroxytryptamine 3 receptor binding affinity,,CHEMBL618128,H,4,,,,,BAO_0000223,104714,,3443,,17358,B,,
Autocuration,,1,,,Compound was tested for the inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor expressed in NG 108-15 cells,,CHEMBL618129,H,4,,,,,BAO_0000219,104714,,3444,,13628,B,In vitro,
Autocuration,,1,,,In vitro Binding affinity towards 5-hydroxytryptamine 3 receptor was determined,,CHEMBL618130,H,4,,,,,BAO_0000223,104714,,3445,,4612,B,,
Autocuration,,1,,,Tested for 5-hydroxytryptamine 3 receptor antagonist activity,,CHEMBL618131,H,4,,,,,BAO_0000019,104714,,3446,,17358,F,,
Autocuration,,1,,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 1 uM,,CHEMBL618132,H,4,,,Cavia porcellus,10141.0,BAO_0000019,104714,,3447,,4639,F,,
Autocuration,,1,,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM,,CHEMBL618133,H,4,,,Cavia porcellus,10141.0,BAO_0000019,104714,,3448,,4639,F,,
Autocuration,,1,,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM in the presence of 30 uM MDL 72222,,CHEMBL618134,H,4,,,Cavia porcellus,10141.0,BAO_0000019,104714,,3449,,4639,F,,
Autocuration,,1,,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,,CHEMBL618135,H,4,,,Cavia porcellus,10141.0,BAO_0000019,104714,,3450,,4639,F,,
Autocuration,,1,,,Binding affinity for the 5-hydroxytryptamine 3 receptor was evaluated in vitro by examining its ability to displace [3H]-BRL 43694.,,CHEMBL618136,H,4,,,,,BAO_0000223,104714,,3451,,511,B,,
Autocuration,,1,,,Binding affinity towards 5-hydroxytryptamine 3 receptor,,CHEMBL618137,H,4,,,,,BAO_0000223,104714,,3452,,1479,B,,
Autocuration,,1,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor using radioligand binding assay,,CHEMBL618138,H,4,,,,,BAO_0000223,104714,,3453,,1317,B,,
Autocuration,,1,,,Tested against 5-hydroxytryptamine 3 receptor in experiment 1,,CHEMBL618139,H,4,,,,,BAO_0000223,104714,,3454,,12146,B,,
Autocuration,,1,,,Tested against 5-hydroxytryptamine 3 receptor in experiment 2,,CHEMBL618140,H,4,,,,,BAO_0000223,104714,,3455,,12146,B,,
Autocuration,,1,,,Binding affinity against 5-hydroxytryptamine 3 receptor was measured using [3H]granisetron as radioligand,,CHEMBL618141,H,4,,,,,BAO_0000223,104714,,3456,,13969,B,,
Expert,,1,,,Binding affinity for 5-hydroxytryptamine 2C receptor,,CHEMBL873478,H,8,,,,,BAO_0000357,108,,3457,,13392,B,,
Autocuration,,1,,,Binding affinity towards 5-hydroxytryptamine 3 receptor,,CHEMBL618142,H,6,,,,,BAO_0000223,104698,,3458,,13392,B,,
Autocuration,,1,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 3 receptor,,CHEMBL618143,H,8,,,,,BAO_0000357,144,,3459,,14159,B,,
Autocuration,,1,,,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,,CHEMBL618144,H,8,,,,,BAO_0000357,144,,3460,,1558,B,,
Autocuration,,1,,,Inhibition of GR-65630 binding to 5-hydroxytryptamine 3 receptor,,CHEMBL618145,H,8,,,,,BAO_0000357,144,,3461,,16655,B,,
Autocuration,,1,,,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,,CHEMBL618146,H,4,,,,,BAO_0000223,104714,,3462,,13020,B,,
Autocuration,,1,,,Inhibition of [3H]-BRL 43 694 binding to 5-hydroxytryptamine 3 receptor of central nervous system,,CHEMBL618147,H,4,,,,,BAO_0000223,104714,,3463,,13021,B,,
Autocuration,,1,,,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,,CHEMBL618148,H,4,,,,,BAO_0000223,104714,,3464,,13020,B,,
Autocuration,,1,,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,,CHEMBL618149,H,8,,,,,BAO_0000019,144,,3465,,10321,B,,
Autocuration,,1,,,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,,CHEMBL872927,H,8,,,,,BAO_0000357,144,,3466,,15818,B,,
Autocuration,,1,,,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,,CHEMBL618150,H,8,,,,,BAO_0000357,144,,3467,,15818,B,,
Autocuration,,1,,,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,,CHEMBL618151,H,8,,,,,BAO_0000357,144,,3468,,17358,B,,
Autocuration,,1,,,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,,CHEMBL875094,H,8,,,,,BAO_0000357,144,,3469,,2222,B,,
Autocuration,,1,,,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,,CHEMBL618152,H,8,,,,,BAO_0000019,144,,3470,,10322,B,,
Autocuration,,1,,,In vitro binding affinity towards 5-hydroxytryptamine 3 receptor was determined,,CHEMBL618153,H,8,,,,,BAO_0000357,144,,3471,,16117,B,,
Autocuration,,1,,,Inhibitory constant against 5-hydroxytryptamine 3 receptor using [3H]GR-65630 radioligand,,CHEMBL618888,H,8,,,,,BAO_0000357,144,,3472,,17200,B,,
Autocuration,,1,,,Tested for 5-hydroxytryptamine 3 receptor agonist activity,,CHEMBL618889,H,8,,,,,BAO_0000019,144,,3473,,17358,F,,
Autocuration,,1,,,The binding affinity towards 5-hydroxytryptamine 3 receptor; No affinity,,CHEMBL618890,H,8,,,,,BAO_0000357,144,,3474,,16700,B,,
Autocuration,,1,,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H](R)-zacopride from ondansetron-treated NG-108-15 cell membranes,,CHEMBL618891,H,8,,,,,BAO_0000019,144,,3475,,1980,B,,
Autocuration,,1,,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H]-BRL 43694 from NG-108-15 cell membranes,,CHEMBL619054,H,8,,,,,BAO_0000019,144,,3476,,1980,B,,
Autocuration,,1,,,Binding affinity against the 5-hydroxytryptamine 3 receptor,,CHEMBL619055,H,4,,,,,BAO_0000223,104714,,3477,,12409,B,,
Autocuration,,1,,,Binding affinity against human 5-hydroxytryptamine 3A receptor,,CHEMBL619056,H,8,,,,,BAO_0000357,144,,3478,,4365,B,,
Autocuration,,1,,,Percent efficacy against 5-hydroxytryptamine 3A receptor,,CHEMBL619057,H,8,,,,,BAO_0000019,144,,3479,,4365,F,,
Autocuration,,1,,,Binding affinity against human 5-hydroxytryptamine 3A receptor,,CHEMBL619058,H,8,,,,,BAO_0000357,144,,3480,,4365,B,,
Expert,,1,Oocytes,,Response at rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes,,CHEMBL619059,D,9,,,Rattus norvegicus,10116.0,BAO_0000219,12020,,3481,,6769,F,,
Expert,,1,Oocytes,,Ability to block serotonin (30 uM)-evoked responses at rat 5HT3-alpha receptor expressed in xenopus oocytes,,CHEMBL619060,D,9,,,Rattus norvegicus,10116.0,BAO_0000219,12020,,3482,,6769,F,,
Expert,,1,Oocytes,,Effect on rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes at concentration up to 100 uM,,CHEMBL875095,D,9,,,Rattus norvegicus,10116.0,BAO_0000219,12020,,3483,,6769,F,,
Intermediate,,1,,,5-hydroxytryptamine 4 receptor agonist activity as percent maximum 5-HT effect in response to electrical stimulation in male guinea pig ileum,,CHEMBL619061,D,9,,,Cavia porcellus,10141.0,BAO_0000221,20033,,3484,Ileum,809,F,,2116.0
Intermediate,,1,,,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum,,CHEMBL619062,D,9,,,Cavia porcellus,10141.0,BAO_0000221,20033,,3485,Ileum,809,F,,2116.0
Intermediate,,1,,,5-hydroxytryptamine 4 receptor agonist activity is expressed as percent of the maximum 5-HT response,,CHEMBL619063,D,9,,,Cavia porcellus,10141.0,BAO_0000019,20033,,3486,,14290,F,,
Intermediate,,1,,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in electrically stimulated longitudinal muscle preparation of guinea pig ileum,,CHEMBL619064,D,9,,,Cavia porcellus,10141.0,BAO_0000221,20033,,3487,Ileum,17358,B,,2116.0
Intermediate,,1,,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in guinea pig distal colon preparation,,CHEMBL619065,D,9,,,Cavia porcellus,10141.0,BAO_0000357,20033,,3488,,17358,B,,
Intermediate,,1,,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in isolated guinea pig ileum longitudinal muscle preparation,,CHEMBL619066,D,9,,,Cavia porcellus,10141.0,BAO_0000221,20033,,3489,Ileum,17358,B,,2116.0
Autocuration,,1,,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,,CHEMBL619775,H,8,,,,,BAO_0000221,10209,,3490,Ileum,17386,B,,2116.0
Autocuration,,1,,,Affinity against 5-hydroxytryptamine 7 receptor,,CHEMBL619776,H,8,,,,,BAO_0000357,10209,,3491,,3269,B,,
Autocuration,,1,,,Ability to displace [3H]5-HT binding from 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,,CHEMBL619777,H,4,,,Cavia porcellus,10141.0,BAO_0000224,104841,,3492,,7721,B,,
Autocuration,,1,,,Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,,CHEMBL619778,H,4,,,Cavia porcellus,10141.0,BAO_0000224,104841,,3493,,7721,B,,
Autocuration,,1,,,Evaluated for inhibition of 5-hydroxytryptamine receptor on guinea pig ileum at 10 uM; No effect,,CHEMBL619779,H,4,,,Cavia porcellus,10141.0,BAO_0000221,104841,,3494,Ileum,9117,B,,2116.0
Autocuration,,1,,,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand, activity is expressed as Kd.",,CHEMBL619780,H,4,,,Cavia porcellus,10141.0,BAO_0000224,104841,,3495,,7721,B,,
Autocuration,,1,,,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor using 1 uM LSD as masking ligand, activity is expressed as Kd.",,CHEMBL619166,H,4,,,Cavia porcellus,10141.0,BAO_0000224,104841,,3496,,7721,B,,
Autocuration,,1,,,5-HT level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,,CHEMBL619167,H,4,,,Cavia porcellus,10141.0,BAO_0000019,104841,,3497,,15796,F,,
Autocuration,,1,,,5-hydroxytryptamine level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,,CHEMBL619168,H,4,,,Cavia porcellus,10141.0,BAO_0000019,104841,,3498,,15796,F,,
Expert,,1,,,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor in the presence of 10 nM compound in isolated human atrial myocytes,,CHEMBL619169,D,9,,,Homo sapiens,9606.0,BAO_0000219,168,,3499,Cardiac atrium,15650,B,,2081.0
Expert,,1,,,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes,,CHEMBL619170,D,9,,,Homo sapiens,9606.0,BAO_0000219,168,,3500,Cardiac atrium,15650,B,,2081.0
Autocuration,,1,,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine",,CHEMBL619171,D,5,,,Homo sapiens,9606.0,BAO_0000019,104841,,3501,,6866,F,,
Expert,,1,,,",Antagonism of stimulation of 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes",,CHEMBL619172,D,9,,,Homo sapiens,9606.0,BAO_0000219,168,,3502,Cardiac atrium,15650,F,,2081.0
Autocuration,,1,,,Ability (10 ug/kg) to inhibit binding of [125I]iododexetimide to 5-hydroxytryptamine receptor in mice,,CHEMBL619173,U,0,,,Mus musculus,10090.0,BAO_0000019,22226,,3503,,10063,B,,
Autocuration,,1,,,Percent inhibition of radioligand [3H]-LSD binding to 5-HT receptor at 10 uM concentration,,CHEMBL619174,U,0,,,Mus musculus,10090.0,BAO_0000019,22226,,3504,,12665,B,,
Autocuration,,1,,,5-hydroxytryptamine receptor binding affinity was determined in rats,,CHEMBL619175,H,4,,,,,BAO_0000019,104705,,3505,,7504,B,,
Autocuration,,1,,,Binding affinity at rat 5-hydroxytryptamine receptor.,,CHEMBL619176,H,4,,,,,BAO_0000224,104705,,3506,,7504,B,,
Autocuration,,1,,,Affinity against 5-hydroxytryptamine receptors in rat fundus model,,CHEMBL619177,H,4,,,,,BAO_0000019,104705,,3507,,7038,B,,
Autocuration,,1,,,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation,,CHEMBL619178,H,4,,,,,BAO_0000224,104705,,3508,,7626,B,,
Autocuration,,1,,,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation; Not determined,,CHEMBL619179,H,4,,,,,BAO_0000224,104705,,3509,,7626,B,,
Autocuration,,1,,,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation,,CHEMBL619180,H,4,,,,,BAO_0000019,104705,,3510,Stomach,7185,F,,945.0
Autocuration,,1,,,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation (resulted in discoloration in the oxygenated muscle bath to give varying results).,,CHEMBL619181,H,4,,,,,BAO_0000019,104705,,3511,Stomach,7185,F,,945.0
Autocuration,,1,,,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,,CHEMBL619182,H,4,,,,,BAO_0000019,104705,,3512,,7185,F,,
Autocuration,,1,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2,,CHEMBL619183,H,4,,,,,BAO_0000224,104705,,3513,,6960,B,,
Autocuration,,1,,,"Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2; Valid pA2, can not be determined because of slope of Schild plot.",,CHEMBL619184,H,4,,,,,BAO_0000224,104705,,3514,,6960,B,,
Autocuration,,1,,,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,,CHEMBL619185,H,8,,,,,BAO_0000221,10576,,3515,Hippocampus,12416,B,,10000000.0
Expert,,1,,,Binding affinity for rat 5-hydroxytryptamine transporter.,,CHEMBL619186,H,8,,,,,BAO_0000357,12198,,3516,,15753,B,,
Autocuration,,1,,,Evaluated for inhibition of specific [3H]5-HT receptor binding in rat cortex.,,CHEMBL619187,H,4,,,,,BAO_0000019,104705,,3517,,8062,B,,
Autocuration,,1,,,Binding affinity at serotonin 5-HT1-type site receptor in rat cortex by displacing [3H]5-HT,,CHEMBL619188,D,5,,,Rattus norvegicus,10116.0,BAO_0000019,104705,,3518,,9036,B,,
Autocuration,,1,,,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,,CHEMBL619189,D,5,,,Rattus norvegicus,10116.0,BAO_0000224,104705,,3519,,15067,B,,
Expert,,1,,,Inhibitory activity against [3H]- 5-hydroxytryptamine reuptake in whole rat brain minus cerebellum,,CHEMBL619190,D,9,,,Rattus norvegicus,10116.0,BAO_0000019,12198,,3520,Brain,15753,F,,955.0
Expert,,1,,,Inhibition of [3H]5-HT reuptake in whole rat brain (minus cerebellum) homogenate.,,CHEMBL619191,D,9,,,Rattus norvegicus,10116.0,BAO_0000221,12198,,3521,Cerebellum,15753,F,,2037.0
Autocuration,,1,,,Displacement of [3H]-citalopram from rat forebrain membrane 5-hydroxytryptamine receptor at 10e-7 M,,CHEMBL619192,D,5,,,Rattus norvegicus,10116.0,BAO_0000019,104705,,3522,,15295,B,,
Autocuration,,1,,,Percent binding affinity against 5-hydroxytryptamine receptor,,CHEMBL619193,D,5,,,Rattus norvegicus,10116.0,BAO_0000224,104705,,3523,,6347,B,,
Autocuration,,1,,,Ability to displace 0.4 nM [3H]paroxetine binding to 5-hydroxytryptamine receptor in rat frontal cortex,,CHEMBL619194,U,0,,,,,BAO_0000019,22226,,3524,,6763,B,,
Autocuration,,1,,,The binding affinity was measured on 5-hydroxytryptamine receptor uptake receptor using [3H]- paroxetine as radioligand.,,CHEMBL619195,D,5,,,Rattus norvegicus,10116.0,BAO_0000224,104705,,3525,,12092,B,,
Autocuration,,1,,,Affinity against 5-hydroxytryptamine receptor was determined,,CHEMBL619196,D,5,,,Rattus norvegicus,10116.0,BAO_0000224,104705,,3526,,1579,B,,
Autocuration,,1,,,Affinity against 5-hydroxytryptamine receptor was determined in rat stomach fundus strip,,CHEMBL619197,D,5,,,Rattus norvegicus,10116.0,BAO_0000019,104705,,3527,Stomach,1579,B,,945.0
Expert,,1,,,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,,CHEMBL619198,D,9,,,Homo sapiens,9606.0,BAO_0000219,121,,3528,,5963,B,In vitro,
Expert,,1,,,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,,CHEMBL875081,D,9,,,Homo sapiens,9606.0,BAO_0000219,121,,3529,,5963,B,In vitro,
Autocuration,,1,,,Ability to compete with radioactive ligands specific to the Serotonergic 5-HT receptor at 10 uM; NA means compound failed to compete,,CHEMBL884712,H,8,,,,,BAO_0000357,18065,,3530,,5030,B,,
Expert,,1,,,Inhibition of 5-hydroxytryptamine reuptake,,CHEMBL884710,H,8,,,,,BAO_0000357,121,,3531,,15796,B,,
Autocuration,,1,,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding",,CHEMBL619199,H,8,,,,,BAO_0000019,18065,,3532,,15413,F,,
Autocuration,,1,,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 1)",,CHEMBL619200,H,8,,,,,BAO_0000019,18065,,3533,,15413,F,,
Autocuration,,1,,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 2)",,CHEMBL619201,H,8,,,,,BAO_0000019,18065,,3534,,15413,F,,
Autocuration,,1,,,Tested for 5-hydroxytryptamine receptor uptake,,CHEMBL619202,H,8,,,,,BAO_0000019,18065,,3535,,12409,F,,
Expert,,1,CHO,,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,,CHEMBL619203,D,9,,449.0,Homo sapiens,9606.0,BAO_0000219,51,,3536,,16909,B,,
Expert,,1,,,Antagonistic affinity tested against isolated human cloned alpha-1d adrenoceptor subtype,,CHEMBL619204,D,9,,,Homo sapiens,9606.0,BAO_0000019,51,,3537,,16909,F,,
Autocuration,,1,,,In vitro binding affinity towards 5-hydroxytryptamine receptor 1A receptor by using [3H]8-OH-DPAT in rat hippocampal membranes.,,CHEMBL619205,H,8,,,Homo sapiens,9606.0,BAO_0000249,10576,,3538,,15629,B,,
Autocuration,,1,,,Tested in vitro for % inhibition against 5-hydroxytryptamine receptor 1A,,CHEMBL619206,H,8,,,,,BAO_0000357,10576,,3539,,15629,B,,
Expert,,1,,,In vitro binding affinity at 5-hydroxytryptamine receptor 1A receptor in rat hippocampal membranes by [3H]8-OH-DPAT displacement.,,CHEMBL619207,H,8,,,,,BAO_0000249,10576,,3540,,15629,B,,
Autocuration,,1,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 0.10 umol/kg,,CHEMBL619208,H,8,,,,,BAO_0000019,10825,,3541,Striatum,10034,F,,2435.0
Autocuration,,1,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 10 umol/kg,,CHEMBL619209,H,8,,,,,BAO_0000019,10825,,3542,Striatum,10034,F,,2435.0
Autocuration,,1,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 0.32 umol/kg,,CHEMBL619210,H,8,,,,,BAO_0000019,10825,,3543,Striatum,10034,F,,2435.0
Autocuration,,1,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 3.2 umol/kg,,CHEMBL619211,H,8,,,,,BAO_0000019,10825,,3544,Striatum,10034,F,,2435.0
Autocuration,,1,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 32 umol/kg,,CHEMBL619212,H,8,,,,,BAO_0000019,10825,,3545,Striatum,10034,F,,2435.0
Autocuration,,1,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 0.032 umol/kg,,CHEMBL620681,H,8,,,,,BAO_0000019,10825,,3546,Striatum,10034,F,,2435.0
Autocuration,,1,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 1.0 umol/kg,,CHEMBL620682,H,8,,,,,BAO_0000019,10825,,3547,Striatum,10034,F,,2435.0
Autocuration,,1,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 10 umol/kg,,CHEMBL620683,H,8,,,,,BAO_0000019,10825,,3548,Striatum,10034,F,,2435.0
Autocuration,,1,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 100 umol/kg,,CHEMBL620684,H,8,,,,,BAO_0000019,10825,,3549,Striatum,10034,F,,2435.0
Autocuration,,1,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 3.2 umol/kg,,CHEMBL620685,H,8,,,,,BAO_0000019,10825,,3550,Striatum,10034,F,,2435.0
Autocuration,,1,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 32 umol/kg,,CHEMBL620686,H,8,,,,,BAO_0000019,10825,,3551,Striatum,10034,F,,2435.0
Autocuration,,1,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.032 umol/kg,,CHEMBL620687,H,8,,,,,BAO_0000019,10825,,3552,Limbic system,10034,F,,349.0
Autocuration,,1,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,,CHEMBL620688,H,8,,,,,BAO_0000019,10825,,3553,Limbic system,10034,F,,349.0
Autocuration,,1,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.32 umol/kg,,CHEMBL620689,H,8,,,,,BAO_0000019,10825,,3554,Limbic system,10034,F,,349.0
Autocuration,,1,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 1.0 umol/kg,,CHEMBL620690,H,8,,,,,BAO_0000019,10825,,3555,Limbic system,10034,F,,349.0
Autocuration,,1,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 10 umol/kg,,CHEMBL620691,H,8,,,,,BAO_0000019,10825,,3556,Limbic system,10034,F,,349.0
Autocuration,,1,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 100 umol/kg,,CHEMBL620692,H,8,,,,,BAO_0000019,10825,,3557,Limbic system,10034,F,,349.0
Autocuration,,1,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 3.2 umol/kg,,CHEMBL620693,H,8,,,,,BAO_0000019,10825,,3558,Limbic system,10034,F,,349.0
Expert,,1,,,Binding affinity against 5-hydroxytryptamine 4 receptor,,CHEMBL620694,H,8,,,,,BAO_0000357,168,,3559,,1274,B,,
Autocuration,,1,,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,CHEMBL857986,H,8,,,,,BAO_0000019,168,,3560,,17358,F,,
Autocuration,,1,,,Inhibitory activity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand at 10e-5 M concentration,,CHEMBL620695,H,8,,,,,BAO_0000357,168,,3561,,14532,B,,
Expert,,1,,,Binding affinity towards Serotonin 5-hydroxytryptamine 4 receptor,,CHEMBL620696,H,8,,,,,BAO_0000357,168,,3562,,16989,B,,
Autocuration,,1,,,Inhibitory constant against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 radioligand,,CHEMBL620697,H,8,,,,,BAO_0000357,168,,3563,,17200,B,,
Autocuration,,1,,,Binding affinity towards 5-hydroxytryptamine 4 receptor,,CHEMBL620698,H,8,,,,,BAO_0000357,168,,3564,,15779,B,,
Autocuration,,1,,,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,,CHEMBL620699,H,8,,,,,BAO_0000357,168,,3565,,15779,B,,
Autocuration,,1,,,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,,CHEMBL620700,H,8,,,,,BAO_0000357,168,,3566,,15779,B,,
Autocuration,,1,COS-7,,Binding affinity was determined against cloned 5-hydroxytryptamine 4A receptor isoform expressed in COS-7 cells,,CHEMBL620701,H,8,,643.0,,,BAO_0000219,168,,3567,,15650,B,,
Autocuration,,1,COS-7,,Binding affinity was determined against cloned 5-hydroxytryptamine 4B receptor isoform expressed in COS-7 cells,,CHEMBL875082,H,8,,643.0,,,BAO_0000219,168,,3568,,15650,B,,
Autocuration,,1,COS-7,,Binding affinity was determined against cloned 5-hydroxytryptamine 4C receptor isoform expressed in COS-7 cells,,CHEMBL620702,H,8,,643.0,,,BAO_0000219,168,,3569,,15650,B,,
Autocuration,,1,COS-7,,Binding affinity was determined against cloned 5-hydroxytryptamine 4D receptor isoform expressed in COS-7 cells,,CHEMBL620703,H,8,,643.0,,,BAO_0000219,168,,3570,,15650,B,,
Autocuration,,1,C6,,Binding affinity of compound towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,,CHEMBL620704,H,8,,673.0,,,BAO_0000219,168,,3571,,17046,B,,
Expert,,1,C6,,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,,CHEMBL620705,H,8,,673.0,,,BAO_0000219,168,,3572,,17046,B,,
Expert,,1,C6,,Binding affinity was determined against cloned 5-hydroxytryptamine 4E receptor isoform expressed in C6 glial cells incubated with 0.2 nM [3H]GR-113808,,CHEMBL620706,H,8,,673.0,,,BAO_0000219,168,,3573,,15650,B,,
Expert,,1,C6,,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand; Not determined,,CHEMBL620707,H,8,,673.0,,,BAO_0000219,168,,3574,,17046,B,,
Expert,,1,,,Binding affinity towards 5-hydroxytryptamine 5 receptor,,CHEMBL620708,H,8,,,,,BAO_0000357,10624,,3575,,17066,B,,
Autocuration,,1,,,Inhibitory constant against human 5-hydroxytryptamine 5A receptor using [3H]LSD radioligand,,CHEMBL620709,H,8,,,,,BAO_0000357,105,,3576,,17200,B,,
Expert,,1,,,Binding affinity against 5-hydroxytryptamine 5A receptor,,CHEMBL620710,D,9,,,Homo sapiens,9606.0,BAO_0000357,10624,,3577,,16146,B,,
Autocuration,,1,CHO,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 5A receptor stably expressed in CHO cells,,CHEMBL620711,H,8,,449.0,,,BAO_0000219,10624,,3578,,15250,B,,
Expert,,1,,,Affinity towards human 5-hydroxytryptamine 5A serotonin receptor,,CHEMBL620712,D,9,,,Homo sapiens,9606.0,BAO_0000357,10624,,3579,,6491,B,,
Expert,,1,,,Binding affinity towards human 5-hydroxytryptamine 5A receptor,,CHEMBL620713,D,9,,,Homo sapiens,9606.0,BAO_0000357,10624,,3580,,17066,B,,
Expert,,1,,,Binding affinity towards human 5-hydroxytryptamine 5A receptor was evaluated using [3H]-5-CT as radioligand,,CHEMBL620714,D,9,,,Homo sapiens,9606.0,BAO_0000357,10624,,3581,,17066,B,,
Expert,,1,,,Binding affinity to cloned human 5-hydroxytryptamine 5A receptor,,CHEMBL620715,D,9,,,Homo sapiens,9606.0,BAO_0000357,10624,,3582,,4234,B,,
Autocuration,,1,,,Binding affinity towards 5-HT5A receptor,,CHEMBL620716,H,8,,,,,BAO_0000357,10624,,3583,,6013,B,,
Expert,,1,,,Binding affinity towards human 5-hydroxytryptamine 5A receptor using LSD as radioligand,,CHEMBL620717,H,8,,,,,BAO_0000357,10624,,3584,,17175,B,,
Autocuration,,1,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 5A receptor,,CHEMBL618072,H,8,,,,,BAO_0000357,10624,,3585,,15818,B,,
Autocuration,,1,,,Binding affinity towards cloned human 5-HT5A receptor was determined,,CHEMBL857987,H,8,,,,,BAO_0000357,10624,,3586,,6166,B,,
Autocuration,,1,HEK293,,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,CHEMBL618073,H,8,,722.0,,,BAO_0000219,10624,,3587,,15779,B,,
Autocuration,,1,HEK293,,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,,CHEMBL618074,H,8,,722.0,,,BAO_0000219,10624,,3588,,15779,B,,
Autocuration,,1,HEK293,,Compound was tested for its binding affinity in 5-hydroxytryptamine 5A receptor (using human cloned receptors in HEK 293 and [3H]5-CTas a radioligand ),,CHEMBL618075,H,8,,722.0,,,BAO_0000219,10624,,3589,,5213,B,,
Expert,,1,,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor,,CHEMBL618076,D,9,,,Mus musculus,10090.0,BAO_0000357,10625,,3590,,17066,B,,
Expert,,1,,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [125I]-2-iodo LSD as radioligand,,CHEMBL618077,D,9,,,Mus musculus,10090.0,BAO_0000357,10625,,3591,,17066,B,,
Expert,,1,,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]- LSD as radioligand,,CHEMBL618078,D,9,,,Mus musculus,10090.0,BAO_0000357,10625,,3592,,17066,B,,
Expert,,1,,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]LSD as radioligand,,CHEMBL881821,D,9,,,Mus musculus,10090.0,BAO_0000357,10625,,3593,,17066,B,,
Expert,,1,,,Binding affinity towards murine 5-hydroxytryptamine 5A receptor,,CHEMBL618079,D,9,,,Mus musculus,10090.0,BAO_0000357,10625,,3594,,17066,B,,
Expert,,1,,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor using LSD as radioligand,,CHEMBL618080,H,8,,,,,BAO_0000357,10625,,3595,,17175,B,,
Autocuration,,1,HEK293,,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,,CHEMBL618081,H,8,,722.0,,,BAO_0000219,10576,,3596,,16190,B,,
Autocuration,,1,HEK293,,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,,CHEMBL618082,H,8,,722.0,,,BAO_0000219,10626,,3597,,16190,B,,
Expert,,1,,,Binding affinity towards 5-HT5a receptor,,CHEMBL618083,H,8,,,,,BAO_0000357,10624,,3598,,4820,B,,
Expert,,1,,,Binding affinity towards 5-hydroxytryptamine 5A receptor,,CHEMBL618084,D,9,,,Homo sapiens,9606.0,BAO_0000357,10624,,3599,,17066,B,,
Expert,,1,,,Binding affinity for rodent 5-hydroxytryptamine 5A receptor,,CHEMBL618085,H,8,,,,,BAO_0000357,10624,,3600,,17066,B,,
Expert,,1,,,Binding affinity towards 5-hydroxytryptamine 5A receptor using lysergic acid diethylamide (LSD) as radioligand,,CHEMBL618086,H,8,,,,,BAO_0000357,10624,,3601,,17175,B,,
Autocuration,,1,,,Binding affinities against 5-hydroxytryptamine 5A receptor,,CHEMBL875092,H,8,,,,,BAO_0000357,10624,,3602,,16633,B,,
Autocuration,,1,,,Binding affinities towards 5-hydroxytryptamine 5A receptor,,CHEMBL618087,H,8,,,,,BAO_0000357,10624,,3603,,16633,B,,
Autocuration,,1,,,The binding affinity towards 5-hydroxytryptamine 5A receptor; No affinity,,CHEMBL872926,H,8,,,,,BAO_0000357,10624,,3604,,16700,B,,
Autocuration,,1,,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.01 uM,,CHEMBL618088,H,4,,,Cavia porcellus,10141.0,BAO_0000019,104714,,3605,,4639,F,,
Autocuration,,1,,,Binding affinity towards 5-HT3 receptor by the displacement of [3H]GR-65630] in human recombinant receptors in mammalian cell,,CHEMBL618089,H,4,,,,,BAO_0000223,104714,,3606,,5486,B,,
Expert,,1,,,Inhibition of human 5-hydroxytryptamine 6 receptor,,CHEMBL618090,D,9,,,Homo sapiens,9606.0,BAO_0000357,10627,,3607,,16146,B,,
Expert,,1,,,Binding affinity towards 5-hydroxytryptamine 6 receptor using [3H]- LSD as radioligand,,CHEMBL618091,D,9,,,Homo sapiens,9606.0,BAO_0000357,10627,,3608,,17273,B,,
Autocuration,,1,,,Inhibition against human 5-hydroxytryptamine 6 receptor,,CHEMBL618092,H,8,,,,,BAO_0000357,10627,,3609,,17687,B,,
Expert,,1,,,Affinity towards human 5-hydroxytryptamine 6 serotonin receptor,,CHEMBL618093,D,9,,,Homo sapiens,9606.0,BAO_0000357,10627,,3610,,6491,B,,
Expert,,1,HeLa,,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells.,,CHEMBL618094,H,8,,308.0,,,BAO_0000219,10627,,3611,,16190,B,,
Expert,,1,,,Binding affinity towards [3H]LSD-labeled human 5-hydroxytryptamine 6 receptor,,CHEMBL618095,D,9,,,Homo sapiens,9606.0,BAO_0000357,10627,,3612,,17066,B,,
Expert,,1,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,CHEMBL875093,D,9,,,Homo sapiens,9606.0,BAO_0000357,10627,,3613,,17066,B,,
Expert,,1,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [125I]-2-iodo LSD as radioligand,,CHEMBL618096,D,9,,,Homo sapiens,9606.0,BAO_0000357,10627,,3614,,17066,B,,
Expert,,1,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [3H]-LSD as radioligand,,CHEMBL618118,D,9,,,Homo sapiens,9606.0,BAO_0000357,10627,,3615,,17066,B,,
Expert,,1,,,Binding affinity against 5-hydroxytryptamine 6 receptor,,CHEMBL618119,D,9,,,Homo sapiens,9606.0,BAO_0000357,10627,,3616,,3555,B,,
Expert,,1,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,CHEMBL618120,H,8,,,,,BAO_0000357,10627,,3617,,5808,B,,
Autocuration,,1,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,CHEMBL618121,H,8,,,,,BAO_0000357,10627,,3618,,6013,B,,
Expert,,1,HEK293,,"Binding affinity for human 5-hydroxytryptamine 6 receptor expressed in HEK 293 human embryonic kidney cells, [3H]-lysergic acid diethylamide as radioligand",,CHEMBL618122,H,8,,722.0,,,BAO_0000219,10627,,3619,,15818,B,,
Autocuration,,1,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor using [3H]LSD as radioligand,,CHEMBL618123,H,8,,,,,BAO_0000357,10627,,3620,,16209,B,,
Expert,,1,HEK293,,Binding affinity against human 5-hydroxytryptamine 6 receptor stably transfected to HEK 293 human embryonic kidney cells using [3H]-lysergic acid diethylamide as radioligand,,CHEMBL618124,H,8,,722.0,,,BAO_0000219,10627,,3621,,3935,B,,
Autocuration,,1,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 6 receptor,,CHEMBL618125,H,8,,,,,BAO_0000357,10627,,3622,,15818,B,,
Expert,,1,HEK293,,Displacement of [3H]LSD from human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,,CHEMBL618126,D,9,,722.0,Homo sapiens,9606.0,BAO_0000219,10627,,3623,,3805,B,,
Expert,,1,,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD,,CHEMBL618236,H,8,,,,,BAO_0000019,10627,,3624,,16441,B,,
Expert,,1,,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD; ND is No Data.,,CHEMBL618237,H,8,,,,,BAO_0000019,10627,,3625,,16441,B,,
Expert,,1,COS-7,,Ability to displace [3H]LSD from human 5-hydroxytryptamine 6 receptor transiently expressed in COS-7 cells,,CHEMBL618238,H,8,,643.0,,,BAO_0000219,10627,,3626,,6786,B,,
Expert,,1,,,In vitro binding affinity to human 5-hydroxytryptamine 6 receptor,,CHEMBL618239,D,9,,,Homo sapiens,9606.0,BAO_0000357,10627,,3627,,4234,B,,
Autocuration,,1,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 6 receptor,,CHEMBL618240,H,8,,,,,BAO_0000019,10627,,3628,,17085,B,,
Autocuration,,1,,,Inhibitory constant against human 5-hydroxytryptamine 6 receptor using [3H]LSD radioligand,,CHEMBL618241,H,8,,,,,BAO_0000357,10627,,3629,,17200,B,,
Autocuration,,1,HEK293,,Antagonism assessed in a functional cAMP binding assay using 5-CT to stimulate human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,,CHEMBL859399,H,8,,722.0,,,BAO_0000219,10627,,3630,,17451,B,,
Autocuration,,1,,,The compound was tested for antagonist activity by inhibition of human 5-HT6 stimulated adenylate cyclase,,CHEMBL618242,H,8,,,,,BAO_0000019,10627,,3631,,3935,F,,
Autocuration,,1,,,Ability to displace the radioligand [3H]LSD from human 5-hydroxytryptamine 6 receptor,,CHEMBL857991,H,8,,,,,BAO_0000357,10627,,3632,,5033,B,,
Expert,,1,,,Binding affinity against human 5-hydroxytryptamine 6 receptor,,CHEMBL619951,H,8,,,,,BAO_0000357,10627,,3633,,4540,B,,
Expert,,1,HeLa,,Binding affinity to human cloned 5-HT6 receptor in HeLa cells using [3H]- LSD as radioligand,,CHEMBL619952,D,9,,308.0,Homo sapiens,9606.0,BAO_0000219,10627,,3634,,4540,B,,
Expert,,1,HeLa,,Binding affinity to human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]- LSD as radioligand,,CHEMBL619953,D,9,,308.0,Homo sapiens,9606.0,BAO_0000219,10627,,3635,,4540,B,,
Autocuration,,1,HeLa,,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells,,CHEMBL619954,H,8,,308.0,,,BAO_0000219,10627,,3636,,17296,B,,
Autocuration,,1,HeLa,,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,,CHEMBL619955,H,8,,308.0,,,BAO_0000219,10627,,3637,,17296,B,,
Autocuration,,1,HeLa,,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,,CHEMBL619956,H,8,,308.0,,,BAO_0000219,10627,,3638,,17296,B,,
Autocuration,,1,CHO,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,,CHEMBL619957,H,8,,449.0,,,BAO_0000219,10627,,3639,,15779,B,,
Autocuration,,1,HEK293,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,CHEMBL619958,H,8,,722.0,,,BAO_0000219,10627,,3640,,15779,B,,
Autocuration,,1,HEK293,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand; ND means no data.,,CHEMBL620627,H,8,,722.0,,,BAO_0000219,10627,,3641,,15779,B,,
Autocuration,,1,HEK293,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,,CHEMBL620628,H,8,,722.0,,,BAO_0000219,10627,,3642,,15779,B,,
Autocuration,,1,HeLa,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HeLa cells using [3H]LSD as radioligand;ND means no data.,,CHEMBL620629,H,8,,308.0,,,BAO_0000219,10627,,3643,,15779,B,,
Autocuration,,1,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,CHEMBL620630,H,8,,,,,BAO_0000357,10627,,3644,,6166,B,,
Autocuration,,1,HeLa,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 6 receptor expressed in HeLa cells using [3H]LSD as radioligand,,CHEMBL620782,H,8,,308.0,,,BAO_0000219,10627,,3645,,17451,B,,
Autocuration,,1,,,Compound was evaluated for its ability to displace [3H]LSD binding from human recombinant 5-hydroxytryptamine 6 receptor,,CHEMBL620783,H,8,,,,,BAO_0000357,10627,,3646,,15316,B,,
Expert,,1,,,Binding affinity against human 5-hydroxytryptamine 6 receptor,,CHEMBL620784,H,8,,,,,BAO_0000357,10627,,3647,,4199,B,,
Expert,,1,HeLa,,Binding affinity against human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]LSD,,CHEMBL620785,H,8,,308.0,,,BAO_0000219,10627,,3648,,15146,B,,
Autocuration,,1,,,Compound was tested for its binding affinity in 5-hydroxytryptamine 6 receptor (using human cloned receptors in HeLa and [3H]LSD as a radioligand ),,CHEMBL857992,H,8,,,,,BAO_0000357,10627,,3649,,5213,B,,
Autocuration,,1,,,In vitro binding affinity at human recombinant 5-hydroxytryptamine 6 receptor in mammalian cells using 3[H]LSD as the radioligand,,CHEMBL620786,H,8,,,,,BAO_0000219,10627,,3650,,16429,B,,
Autocuration,,1,HeLa,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]5-LSD.,,CHEMBL620787,H,8,,308.0,,,BAO_0000219,10627,,3651,,14818,B,,
Autocuration,,1,HeLa,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=3",,CHEMBL620788,H,8,,308.0,,,BAO_0000219,10627,,3652,,4829,B,,
Autocuration,,1,HeLa,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=9",,CHEMBL620789,H,8,,308.0,,,BAO_0000219,10627,,3653,,4829,B,,
Autocuration,,1,HeLa,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]LSD as radioligand; n=3",,CHEMBL620790,H,8,,308.0,,,BAO_0000219,10627,,3654,,4829,B,,
Autocuration,,1,CHO,,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 6 receptor stably expressed in CHO cells,,CHEMBL620791,H,8,,449.0,,,BAO_0000219,10628,,3655,,15250,B,,
Autocuration,,1,,,Binding affinity against 5-hydroxytryptamine 6 receptor from CHO cell membranes using [3H]5-HT as the radioligand.,,CHEMBL620792,H,8,,,,,BAO_0000019,10628,,3656,,14423,B,,
Autocuration,,1,,,The compound was tested for binding affinity against 5-hydroxytryptamine 6 receptor,,CHEMBL620793,H,8,,,,,BAO_0000357,10628,,3657,,15086,B,,
Autocuration,,1,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor was determined,,CHEMBL620794,H,8,,,,,BAO_0000357,10628,,3658,,4342,B,,
Autocuration,,1,HeLa,,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells,,CHEMBL620795,D,9,,308.0,Homo sapiens,9606.0,BAO_0000219,10627,,3659,,16190,B,,
Expert,,1,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,CHEMBL620796,H,8,,,,,BAO_0000357,10627,,3660,,4820,B,,
Autocuration,,1,,,Percentage of displacement at 5-hydroxytryptamine 6 receptor at 10e-8 M,,CHEMBL620797,H,8,,,,,BAO_0000357,10627,,3661,,4639,B,,
Expert,,1,,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,,CHEMBL620798,D,9,,,Homo sapiens,9606.0,BAO_0000019,10627,,3662,,17066,F,,
Autocuration,,1,,,Inhibition of binding towards 5-hydroxytryptamine 6 receptor at 100 nM concentration,,CHEMBL620799,H,8,,,,,BAO_0000357,10627,,3663,,6011,B,,
Expert,,1,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,CHEMBL620800,H,8,,,,,BAO_0000357,10627,,3664,,17066,B,,
Autocuration,,1,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor; inactive at 10 uM,,CHEMBL620801,H,8,,,,,BAO_0000357,10627,,3665,,17515,B,,
Autocuration,,1,,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 6 receptor,,CHEMBL875100,H,8,,,,,BAO_0000357,10627,,3666,,5014,B,,
Autocuration,,1,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 6 receptor was determined,,CHEMBL620802,H,8,,,,,BAO_0000357,10627,,3667,,4373,B,,
Expert,,1,,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor,,CHEMBL620803,H,8,,,,,BAO_0000019,10627,,3668,,17066,F,,
Expert,,1,,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,,CHEMBL620804,H,8,,,,,BAO_0000019,10627,,3669,,17066,F,,
Autocuration,,1,,,Binding affinity for 5-hydroxytryptamine 6 receptor was determined,,CHEMBL620805,H,8,,,,,BAO_0000357,10627,,3670,,4373,B,,
Autocuration,,1,,,Evaluated for the binding affinity towards 5-hydroxytryptamine 6 receptor,,CHEMBL620806,H,8,,,,,BAO_0000357,10627,,3671,,4687,B,,
Autocuration,,1,,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-6 M,,CHEMBL620807,H,8,,,,,BAO_0000357,10627,,3672,,16946,B,,
Autocuration,,1,,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-8 M,,CHEMBL620808,H,8,,,,,BAO_0000357,10627,,3673,,16946,B,,
Autocuration,,1,,,Binding affinities against 5-hydroxytryptamine 6 receptor,,CHEMBL620809,H,8,,,,,BAO_0000357,10627,,3674,,16633,B,,
Autocuration,,1,,,Binding affinities towards 5-hydroxytryptamine 6 receptor,,CHEMBL620810,H,8,,,,,BAO_0000357,10627,,3675,,16633,B,,
Expert,,1,,,Binding affinity towards 5-hydroxytryptamine 6 receptor,,CHEMBL620811,D,9,,,Homo sapiens,9606.0,BAO_0000357,10627,,3676,,17066,B,,
Autocuration,,1,,,The binding affinity towards 5-hydroxytryptamine 6 receptor; No affinity,,CHEMBL620812,H,8,,,,,BAO_0000357,10627,,3677,,16700,B,,
Autocuration,,1,,,Affinity against 5-hydroxytryptamine 6 receptor,,CHEMBL620813,H,8,,,,,BAO_0000357,10627,,3678,,3269,B,,
Autocuration,,1,,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-CT],,CHEMBL620814,H,8,,,,,BAO_0000357,10627,,3679,,5486,B,,
Expert,,1,,,Inhibition of human 5-hydroxytryptamine 7 receptor,,CHEMBL620815,D,9,,,Homo sapiens,9606.0,BAO_0000357,10209,,3680,,16146,B,,
Autocuration,,1,HEK293,,Compound was tested for its binding affinity towards human 5-hydroxytryptamine 7 receptor from HEK293 cells using radioligand [3H]LSD,,CHEMBL620816,H,8,,722.0,,,BAO_0000219,10209,,3681,,5014,B,,
Autocuration,,1,,,Compound at 1 uM was tested for the inhibition of radioligand [3H]LSD binding to recombinant human 5-hydroxytryptamine 7 receptor,,CHEMBL620817,H,8,,,,,BAO_0000357,10209,,3682,,15463,B,,
Autocuration,,1,,,In vitro binding affinity against human 5-hydroxytryptamine 7 receptor at a concentration of 100 (nM),,CHEMBL620818,H,8,,,,,BAO_0000357,10209,,3683,,3805,B,,
Expert,,1,HEK293,,Inhibition (at 1 uM) of radioligand [3H]LSD binding to human 5-hydroxytryptamine 7 receptor on HEK293 cells,,CHEMBL620819,H,8,,722.0,,,BAO_0000219,10209,,3684,,5014,B,,
Expert,,1,,,Affinity towards human 5-hydroxytryptamine 7 serotonin receptor,,CHEMBL620820,D,9,,,Homo sapiens,9606.0,BAO_0000357,10209,,3685,,6491,B,,
Autocuration,,1,CHO,,Binding affinity for 5-hydroxytryptamine 7 receptor human cloned receptors in CHO cells using [3H]5-HT,,CHEMBL620821,H,8,,449.0,,,BAO_0000219,10209,,3686,,16190,B,,
Expert,,1,,,Binding affinity towards human 5-hydroxytryptamine 7 receptor,,CHEMBL620822,D,9,,,Homo sapiens,9606.0,BAO_0000357,10209,,3687,,17066,B,,
Expert,,1,,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 7 receptor,,CHEMBL620823,D,9,,,Homo sapiens,9606.0,BAO_0000357,10209,,3688,,17066,B,,
Expert,,1,,,Binding affinity against 5-hydroxytryptamine 7 receptor,,CHEMBL620824,D,9,,,Homo sapiens,9606.0,BAO_0000357,10209,,3689,,3555,B,,
Expert,,1,CHO,,Binding affinity towards human 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-HT radioligand from the cloned receptor expressed in CHO cells,,CHEMBL620825,H,8,,449.0,,,BAO_0000219,10209,,3690,,6588,B,,
Autocuration,,1,,,Binding affinity towards recombinant human 5-hydroxytryptamine 7 receptor was determined using [3H]LSD as radioligand,,CHEMBL872930,H,8,,,,,BAO_0000357,10209,,3691,,15463,B,,
Autocuration,,1,,,Binding affinity towards 5-hydroxytryptamine 7 receptor,,CHEMBL620826,H,8,,,,,BAO_0000357,10209,,3692,,6013,B,,
Autocuration,,1,,,Binding affinity towards human 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,,CHEMBL620827,H,8,,,,,BAO_0000357,10209,,3693,,16209,B,,
Autocuration,,1,,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 7 receptor,,CHEMBL620828,H,8,,,,,BAO_0000357,10209,,3694,,3935,B,,
Autocuration,,1,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 7 receptor,,CHEMBL620829,H,8,,,,,BAO_0000357,10209,,3695,,15818,B,,
Expert,,1,HEK293,,Binding affinity towards human 5-hydroxytryptamine 7 receptor on HEK293 cells using radioligand [3H]LSD,,CHEMBL620830,H,8,,722.0,,,BAO_0000219,10209,,3696,,5014,B,,
Expert,,1,,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD,,CHEMBL620831,H,8,,,,,BAO_0000019,10209,,3697,,16441,B,,
Expert,,1,,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD; ND is No Data.,,CHEMBL620832,H,8,,,,,BAO_0000019,10209,,3698,,16441,B,,
Expert,,1,,,In vitro binding affinity to human 5-hydroxytryptamine 7 receptor,,CHEMBL621548,D,9,,,Homo sapiens,9606.0,BAO_0000357,10209,,3699,,4234,B,,
Autocuration,,1,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor,,CHEMBL621549,H,8,,,,,BAO_0000019,10209,,3700,,17085,B,,
Autocuration,,1,,,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]LSD radioligand,,CHEMBL621550,H,8,,,,,BAO_0000357,10209,,3701,,17200,B,,
Autocuration,,1,CHO,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]-LSD as radioligand; Not determined,,CHEMBL621551,H,8,,449.0,,,BAO_0000219,10209,,3702,,17451,B,,
Autocuration,,1,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor; ND means not determined,,CHEMBL621552,H,8,,,,,BAO_0000019,10209,,3703,,17085,B,,
Autocuration,,1,,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor,,CHEMBL857077,H,8,,,,,BAO_0000357,10209,,3704,,5104,B,,
Autocuration,,1,,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor; Not tested,,CHEMBL618158,H,8,,,,,BAO_0000357,10209,,3705,,5104,B,,
Expert,,1,COS-7,,Ability to displace the radioligand [3H]5-carboxyamidotryptamine ([3H]5-CT) from human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,,CHEMBL618159,D,9,,643.0,Homo sapiens,9606.0,BAO_0000219,10209,,3706,,5033,B,,
Autocuration,,1,COS-7,,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-5-CT) from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,,CHEMBL875101,H,8,,643.0,,,BAO_0000219,10209,,3707,,5486,B,,
Expert,,1,HEK293,,Binding affinity to human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]-5-CT as radioligand,,CHEMBL618160,D,9,,722.0,Homo sapiens,9606.0,BAO_0000219,10209,,3708,,4540,B,,
Expert,,1,,,Binding affinity at human cloned 5-hydroxytryptamine 7 receptor.,,CHEMBL618161,H,8,,,,,BAO_0000357,10209,,3709,,6166,B,,
Expert,,1,HEK293,,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor was determined in HEK293 cells using [3H]5-CT as radioligand,,CHEMBL618162,H,8,,722.0,,,BAO_0000219,10209,,3710,,17342,B,,
Expert,,1,,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor was determined using [3H]5-CT as radioligand,,CHEMBL618163,H,8,,,,,BAO_0000357,10209,,3711,,17342,B,,
Autocuration,,1,,,Binding affinity against 5-hydroxytryptamine 7 human receptors,,CHEMBL618164,H,8,,,,,BAO_0000357,10209,,3712,,17296,B,,
Expert,,1,,,Binding affinity to human recombinant 5-hydroxytryptamine 7 receptor in mammalian cells using [3H]5-CT as radioligand,,CHEMBL618165,H,8,,,,,BAO_0000219,10209,,3713,,16429,B,,
Autocuration,,1,HEK293,,Binding affinity toward 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]-5-CT as radioligand.,,CHEMBL618166,H,8,,722.0,,,BAO_0000219,10209,,3714,,15779,B,,
Autocuration,,1,HEK293,,Binding affinity towards 5-hydroxytryptamine 7 receptor (a) (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,,CHEMBL857989,H,8,,722.0,,,BAO_0000219,10209,,3715,,15779,B,,
Autocuration,,1,HEK293,,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,,CHEMBL619888,H,8,,722.0,,,BAO_0000219,10209,,3716,,15779,B,,
Autocuration,,1,HEK293,,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,,CHEMBL619889,H,8,,722.0,,,BAO_0000219,10209,,3717,,15779,B,,
Autocuration,,1,HEK293,,Binding affinity towards 5-hydroxytryptamine 7 receptor 7(a) (human cloned receptor in HEK 293 cells using [3H]5-CT as radioligand.,,CHEMBL619890,H,8,,722.0,,,BAO_0000219,10209,,3718,,15779,B,,
Autocuration,,1,CHO,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]LSD as radioligand,,CHEMBL619891,H,8,,449.0,,,BAO_0000219,10209,,3719,,17451,B,,
Autocuration,,1,HEK293,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand (n=3),,CHEMBL619892,H,8,,722.0,,,BAO_0000219,10209,,3720,,4199,B,,
Expert,,1,HEK293,,Displacement of [3H]-5-CT from human 5-hydroxytryptamine 7 receptor expressed in HEK-293 cells,,CHEMBL619893,D,9,,722.0,,,BAO_0000219,10209,,3721,,4199,B,,
Autocuration,,1,HEK293,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand(n=6),,CHEMBL619894,H,8,,722.0,,,BAO_0000219,10209,,3722,,4199,B,,
Intermediate,,1,HEK293,,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells,,CHEMBL619895,D,9,,722.0,,,BAO_0000219,10209,,3723,,3680,B,,
Intermediate,,1,,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor using [3H]5-CT as radioligand,,CHEMBL619896,D,9,,,,,BAO_0000357,10209,,3724,,3680,B,,
Autocuration,,1,COS-7,,Compound was evaluated for its ability to displace [3H]5-CT binding from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells.,,CHEMBL619897,H,8,,643.0,,,BAO_0000219,10209,,3725,,15316,B,,
Autocuration,,1,HEK293,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT,,CHEMBL619898,H,8,,722.0,,,BAO_0000219,10209,,3726,,15146,B,,
Expert,,1,HEK293,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor in HEK 293 using [3H]5-CT as a radioligand,,CHEMBL619899,H,8,,722.0,,,BAO_0000219,10209,,3727,,5213,B,,
Autocuration,,1,HEK293,,Compound was tested for its binding affinity in 5-hydroxytryptamine 7 receptor (using human cloned receptors in HEK 293 and [3H]5-CT as a radioligand ),,CHEMBL619900,H,8,,722.0,,,BAO_0000219,10209,,3728,,5213,B,,
Expert,,1,HEK293,,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT,,CHEMBL619901,D,9,,722.0,Homo sapiens,9606.0,BAO_0000219,10209,,3729,,14818,B,,
Autocuration,,1,HEK293,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT. ,,CHEMBL620580,H,8,,722.0,,,BAO_0000219,10209,,3730,,14818,B,,
Autocuration,,1,HEK293,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT.,,CHEMBL620581,H,8,,722.0,,,BAO_0000219,10209,,3731,,14818,B,,
Autocuration,,1,HEK293,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 7 receptor in HEK293 cells, using [3H]5-CT as radioligand",,CHEMBL620733,H,8,,722.0,,,BAO_0000219,10209,,3732,,4829,B,,
Autocuration,,1,,,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]-LSD radioligand; Not determined,,CHEMBL620734,D,9,,,Homo sapiens,9606.0,BAO_0000357,10209,,3733,,17200,B,,
Expert,,1,,,Binding affinity towards mouse 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,,CHEMBL620735,D,9,,,Mus musculus,10090.0,BAO_0000357,10022,,3734,,17066,B,,
Autocuration,,1,,,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 7 receptor in the endothelium denuded rabbit jugular vein.,,CHEMBL620736,H,8,,,Oryctolagus cuniculus,9986.0,BAO_0000019,10209,,3735,,14025,B,,
Autocuration,,1,CHO,,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 7 receptor stably expressed in CHO cells,,CHEMBL620737,H,8,,449.0,,,BAO_0000219,11923,,3736,,15250,B,,
Autocuration,,1,CHO,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 10000 nM,,CHEMBL620738,H,8,,449.0,,,BAO_0000219,11923,,3737,,16372,B,,
Autocuration,,1,CHO,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 100 nM,,CHEMBL620739,H,8,,449.0,,,BAO_0000219,11923,,3738,,16372,B,,
Autocuration,,1,CHO,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 1 nM,,CHEMBL620740,H,8,,449.0,,,BAO_0000219,11923,,3739,,16372,B,,
Autocuration,,1,CHO,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 10000 nM 5-HT.,,CHEMBL620741,H,8,,449.0,,,BAO_0000219,11923,,3740,,16372,B,,
Autocuration,,1,CHO,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 100 nM 5-HT.,,CHEMBL620742,H,8,,449.0,,,BAO_0000219,11923,,3741,,16372,B,,
Autocuration,,1,CHO,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 1 nM 5-HT,,CHEMBL620743,H,8,,449.0,,,BAO_0000219,11923,,3742,,16372,B,,
Autocuration,,1,CHO,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 10000 nM,,CHEMBL620744,H,8,,449.0,,,BAO_0000219,11923,,3743,,16372,B,,
Autocuration,,1,CHO,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 100 nM,,CHEMBL620745,H,8,,449.0,,,BAO_0000219,11923,,3744,,16372,B,,
Autocuration,,1,CHO,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM,,CHEMBL620746,H,8,,449.0,,,BAO_0000219,11923,,3745,,16372,B,,
Autocuration,,1,CHO,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 10000 nM 5-HT.,,CHEMBL620747,H,8,,449.0,,,BAO_0000219,11923,,3746,,16372,B,,
Autocuration,,1,CHO,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 100 nM 5-HT.,,CHEMBL620748,H,8,,449.0,,,BAO_0000219,11923,,3747,,16372,B,,
Autocuration,,1,CHO,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT.,,CHEMBL620749,H,8,,449.0,,,BAO_0000219,11923,,3748,,16372,B,,
Expert,,1,,,Binding affinity towards rat 5-hydroxytryptamine 7 receptor,,CHEMBL620750,H,8,,,,,BAO_0000357,11923,,3749,,17066,B,,
Expert,,1,,,Binding affinity towards rat 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,,CHEMBL620751,D,9,,,Rattus norvegicus,10116.0,BAO_0000357,11923,,3750,,17066,B,,
Expert,,1,,,Binding affinity to the rat 5-hydroxytryptamine 7 receptor,,CHEMBL620752,H,8,,,,,BAO_0000357,11923,,3751,,17386,B,,
Autocuration,,1,,,Binding affinity against 5-hydroxytryptamine 7 receptor using from CHO cell membranes [3H]5-HT as the radioligand.,,CHEMBL872929,H,8,,,,,BAO_0000019,11923,,3752,,14423,B,,
Expert,,1,,,Binding affinity against Rat 5-hydroxytryptamine 7 receptor using [3H]5-HT,,CHEMBL620753,D,9,,,Rattus norvegicus,10116.0,BAO_0000357,11923,,3753,,15874,B,,
Expert,,1,,,Displacement of [3H]5-HT from over-expressed rat 5-hydroxytryptamine 7 receptor,,CHEMBL620754,D,9,,,Rattus norvegicus,10116.0,BAO_0000357,11923,,3754,,15874,B,,
Expert,,1,CHO,,Displacement of [3H]5-HT from rat 5-hydroxytryptamine 7 receptor expressed in CHO cells,,CHEMBL620755,D,9,,449.0,Rattus norvegicus,10116.0,BAO_0000219,11923,,3755,,16372,B,,
Autocuration,,1,,,In vitro binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,,CHEMBL620756,H,8,,,,,BAO_0000357,11923,,3756,,4622,B,,
Autocuration,,1,,,The compound was tested for binding affinity against 5-hydroxytryptamine 7 receptor,,CHEMBL620757,H,8,,,,,BAO_0000357,11923,,3757,,15086,B,,
Autocuration,,1,CHO,,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; Not tested",,CHEMBL620758,H,8,,449.0,,,BAO_0000219,11923,,3758,,16372,B,,
Autocuration,,1,CHO,,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; not tested",,CHEMBL620759,H,8,,449.0,,,BAO_0000219,11923,,3759,,16372,B,,
Autocuration,,1,CHO,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM; not tested,,CHEMBL620760,H,8,,449.0,,,BAO_0000219,11923,,3760,,16372,B,,
Autocuration,,1,CHO,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT; Not tested,,CHEMBL620761,H,8,,449.0,,,BAO_0000219,11923,,3761,,16372,B,,
Autocuration,,1,,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,,CHEMBL620762,H,8,,,,,BAO_0000221,11923,,3762,Ileum,17386,F,,2116.0
Autocuration,,1,,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,,CHEMBL620763,H,8,,,,,BAO_0000221,11923,,3763,Ileum,17386,F,,2116.0
Autocuration,,1,,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine receptor desensitization,,CHEMBL620764,H,8,,,,,BAO_0000221,11923,,3764,Ileum,17386,F,,2116.0
Expert,,1,,,Inhibition of [3H]-5-CT binding to 5-hydroxytryptamine 7 receptor of rat cortical membranes,Membranes,CHEMBL857990,D,9,,,Rattus norvegicus,10116.0,BAO_0000249,11923,,3765,,5831,B,,
Autocuration,,1,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor was determined,,CHEMBL620765,H,8,,,,,BAO_0000357,11923,,3766,,4342,B,,
Expert,,1,,,Binding affinity at rat 5-hydroxytryptamine 7 receptor.,,CHEMBL620766,H,8,,,,,BAO_0000357,11923,,3767,,17319,B,,
Expert,,1,,,Binding affinity towards 5-hydroxytryptamine receptor 7 on rat hypothalamus membranes using [3H]5-CT as radioligand.,,CHEMBL620767,H,8,,,,,BAO_0000019,11923,,3768,Hypothalamus,17342,B,,1898.0
Autocuration,,1,,,Binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor was determined using [3H]5-HT as radioligand,,CHEMBL620768,H,8,,,,,BAO_0000357,11923,,3769,,17342,B,,
Expert,,1,,,Binding affinity against 5-hydroxytryptamine 7 receptor using [3H]-5-CT in rat hypothalamus membranes,,CHEMBL619051,H,8,,,,,BAO_0000249,11923,,3770,Hypothalamus,3680,B,,1898.0
Expert,,1,,,Binding affinity towards 5-hydroxytryptamine 7 receptor,,CHEMBL619052,H,8,,,,,BAO_0000357,11923,,3771,,3680,B,,
Expert,,1,HEK293,,Agonistic activity against rat 5-HT7 adenyl cyclase expressed by HEK293 cells,,CHEMBL619053,D,9,,722.0,Rattus norvegicus,10116.0,BAO_0000219,11923,,3772,,17319,F,,
Expert,,1,HEK293,,Agonistic activity against rat 5-HT7 adenyl cyclase expressed in HEK293 cells; Active,,CHEMBL619703,D,9,,722.0,Rattus norvegicus,10116.0,BAO_0000219,11923,,3773,,17319,F,,
Autocuration,,1,HEK293,,Agonistic activity against rat 5-HT7-adenyl cyclase expressed by HEK293 cells; Active,,CHEMBL619704,D,9,,722.0,Rattus norvegicus,10116.0,BAO_0000219,11923,,3774,,17319,F,,
Expert,,1,,,Binding affinity towards 5-hydroxytryptamine 7 receptor,,CHEMBL619851,H,8,,,,,BAO_0000357,10209,,3775,,4820,B,,
Autocuration,,1,,,Percentage of displacement at 5-hydroxytryptamine 7 receptor at 10e-8 M,,CHEMBL619852,H,8,,,,,BAO_0000357,10209,,3776,,4639,B,,
Autocuration,,1,,,Inhibition of binding towards 5-hydroxytryptamine 7 receptor at 100 nM concentration,,CHEMBL619853,H,8,,,,,BAO_0000357,10209,,3777,,6011,B,,
Expert,,1,,,Binding affinity towards human 5-hydroxytryptamine 7 receptor,,CHEMBL619854,D,9,,,Homo sapiens,9606.0,BAO_0000357,10209,,3778,,17066,B,,
Expert,,1,,,Binding affinity of compound towards rodent 5-hydroxytryptamine 7 receptor,,CHEMBL619855,H,8,,,,,BAO_0000357,10209,,3779,,17066,B,,
Autocuration,,1,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor; inactive at 10 uM,,CHEMBL619856,H,8,,,,,BAO_0000357,10209,,3780,,17515,B,,
Autocuration,,1,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,,CHEMBL619857,H,8,,,,,BAO_0000357,10209,,3781,,4373,B,,
Expert,,1,,,Antagonistic activity towards 5-hydroxytryptamine 7 receptor was evaluated by cAMP assay,,CHEMBL619858,H,8,,,,,BAO_0000019,10209,,3782,,17066,F,,
Autocuration,,1,,,Binding affinity for 5-hydroxytryptamine 7 receptor was determined,,CHEMBL619859,H,8,,,,,BAO_0000357,10209,,3783,,4373,B,,
Autocuration,,1,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,,CHEMBL619860,H,8,,,,,BAO_0000357,10209,,3784,,4373,B,,
Autocuration,,1,,,Evaluated for the binding affinity to 5-hydroxytryptamine 7 receptor,,CHEMBL619861,H,8,,,,,BAO_0000357,10209,,3785,,4687,B,,
Expert,,1,,,Non-selective inhibitory activity was determined against 5-hydroxytryptamine 7 receptor,,CHEMBL619862,H,8,,,,,BAO_0000357,10209,,3786,,17342,B,,
Autocuration,,1,,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-6 M,,CHEMBL619863,H,8,,,,,BAO_0000357,10209,,3787,,16946,B,,
Autocuration,,1,,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-8 M,,CHEMBL619864,H,8,,,,,BAO_0000357,10209,,3788,,16946,B,,
Autocuration,,1,,,Binding affinities against 5-hydroxytryptamine 7 receptor,,CHEMBL872928,H,8,,,,,BAO_0000357,10209,,3789,,16633,B,,
Autocuration,,1,,,Binding affinities towards 5-hydroxytryptamine 7 receptor,,CHEMBL619865,H,8,,,,,BAO_0000357,10209,,3790,,16633,B,,
Expert,,1,,,Binding affinity towards rodent 5-hydroxytryptamine 7 receptor,,CHEMBL619866,H,8,,,,,BAO_0000357,10209,,3791,,17066,B,,
Autocuration,,1,,,The binding affinity towards 5-hydroxytryptamine 7 receptor; No affinity,,CHEMBL619867,H,8,,,,,BAO_0000357,10209,,3792,,16700,B,,
Autocuration,,1,,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,,CHEMBL619868,H,8,,,,,BAO_0000221,10209,,3793,Ileum,17386,B,,2116.0
Autocuration,,1,,,Compound was evaluated for the potency to inhibit oxidation of arachidonic acid by human recombinant 5-Lipoxygenase using a spectrophotometric assay,,CHEMBL619869,H,8,,,,,BAO_0000019,55,,3794,,14080,F,,
Expert,,1,,,Inhibition of oxidation of arachidonic acid by human 5-Lipoxygenase using spectrophotometric assay,,CHEMBL619870,D,9,,,Homo sapiens,9606.0,BAO_0000019,55,,3795,,14080,F,,
Autocuration,,1,,,In vitro inhibition of human recombinant 5-lipoxygenase enzyme,,CHEMBL619871,H,8,,,,,BAO_0000357,55,,3796,,409,B,,
Autocuration,,1,,,In vitro inhibition of human recombinant lipoxygenase enzyme,,CHEMBL619872,H,8,,,,,BAO_0000357,55,,3797,,409,B,,
Autocuration,,1,,,In vitro inhibition of human recombinant lipoxygenase enzyme; No inhibition,,CHEMBL619873,H,8,,,,,BAO_0000357,55,,3798,,409,B,,
Expert,,1,,,Inhibition of 5-lipoxygenase in human whole blood.,,CHEMBL619874,H,8,,,,,BAO_0000357,55,,3799,Blood,11090,B,,178.0
Expert,,1,,,Inhibition of 5-lipoxygenase in human whole blood.,,CHEMBL619875,H,8,,,,,BAO_0000357,55,,3800,Blood,11090,B,,178.0
Autocuration,,1,,,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of 5-HETE,,CHEMBL619876,H,8,,,,,BAO_0000357,55,,3801,,948,B,,
Autocuration,,1,,,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of leukotriene B4 (LTB4),,CHEMBL619877,H,8,,,,,BAO_0000357,55,,3802,,948,B,,
Expert,,1,,,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human polymorphonuclear leukocytes.,,CHEMBL619878,H,8,,,,,BAO_0000219,55,,3803,,13622,F,,
Autocuration,,1,,,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human whole blood,,CHEMBL619879,H,8,,,,,BAO_0000019,55,,3804,Blood,13622,F,,178.0
Autocuration,,1,,,In vitro inhibition of 5-lipoxygenase from human polymorphs,,CHEMBL619880,H,8,,,,,BAO_0000357,55,,3805,,9637,B,,
Autocuration,,1,,,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-LPO (5-lipoxygenase),,CHEMBL619881,H,8,,,,,BAO_0000357,55,,3806,,11320,B,,
Expert,,1,,,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-lipoxygenase,,CHEMBL619882,H,8,,,,,BAO_0000357,55,,3807,,11320,B,,
Autocuration,,1,,,In vitro inhibitory activity against 5-lipoxygenase in a human whole blood assay,,CHEMBL619883,H,8,,,,,BAO_0000357,55,,3808,,6838,B,,
Expert,,1,,,Inhibition of 5-Lipoxygenase (5-LO) of human whole blood (HWB),,CHEMBL619884,D,9,,,Homo sapiens,9606.0,BAO_0000357,55,,3809,Blood,17667,B,,178.0
Autocuration,,1,,,In vitro potency against human 5-Lipoxygenase,,CHEMBL619885,H,8,,,,,BAO_0000357,55,,3810,,12703,B,,
Expert,,1,,,Inhibitory activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay,,CHEMBL619886,D,9,,,Homo sapiens,9606.0,BAO_0000019,55,,3811,,14312,F,,
Autocuration,,1,,,Inhibition activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay; No data,,CHEMBL619887,H,8,,,,,BAO_0000019,55,,3812,Blood,14312,F,,178.0
Autocuration,,1,,,Inhibition of 5-lipoxygenase activity of compound evaluated as determined by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,,CHEMBL875097,H,8,,,,,BAO_0000019,55,,3813,,5364,F,,
Autocuration,,1,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE,,CHEMBL618001,H,8,,,,,BAO_0000219,55,,3814,,951,B,,
Autocuration,,1,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE; NA means Not active,,CHEMBL618002,H,8,,,,,BAO_0000219,55,,3815,,951,B,,
Autocuration,,1,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4,,CHEMBL618003,H,8,,,,,BAO_0000219,55,,3816,,951,B,,
Autocuration,,1,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4; NA means Not active,,CHEMBL618004,H,8,,,,,BAO_0000219,55,,3817,,951,B,,
Autocuration,,1,,,Inhibition of human 5-lipoxygenase in human cells,,CHEMBL618005,H,8,,,,,BAO_0000219,55,,3818,,12365,B,,
Expert,,1,,,Inhibition of human neutrophil 5-lipoxygenase,,CHEMBL618006,H,8,,,,,BAO_0000357,55,,3819,,10603,B,,
Autocuration,,1,,,Inhibitory activity against 5-lipoxygenase expressed from human polymorphonuclear cells,,CHEMBL875086,H,8,,,,,BAO_0000019,55,,3820,,10501,B,,
Expert,,1,,,Inhibition of 5-lipoxygenase from human whole blood,,CHEMBL618007,H,8,,,,,BAO_0000357,55,,3821,Blood,12281,B,,178.0
Autocuration,,1,,,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,,CHEMBL618008,H,8,,,,,BAO_0000357,55,,3822,,2567,B,,
Autocuration,,1,,,Inhibitory concentration required against 5-lipoxygenase activity in intact cells of human neutrophils,,CHEMBL618009,H,8,,,,,BAO_0000219,55,,3823,,2567,B,,
Expert,,1,,,In vitro inhibition of polymorphonuclear leukocyte derived human 5-lipoxygenase,,CHEMBL618010,H,8,,,,,BAO_0000357,55,,3824,,10193,B,,
Autocuration,,1,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,,CHEMBL618011,H,8,,,,,BAO_0000357,55,,3825,,10193,B,,
Expert,,1,,,Potency to inhibit oxidation of arachidonic acid by recombinant human 5-lipoxygenase,,CHEMBL618012,H,8,,,,,BAO_0000357,55,,3826,,13623,B,,
Autocuration,,1,,,Tested against 5-lipoxygenase,,CHEMBL882927,H,8,,,,,BAO_0000357,55,,3827,,12780,B,,
Autocuration,,1,,,Tested for activity against 5-Lipoxygenase (5-LO),,CHEMBL618013,H,8,,,,,BAO_0000357,55,,3828,,12780,B,,
Autocuration,,1,,,Tested for activity against 5-lipoxygenase,,CHEMBL618014,H,8,,,,,BAO_0000357,55,,3829,,12780,B,,
Autocuration,,1,,,Tested for inhibition of 5-HPETE production by human 5-LO,,CHEMBL618015,H,8,,,,,BAO_0000357,55,,3830,,11966,B,,
Autocuration,,1,,,The 5-lipoxygenase activity by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,,CHEMBL618016,H,8,,,,,BAO_0000019,55,,3831,,5364,F,,
Expert,,1,,,Inhibition of Human 5-lipoxygenase,,CHEMBL618017,H,8,,,,,BAO_0000357,55,,3832,,13165,B,,
Autocuration,,1,,,The compound was evaluated for its inhibitory activity against 5-lipoxygenase using granulocytes-type cells,,CHEMBL618018,H,8,,,,,BAO_0000019,55,,3833,,5364,B,,
Autocuration,,1,,,The compound was tested for inhibitory activity against 5-lipoxygenase in human polymorphonuclear leukocytes[PMNS],,CHEMBL875087,H,8,,,,,BAO_0000219,55,,3834,,11311,B,,
Autocuration,,1,,,The compound was tested for inhibitory activity against LT synthesis in human polymorphonuclear leukocytes[PMNS],,CHEMBL618019,H,8,,,,,BAO_0000219,55,,3835,,11311,B,,
Autocuration,,1,,,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50.,,CHEMBL618020,H,8,,,,,BAO_0000019,55,,3836,,14863,B,,
Autocuration,,1,,,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50; Not tested,,CHEMBL618021,H,8,,,,,BAO_0000019,55,,3837,,14863,B,,
Autocuration,,1,,,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in human whole blood (HWBL),,CHEMBL618022,H,8,,,,,BAO_0000357,55,,3838,Blood,11087,B,,178.0
Autocuration,,1,,,The compound was tested in vitro for inhibition against 5-lipoxygenase in intact human neutrophils,,CHEMBL618023,H,8,,,,,BAO_0000357,55,,3839,,455,B,,
Autocuration,,1,,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),,CHEMBL618024,H,8,,,,,BAO_0000357,55,,3840,,13183,B,,
Expert,,1,,,In vitro inhibitory activity against 5-lipoxygenase in human polymorphonuclear (PMN) cells,,CHEMBL873950,H,8,,,,,BAO_0000019,55,,3841,,10319,B,,
Autocuration,,1,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,,CHEMBL618025,H,8,,,,,BAO_0000357,55,,3842,,10193,B,,
Autocuration,,1,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM,,CHEMBL618026,H,8,,,,,BAO_0000219,55,,3843,,951,B,,
Autocuration,,1,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM; NA means Inactive,,CHEMBL618027,H,8,,,,,BAO_0000219,55,,3844,,951,B,,
Autocuration,,1,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM,,CHEMBL618028,H,8,,,,,BAO_0000219,55,,3845,,951,B,,
Autocuration,,1,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM; NA means Inactive,,CHEMBL618029,H,8,,,,,BAO_0000219,55,,3846,,951,B,,
Expert,,1,,,Inhibitory activity against 5-lipoxygenase at 10 uM concentration,,CHEMBL618030,H,8,,,,,BAO_0000357,55,,3847,,9859,B,,
Expert,,1,,,Inhibitory activity against 5-lipoxygenase at 1 uM concentration,,CHEMBL618031,H,8,,,,,BAO_0000357,55,,3848,,9859,B,,
Autocuration,,1,,,Inhibitory activity against lipoxygenase (LO) at 10 uM concentration,,CHEMBL618032,H,8,,,,,BAO_0000357,55,,3849,,9859,B,,
Autocuration,,1,,,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,,CHEMBL618033,H,8,,,,,BAO_0000357,55,,3850,,2567,B,,
Autocuration,,1,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 1 uM,,CHEMBL618034,H,8,,,,,BAO_0000357,55,,3851,,10193,B,,
Autocuration,,1,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,,CHEMBL875088,H,8,,,,,BAO_0000357,55,,3852,,10193,B,,
Autocuration,,1,,,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; IA= Inactive,,CHEMBL618035,H,8,,,,,BAO_0000019,55,,3853,,949,B,,
Autocuration,,1,,,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; value ranges from 70-90,,CHEMBL618036,H,8,,,,,BAO_0000019,55,,3854,,949,B,,
Expert,,1,,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 0.1 uM,,CHEMBL618037,H,8,,,,,BAO_0000357,55,,3855,,10603,B,,
Expert,,1,,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,,CHEMBL618038,H,8,,,,,BAO_0000357,55,,3856,,10603,B,,
Autocuration,,1,,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,,CHEMBL618761,H,8,,,,,BAO_0000019,55,,3857,,10603,F,,
Expert,,1,,,Inhibition of lipoxygenase at the concentration of 0.1 uM,,CHEMBL618762,H,8,,,,,BAO_0000357,55,,3858,,10603,B,,
Expert,,1,,,Inhibition of lipoxygenase at the concentration of 1 uM,,CHEMBL618763,H,8,,,,,BAO_0000357,55,,3859,,10603,B,,
Autocuration,,1,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell,,CHEMBL618764,H,8,,,,,BAO_0000357,55,,3860,,10193,B,,
Expert,,1,,,Inhibition of 5-Lipoxygenase (5-LOX),,CHEMBL618765,D,9,,,Homo sapiens,9606.0,BAO_0000357,55,,3861,,14580,B,,
Expert,,1,,,Inhibition of 5-lipoxygenase in mouse macrophages.,,CHEMBL618766,H,8,,,,,BAO_0000357,17087,,3862,,11090,B,,
Expert,,1,,,Inhibition of 5-lipoxygenase in mouse macrophages.,,CHEMBL618767,H,8,,,,,BAO_0000357,17087,,3863,,11090,B,,
Autocuration,,1,,,Inhibitory activity against lipoxygenase-2 in mice,,CHEMBL619380,H,8,,,,,BAO_0000357,17087,,3864,,6339,B,,
Expert,,1,,,Inhibitory activity against murine lipoxygenase-2.,,CHEMBL619381,H,8,,,,,BAO_0000357,17087,,3865,,6339,B,,
Expert,,1,,,Inhibition of 5-lipoxygenase from mouse macrophage,,CHEMBL619382,D,9,,,Mus musculus,10090.0,BAO_0000357,17087,,3866,,12281,B,,
Autocuration,,1,,,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse macrophages,,CHEMBL619383,H,8,,,,,BAO_0000357,17087,,3867,,11311,B,,
Autocuration,,1,,,The compound was tested for the inhibition of Arachidonate 5-lipoxygenase purified from porcine leukocytes.,,CHEMBL619384,H,8,,,Sus scrofa,9823.0,BAO_0000019,55,,3868,,11089,B,,
Autocuration,,1,,,Inhibition of 5-lipoxygenase reaction catalyzed by purified enzyme from porcine leukocytes,,CHEMBL619385,H,8,,,Sus scrofa,9823.0,BAO_0000019,55,,3869,,10091,B,,
Autocuration,,1,,,Inhibitory concentration against 5-lipoxygenase from isolated rabbit granulocytes,,CHEMBL882928,H,8,,,Oryctolagus cuniculus,9986.0,BAO_0000019,55,,3870,,14352,B,,
Expert,,1,,,5-lipoxygenase Inhibitory activity against rat polymorphonuclear leucocytes using 5-HETE,,CHEMBL619386,D,9,,,Rattus norvegicus,10116.0,BAO_0000019,12166,,3871,,13329,B,,
Autocuration,,1,,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE. ",,CHEMBL619387,H,8,,,,,BAO_0000019,12166,,3872,,13329,B,,
Autocuration,,1,,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",,CHEMBL619388,H,8,,,,,BAO_0000019,12166,,3873,,13329,B,,
Autocuration,,1,,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4.",,CHEMBL619389,H,8,,,,,BAO_0000019,12166,,3874,,13329,B,,
Expert,,1,,,Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay (inhibition of 5-HETE formation),,CHEMBL619390,H,8,,,,,BAO_0000019,12166,,3875,,13329,B,,
Expert,,1,,,"Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay, by ability to inhibit formation of LTB4 AT 10 uM",,CHEMBL619391,H,8,,,,,BAO_0000019,12166,,3876,,13329,B,,
Autocuration,,1,,,Inhibition of 5-lipoxygenase pathway was evaluated in rat polymorphonuclear assay by compound (50 uM) ability to inhibit formation of 5-HETE,,CHEMBL619392,H,8,,,,,BAO_0000019,12166,,3877,,13329,B,,
Autocuration,,1,,,The effective dose for inhibition of 5-lipoxygenase in rat blood leukocyte (ex vivo),,CHEMBL619393,H,8,,,,,BAO_0000019,12166,,3878,,11311,B,,
Autocuration,,1,,,The effective dose for inhibition of 5-lipoxygenase in rat passive Arthus model after oral administration,,CHEMBL619394,H,8,,,,,BAO_0000019,12166,,3879,,11311,B,,
Autocuration,,1,RBL-1,,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",,CHEMBL619395,H,8,,702.0,,,BAO_0000219,12166,,3880,,105,B,,
Autocuration,,1,RBL-1,,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",,CHEMBL619396,H,8,,702.0,,,BAO_0000219,12166,,3881,,105,B,,
Autocuration,,1,,,Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),,CHEMBL619397,H,8,,,,,BAO_0000357,12166,,3882,,9138,B,,
Autocuration,,1,,,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),",,CHEMBL619398,H,8,,,,,BAO_0000357,12166,,3883,,9138,B,,
Autocuration,,1,,,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO), (at a concentration of 0.2 nM ),",,CHEMBL619399,H,8,,,,,BAO_0000357,12166,,3884,,9138,B,,
Autocuration,,1,,,5-LO inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,,CHEMBL619400,H,8,,,,,BAO_0000357,12166,,3885,,14427,B,,
Autocuration,,1,,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",,CHEMBL619401,H,8,,,,,BAO_0000019,12166,,3886,,13329,B,,
Autocuration,,1,,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4. ",,CHEMBL619402,H,8,,,,,BAO_0000019,12166,,3887,,13329,B,,
Expert,,1,RBL-2H3,,Inhibition of 5-lipoxygenase mediated conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cells,,CHEMBL619403,D,9,,663.0,Rattus norvegicus,10116.0,BAO_0000219,12166,,3888,,14427,B,,
Autocuration,,1,,,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,,CHEMBL619404,H,8,,,,,BAO_0000357,12166,,3889,,14427,B,,
Autocuration,,1,,,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography.,,CHEMBL619405,H,8,,,,,BAO_0000357,12166,,3890,,14427,B,,
Expert,,1,RBL-1,,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line,,CHEMBL619406,H,8,,702.0,,,BAO_0000219,12166,,3891,,10293,B,,
Expert,,1,RBL-1,,Inhibition of 5-Lipoxygenase of rat basophilic leukemia cells,,CHEMBL619407,D,9,,702.0,Rattus norvegicus,10116.0,BAO_0000219,12166,,3892,,338,B,,
Autocuration,,1,,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase),,CHEMBL619408,H,8,,,,,BAO_0000357,12166,,3893,,303,B,,
Autocuration,,1,RBL-1,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) in intact RBL-1 cell line assay,,CHEMBL619409,H,8,,702.0,,,BAO_0000219,12166,,3894,,303,B,,
Expert,,1,RBL-1,,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-lipoxygenase,,CHEMBL619410,H,8,,702.0,,,BAO_0000219,12166,,3895,,9247,B,,
Autocuration,,1,RBL-1,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,,CHEMBL619753,H,8,,702.0,,,BAO_0000219,12166,,3896,,9247,B,,
Autocuration,,1,RBL-1,,Compound was evaluated in an intact RBL-1 cell line for inhibition of 5-lipoxygenase,,CHEMBL619754,H,8,,702.0,,,BAO_0000219,12166,,3897,,137,B,,
Expert,,1,,,Evaluated in vitro for its inhibitory activity against 5-lipoxygenase,,CHEMBL619903,H,8,,,,,BAO_0000357,12166,,3898,,11481,B,,
Expert,,1,,,"Evaluated in vitro for its inhibitory activity against 5-lipoxygenase; N=Inactive, <50% inhibition at 10 uM concentration",,CHEMBL619904,H,8,,,,,BAO_0000357,12166,,3899,,11481,B,,
Expert,,1,,,Inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase in vitro,,CHEMBL619905,H,8,,,,,BAO_0000357,12166,,3900,,9029,B,,
Autocuration,,1,,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells,,CHEMBL619906,H,8,,,,,BAO_0000019,12166,,3901,,1701,B,,
Autocuration,,1,,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 32 uM; Not active,,CHEMBL619907,H,8,,,,,BAO_0000019,12166,,3902,,1701,B,,
Autocuration,,1,,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 50 uM; Not active,,CHEMBL619908,H,8,,,,,BAO_0000019,12166,,3903,,1701,B,,
Autocuration,,1,,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells; No data,,CHEMBL619909,H,8,,,,,BAO_0000019,12166,,3904,,1701,B,,
Expert,,1,RBL-1,,Inhibition of 5-lipoxygenase by measuring 5-HETE levels in RBL-1 cell-free supernatant,,CHEMBL619910,H,8,,702.0,,,BAO_0000219,12166,,3905,,13358,F,,
Expert,,1,RBL-1,,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells,,CHEMBL882929,H,8,,702.0,,,BAO_0000219,12166,,3906,,1175,B,,
Expert,,1,RBL-1,,Ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells.,,CHEMBL619911,H,8,,702.0,,,BAO_0000219,12166,,3907,,8797,B,,
Autocuration,,1,,,Compound was tested for its ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells; No data,,CHEMBL619912,H,8,,,,,BAO_0000019,12166,,3908,,8797,B,,
Expert,,1,,,Inhibition of rat basophilic leukemia cell 5-lipoxygenase,,CHEMBL619913,D,9,,,Rattus norvegicus,10116.0,BAO_0000357,12166,,3909,,577,B,,
Expert,,1,RBL-1,,In vitro inhibitory activity against RBL-1 5-LO,,CHEMBL619914,H,8,,702.0,,,BAO_0000219,12166,,3910,,9295,B,,
Autocuration,,1,RBL-1,,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (insoluble above 45 uM),,CHEMBL619915,H,8,,702.0,,,BAO_0000219,12166,,3911,,9295,B,,
Autocuration,,1,RBL-1,,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (time dependent),,CHEMBL619916,H,8,,702.0,,,BAO_0000219,12166,,3912,,9295,B,,
Autocuration,,1,,,Compound was tested for its inhibition activity against 5-LO of the whole cell in vitro in rat.,,CHEMBL619917,H,8,,,,,BAO_0000218,12166,,3913,,9295,B,,
Autocuration,,1,,,Compound was tested for its inhibition activity against the 5-LO in isolated enzyme,,CHEMBL619918,H,8,,,,,BAO_0000357,12166,,3914,,9295,B,,
Autocuration,,1,,,Compound was tested for its inhibitory activity against 5-lipoxygenase in rat.,,CHEMBL619919,H,8,,,,,BAO_0000218,12166,,3915,,216,B,,
Autocuration,,1,RBL-1,,Compound was tested for the inhibition of 5-lipoxygenase (5-LPO) in rat basophilic leukemia (RBL) cells.,,CHEMBL883710,H,8,,702.0,,,BAO_0000219,12166,,3916,,11090,B,,
Autocuration,,1,,,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in rat whole blood.,,CHEMBL619920,H,8,,,,,BAO_0000019,12166,,3917,Blood,11090,B,,178.0
Expert,,1,,,Concentration required for 50 % inhibition of arachidonic acid oxidation by rat 5-lipoxygenase,,CHEMBL619921,H,8,,,,,BAO_0000357,12166,,3918,,10091,B,,
Autocuration,,1,,,Concentration that produces 50% inhibition of A-23187-stimulated radiolabeled 5-HETE and TXB2 synthesis by PMN 5-lipoxygenase.,,CHEMBL619922,H,8,,,,,BAO_0000019,12166,,3919,,10274,F,,
Autocuration,,1,,,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in rat polymorphonuclear leukocytes,,CHEMBL619923,H,8,,,,,BAO_0000219,12166,,3920,,13622,F,,
Expert,,1,RBL-1,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined,,CHEMBL619924,H,8,,702.0,,,BAO_0000219,12166,,3921,,12118,B,,
Expert,,1,,,In vitro inhibition of 5-lipoxygenase (5-HETE) derived from the 9000xg supernatant of RBL broken cell assay,,CHEMBL619925,H,8,,,,,BAO_0000357,12166,,3922,,12576,B,,
Expert,,1,RBL-1,,In vitro inhibition of 5-lipoxygenase from RBL-1 cells,,CHEMBL619926,H,8,,702.0,,,BAO_0000219,12166,,3923,,9546,B,,
Autocuration,,1,RBL-1,,In vitro inhibition of 5-lipoxygenase in RBL-1 cells,,CHEMBL619927,H,8,,702.0,,,BAO_0000219,12166,,3924,,9521,B,,
Expert,,1,RBL-1,,In vitro inhibition of 5-lipoxygenase pathway in rat basophilic leukemia (RBL-1) cells,,CHEMBL619928,H,8,,702.0,,,BAO_0000219,12166,,3925,,10626,B,,
Autocuration,,1,RBL-1,,In vitro inhibition of RBL-1 5-lipoxygenase,,CHEMBL619929,H,8,,702.0,,,BAO_0000219,12166,,3926,,9225,B,,
Autocuration,,1,RBL-1,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.18-0.31,,CHEMBL875089,H,8,,702.0,,,BAO_0000219,12166,,3927,,9225,B,,
Autocuration,,1,RBL-1,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.3-1.6,,CHEMBL619930,H,8,,702.0,,,BAO_0000219,12166,,3928,,9225,B,,
Autocuration,,1,RBL-1,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.4-2.2,,CHEMBL619931,H,8,,702.0,,,BAO_0000219,12166,,3929,,9225,B,,
Autocuration,,1,RBL-1,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.72-1.07,,CHEMBL619932,H,8,,702.0,,,BAO_0000219,12166,,3930,,9225,B,,
Autocuration,,1,RBL-1,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.9-4.0,,CHEMBL619933,H,8,,702.0,,,BAO_0000219,12166,,3931,,9225,B,,
Autocuration,,1,RBL-1,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.5,,CHEMBL619934,H,8,,702.0,,,BAO_0000219,12166,,3932,,9225,B,,
Autocuration,,1,RBL-1,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.7,,CHEMBL619935,H,8,,702.0,,,BAO_0000219,12166,,3933,,9225,B,,
Autocuration,,1,RBL-1,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-2.4,,CHEMBL619936,H,8,,702.0,,,BAO_0000219,12166,,3934,,9225,B,,
Autocuration,,1,RBL-1,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.07-5.54,,CHEMBL619937,H,8,,702.0,,,BAO_0000219,12166,,3935,,9225,B,,
Autocuration,,1,RBL-1,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.1-1.6,,CHEMBL619938,H,8,,702.0,,,BAO_0000219,12166,,3936,,9225,B,,
Autocuration,,1,RBL-1,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.3-2.8,,CHEMBL619939,H,8,,702.0,,,BAO_0000219,12166,,3937,,9225,B,,
Autocuration,,1,RBL-1,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.4-3.2,,CHEMBL619940,H,8,,702.0,,,BAO_0000219,12166,,3938,,9225,B,,
Autocuration,,1,RBL-1,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.7-2.6,,CHEMBL875090,H,8,,702.0,,,BAO_0000219,12166,,3939,,9225,B,,
Autocuration,,1,RBL-1,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-2.8,,CHEMBL619941,H,8,,702.0,,,BAO_0000219,12166,,3940,,9225,B,,
Autocuration,,1,RBL-1,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-5.7,,CHEMBL619942,H,8,,702.0,,,BAO_0000219,12166,,3941,,9225,B,,
Autocuration,,1,RBL-1,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.9-2.4,,CHEMBL883711,H,8,,702.0,,,BAO_0000219,12166,,3942,,9225,B,,
Autocuration,,1,RBL-1,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.3-.8,,CHEMBL619943,H,8,,702.0,,,BAO_0000219,12166,,3943,,9225,B,,
Autocuration,,1,RBL-1,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.46-2.63,,CHEMBL619944,H,8,,702.0,,,BAO_0000219,12166,,3944,,9225,B,,
Autocuration,,1,RBL-1,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.3-3.5,,CHEMBL619945,H,8,,702.0,,,BAO_0000219,12166,,3945,,9225,B,,
Autocuration,,1,RBL-1,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.8-7.1,,CHEMBL619946,H,8,,702.0,,,BAO_0000219,12166,,3946,,9225,B,,
Autocuration,,1,RBL-1,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.0-6.4,,CHEMBL619947,H,8,,702.0,,,BAO_0000219,12166,,3947,,9225,B,,
Autocuration,,1,RBL-1,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.9-11.6,,CHEMBL619948,H,8,,702.0,,,BAO_0000219,12166,,3948,,9225,B,,
Autocuration,,1,RBL-1,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 7.5-11.8,,CHEMBL619949,H,8,,702.0,,,BAO_0000219,12166,,3949,,9225,B,,
Expert,,1,,,In vitro inhibitory activity against 5-lipoxygenase from rat basophilic leukemia cells.,,CHEMBL619950,H,8,,,,,BAO_0000019,12166,,3950,,9401,B,,
Autocuration,,1,,,In vitro inhibitory activity against 5-Lipoxygenase in rat by Peritoneal 5-lipoxygenase assay,,CHEMBL618050,H,8,,,,,BAO_0000019,12166,,3951,,10325,B,,
Expert,,1,RBL-2H3,,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells.,,CHEMBL875091,H,8,,663.0,,,BAO_0000219,12166,,3952,,1556,F,,
Expert,,1,RBL-2H3,,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells; Not tested,,CHEMBL618051,H,8,,663.0,,,BAO_0000219,12166,,3953,,1556,F,,
Expert,,1,RBL-1,,Inhibition of 5-lipoxygenase from rat basophilic leukemia(RBL-1) cells,,CHEMBL618052,D,9,,702.0,Rattus norvegicus,10116.0,BAO_0000219,12166,,3954,,961,B,,
Autocuration,,1,,,In vitro inhibitory activity against 5-lipoxygenase in an RBL-2H3 cell lysate,,CHEMBL618053,H,8,,,,,BAO_0000019,12166,,3955,,6838,B,,
Expert,,1,,,In vitro inhibition of 5-lipoxygenase in rat (peritoneal assay),,CHEMBL618054,H,8,,,,,BAO_0000019,12166,,3956,,10325,B,,
Expert,,1,RBL-1,,In vitro inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,,CHEMBL618055,D,9,,702.0,Rattus norvegicus,10116.0,BAO_0000219,12166,,3957,,9209,B,,
Expert,,1,RBL-1,,inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cell line.,,CHEMBL618056,H,8,,702.0,,,BAO_0000219,12166,,3958,,11520,B,,
Autocuration,,1,,,In vitro inhibitory activity against 5-lipoxygenase was determined,,CHEMBL618057,H,8,,,,,BAO_0000357,12166,,3959,,137,B,,
Autocuration,,1,RBL-1,,In vitro inhibitory concentration against 5-lipoxygenase in RBL-1 cells,,CHEMBL618058,H,8,,702.0,,,BAO_0000219,12166,,3960,,4717,B,,
Expert,,1,RBL-1,,Inhibition of 5-lipoxygenase in intact RBL-1 cell line,,CHEMBL618059,H,8,,702.0,,,BAO_0000219,12166,,3961,,10636,B,,
Expert,,1,,,Inhibitory activity against 5-lipoxygenase catalysis (5-LO) in sonicated rat basophilic leukemia cell lysate,,CHEMBL618060,D,9,,,Rattus norvegicus,10116.0,BAO_0000019,12166,,3962,,14312,F,,
Autocuration,,1,RBL-1,,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemia cells,,CHEMBL618061,H,8,,702.0,,,BAO_0000219,12166,,3963,,1203,B,,
Autocuration,,1,,,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemic cells,,CHEMBL618062,H,8,,,,,BAO_0000019,12166,,3964,,1203,B,,
Expert,,1,RBL-1,,Inhibition of 5-lipoxygenase catalysis in rat basophilic leukemia (RBL) cells by measuring 5-HETE product formation,,CHEMBL618063,H,8,,702.0,,,BAO_0000219,12166,,3965,,13622,B,,
Autocuration,,1,,,Inhibition of 5-lipoxygenase from rat peritoneal neutrophils after oral administration,,CHEMBL618064,H,8,,,,,BAO_0000357,12166,,3966,,9793,B,,
Expert,,1,RBL-1,,Inhibition of 5-lipoxygenase of rat basophilic leukemia (RBL) cell cytosolic enzymes,,CHEMBL618065,D,9,,702.0,Rattus norvegicus,10116.0,BAO_0000219,12166,,3967,,1143,B,,
Expert,,1,RBL-1,,Inhibition 5-lipoxygenase mediated LTB4 formation in rat basophilic leukemia (RBL-1) cells,,CHEMBL618066,D,9,,702.0,Rattus norvegicus,10116.0,BAO_0000219,12166,,3968,,11854,B,,
Autocuration,,1,RBL-1,,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),,CHEMBL618067,H,8,,702.0,,,BAO_0000219,12166,,3969,,3595,B,,
Autocuration,,1,RBL-1,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),,CHEMBL618068,H,8,,702.0,,,BAO_0000219,12166,,3970,,3595,B,,
Expert,,1,RBL-1,,Inhibition of 5-lipoxygenase in rat RBL-1 cells,,CHEMBL618069,D,9,,702.0,Rattus norvegicus,10116.0,BAO_0000219,12166,,3971,,10501,B,,
Expert,,1,RBL-1,,Inhibition of 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,CHEMBL618070,H,8,,702.0,,,BAO_0000219,12166,,3972,,12526,B,,
Autocuration,,1,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 32 umol/kg,,CHEMBL618071,H,8,,,,,BAO_0000019,10825,,3973,Limbic system,10034,F,,349.0
Autocuration,,1,,,Compound was tested for its effects on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,,CHEMBL619247,H,8,,,,,BAO_0000019,10825,,3974,Limbic system,10034,F,,349.0
Autocuration,,1,,,Approximate dose levels for a half maximal reduction of 5-HTP levels,,CHEMBL619248,H,8,,,,,BAO_0000019,10825,,3975,,10034,F,,
Autocuration,,1,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,,CHEMBL619249,H,8,,,,,BAO_0000221,10576,,3976,Hippocampus,10046,B,,10000000.0
Autocuration,,1,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,,CHEMBL619250,H,8,,,,,BAO_0000221,10576,,3977,Hippocampus,10046,B,,10000000.0
Autocuration,,1,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,,CHEMBL619251,H,8,,,,,BAO_0000019,10577,,3978,,10046,B,,
Autocuration,,1,,,Inhibitory concentration against human platelet 5-lipoxygenase in dog whole blood,,CHEMBL619252,H,8,,,Canis lupus familiaris,9615.0,BAO_0000019,55,,3979,Blood,12079,F,,178.0
Autocuration,,1,,,Inhibitory concentration against human platelet 5-lipoxygenase in human whole blood,,CHEMBL619253,H,8,,,,,BAO_0000019,55,,3980,Blood,12079,F,,178.0
Autocuration,,1,,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat polymorphonuclear leukocytes[PMNS],,CHEMBL619254,H,8,,,,,BAO_0000219,12166,,3981,,11311,B,,
Expert,,1,,,Inhibition of 5-lipoxygenase in bovine polymorphonuclear leukocytes,,CHEMBL619255,H,8,,,,,BAO_0000219,17140,,3982,,12338,B,,
Expert,,1,,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL).,,CHEMBL619256,H,8,,,,,BAO_0000219,17140,,3983,,12143,B,,
Autocuration,,1,,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL),,CHEMBL875418,H,8,,,,,BAO_0000219,17140,,3984,,12143,B,,
Expert,,1,,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,,CHEMBL619257,H,8,,,,,BAO_0000219,17140,,3985,,12143,B,,
Autocuration,,1,,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,,CHEMBL619258,H,8,,,,,BAO_0000219,17140,,3986,,12143,B,,
Expert,,1,,,Inhibition of 5-lipoxygenase in bovine PMNL cell assay.,,CHEMBL619259,H,8,,,,,BAO_0000357,17140,,3987,,12365,B,,
Expert,,1,,,Tested for inhibition of 5-lipoxygenase as inhibition of 5-HETE and LTB4 biosynthesis in bovine PMNL,,CHEMBL619260,H,8,,,,,BAO_0000357,17140,,3988,,13500,B,,
Autocuration,,1,,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",,CHEMBL619261,H,8,,,Canis lupus familiaris,9615.0,BAO_0000218,55,,3989,Blood,12832,F,In vivo,178.0
Autocuration,,1,,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",,CHEMBL619263,H,8,,,Canis lupus familiaris,9615.0,BAO_0000218,55,,3990,Blood,12832,F,In vivo,178.0
Autocuration,,1,,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",,CHEMBL619264,H,8,,,Canis lupus familiaris,9615.0,BAO_0000218,55,,3991,Blood,12832,F,In vivo,178.0
Autocuration,,1,,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",,CHEMBL619265,H,8,,,Canis lupus familiaris,9615.0,BAO_0000218,55,,3992,Blood,12832,F,In vivo,178.0
Autocuration,,1,,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",,CHEMBL619266,H,8,,,Canis lupus familiaris,9615.0,BAO_0000218,55,,3993,Blood,12832,F,In vivo,178.0
Autocuration,,1,,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",,CHEMBL619902,H,8,,,Canis lupus familiaris,9615.0,BAO_0000218,55,,3994,Blood,12832,F,In vivo,178.0
Autocuration,,1,,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",,CHEMBL620058,H,8,,,Canis lupus familiaris,9615.0,BAO_0000218,55,,3995,Blood,12832,F,In vivo,178.0
Autocuration,,1,,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",,CHEMBL620059,H,8,,,Canis lupus familiaris,9615.0,BAO_0000218,55,,3996,Blood,12832,F,In vivo,178.0
Autocuration,,1,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",,CHEMBL620060,H,8,,,Canis lupus familiaris,9615.0,BAO_0000218,55,,3997,Blood,12832,F,In vivo,178.0
Autocuration,,1,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",,CHEMBL620061,H,8,,,Canis lupus familiaris,9615.0,BAO_0000218,55,,3998,Blood,12832,F,In vivo,178.0
Autocuration,,1,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 0.3 mg/kg",,CHEMBL620062,H,8,,,Canis lupus familiaris,9615.0,BAO_0000218,55,,3999,Blood,12832,F,In vivo,178.0
Autocuration,,1,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",,CHEMBL620063,H,8,,,Canis lupus familiaris,9615.0,BAO_0000218,55,,4000,Blood,12832,F,In vivo,178.0
Autocuration,,1,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 3.0 mg/kg",,CHEMBL620064,H,8,,,Canis lupus familiaris,9615.0,BAO_0000218,55,,4001,Blood,12832,F,In vivo,178.0
Autocuration,,1,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",,CHEMBL620065,H,8,,,Canis lupus familiaris,9615.0,BAO_0000218,55,,4002,Blood,12832,F,In vivo,178.0
Autocuration,,1,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 0.3 mg/kg",,CHEMBL620066,H,8,,,Canis lupus familiaris,9615.0,BAO_0000218,55,,4003,Blood,12832,F,In vivo,178.0
Autocuration,,1,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 1.0 mg/kg",,CHEMBL620067,H,8,,,Canis lupus familiaris,9615.0,BAO_0000218,55,,4004,Blood,12832,F,In vivo,178.0
Autocuration,,1,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 3.0 mg/kg",,CHEMBL620068,H,8,,,Canis lupus familiaris,9615.0,BAO_0000218,55,,4005,Blood,12832,F,In vivo,178.0
Autocuration,,1,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",,CHEMBL620069,H,8,,,Canis lupus familiaris,9615.0,BAO_0000218,55,,4006,Blood,12832,F,In vivo,178.0
Autocuration,,1,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 0.3 mg/kg",,CHEMBL620070,H,8,,,Canis lupus familiaris,9615.0,BAO_0000218,55,,4007,Blood,12832,F,In vivo,178.0
Autocuration,,1,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 1.0 mg/kg",,CHEMBL620071,H,8,,,Canis lupus familiaris,9615.0,BAO_0000218,55,,4008,Blood,12832,F,In vivo,178.0
Autocuration,,1,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 3.0 mg/kg",,CHEMBL620072,H,8,,,Canis lupus familiaris,9615.0,BAO_0000218,55,,4009,Blood,12832,F,In vivo,178.0
Autocuration,,1,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",,CHEMBL620036,H,8,,,Canis lupus familiaris,9615.0,BAO_0000218,55,,4010,Blood,12832,F,In vivo,178.0
Autocuration,,1,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 0.3 mg/kg",,CHEMBL857702,H,8,,,Canis lupus familiaris,9615.0,BAO_0000218,55,,4011,Blood,12832,F,In vivo,178.0
Autocuration,,1,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 1.0 mg/kg",,CHEMBL620037,H,8,,,Canis lupus familiaris,9615.0,BAO_0000218,55,,4012,Blood,12832,F,In vivo,178.0
Autocuration,,1,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 3.0 mg/kg",,CHEMBL620038,H,8,,,Canis lupus familiaris,9615.0,BAO_0000218,55,,4013,Blood,12832,F,In vivo,178.0
Autocuration,,1,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",,CHEMBL620039,H,8,,,Canis lupus familiaris,9615.0,BAO_0000218,55,,4014,Blood,12832,F,In vivo,178.0
Autocuration,,1,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 0.3 mg/kg",,CHEMBL620040,H,8,,,Canis lupus familiaris,9615.0,BAO_0000218,55,,4015,Blood,12832,F,In vivo,178.0
Autocuration,,1,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 1.0 mg/kg",,CHEMBL620041,H,8,,,Canis lupus familiaris,9615.0,BAO_0000218,55,,4016,Blood,12832,F,In vivo,178.0
Autocuration,,1,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 3.0 mg/kg",,CHEMBL620042,H,8,,,Canis lupus familiaris,9615.0,BAO_0000218,55,,4017,Blood,12832,F,In vivo,178.0
Autocuration,,1,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",,CHEMBL620043,H,8,,,Canis lupus familiaris,9615.0,BAO_0000218,55,,4018,Blood,12832,F,In vivo,178.0
Autocuration,,1,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 0.3 mg/kg",,CHEMBL620044,H,8,,,Canis lupus familiaris,9615.0,BAO_0000218,55,,4019,Blood,12832,F,In vivo,178.0
Autocuration,,1,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 1.0 mg/kg",,CHEMBL620045,H,8,,,Canis lupus familiaris,9615.0,BAO_0000218,55,,4020,Blood,12832,F,In vivo,178.0
Autocuration,,1,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 3.0 mg/kg",,CHEMBL620046,H,8,,,Canis lupus familiaris,9615.0,BAO_0000218,55,,4021,Blood,12832,F,In vivo,178.0
Autocuration,,1,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",,CHEMBL620047,H,8,,,Canis lupus familiaris,9615.0,BAO_0000218,55,,4022,Blood,12832,F,In vivo,178.0
Autocuration,,1,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 0.3 mg/kg",,CHEMBL620048,H,8,,,Canis lupus familiaris,9615.0,BAO_0000218,55,,4023,Blood,12832,F,In vivo,178.0
Autocuration,,1,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 1.0 mg/kg",,CHEMBL857703,H,8,,,Canis lupus familiaris,9615.0,BAO_0000218,55,,4024,Blood,12832,F,In vivo,178.0
Autocuration,,1,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 3.0 mg/kg",,CHEMBL620049,H,8,,,Canis lupus familiaris,9615.0,BAO_0000218,55,,4025,Blood,12832,F,In vivo,178.0
Autocuration,,1,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",,CHEMBL620050,H,8,,,Canis lupus familiaris,9615.0,BAO_0000218,55,,4026,Blood,12832,F,In vivo,178.0
Autocuration,,1,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",,CHEMBL620051,H,8,,,Canis lupus familiaris,9615.0,BAO_0000218,55,,4027,Blood,12832,F,In vivo,178.0
Autocuration,,1,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",,CHEMBL619213,H,8,,,Canis lupus familiaris,9615.0,BAO_0000218,55,,4028,Blood,12832,F,In vivo,178.0
Autocuration,,1,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",,CHEMBL619214,H,8,,,Canis lupus familiaris,9615.0,BAO_0000218,55,,4029,Blood,12832,F,In vivo,178.0
Autocuration,,1,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",,CHEMBL619804,H,8,,,Canis lupus familiaris,9615.0,BAO_0000218,55,,4030,Blood,12832,F,In vivo,178.0
Autocuration,,1,,,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",,CHEMBL619805,H,8,,,Canis lupus familiaris,9615.0,BAO_0000218,55,,4031,Blood,12832,F,In vivo,178.0
Autocuration,,1,,,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",,CHEMBL619806,H,8,,,Canis lupus familiaris,9615.0,BAO_0000218,55,,4032,Blood,12832,F,In vivo,178.0
Autocuration,,1,,,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",,CHEMBL619807,H,8,,,Canis lupus familiaris,9615.0,BAO_0000218,55,,4033,Blood,12832,F,In vivo,178.0
Autocuration,,1,,,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",,CHEMBL619808,H,8,,,Canis lupus familiaris,9615.0,BAO_0000218,55,,4034,Blood,12832,F,In vivo,178.0
Autocuration,,1,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r,,CHEMBL619809,H,8,,,Canis lupus familiaris,9615.0,BAO_0000218,55,,4035,,3595,B,,
Autocuration,,1,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r to canine,,CHEMBL619810,H,8,,,Canis lupus familiaris,9615.0,BAO_0000218,55,,4036,,3595,B,,
Autocuration,,1,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr,,CHEMBL619811,H,8,,,Canis lupus familiaris,9615.0,BAO_0000218,55,,4037,,3595,B,,
Autocuration,,1,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr to canine,,CHEMBL620769,H,8,,,Canis lupus familiaris,9615.0,BAO_0000218,55,,4038,,3595,B,,
Autocuration,,1,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr,,CHEMBL620770,H,8,,,Canis lupus familiaris,9615.0,BAO_0000218,55,,4039,,3595,B,,
Autocuration,,1,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr to canine,,CHEMBL620771,H,8,,,Canis lupus familiaris,9615.0,BAO_0000218,55,,4040,,3595,B,,
Autocuration,,1,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr,,CHEMBL620772,H,8,,,Canis lupus familiaris,9615.0,BAO_0000218,55,,4041,,3595,B,,
Autocuration,,1,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr to canine,,CHEMBL620773,H,8,,,Canis lupus familiaris,9615.0,BAO_0000218,55,,4042,,3595,B,,
Autocuration,,1,,,Ability to inhibit 5-lipoxygenase in guinea pig,,CHEMBL620774,H,8,,,Cavia porcellus,10141.0,BAO_0000357,55,,4043,,9203,B,,
Expert,,1,,,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-lipoxygenase in vitro (guinea pig PMN),,CHEMBL620775,H,8,,,Cavia porcellus,10141.0,BAO_0000357,55,,4044,,82,B,,
Autocuration,,1,,,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in guinea pig.,,CHEMBL620776,H,8,,,Cavia porcellus,10141.0,BAO_0000357,55,,4045,,11090,B,,
Autocuration,,1,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 12 h, following intravenous administration at the dose of 1.0 mg/kg",,CHEMBL620777,H,8,,,Cavia porcellus,10141.0,BAO_0000218,55,,4046,Blood,12832,B,,178.0
Autocuration,,1,,,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on 5-hydroxyeicosapentaenoic acid (5-HETE) production,,CHEMBL620778,H,8,,,Cavia porcellus,10141.0,BAO_0000357,55,,4047,,1065,B,,
Autocuration,,1,,,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on LTB4 production,,CHEMBL620779,H,8,,,Cavia porcellus,10141.0,BAO_0000357,55,,4048,,1065,B,,
Expert,,1,,,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]-AA to 5-HETE in guinea pig peritoneal polymorphonuclear leukocytes,,CHEMBL621500,H,8,,,Cavia porcellus,10141.0,BAO_0000019,55,,4049,,12832,B,,
Expert,,1,,,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,,CHEMBL621501,H,8,,,Cavia porcellus,10141.0,BAO_0000019,55,,4050,,12832,B,,
Autocuration,,1,,,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,,CHEMBL618098,H,8,,,Cavia porcellus,10141.0,BAO_0000019,55,,4051,,12832,B,,
Autocuration,,1,,,Inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,,CHEMBL618099,H,8,,,Cavia porcellus,10141.0,BAO_0000019,55,,4052,,10504,B,,
Autocuration,,1,,,Inhibitory activity against 5-lipoxygenase,,CHEMBL618100,H,8,,,Cavia porcellus,10141.0,BAO_0000357,55,,4053,,7788,B,,
Autocuration,,1,,,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte,,CHEMBL618101,H,8,,,Cavia porcellus,10141.0,BAO_0000357,55,,4054,,10001,B,,
Autocuration,,1,,,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant,,CHEMBL618102,H,8,,,Cavia porcellus,10141.0,BAO_0000357,55,,4055,,10193,B,,
Autocuration,,1,,,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase,,CHEMBL618103,H,8,,,Cavia porcellus,10141.0,BAO_0000357,55,,4056,,13243,B,,
Autocuration,,1,,,Inhibitory activity uM,,CHEMBL618104,H,8,,,Cavia porcellus,10141.0,BAO_0000357,55,,4057,,13243,B,,
Autocuration,,1,,,Inhibitory activity against 5-lipoxygenase in guinea pig leukocytes was determined,,CHEMBL883712,H,8,,,Cavia porcellus,10141.0,BAO_0000219,55,,4058,,969,B,,
Autocuration,,1,,,Inhibitory activity against 5-lipoxygenase at 10 uM,,CHEMBL618105,H,8,,,Cavia porcellus,10141.0,BAO_0000357,55,,4059,,10001,B,,
Autocuration,,1,,,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,,CHEMBL618106,H,8,,,Cavia porcellus,10141.0,BAO_0000357,55,,4060,,7788,B,,
Autocuration,,1,,,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte at 30 uM,,CHEMBL618107,H,8,,,Cavia porcellus,10141.0,BAO_0000357,55,,4061,,10001,B,,
Autocuration,,1,,,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,,CHEMBL618108,H,8,,,Cavia porcellus,10141.0,BAO_0000357,55,,4062,,10193,B,,
Autocuration,,1,,,Inhibitory activity uM,,CHEMBL618109,H,8,,,Cavia porcellus,10141.0,BAO_0000357,55,,4063,,13243,B,,
Autocuration,,1,,,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase at 10 uM,,CHEMBL618110,H,8,,,Cavia porcellus,10141.0,BAO_0000357,55,,4064,,13243,B,,
Expert,,1,,,Inhibitory activity uM,,CHEMBL618111,H,8,,,Cavia porcellus,10141.0,BAO_0000357,55,,4065,,13243,B,,
Autocuration,,1,,,Inhibitory activity uM,,CHEMBL618112,H,8,,,Cavia porcellus,10141.0,BAO_0000019,55,,4066,,13243,F,,
Autocuration,,1,,,Percent inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,,CHEMBL618113,H,8,,,Cavia porcellus,10141.0,BAO_0000019,55,,4067,,10504,B,,
Autocuration,,1,,,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,,CHEMBL618114,H,8,,,Cavia porcellus,10141.0,BAO_0000357,55,,4068,,7788,B,,
Expert,,1,,,Evaluated for inhibition of the formation and release of 5-lipoxygenase in isolated guinea pig ileum,,CHEMBL620871,H,8,,,Cavia porcellus,10141.0,BAO_0000221,55,,4069,Ileum,10546,F,,2116.0
Autocuration,,1,,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),,CHEMBL620872,H,8,,,,,BAO_0000357,55,,4070,,13183,B,,
Autocuration,,1,,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),,CHEMBL620873,H,8,,,,,BAO_0000357,55,,4071,,13183,B,,
Autocuration,,1,,,Compound was evaluated for in vitro inhibition of recombinant human 5-lipoxygenase (5-LO),,CHEMBL620874,H,8,,,,,BAO_0000357,55,,4072,,2578,B,,
Expert,,1,,,In vitro inhibition of human 5-Lipoxygenase.,,CHEMBL620875,H,8,,,,,BAO_0000357,55,,4073,,12780,B,,
Autocuration,,1,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,Microsomes,CHEMBL620876,U,0,,,Rattus norvegicus,10116.0,BAO_0000251,22226,,4074,Liver,7411,B,,2107.0
Autocuration,,1,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,Microsomes,CHEMBL620877,U,0,,,Rattus norvegicus,10116.0,BAO_0000251,22226,,4075,Liver,7411,B,,2107.0
Autocuration,,1,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,Microsomes,CHEMBL857854,U,0,,,Rattus norvegicus,10116.0,BAO_0000251,22226,,4076,Liver,7411,B,,2107.0
Autocuration,,1,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM exposed 100 uM,Microsomes,CHEMBL620878,U,0,,,Rattus norvegicus,10116.0,BAO_0000251,22226,,4077,Liver,7411,B,,2107.0
Autocuration,,1,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,Microsomes,CHEMBL620879,U,0,,,Rattus norvegicus,10116.0,BAO_0000251,22226,,4078,Liver,7411,B,,2107.0
Autocuration,,1,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,Microsomes,CHEMBL620880,U,0,,,Rattus norvegicus,10116.0,BAO_0000251,22226,,4079,Liver,7411,B,,2107.0
Autocuration,,1,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,Microsomes,CHEMBL620881,U,0,,,Rattus norvegicus,10116.0,BAO_0000251,22226,,4080,Liver,7411,B,,2107.0
Autocuration,,1,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,Microsomes,CHEMBL620882,U,0,,,Rattus norvegicus,10116.0,BAO_0000251,22226,,4081,Liver,7411,B,,2107.0
Autocuration,,1,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,Microsomes,CHEMBL620883,U,0,,,Rattus norvegicus,10116.0,BAO_0000251,22226,,4082,Liver,7411,B,,2107.0
Autocuration,,1,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,Microsomes,CHEMBL620884,U,0,,,Rattus norvegicus,10116.0,BAO_0000251,22226,,4083,Liver,7411,B,,2107.0
Autocuration,,1,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,Microsomes,CHEMBL620885,U,0,,,Rattus norvegicus,10116.0,BAO_0000251,22226,,4084,Liver,7411,B,,2107.0
Autocuration,,1,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 27.5 uM,Microsomes,CHEMBL620886,U,0,,,Rattus norvegicus,10116.0,BAO_0000251,22226,,4085,Liver,7411,B,,2107.0
Autocuration,,1,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,Microsomes,CHEMBL620887,U,0,,,Rattus norvegicus,10116.0,BAO_0000251,22226,,4086,Liver,7411,B,,2107.0
Autocuration,,1,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,Microsomes,CHEMBL618039,U,0,,,Rattus norvegicus,10116.0,BAO_0000251,22226,,4087,Liver,7411,B,,2107.0
Autocuration,,1,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,Microsomes,CHEMBL618040,U,0,,,Rattus norvegicus,10116.0,BAO_0000251,22226,,4088,Liver,7411,B,,2107.0
Autocuration,,1,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to exposed to 3-methylcholanthrene at concentration of 200 uM,Microsomes,CHEMBL618041,U,0,,,Rattus norvegicus,10116.0,BAO_0000251,22226,,4089,Liver,7411,B,,2107.0
Autocuration,,1,,,"Compound was evaluated for inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",Microsomes,CHEMBL618216,U,0,,,Rattus norvegicus,10116.0,BAO_0000251,22226,,4090,Liver,7411,B,,2107.0
Autocuration,,1,,,"Compound was evaluated for inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",Microsomes,CHEMBL618217,U,0,,,Rattus norvegicus,10116.0,BAO_0000251,22226,,4091,Liver,7411,B,,2107.0
Autocuration,,1,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 100 uM,Microsomes,CHEMBL618218,U,0,,,Rattus norvegicus,10116.0,BAO_0000251,22226,,4092,Liver,7411,B,,2107.0
Autocuration,,1,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 200 uM,Microsomes,CHEMBL618219,U,0,,,Rattus norvegicus,10116.0,BAO_0000251,22226,,4093,Liver,7411,B,,2107.0
Autocuration,,1,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 50 uM,Microsomes,CHEMBL618220,U,0,,,Rattus norvegicus,10116.0,BAO_0000251,22226,,4094,Liver,7411,B,,2107.0
Autocuration,,1,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 5 uM,Microsomes,CHEMBL618221,U,0,,,Rattus norvegicus,10116.0,BAO_0000251,22226,,4095,Liver,7411,B,,2107.0
Autocuration,,1,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 50 uM,Microsomes,CHEMBL618222,U,0,,,Rattus norvegicus,10116.0,BAO_0000251,22226,,4096,Liver,7411,B,,2107.0
Autocuration,,1,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,Microsomes,CHEMBL618223,U,0,,,Rattus norvegicus,10116.0,BAO_0000251,22226,,4097,Liver,7411,B,,2107.0
Autocuration,,1,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,Microsomes,CHEMBL618224,U,0,,,Rattus norvegicus,10116.0,BAO_0000251,22226,,4098,Liver,7411,B,,2107.0
Autocuration,,1,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 1 uM,Microsomes,CHEMBL618225,U,0,,,Rattus norvegicus,10116.0,BAO_0000251,22226,,4099,Liver,7411,B,,2107.0
Autocuration,,1,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 20 uM,Microsomes,CHEMBL618226,U,0,,,Rattus norvegicus,10116.0,BAO_0000251,22226,,4100,Liver,7411,B,,2107.0
Autocuration,,1,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,Microsomes,CHEMBL618227,U,0,,,Rattus norvegicus,10116.0,BAO_0000251,22226,,4101,Liver,7411,B,,2107.0
Autocuration,,1,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,Microsomes,CHEMBL618228,U,0,,,Rattus norvegicus,10116.0,BAO_0000251,22226,,4102,Liver,7411,B,,2107.0
Autocuration,,1,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,Microsomes,CHEMBL618229,U,0,,,Rattus norvegicus,10116.0,BAO_0000251,22226,,4103,Liver,7411,B,,2107.0
Autocuration,,1,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,Microsomes,CHEMBL618230,U,0,,,Rattus norvegicus,10116.0,BAO_0000251,22226,,4104,Liver,7411,B,,2107.0
Autocuration,,1,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,Microsomes,CHEMBL618231,U,0,,,Rattus norvegicus,10116.0,BAO_0000251,22226,,4105,Liver,7411,B,,2107.0
Autocuration,,1,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,Microsomes,CHEMBL618232,U,0,,,Rattus norvegicus,10116.0,BAO_0000251,22226,,4106,Liver,7411,B,,2107.0
Autocuration,,1,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,Microsomes,CHEMBL618233,U,0,,,Rattus norvegicus,10116.0,BAO_0000251,22226,,4107,Liver,7411,B,,2107.0
Autocuration,,1,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,Microsomes,CHEMBL618234,U,0,,,Rattus norvegicus,10116.0,BAO_0000251,22226,,4108,Liver,7411,B,,2107.0
Autocuration,,1,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,Microsomes,CHEMBL618235,U,0,,,Rattus norvegicus,10116.0,BAO_0000251,22226,,4109,Liver,7411,B,,2107.0
Autocuration,,1,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,Microsomes,CHEMBL618115,U,0,,,Rattus norvegicus,10116.0,BAO_0000251,22226,,4110,Liver,7411,B,,2107.0
Autocuration,,1,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,Microsomes,CHEMBL618116,U,0,,,Rattus norvegicus,10116.0,BAO_0000251,22226,,4111,Liver,7411,B,,2107.0
Autocuration,,1,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,Microsomes,CHEMBL618117,U,0,,,Rattus norvegicus,10116.0,BAO_0000251,22226,,4112,Liver,7411,B,,2107.0
Autocuration,,1,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,Microsomes,CHEMBL619968,U,0,,,Rattus norvegicus,10116.0,BAO_0000251,22226,,4113,Liver,7411,B,,2107.0
Autocuration,,1,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,Microsomes,CHEMBL619969,U,0,,,Rattus norvegicus,10116.0,BAO_0000251,22226,,4114,Liver,7411,B,,2107.0
Autocuration,,1,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,Microsomes,CHEMBL619970,U,0,,,Rattus norvegicus,10116.0,BAO_0000251,22226,,4115,Liver,7411,B,,2107.0
Autocuration,,1,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1000 uM,Microsomes,CHEMBL619971,U,0,,,Rattus norvegicus,10116.0,BAO_0000251,22226,,4116,Liver,7411,B,,2107.0
Autocuration,,1,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1500 uM,Microsomes,CHEMBL619972,U,0,,,Rattus norvegicus,10116.0,BAO_0000251,22226,,4117,Liver,7411,B,,2107.0
Autocuration,,1,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 27.5 uM,Microsomes,CHEMBL619973,U,0,,,Rattus norvegicus,10116.0,BAO_0000251,22226,,4118,Liver,7411,B,,2107.0
Autocuration,,1,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 500 uM,Microsomes,CHEMBL619974,U,0,,,Rattus norvegicus,10116.0,BAO_0000251,22226,,4119,Liver,7411,B,,2107.0
Autocuration,,1,,,Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,Microsomes,CHEMBL619975,U,0,,,Rattus norvegicus,10116.0,BAO_0000251,22226,,4120,Liver,7411,B,,2107.0
Autocuration,,1,,,Vmax determined by 7-ethoxycoumarin deethylation in the presence by liver microsomes from rats exposed to 3-methylcholanthrene at concentration of 10 uM,Microsomes,CHEMBL619976,U,0,,,Rattus norvegicus,10116.0,BAO_0000251,22226,,4121,,7411,B,,
Autocuration,,1,,,"Compound was evaluated for alpha -rate constant, in liver microsomes from 3-methylcholanthrene-exposed rats",Microsomes,CHEMBL619977,U,0,,,Rattus norvegicus,10116.0,BAO_0000251,22226,,4122,Liver,7411,B,,2107.0
Autocuration,,1,,,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats",Microsomes,CHEMBL619978,U,0,,,Rattus norvegicus,10116.0,BAO_0000251,22226,,4123,Liver,7411,B,,2107.0
Autocuration,,1,,,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats; competitive inhibition",Microsomes,CHEMBL619979,U,0,,,Rattus norvegicus,10116.0,BAO_0000251,22226,,4124,Liver,7411,B,,2107.0
Autocuration,,1,,,"Compound was evaluated for alpha inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",Microsomes,CHEMBL619980,U,0,,,Rattus norvegicus,10116.0,BAO_0000251,22226,,4125,Liver,7411,B,,2107.0
Autocuration,,1,,,"Compound was evaluated for alpha inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",Microsomes,CHEMBL619981,U,0,,,Rattus norvegicus,10116.0,BAO_0000251,22226,,4126,Liver,7411,B,,2107.0
Intermediate,,1,RPMI-8226,,In vitro inhibition of 7226/S myeloma cancer cell line,,CHEMBL619982,N,1,,741.0,Homo sapiens,9606.0,BAO_0000219,80433,,4127,,10797,F,,
Intermediate,,1,BEL-7404 tumor cell line,,In vitro antitumor activity of compound against 7404 cell line (human liver carcinoma cells),,CHEMBL619983,N,1,,993.0,Homo sapiens,9606.0,BAO_0000219,80698,,4128,,6881,F,,
Intermediate,,1,786-0,,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,,CHEMBL620031,N,1,,391.0,Homo sapiens,9606.0,BAO_0000219,80640,,4129,,3838,F,,
Intermediate,,1,786-0,,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,,CHEMBL620032,N,1,,391.0,Homo sapiens,9606.0,BAO_0000219,80640,,4130,,3838,F,,
Expert,,1,V79,,Net accumulation of the [99mTc]Isonitrile complex was measured in 77A cell lines in the presence of Verapamil.,,CHEMBL620033,N,1,,505.0,Cricetulus griseus,10029.0,BAO_0000219,81264,,4131,,12981,F,,
Expert,,1,V79,,Verapamil index represents the ratio of net uptake in the presense of verapamil over control in 77A cell lines.,,CHEMBL620034,N,1,,505.0,Cricetulus griseus,10029.0,BAO_0000219,81264,,4132,,12981,F,,
Intermediate,,1,7800C1 cell line,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 10 ug/mL dose,,CHEMBL620035,N,1,,1119.0,Rattus norvegicus,10116.0,BAO_0000219,80635,,4133,,7653,F,,
Intermediate,,1,7800C1 cell line,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 2 ug/mL dose,,CHEMBL618318,N,1,,1119.0,Rattus norvegicus,10116.0,BAO_0000219,80635,,4134,,7653,F,,
Intermediate,,1,7800C1 cell line,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 20 ug/mL dose,,CHEMBL618319,N,1,,1119.0,Rattus norvegicus,10116.0,BAO_0000219,80635,,4135,,7653,F,,
Intermediate,,1,7800C1 cell line,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 5 ug/mL dose,,CHEMBL618320,N,1,,1119.0,Rattus norvegicus,10116.0,BAO_0000219,80635,,4136,,7653,F,,
Intermediate,,1,7800C1 cell line,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 50 ug/mL dose,,CHEMBL618321,N,1,,1119.0,Rattus norvegicus,10116.0,BAO_0000219,80635,,4137,,7653,F,,
Intermediate,,1,7800C1 cell line,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 75 ug/mL dose,,CHEMBL883118,N,1,,1119.0,Rattus norvegicus,10116.0,BAO_0000219,80635,,4138,,7653,F,,
Intermediate,,1,786-0,,In vitro antitumor activity against renal 786-0 tumor cell lines,,CHEMBL883795,N,1,,391.0,Homo sapiens,9606.0,BAO_0000219,80640,,4139,,17229,F,,
Intermediate,,1,786-0,,Cytotoxic activity against 786-0 Renal cancer cell line,,CHEMBL618322,N,1,,391.0,Homo sapiens,9606.0,BAO_0000219,80640,,4140,,12858,F,,
Intermediate,,1,786-0,,Growth inhibitory activity was determined against 786-0 cancer cell line of Renal cancer,,CHEMBL618323,N,1,,391.0,Homo sapiens,9606.0,BAO_0000219,80640,,4141,,16325,F,,
Intermediate,,1,786-0,,Growth inhibitory activity was determined against 786-0 cancer cell line of renal cancer,,CHEMBL618324,N,1,,391.0,Homo sapiens,9606.0,BAO_0000219,80640,,4142,,16325,F,,
Intermediate,,1,786-0,,In vitro antitumor activity against human renal 786-0 cell line,,CHEMBL618325,N,1,,391.0,Homo sapiens,9606.0,BAO_0000219,80640,,4143,,5858,F,,
Intermediate,,1,786-0,,Inhibition of Renal cancer in 786-0 cancer cell lines,,CHEMBL875416,N,1,,391.0,Homo sapiens,9606.0,BAO_0000219,80640,,4144,,16325,F,,
Intermediate,,1,786-0,,Inhibition of the growth of renal cancer(786-0) cell line. value in parentheses is percent inhibition at 0.01 uM,,CHEMBL618326,N,1,,391.0,Homo sapiens,9606.0,BAO_0000219,80640,,4145,,14696,F,,
Intermediate,,1,786-0,,The compound was tested for its cytotoxic activity against the following renal cancer cell lines 786-0,,CHEMBL618327,N,1,,391.0,Homo sapiens,9606.0,BAO_0000219,80640,,4146,,3786,F,,
Intermediate,,1,786-0,,inhibition of the growth of renal cancer(786-0) cell line,,CHEMBL619215,N,1,,391.0,Homo sapiens,9606.0,BAO_0000219,80640,,4147,,14696,F,,
Intermediate,,1,786-0,,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),,CHEMBL619216,N,1,,391.0,Homo sapiens,9606.0,BAO_0000219,80640,,4148,,14769,F,,
Intermediate,,1,786-0,,Compound was tested for the growth inhibition of 786-0 renal tumor cell line,,CHEMBL619217,N,1,,391.0,Homo sapiens,9606.0,BAO_0000219,80640,,4149,,15354,F,,
Intermediate,,1,786-0,,The IC50 value was measured on 786-0 cell line in ovarian tumor,,CHEMBL619218,N,1,,391.0,Homo sapiens,9606.0,BAO_0000219,80640,,4150,,14255,F,,
Intermediate,,1,786-0,,The IC50 value was measured on 786-0 cell line in ovarian tumor t,,CHEMBL619219,N,1,,391.0,Homo sapiens,9606.0,BAO_0000219,80640,,4151,,14255,F,,
Intermediate,,1,786-0,,The IC50 value was measured on 786-0 cell line in renal tumor type.,,CHEMBL619220,N,1,,391.0,Homo sapiens,9606.0,BAO_0000219,80640,,4152,,14255,F,,
Intermediate,,1,786-0,,Inhibition of the growth of renal cancer(786-0) cell line at 0.01 uM,,CHEMBL619221,N,1,,391.0,Homo sapiens,9606.0,BAO_0000219,80640,,4153,,14696,F,,
Intermediate,,1,786-0,,Tested for cytotoxic activity against renal cancer 786-0 cell line,,CHEMBL619222,N,1,,391.0,Homo sapiens,9606.0,BAO_0000219,80640,,4154,,12016,F,,
Intermediate,,1,786-0,,Compound was tested for growth inhibitory activity against 786-0 cell line,,CHEMBL857454,N,1,,391.0,Homo sapiens,9606.0,BAO_0000219,80640,,4155,,2597,F,,
Autocuration,,1,RBL-1,,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; Inactive(N)= <50% inhibition at 10 uM,,CHEMBL619223,H,8,,702.0,,,BAO_0000219,12166,,4156,,12526,B,,
Autocuration,,1,RBL-1,,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; N=Inactive,,CHEMBL619224,H,8,,702.0,,,BAO_0000219,12166,,4157,,12526,B,,
Autocuration,,1,,,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,,CHEMBL619225,H,8,,,,,BAO_0000019,12166,,4158,,14799,B,,
Expert,,1,RBL-1,,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),,CHEMBL619226,H,8,,702.0,,,BAO_0000219,12166,,4159,,3595,B,,
Expert,,1,RBL-1,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),,CHEMBL619227,H,8,,702.0,,,BAO_0000219,12166,,4160,,3595,B,,
Autocuration,,1,,,Inhibitory activity against rat basophilic leukemia 5-lipoxygenase,,CHEMBL619228,H,8,,,,,BAO_0000357,12166,,4161,,12767,B,,
Autocuration,,1,,,Inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes,,CHEMBL619229,H,8,,,,,BAO_0000219,12166,,4162,,10997,B,,
Autocuration,,1,RBL-1,,Inhibitory activity against 5-lipoxygenase of RBL-1 cell line,,CHEMBL619230,H,8,,702.0,,,BAO_0000219,12166,,4163,,11388,B,,
Autocuration,,1,,,Inhibitory activity against RBL broken cell-supematant 5-lipoxygenase was evaluated,,CHEMBL619231,H,8,,,,,BAO_0000357,12166,,4164,,167,B,,
Autocuration,,1,,,"Inhibitory activity against intact rat PMNL, LTB4 5-lipoxygenase was evaluated",,CHEMBL619232,H,8,,,,,BAO_0000357,12166,,4165,,167,B,,
Expert,,1,,,Inhibitory activity against rat 5-lipoxygenase by using continuous oxygen consumption assay.,,CHEMBL619233,H,8,,,,,BAO_0000357,12166,,4166,,13744,B,,
Autocuration,,1,,,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase,,CHEMBL619234,H,8,,,,,BAO_0000357,12166,,4167,,1630,B,,
Autocuration,,1,,,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase (5-LO),,CHEMBL619235,H,8,,,,,BAO_0000357,12166,,4168,,1630,B,,
Expert,,1,,,"Inhibitory activity against 5-lipoxygenase in rat neutrophils as inhibition of A 23,187-induced LTB4 production",,CHEMBL619236,D,9,,,Rattus norvegicus,10116.0,BAO_0000019,12166,,4169,,969,B,,
Autocuration,,1,RBL-1,,Inhibitory concentration against 5-lipoxygenase in rat RBL-1 cells,,CHEMBL619237,H,8,,702.0,,,BAO_0000219,12166,,4170,,13621,B,,
Autocuration,,1,,,Inhibitory concentration to inhibit 5-lipoxygenase in the rat,,CHEMBL619238,H,8,,,,,BAO_0000357,12166,,4171,,10089,B,,
Expert,,1,,,In vitro inhibition of rat polymorphonuclear leukocyte 5-lipoxygenase,,CHEMBL619239,H,8,,,,,BAO_0000357,12166,,4172,,10193,B,,
Autocuration,,1,,,Tested for inhibition of 5-HPETE production by rat 5-LO; value ranges from 16-36 nM,,CHEMBL619240,H,8,,,,,BAO_0000357,12166,,4173,,11966,B,,
Autocuration,,1,,,Tested for inhibition of 5-LO by measuring the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,,CHEMBL875417,H,8,,,,,BAO_0000019,12166,,4174,,12251,B,,
Autocuration,,1,RBL-1,,Tested for inhibition of 5-Lipoxygenase (ARBL) in calcium-stimulated rat basophilic leukemia cells(RBL-1),,CHEMBL619241,H,8,,702.0,,,BAO_0000219,12166,,4175,,211,B,,
Expert,,1,,,Inhibition of 5-lipoxygenase measured by the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,,CHEMBL619242,H,8,,,,,BAO_0000019,12166,,4176,,12251,F,,
Autocuration,,1,RBL-1,,Tested for inhibitory activity against 5-lipoxygenase in microsome of RBL-1 cells,,CHEMBL883796,H,8,,702.0,,,BAO_0000219,12166,,4177,,12495,B,,
Autocuration,,1,,,Tested for its inhibitory activity against 5-lipoxygenase,,CHEMBL619243,H,8,,,,,BAO_0000357,12166,,4178,,414,B,,
Autocuration,,1,,,Tested for its inhibitory activity against 5-lipoxygenase; Not determined,,CHEMBL619244,H,8,,,,,BAO_0000357,12166,,4179,,414,B,,
Expert,,1,,,"Iin vitro inhibition of 5-lipoxygenase activity in rat basophil leukemia type 1(RBL1) cell homogenates, (reduction of [14C]-5-HETE formation)",,CHEMBL619245,H,8,,,,,BAO_0000019,12166,,4180,,10325,B,,
Expert,,1,,,In vitro test for inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,,CHEMBL619246,H,8,,,,,BAO_0000019,12166,,4181,,11966,B,,
Expert,,1,RBL-1,,In vitro inhibition of 5-lipoxygenase activity in RBL-1 cells.,,CHEMBL619984,H,8,,702.0,,,BAO_0000219,12166,,4182,,165,B,,
Autocuration,,1,RBL-1,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells; No significant inhibitory activity up to 30 uM,,CHEMBL619985,H,8,,702.0,,,BAO_0000219,12166,,4183,,165,B,,
Autocuration,,1,RBL-1,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,,CHEMBL619986,H,8,,702.0,,,BAO_0000219,12166,,4184,,165,B,,
Expert,,1,RBL-1,,In vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,,CHEMBL619987,H,8,,702.0,,,BAO_0000219,12166,,4185,,165,B,,
Autocuration,,1,,,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse,,CHEMBL619988,H,8,,,,,BAO_0000218,12166,,4186,,11311,B,,
Autocuration,,1,RBL-1,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1,,CHEMBL619989,H,8,,702.0,,,BAO_0000219,12166,,4187,,11311,B,,
Autocuration,,1,RBL-1,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,,CHEMBL619990,H,8,,702.0,,,BAO_0000219,12166,,4188,,11311,B,,
Autocuration,,1,,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS],,CHEMBL619991,H,8,,,,,BAO_0000219,12166,,4189,,11311,B,,
Autocuration,,1,,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vitro),,CHEMBL619992,H,8,,,,,BAO_0000219,12166,,4190,,11311,B,,
Autocuration,,1,,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vivo),,CHEMBL619993,H,8,,,,,BAO_0000218,12166,,4191,,11311,B,In vivo,
Autocuration,,1,RBL-2H3,,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in RBL-2H3 cells,,CHEMBL619994,H,8,,663.0,,,BAO_0000219,12166,,4192,,11311,F,,
Autocuration,,1,RBL-2H3,,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in rat RBL-2H3 cells,,CHEMBL619995,H,8,,663.0,,,BAO_0000219,12166,,4193,,11311,F,,
Autocuration,,1,,,The compound was tested for inhibitory activity against 5-lipoxygenase using rat polymorphonuclear leukocytes[PMNS],,CHEMBL619996,H,8,,,,,BAO_0000019,12166,,4194,,11311,B,,
Autocuration,,1,,,The compound was tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase,,CHEMBL619997,H,8,,,,,BAO_0000019,12166,,4195,,11732,B,,
Expert,,1,,,Tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase.,,CHEMBL619998,H,8,,,,,BAO_0000019,12166,,4196,,11732,B,,
Expert,,1,,,In vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells,,CHEMBL619999,H,8,,,,,BAO_0000019,12166,,4197,,11087,B,,
Autocuration,,1,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells,,CHEMBL620000,H,8,,,,,BAO_0000019,12166,,4198,,11087,B,,
Autocuration,,1,RBL-1,,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in homogenized rat basophilic leukemia (RBL-1) cells,,CHEMBL620001,H,8,,702.0,,,BAO_0000219,12166,,4199,,11087,B,,
Expert,,1,,,Inhibition of 5-lipoxygenase (5-lo) in intact rat polymorphonuclear leukocyte RPMNL,,CHEMBL620002,D,9,,,Rattus norvegicus,10116.0,BAO_0000357,12166,,4200,,11087,B,,
Autocuration,,1,RBL-1,,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells,,CHEMBL620003,H,8,,702.0,,,BAO_0000219,12166,,4201,,496,B,,
Expert,,1,RBL-1,,Inhibition of 5-lipoxygenase on rat basophil leukemia cell line lysate (RBL-1 2H3 subline) by measuring 5-HETE production,,CHEMBL620004,H,8,,702.0,,,BAO_0000219,12166,,4202,,13986,F,,
Autocuration,,1,,,Compound was evaluated for the inhibition of 5-lipoxygenase,,CHEMBL874063,H,8,,,,,BAO_0000357,12166,,4203,,11520,B,,
Autocuration,,1,RBL-1,,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line at a concentration of 25 uM,,CHEMBL620005,H,8,,702.0,,,BAO_0000219,12166,,4204,,10293,B,,
Autocuration,,1,RBL-1,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay,,CHEMBL620006,H,8,,702.0,,,BAO_0000219,12166,,4205,,303,B,,
Autocuration,,1,RBL-1,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay; Less than 5% inhibition at 10 uM reported as not active,,CHEMBL620007,H,8,,702.0,,,BAO_0000219,12166,,4206,,303,B,,
Autocuration,,1,RBL-1,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 10 uM,,CHEMBL620008,H,8,,702.0,,,BAO_0000219,12166,,4207,,9247,B,,
Expert,,1,RBL-1,,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM,,CHEMBL620009,D,9,,702.0,Rattus norvegicus,10116.0,BAO_0000219,12166,,4208,,9247,B,,
Autocuration,,1,RBL-1,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,,CHEMBL620010,H,8,,702.0,,,BAO_0000219,12166,,4209,,9247,B,,
Autocuration,,1,RBL-1,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 30 uM,,CHEMBL620011,H,8,,702.0,,,BAO_0000219,12166,,4210,,9247,B,,
Autocuration,,1,RBL-1,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 300 uM,,CHEMBL620677,H,8,,702.0,,,BAO_0000219,12166,,4211,,9247,B,,
Autocuration,,1,RBL-1,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 33 uM,,CHEMBL620678,H,8,,702.0,,,BAO_0000219,12166,,4212,,9247,B,,
Autocuration,,1,RBL-1,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 40 uM,,CHEMBL620679,H,8,,702.0,,,BAO_0000219,12166,,4213,,9247,B,,
Autocuration,,1,RBL-1,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 75 uM,,CHEMBL620680,H,8,,702.0,,,BAO_0000219,12166,,4214,,9247,B,,
Expert,,1,,,Inhibitory activity against 5-lipoxygenase at 10 uM,,CHEMBL620838,D,9,,,Rattus norvegicus,10116.0,BAO_0000357,12166,,4215,,11481,B,,
Autocuration,,1,,,In vitro inhibition of 5-lipoxygenase; NS means no significant inhibition,,CHEMBL620839,H,8,,,,,BAO_0000357,12166,,4216,,105,B,,
Expert,,1,,,In vitro inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase at 10 uM,,CHEMBL620840,H,8,,,,,BAO_0000357,12166,,4217,,9029,B,,
Expert,,1,RBL-1,,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells at 20 uM,,CHEMBL620841,H,8,,702.0,,,BAO_0000219,12166,,4218,,1175,B,,
Autocuration,,1,RBL-1,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 100 uM,,CHEMBL620842,H,8,,702.0,,,BAO_0000219,12166,,4219,,12118,B,,
Autocuration,,1,RBL-1,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 10e-4 M,,CHEMBL620843,H,8,,702.0,,,BAO_0000219,12166,,4220,,12118,B,,
Autocuration,,1,RBL-1,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determinedb at 100 uM,,CHEMBL620844,H,8,,702.0,,,BAO_0000219,12166,,4221,,12118,B,,
Autocuration,,1,RBL-1,,In vitro inhibition of RBL-1 5-lipoxygenase at 20 uM,,CHEMBL620845,H,8,,702.0,,,BAO_0000219,12166,,4222,,9225,B,,
Autocuration,,1,,,In vitro inhibitory activity against 5-Lipoxygenase from rat basophilic leukemia cells at 30 uM concentration,,CHEMBL620846,H,8,,,,,BAO_0000019,12166,,4223,,9401,B,,
Autocuration,,1,,,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,,CHEMBL873951,H,8,,,,,BAO_0000357,12166,,4224,,137,B,,
Autocuration,,1,,,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,,CHEMBL620847,H,8,,,,,BAO_0000357,12166,,4225,,137,B,,
Autocuration,,1,RBL-1,,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,,CHEMBL620848,H,8,,702.0,,,BAO_0000219,12166,,4226,,4717,B,,
Autocuration,,1,RBL-1,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,,CHEMBL620849,H,8,,702.0,,,BAO_0000219,12166,,4227,,3595,B,,
Autocuration,,1,RBL-1,,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at 40 uM concentration,,CHEMBL620850,H,8,,702.0,,,BAO_0000219,12166,,4228,,10501,B,,
Autocuration,,1,RBL-1,,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM,,CHEMBL620851,H,8,,702.0,,,BAO_0000219,12166,,4229,,10501,B,,
Autocuration,,1,RBL-1,,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM.,,CHEMBL620852,H,8,,702.0,,,BAO_0000219,12166,,4230,,10501,B,,
Autocuration,,1,RBL-1,,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,CHEMBL875098,H,8,,702.0,,,BAO_0000219,12166,,4231,,12526,B,,
Expert,,1,RBL-1,,Inhibition of 5-lipoxygenase of rat basophilic leukemia cells at 30 uM,,CHEMBL620853,D,9,,702.0,Rattus norvegicus,10116.0,BAO_0000219,12166,,4232,,14799,B,,
Autocuration,,1,,,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells at 30 uM concentration; NT=Not tested,,CHEMBL620854,H,8,,,,,BAO_0000019,12166,,4233,,14799,B,,
Autocuration,,1,RBL-1,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,,CHEMBL620855,H,8,,702.0,,,BAO_0000219,12166,,4234,,3595,B,,
Expert,,1,RBL-1,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,,CHEMBL839884,H,8,,702.0,,,BAO_0000219,12166,,4235,,3595,B,,
Autocuration,,1,RBL-1,,Inhibitory activity at 10 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,CHEMBL620856,H,8,,702.0,,,BAO_0000219,12166,,4236,,12526,B,,
Autocuration,,1,RBL-1,,Inhibitory activity at 1 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,CHEMBL620857,H,8,,702.0,,,BAO_0000219,12166,,4237,,12526,B,,
Autocuration,,1,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,,CHEMBL620858,H,8,,,,,BAO_0000019,12166,,4238,,10193,B,,
Autocuration,,1,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,,CHEMBL620859,H,8,,,,,BAO_0000019,12166,,4239,,10193,B,,
Autocuration,,1,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,,CHEMBL620860,H,8,,,,,BAO_0000019,12166,,4240,,10193,B,,
Autocuration,,1,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 3 uM,,CHEMBL620861,H,8,,,,,BAO_0000019,12166,,4241,,10193,B,,
Expert,,1,,,Percent inhibition of rat neutrophil 5-lipoxygenase (5-LO),,CHEMBL620862,H,8,,,,,BAO_0000357,12166,,4242,,9138,B,,
Autocuration,,1,,,Percent inhibition of rat neutrophil 5- Lipoxygenase (5-LO) at 100 uM,,CHEMBL620863,H,8,,,,,BAO_0000357,12166,,4243,,9138,B,,
Autocuration,,1,,,Tested in vitro for the inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,,CHEMBL620864,H,8,,,,,BAO_0000019,12166,,4244,,11966,B,,
Autocuration,,1,RBL-1,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 100 uM,,CHEMBL620865,H,8,,702.0,,,BAO_0000219,12166,,4245,,165,B,,
Autocuration,,1,RBL-1,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 30 uM,,CHEMBL620866,H,8,,702.0,,,BAO_0000219,12166,,4246,,165,B,,
Autocuration,,1,RBL-2H3,,The compound was tested for inhibition of 5-lipoxygenase in rat RBL-2H3 cells,,CHEMBL620867,H,8,,663.0,,,BAO_0000219,12166,,4247,,11311,B,,
Autocuration,,1,RBL-2H3,,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,,CHEMBL620868,H,8,,663.0,,,BAO_0000219,12166,,4248,,11311,B,,
Autocuration,,1,RBL-2H3,,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,,CHEMBL620869,H,8,,663.0,,,BAO_0000219,12166,,4249,,11311,F,,
Autocuration,,1,,,The compound was tested for inhibition of LTB4 synthesis on isolated 5-lipoxygenase,,CHEMBL873952,H,8,,,,,BAO_0000019,12166,,4250,,11311,F,,
Autocuration,,1,,,The compound was tested for inhibition of isolated 5-lipoxygenase,,CHEMBL875099,H,8,,,,,BAO_0000357,12166,,4251,,11311,B,,
Autocuration,,1,RBL-2H3,,The compound was tested for inhibition of isolated 5-lipoxygenase translocation into rat RBL-2H3 cells,,CHEMBL620870,H,8,,663.0,,,BAO_0000219,12166,,4252,,11311,F,,
Autocuration,,1,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 30 uM,,CHEMBL618261,H,8,,,,,BAO_0000019,12166,,4253,,11087,B,,
Autocuration,,1,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 32 uM,,CHEMBL618262,H,8,,,,,BAO_0000019,12166,,4254,,11087,B,,
Autocuration,,1,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells measured at a concentration of 30 uM,,CHEMBL619428,H,8,,,,,BAO_0000019,12166,,4255,,11087,B,,
Autocuration,,1,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,,CHEMBL619429,H,8,,,,,BAO_0000019,12166,,4256,,11087,B,,
Autocuration,,1,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,,CHEMBL619430,H,8,,,,,BAO_0000019,12166,,4257,,11087,B,,
Autocuration,,1,RBL-1,,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 1.0 uM,,CHEMBL620017,H,8,,702.0,,,BAO_0000219,12166,,4258,,496,B,,
Autocuration,,1,RBL-1,,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 10 uM,,CHEMBL620018,H,8,,702.0,,,BAO_0000219,12166,,4259,,496,B,,
Autocuration,,1,RBL-1,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.1 uM,,CHEMBL620019,H,8,,702.0,,,BAO_0000219,12166,,4260,,13986,F,,
Autocuration,,1,RBL-1,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.195 uM,,CHEMBL620020,H,8,,702.0,,,BAO_0000219,12166,,4261,,13986,F,,
Autocuration,,1,RBL-1,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.2 at uM,,CHEMBL620021,H,8,,702.0,,,BAO_0000219,12166,,4262,,13986,F,,
Autocuration,,1,RBL-1,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.25 uM,,CHEMBL620022,H,8,,702.0,,,BAO_0000219,12166,,4263,,13986,F,,
Autocuration,,1,RBL-1,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39,,CHEMBL620023,H,8,,702.0,,,BAO_0000219,12166,,4264,,13986,F,,
Autocuration,,1,RBL-1,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39 uM,,CHEMBL620024,H,8,,702.0,,,BAO_0000219,12166,,4265,,13986,F,,
Autocuration,,1,RBL-1,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.195 uM,,CHEMBL620025,H,8,,702.0,,,BAO_0000219,12166,,4266,,13986,F,,
Autocuration,,1,RBL-1,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.2 uM,,CHEMBL620026,H,8,,702.0,,,BAO_0000219,12166,,4267,,13986,F,,
Autocuration,,1,RBL-1,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.39 uM,,CHEMBL620027,H,8,,702.0,,,BAO_0000219,12166,,4268,,13986,F,,
Expert,,1,,,Inhibition of 5-lipoxygenase on rat basophil leukemia cell (RBL-2H3) lysate as 5-HETE production at 32 uM,,CHEMBL620028,D,9,,,Rattus norvegicus,10116.0,BAO_0000019,12166,,4269,,13986,F,,
Autocuration,,1,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase,,CHEMBL620029,H,8,,,,,BAO_0000357,12166,,4270,,10193,B,,
Autocuration,,1,,,Compound was tested for the percent of inhibition against 5-LO at 10 uM,,CHEMBL620030,H,8,,,,,BAO_0000357,12166,,4271,,9295,B,,
Autocuration,,1,RBL-1,,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 1 uM concentration,,CHEMBL875415,H,8,,702.0,,,BAO_0000219,12166,,4272,,4717,B,,
Autocuration,,1,RBL-1,,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,,CHEMBL618256,H,8,,702.0,,,BAO_0000219,12166,,4273,,4717,B,,
Autocuration,,1,RBL-1,,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line,,CHEMBL618257,H,8,,702.0,,,BAO_0000219,12166,,4274,,11854,B,,
Autocuration,,1,RBL-1,,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 10 uM,,CHEMBL618258,H,8,,702.0,,,BAO_0000219,12166,,4275,,11854,B,,
Autocuration,,1,RBL-1,,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 16 uM,,CHEMBL618259,H,8,,702.0,,,BAO_0000219,12166,,4276,,11854,B,,
Autocuration,,1,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,,CHEMBL618260,H,8,,,,,BAO_0000019,12166,,4277,,10193,B,,
Autocuration,,1,RBL-1,,Percent inhibition against RBL-1 5-LO in vitro at 10 uM,,CHEMBL618215,H,8,,702.0,,,BAO_0000219,12166,,4278,,9295,B,,
Autocuration,,1,RBL-1,,Percent inhibition against RBL-1 5-LO in vitro at 100 uM,,CHEMBL618390,H,8,,702.0,,,BAO_0000219,12166,,4279,,9295,B,,
Autocuration,,1,RBL-1,,Percent inhibition against RBL-1 5-LO in vitro at 30 uM,,CHEMBL618391,H,8,,702.0,,,BAO_0000219,12166,,4280,,9295,B,,
Autocuration,,1,RBL-1,,Percent inhibition against RBL-1 5-LO in vitro at 300 uM,,CHEMBL618392,H,8,,702.0,,,BAO_0000219,12166,,4281,,9295,B,,
Autocuration,,1,RBL-1,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 20 uM,,CHEMBL618393,H,8,,702.0,,,BAO_0000219,12166,,4282,,165,B,,
Autocuration,,1,,,The compound was tested for inhibition against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] at 10 uM concentration,,CHEMBL618394,H,8,,,,,BAO_0000219,12166,,4283,,11311,B,,
Expert,,1,RBL-1,,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),,CHEMBL618395,H,8,,702.0,Homo sapiens,9606.0,BAO_0000219,12166,,4284,,10489,B,,
Expert,,1,RBL-1,,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),,CHEMBL618396,D,9,,702.0,Rattus norvegicus,10116.0,BAO_0000219,12166,,4285,,10489,B,,
Expert,,1,RBL-1,,Logarithmic value of inhibitory concentration against 5-lipoxygenase in rat basophilic leukemia cells (RBL-1),,CHEMBL858253,D,9,,702.0,Rattus norvegicus,10116.0,BAO_0000219,12166,,4286,,10489,B,,
Autocuration,,1,,,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,,CHEMBL618397,D,9,,,Rattus norvegicus,10116.0,BAO_0000019,12166,,4287,,14799,B,,
Autocuration,,1,,,Compound was tested for the percent of inhibition against soybean 15-LO (at 100 uM),,CHEMBL618398,H,8,,,Glycine max,3847.0,BAO_0000357,12054,,4288,,9295,B,,
Autocuration,,1,,,"Inhibitory activity against 5-lipoxygenase, by using soybean lipoxygenase spectrophotometric assay",,CHEMBL618399,U,0,,,,,BAO_0000019,22226,,4289,,16811,B,,
Expert,,1,,,In vitro inhibition of 5-Lipoxygenase; Inactive.,,CHEMBL618400,H,8,,,,,BAO_0000357,55,,4290,,168,B,,
Autocuration,,1,,,Inhibitory concentration against 5-lipoxygenase was determined; No inhibition,,CHEMBL618401,H,8,,,,,BAO_0000357,55,,4291,,6309,B,,
Autocuration,,1,,,Inhibitory concentration against 5-lipoxygenase; No inhibition,,CHEMBL618402,H,8,,,,,BAO_0000357,55,,4292,,6309,B,,
Autocuration,,1,RBL-1,,Evaluated for inhibitory activity against RBL-1 cell 5-lipoxygenase in guinea pig,,CHEMBL876400,H,8,,702.0,,,BAO_0000219,55,,4293,,3092,B,,
Expert,,1,,,Inhibitory activity against 5-lipoxygenase.,,CHEMBL618403,H,8,,,,,BAO_0000357,55,,4294,,168,B,,
Autocuration,,1,,,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive,,CHEMBL618404,H,8,,,,,BAO_0000357,55,,4295,,168,B,,
Autocuration,,1,,,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive at concentrations less than 32 uM,,CHEMBL618405,H,8,,,,,BAO_0000357,55,,4296,,168,B,,
Autocuration,,1,,,Inhibitory Activity against 5-Lipoxygenase was determined; NA=No significant inhibitory activity up to 300 uM,,CHEMBL618406,H,8,,,,,BAO_0000357,55,,4297,,168,B,,
Expert,,1,,,Inhibitory concentration against arachidonic acid 5-lipoxygenation,,CHEMBL618407,H,8,,,,,BAO_0000019,55,,4298,,12338,F,,
Autocuration,,1,,,Tested for the inhibitory activity against 5-lipoxygenase,,CHEMBL618408,H,8,,,,,BAO_0000357,55,,4299,,4501,B,,
Autocuration,,1,,,Compound was tested for its inhibitory activity against 5-lipoxygenase,,CHEMBL618409,H,8,,,,,BAO_0000357,55,,4300,,1132,B,,
Autocuration,,1,,,Compound was tested for inhibition of 5-lipoxygenase at 50 uM; NI means no inhibition was observed,,CHEMBL618410,H,8,,,,,BAO_0000357,55,,4301,,2117,B,,
Autocuration,,1,,,Inhibitory Activity against 5-Lipoxygenase at 30 uM was determined; Weakly active,,CHEMBL618411,H,8,,,,,BAO_0000357,55,,4302,,168,B,,
Autocuration,,1,,,Inhibitory Activity against 5-Lipoxygenase at concentration 32 uM was determined,,CHEMBL618412,H,8,,,,,BAO_0000357,55,,4303,,168,B,,
Autocuration,,1,RBL-1,,Concentration required to inhibit RBL-1 supernatant 5-lipoxygenase,,CHEMBL618413,H,8,,702.0,,,BAO_0000219,12166,,4304,,13575,B,,
Autocuration,,1,,,,,CHEMBL618414,H,8,,,,,BAO_0000357,12166,,4305,,11089,B,,
Autocuration,,1,,,Compound was tested for its binding activity towards 5-lipoxygenase activating protein (FLAP),,CHEMBL618415,H,8,,,,,BAO_0000357,10102,,4306,,216,B,,
Autocuration,,1,,,Inhibition of 5-lipoxygenase activating protein using human leukocyte membrane preparations,,CHEMBL618416,H,8,,,,,BAO_0000019,10102,,4307,,13165,B,,
Autocuration,,1,,,Measuring the affinity of leukotriene synthesis inhibitor for 5-Lipoxygenase activating protein (FLAP) by using [125I]L-691831 as radioligand.,,CHEMBL876401,H,8,,,,,BAO_0000357,10102,,4308,,3278,B,,
Expert,,1,,,Measuring the affinity of leukotriene synthesis inhibitor for 5-lipoxygenase activating protein by using [125I]L-691831 as radioligand.,,CHEMBL618417,H,8,,,,,BAO_0000357,10102,,4309,,3278,B,,
Autocuration,,1,,,Tested for inhibition of leukotriene biosynthesis by binding to 5-lipoxygenase activating protein,,CHEMBL618418,H,8,,,,,BAO_0000357,10102,,4310,,11966,B,,
Autocuration,,1,,,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein",,CHEMBL618419,H,8,,,,,BAO_0000357,10102,,4311,,175,B,,
Autocuration,,1,,,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein (FLAP)",,CHEMBL618420,H,8,,,,,BAO_0000357,10102,,4312,,175,B,,
Autocuration,,1,,,Binding affinity of compound for 5-lipoxygenase activating protein protein by FLAP binding assay,,CHEMBL618421,H,8,,,,,BAO_0000357,10102,,4313,,13449,B,,
Autocuration,,1,,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane,,CHEMBL618422,H,8,,,,,BAO_0000019,11238,,4314,,12014,B,,
Autocuration,,1,,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (R metabolically resistant),,CHEMBL618423,H,8,,,,,BAO_0000019,11238,,4315,,12014,B,,
Autocuration,,1,,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (S substrate),,CHEMBL618424,H,8,,,,,BAO_0000019,11238,,4316,,12014,B,,
Intermediate,,1,,,Inhibition of protein biosynthesis at the level of the peptidyl transferase center of the 50 s ribosomal subunit,,CHEMBL618425,S,2,,,,,BAO_0000220,100284,,4317,,99,B,,
Autocuration,,1,,,The dark toxicity against 543 human galactophore carcinoma cells,,CHEMBL618426,U,0,,,Homo sapiens,9606.0,BAO_0000019,22226,,4318,,4349,F,,
Expert,,1,Panel (56 tumour cell lines),,Tested in vitro for cytotoxicity against 56 human tumor cell lines,,CHEMBL618427,N,1,,390.0,Homo sapiens,9606.0,BAO_0000219,80623,,4319,,4071,F,,
Expert,,1,5637,,Cytotoxic activity against human 5637 cell line at 20 uM expressed as percent growth value,,CHEMBL618428,N,1,,345.0,Homo sapiens,9606.0,BAO_0000219,80008,,4320,,17589,F,,
Intermediate,,1,5637,,Antitumor activity was evaluated against human bladder carcinoma cell line 5637.,,CHEMBL618429,N,1,,345.0,Homo sapiens,9606.0,BAO_0000219,80008,,4321,,15002,F,,
Intermediate,,1,5637,,"Compound was tested for antiproliferative activity against 5637, human bladder carcinoma cell line",,CHEMBL618430,N,1,,345.0,Homo sapiens,9606.0,BAO_0000219,80008,,4322,,13958,F,,
Expert,,1,5637,,Growth inhibition against human 5637 cell lines,,CHEMBL618431,N,1,,345.0,Homo sapiens,9606.0,BAO_0000219,80008,,4323,,17589,F,,
Expert,,1,5637,,Antitumor activity against human bladder carcinoma 5637 cells.,,CHEMBL883799,N,1,,345.0,Homo sapiens,9606.0,BAO_0000219,80008,,4324,,16748,F,,
Intermediate,,1,5637,,Antitumor activity against human bladder carcinoma 5637 cells,,CHEMBL618432,N,1,,345.0,Homo sapiens,9606.0,BAO_0000219,80008,,4325,,16747,F,,
Intermediate,,1,5637,,Antitumor activity against human bladder carcinoma 5637 cells,,CHEMBL618433,N,1,,345.0,Homo sapiens,9606.0,BAO_0000219,80008,,4326,,16747,F,,
Expert,,1,,,In vitro inhibition of bovine trypsin(Trp).,,CHEMBL618434,D,9,,,Bos taurus,9913.0,BAO_0000357,10443,,4327,,15285,B,,
Expert,,1,CV-1,,Transcriptional activation in CV-1 cells expressing retinoic acid gamma receptor,,CHEMBL618435,H,8,,407.0,Cercopithecidae,9527.0,BAO_0000219,240,,4328,,3726,B,,
Autocuration,,1,,,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-HT1B receptor,,CHEMBL876402,H,8,,,,,BAO_0000357,10577,,4329,,5033,B,,
Autocuration,,1,,,In vitro antagonism of the 5-HT-3 receptor determined by inhibition of 5-HT-induced depolarization of the isolated rat vagus nerve.,,CHEMBL618436,H,6,,,,,BAO_0000019,104698,,4330,,11756,F,,
Autocuration,,1,,,Concentration required to inhibit pressor response to serotonin after 15 min i.v. administration of compound mediated via activation of vascular 5-HT2 receptors in rat,,CHEMBL618437,U,0,,,,,BAO_0000218,22226,,4331,,11953,F,In vivo,
Intermediate,,1,,,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-HT4 receptor,,CHEMBL618438,D,9,,,Cavia porcellus,10141.0,BAO_0000357,20033,,4332,,5033,B,,
Expert,,1,,,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,Microsomes,CHEMBL883800,H,8,,,Rattus norvegicus,10116.0,BAO_0000251,17045,,4333,,11347,A,,
Expert,,1,,,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,Microsomes,CHEMBL618439,H,8,,,Rattus norvegicus,10116.0,BAO_0000251,17045,,4334,,11347,A,,
Intermediate,,1,,,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,,CHEMBL618440,U,0,,,,,BAO_0000019,22226,,4335,,1229,F,,
Intermediate,,1,,,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,,CHEMBL618441,U,0,,,,,BAO_0000019,22226,,4336,,1229,F,,
Expert,,1,,,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli,,CHEMBL618442,H,8,,,Trypanosoma brucei,5691.0,BAO_0000019,11938,,4337,,17588,B,,
Autocuration,,1,,,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli; NI denotes no inhibition,,CHEMBL618443,H,8,,,Trypanosoma brucei,5691.0,BAO_0000019,11938,,4338,,17588,B,,
Expert,,1,,,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver,,CHEMBL619158,H,8,,,Ovis aries,9940.0,BAO_0000019,11938,,4339,,17588,B,,
Autocuration,,1,,,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver; NI denotes no inhibition,,CHEMBL620974,H,8,,,Ovis aries,9940.0,BAO_0000019,11938,,4340,,17588,B,,
Autocuration,,1,,,log Kd which is the binding affinity against 6-phosphogluconate dehydrogenase,,CHEMBL620975,H,8,,,,,BAO_0000357,11938,,4341,,16485,B,,
Intermediate,,1,,,Average inhibitory concentration against 60 human cell lines was reported,,CHEMBL620976,U,0,,,Homo sapiens,9606.0,BAO_0000019,22226,,4342,,4337,F,,
Expert,,1,,,Inhibition of proliferation in NCI panel of 60 human tumor cell lines,,CHEMBL620977,U,0,,,Homo sapiens,9606.0,BAO_0000019,22226,,4343,,4112,F,,
Intermediate,,1,Panel NCI-60 (60 carcinoma cell lines),,Cancer specificity was measured from the +/- value under average log LC50 60-cell line,,CHEMBL620978,N,1,,542.0,Homo sapiens,9606.0,BAO_0000219,80315,,4344,,16160,F,,
Intermediate,,1,Panel NCI-60 (60 carcinoma cell lines),,Cancer specificity was measured from the +/- value under average log LC50 60-cell line. ,,CHEMBL620979,N,1,,542.0,Homo sapiens,9606.0,BAO_0000219,80315,,4345,,16160,F,,
Expert,,1,Panel NCI-60 (60 carcinoma cell lines),,In vitro mean growth inhibitory activity against 60-cell panel,,CHEMBL620980,N,1,,542.0,,,BAO_0000219,80315,,4346,,17376,F,,
Expert,,1,Panel NCI-60 (60 carcinoma cell lines),,In vitro mean growth lethal concentration against 60-cell panel,,CHEMBL620981,N,1,,542.0,,,BAO_0000219,80315,,4347,,17376,F,,
Expert,,1,Panel NCI-60 (60 carcinoma cell lines),,In vitro mean growth lethal concentration in colon subpanel against 60-cell panel,,CHEMBL620982,N,1,,542.0,,,BAO_0000219,80315,,4348,,17376,F,,
Expert,,1,Panel NCI-60 (60 carcinoma cell lines),,In vitro mean growth lethal concentration in renal subpanel against 60-cell panel,,CHEMBL620983,N,1,,542.0,,,BAO_0000219,80315,,4349,,17376,F,,
Autocuration,,1,,,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,,CHEMBL620984,H,4,,,,,BAO_0000019,104775,,4350,,3241,F,,
Autocuration,,1,,,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,,CHEMBL620985,H,4,,,,,BAO_0000019,104775,,4351,,3241,F,,
Expert,,1,,,Transcriptional activation in CV-1 expressing retinoid X receptor RXR alpha,,CHEMBL620986,H,8,,,,,BAO_0000357,275,,4352,,3725,B,,
Expert,,1,,,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase,,CHEMBL620987,N,1,,,Plasmodium falciparum,5833.0,BAO_0000218,50425,,4353,,10805,F,,
Expert,,1,,,In vitro inhibition of Plasmodium falciparum 68 neutral proteinase activity by reinvasion of red blood cells,,CHEMBL620988,N,1,,,Plasmodium falciparum,5833.0,BAO_0000218,50425,,4354,,10805,F,,
Expert,,1,,,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase.,,CHEMBL620989,N,1,,,Plasmodium falciparum,5833.0,BAO_0000218,50425,,4355,,10805,F,,
Expert,,1,,,Substrate affinity for Plasmodium falciparum 68 neutral proteinase.,,CHEMBL620990,N,1,,,Plasmodium falciparum,5833.0,BAO_0000218,50425,,4356,,10805,F,,
Intermediate,,1,,,Reaction velocity for Plasmodium falciparum 68 neutral proteinase.,,CHEMBL620991,N,1,,,Plasmodium falciparum,5833.0,BAO_0000218,50425,,4357,,10805,F,,
Intermediate,,1,6C3HED,,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,,CHEMBL620992,N,1,,850.0,Mus musculus,10090.0,BAO_0000218,80628,,4358,,10144,F,,
Intermediate,,1,6C3HED,,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,,CHEMBL620993,N,1,,850.0,Mus musculus,10090.0,BAO_0000218,80628,,4359,,10144,F,,
Intermediate,,1,6C3HED,,Percent inhibition against 6C3HED lymphosarcoma at dose 200 mg/kg in C3H mice,,CHEMBL620994,N,1,,850.0,Mus musculus,10090.0,BAO_0000218,80628,,4360,,10144,F,,
Intermediate,,1,6C3HED,,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,,CHEMBL620995,N,1,,850.0,Mus musculus,10090.0,BAO_0000218,80628,,4361,,10144,F,,
Intermediate,,1,6C3HED,,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,,CHEMBL620996,N,1,,850.0,Mus musculus,10090.0,BAO_0000218,80628,,4362,,10144,F,,
Intermediate,,1,6C3HED,,Percent inhibition against 6C3HED lymphosarcoma at dose 6 mg/kg in C3H mice,,CHEMBL875581,N,1,,850.0,Mus musculus,10090.0,BAO_0000218,80628,,4363,,10144,F,,
Autocuration,,1,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 100 mg/kg,,CHEMBL620997,U,0,,,Mus musculus,10090.0,BAO_0000218,22224,,4364,,10685,F,In vivo,
Autocuration,,1,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 150 mg/kg,,CHEMBL620998,U,0,,,Mus musculus,10090.0,BAO_0000218,22224,,4365,,10685,F,In vivo,
Autocuration,,1,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 1600 mg/kg (intraperitoneal dosing for 8 days),,CHEMBL620999,U,0,,,Mus musculus,10090.0,BAO_0000218,22224,,4366,,10685,F,In vivo,
Autocuration,,1,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 200 mg/kg,,CHEMBL621000,U,0,,,Mus musculus,10090.0,BAO_0000218,22224,,4367,,10685,F,In vivo,
Autocuration,,1,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 225 mg/kg,,CHEMBL621001,U,0,,,Mus musculus,10090.0,BAO_0000218,22224,,4368,,10685,F,In vivo,
Autocuration,,1,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 270 mg/kg,,CHEMBL621002,U,0,,,Mus musculus,10090.0,BAO_0000218,22224,,4369,,10685,F,In vivo,
Autocuration,,1,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 275 mg/kg,,CHEMBL621003,U,0,,,Mus musculus,10090.0,BAO_0000218,22224,,4370,,10685,F,In vivo,
Autocuration,,1,,,"Antitumor activity in vivo against the 6C3HED lymphosarcoma, dosed for 10 days at 300 mg/kg",,CHEMBL621004,U,0,,,Mus musculus,10090.0,BAO_0000218,22224,,4371,,10685,F,In vivo,
Autocuration,,1,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (intraperitoneal dosing for 8 days),,CHEMBL621005,U,0,,,Mus musculus,10090.0,BAO_0000218,22224,,4372,,10685,F,In vivo,
Autocuration,,1,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (ip dosing daily for 8 days),,CHEMBL621006,U,0,,,Mus musculus,10090.0,BAO_0000218,22224,,4373,,10685,F,In vivo,
Autocuration,,1,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 600 mg/kg,,CHEMBL621007,U,0,,,Mus musculus,10090.0,BAO_0000218,22224,,4374,,10685,F,In vivo,
Autocuration,,1,,,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,,CHEMBL621008,U,0,,,Mus musculus,10090.0,BAO_0000218,22224,,4375,,10144,F,,
Autocuration,,1,,,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,,CHEMBL621009,U,0,,,Mus musculus,10090.0,BAO_0000218,22224,,4376,,10144,F,,
Autocuration,,1,,,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,,CHEMBL857705,U,0,,,Mus musculus,10090.0,BAO_0000218,22224,,4377,,10144,F,,
Autocuration,,1,,,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,,CHEMBL619828,U,0,,,Mus musculus,10090.0,BAO_0000218,22224,,4378,,10144,F,,
Autocuration,,1,,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 100 mg/kg dosage administered for 8 days intraperitoneally,,CHEMBL619829,U,0,,,Mus musculus,10090.0,BAO_0000218,22224,,4379,,10685,F,,
Autocuration,,1,,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 10 days intraperitoneally,,CHEMBL619830,U,0,,,Mus musculus,10090.0,BAO_0000218,22224,,4380,,10685,F,,
Autocuration,,1,,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 8 days intraperitoneally,,CHEMBL619831,U,0,,,Mus musculus,10090.0,BAO_0000218,22224,,4381,,10685,F,,
Autocuration,,1,,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 50 mg/kg dosage administered for 8 days intraperitoneally,,CHEMBL619832,U,0,,,Mus musculus,10090.0,BAO_0000218,22224,,4382,,10685,F,,
Autocuration,,1,,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 100 mg/kg dosage administered for 8 days intraperitoneally; 0/10,,CHEMBL619833,U,0,,,Mus musculus,10090.0,BAO_0000218,22224,,4383,,10685,A,,
Autocuration,,1,,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 8 days perorally; 1/10,,CHEMBL619834,U,0,,,Mus musculus,10090.0,BAO_0000218,22224,,4384,,10685,A,,
Autocuration,,1,,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 10 days intraperitoneally; 1/10,,CHEMBL619835,U,0,,,Mus musculus,10090.0,BAO_0000218,22224,,4385,,10685,A,,
Autocuration,,1,,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 50 mg/kg dosage administered for 8 days perorally; 3/10,,CHEMBL619836,U,0,,,Mus musculus,10090.0,BAO_0000218,22224,,4386,,10685,A,,
Intermediate,,1,6C3HED,,"Compound was evaluated for the antitumor activity against 6C3HED lymphosarcoma for ip administration and daily x 8 schedule; Number of toxic deaths over total number of mice per group (T/C), 0/10 at dose of 35 mg/kg",,CHEMBL619837,N,1,,850.0,Mus musculus,10090.0,BAO_0000218,80628,,4387,,8831,F,,
Autocuration,,1,,,In vivo antitumor activity against 6C3HED tumor type after intraperitoneal administration of 400 mg/kg,,CHEMBL619838,U,0,,,,,BAO_0000218,22224,,4388,,11704,F,In vivo,
Intermediate,,1,,,In vivo antitumor activity against 6C3HED tumor type was expressed as toxic deaths/total treated mice at 400 mg/kg dose; 2/10,,CHEMBL619839,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4389,,11704,A,,
Intermediate,,1,6C3HED,,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line,,CHEMBL619840,N,1,,850.0,Mus musculus,10090.0,BAO_0000218,80628,,4390,,10685,F,In vivo,
Intermediate,,1,6C3HED,,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line; 95-100% inhibition,,CHEMBL619841,N,1,,850.0,Mus musculus,10090.0,BAO_0000218,80628,,4391,,10685,F,In vivo,
Expert,,1,6C3HED,,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 150 mg/kg given orally(daily x 8),,CHEMBL857704,N,1,,850.0,Mus musculus,10090.0,BAO_0000218,80628,,4392,,11368,F,,
Intermediate,,1,6C3HED,,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 200 mg/kg given orally(daily x 8),,CHEMBL619842,N,1,,850.0,Mus musculus,10090.0,BAO_0000218,80628,,4393,,11368,F,,
Expert,,1,6C3HED,,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 300 mg/kg given orally (daily x 8),,CHEMBL619843,N,1,,850.0,Mus musculus,10090.0,BAO_0000218,80628,,4394,,11368,F,,
Autocuration,,1,,,"Inhibition of Staphylococcus aureus 7,8-dihydroneopterin aldolase",,CHEMBL619844,U,0,,,Staphylococcus aureus,1280.0,BAO_0000019,22226,,4395,,17763,B,,
Autocuration,,1,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at a concentration of 5 uM,Microsomes,CHEMBL857855,U,0,,,Rattus norvegicus,10116.0,BAO_0000251,22226,,4396,Liver,7411,B,,2107.0
Autocuration,,1,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,Microsomes,CHEMBL619845,U,0,,,Rattus norvegicus,10116.0,BAO_0000251,22226,,4397,Liver,7411,B,,2107.0
Autocuration,,1,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 1 uM,Microsomes,CHEMBL619846,U,0,,,Rattus norvegicus,10116.0,BAO_0000251,22226,,4398,Liver,7411,B,,2107.0
Autocuration,,1,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 20 uM,Microsomes,CHEMBL619847,U,0,,,Rattus norvegicus,10116.0,BAO_0000251,22226,,4399,Liver,7411,B,,2107.0
Autocuration,,1,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 25 uM,Microsomes,CHEMBL619848,U,0,,,Rattus norvegicus,10116.0,BAO_0000251,22226,,4400,Liver,7411,B,,2107.0
Autocuration,,1,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 50 uM,Microsomes,CHEMBL620893,U,0,,,Rattus norvegicus,10116.0,BAO_0000251,22226,,4401,Liver,7411,B,,2107.0
Autocuration,,1,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 5 uM,Microsomes,CHEMBL620894,U,0,,,Rattus norvegicus,10116.0,BAO_0000251,22226,,4402,Liver,7411,B,,2107.0
Autocuration,,1,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 10 uM,Microsomes,CHEMBL620895,U,0,,,Rattus norvegicus,10116.0,BAO_0000251,22226,,4403,Liver,7411,B,,2107.0
Autocuration,,1,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,Microsomes,CHEMBL620896,U,0,,,Rattus norvegicus,10116.0,BAO_0000251,22226,,4404,Liver,7411,B,,2107.0
Autocuration,,1,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,Microsomes,CHEMBL620897,U,0,,,Rattus norvegicus,10116.0,BAO_0000251,22226,,4405,Liver,7411,B,,2107.0
Autocuration,,1,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,Microsomes,CHEMBL620898,U,0,,,Rattus norvegicus,10116.0,BAO_0000251,22226,,4406,Liver,7411,B,,2107.0
Autocuration,,1,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,Microsomes,CHEMBL620899,U,0,,,Rattus norvegicus,10116.0,BAO_0000251,22226,,4407,Liver,7411,B,,2107.0
Autocuration,,1,,,The apparent total plasma clearance in monkey,,CHEMBL620900,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,4408,Plasma,347,A,In vivo,1969.0
Autocuration,,1,,,Compound was evaluated for Hepatic clearance in monkey,,CHEMBL620901,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,4409,,3341,A,In vivo,
Autocuration,,1,,,Lower clearance in monkey (i.v.) at 0.5 mpk,,CHEMBL620902,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,4410,,17853,A,In vivo,
Autocuration,,1,,,Plasma clearance in rhesus monkey,,CHEMBL620903,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,4411,,4514,A,In vivo,
Autocuration,,1,,,Plasma clearance for the compound was measured in monkey after an iv dose of 1 mg/kg,,CHEMBL620904,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,4412,,6062,A,In vivo,
Autocuration,,1,,,Plasma clearance of compound was determined in monkey,,CHEMBL620905,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,4413,,6821,A,In vivo,
Autocuration,,1,,,Plasma clearance was calculated in rhesus monkey,,CHEMBL620906,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,4414,,6057,A,In vivo,
Autocuration,,1,,,Plasma clearance in rhesus monkey,,CHEMBL875420,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,4415,,5145,A,In vivo,
Autocuration,,1,,,Plasma clearance in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),,CHEMBL620907,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,4416,,6641,A,In vivo,
Autocuration,,1,,,Plasma clearance was evaluated in rhesus,,CHEMBL620908,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,4417,,5472,A,In vivo,
Autocuration,,1,,,Plasma clearance value was determined in monkey after a 3 mg/kg of iv dose,,CHEMBL620909,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,4418,,4257,A,In vivo,
Autocuration,,1,,,Plasma clearance was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,,CHEMBL620910,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,4419,,5546,A,In vivo,
Autocuration,,1,,,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),,CHEMBL620911,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,4420,,5334,A,In vivo,
Autocuration,,1,,,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),,CHEMBL620912,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,4421,,5334,A,In vivo,
Autocuration,,1,,,Cmax 24 hr after 2 mg/kg oral administration in monkeys,,CHEMBL620913,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,4422,,17509,A,In vivo,
Autocuration,,1,,,Cmax in monkey after administration of 1 mg/kg iv,,CHEMBL620914,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,4423,,6535,A,In vivo,
Autocuration,,1,,,Cmax was determine after peroral administration at 10 mpk in Rhesus,,CHEMBL620915,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,4424,,5668,A,In vivo,
Autocuration,,1,,,Cmax in cynomolgus monkey by iv administration,,CHEMBL620916,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,4425,,5922,A,In vivo,
Autocuration,,1,,,Cmax in cynomolgus monkey by po administration,,CHEMBL620917,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,4426,,5922,A,In vivo,
Autocuration,,1,,,Cmax value evaluated in monkey,,CHEMBL620918,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,4427,,6078,A,In vivo,
Autocuration,,1,,,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female cynomolgus monkey,,CHEMBL620919,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,4428,,2661,A,In vivo,
Autocuration,,1,,,Maximal concentration (Cmax) in rhesus monkey plasma at a dose of 5 mg/kg,,CHEMBL620920,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,4429,Plasma,3249,A,In vivo,1969.0
Autocuration,,1,,,Maximal concentration (Cmax) in squirrel monkey plasma at a dose of 5 mg/kg,,CHEMBL620921,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,4430,Plasma,3249,A,In vivo,1969.0
Autocuration,,1,,,Maximal plasma concentration in squirrel monkeys,,CHEMBL620922,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,4431,Plasma,5553,A,In vivo,1969.0
Autocuration,,1,,,Maximum concentration was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,CHEMBL620923,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,4432,,1916,A,In vivo,
Autocuration,,1,,,Maximum plasma concentration (Cmax) in rhesus monkey(in vivo) at a dose of 5 mg/kg,,CHEMBL620924,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,4433,Plasma,6227,A,In vivo,1969.0
Autocuration,,1,,,Pharmacokinetic parameter Cmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),,CHEMBL620925,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,4434,,4809,A,In vivo,
Autocuration,,1,,,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means Not applicable,,CHEMBL620926,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,4435,,5355,A,In vivo,
Autocuration,,1,,,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means not applicable,,CHEMBL620927,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,4436,,5355,A,In vivo,
Autocuration,,1,,,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys;NA means not applicable,,CHEMBL620928,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,4437,,5355,A,In vivo,
Autocuration,,1,,,The peak concentration (Cmax) value after oral administration in cynomolgus monkeys,,CHEMBL620929,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,4438,,5355,A,In vivo,
Autocuration,,1,,,The peak plasma concentration after 5 hr administration (2.5 mg/kg) in monkey was determined,,CHEMBL620930,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,4439,Plasma,6221,A,In vivo,1969.0
Autocuration,,1,,,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 0.4 hours,,CHEMBL620931,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,4440,,167,A,,
Autocuration,,1,,,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 1.0 hours,,CHEMBL620932,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,4441,,167,A,,
Autocuration,,1,,,Absolute bioavailability was evaluated in monkey,,CHEMBL620933,U,0,,,monkey,9443.0,BAO_0000218,22224,,4442,,4257,A,In vivo,
Autocuration,,1,,,Bioavailability after oral administration (2.5 mg/kg) in monkey was determined,,CHEMBL620934,U,0,,,monkey,9443.0,BAO_0000218,22224,,4443,,6221,A,In vivo,
Autocuration,,1,,,Bioavailability of compound at 3 mg/kg in monkey after i.v. administration,,CHEMBL620935,U,0,,,monkey,9443.0,BAO_0000218,22224,,4444,,17667,A,In vivo,
Autocuration,,1,,,Bioavailability of compound was determined in rhesus monkey,,CHEMBL620936,U,0,,,Macaca mulatta,9544.0,BAO_0000218,22224,,4445,,17267,A,In vivo,
Autocuration,,1,,,Bioavailability determined after oral administration in marmoset,,CHEMBL620937,U,0,,,marmosets,38020.0,BAO_0000218,22224,,4446,,4256,A,In vivo,
Autocuration,,1,,,Oral bioavailability in cynomolgus monkey,,CHEMBL620938,U,0,,,Macaca fascicularis,9541.0,BAO_0000218,22224,,4447,,4256,A,In vivo,
Autocuration,,1,,,Bioavailability in monkey (p.o.) at 2.0 mpk,,CHEMBL620939,U,0,,,monkey,9443.0,BAO_0000218,22224,,4448,,17853,A,In vivo,
Autocuration,,1,,,Bioavailability was evaluated after oral administration in monkey,,CHEMBL620940,U,0,,,monkey,9443.0,BAO_0000218,22224,,4449,,16365,A,In vivo,
Autocuration,,1,,,Bioavailability was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,CHEMBL620941,U,0,,,Macaca fascicularis,9541.0,BAO_0000218,22224,,4450,,1916,A,In vivo,
Autocuration,,1,,,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),,CHEMBL620942,U,0,,,Macaca mulatta,9544.0,BAO_0000218,22224,,4451,,5334,A,In vivo,
Autocuration,,1,,,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),,CHEMBL620943,U,0,,,Macaca mulatta,9544.0,BAO_0000218,22224,,4452,,5334,A,In vivo,
Autocuration,,1,,,Bioavailability of the compound was determined in monkey,,CHEMBL620944,U,0,,,monkey,9443.0,BAO_0000218,22224,,4453,,17592,A,In vivo,
Autocuration,,1,,,Bioavailability in squirrel monkey (dose 5 mg/kg),,CHEMBL620945,U,0,,,Saimiri sciureus,9521.0,BAO_0000218,22224,,4454,,1399,A,In vivo,
Autocuration,,1,,,Bioavailability was determined in monkey after (po) administration of a dose of 50 (uM/kg),,CHEMBL620946,U,0,,,monkey,9443.0,BAO_0000218,22224,,4455,,4809,A,In vivo,
Autocuration,,1,,,Oral bioavailability in monkey,,CHEMBL620947,U,0,,,monkey,9443.0,BAO_0000218,22224,,4456,,3341,A,In vivo,
Autocuration,,1,,,Compound was tested for bioavailability in squirrel monkey,,CHEMBL620948,U,0,,,Saimiri sciureus,9521.0,BAO_0000218,22224,,4457,,64,A,In vivo,
Autocuration,,1,,,Oral bioavailability in Rhesus monkey,,CHEMBL620949,U,0,,,Macaca mulatta,9544.0,BAO_0000218,22224,,4458,,5005,A,In vivo,
Autocuration,,1,,,Oral bioavailability in Rhesus monkey (dose of 0.75 mg/kg i.v. and 1.5 mg/kg p.o.),,CHEMBL620950,U,0,,,Macaca mulatta,9544.0,BAO_0000218,22224,,4459,,5005,A,In vivo,
Autocuration,,1,,,Oral bioavailability in cynomolgus monkeys for the compound was determined; Acceptable,,CHEMBL620951,U,0,,,Macaca fascicularis,9541.0,BAO_0000218,22224,,4460,,5237,A,In vivo,
Autocuration,,1,,,Oral bioavailability in cynomolgus monkeys was determined; Acceptable,,CHEMBL620952,U,0,,,Macaca fascicularis,9541.0,BAO_0000218,22224,,4461,,5237,A,In vivo,
Autocuration,,1,,,Oral bioavailability in monkey (dose 5 mg/kg),,CHEMBL875421,U,0,,,monkey,9443.0,BAO_0000218,22224,,4462,,5302,A,In vivo,
Autocuration,,1,,,Oral bioavailability of compound at 5 mg/kg in monkey,,CHEMBL620953,U,0,,,monkey,9443.0,BAO_0000218,22224,,4463,,17667,A,In vivo,
Intermediate,,1,,,Pharmacokinetic profile in terms of half life was determined at a dose of 0.5 mg/kg administered intravenously in dog,,CHEMBL873491,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,4464,,6161,A,In vivo,
Intermediate,,1,,,Pharmacokinetic profile in terms of half life was determined at a dose of 5 mg/kg administered intravenously in dog,,CHEMBL620954,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,4465,,6161,A,In vivo,
Intermediate,,1,,,Plasma half life determined,,CHEMBL620955,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,4466,Plasma,3854,A,,1969.0
Intermediate,,1,,,Plasma half life in dog,,CHEMBL618097,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,4467,Plasma,993,A,,1969.0
Intermediate,,1,,,Plasma half-life in Beagle dogs,,CHEMBL618268,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,4468,Plasma,4514,A,,1969.0
Intermediate,,1,,,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),,CHEMBL618269,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,4469,Plasma,5334,A,In vivo,1969.0
Intermediate,,1,,,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg respectively in Beagle dog (male),,CHEMBL618270,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,4470,Plasma,5334,A,In vivo,1969.0
Intermediate,,1,,,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in dog,,CHEMBL618271,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,4471,,1466,A,In vivo,
Intermediate,,1,,,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in dog,,CHEMBL873493,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,4472,,1466,A,In vivo,
Intermediate,,1,,,Tested for the half life period in dog,,CHEMBL621031,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,4473,,5313,A,,
Intermediate,,1,,,Tested for the half life period in dog at dosage of 10 mpk,,CHEMBL621032,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,4474,,5313,A,In vivo,
Intermediate,,1,,,The compound was tested for half life in dog,,CHEMBL621033,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,4475,,3880,A,,
Intermediate,,1,,,"The compound was tested for time taken to decrease, half of its initial concentration in dog plasma.",,CHEMBL621034,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,4476,Plasma,3639,A,,1969.0
Intermediate,,1,,,The half life was determined,,CHEMBL621035,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,4477,,3880,A,,
Intermediate,,1,,,The plasma half-life in dogs,,CHEMBL621036,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,4478,Plasma,3918,A,,1969.0
Intermediate,,1,,,suboptimal plasma half-life caused a10% prolongation of QTc interval in dogs at a plasma level of 2.5 M,,CHEMBL621037,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,4479,Plasma,16452,A,,1969.0
Intermediate,,1,,,Half life in dog,,CHEMBL619812,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,4480,,17796,A,,
Intermediate,,1,,,Pharmacokinetic property (t1/2beta) was measured in dog at the dose of 0.032 mg/kg i.v.,,CHEMBL619813,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,4481,,5983,A,In vivo,
Intermediate,,1,,,tmax upon peroral administration of 10.0 mg/Kg dose in dog,,CHEMBL873335,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,4482,,1466,A,In vivo,
Intermediate,,1,,,Volume of distribution in Beagle dogs after intravenous administration at a dose of 10 mg/kg,,CHEMBL619814,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,4483,,16456,A,In vivo,
Expert,,1,,,Cmax in ferrets after 30 mg/kg oral dose,,CHEMBL619815,N,1,,,Mustela putorius furo,9669.0,BAO_0000218,50506,,4484,,6113,A,In vivo,
Expert,,1,,,Emesis in ferrets at 30 mg/kg oral dose,,CHEMBL619816,N,1,,,Mustela putorius furo,9669.0,BAO_0000218,50506,,4485,,6113,F,In vivo,
Autocuration,,1,,,Bioavailability in cynomolgus monkey,,CHEMBL619817,U,0,,,Macaca fascicularis,9541.0,BAO_0000218,22224,,4486,,17796,A,In vivo,
Intermediate,,1,,,Volume of distribution in cynomolgus,,CHEMBL619818,N,1,,,Macaca fascicularis,9541.0,BAO_0000218,100710,,4487,,17796,A,In vivo,
Autocuration,,1,,,AUC tested in guinea pig when 3 mg/kg dose was given perorally,,CHEMBL619819,U,0,,,Cavia porcellus,10141.0,BAO_0000218,22224,,4488,Plasma,5308,A,,1969.0
Autocuration,,1,,,Tested for concentration as Area Under Curve against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,,CHEMBL619820,U,0,,,Cavia porcellus,10141.0,BAO_0000218,22224,,4489,,4877,A,,
Autocuration,,1,,,"Tested for the pharmacokinetic parameter in guinea pig, administered orally at 5 mg/kg",,CHEMBL875419,U,0,,,Cavia porcellus,10141.0,BAO_0000218,22224,,4490,,4876,A,,
Autocuration,,1,,,AUC in guinea pig after 3mg/kg oral dose,,CHEMBL619821,U,0,,,Cavia porcellus,10141.0,BAO_0000218,22224,,4491,Plasma,4878,A,In vivo,1969.0
Autocuration,,1,,,Bioavailability in guinea pig was tested,,CHEMBL619822,U,0,,,Cavia porcellus,10141.0,BAO_0000218,22224,,4492,,5308,A,In vivo,
Autocuration,,1,,,Tested for oral bioavailability in guinea pig at 5 mg/kg,,CHEMBL619823,U,0,,,Cavia porcellus,10141.0,BAO_0000218,22224,,4493,,4877,A,In vivo,
Autocuration,,1,,,Tested for the oral bioavailability of the compound,,CHEMBL619824,U,0,,,Cavia porcellus,10141.0,BAO_0000218,22224,,4494,,4876,A,In vivo,
Autocuration,,1,,,Compound at a dose 5 mg/kg was administered orally to guinea pig and the pharmacokinetic parameter (Cmax) was reported,,CHEMBL619825,U,0,,,Cavia porcellus,10141.0,BAO_0000218,22224,,4495,,4876,A,In vivo,
Autocuration,,1,,,Maximum plsma drug concentration in guinea pig when 3 mg/kg dose was given perorally,,CHEMBL619826,U,0,,,Cavia porcellus,10141.0,BAO_0000218,22224,,4496,,5308,A,In vivo,
Autocuration,,1,,,Tested for maximum concentration against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,,CHEMBL619827,U,0,,,Cavia porcellus,10141.0,BAO_0000218,22224,,4497,Lung,4877,A,In vivo,2048.0
Autocuration,,1,,,Cmax in guinea pig after 3mg/kg oral dose,,CHEMBL618167,U,0,,,Cavia porcellus,10141.0,BAO_0000218,22224,,4498,,4878,A,In vivo,
Autocuration,,1,,,Distribution in blood expressed as [18F]- organ uptake in % of injected activity/gram,,CHEMBL618168,U,0,,,Cavia porcellus,10141.0,BAO_0000019,22224,,4499,Blood,5689,A,,178.0
Autocuration,,1,,,Distribution in brain expressed as [18F]- organ uptake in % of injected activity/gram,,CHEMBL618169,U,0,,,Cavia porcellus,10141.0,BAO_0000019,22224,,4500,Brain,5689,A,,955.0
Autocuration,,1,,,Distribution in heart expressed as [18F]- organ uptake in % of injected activity/gram,,CHEMBL618170,U,0,,,Cavia porcellus,10141.0,BAO_0000019,22224,,4501,,5689,A,,
Autocuration,,1,,,Distribution in intestine expressed as [18F]- organ uptake in % of injected activity/gram,,CHEMBL618171,U,0,,,Cavia porcellus,10141.0,BAO_0000019,22224,,4502,Intestine,5689,A,,160.0
Autocuration,,1,,,Distribution in kidney expressed as [18F]- organ uptake in % of injected activity/gram,,CHEMBL618172,U,0,,,Cavia porcellus,10141.0,BAO_0000019,22224,,4503,Kidney,5689,A,,2113.0
Autocuration,,1,,,Distribution in liver expressed as [18F]- organ uptake in % of injected activity/gram,,CHEMBL618173,U,0,,,Cavia porcellus,10141.0,BAO_0000019,22224,,4504,Liver,5689,A,,2107.0
Autocuration,,1,,,Distribution in lung expressed as [18F]- organ uptake in % of injected activity/gram,,CHEMBL618174,U,0,,,Cavia porcellus,10141.0,BAO_0000019,22224,,4505,,5689,A,,
Autocuration,,1,,,Distribution in spleen expressed as [18F]- organ uptake in % of injected activity/gram,,CHEMBL875408,U,0,,,Cavia porcellus,10141.0,BAO_0000019,22224,,4506,Spleen,5689,A,,2106.0
Autocuration,,1,,,Elimination T1/2 in Guinea pig (PO dose),,CHEMBL839827,U,0,,,Cavia porcellus,10141.0,BAO_0000218,22224,,4507,,14465,A,In vivo,
Autocuration,,1,,,Partition coefficient was measured as -log (counts per min ),,CHEMBL618175,U,0,,,Cavia porcellus,10141.0,BAO_0000019,22224,,4508,,5689,A,,
Autocuration,,1,,,Biological half life when administered at 0.1 umol/kg intravenously to guinea pig in GR-64349 antagonism,,CHEMBL618176,U,0,,,Cavia porcellus,10141.0,BAO_0000218,22224,,4509,,611,A,In vivo,
Autocuration,,1,,,Biological half life when administered at 5 umol/kg intravenously to guinea pig in GR-64349 antagonism,,CHEMBL618177,U,0,,,Cavia porcellus,10141.0,BAO_0000218,22224,,4510,,611,A,In vivo,
Autocuration,,1,,,Elimination T1/2 in Guinea pig (PO dose),,CHEMBL618178,U,0,,,Cavia porcellus,10141.0,BAO_0000218,22224,,4511,,14465,A,In vivo,
Autocuration,,1,,,"Tested for the half life period of the compound, intravenously",,CHEMBL618179,U,0,,,Cavia porcellus,10141.0,BAO_0000218,22224,,4512,,4876,A,In vivo,
Autocuration,,1,,,Half-life was measured,,CHEMBL873489,U,0,,,Cavia porcellus,10141.0,BAO_0000019,22224,,4513,,5689,A,,
Autocuration,,1,,,The time required for onset of inotropy after addition of a single dose of delta F75,,CHEMBL618180,U,0,,,Cavia porcellus,10141.0,BAO_0000019,22224,,4514,,7515,A,,
Autocuration,,1,,,Bioavailability of compound at 10 mg/kg in guinea pig after i.v. administration,,CHEMBL618181,U,0,,,Cavia porcellus,10141.0,BAO_0000218,22224,,4515,,17667,A,In vivo,
Autocuration,,1,,,Bioavailability of compound at 3 mg/kg in guinea pig after i.v. administration,,CHEMBL618182,U,0,,,Cavia porcellus,10141.0,BAO_0000218,22224,,4516,,17667,A,In vivo,
Autocuration,,1,,,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,,CHEMBL618183,U,0,,,Cricetulus griseus,10029.0,BAO_0000218,22224,,4517,,4727,A,In vivo,
Intermediate,,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,CHEMBL618184,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4518,,10107,A,In vivo,
Intermediate,,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,CHEMBL618185,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4519,,10107,A,In vivo,
Intermediate,,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,CHEMBL618186,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4520,,10107,A,In vivo,
Intermediate,,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,CHEMBL618187,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4521,,10107,A,In vivo,
Intermediate,,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hr,,CHEMBL618188,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4522,,10107,A,In vivo,
Intermediate,,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,CHEMBL875409,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4523,,10107,A,In vivo,
Intermediate,,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,CHEMBL618189,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4524,,10107,A,In vivo,
Intermediate,,1,,,Biodistribution of the injected compound in blood of female BALB/C mice for 0.5 hours,,CHEMBL618190,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4525,Blood,3655,A,In vivo,178.0
Intermediate,,1,,,Biodistribution of the injected compound in blood of female BALB/C mice for 2.5 hours,,CHEMBL618191,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4526,Blood,3655,A,In vivo,178.0
Intermediate,,1,,,Biodistribution of the injected compound in blood of female BALB/C mice for 5 hours,,CHEMBL618192,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4527,Blood,3655,A,In vivo,178.0
Intermediate,,1,,,Biodistribution of the injected compound in bone of female BALB/C mice for 0.5 hours,,CHEMBL618193,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4528,Bone,3655,A,In vivo,10000001.0
Intermediate,,1,,,Biodistribution of the injected compound in bone of female BALB/C mice for 2.5 hours,,CHEMBL618194,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4529,Bone,3655,A,In vivo,10000001.0
Intermediate,,1,,,Biodistribution of the injected compound in bone of female BALB/C mice for 5 hours,,CHEMBL618195,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4530,Bone,3655,A,In vivo,10000001.0
Intermediate,,1,,,Biodistribution of the injected compound in brain of female BALB/C mice for 0.5 hours,,CHEMBL618196,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4531,Brain,3655,A,In vivo,955.0
Intermediate,,1,,,Biodistribution of the injected compound in brain of female BALB/C mice for 2.5 hours,,CHEMBL618197,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4532,Brain,3655,A,In vivo,955.0
Intermediate,,1,,,Biodistribution of the injected compound in brain of female BALB/C mice for 5 hours,,CHEMBL618198,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4533,Brain,3655,A,In vivo,955.0
Intermediate,,1,,,Biodistribution of the injected compound in heart of female BALB/C mice for 0.5 hours,,CHEMBL618199,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4534,Heart,3655,A,In vivo,948.0
Intermediate,,1,,,Biodistribution of the injected compound in heart of female BALB/C mice for 2.5 hours,,CHEMBL618200,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4535,Heart,3655,A,In vivo,948.0
Intermediate,,1,,,Biodistribution of the injected compound in heart of female BALB/C mice for 5 hours,,CHEMBL618201,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4536,Heart,3655,A,In vivo,948.0
Intermediate,,1,,,Biodistribution of the injected compound in intestines of female BALB/C mice for 0.5 hours,,CHEMBL618202,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4537,Intestine,3655,A,In vivo,160.0
Intermediate,,1,,,Biodistribution of the injected compound in intestines of female BALB/C mice for 2.5 hours,,CHEMBL618203,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4538,Intestine,3655,A,In vivo,160.0
Intermediate,,1,,,Biodistribution of the injected compound in intestines of female BALB/C mice for 5 hours,,CHEMBL618204,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4539,Intestine,3655,A,In vivo,160.0
Intermediate,,1,,,Biodistribution of the injected compound in kidneys of female BALB/C mice for 0.5 hours,,CHEMBL618205,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4540,Kidney,3655,A,In vivo,2113.0
Intermediate,,1,,,Biodistribution of the injected compound in kidneys of female BALB/C mice for 2.5 hours,,CHEMBL618206,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4541,Kidney,3655,A,In vivo,2113.0
Intermediate,,1,,,Biodistribution of the injected compound in kidneys of female BALB/C mice for 5 hours,,CHEMBL618207,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4542,Kidney,3655,A,In vivo,2113.0
Intermediate,,1,,,Biodistribution of the injected compound in liver of female BALB/C mice for 0.5 hours,,CHEMBL618208,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4543,Liver,3655,A,In vivo,2107.0
Intermediate,,1,,,Biodistribution of the injected compound in liver of female BALB/C mice for 2.5 hours,,CHEMBL618932,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4544,Liver,3655,A,In vivo,2107.0
Intermediate,,1,,,Biodistribution of the injected compound in liver of female BALB/C mice for 5 hours,,CHEMBL618933,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4545,Liver,3655,A,In vivo,2107.0
Intermediate,,1,,,Biodistribution of the injected compound in lung of female BALB/C mice for 0.5 hours,,CHEMBL618934,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4546,Lung,3655,A,In vivo,2048.0
Intermediate,,1,,,Biodistribution of the injected compound in lung of female BALB/C mice for 2.5 hours,,CHEMBL618935,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4547,Lung,3655,A,In vivo,2048.0
Intermediate,,1,,,Biodistribution of the injected compound in lung of female BALB/C mice for 5 hours,,CHEMBL618936,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4548,Lung,3655,A,In vivo,2048.0
Intermediate,,1,,,Biodistribution of the injected compound in muscle of female BALB/C mice for 0.5 hours,,CHEMBL618937,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4549,Muscle tissue,3655,A,In vivo,2385.0
Intermediate,,1,,,Biodistribution of the injected compound in muscle of female BALB/C mice for 2.5 hours,,CHEMBL618938,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4550,Muscle tissue,3655,A,In vivo,2385.0
Intermediate,,1,,,Biodistribution of the injected compound in muscle of female BALB/C mice for 5 hours,,CHEMBL619104,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4551,Muscle tissue,3655,A,In vivo,2385.0
Intermediate,,1,,,Biodistribution of the injected compound in spleen of female BALB/C mice for 0.5 hours,,CHEMBL619105,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4552,Spleen,3655,A,In vivo,2106.0
Intermediate,,1,,,Biodistribution of the injected compound in spleen of female BALB/C mice for 2.5 hours,,CHEMBL619106,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4553,Spleen,3655,A,In vivo,2106.0
Intermediate,,1,,,Biodistribution of the injected compound in spleen of female BALB/C mice for 5 hours,,CHEMBL619107,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4554,Spleen,3655,A,In vivo,2106.0
Intermediate,,1,,,Biodistribution of the injected compound in stomach of female BALB/C mice for 0.5 hours,,CHEMBL875410,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4555,Stomach,3655,A,In vivo,945.0
Intermediate,,1,,,Biodistribution of the injected compound in stomach of female BALB/C mice for 2.5 hours,,CHEMBL619108,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4556,Stomach,3655,A,In vivo,945.0
Intermediate,,1,,,Biodistribution of the injected compound in stomach of female BALB/C mice for 5 hours,,CHEMBL619109,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4557,Stomach,3655,A,In vivo,945.0
Intermediate,,1,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,,CHEMBL619110,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4558,,16597,A,In vivo,
Intermediate,,1,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,,CHEMBL619111,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4559,,16597,F,In vivo,
Intermediate,,1,,,MRT value at a dose of 10 mg/kg intravenous administration in mice.,,CHEMBL619112,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4560,,16597,A,In vivo,
Intermediate,,1,,,MRT value at a dose of 10 mg/kg peroral administration in mice.,,CHEMBL619113,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4561,,16597,A,In vivo,
Intermediate,,1,,,Mean-residence time of compound after intravenous administration in mice at 24 uM/kg,,CHEMBL619114,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4562,,17764,A,In vivo,
Intermediate,,1,,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 18 uM/kg,,CHEMBL619115,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4563,,17764,F,In vivo,
Intermediate,,1,A2780,,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C after 96 hr,,CHEMBL619116,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,4564,,3830,F,,
Intermediate,,1,A2780,,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C for 96 hr,,CHEMBL619117,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,4565,,3829,F,,
Intermediate,,1,A2780,,Compound was evaluated for cytotoxicity against A2780 cell lines.,,CHEMBL619118,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,4566,,2040,F,,
Intermediate,,1,A2780,,Potentiation of growth inhibition of A2780 by compound alone in experiment 1,,CHEMBL619119,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,4567,,15684,F,,
Intermediate,,1,A2780,,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,,CHEMBL619120,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,4568,,15684,F,,
Intermediate,,1,A2780,,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,,CHEMBL619121,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,4569,,15684,F,,
Intermediate,,1,A2780,,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,,CHEMBL619122,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,4570,,15684,F,,
Intermediate,,1,A2780,,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,,CHEMBL619123,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,4571,,15684,F,,
Intermediate,,1,A2780,,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,,CHEMBL619124,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,4572,,15684,F,,
Intermediate,,1,A2780,,Compound was evaluated for cytotoxicity against A2780 cell line,,CHEMBL619125,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,4573,,2859,F,,
Intermediate,,1,A2780,,In vitro inhibitory activity against human tumor cell line A2780,,CHEMBL875411,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,4574,,5618,F,,
Intermediate,,1,A2780,,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 1,,CHEMBL619126,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,4575,,15684,F,,
Intermediate,,1,A2780,,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,,CHEMBL619127,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,4576,,15684,F,,
Intermediate,,1,A2780,,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,,CHEMBL619128,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,4577,,15684,F,,
Intermediate,,1,A2780,,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,,CHEMBL619129,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,4578,,15684,F,,
Intermediate,,1,A2780,,The compound was tested for cytotoxic potency against A2780 human tumor cell lines,,CHEMBL619130,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,4579,,2113,F,,
Intermediate,,1,A2780,,The compound was tested for cytotoxic potency against A2780 human tumor cell lines.,,CHEMBL619131,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,4580,,2113,F,,
Intermediate,,1,A2780,,cytotoxicity against A2780 cells incubated for 24 hr in MTT assay.,,CHEMBL619132,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,4581,,16745,F,,
Expert,,1,A2780,,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,,CHEMBL619133,N,1,,478.0,Homo sapiens,9606.0,BAO_0000218,81034,,4582,,16597,F,,
Intermediate,,1,A2780,,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,,CHEMBL619134,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,4583,,15684,F,,
Intermediate,,1,A2780,,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,,CHEMBL619135,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,4584,,15684,F,,
Intermediate,,1,A2780,,Compound was evaluated for cytotoxicity against A2780 cis cell lines.,,CHEMBL619136,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,4585,,2040,F,,
Intermediate,,1,A2780,,Relative resistance factor in A2780 cisplatin-resistant line,,CHEMBL619137,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,4586,,2040,F,,
Intermediate,,1,A2780,,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells,,CHEMBL883713,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,4587,,16165,F,,
Intermediate,,1,A2780,,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells.,,CHEMBL875412,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,4588,,16165,F,,
Expert,,1,A2780,,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,,CHEMBL619138,N,1,,478.0,Homo sapiens,9606.0,BAO_0000218,81034,,4589,,16597,F,,
Expert,,1,A2780,,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,,CHEMBL619262,N,1,,478.0,Homo sapiens,9606.0,BAO_0000218,81034,,4590,,16597,F,,
Intermediate,,1,A2780,,Cytotoxicity against A2780 ovarian carcinoma cells was evaluated using standard sulforhodamine 96h assay test,,CHEMBL619139,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,4591,,3992,F,,
Intermediate,,1,A2780,,In vitro cytotoxicity was determined against A2780 human ovarian cell line using NCI screen,,CHEMBL619140,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,4592,,10553,F,,
Intermediate,,1,A2780,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin,,CHEMBL619141,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,4593,,15608,F,,
Intermediate,,1,A2780,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 1,,CHEMBL619142,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,4594,,15608,F,,
Intermediate,,1,A2780,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 2,,CHEMBL619143,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,4595,,15608,F,,
Intermediate,,1,A2780,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 3,,CHEMBL619144,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,4596,,15608,F,,
Intermediate,,1,A2780,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 5,,CHEMBL619145,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,4597,,15608,F,,
Intermediate,,1,A2780,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 8,,CHEMBL619146,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,4598,,15608,F,,
Intermediate,,1,A2780,,Cytotoxic activity in a panel of Human ovarian tumor A2780/CDDP cell line after 96h of drug exposure,,CHEMBL619147,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,4599,,15569,F,,
Intermediate,,1,A2780,,Antiproliferative effect of compound on A2780/DX cell line,,CHEMBL619148,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,4600,,17420,F,,
Intermediate,,1,A2780,,Antiproliferative effect of compound on A2780/DX cell line; n.d. indicates not determined,,CHEMBL619149,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,4601,,17420,F,,
Intermediate,,1,A2780,,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/DX(RI),,CHEMBL619150,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,4602,,15099,F,,
Intermediate,,1,A2780,,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/Dx(RI),,CHEMBL619151,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,4603,,15099,F,,
Intermediate,,1,A2780,,Cytotoxicity against ovarian carcinoma A2780/cis tumor cell lines,,CHEMBL883794,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,4604,,17672,F,,
Intermediate,,1,A2780,,Cytotoxicity against ovarian carcinoma A2780/cis90 tumor cell lines,,CHEMBL619152,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,4605,,17672,F,,
Intermediate,,1,A2780,,In vitro cytotoxicity against A2780ADR cell line,,CHEMBL619153,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,4606,,17270,F,,
Intermediate,,1,A2780,,In vitro cytotoxicity against A2780CIS cell line,,CHEMBL619154,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,4607,,17270,F,,
Intermediate,,1,A2780,,In vitro cytotoxic activity against human tumor cell line A2780CisR after incubation for 96 hours,,CHEMBL619155,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,4608,,5574,F,,
Intermediate,,1,A2780,,The compound was tested for cytotoxic potency against A2780R human tumor cell lines.,,CHEMBL619156,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,4609,,2113,F,,
Intermediate,,1,A2780,,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-resistant A2780/R human tumor cell lines",,CHEMBL619157,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,4610,,16913,F,,
Intermediate,,1,A2780,,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-resistant A2780/R human tumor cell lines",,CHEMBL619797,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,4611,,16913,F,,
Autocuration,,1,,,Oral bioavailability of compound in rhesus macaques,,CHEMBL619798,U,0,,,Macaca mulatta,9544.0,BAO_0000218,22224,,4612,,17839,A,In vivo,
Autocuration,,1,,,Oral bioavailability in monkey,,CHEMBL619799,U,0,,,monkey,9443.0,BAO_0000218,22224,,4613,,6821,A,In vivo,
Autocuration,,1,,,Oral bioavailability evaluated in monkey,,CHEMBL619800,U,0,,,monkey,9443.0,BAO_0000218,22224,,4614,,6078,A,In vivo,
Autocuration,,1,,,Oral bioavailability in monkey (dose 1 mg/kg p.o.),,CHEMBL619801,U,0,,,monkey,9443.0,BAO_0000218,22224,,4615,,6535,A,In vivo,
Autocuration,,1,,,Oral bioavailability in Rhesus monkey,,CHEMBL619802,U,0,,,Macaca mulatta,9544.0,BAO_0000218,22224,,4616,,4449,A,In vivo,
Autocuration,,1,,,Oral bioavailability was calculated in rhesus monkey,,CHEMBL619803,U,0,,,Macaca mulatta,9544.0,BAO_0000218,22224,,4617,,6057,A,In vivo,
Autocuration,,1,,,Oral bioavailability in cynomolgus monkey,,CHEMBL619965,U,0,,,Macaca fascicularis,9541.0,BAO_0000218,22224,,4618,,5922,A,In vivo,
Autocuration,,1,,,Oral bioavailability in monkey,,CHEMBL619966,U,0,,,monkey,9443.0,BAO_0000218,22224,,4619,,5940,A,In vivo,
Autocuration,,1,,,Oral bioavailability in monkey,,CHEMBL619967,U,0,,,monkey,9443.0,BAO_0000218,22224,,4620,,6265,A,In vivo,
Autocuration,,1,,,Oral bioavailability in monkey (dose 1 mg/kg),,CHEMBL620073,U,0,,,monkey,9443.0,BAO_0000218,22224,,4621,,6265,A,In vivo,
Autocuration,,1,,,Oral bioavailability in monkey (dose 5 mg/kg),,CHEMBL620074,U,0,,,monkey,9443.0,BAO_0000218,22224,,4622,,6265,A,In vivo,
Autocuration,,1,,,Oral bioavailability in monkey,,CHEMBL620075,U,0,,,monkey,9443.0,BAO_0000218,22224,,4623,,5940,A,In vivo,
Autocuration,,1,,,Oral bioavailability in monkey,,CHEMBL620076,U,0,,,monkey,9443.0,BAO_0000218,22224,,4624,,5940,A,In vivo,
Autocuration,,1,,,Oral bioavailability in rhesus monkey,,CHEMBL620077,U,0,,,Macaca mulatta,9544.0,BAO_0000218,22224,,4625,,4514,A,In vivo,
Autocuration,,1,,,Oral bioavailability in rhesus monkey at a dose of 2 mg/kg by po administration,,CHEMBL620078,U,0,,,Macaca mulatta,9544.0,BAO_0000218,22224,,4626,,5546,A,In vivo,
Autocuration,,1,,,Oral bioavailability in squirrel monkey at a dose of 10 mg/kg,,CHEMBL620079,U,0,,,Saimiri sciureus,9521.0,BAO_0000218,22224,,4627,,5553,A,In vivo,
Autocuration,,1,,,Oral bioavailability in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),,CHEMBL620080,U,0,,,monkey,9443.0,BAO_0000218,22224,,4628,,6641,A,In vivo,
Autocuration,,1,,,Oral bioavailability in Rhesus monkey,,CHEMBL620081,U,0,,,Macaca mulatta,9544.0,BAO_0000218,22224,,4629,,5472,A,In vivo,
Autocuration,,1,,,Oral bioavailability in Rhesus monkey (dose 10 mg/kg p.o.),,CHEMBL620082,U,0,,,Macaca mulatta,9544.0,BAO_0000218,22224,,4630,,5668,A,In vivo,
Autocuration,,1,,,Oral bioavailability in monkey at 10 mg/kg of the compound,,CHEMBL620083,U,0,,,monkey,9443.0,BAO_0000218,22224,,4631,,5711,A,In vivo,
Autocuration,,1,,,Bioavailability in Rhesus monkey,,CHEMBL620084,U,0,,,Macaca mulatta,9544.0,BAO_0000218,22224,,4632,,5145,A,In vivo,
Autocuration,,1,,,Glomerular Filtration Rate(GFR) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,CHEMBL620085,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,4633,,3443,A,,
Autocuration,,1,,,Glomerular Filtration Rate(GFR)of the compound compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,CHEMBL874595,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,4634,,3443,A,,
Autocuration,,1,,,Half life by ''Cr'' assay in rhesus monkey at a dose of 5 mg/kg,,CHEMBL873352,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,4635,,3249,A,In vivo,
Autocuration,,1,,,Half life the of compound was determined by ''Cr'' assay in squirrel monkey at a dose of 5 mg/kg,,CHEMBL620086,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,4636,,3249,A,In vivo,
Autocuration,,1,,,Mean residence time was determined after intravenous administration in cynomolgus monkeys,,CHEMBL620087,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,4637,,5355,A,In vivo,
Autocuration,,1,,,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means Not applicable,,CHEMBL620088,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,4638,,5355,A,In vivo,
Autocuration,,1,,,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means not applicable,,CHEMBL620089,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,4639,,5355,A,In vivo,
Autocuration,,1,,,Pharmacokinetic parameter MRT was determined in monkey after (iv) administration of a dose of 13 (uM/kg),,CHEMBL620090,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,4640,,4809,A,In vivo,
Autocuration,,1,,,Pharmacokinetic parameter MRT was determined in monkey after (po) administration of a dose of 50 (uM/kg),,CHEMBL620091,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,4641,,4809,A,In vivo,
Autocuration,,1,,,Metabolism of compound in monkey S9 microsomes ('+''indicates <20% largest observed peak),Microsomes,CHEMBL620092,U,0,,,Cercopithecidae,9527.0,BAO_0000251,22224,,4642,,14294,A,,
Autocuration,,1,,,Metabolism of compound in monkey S9 microsomes ('++''indicates 20-50% largest observed peak),Microsomes,CHEMBL620093,U,0,,,Cercopithecidae,9527.0,BAO_0000251,22224,,4643,,14294,A,,
Autocuration,,1,,,Metabolism of compound in monkey S9 microsomes ('+++'indicates 50-80% largest observed peak),Microsomes,CHEMBL620094,U,0,,,Cercopithecidae,9527.0,BAO_0000251,22224,,4644,,14294,A,,
Autocuration,,1,,,Metabolism of compound in monkey S9 microsomes ('++++' indicates largest observed peak),Microsomes,CHEMBL620095,U,0,,,Cercopithecidae,9527.0,BAO_0000251,22224,,4645,,14294,A,,
Autocuration,,1,,,Plasma clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,CHEMBL620096,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,4646,,3443,A,In vivo,
Autocuration,,1,,,Plasma clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,CHEMBL620097,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,4647,,3443,A,In vivo,
Autocuration,,1,,,Clearance from plasma(with matabolite-corrected plasma radioactivity-time integral) at 30 min after administration.,,CHEMBL620098,U,0,,,Cercopithecidae,9527.0,BAO_0000019,22224,,4648,,11271,A,,
Autocuration,,1,,,Renal clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,CHEMBL620099,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,4649,,3443,A,,
Autocuration,,1,,,Renal clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,CHEMBL620100,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,4650,,3443,A,,
Autocuration,,1,,,Elimination Half-life of compound was determined in monkey,,CHEMBL620101,U,0,,,Cercopithecidae,9527.0,BAO_0000019,22224,,4651,,6821,A,,
Autocuration,,1,,,Half life of compound was determined in rhesus monkey,,CHEMBL620102,U,0,,,Cercopithecidae,9527.0,BAO_0000019,22224,,4652,,17267,A,,
Autocuration,,1,,,Half life in monkey plasma,,CHEMBL620103,U,0,,,Cercopithecidae,9527.0,BAO_0000366,22224,,4653,Plasma,5819,A,,1969.0
Autocuration,,1,,,Half life in monkey plasma; Not detected,,CHEMBL620104,U,0,,,Cercopithecidae,9527.0,BAO_0000366,22224,,4654,Plasma,5819,A,,1969.0
Autocuration,,1,,,Half life period was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,CHEMBL874596,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,4655,,1916,A,In vivo,
Autocuration,,1,,,Half-life 24 hr after 2 mg/kg iv administration in monkeys,,CHEMBL873490,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,4656,,17509,A,In vivo,
Autocuration,,1,,,Terminal half life of the compound.,,CHEMBL620105,U,0,,,Cercopithecidae,9527.0,BAO_0000019,22224,,4657,,1399,A,,
Autocuration,,1,,,Maximum time was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,CHEMBL620780,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,4658,,1916,A,In vivo,
Autocuration,,1,,,Pharmacokinetic parameter Tmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),,CHEMBL620781,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,4659,,4809,A,In vivo,
Autocuration,,1,,,Unbound plasma was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,,CHEMBL620956,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,4660,,5546,A,,
Autocuration,,1,,,Urinary recovery evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,CHEMBL620957,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,4661,Urine,3443,A,,1088.0
Autocuration,,1,,,Urinary recovery compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,CHEMBL620958,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,4662,Urine,3443,A,,1088.0
Autocuration,,1,,,Volume of distribution was determined in monkey after a 3 mg/kg of iv dose,,CHEMBL620959,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,4663,,4257,A,In vivo,
Autocuration,,1,,,Volume distribution after oral administration (2.5 mg/kg) in monkey was determined,,CHEMBL620960,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,4664,,6221,A,In vivo,
Autocuration,,1,,,Volume of distribution was evaluated in rhesus,,CHEMBL620961,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,4665,,5472,A,In vivo,
Autocuration,,1,,,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,,CHEMBL620962,U,0,,,Cricetulus griseus,10029.0,BAO_0000218,22224,,4666,,4727,A,In vivo,
Autocuration,,1,,,Plasma clearance was measured in hamster at the dose of 3 mg/kg by intravenous administration,,CHEMBL620963,U,0,,,Cricetulus griseus,10029.0,BAO_0000218,22224,,4667,,4727,A,In vivo,
Autocuration,,1,,,Bioavailability in hamster was determined,,CHEMBL620964,U,0,,,Cricetulus griseus,10029.0,BAO_0000218,22224,,4668,,4727,A,In vivo,
Autocuration,,1,,,Bioavailability in hamster at a dose of 3 mg/kg by intravenous administration,,CHEMBL620965,U,0,,,Cricetulus griseus,10029.0,BAO_0000218,22224,,4669,,4727,A,In vivo,
Autocuration,,1,,,Bioavailability in hamster at a dose of 3 mg/kg by oral administration,,CHEMBL620966,U,0,,,Cricetulus griseus,10029.0,BAO_0000218,22224,,4670,,4727,A,In vivo,
Autocuration,,1,,,Half life of compound was determined in hamster blood,,CHEMBL620967,U,0,,,Cricetulus griseus,10029.0,BAO_0000221,22224,,4671,Blood,4727,A,,178.0
Autocuration,,1,,,Michaelis-Menten constant of the compound.,,CHEMBL620968,U,0,,,Sus scrofa,9823.0,BAO_0000019,22224,,4672,,1452,A,,
Autocuration,,1,,,Vmax value was measured at 0 uM concentration of silyl ether.,,CHEMBL874597,U,0,,,Sus scrofa,9823.0,BAO_0000019,22224,,4673,,1452,A,,
Autocuration,,1,,,Vmax value was measured at 10 uM concentration of silyl ether.,,CHEMBL620969,U,0,,,Sus scrofa,9823.0,BAO_0000019,22224,,4674,,1452,A,,
Autocuration,,1,,,Vmax value was measured at 5 uM concentration of silyl ether.,,CHEMBL620970,U,0,,,Sus scrofa,9823.0,BAO_0000019,22224,,4675,,1452,A,,
Expert,,1,,,Inactivation of human leukocyte (neutrophil) elastase(HLE)(HNE) as rate constant,,CHEMBL620971,D,9,,,Homo sapiens,9606.0,BAO_0000357,235,,4676,,11706,B,,
Autocuration,,1,,,Area under curve was evaluated against man at a dose of 10 mg/kg after po administration,,CHEMBL620972,U,0,,,Homo sapiens,9606.0,BAO_0000218,22224,,4677,,1916,A,,
Autocuration,,1,,,Compound was evaluated for area under the curve expressed as (h*ug/ml),,CHEMBL620973,U,0,,,Homo sapiens,9606.0,BAO_0000019,22224,,4678,,17791,A,,
Autocuration,,1,,,Active metabolite of ifosfamide determined in humans; A-Active,,CHEMBL618243,U,0,,,Homo sapiens,9606.0,BAO_0000019,22224,,4679,,7766,A,,
Autocuration,,1,,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis,,CHEMBL618244,U,0,,,Homo sapiens,9606.0,BAO_0000019,22224,,4680,,6567,A,,
Autocuration,,1,,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; -0.5 to 1,,CHEMBL618245,U,0,,,Homo sapiens,9606.0,BAO_0000019,22224,,4681,,6567,A,,
Autocuration,,1,,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; 1-2,,CHEMBL618246,U,0,,,Homo sapiens,9606.0,BAO_0000019,22224,,4682,,6567,A,,
Autocuration,,1,,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; trace,,CHEMBL618247,U,0,,,Homo sapiens,9606.0,BAO_0000019,22224,,4683,,6567,A,,
Autocuration,,1,,,Compound was evaluated for oral bioavailability in human,,CHEMBL618248,U,0,,,Homo sapiens,9606.0,BAO_0000218,22224,,4684,,17791,A,,
Autocuration,,1,,,Metabolite of ifosfamide determined in urine; NF-Not found,,CHEMBL618249,U,0,,,Homo sapiens,9606.0,BAO_0000019,22224,,4685,Urine,7766,A,,1088.0
Autocuration,,1,,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection (Group A and B),,CHEMBL618250,U,0,,,Homo sapiens,9606.0,BAO_0000019,22224,,4686,,6852,A,,
Autocuration,,1,,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics,,CHEMBL874598,U,0,,,Homo sapiens,9606.0,BAO_0000019,22224,,4687,,6852,A,,
Autocuration,,1,,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics and lactose,,CHEMBL618251,U,0,,,Homo sapiens,9606.0,BAO_0000019,22224,,4688,,6852,A,,
Autocuration,,1,,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics,,CHEMBL618252,U,0,,,Homo sapiens,9606.0,BAO_0000019,22224,,4689,,6852,A,,
Autocuration,,1,,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics and lactose,,CHEMBL618253,U,0,,,Homo sapiens,9606.0,BAO_0000019,22224,,4690,,6852,A,,
Autocuration,,1,,,Percent of compound in cirrhotic patients of sterile ascitic fluid (Group C),,CHEMBL618254,U,0,,,Homo sapiens,9606.0,BAO_0000019,22224,,4691,,6852,A,,
Autocuration,,1,,,Percent of compound in healthy individuals (Group D),,CHEMBL618255,U,0,,,Homo sapiens,9606.0,BAO_0000019,22224,,4692,,6852,A,,
Autocuration,,1,,,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,Microsomes,CHEMBL618983,U,0,,,Homo sapiens,9606.0,BAO_0000251,22224,,4693,Liver,4397,A,,2107.0
Autocuration,,1,,,Binding towards human plasma protein at 10 uM,,CHEMBL618984,U,0,,,Homo sapiens,9606.0,BAO_0000019,22224,,4694,,17409,A,,
Autocuration,,1,,,Binding towards human plasma protein at 100 uM,,CHEMBL618985,U,0,,,Homo sapiens,9606.0,BAO_0000019,22224,,4695,,17409,A,,
Autocuration,,1,,,Human plasma protein binding activity was determined,,CHEMBL618986,U,0,,,Homo sapiens,9606.0,BAO_0000019,22224,,4696,,17176,A,,
Autocuration,,1,,,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),,CHEMBL618987,U,0,,,Homo sapiens,9606.0,BAO_0000019,22224,,4697,,15444,A,,
Autocuration,,1,,,Percent binding of compound towards human plasma protein was determined,,CHEMBL618988,U,0,,,Homo sapiens,9606.0,BAO_0000019,22224,,4698,,17267,A,,
Autocuration,,1,,,Plasma clearance in human liver microsomes,Microsomes,CHEMBL618989,U,0,,,Homo sapiens,9606.0,BAO_0000251,22224,,4699,Liver,5944,A,In vitro,2107.0
Autocuration,,1,,,In vitro intrinsic clearance in human liver microsome,Microsomes,CHEMBL618990,U,0,,,Homo sapiens,9606.0,BAO_0000251,22224,,4700,Liver,5668,A,In vitro,2107.0
Autocuration,,1,,,In vitro intrinsic clearance in human liver microsome,Microsomes,CHEMBL618991,U,0,,,Homo sapiens,9606.0,BAO_0000251,22224,,4701,Liver,5669,A,In vitro,2107.0
Autocuration,,1,,,In vitro microsome metabolism clearance in human was determined,Microsomes,CHEMBL876725,U,0,,,Homo sapiens,9606.0,BAO_0000251,22224,,4702,,5041,A,In vitro,
Autocuration,,1,,,In vitro microsome metabolism clearance in human was determined; High,Microsomes,CHEMBL618992,U,0,,,Homo sapiens,9606.0,BAO_0000251,22224,,4703,,5041,A,In vitro,
Autocuration,,1,,,In vitro microsome metabolism clearance in human was determined; ND denotes no data,Microsomes,CHEMBL618993,U,0,,,Homo sapiens,9606.0,BAO_0000251,22224,,4704,,5041,A,In vitro,
Autocuration,,1,,,Pharmacokinetic property (clearance) in human liver microsome,Microsomes,CHEMBL618994,U,0,,,Homo sapiens,9606.0,BAO_0000251,22224,,4705,Liver,5676,A,In vitro,2107.0
Autocuration,,1,,,Plasma clearance in human liver microsomes,Microsomes,CHEMBL618995,U,0,,,Homo sapiens,9606.0,BAO_0000251,22224,,4706,Liver,5944,A,In vitro,2107.0
Autocuration,,1,,,In vitro clearance in human liver microsomes,Microsomes,CHEMBL618996,U,0,,,Homo sapiens,9606.0,BAO_0000251,22224,,4707,Liver,17538,A,In vitro,2107.0
Autocuration,,1,,,Intrinsic clearance in human liver microsomes was determined,Microsomes,CHEMBL618997,U,0,,,Homo sapiens,9606.0,BAO_0000251,22224,,4708,Liver,6331,A,In vitro,2107.0
Autocuration,,1,,,Intrinsic clearance in human liver microsomes was determined,Microsomes,CHEMBL618998,U,0,,,Homo sapiens,9606.0,BAO_0000251,22224,,4709,Liver,5948,A,In vitro,2107.0
Autocuration,,1,,,Cmax (Tissue distribution) of compound was determined at a dose of 5 mg/kg in human,,CHEMBL618999,U,0,,,Homo sapiens,9606.0,BAO_0000218,22224,,4710,,5965,A,In vivo,
Autocuration,,1,,,Maximum concentration was evaluated against man at a dose of 10 mg/kg after po administration,,CHEMBL620223,U,0,,,Homo sapiens,9606.0,BAO_0000218,22224,,4711,,1916,A,In vivo,
Autocuration,,1,,,Cmin (Clearance) of compound was determined at a dose of 5 mg/kg in human,,CHEMBL620224,U,0,,,Homo sapiens,9606.0,BAO_0000218,22224,,4712,,5965,A,,
Autocuration,,1,,,Stability in human plasma 2 hr after incubation expressed as percent concentration,,CHEMBL620225,U,0,,,Homo sapiens,9606.0,BAO_0000019,22224,,4713,,1299,A,,
Autocuration,,1,,,Stability in human plasma 4 hr after incubation expressed as percent concentration,,CHEMBL620226,U,0,,,Homo sapiens,9606.0,BAO_0000019,22224,,4714,,1299,A,,
Autocuration,,1,,,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 3 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,CHEMBL620227,U,0,,,Homo sapiens,9606.0,BAO_0000019,22224,,4715,Urine,7766,A,,1088.0
Autocuration,,1,,,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 7 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,CHEMBL876726,U,0,,,Homo sapiens,9606.0,BAO_0000019,22224,,4716,Urine,7766,A,,1088.0
Autocuration,,1,,,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 6 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,CHEMBL620228,U,0,,,Homo sapiens,9606.0,BAO_0000019,22224,,4717,Urine,7766,A,,1088.0
Autocuration,,1,,,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 8 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,CHEMBL620229,U,0,,,Homo sapiens,9606.0,BAO_0000019,22224,,4718,Urine,7766,A,,1088.0
Intermediate,,1,,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 23 uM/kg,,CHEMBL620230,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4719,,17764,F,In vivo,
Intermediate,,1,,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 25 uM/kg,,CHEMBL620231,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4720,,17764,F,In vivo,
Intermediate,,1,,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 26 uM/kg,,CHEMBL620232,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4721,,17764,F,In vivo,
Intermediate,,1,,,Mean-residence time was determined for compound intravenous administration in mice at 23 uM/kg,,CHEMBL620233,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4722,,17764,F,In vivo,
Intermediate,,1,,,Metabolism of compound in Mouse S9 microsomes ('++++'indicates largest observed peak),,CHEMBL620234,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4723,,14294,A,,
Intermediate,,1,,,Metabolism of compound in mouse S9 microsomes ('+''indicates <20% largest observed peak),,CHEMBL620235,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4724,,14294,A,,
Intermediate,,1,,,Metabolism of compound in mouse S9 microsomes ('++++' indicates largest observed peak),,CHEMBL620236,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4725,,14294,A,,
Intermediate,,1,,,In vitro metabolic potential in mouse liver microsomes,,CHEMBL620237,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4726,Liver,6251,A,,2107.0
Intermediate,,1,,,Ability of compound to bind to plasma protein was evaluated in HSA cells,,CHEMBL620238,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4727,,17582,A,,
Intermediate,,1,,,Compound was tested for radioactivity level in mice adrenal glands (Compound is radiolabeled),,CHEMBL620239,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4728,Adrenal gland,17811,A,,2369.0
Intermediate,,1,,,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.2-4.9% ID/g,,CHEMBL620240,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4729,Brain,17811,A,,955.0
Intermediate,,1,,,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.6-4.4% ID/g,,CHEMBL620241,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4730,Brain,17811,A,,955.0
Intermediate,,1,,,Compound was tested for radioactivity level in mice heart (Compound is radiolabeled),,CHEMBL876727,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4731,,17811,A,,
Intermediate,,1,,,Compound was tested for radioactivity level in mice kidney (Compound is radiolabeled),,CHEMBL620242,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4732,Kidney,17811,A,,2113.0
Intermediate,,1,,,Compound was tested for radioactivity level in mice lungs (Compound is radiolabeled),,CHEMBL620243,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4733,,17811,A,,
Intermediate,,1,,,Tested for urinary recovery in mice after subcutaneous administration of 20 mg/Kg,,CHEMBL620244,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4734,,5288,A,,
Intermediate,,1,,,Compound was evaluated for its potency in CDF1 mice and the serum cholesterol levels were determined,,CHEMBL620245,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4735,Serum,2717,A,,1977.0
Intermediate,,1,,,Compound was evaluated for its potency in CDF1 mice and the serum metabolite levels were determined,,CHEMBL620246,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4736,Serum,2717,A,,1977.0
Intermediate,,1,,,Compound was evaluated for its potency in CDF1 mice and the serum triglyceride levels were determined,,CHEMBL620247,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4737,Serum,2717,A,,1977.0
Intermediate,,1,,,Half life of compound was determined in plasma of mice at 24 mg/Kg,,CHEMBL620248,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4738,Plasma,17753,A,In vivo,1969.0
Intermediate,,1,,,Half life of compound was determined in plasma of mice at 40 mg/Kg,,CHEMBL873497,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4739,Plasma,17753,A,In vivo,1969.0
Intermediate,,1,,,Half life of compound was determined in plasma of mice at 5 mg/Kg,,CHEMBL620249,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4740,Plasma,17753,A,In vivo,1969.0
Intermediate,,1,,,Half life after intraperitoneal administration in mice at 18 uM/kg,,CHEMBL620250,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4741,,17764,F,In vivo,
Intermediate,,1,,,Half life after intraperitoneal administration in mice at 23 uM/kg,,CHEMBL620251,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4742,,17764,F,In vivo,
Intermediate,,1,,,Half life after intraperitoneal administration in mice at 25 uM/kg,,CHEMBL620252,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4743,,17764,F,In vivo,
Intermediate,,1,,,Half life after intraperitoneal administration in mice at 26 uM/kg,,CHEMBL620253,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4744,,17764,F,In vivo,
Intermediate,,1,,,Half life after intravenous administration in mice at 23 uM/kg,,CHEMBL620254,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4745,,17764,F,In vivo,
Intermediate,,1,,,Half life after intravenous administration in mice at 24 uM/kg,,CHEMBL620255,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4746,,17764,A,In vivo,
Intermediate,,1,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,,CHEMBL620256,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4747,,16597,A,In vivo,
Intermediate,,1,,,Maximum time required to reach Cp max was evaluated in mice after intravenous administration; T max Not determined,,CHEMBL876728,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4748,,2675,A,In vivo,
Intermediate,,1,,,Maximum time required to reach Cp max was evaluated in mice after oral administration,,CHEMBL620257,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4749,,2675,A,In vivo,
Intermediate,,1,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),,CHEMBL620258,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4750,,16597,A,In vivo,
Intermediate,,1,,,"Compound was evaluated for the pharmacokinetic parameter, Terminal half life period",,CHEMBL620259,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4751,,4890,A,In vivo,
Intermediate,,1,,,Evaluated for pharmacokinetic parameter half-life in mouse at the dose 20 mg/kg,,CHEMBL620260,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4752,,429,A,In vivo,
Intermediate,,1,,,Half life of compound in mouse blood following i.v. administration of 10 mg/kg,,CHEMBL620261,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4753,Blood,17837,A,In vivo,178.0
Intermediate,,1,,,Half life at a dose of 10 mg/kg intravenous administration in mice.,,CHEMBL620262,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4754,,16597,A,In vivo,
Intermediate,,1,,,Half life at a dose of 10 mg/kg peroral administration in mice.,,CHEMBL620263,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4755,,16597,A,In vivo,
Intermediate,,1,,,Half life in ob/ob mice,,CHEMBL620264,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4756,,6619,A,,
Intermediate,,1,,,Half-life at a single subcutaneous administration of 40 mg/kg in mice,,CHEMBL620265,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4757,,4066,A,In vivo,
Intermediate,,1,,,Half-life was measured in mouse,,CHEMBL620266,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4758,,4239,A,,
Intermediate,,1,,,In vivo half life period was determined in murine septicemia at dose of 50 mg/kg,,CHEMBL620267,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4759,,5969,A,In vivo,
Intermediate,,1,,,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation,,CHEMBL619364,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4760,,8999,A,,
Intermediate,,1,,,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation; 10 % hydrolysis at 60 mins,,CHEMBL619365,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4761,,8999,A,,
Intermediate,,1,,,T2 in brain of mice at the oral dose of 50 mg/kg,,CHEMBL619366,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4762,Brain,17641,A,,955.0
Intermediate,,1,,,T2 in kidney of mice at the oral dose of 50 mg/kg,,CHEMBL619367,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4763,Kidney,17641,A,,2113.0
Intermediate,,1,,,T2 in liver of mice at the oral dose of 50 mg/kg,,CHEMBL619368,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4764,Liver,17641,A,,2107.0
Intermediate,,1,,,T2 in lungs of mice at the oral dose of 50 mg/kg,,CHEMBL619369,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4765,Lung,17641,A,,2048.0
Intermediate,,1,,,T2 in spleen of mice at the oral dose of 50 mg/kg,,CHEMBL876729,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4766,Spleen,17641,A,,2106.0
Intermediate,,1,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,,CHEMBL619370,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4767,,16597,A,In vivo,
Intermediate,,1,,,"Compound was evaluated for the pharmacokinetic parameter, maximum time constant",,CHEMBL619371,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4768,,4890,A,In vivo,
Intermediate,,1,,,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg,,CHEMBL619372,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4769,,429,A,In vivo,
Intermediate,,1,,,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg was determined,,CHEMBL620012,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4770,,429,A,In vivo,
Intermediate,,1,,,In vivo Tmax was determined in murine septicemia at dose of 100 mg/kg,,CHEMBL620013,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4771,,5969,A,In vivo,
Intermediate,,1,A2780,,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",,CHEMBL620014,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,4772,,16913,F,,
Intermediate,,1,A2780,,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",,CHEMBL620015,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,4773,,16913,F,,
Intermediate,,1,A2780,,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-sensitive A2780/S human tumor cell lines",,CHEMBL621010,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,4774,,16913,F,,
Intermediate,,1,A2780,,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-sensitive A2780/S human tumor cell lines",,CHEMBL621011,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,4775,,16913,F,,
Intermediate,,1,A2780,,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",,CHEMBL621012,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,4776,,16913,F,,
Intermediate,,1,A2780,,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",,CHEMBL621013,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,4777,,16913,F,,
Intermediate,,1,A2780,,In vitro cytotoxicity against A2780TAX cell line,,CHEMBL621014,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,4778,,17270,F,,
Intermediate,,1,A2780cisR,,In vitro inhibitory activity against human tumor cell line A2780cis,,CHEMBL618154,N,1,,481.0,Homo sapiens,9606.0,BAO_0000219,80017,,4779,,5618,F,,
Expert,,1,A2780,,Growth inhibition against A2780 cisplatin resistant wild-type ovarian cell lines,,CHEMBL618155,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,4780,,17777,F,,
Intermediate,,1,A2780cisR,,Antitumor activity of compound for 96-h exposure in A2780cisR (acquired resistance to cisplatin) human ovarian cell line,,CHEMBL618156,N,1,,481.0,Homo sapiens,9606.0,BAO_0000219,80017,,4781,,16112,F,,
Intermediate,,1,A2780cisR,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),,CHEMBL618157,N,1,,481.0,Homo sapiens,9606.0,BAO_0000219,80017,,4782,,15748,F,,
Intermediate,,1,A2780,,Concentration required to inhibit A2780cisR cell growth when compared with control after incubation for 96 h at 37 C,,CHEMBL618328,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,4783,,6633,F,,
Intermediate,,1,A2780,,Compound was evaluated against human Ovarian carcinoma cell line A2780cisR,,CHEMBL618329,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,4784,,16930,F,,
Intermediate,,1,A2780,,Cytotoxicity against human ovarian carcinoma A2780cisR cell line,,CHEMBL618330,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,4785,,17496,F,,
Expert,,1,A2780,,In vitro antitumor activity against A2780cisR cell line.,,CHEMBL618331,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,4786,,12989,F,,
Intermediate,,1,A2780,,Tested for the cytotoxicity in A2780cisR ovarian cell line (cisR denotes resistance to cisplatin),,CHEMBL618332,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,4787,,4840,F,,
Expert,,1,A2780,,Resistant factor determined between IC50 of resistant line to that of A2780cisR cell line,,CHEMBL618333,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,4788,,12989,F,,
Intermediate,,1,A2780cisR,,cytotoxicity against A2780cisR cells incubated for 24 hr in MTT assay,,CHEMBL618334,N,1,,481.0,Homo sapiens,9606.0,BAO_0000219,80017,,4789,,16745,F,,
Expert,,1,A2780,,Inhibition of A2780 / DDP-S human ovarian carcinoma cell proliferation,,CHEMBL618335,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,4790,,16597,F,,
Expert,,1,,,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes,,CHEMBL618336,D,9,,,Rattus norvegicus,10116.0,BAO_0000019,11736,,4791,,16547,B,,
Expert,,1,,,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),,CHEMBL618337,H,8,,,,,BAO_0000019,11736,,4792,,16547,F,,
Expert,,1,,,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),,CHEMBL618338,D,9,,,Rattus norvegicus,10116.0,BAO_0000019,11736,,4793,,16547,F,,
Expert,,1,HEK293,,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells uisng [3H]ZM-241385 or [125I]-IABOPX,,CHEMBL618339,D,9,,722.0,Homo sapiens,9606.0,BAO_0000219,278,,4794,,15856,F,,
Expert,,1,HEK293,,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells using [3H]ZM-241385 (or) [125 I]IABOPX at 10e-5 M,,CHEMBL618340,D,9,,722.0,Homo sapiens,9606.0,BAO_0000219,278,,4795,,15856,F,,
Expert,,1,,,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes,,CHEMBL618341,D,9,,,Mus musculus,10090.0,BAO_0000019,11831,,4796,,16547,B,,
Expert,,1,,,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),,CHEMBL618342,H,8,,,,,BAO_0000019,11831,,4797,,16547,F,,
Expert,,1,,,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),,CHEMBL618343,D,9,,,Mus musculus,10090.0,BAO_0000019,11831,,4798,,16547,F,,
Expert,,1,,,Ability to displace the binding of [3H]-MRE 3008-F20 to the ligand binding site of CHO:hA3 (human Adenosine receptor) at concentration of 10 uM,,CHEMBL621038,H,8,,,,,BAO_0000357,280,,4799,,17402,B,,
Autocuration,,1,T-cells,,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01),,CHEMBL621039,U,0,,574.0,Homo sapiens,9606.0,BAO_0000219,22226,,4800,,11746,F,,
Autocuration,,1,T-cells,,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01); Not active,,CHEMBL621040,U,0,,574.0,Homo sapiens,9606.0,BAO_0000219,22226,,4801,,11746,F,,
Intermediate,,1,A-375,,Compound was evaluated for cytotoxic activity against human melanoma cell line A375,,CHEMBL621041,N,1,,455.0,Homo sapiens,9606.0,BAO_0000219,80018,,4802,,5455,F,,
Intermediate,,1,A-375,,In vitro antitumor activity against A375 (melanoma) human tumor cell lines.,,CHEMBL621042,N,1,,455.0,Homo sapiens,9606.0,BAO_0000219,80018,,4803,,2068,F,,
Intermediate,,1,A-375,,In vitro antitumor activity against A375cell line extracted form melanoma,,CHEMBL621043,N,1,,455.0,Homo sapiens,9606.0,BAO_0000219,80018,,4804,,2683,F,,
Expert,,1,A-375,,Inhibition of cell growth in (A375) melan cell line,,CHEMBL621044,N,1,,455.0,Homo sapiens,9606.0,BAO_0000219,80018,,4805,,15313,F,,
Intermediate,,1,A-375,,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines A375,,CHEMBL621045,N,1,,455.0,Homo sapiens,9606.0,BAO_0000219,80018,,4806,,13739,F,,
Intermediate,,1,A-375,,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines. A375,,CHEMBL621046,N,1,,455.0,Homo sapiens,9606.0,BAO_0000219,80018,,4807,,13739,F,,
Intermediate,,1,A-375,,Compound was tested in vitro for cytotoxicity against A375 cell lines from melanoma.,,CHEMBL621047,N,1,,455.0,Homo sapiens,9606.0,BAO_0000219,80018,,4808,,14750,F,,
Intermediate,,1,A-427,,Antiproliferative activity measured against A427 human lung carcinoma,,CHEMBL621048,N,1,,797.0,Homo sapiens,9606.0,BAO_0000219,80019,,4809,,14777,F,,
Intermediate,,1,A-427,,Antiproliferative activity measured against A427 human lung carcinoma,,CHEMBL883798,N,1,,797.0,Homo sapiens,9606.0,BAO_0000219,80019,,4810,,14777,F,,
Intermediate,,1,A-427,,Cytotoxicity against lung carcinoma A427 tumor cell lines,,CHEMBL621049,N,1,,797.0,Homo sapiens,9606.0,BAO_0000219,80019,,4811,,17672,F,,
Intermediate,,1,A-427,,Inhibition of large cell lung carcinoma (A427),,CHEMBL621050,N,1,,797.0,Homo sapiens,9606.0,BAO_0000219,80019,,4812,,14368,F,,
Intermediate,,1,A-427,,Inhibition of large cell lung carcinoma (A427) after 48-h treatment,,CHEMBL621051,N,1,,797.0,Homo sapiens,9606.0,BAO_0000219,80019,,4813,,14368,F,,
Intermediate,,1,A-427,,Inhibitory activity against A427 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,,CHEMBL621052,N,1,,797.0,Homo sapiens,9606.0,BAO_0000219,80019,,4814,,13866,F,,
Intermediate,,1,A-427,,Inhibitory concentration in human lung carcinoma A427 cell line,,CHEMBL621053,N,1,,797.0,Homo sapiens,9606.0,BAO_0000219,80019,,4815,,2545,F,,
Intermediate,,1,A-427,,Inhibitory concentration in human lung carcinoma A427/VCR cell line,,CHEMBL621054,N,1,,797.0,Homo sapiens,9606.0,BAO_0000219,80019,,4816,,2545,F,,
Autocuration,,1,,,Terminal phase volume of distribution was measured in monkey after an iv dose of 1 mg/kg,,CHEMBL621055,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,4817,,6062,A,In vivo,
Autocuration,,1,,,Tested for volume of distribution upon iv administration to african green monkey,,CHEMBL876398,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,4818,,4578,A,In vivo,
Autocuration,,1,,,Volume of distribution in monkey,,CHEMBL621056,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,4819,,17592,A,In vivo,
Autocuration,,1,,,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,,CHEMBL621057,U,0,,,Macaca mulatta,9544.0,BAO_0000218,22224,,4820,,5005,A,In vivo,
Autocuration,,1,,,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,,CHEMBL621058,U,0,,,Macaca mulatta,9544.0,BAO_0000218,22224,,4821,,5005,A,In vivo,
Autocuration,,1,,,Pharmacokinetic property(Vdss) in cynomolgus monkey,,CHEMBL621059,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,4822,,5922,A,In vivo,
Autocuration,,1,,,The distribution volume after intravenous administration in cynomolgus monkeys,,CHEMBL621060,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,4823,,5355,A,In vivo,
Autocuration,,1,,,The distribution volume after oral administration in cynomolgus monkeys; NA means Not applicable,,CHEMBL621061,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,4824,,5355,A,In vivo,
Autocuration,,1,,,The distribution volume after oral administration in cynomolgus monkeys; NA means not applicable,,CHEMBL621062,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,4825,,5355,A,In vivo,
Autocuration,,1,,,Volume displacement was calculated in rhesus monkey,,CHEMBL621063,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,4826,,6057,A,In vivo,
Autocuration,,1,,,Volume of distribution in steady state was determined in rhesus monkey,,CHEMBL621064,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,4827,,5145,A,In vivo,
Autocuration,,1,,,Volume of distribution of compound was determined in monkey,,CHEMBL621065,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,4828,,6821,A,In vivo,
Autocuration,,1,,,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),,CHEMBL621066,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,4829,,5334,A,In vivo,
Autocuration,,1,,,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),,CHEMBL621067,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,4830,,5334,A,In vivo,
Autocuration,,1,,,Volumes of distribution in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),,CHEMBL621068,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,4831,,6641,A,In vivo,
Autocuration,,1,,,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female cynomolgus monkey,,CHEMBL876399,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,4832,,2661,A,In vivo,
Autocuration,,1,,,Volume distribution in monkey after administration of 1 mg/kg iv,,CHEMBL621069,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,4833,,6535,A,In vivo,
Autocuration,,1,,,Volume distribution was determined in monkey after (iv) administration of a dose of 13 (uM/kg),,CHEMBL621070,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,4834,,4809,A,In vivo,
Autocuration,,1,,,Volume of distribution was measured in monkey after an iv dose of 1 mg/kg,,CHEMBL621071,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,4835,,6062,A,In vivo,
Autocuration,,1,,,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,CHEMBL621072,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,4836,,3443,A,In vivo,
Autocuration,,1,,,Oral systemic bioavailability upon iv administration to african green monkey,,CHEMBL618209,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,4837,,4578,A,In vivo,
Autocuration,,1,,,Plasma clearance was determined in monkey after (iv) administration of a dose of 13 (uM/kg),,CHEMBL618210,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,4838,,4809,A,In vivo,
Autocuration,,1,,,Baboon plasma free fraction. ,,CHEMBL618211,U,0,,,Cercopithecidae,9527.0,BAO_0000019,22224,,4839,,11271,A,,
Autocuration,,1,,,Area under the curve was calculated in rhesus monkey after iv administration,,CHEMBL618212,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,4840,,6057,A,,
Autocuration,,1,,,Area under the curve was calculated in rhesus monkey after peroral administration,,CHEMBL618213,U,0,,,Cercopithecidae,9527.0,BAO_0000019,22224,,4841,,6057,A,,
Autocuration,,1,,,Dose-normalized area under curve in monkey (p.o.) at 2.0 mpk,,CHEMBL618214,U,0,,,Cercopithecidae,9527.0,BAO_0000019,22224,,4842,,17853,A,,
Autocuration,,1,,,Half life period in monkey after 5 mg/kg dose,,CHEMBL873492,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,4843,,5302,A,In vivo,
Autocuration,,1,,,Half-life was determined in monkey after 3 mg/kg of i.v. dose,,CHEMBL618272,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,4844,,4257,A,In vivo,
Autocuration,,1,,,Half-life was determined in monkey after 3 mg/kg of i.v. dose; Not determined,,CHEMBL618273,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,4845,,4257,A,In vivo,
Autocuration,,1,,,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,,CHEMBL618274,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,4846,Plasma,13501,A,In vivo,1969.0
Autocuration,,1,,,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for half life after administration into monkey at 3 mg/kg,,CHEMBL618275,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,4847,,5394,A,In vivo,
Autocuration,,1,,,Compound was evaluated for half-life after treatment with iv dose of 1 mgkg to female cynomolgus monkey,,CHEMBL618276,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,4848,,2661,A,In vivo,
Autocuration,,1,,,Compound was evaluated for terminal half life in monkey,,CHEMBL618277,U,0,,,Cercopithecidae,9527.0,BAO_0000019,22224,,4849,,3341,A,,
Autocuration,,1,,,Compound was evaluated for the half life period after iv administration in cynomolgus monkey,,CHEMBL618278,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,4850,,3045,A,In vivo,
Autocuration,,1,,,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,,CHEMBL618279,U,0,,,Macaca mulatta,9544.0,BAO_0000218,22224,,4851,Plasma,5005,A,In vivo,1969.0
Autocuration,,1,,,Half life of compound was determined in squirrel monkey,,CHEMBL618280,U,0,,,Cercopithecidae,9527.0,BAO_0000019,22224,,4852,,4847,A,,
Autocuration,,1,,,Half life after iv administration in cynomolgus monkey,,CHEMBL618281,U,0,,,Macaca fascicularis,9541.0,BAO_0000218,22224,,4853,,4256,A,In vivo,
Autocuration,,1,,,Half life in monkey plasma after administration of 1 mg/kg iv,,CHEMBL618282,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,4854,Plasma,6535,A,In vivo,1969.0
Autocuration,,1,,,Half life was calculated in rhesus monkey,,CHEMBL618283,U,0,,,Cercopithecidae,9527.0,BAO_0000019,22224,,4855,,6057,A,,
Autocuration,,1,,,Half life in monkey,,CHEMBL618284,U,0,,,Cercopithecidae,9527.0,BAO_0000019,22224,,4856,,17592,A,,
Autocuration,,1,,,Half life in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),,CHEMBL618285,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,4857,,6641,A,In vivo,
Autocuration,,1,,,Half life was evaluated in rhesus,,CHEMBL618286,U,0,,,Cercopithecidae,9527.0,BAO_0000019,22224,,4858,,5472,A,,
Autocuration,,1,,,Half life period after oral administration (2.5 mg/kg) in monkey was determined,,CHEMBL618287,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,4859,,6221,A,In vivo,
Autocuration,,1,,,Half life period was determine after peroral administration at 10 mpk in Rhesus,,CHEMBL618288,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,4860,,5668,A,In vivo,
Autocuration,,1,,,Half life period was determined in monkey after (iv) administration of a dose of 13 (uM/kg),,CHEMBL876393,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,4861,,4809,A,In vivo,
Autocuration,,1,,,Half life period was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,,CHEMBL618289,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,4862,,5546,A,In vivo,
Autocuration,,1,,,Half life period was determined in squirrel monkey after iv administration at a dose of 5 mg/kg,,CHEMBL618290,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,4863,,5553,A,In vivo,
Autocuration,,1,,,Half-life was calculated in monkey,,CHEMBL618291,U,0,,,Cercopithecidae,9527.0,BAO_0000019,22224,,4864,,6078,A,,
Autocuration,,1,,,Half-life in Squirrel monkey,,CHEMBL618292,U,0,,,Cercopithecidae,9527.0,BAO_0000019,22224,,4865,,5147,A,,
Autocuration,,1,,,Half-life in rhesus monkey,,CHEMBL618293,U,0,,,Cercopithecidae,9527.0,BAO_0000019,22224,,4866,,5145,A,,
Autocuration,,1,,,Half-life was measured in monkey after an iv dose of 1 mg/kg,,CHEMBL618294,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,4867,,6062,A,In vivo,
Autocuration,,1,,,Half-life period after intravenous administration in cynomolgus monkeys,,CHEMBL618295,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,4868,,5355,A,In vivo,
Autocuration,,1,,,Half-life period after oral administration in cynomolgus monkeys,,CHEMBL618296,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,4869,,5355,A,In vivo,
Autocuration,,1,,,Half-life period after oral administration in cynomolgus monkeys; ND meansn Not determined,,CHEMBL618297,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,4870,,5355,A,In vivo,
Autocuration,,1,,,Portion of holoxan excreted in the form of the metabolite from 1500 mL of urine on day 9 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,CHEMBL618298,U,0,,,Homo sapiens,9606.0,BAO_0000019,22224,,4871,Urine,7766,A,,1088.0
Autocuration,,1,,,Portion of holoxan excreted in the form of the metabolite from 1600 mL of urine on day 10 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,CHEMBL618299,U,0,,,Homo sapiens,9606.0,BAO_0000019,22224,,4872,Urine,7766,A,,1088.0
Autocuration,,1,,,Portion of holoxan excreted in the form of the metabolite from 1700 mL of urine on day 5 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,CHEMBL618300,U,0,,,Homo sapiens,9606.0,BAO_0000019,22224,,4873,Urine,7766,A,,1088.0
Autocuration,,1,,,Portion of holoxan excreted in the form of the metabolite from 2310 mL of urine on day 4 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,CHEMBL618301,U,0,,,Homo sapiens,9606.0,BAO_0000019,22224,,4874,Urine,7766,A,,1088.0
Autocuration,,1,,,Percent ratio of the enantiomeric form (+)R extracted from the urine of alveolar rhabdomyosarcoma patients was determined,,CHEMBL618302,U,0,,,Homo sapiens,9606.0,BAO_0000019,22224,,4875,Urine,7766,A,,1088.0
Autocuration,,1,,,Percent ratio of the enantiomeric form (+)R extracted from the urine of embryonal rhabdomyosarcoma patients was determined,,CHEMBL876394,U,0,,,Homo sapiens,9606.0,BAO_0000019,22224,,4876,Urine,7766,A,,1088.0
Autocuration,,1,,,Percent ratio of the enantiomeric form (-)S extracted from the urine of alveolar rhabdomyosarcoma patients was determined,,CHEMBL618303,U,0,,,Homo sapiens,9606.0,BAO_0000019,22224,,4877,Urine,7766,A,,1088.0
Autocuration,,1,,,Percent ratio of the enantiomeric form (-)S extracted from the urine of embryonal rhabdomyosarcoma patients was determined,,CHEMBL618304,U,0,,,Homo sapiens,9606.0,BAO_0000019,22224,,4878,Urine,7766,A,,1088.0
Autocuration,,1,,,Bioavailability was evaluated in man at a dose of 10 mg/kg after po administration; not determined,,CHEMBL618305,U,0,,,Homo sapiens,9606.0,BAO_0000218,22224,,4879,,1916,A,In vivo,
Autocuration,,1,,,Oral bioavailability in human,,CHEMBL618306,U,0,,,Homo sapiens,9606.0,BAO_0000218,22224,,4880,,16643,A,In vivo,
Autocuration,,1,,,Compound was tested for human plasma protein binding,,CHEMBL618307,U,0,,,Homo sapiens,9606.0,BAO_0000019,22224,,4881,,17248,A,,
Autocuration,,1,,,Compound was tested for human plasma protein binding; Not determined,,CHEMBL618308,U,0,,,Homo sapiens,9606.0,BAO_0000019,22224,,4882,,17248,A,,
Autocuration,,1,,,Protein binding activity of compound in human plasma; % Free,,CHEMBL618309,U,0,,,Homo sapiens,9606.0,BAO_0000019,22224,,4883,,6241,A,,
Autocuration,,1,,,Unbound fraction (plasma),,CHEMBL618310,U,0,,,Homo sapiens,9606.0,BAO_0000019,22224,,4884,,17716,A,,
Autocuration,,1,,,Half life for the hydrolysis of compound in human blood serum,,CHEMBL873353,U,0,,,Homo sapiens,9606.0,BAO_0000366,22224,,4885,Plasma,17605,A,,1969.0
Autocuration,,1,,,Half life period in human plasma using phosphate buffer (0.08 M),,CHEMBL618311,U,0,,,Homo sapiens,9606.0,BAO_0000366,22224,,4886,Plasma,17625,A,,1969.0
Autocuration,,1,,,Half life period in human plasma using phosphate buffer (0.1 M),,CHEMBL618312,U,0,,,Homo sapiens,9606.0,BAO_0000366,22224,,4887,Plasma,17625,A,,1969.0
Autocuration,,1,,,Half-life in human plasma was determined,,CHEMBL618313,U,0,,,Homo sapiens,9606.0,BAO_0000366,22224,,4888,Plasma,17747,A,,1969.0
Autocuration,,1,,,Concentration required for 50% toxicity in metastatic lung carcinoma (MV522) cells.,,CHEMBL618314,U,0,,,Homo sapiens,9606.0,BAO_0000019,22224,,4889,,15613,A,,
Autocuration,,1,,,Effect of compound on gelation time of human serum induced by dithiothreitol (DTT),,CHEMBL618315,U,0,,,Homo sapiens,9606.0,BAO_0000019,22224,,4890,,354,A,,
Autocuration,,1,,,"Rate constant in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",,CHEMBL618316,U,0,,,Homo sapiens,9606.0,BAO_0000019,22224,,4891,,3741,A,,
Autocuration,,1,,,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",,CHEMBL618317,U,0,,,Homo sapiens,9606.0,BAO_0000019,22224,,4892,,3741,A,,
Autocuration,,1,,,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",,CHEMBL620138,U,0,,,Homo sapiens,9606.0,BAO_0000019,22224,,4893,,3741,A,,
Autocuration,,1,,,Partition coefficient (logP),,CHEMBL858280,U,0,,,Homo sapiens,9606.0,BAO_0000019,22224,,4894,,17599,A,,
Autocuration,,1,,,In vitro metabolic stability in human was measured as pmol/min/mg/protein,,CHEMBL620139,U,0,,,Homo sapiens,9606.0,BAO_0000019,22224,,4895,,5486,A,,
Autocuration,,1,,,In vitro metabolic stability determined after 30 min of incubation in human hepatic microsomes,Microsomes,CHEMBL620140,U,0,,,Homo sapiens,9606.0,BAO_0000251,22224,,4896,,5600,A,,
Autocuration,,1,,,Metabolism of compound in human liver slices (male) ('+''indicates <20% largest observed peak),,CHEMBL620141,U,0,,,Homo sapiens,9606.0,BAO_0000019,22224,,4897,,14294,A,,
Autocuration,,1,,,Metabolism of compound in human liver slices (male) ('++''indicates 20-50% largest observed peak),,CHEMBL620142,U,0,,,Homo sapiens,9606.0,BAO_0000019,22224,,4898,,14294,A,,
Autocuration,,1,,,Metabolism of compound in human liver slices (male) ('++++' indicates largest observed peak),,CHEMBL620143,U,0,,,Homo sapiens,9606.0,BAO_0000019,22224,,4899,,14294,A,,
Autocuration,,1,,,Metabolism of compound in human microsomes ('+''indicates <20% largest observed peak),Microsomes,CHEMBL620144,U,0,,,Homo sapiens,9606.0,BAO_0000251,22224,,4900,,14294,A,,
Autocuration,,1,,,Metabolism of compound in human microsomes ('++++' indicates largest observed peak),Microsomes,CHEMBL620145,U,0,,,Homo sapiens,9606.0,BAO_0000251,22224,,4901,,14294,A,,
Autocuration,,1,,,Metabolism of compound in human microsomes; Trace,Microsomes,CHEMBL620146,U,0,,,Homo sapiens,9606.0,BAO_0000251,22224,,4902,,14294,A,,
Autocuration,,1,,,Percent of compound remaining after 120 min of Metabolization upon incubation with human liver microsomes,Microsomes,CHEMBL620147,U,0,,,Homo sapiens,9606.0,BAO_0000251,22224,,4903,Liver,6260,A,,2107.0
Autocuration,,1,,,Percent metabolized in an in vitro human liver microsomal incubation assay after 60 min,Microsomes,CHEMBL620148,U,0,,,Homo sapiens,9606.0,BAO_0000251,22224,,4904,,6187,A,,
Autocuration,,1,,,In vitro metabolic potential in human liver microsomes,Microsomes,CHEMBL620149,U,0,,,Homo sapiens,9606.0,BAO_0000251,22224,,4905,Liver,6251,A,,2107.0
Autocuration,,1,,,Metabolism by recombinant human NAD(P)H:quinone oxidoreductase (NQO1) was evaluated,,CHEMBL876412,U,0,,,Homo sapiens,9606.0,BAO_0000019,22224,,4906,,3246,A,,
Autocuration,,1,,,Tested for human plasma protein binding of the compound; Not tested,,CHEMBL619352,U,0,,,Homo sapiens,9606.0,BAO_0000019,22224,,4907,,17313,A,,
Autocuration,,1,,,Compound was tested for percent protein binding (PB) in human,,CHEMBL619353,U,0,,,Homo sapiens,9606.0,BAO_0000019,22224,,4908,,6227,A,,
Autocuration,,1,,,Protein binding in human plasma,,CHEMBL619354,U,0,,,Homo sapiens,9606.0,BAO_0000019,22224,,4909,Plasma,5530,A,,1969.0
Autocuration,,1,,,Permeability coefficient (B to A) in Caco-2 cell,,CHEMBL619355,U,0,,,Homo sapiens,9606.0,BAO_0000019,22224,,4910,,6108,A,,
Autocuration,,1,,,Permeability directional ratio (PB-A/PA-B) in Caco-2 cell,,CHEMBL619356,U,0,,,Homo sapiens,9606.0,BAO_0000019,22224,,4911,,6108,A,,
Autocuration,,1,,,Apparent permeability coefficient (Papp) was determined in human Caco-2 cell monolayer (n = 3),,CHEMBL619357,U,0,,,Homo sapiens,9606.0,BAO_0000019,22224,,4912,,2774,A,,
Autocuration,,1,,,In vitro rate of absorption observed as Caco-2 permeability in humans,,CHEMBL619358,U,0,,,Homo sapiens,9606.0,BAO_0000019,22224,,4913,,16643,A,,
Autocuration,,1,Caco-2,,Cellular permeability of compound was determined in Caco-2 cells; High,,CHEMBL619359,U,0,,495.0,Homo sapiens,9606.0,BAO_0000219,22224,,4914,,17582,A,,
Autocuration,,1,Caco-2,,Permeability in Caco-2 cells of compound,,CHEMBL619360,U,0,,495.0,Homo sapiens,9606.0,BAO_0000219,22224,,4915,,6838,A,,
Autocuration,,1,,,Permeability coefficient (A to B) in Caco-2 cell,,CHEMBL619361,U,0,,,Homo sapiens,9606.0,BAO_0000019,22224,,4916,,6108,A,,
Autocuration,,1,,,Permeability coefficient (B to A) in Caco-2 cell,,CHEMBL619362,U,0,,,Homo sapiens,9606.0,BAO_0000019,22224,,4917,,6108,A,,
Autocuration,,1,,,Permeability coefficient (Papp) (Caco-2 cell monolayer),,CHEMBL619363,U,0,,,Homo sapiens,9606.0,BAO_0000019,22224,,4918,,6108,A,,
Autocuration,,1,,,Compound was measured for binding rate for human serum at a carbapenem concentration of 10 ug/mL,,CHEMBL618942,U,0,,,Homo sapiens,9606.0,BAO_0000019,22224,,4919,,2146,A,,
Autocuration,,1,,,Compound was tested for protein binding in human plasma,,CHEMBL618943,U,0,,,Homo sapiens,9606.0,BAO_0000019,22224,,4920,,4514,A,,
Autocuration,,1,,,Transcellular permeability of the [(PA-B+PB-A)/2)] compound was determined in Caco-2 cell,,CHEMBL618944,U,0,,,Homo sapiens,9606.0,BAO_0000019,22224,,4921,,6108,A,,
Autocuration,,1,,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 3,,CHEMBL618945,U,0,,,Homo sapiens,9606.0,BAO_0000019,22224,,4922,Urine,7766,A,,1088.0
Intermediate,,1,,,In vivo Tmax was determined in murine septicemia at dose of 50 mg/kg,,CHEMBL618946,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4923,,5969,A,In vivo,
Intermediate,,1,,,Maximum time was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),,CHEMBL876413,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4924,,3277,A,In vivo,
Intermediate,,1,,,Tested for Tmax value at the dose of 10 mg/kg when administered perorally in mouse,,CHEMBL618947,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4925,,3802,A,In vivo,
Intermediate,,1,,,Time taken to reach maximum concentration in plasma upon oral administration in mouse,,CHEMBL618948,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4926,Plasma,2862,A,In vivo,1969.0
Intermediate,,1,,,Time to reach maximum plasma concentration was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,CHEMBL618949,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4927,Plasma,6348,A,In vivo,1969.0
Intermediate,,1,,,Tmax after intraperitoneal administration in mice at 23 uM/kg,,CHEMBL618950,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4928,,17764,F,In vivo,
Intermediate,,1,,,Tmax after oral administration at 30 mg/kg in ICR mouse,,CHEMBL618951,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4929,,5781,A,In vivo,
Intermediate,,1,,,Tmax after peroral administration in mice at 2.4 uM/kg,,CHEMBL618952,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4930,,17764,A,In vivo,
Intermediate,,1,,,Tmax at a single subcutaneous administration of 40 mg/kg in mice,,CHEMBL618953,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4931,,4066,A,In vivo,
Intermediate,,1,,,Tmax in brain of mice at the oral dose of 50 mg/kg,,CHEMBL618954,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4932,Brain,17641,A,In vivo,955.0
Intermediate,,1,,,Tmax in kidney of mice at the oral dose of 50 mg/kg,,CHEMBL618955,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4933,Kidney,17641,A,In vivo,2113.0
Intermediate,,1,,,Tmax in liver of mice at the oral dose of 50 mg/kg,,CHEMBL618956,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4934,Liver,17641,A,In vivo,2107.0
Intermediate,,1,,,Tmax in lungs of mice at the oral dose of 50 mg/kg,,CHEMBL618957,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4935,Lung,17641,A,In vivo,2048.0
Intermediate,,1,,,Tmax in mice at 18 uM/kg i.p. administration,,CHEMBL618958,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4936,,17764,F,In vivo,
Intermediate,,1,,,Tmax in mice at 23 uM/kg i.v. administration,,CHEMBL618959,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4937,,17764,F,In vivo,
Intermediate,,1,,,Tmax in mice at 25 uM/kg i.p. administration,,CHEMBL618960,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4938,,17764,F,In vivo,
Intermediate,,1,,,Tmax in mice at 26 uM/kg i.p. administration,,CHEMBL876723,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4939,,17764,F,In vivo,
Intermediate,,1,,,Tmax in spleen of mice at the oral dose of 50 mg/kg,,CHEMBL618961,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4940,Spleen,17641,A,In vivo,2106.0
Intermediate,,1,,,Tmax value at a dose of 10 mg/kg intravenous administration in mice.,,CHEMBL618962,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4941,,16597,A,In vivo,
Intermediate,,1,,,Tmax value at a dose of 10 mg/kg peroral administration in mice.,,CHEMBL618963,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4942,,16597,A,In vivo,
Intermediate,,1,,,Tmax value in IRC mice,,CHEMBL618964,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4943,,5951,A,,
Intermediate,,1,,,Tmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,,CHEMBL618965,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4944,,5506,A,In vivo,
Intermediate,,1,,,Tmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,,CHEMBL618966,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4945,,5506,A,In vivo,
Intermediate,,1,,,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg ( 0-24 hr ),,CHEMBL618967,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4946,Urine,429,A,,1088.0
Intermediate,,1,,,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg (0-24 hr),,CHEMBL618968,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4947,Urine,429,A,,1088.0
Intermediate,,1,,,Urinary recovery by disk method using Streptococcus pyogenes (0-24 h),,CHEMBL618969,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4948,Urine,4066,A,,1088.0
Intermediate,,1,,,The first compartment constitutes the majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,,CHEMBL618970,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4949,,17734,A,,
Intermediate,,1,,,The second majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,,CHEMBL618971,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4950,,17734,A,,
Intermediate,,1,,,Terminal phase volume of distribution was measured in mouse after an iv dose of 1 mg/kg,,CHEMBL618972,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4951,,6062,A,In vivo,
Intermediate,,1,,,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 100 mg/kg,,CHEMBL618973,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4952,,5969,A,In vivo,
Intermediate,,1,,,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg,,CHEMBL618974,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4953,,5969,A,In vivo,
Intermediate,,1,,,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,,CHEMBL618975,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4954,,5969,A,In vivo,
Intermediate,,1,,,Vd in mice,,CHEMBL618976,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4955,,5980,A,In vivo,
Intermediate,,1,,,Volume of distribution in mouse,,CHEMBL618977,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4956,,17592,A,In vivo,
Intermediate,,1,,,Volume of distribution was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,CHEMBL876724,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4957,,6348,A,In vivo,
Intermediate,,1,,,Volume of distribution of compound in plasma was determined at 24 mg/Kg,,CHEMBL618978,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4958,,17753,A,In vivo,
Intermediate,,1,,,Volume of distribution of compound in plasma was determined at 40 mg/Kg,,CHEMBL618979,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4959,,17753,A,In vivo,
Intermediate,,1,,,Volume of distribution of compound in plasma was determined at 5 mg/Kg,,CHEMBL618980,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4960,,17753,A,In vivo,
Intermediate,,1,,,Pharmacokinetic property (vdss) was measured in mouse,,CHEMBL618981,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4961,,4239,A,In vivo,
Intermediate,,1,,,Value distribution upon iv administration in mouse,,CHEMBL618982,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4962,,2862,A,In vivo,
Intermediate,,1,,,Volume of distribution after intraperitoneal administration of 100 mg/kg in mice,,CHEMBL620150,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4963,,17734,A,In vivo,
Intermediate,,1,,,Volume of distribution was evaluated in mice after intravenous administration,,CHEMBL620151,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4964,,2675,A,In vivo,
Intermediate,,1,,,Volume of distribution was evaluated in mice after oral administration,,CHEMBL620152,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4965,,2675,A,In vivo,
Intermediate,,1,,,Steady state volume of distribution of compound in mouse blood following i.v. administration of 10 mg/kg,,CHEMBL620153,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4966,,17837,A,In vivo,
Intermediate,,1,,,Steady state volume of distribution was determined in mice,,CHEMBL876395,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4967,,5727,A,In vivo,
Intermediate,,1,,,Volume distribution (steady state) of compound was determined in mouse,,CHEMBL620154,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4968,,17852,A,In vivo,
Intermediate,,1,,,Volume of solubility in solution after intravenous administration in mice at 24 uM/kg,,CHEMBL620155,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4969,,17764,A,In vivo,
Intermediate,,1,,,Vss value at a dose of 10 mg/kg intravenous administration in mice.,,CHEMBL620156,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4970,,16597,A,In vivo,
Intermediate,,1,,,Volume of distribution was measured in mouse after an iv dose of 1 mg/kg,,CHEMBL620157,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4971,,6062,A,In vivo,
Intermediate,,1,,,Biodistribution of compound (oxidized form) in in kidney tissue,,CHEMBL620158,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4972,Kidney,16438,A,In vivo,2113.0
Intermediate,,1,,,Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip administration in DMSO solution,,CHEMBL620159,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4973,Blood,16438,A,In vivo,178.0
Intermediate,,1,,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",,CHEMBL620160,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4974,Blood,16438,A,In vivo,178.0
Intermediate,,1,,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,CHEMBL620161,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,4975,Blood,16438,A,In vivo,178.0
Intermediate,,1,A-427,,Evaluated for the inhibitory concentration required to cause growth inhibition of A427Mer- cell line of lung using the MTT Cytotoxicity Assay,,CHEMBL620162,N,1,,797.0,Homo sapiens,9606.0,BAO_0000219,80019,,4976,,10708,F,,
Expert,,1,A-431,,Inhibition of A431 human squamous cell carcinoma cell proliferation,,CHEMBL620163,N,1,,500.0,Homo sapiens,9606.0,BAO_0000219,80852,,4977,,16597,F,,
Expert,,1,A-431,,Inhibition of cell growth of human epidermoid carcinoma xenograft (A431) model using cell based assay,,CHEMBL620833,N,1,,500.0,Homo sapiens,9606.0,BAO_0000219,80852,,4978,,16062,F,,
Expert,,1,A-431,,Inhibition of human epidermoid carcinoma xenograft (A431) tumor growth,,CHEMBL876396,N,1,,500.0,Homo sapiens,9606.0,BAO_0000219,80852,,4979,,16062,F,,
Expert,,1,A-431,,Concentration required to inhibit growth of human carcinoma epidermoid (A431) cell line,,CHEMBL620834,N,1,,500.0,Homo sapiens,9606.0,BAO_0000219,80852,,4980,,16958,F,,
Expert,,1,A-431,,Inhibition of A431 human carcinoma cell proliferation,,CHEMBL620835,N,1,,500.0,Homo sapiens,9606.0,BAO_0000219,80852,,4981,,6700,F,,
Expert,,1,A-431,,In vitro inhibition of A431 (human carcinoma) cell basal growth.,,CHEMBL620836,N,1,,500.0,Homo sapiens,9606.0,BAO_0000219,80852,,4982,,17226,F,,
Intermediate,,1,A-431,,Inhibitory concentration of compound against growth of human A431 cell line; Resistant,,CHEMBL620837,N,1,,500.0,Homo sapiens,9606.0,BAO_0000219,80852,,4983,,6828,F,,
Intermediate,,1,A-431,,In vitro cytotoxicity against epidermoid carcinoma cell line,,CHEMBL621017,N,1,,500.0,Homo sapiens,9606.0,BAO_0000219,80852,,4984,,12314,F,,
Expert,,1,A-431,,"In vivo efficacy following oral administration in nude mouse tumor model, xenograft A431 cells expressing EGF-R",,CHEMBL621018,D,9,,500.0,Homo sapiens,9606.0,BAO_0000218,9,,4985,,13412,F,,
Intermediate,,1,A-431,,Antiproliferative activity of compound was measured on human tumor cell line A431.,,CHEMBL621019,N,1,,500.0,Homo sapiens,9606.0,BAO_0000219,80852,,4986,,13299,F,,
Intermediate,,1,A-431,,Antiproliferative effect of compound on A431 cell line expressing mutant p53,,CHEMBL621020,N,1,,500.0,Homo sapiens,9606.0,BAO_0000219,80852,,4987,,17420,F,,
Intermediate,,1,A-431,,Compound was evaluated for cell growth inhibition against A 431 cell line by irradiation in the presence of examined compound,,CHEMBL621021,N,1,,500.0,Homo sapiens,9606.0,BAO_0000219,80852,,4988,,13678,F,,
Expert,,1,A-431,,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells.,,CHEMBL621022,H,8,,500.0,,,BAO_0000219,9,,4989,,14171,F,,
Expert,,1,A-431,,Tested for antiproliferative activity against human A431 cells,,CHEMBL621023,N,1,,500.0,Homo sapiens,9606.0,BAO_0000219,80852,,4990,,6333,F,,
Expert,,1,A-431,,Inhibition of epidermal growth factor receptor (EGF-R) autophosphorylation in A431 cells,,CHEMBL621024,D,9,,500.0,Homo sapiens,9606.0,BAO_0000219,9,,4991,,2356,F,,
Expert,,1,A-431,,Concentration needed to inhibit 50% growth of the human A431 (epidermoid carcinoma) cell lines,,CHEMBL621025,N,1,,500.0,Homo sapiens,9606.0,BAO_0000219,80852,,4992,,15578,F,,
Expert,,1,A-431,,Inhibition of A431 cell proliferation,,CHEMBL621026,N,1,,500.0,Homo sapiens,9606.0,BAO_0000219,80852,,4993,,5126,F,,
Expert,,1,A-431,,Cytotoxic effect on A431 human epidermoid carcinoma cells,,CHEMBL621027,N,1,,500.0,Homo sapiens,9606.0,BAO_0000219,80852,,4994,,6844,F,,
Expert,,1,A-431,,Cytotoxic effect on A431 human epidermoid carcinoma cells (No response to 1 mM),,CHEMBL876397,N,1,,500.0,Homo sapiens,9606.0,BAO_0000219,80852,,4995,,6844,F,,
Intermediate,,1,A-431,,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line,,CHEMBL883797,N,1,,500.0,Homo sapiens,9606.0,BAO_0000219,80852,,4996,,4925,F,,
Intermediate,,1,A-431,,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line; NT=Not tested,,CHEMBL621028,N,1,,500.0,Homo sapiens,9606.0,BAO_0000219,80852,,4997,,4925,F,,
Intermediate,,1,A-431,,In vitro Growth Inhibitory activity against A431 Human vulva cancer cell line,,CHEMBL621029,N,1,,500.0,Homo sapiens,9606.0,BAO_0000219,80852,,4998,,13978,F,,
Intermediate,,1,A-431,,In vitro cytotoxicity of compound against human A431 (epidermoid) cancer cell line after 72 hr of drug exposure,,CHEMBL621030,N,1,,500.0,Homo sapiens,9606.0,BAO_0000219,80852,,4999,,16786,F,,
Expert,,1,A-431,,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells expressing EGF-R,,CHEMBL621147,H,8,,500.0,,,BAO_0000219,9,,5000,,13412,F,,
Intermediate,,1,A-431,,In vivo antiproliferative activity against A431 cell line,,CHEMBL621148,N,1,,500.0,Homo sapiens,9606.0,BAO_0000218,80852,,5001,,17824,F,,
Expert,,1,A-431,,Inhibition of EGF-dependent autophosphorylation of EGF-R in human A431 cells,,CHEMBL621149,D,9,,500.0,Homo sapiens,9606.0,BAO_0000219,9,,5002,,12751,F,,
Expert,,1,A-431,,Inhibition of A431 human epidermoid carcinoma cell proliferation,,CHEMBL621150,N,1,,500.0,Homo sapiens,9606.0,BAO_0000219,80852,,5003,,12380,F,,
Expert,,1,A-431,,Inhibition of autophosphorylation of human epidermal growth factor-receptor (EGF-R) expressed in A431 cells,,CHEMBL621151,D,9,,500.0,Homo sapiens,9606.0,BAO_0000219,9,,5004,,4959,F,,
Intermediate,,1,A-431,,Inhibitory effect on nonphospho-Src after EGF (100 uM) stimulation of A431 cells (control=178),,CHEMBL621152,N,1,,500.0,Homo sapiens,9606.0,BAO_0000219,80852,,5005,,6333,F,,
Intermediate,,1,A-431,,Inhibitory effect on phospho-Src (Tyr416) after EGF (100 uM) stimulation of A431 cells (38),,CHEMBL621153,N,1,,500.0,Homo sapiens,9606.0,BAO_0000219,80852,,5006,,6333,F,,
Intermediate,,1,A-431,,Inhibitory effect on phospho-Src/nonphospho after EGF (100 uM) stimulation of A431 cells (21),,CHEMBL884000,N,1,,500.0,Homo sapiens,9606.0,BAO_0000219,80852,,5007,,6333,F,,
Expert,,1,,,Inhibition of EGFR overexpressing A431 cell proliferation,,CHEMBL621154,D,9,,,Homo sapiens,9606.0,BAO_0000019,9,,5008,,5296,F,,
Expert,,1,A-431,,Inhibition of A431 cell proliferation,,CHEMBL621155,N,1,,500.0,Homo sapiens,9606.0,BAO_0000219,80852,,5009,,12624,F,,
Expert,,1,A-431,,No inhibition of EGFR phosphorylation in A431 cells 8 hour after washing cells free of the inhibitor,,CHEMBL621156,D,9,,500.0,Homo sapiens,9606.0,BAO_0000219,9,,5010,,14926,F,,
Expert,,1,A-431,,"Partial inhibition of EGFR phosphorylation in A431 cells, 8 hour after washing cells free of the inhibitor",,CHEMBL621157,D,9,,500.0,Homo sapiens,9606.0,BAO_0000219,9,,5011,,14926,F,,
Expert,,1,A-431,,Irreversible inhibition of ATP binding site of EGFR (lack of phosphorylated EGFR) in A431 cells 8 hour after washing cells free of the inhibitor),,CHEMBL621158,H,8,,500.0,,,BAO_0000219,9,,5012,,14926,F,,
Intermediate,,1,A-431,,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,,CHEMBL621159,N,1,,500.0,Homo sapiens,9606.0,BAO_0000219,80852,,5013,,15144,F,,
Intermediate,,1,A-431,,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,,CHEMBL621160,N,1,,500.0,Homo sapiens,9606.0,BAO_0000219,80852,,5014,,15144,F,,
Intermediate,,1,A-431,,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration at 2 uM after 48 h; Did not affect the viability,,CHEMBL621161,N,1,,500.0,Homo sapiens,9606.0,BAO_0000219,80852,,5015,,5245,F,,
Intermediate,,1,A-431,,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration in the range of 1-10 uM after 48 h; Did not affect the viability,,CHEMBL621162,N,1,,500.0,Homo sapiens,9606.0,BAO_0000219,80852,,5016,,5245,F,,
Intermediate,,1,A-431,,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,,CHEMBL621163,N,1,,500.0,Homo sapiens,9606.0,BAO_0000219,80852,,5017,,5245,F,,
Intermediate,,1,A-431,,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 0.01 uM after 48 h; Cell death,,CHEMBL621164,N,1,,500.0,Homo sapiens,9606.0,BAO_0000219,80852,,5018,,5245,F,,
Intermediate,,1,A-431,,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 2 uM after 48 h; Cell death,,CHEMBL621165,N,1,,500.0,Homo sapiens,9606.0,BAO_0000219,80852,,5019,,5245,F,,
Autocuration,,1,,,Half-life period in cynomolgus monkey,,CHEMBL619159,U,0,,,Cercopithecidae,9527.0,BAO_0000019,22224,,5020,,5922,A,,
Autocuration,,1,,,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in monkey plasma",,CHEMBL619160,U,0,,,Cercopithecidae,9527.0,BAO_0000366,22224,,5021,Plasma,1116,A,In vitro,1969.0
Autocuration,,1,,,Longer half-life in monkey (i.v.) at 0.5 mpk,,CHEMBL619161,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,5022,,17853,A,In vivo,
Autocuration,,1,,,Plasma half life in monkey,,CHEMBL619162,U,0,,,Cercopithecidae,9527.0,BAO_0000366,22224,,5023,Plasma,993,A,,1969.0
Autocuration,,1,,,Plasma half-life in rhesus monkey,,CHEMBL619163,U,0,,,Cercopithecidae,9527.0,BAO_0000366,22224,,5024,Plasma,4514,A,,1969.0
Autocuration,,1,,,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),,CHEMBL619164,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,5025,Plasma,5334,A,In vivo,1969.0
Autocuration,,1,,,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),,CHEMBL619320,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,5026,Plasma,5334,A,In vivo,1969.0
Autocuration,,1,,,Tested for half life upon iv administration to african green monkey,,CHEMBL619321,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,5027,,4578,A,In vivo,
Autocuration,,1,,,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female cynomolgus monkey,,CHEMBL873336,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,5028,,2661,A,In vivo,
Autocuration,,1,,,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means Not applicable,,CHEMBL619322,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,5029,,5355,A,In vivo,
Autocuration,,1,,,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means not applicable,,CHEMBL619323,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,5030,,5355,A,In vivo,
Autocuration,,1,,,The time for peak concentration value after oral administration in cynomolgus monkeys,,CHEMBL619324,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,5031,,5355,A,In vivo,
Autocuration,,1,,,Percentage of tracer or metabolite (CO2) in baboon plasma at 10 min after injection of the compound,,CHEMBL619325,U,0,,,Cercopithecidae,9527.0,BAO_0000019,22224,,5032,,11271,A,,
Autocuration,,1,,,Percentage of tracer or metabolite (CO2) in baboon plasma at 1 min after injection of the compound,,CHEMBL876411,U,0,,,Cercopithecidae,9527.0,BAO_0000019,22224,,5033,,11271,A,,
Autocuration,,1,,,Percentage of tracer or metabolite (CO2) in baboon plasma at 30 min after injection of the compound,,CHEMBL619326,U,0,,,Cercopithecidae,9527.0,BAO_0000019,22224,,5034,,11271,A,,
Autocuration,,1,,,Percentage of tracer or metabolite (CO2) in baboon plasma at 5 min after injection of the compound,,CHEMBL619327,U,0,,,Cercopithecidae,9527.0,BAO_0000019,22224,,5035,,11271,A,,
Autocuration,,1,,,Percentage of tracer or metabolite(EME) in baboon plasma at 10 min after injection of the compound,,CHEMBL619328,U,0,,,Cercopithecidae,9527.0,BAO_0000019,22224,,5036,,11271,A,,
Autocuration,,1,,,Percentage of tracer or metabolite(EME) in baboon plasma at 1 min after injection of the compound,,CHEMBL619329,U,0,,,Cercopithecidae,9527.0,BAO_0000019,22224,,5037,,11271,A,,
Autocuration,,1,,,Percentage of tracer or metabolite(EME) in baboon plasma at 30 min after injection of the compound,,CHEMBL619330,U,0,,,Cercopithecidae,9527.0,BAO_0000019,22224,,5038,,11271,A,,
Autocuration,,1,,,Percentage of tracer or metabolite(EME) in baboon plasma at 5 min after injection of the compound,,CHEMBL619331,U,0,,,Cercopithecidae,9527.0,BAO_0000019,22224,,5039,,11271,A,,
Autocuration,,1,,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 10 min after injection of the compound,,CHEMBL619332,U,0,,,Cercopithecidae,9527.0,BAO_0000019,22224,,5040,,11271,A,,
Autocuration,,1,,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 1 min after injection of the compound,,CHEMBL619333,U,0,,,Cercopithecidae,9527.0,BAO_0000019,22224,,5041,,11271,A,,
Autocuration,,1,,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 30 min after injection of the compound,,CHEMBL619334,U,0,,,Cercopithecidae,9527.0,BAO_0000019,22224,,5042,,11271,A,,
Autocuration,,1,,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 5 min after injection of the compound,,CHEMBL619335,U,0,,,Cercopithecidae,9527.0,BAO_0000019,22224,,5043,,11271,A,,
Autocuration,,1,,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 10 min after injection of the compound,,CHEMBL619336,U,0,,,Cercopithecidae,9527.0,BAO_0000019,22224,,5044,,11271,A,,
Autocuration,,1,,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 1 min after injection of the compound,,CHEMBL619337,U,0,,,Cercopithecidae,9527.0,BAO_0000019,22224,,5045,,11271,A,,
Autocuration,,1,,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 30 min after injection of the compound,,CHEMBL619338,U,0,,,Cercopithecidae,9527.0,BAO_0000019,22224,,5046,,11271,A,,
Autocuration,,1,,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 5 min after injection of the compound,,CHEMBL619339,U,0,,,Cercopithecidae,9527.0,BAO_0000019,22224,,5047,,11271,A,,
Intermediate,,1,,,Bioavailability in rat (cannulated) (dose 2 mg/kg),,CHEMBL619340,N,1,,,Rattus norvegicus,10116.0,BAO_0000218,50597,,5048,,5809,A,In vivo,
Intermediate,,1,,,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,,CHEMBL873496,N,1,,,Rattus norvegicus,10116.0,BAO_0000218,50597,,5049,Plasma,17720,A,In vivo,1969.0
Intermediate,,1,,,AUC value in rat after IV administration at a dose of 10 mg/kg,,CHEMBL619341,N,1,,,Rattus norvegicus,10116.0,BAO_0000218,50597,,5050,Plasma,3546,A,,1969.0
Intermediate,,1,,,AUC value in rat after oral administration at a dose of 10 mg/kg,,CHEMBL619342,N,1,,,Rattus norvegicus,10116.0,BAO_0000218,50597,,5051,Plasma,3546,A,,1969.0
Intermediate,,1,,,Cmax value in rat after oral administration at a dose of 10 mg/kg,,CHEMBL619343,N,1,,,Rattus norvegicus,10116.0,BAO_0000218,50597,,5052,,3546,A,In vivo,
Intermediate,,1,,,Bioavailability in rat after oral administration at a dose of 10 mg/kg,,CHEMBL619344,N,1,,,Rattus norvegicus,10116.0,BAO_0000218,50597,,5053,,3546,A,In vivo,
Intermediate,,1,,,Tmax value in rat after oral administration at a dose of 10 mg/kg,,CHEMBL619345,N,1,,,Rattus norvegicus,10116.0,BAO_0000218,50597,,5054,,3546,A,In vivo,
Intermediate,,1,,,Vc value in rat after IV administration at a dose of 10 mg/kg,,CHEMBL619346,N,1,,,Rattus norvegicus,10116.0,BAO_0000218,50597,,5055,,3546,A,,
Intermediate,,1,,,Half life period in rat after IV administration at a dose of 10 mg/kg,,CHEMBL619347,N,1,,,Rattus norvegicus,10116.0,BAO_0000218,50597,,5056,,3546,A,In vivo,
Autocuration,,1,,,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,,CHEMBL619348,U,0,,,Papio hamadryas,9557.0,BAO_0000019,22224,,5057,,10625,A,,
Autocuration,,1,,,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 0.5 min after injection in baboon; (Range = 0.08-0.11),,CHEMBL619349,U,0,,,Papio hamadryas,9557.0,BAO_0000019,22224,,5058,,10625,A,,
Autocuration,,1,,,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 1.5 min after injection in baboon; (Range = 0.08-0.11),,CHEMBL619350,U,0,,,Papio hamadryas,9557.0,BAO_0000019,22224,,5059,,10625,A,,
Autocuration,,1,,,The amount of unchanged tracer in baboon plasma was determined 1 min after injection of the carbon-11 labeled compound,,CHEMBL619351,U,0,,,Papio hamadryas,9557.0,BAO_0000019,22224,,5060,,10625,A,,
Autocuration,,1,,,The amount of unchanged tracer in baboon plasma was determined 10 min after injection of the carbon-11 labeled compound,,CHEMBL875953,U,0,,,Papio hamadryas,9557.0,BAO_0000019,22224,,5061,,10625,A,,
Autocuration,,1,,,The amount of unchanged tracer in baboon plasma was determined 30 min after injection of the carbon-11 labeled compound,,CHEMBL621716,U,0,,,Papio hamadryas,9557.0,BAO_0000019,22224,,5062,,10625,A,,
Autocuration,,1,,,The amount of unchanged tracer in baboon plasma was determined 60 min after injection of the carbon-11 labeled compound,,CHEMBL621717,U,0,,,Papio hamadryas,9557.0,BAO_0000019,22224,,5063,,10625,A,,
Autocuration,,1,,,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,,CHEMBL621718,U,0,,,Papio hamadryas,9557.0,BAO_0000019,22224,,5064,,10625,A,,
Autocuration,,1,,,Area under curve after 1 mpk peroral administration to beagles,,CHEMBL621719,U,0,,,beagle,9615.0,BAO_0000019,22224,,5065,,3510,A,,
Autocuration,,1,,,Area under curve after 2 mpk peroral administration to beagles,,CHEMBL621720,U,0,,,beagle,9615.0,BAO_0000019,22224,,5066,,3510,A,,
Autocuration,,1,,,Cmax value after 1 mpk peroral administration to beagles,,CHEMBL621721,U,0,,,beagle,9615.0,BAO_0000218,22224,,5067,,3510,A,In vivo,
Autocuration,,1,,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 7,,CHEMBL621722,U,0,,,Homo sapiens,9606.0,BAO_0000019,22224,,5068,Urine,7766,A,,1088.0
Autocuration,,1,,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 6,,CHEMBL621723,U,0,,,Homo sapiens,9606.0,BAO_0000019,22224,,5069,Urine,7766,A,,1088.0
Autocuration,,1,,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 8,,CHEMBL621724,U,0,,,Homo sapiens,9606.0,BAO_0000019,22224,,5070,Urine,7766,A,,1088.0
Autocuration,,1,,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1500 mL of urine tested on day 9,,CHEMBL623443,U,0,,,Homo sapiens,9606.0,BAO_0000019,22224,,5071,Urine,7766,A,,1088.0
Autocuration,,1,,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1600 mL of urine tested on day 10,,CHEMBL623444,U,0,,,Homo sapiens,9606.0,BAO_0000019,22224,,5072,Urine,7766,A,,1088.0
Autocuration,,1,,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1700 mL of urine tested on day 5,,CHEMBL623445,U,0,,,Homo sapiens,9606.0,BAO_0000019,22224,,5073,Urine,7766,A,,1088.0
Autocuration,,1,,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 2310 mL of urine tested on day 4,,CHEMBL623446,U,0,,,Homo sapiens,9606.0,BAO_0000019,22224,,5074,Urine,7766,A,,1088.0
Autocuration,,1,,,Metabolic stability observed at 30 min after administration in human liver microsomes,Microsomes,CHEMBL623447,U,0,,,Homo sapiens,9606.0,BAO_0000251,22224,,5075,Liver,16643,A,,2107.0
Autocuration,,1,,,Percent recovery of 100 ug/mL compound after administration in cirrhotic patients,,CHEMBL623448,U,0,,,Homo sapiens,9606.0,BAO_0000019,22224,,5076,,6852,A,,
Autocuration,,1,,,Percent recovery of 10 ug/mL compound after administration in cirrhotic patients,,CHEMBL623449,U,0,,,Homo sapiens,9606.0,BAO_0000019,22224,,5077,,6852,A,,
Autocuration,,1,,,Percent recovery of 500 ug/mL compound after administration in cirrhotic patients,,CHEMBL623450,U,0,,,Homo sapiens,9606.0,BAO_0000019,22224,,5078,,6852,A,,
Autocuration,,1,,,"Compound remaining after incubation with 2 mg/mL of human liver microsomes at 37 degrees C for 30 min in a pH 7.4, 0.05 M phosphate buffer",Microsomes,CHEMBL623451,U,0,,,Homo sapiens,9606.0,BAO_0000251,22224,,5079,Liver,6567,A,,2107.0
Autocuration,,1,,,Metabolic stability (% remaining at 30 mins) in human S9.,,CHEMBL623452,U,0,,,Homo sapiens,9606.0,BAO_0000019,22224,,5080,,6570,A,,
Autocuration,,1,,,Metabolic stability determined as remaining percent after 30 min of incubation in human isolated liver S9 preparations; N/D= Not determined,,CHEMBL623453,U,0,,,Homo sapiens,9606.0,BAO_0000019,22224,,5081,,6570,A,,
Autocuration,,1,,,Percent parent compound remaining after 20 min incubation with human liver microsomes,Microsomes,CHEMBL623454,U,0,,,Homo sapiens,9606.0,BAO_0000251,22224,,5082,Liver,5237,A,,2107.0
Autocuration,,1,,,Percent parent compound remaining after 20 min incubation with human liver microsomes; ND=No data,Microsomes,CHEMBL623455,U,0,,,Homo sapiens,9606.0,BAO_0000251,22224,,5083,Liver,5237,A,,2107.0
Autocuration,,1,,,Percent parent compound remaining after 20 min incubation with human liver microsomes; No data,Microsomes,CHEMBL624371,U,0,,,Homo sapiens,9606.0,BAO_0000251,22224,,5084,Liver,5237,A,,2107.0
Autocuration,,1,,,First pass metabolism and metabolic bioavailability using human hepatic microsomes,,CHEMBL624372,U,0,,,Homo sapiens,9606.0,BAO_0000218,22224,,5085,,5202,A,,
Autocuration,,1,,,Percent compound remaining in human plasma after incubation for 60 min at 37 C.,,CHEMBL624373,U,0,,,Homo sapiens,9606.0,BAO_0000019,22224,,5086,,5481,A,,
Autocuration,,1,,,Percent remaining in human plasma after incubation for 60 min at 37 C.,,CHEMBL624374,U,0,,,Homo sapiens,9606.0,BAO_0000019,22224,,5087,,5481,A,,
Autocuration,,1,,,The percent remaining in human plasma after 30 min was determined,,CHEMBL624556,U,0,,,Homo sapiens,9606.0,BAO_0000019,22224,,5088,,3956,A,,
Autocuration,,1,,,Conversion rate of the prodrug in human plasma,,CHEMBL624557,U,0,,,Homo sapiens,9606.0,BAO_0000366,22224,,5089,Plasma,5074,A,,1969.0
Autocuration,,1,,,Conversion rate of the prodrug in human plasma; ND means no data,,CHEMBL624558,U,0,,,Homo sapiens,9606.0,BAO_0000366,22224,,5090,Plasma,5074,A,,1969.0
Autocuration,,1,,,Half life of compound was determined in human blood,,CHEMBL624559,U,0,,,Homo sapiens,9606.0,BAO_0000221,22224,,5091,Blood,4727,A,,178.0
Autocuration,,1,,,Half life of compound was determined in man with once daily dosing,,CHEMBL624560,U,0,,,Homo sapiens,9606.0,BAO_0000019,22224,,5092,,5965,A,,
Autocuration,,1,,,Half life in human microsomes,Microsomes,CHEMBL624561,U,0,,,Homo sapiens,9606.0,BAO_0000251,22224,,5093,,5732,A,In vitro,
Autocuration,,1,,,Half life in human plasma,,CHEMBL624562,U,0,,,Homo sapiens,9606.0,BAO_0000366,22224,,5094,Plasma,5819,A,,1969.0
Autocuration,,1,,,Half life in human plasma; Not detected,,CHEMBL624563,U,0,,,Homo sapiens,9606.0,BAO_0000366,22224,,5095,Plasma,5819,A,,1969.0
Autocuration,,1,,,Half life period was evaluated against man at a dose of 10 mg/kg after po administration,,CHEMBL624564,U,0,,,Homo sapiens,9606.0,BAO_0000218,22224,,5096,,1916,A,In vivo,
Autocuration,,1,,,Half-life for oxidative metabolic stability was determined using rat liver microsomes,Microsomes,CHEMBL624565,U,0,,,Homo sapiens,9606.0,BAO_0000251,22224,,5097,Liver,6597,A,In vitro,2107.0
Autocuration,,1,,,Half-life in human plasma,,CHEMBL875152,U,0,,,Homo sapiens,9606.0,BAO_0000366,22224,,5098,Plasma,5229,A,,1969.0
Autocuration,,1,,,Half-life of the parent prodrug in plasma,,CHEMBL624566,U,0,,,Homo sapiens,9606.0,BAO_0000366,22224,,5099,Plasma,5229,A,,1969.0
Autocuration,,1,,,In vitro half life in human plasma was determined,,CHEMBL873805,U,0,,,Homo sapiens,9606.0,BAO_0000366,22224,,5100,Plasma,2192,A,In vitro,1969.0
Autocuration,,1,,,The compound was tested In Vitro for half life in human liver microsomes.,Microsomes,CHEMBL624567,U,0,,,Homo sapiens,9606.0,BAO_0000251,22224,,5101,Liver,3032,A,In vitro,2107.0
Autocuration,,1,,,Maximum time was evaluated against man at a dose of 10 mg/kg after po administration,,CHEMBL624568,U,0,,,Homo sapiens,9606.0,BAO_0000218,22224,,5102,,1916,A,In vivo,
Autocuration,,1,,,Observed volume of distribution,,CHEMBL624569,U,0,,,Homo sapiens,9606.0,BAO_0000218,22224,,5103,,17716,A,In vivo,
Autocuration,,1,,,Oral bioavailability in human,,CHEMBL624570,U,0,,,Homo sapiens,9606.0,BAO_0000218,22224,,5104,,15778,A,In vivo,
Autocuration,,1,,,Tested for human plasma protein binding of the compound,,CHEMBL624571,U,0,,,Homo sapiens,9606.0,BAO_0000019,22224,,5105,,17313,A,,
Autocuration,,1,,,"First order rate constant, k was determined in human plasma",,CHEMBL624572,U,0,,,Homo sapiens,9606.0,BAO_0000019,22224,,5106,,4231,A,,
Autocuration,,1,,,Observed rate constant in 80% human plasma at 37 degree Centigrade,,CHEMBL624573,U,0,,,Homo sapiens,9606.0,BAO_0000019,22224,,5107,,4755,A,,
Autocuration,,1,,,Observed rate constant in 80% human plasma at 37 degree Centigrade,,CHEMBL875153,U,0,,,Homo sapiens,9606.0,BAO_0000019,22224,,5108,,4755,A,,
Autocuration,,1,,,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,Microsomes,CHEMBL624574,U,0,,,Homo sapiens,9606.0,BAO_0000251,22224,,5109,Liver,16907,A,,2107.0
Autocuration,,1,,,The compound was tested for the plasma binding in human,,CHEMBL624575,U,0,,,Homo sapiens,9606.0,BAO_0000019,22224,,5110,,10839,A,,
Autocuration,,1,,,Plasma protein binding (human),,CHEMBL624576,U,0,,,Homo sapiens,9606.0,BAO_0000019,22224,,5111,,10839,A,,
Autocuration,,1,,,Compound was evaluated for half-life in human liver microsomes,Microsomes,CHEMBL624577,U,0,,,Homo sapiens,9606.0,BAO_0000251,22224,,5112,Liver,3199,A,In vitro,2107.0
Autocuration,,1,,,Half life measured in vitro for its stability in human blood,,CHEMBL624578,U,0,,,Homo sapiens,9606.0,BAO_0000221,22224,,5113,Blood,1345,A,In vitro,178.0
Autocuration,,1,,,Half life in human serum,,CHEMBL622796,U,0,,,Homo sapiens,9606.0,BAO_0000019,22224,,5114,Serum,4297,A,,1977.0
Autocuration,,1,,,Half life in human serum; ND=not determined,,CHEMBL622797,U,0,,,Homo sapiens,9606.0,BAO_0000019,22224,,5115,Serum,4297,A,,1977.0
Autocuration,,1,,,Half life were determined in CEM-SS cell extract in decomposition step 1,,CHEMBL622798,U,0,,,Homo sapiens,9606.0,BAO_0000019,22224,,5116,,4297,A,,
Autocuration,,1,,,Half life were determined in CEM-SS cell extract in decomposition step 2,,CHEMBL622799,U,0,,,Homo sapiens,9606.0,BAO_0000019,22224,,5117,,4297,A,,
Autocuration,,1,,,Half life of the in human plasma,,CHEMBL622800,U,0,,,Homo sapiens,9606.0,BAO_0000366,22224,,5118,Plasma,4231,A,,1969.0
Autocuration,,1,,,Half life period in human hepatic S9 fraction was determined,S9,CHEMBL622801,U,0,,,Homo sapiens,9606.0,BAO_0000220,22224,,5119,,5633,A,In vitro,
Autocuration,,1,,,Half life period in human liver microsome was determined,Microsomes,CHEMBL622802,U,0,,,Homo sapiens,9606.0,BAO_0000251,22224,,5120,Liver,5633,A,In vitro,2107.0
Autocuration,,1,,,Half life period was determined; 6-7,,CHEMBL622803,U,0,,,Homo sapiens,9606.0,BAO_0000019,22224,,5121,,17791,A,,
Autocuration,,1,,,Half life period was evaluated in human,,CHEMBL875154,U,0,,,Homo sapiens,9606.0,BAO_0000019,22224,,5122,,17791,A,,
Autocuration,,1,,,Half life time in human plasma,,CHEMBL622804,U,0,,,Homo sapiens,9606.0,BAO_0000366,22224,,5123,Plasma,3160,A,,1969.0
Intermediate,,1,,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,CHEMBL622805,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5124,Brain,16438,A,In vivo,955.0
Intermediate,,1,,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,CHEMBL622611,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5125,Heart,16438,A,In vivo,948.0
Intermediate,,1,,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,CHEMBL622612,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5126,Heart,16438,A,In vivo,948.0
Intermediate,,1,,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after dosing, in DMSO sol.",,CHEMBL875160,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5127,Kidney,16438,A,In vivo,2113.0
Intermediate,,1,,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",,CHEMBL622613,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5128,Kidney,16438,A,In vivo,2113.0
Intermediate,,1,,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,CHEMBL622614,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5129,Kidney,16438,A,In vivo,2113.0
Intermediate,,1,,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after dosing, in DMSO sol.",,CHEMBL622615,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5130,Liver,16438,A,In vivo,2107.0
Intermediate,,1,,,Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after ip administration in DMSO solution,,CHEMBL622616,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5131,Liver,16438,A,In vivo,2107.0
Intermediate,,1,,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,CHEMBL622617,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5132,Liver,16438,A,In vivo,2107.0
Intermediate,,1,,,Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip administration in DMSO solution,,CHEMBL622618,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5133,Spleen,16438,A,In vivo,2106.0
Intermediate,,1,,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",,CHEMBL622619,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5134,Spleen,16438,A,In vivo,2106.0
Intermediate,,1,,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,CHEMBL622620,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5135,Spleen,16438,A,In vivo,2106.0
Intermediate,,1,,,"Biodistribution in mice, total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,CHEMBL622621,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5136,Brain,16438,A,In vivo,955.0
Intermediate,,1,,,Biodistribution of compound (oxidized form) in blood tissue,,CHEMBL622622,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5137,Blood,16438,A,In vivo,178.0
Intermediate,,1,,,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,CHEMBL622623,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5138,Blood,16438,A,In vivo,178.0
Intermediate,,1,,,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",,CHEMBL622624,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5139,Blood,16438,A,In vivo,178.0
Intermediate,,1,,,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,CHEMBL622625,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5140,Blood,16438,A,In vivo,178.0
Intermediate,,1,,,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,CHEMBL622626,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5141,Blood,16438,A,In vivo,178.0
Intermediate,,1,,,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",,CHEMBL622627,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5142,Blood,16438,A,In vivo,178.0
Intermediate,,1,,,Biodistribution of compound (oxidized form) in brain tissue of mice,,CHEMBL622628,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5143,Brain,16438,A,In vivo,955.0
Intermediate,,1,,,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,CHEMBL622629,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5144,Brain,16438,A,In vivo,955.0
Intermediate,,1,,,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO",,CHEMBL622630,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5145,Brain,16438,A,In vivo,955.0
Intermediate,,1,,,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,CHEMBL622631,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5146,Brain,16438,A,In vivo,955.0
Intermediate,,1,,,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",,CHEMBL622632,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5147,Brain,16438,A,In vivo,955.0
Intermediate,,1,,,"Biodistribution of compound (oxidized form) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO solution",,CHEMBL622633,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5148,Brain,16438,A,In vivo,955.0
Intermediate,,1,,,Biodistribution of compound (oxidized form) in heart tissue of mice,,CHEMBL622634,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5149,Heart,16438,A,In vivo,948.0
Intermediate,,1,,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,CHEMBL622635,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5150,Heart,16438,A,In vivo,948.0
Intermediate,,1,,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,CHEMBL875161,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5151,Heart,16438,A,In vivo,948.0
Intermediate,,1,,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO",,CHEMBL622636,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5152,Heart,16438,A,In vivo,948.0
Intermediate,,1,,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,CHEMBL623335,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5153,Heart,16438,A,In vivo,948.0
Intermediate,,1,,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",,CHEMBL623336,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5154,Heart,16438,A,In vivo,948.0
Intermediate,,1,,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,CHEMBL623337,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5155,Kidney,16438,A,In vivo,2113.0
Intermediate,,1,,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",,CHEMBL623338,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5156,Kidney,16438,A,In vivo,2113.0
Intermediate,,1,,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO",,CHEMBL623339,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5157,Kidney,16438,A,In vivo,2113.0
Intermediate,,1,,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,CHEMBL623524,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5158,Kidney,16438,A,In vivo,2113.0
Intermediate,,1,,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",,CHEMBL623525,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5159,Kidney,16438,A,In vivo,2113.0
Intermediate,,1,,,Biodistribution of compound (oxidized form) in liver tissue,,CHEMBL623526,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5160,Liver,16438,A,In vivo,2107.0
Intermediate,,1,,,"Biodistribution of compound (oxidized form) in liver tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,CHEMBL623527,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5161,Liver,16438,A,In vivo,2107.0
Intermediate,,1,,,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,CHEMBL623528,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5162,Liver,16438,A,In vivo,2107.0
Intermediate,,1,A-431,,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration in the range of 1-10 uM of the compound after 48 h; Cell death,,CHEMBL624615,N,1,,500.0,Homo sapiens,9606.0,BAO_0000219,80852,,5163,,5245,F,,
Intermediate,,1,A-431,,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,,CHEMBL621672,N,1,,500.0,Homo sapiens,9606.0,BAO_0000219,80852,,5164,,5245,F,,
Expert,,1,A-431,,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 10-24 days)",,CHEMBL621673,N,1,,500.0,,,BAO_0000218,80852,,5165,,16289,F,,
Expert,,1,A-431,,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 12-26 days)",,CHEMBL621674,N,1,,500.0,,,BAO_0000218,80852,,5166,,16289,F,,
Expert,,1,A-431,,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,,CHEMBL884002,D,9,,500.0,Homo sapiens,9606.0,BAO_0000219,9,,5167,,16093,F,,
Intermediate,,1,A-431,,"Concentration required to inhibit the epidermoid A431 cell growth by 50%, P53 status of cell line used was wild-type. ",,CHEMBL621850,N,1,,500.0,Homo sapiens,9606.0,BAO_0000219,80852,,5168,,16825,F,,
Intermediate,,1,A-431,,Inhibitory activity against proliferation of human epidermoid carcinoma (A431) cells,,CHEMBL621851,N,1,,500.0,Homo sapiens,9606.0,BAO_0000219,80852,,5169,,4848,F,,
Expert,,1,A-431,,Inhibition of EGF-dependent autophosphorylation of EGF-R in A431 cells,,CHEMBL621852,D,9,,500.0,Homo sapiens,9606.0,BAO_0000219,9,,5170,,14827,F,,
Expert,,1,A-431,,Inhibition of autophosphorylation of epidermal growth factor receptor in A431 cells in culture,,CHEMBL621853,D,9,,500.0,Homo sapiens,9606.0,BAO_0000219,9,,5171,,14827,F,,
Expert,,1,A-431,,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 10-24 days)",,CHEMBL621854,N,1,,500.0,,,BAO_0000218,80852,,5172,,16289,F,,
Expert,,1,A-431,,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",,CHEMBL621855,N,1,,500.0,,,BAO_0000218,80852,,5173,,16289,F,,
Expert,,1,A-431,,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",,CHEMBL623724,N,1,,500.0,,,BAO_0000218,80852,,5174,,16289,F,,
Expert,,1,A-431,,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 24",,CHEMBL623725,N,1,,500.0,,,BAO_0000218,80852,,5175,,16289,F,,
Expert,,1,A-431,,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 26",,CHEMBL623726,N,1,,500.0,,,BAO_0000218,80852,,5176,,16289,F,,
Expert,,1,A-431,,"Irreversible inhibition of EGF-R phosphorylation in A431 cells, 8 hr after washing cells free of compound",,CHEMBL623727,D,9,,500.0,Homo sapiens,9606.0,BAO_0000219,9,,5177,,16289,F,,
Expert,,1,A-431,,Irreversible inhibition of formation of phosphorylated EGFR in A431 cells 8 hr after washing cells free of compound,,CHEMBL623728,H,8,,500.0,,,BAO_0000219,9,,5178,,16289,F,,
Expert,,1,A-431,,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 10-24",,CHEMBL623729,N,1,,500.0,,,BAO_0000218,80852,,5179,,16289,F,,
Expert,,1,A-431,,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",,CHEMBL623730,N,1,,500.0,,,BAO_0000218,80852,,5180,,16289,F,,
Expert,,1,A-431,,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",,CHEMBL623731,N,1,,500.0,,,BAO_0000218,80852,,5181,,16289,F,,
Expert,,1,A-431,,"Ratio of treated and control A431 cell tumor mass in mice at 5 mg/kg peroral dose, days 7-21 administration",,CHEMBL623732,N,1,,500.0,Mus musculus,10090.0,BAO_0000218,80852,,5182,,14555,F,,
Expert,,1,A-431,,"Difference in days for treated (T) and control (C) A431 cell tumors to reach 750 mg in mice at 5 mg/kg peroral dose, days 7-21 administration",,CHEMBL623733,N,1,,500.0,Mus musculus,10090.0,BAO_0000218,80852,,5183,,14555,F,,
Expert,,1,A-431,,"Net reduction in tumor burden between first and last treatments of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",,CHEMBL623734,N,1,,500.0,Mus musculus,10090.0,BAO_0000218,80852,,5184,,14555,F,,
Expert,,1,A-431,,"Weight change of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",,CHEMBL623735,N,1,,500.0,Mus musculus,10090.0,BAO_0000218,80852,,5185,,14555,F,,
Expert,,1,A-431,,In vitro antiproliferative effect against A431 human epidermoid carcinoma cells,,CHEMBL623736,N,1,,500.0,Homo sapiens,9606.0,BAO_0000219,80852,,5186,,1937,F,,
Intermediate,,1,A-431,,In vitro tumor cell growth inhibitory activity against Human leiomyosarcoma A431 cell lines,,CHEMBL623737,N,1,,500.0,Homo sapiens,9606.0,BAO_0000219,80852,,5187,,13739,F,,
Intermediate,,1,A-431,,Cytotoxicity against A437 cells is the dose giving 50% decrease in the formation of formazan dye,,CHEMBL623738,N,1,,500.0,Homo sapiens,9606.0,BAO_0000219,80852,,5188,,3558,F,,
Intermediate,,1,A-431,,Dose giving a 50% decrease in the living cell number (A437 cells),,CHEMBL875168,N,1,,500.0,Homo sapiens,9606.0,BAO_0000219,80852,,5189,,3558,F,,
Expert,,1,A549,,In vitro inhibitory concentration against proliferation of A459 cell line.,,CHEMBL623739,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5190,,17686,F,,
Intermediate,,1,A549,,Inhibitory concentration of compound for cytotoxicity against A459 human lung cells was determined,,CHEMBL623740,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5191,,5305,F,,
Intermediate,,1,A549,,Inhibition of growth of human NSCL non small cell lung carcinoma cell line (A459) after 72 hr of drug exposure,,CHEMBL624424,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5192,,3614,F,,
Intermediate,,1,A498,,In vitro antitumor activity against renal A498 tumor cell lines,,CHEMBL624425,N,1,,624.0,Homo sapiens,9606.0,BAO_0000219,80021,,5193,,17229,F,,
Intermediate,,1,A498,,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors",,CHEMBL624426,N,1,,624.0,Homo sapiens,9606.0,BAO_0000219,80021,,5194,,15935,F,,
Intermediate,,1,A498,,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors in folate deficient medium",,CHEMBL624427,N,1,,624.0,Homo sapiens,9606.0,BAO_0000219,80021,,5195,,15935,F,,
Intermediate,,1,A498,,Cytotoxicity against A498 Tumor cell line in SRB Cell viability test,,CHEMBL624428,N,1,,624.0,Homo sapiens,9606.0,BAO_0000219,80021,,5196,,15560,F,,
Intermediate,,1,A498,,Cytotoxicity concentration against human kidney carcinoma A-498 cell line,,CHEMBL624429,N,1,,624.0,Homo sapiens,9606.0,BAO_0000219,80021,,5197,,13891,F,,
Intermediate,,1,A498,,Cytotoxicity concentration against human kidney carcinoma A-498 cell line; NT =Not tested,,CHEMBL624620,N,1,,624.0,Homo sapiens,9606.0,BAO_0000219,80021,,5198,,13891,F,,
Intermediate,,1,A498,,Cytotoxicity on kidney carcinoma (A-498) cell line,,CHEMBL624621,N,1,,624.0,Homo sapiens,9606.0,BAO_0000219,80021,,5199,,13788,F,,
Intermediate,,1,A498,,Compound was evaluated against Human cell line renal A498,,CHEMBL624622,N,1,,624.0,Homo sapiens,9606.0,BAO_0000219,80021,,5200,,15403,F,,
Intermediate,,1,A498,,Compound was tested for inhibition of A498 human renal cancer cell line,,CHEMBL624623,N,1,,624.0,Homo sapiens,9606.0,BAO_0000219,80021,,5201,,1009,F,,
Intermediate,,1,A498,,Growth inhibitory activity against A498 human cancer cell line,,CHEMBL874365,N,1,,624.0,Homo sapiens,9606.0,BAO_0000219,80021,,5202,,1043,F,,
Intermediate,,1,A498,,In vitro antitumor activity against human renal A498 cell line,,CHEMBL624624,N,1,,624.0,Homo sapiens,9606.0,BAO_0000219,80021,,5203,,5858,F,,
Intermediate,,1,A498,,In vitro cytotoxic activity against renal (A498) cell line,,CHEMBL624625,N,1,,624.0,Homo sapiens,9606.0,BAO_0000219,80021,,5204,,5958,F,,
Intermediate,,1,A498,,In vitro cytotoxic activity against human renal cancer (A498) cell line,,CHEMBL624626,N,1,,624.0,Homo sapiens,9606.0,BAO_0000219,80021,,5205,,5506,F,,
Intermediate,,1,A498,,Tested for cytostatic activity against renal A498 cell line,,CHEMBL624627,N,1,,624.0,Homo sapiens,9606.0,BAO_0000219,80021,,5206,,12781,F,,
Intermediate,,1,A498,,The compound was tested for the concentration to inhibit 50% of renal A498 cell lines.,,CHEMBL883157,N,1,,624.0,Homo sapiens,9606.0,BAO_0000219,80021,,5207,,14399,F,,
Expert,,1,A498,,In vitro cytotoxic activity against renal (A498) cell line at a concentration of 10e-5 M,,CHEMBL624628,N,1,,624.0,Homo sapiens,9606.0,BAO_0000219,80021,,5208,,5958,F,,
Autocuration,,1,,,Cmax value after 2 mpk peroral administration to beagles,,CHEMBL624629,U,0,,,beagle,9615.0,BAO_0000218,22224,,5209,,3510,A,In vivo,
Autocuration,,1,,beagle,Bioavailability,,CHEMBL623551,U,0,,,Canis lupus familiaris,9615.0,BAO_0000218,22224,,5210,,3510,A,In vivo,
Autocuration,,1,,beagle,Bioavailability after 1 mpk peroral administration to beagles,,CHEMBL623552,U,0,,,Canis lupus familiaris,9615.0,BAO_0000218,22224,,5211,,3510,A,In vivo,
Autocuration,,1,,beagle,Bioavailability after 2 mpk peroral administration to beagles,,CHEMBL623553,U,0,,,Canis lupus familiaris,9615.0,BAO_0000218,22224,,5212,,3510,A,In vivo,
Autocuration,,1,,,Specificity constant of the BSA-catalyzed deprotonation of compound at pH 9,,CHEMBL623554,U,0,,,Bos taurus,9913.0,BAO_0000019,22224,,5213,,3085,A,,
Autocuration,,1,,,Specificity constant of the bovine serum albumin catalyzed reaction expressed as (kcat/KM)/kuncat,,CHEMBL623555,U,0,,,Bos taurus,9913.0,BAO_0000019,22224,,5214,,3085,A,,
Autocuration,,1,,,Michaelis-Menten kinetics of the bovine serum albumin catalyzed reaction of the compound,,CHEMBL623556,U,0,,,Bos taurus,9913.0,BAO_0000019,22224,,5215,,3085,A,,
Autocuration,,1,,,Solubility against bovine alpha-chymotrypsin,,CHEMBL623557,U,0,,,Bos taurus,9913.0,BAO_0000019,22224,,5216,,9372,A,,
Autocuration,,1,,,Rate constant of the bovine serum albumin catalyzed reaction of the compound,,CHEMBL623558,U,0,,,Bos taurus,9913.0,BAO_0000019,22224,,5217,,3085,A,,
Autocuration,,1,,,Rate constant of the bovine serum albumin catalyzed reaction of the compound,,CHEMBL623559,U,0,,,Bos taurus,9913.0,BAO_0000019,22224,,5218,,3085,A,,
Autocuration,,1,,,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards calf spleen (CS-PDE) at a concentration of 20 microg,,CHEMBL623560,U,0,,,Bos taurus,9913.0,BAO_0000221,22224,,5219,Spleen,1469,A,,2106.0
Autocuration,,1,,,Half life in culture medium containing 10% of heat inactivated foetal calf serum,,CHEMBL623561,U,0,,,Bos taurus,9913.0,BAO_0000019,22224,,5220,,4297,A,,
Autocuration,,1,,,Half life in culture medium containing 10% of heat inactivated foetal calf serum; ND=not determined,,CHEMBL623562,U,0,,,Bos taurus,9913.0,BAO_0000019,22224,,5221,,4297,A,,
Autocuration,,1,,,Ability to get deaminated by adenosine deaminase (ADA); Expressed as t1/2,,CHEMBL623563,U,0,,,Bos taurus,9913.0,BAO_0000019,22224,,5222,,17585,A,,
Autocuration,,1,,,Enzymatic stability was assessed with bovine spleen phosphodiesterase (BS PDE) exonuclase,,CHEMBL623564,U,0,,,Bos taurus,9913.0,BAO_0000221,22224,,5223,Spleen,1336,A,,2106.0
Autocuration,,1,,,Half life in presence of 2 mg/mL BSA at pH 8.8,,CHEMBL873806,U,0,,,Bos taurus,9913.0,BAO_0000019,22224,,5224,,3085,A,,
Autocuration,,1,,,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 1,,CHEMBL623565,U,0,,,Bos taurus,9913.0,BAO_0000019,22224,,5225,,2857,A,,
Autocuration,,1,,,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2,,CHEMBL623566,U,0,,,Bos taurus,9913.0,BAO_0000019,22224,,5226,,2857,A,,
Autocuration,,1,,,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2; Not determined,,CHEMBL623567,U,0,,,Bos taurus,9913.0,BAO_0000019,22224,,5227,,2857,A,,
Autocuration,,1,,,Half-life in the culture medium (RPMI 1640+10% fetal calf serum FCS),,CHEMBL623568,U,0,,,Bos taurus,9913.0,BAO_0000019,22224,,5228,,1540,A,,
Intermediate,,1,,,AUC (Area Under Plasma concentration-time curve) was after oral administration at 5 mg/kg,,CHEMBL623569,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5229,Plasma,6316,A,,1969.0
Intermediate,,1,,,AUC after administration at 100 mg/kg/day in dogs,,CHEMBL623570,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5230,Plasma,17594,A,,1969.0
Intermediate,,1,,,AUC in dog at 0-24 hr by peroral administration at 3 mpk,,CHEMBL624254,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5231,Plasma,4953,A,,1969.0
Intermediate,,1,,,AUC value after 15 mg/kg iv dose in Dogs,,CHEMBL624255,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5232,Plasma,16907,A,,1969.0
Intermediate,,1,,,AUC value after 30 mg/kg po dose in Dogs,,CHEMBL624256,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5233,Plasma,16907,A,,1969.0
Intermediate,,1,,,AUC value after administration of 4 mg/Kg oral dose in dog,,CHEMBL624257,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5234,Plasma,2959,A,,1969.0
Intermediate,,1,,,AUC0-infinity after single intravenous bolus of 1 mg/kg in dogs,,CHEMBL624258,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5235,Plasma,17594,A,,1969.0
Intermediate,,1,,,Area Under Curve for the compound was determined in dogs at 1 mg/kg oral dosing; 25-50 ug min/mL,,CHEMBL875277,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5236,,5356,A,,
Intermediate,,1,,,Area under curve (AUC) value in dogs after an intravenous dose of 0.2 mg/Kg in 0.025 M aqueous methanesulfonic acid solution with 5% mannitol at a concentration of 0.2,,CHEMBL622667,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5237,,16807,A,,
Intermediate,,1,,,Area under curve by intravenous administration at a dose of 1 uM/kg in dog was determined,,CHEMBL622668,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5238,,4527,A,,
Intermediate,,1,,,Area under curve by oral administration at a dose of 10 uM/kg in dog was determined,,CHEMBL622669,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5239,,4527,A,,
Intermediate,,1,,,Area under curve determined in dogs after intravenous administration of 3 mg/kg,,CHEMBL622670,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5240,,15660,A,,
Intermediate,,1,,,Area under curve determined in dogs after oral administration of 10 mg/kg,,CHEMBL622671,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5241,,15660,A,,
Intermediate,,1,,,Area under curve of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,,CHEMBL622672,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5242,,5802,A,,
Expert,,1,,,Area under curve of compound determined in dog after iv administration at a dose of 10 mg/kg,,CHEMBL622673,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5243,,3598,A,,
Expert,,1,,,Area under curve of compound from zero time to infinity determined in dog after iv administration at a dose of 10 mg/kg,,CHEMBL622674,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5244,,3598,A,,
Intermediate,,1,,,Area under curve determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),,CHEMBL622675,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5245,,5944,A,,
Intermediate,,1,,,Area under curve determined in dog at a dose of 10 mg/kg by oral administration,,CHEMBL622676,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5246,,5944,A,,
Intermediate,,1,,,Area under curve determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),,CHEMBL622677,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5247,,5944,A,,
Intermediate,,1,,,Area under curve determined in dog at a dose of 5 mg/kg by oral administration,,CHEMBL622678,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5248,,5944,A,,
Intermediate,,1,,,Area under curve in dog after administration of 20 mg/kg dose through peroral route,,CHEMBL622679,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5249,,4186,A,,
Intermediate,,1,,,Area under curve in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),,CHEMBL622680,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5250,,5007,A,,
Intermediate,,1,,,Area under curve was determine after peroral administration at 10 mpk in dog,,CHEMBL622681,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5251,,5668,A,,
Intermediate,,1,,,Area under curve was determine after peroral administration at 5 mpk in dog,,CHEMBL875278,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5252,,5668,A,,
Intermediate,,1,,,Area under curve was determined,,CHEMBL622682,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5253,,5006,A,,
Intermediate,,1,,,Area under curve in dogs,,CHEMBL622683,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5254,,5006,A,,
Intermediate,,1,,,Area under curve in dogs at 10 mg/kg dose fo oral administration,,CHEMBL622684,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5255,,3771,A,,
Intermediate,,1,,,Area under curve in dogs at 10 mg/kg dose fo oral administration (Evokes hyperglycerolemia),,CHEMBL622685,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5256,,3771,A,,
Intermediate,,1,,,Area under curve in dogs at 3 mg/kg dose fo intravenous administration,,CHEMBL622686,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5257,,3771,A,,
Intermediate,,1,,,Area under curve was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,CHEMBL618344,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5258,,1916,A,,
Intermediate,,1,,,Area under curve value in dog at a dose of 5 mg/kg,,CHEMBL875582,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5259,,5302,A,,
Intermediate,,1,,,Area under curve was determined after 0.1 mg/kg iv administration in dog,,CHEMBL618345,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5260,,5600,A,,
Intermediate,,1,,,Area under curve was determined after 0.3 mg/kg po administration in dog,,CHEMBL618346,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5261,,5600,A,,
Intermediate,,1,,,Area under curve was determined for compound after intravenous administration in dogs at 1.2 uM/kg,,CHEMBL618347,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5262,,17764,A,,
Intermediate,,1,,,Area under curve was determined for the compound by intravenous administration of 1.2 mg/kg in dog,,CHEMBL618348,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5263,,4368,A,,
Autocuration,,1,,,Tested for half life period at 37 degree Celsius in PBS buffer at 10.5 pH containing human serum esterase,,CHEMBL618349,U,0,,,Homo sapiens,9606.0,BAO_0000019,22224,,5264,,5318,A,,
Autocuration,,1,,,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,,CHEMBL618350,U,0,,,Homo sapiens,9606.0,BAO_0000019,22224,,5265,,5318,A,,
Autocuration,,1,,,Tested for half life period at 37 degree Celsius in PBS buffer at 8.0 pH containing human serum esterase,,CHEMBL618351,U,0,,,Homo sapiens,9606.0,BAO_0000019,22224,,5266,,5318,A,,
Autocuration,,1,,,Tested for half life period at 37 degree Celsius in PBS buffer at 8.8 pH containing human serum esterase,,CHEMBL618352,U,0,,,Homo sapiens,9606.0,BAO_0000019,22224,,5267,,5318,A,,
Autocuration,,1,,,Time taken to reduce 50% of the concentration of compound in blood plasma,,CHEMBL873494,U,0,,,Homo sapiens,9606.0,BAO_0000221,22224,,5268,Blood,14518,A,,178.0
Autocuration,,1,,,"Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",,CHEMBL618353,U,0,,,Homo sapiens,9606.0,BAO_0000366,22224,,5269,Plasma,2209,A,,1969.0
Autocuration,,1,,,Half life in human plasma,,CHEMBL618354,U,0,,,Homo sapiens,9606.0,BAO_0000366,22224,,5270,Plasma,6787,A,,1969.0
Autocuration,,1,,,Half life in human plasma was reported,,CHEMBL875583,U,0,,,Homo sapiens,9606.0,BAO_0000366,22224,,5271,Plasma,4898,A,,1969.0
Autocuration,,1,,,Half life in human serum,,CHEMBL618355,U,0,,,Homo sapiens,9606.0,BAO_0000019,22224,,5272,Serum,6072,A,,1977.0
Autocuration,,1,,,Half life upon exposure to human plasma,,CHEMBL618356,U,0,,,Homo sapiens,9606.0,BAO_0000366,22224,,5273,Plasma,16907,A,,1969.0
Autocuration,,1,,,t1/2 in human microsomes,Microsomes,CHEMBL618357,U,0,,,Homo sapiens,9606.0,BAO_0000251,22224,,5274,,5656,A,In vitro,
Autocuration,,1,,,Half life period in 80% human plasma at 37 degree Centigrade,,CHEMBL618358,U,0,,,Homo sapiens,9606.0,BAO_0000366,22224,,5275,Plasma,4755,A,,1969.0
Autocuration,,1,,,Half-life for rate of hydrolysis was determined in in human skin homogenate (pH 7.4),,CHEMBL618359,U,0,,,Homo sapiens,9606.0,BAO_0000221,22224,,5276,Zone of skin,17503,A,,14.0
Autocuration,,1,,,Half-life measured in in vitro Cathepsin B assay in human plasma,,CHEMBL618360,U,0,,,Homo sapiens,9606.0,BAO_0000366,22224,,5277,Plasma,12357,A,In vitro,1969.0
Autocuration,,1,,,Half-life at initial concentration of 5*10e-5 M in CEM cell extract,,CHEMBL618361,U,0,,,Homo sapiens,9606.0,BAO_0000019,22224,,5278,,3076,A,,
Autocuration,,1,,,Half-life determined by human liver microsome stability assay at a concentration of 5 uM,Microsomes,CHEMBL618362,U,0,,,Homo sapiens,9606.0,BAO_0000251,22224,,5279,Liver,6410,A,In vitro,2107.0
Autocuration,,1,,,"Half-life in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",,CHEMBL618363,U,0,,,Homo sapiens,9606.0,BAO_0000366,22224,,5280,Plasma,3741,A,,1969.0
Autocuration,,1,,,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",,CHEMBL618364,U,0,,,Homo sapiens,9606.0,BAO_0000366,22224,,5281,Plasma,3741,A,,1969.0
Autocuration,,1,,,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",,CHEMBL875584,U,0,,,Homo sapiens,9606.0,BAO_0000366,22224,,5282,Plasma,3741,A,,1969.0
Autocuration,,1,,,Half-life in the CEM cell extracts,,CHEMBL618365,U,0,,,Homo sapiens,9606.0,BAO_0000019,22224,,5283,,1540,A,,
Autocuration,,1,,,Half-life was calculated by Human plasma stability assay at 37 degree Centigrade,,CHEMBL873495,U,0,,,Homo sapiens,9606.0,BAO_0000366,22224,,5284,Plasma,2905,A,,1969.0
Autocuration,,1,,,Half-life was calculated by Human plasma stability assay at 37 degree centigrade; Not hydrolyzed,,CHEMBL618366,U,0,,,Homo sapiens,9606.0,BAO_0000366,22224,,5285,Plasma,2905,A,,1969.0
Autocuration,,1,,,Half-life was determined,,CHEMBL618367,U,0,,,Homo sapiens,9606.0,BAO_0000019,22224,,5286,,5523,A,,
Autocuration,,1,,,Half-life (human blood stability),,CHEMBL618368,U,0,,,Homo sapiens,9606.0,BAO_0000221,22224,,5287,Blood,1499,A,,178.0
Autocuration,,1,,,Half-life (human blood stability); no data,,CHEMBL618369,U,0,,,Homo sapiens,9606.0,BAO_0000221,22224,,5288,Blood,1499,A,,178.0
Autocuration,,1,,,Half-life in human plasma,,CHEMBL618370,U,0,,,Homo sapiens,9606.0,BAO_0000366,22224,,5289,Plasma,17065,A,,1969.0
Autocuration,,1,,,CYP3A4 metabolism half-life (t1/2),,CHEMBL618371,U,0,,,Homo sapiens,9606.0,BAO_0000019,22224,,5290,,6861,A,,
Autocuration,,1,,,Half-life was determined; 88% of parent remained after incubation for 120 min (human blood stability),,CHEMBL618372,U,0,,,Homo sapiens,9606.0,BAO_0000221,22224,,5291,Blood,1499,A,,178.0
Autocuration,,1,,,In vitro half life in human plasma,,CHEMBL618373,U,0,,,Homo sapiens,9606.0,BAO_0000366,22224,,5292,Plasma,530,A,In vitro,1969.0
Autocuration,,1,,,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in human plasma",,CHEMBL618374,U,0,,,Homo sapiens,9606.0,BAO_0000366,22224,,5293,Plasma,1116,A,In vitro,1969.0
Autocuration,,1,,,In vitro hydrolysis in human plasma,,CHEMBL618375,U,0,,,Homo sapiens,9606.0,BAO_0000366,22224,,5294,Plasma,6695,A,In vitro,1969.0
Autocuration,,1,,,In vitro hydrolysis in human plasma; no data,,CHEMBL618376,U,0,,,Homo sapiens,9606.0,BAO_0000366,22224,,5295,Plasma,6695,A,In vitro,1969.0
Autocuration,,1,,,In vitro metabolic stability at 5 uM was determined by incubating with human liver microsomes at 37 degree C,Microsomes,CHEMBL618377,U,0,,,Homo sapiens,9606.0,BAO_0000251,22224,,5296,Liver,10,A,In vitro,2107.0
Autocuration,,1,,,Plasma half life in human,,CHEMBL618378,U,0,,,Homo sapiens,9606.0,BAO_0000366,22224,,5297,Plasma,993,A,,1969.0
Autocuration,,1,,,Stability after incubation with human plasma (at 37 degree C),,CHEMBL618379,U,0,,,Homo sapiens,9606.0,BAO_0000366,22224,,5298,Plasma,15429,A,,1969.0
Autocuration,,1,,,T1/2 was evaluated in human plasma,,CHEMBL618380,U,0,,,Homo sapiens,9606.0,BAO_0000366,22224,,5299,Plasma,1675,A,,1969.0
Autocuration,,1,,,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",,CHEMBL618381,U,0,,,Homo sapiens,9606.0,BAO_0000366,22224,,5300,Plasma,2209,A,,1969.0
Autocuration,,1,,,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I); Not determined",,CHEMBL618382,U,0,,,Homo sapiens,9606.0,BAO_0000366,22224,,5301,Plasma,2209,A,,1969.0
Autocuration,,1,,,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,,CHEMBL618383,U,0,,,Homo sapiens,9606.0,BAO_0000019,22224,,5302,,5318,A,,
Autocuration,,1,,,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase,,CHEMBL618384,U,0,,,Homo sapiens,9606.0,BAO_0000019,22224,,5303,,2412,A,In vitro,
Autocuration,,1,,,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase; ND=Not determined,,CHEMBL618385,U,0,,,Homo sapiens,9606.0,BAO_0000019,22224,,5304,,2412,A,In vitro,
Autocuration,,1,,,The release rate of the free drug from the substrate in human plasma by human plasma stability assay,,CHEMBL619099,U,0,,,Homo sapiens,9606.0,BAO_0000366,22224,,5305,Plasma,2906,A,,1969.0
Autocuration,,1,,,The release rate of the free drug from the substrate in human plasma by human plasma stability assay; Not hydrolyzed,,CHEMBL619100,U,0,,,Homo sapiens,9606.0,BAO_0000366,22224,,5306,Plasma,2906,A,,1969.0
Autocuration,,1,,,Time taken for 50% to be consumed by serum PON1 was determined,,CHEMBL619101,U,0,,,Homo sapiens,9606.0,BAO_0000019,22224,,5307,,5495,A,,
Autocuration,,1,,,Time taken for 50% to be consumed by serum PON1; NH is Not hydrolysed,,CHEMBL619102,U,0,,,Homo sapiens,9606.0,BAO_0000019,22224,,5308,,5495,A,,
Autocuration,,1,,,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,Microsomes,CHEMBL619103,U,0,,,Homo sapiens,9606.0,BAO_0000251,22224,,5309,Liver,4397,A,,2107.0
Autocuration,,1,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 1 hour,,CHEMBL619268,U,0,,,Mus sp.,10095.0,BAO_0000218,22224,,5310,,2413,A,,
Autocuration,,1,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 3 hour,,CHEMBL619269,U,0,,,Mus sp.,10095.0,BAO_0000218,22224,,5311,,2413,A,,
Autocuration,,1,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 1 hour,,CHEMBL619270,U,0,,,Mus sp.,10095.0,BAO_0000218,22224,,5312,,2413,A,,
Autocuration,,1,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 3 hour,,CHEMBL619271,U,0,,,Mus sp.,10095.0,BAO_0000218,22224,,5313,,2413,A,,
Autocuration,,1,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 1 hour,,CHEMBL875585,U,0,,,Mus sp.,10095.0,BAO_0000218,22224,,5314,,2413,A,,
Autocuration,,1,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 24 hour,,CHEMBL619272,U,0,,,Mus sp.,10095.0,BAO_0000218,22224,,5315,,2413,A,,
Intermediate,,1,786-0,,Compound tested for growth inhibition of renal cancer cell line 786-0,,CHEMBL619273,N,1,,391.0,Homo sapiens,9606.0,BAO_0000219,80640,,5316,,6058,F,,
Intermediate,,1,786-0,,Compound was tested for 50% growth inhibition against human renal cancer 786-0 cell line,,CHEMBL619274,N,1,,391.0,Homo sapiens,9606.0,BAO_0000219,80640,,5317,,17708,F,,
Expert,,1,786-0,,Concentration which reduced cell growth to 50 % of level against 786-0 renal cancer line,,CHEMBL619275,N,1,,391.0,Homo sapiens,9606.0,BAO_0000219,80640,,5318,,14017,F,,
Intermediate,,1,786-0,,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-4 concentration",,CHEMBL619276,N,1,,391.0,Homo sapiens,9606.0,BAO_0000219,80640,,5319,,16818,F,,
Intermediate,,1,786-0,,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-6 concentration",,CHEMBL619277,N,1,,391.0,Homo sapiens,9606.0,BAO_0000219,80640,,5320,,16818,F,,
Intermediate,,1,786-0,,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-8 concentration",,CHEMBL619278,N,1,,391.0,Homo sapiens,9606.0,BAO_0000219,80640,,5321,,16818,F,,
Intermediate,,1,786-0,,Tested for cytotoxicity against 786-0 cell lines in renal cancer,,CHEMBL619279,N,1,,391.0,Homo sapiens,9606.0,BAO_0000219,80640,,5322,,11970,F,,
Intermediate,,1,786-0,,Tested in vitro for cytotoxicity in 786-0 cell line of Renal cancer,,CHEMBL858458,N,1,,391.0,Homo sapiens,9606.0,BAO_0000219,80640,,5323,,12400,F,,
Expert,,1,786-0,,Cytotoxic effect on renal cancer line 786-0,,CHEMBL619280,N,1,,391.0,Homo sapiens,9606.0,BAO_0000219,80640,,5324,,12888,F,,
Intermediate,,1,786-0,,In vitro antitumor activity against Renal cancer 786-0 cell lines by 6-day assay,,CHEMBL619281,N,1,,391.0,Homo sapiens,9606.0,BAO_0000219,80640,,5325,,15300,F,,
Intermediate,,1,786-0,,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),,CHEMBL619282,N,1,,391.0,Homo sapiens,9606.0,BAO_0000219,80640,,5326,,14769,F,,
Intermediate,,1,786-0,,"Cytotoxicity against NCI tumor panel, 786-0 renal cancer cell line",,CHEMBL619283,N,1,,391.0,Homo sapiens,9606.0,BAO_0000219,80640,,5327,,15895,F,,
Intermediate,,1,786-0,,Concentration of compound that cause 50% cytotoxicity of 786-0 renal cancer cell line,,CHEMBL619284,N,1,,391.0,Homo sapiens,9606.0,BAO_0000219,80640,,5328,,17376,F,,
Intermediate,,1,786-0,,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration that inhibits 50% net cell growth).,,CHEMBL619285,N,1,,391.0,Homo sapiens,9606.0,BAO_0000219,80640,,5329,,14882,F,,
Intermediate,,1,786-0,,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration leading to 50% net cell death),,CHEMBL619286,N,1,,391.0,Homo sapiens,9606.0,BAO_0000219,80640,,5330,,14882,F,,
Intermediate,,1,786-0,,Growth inhibition of the 786-O Renal cancer cell line for 2-day in vitro assay.,,CHEMBL619287,N,1,,391.0,Homo sapiens,9606.0,BAO_0000219,80640,,5331,,15176,F,,
Intermediate,,1,786-0,,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,,CHEMBL857455,N,1,,391.0,Homo sapiens,9606.0,BAO_0000219,80640,,5332,,12696,F,,
Intermediate,,1,786-0,,The compound was tested in vitro for cytotoxic activity against 786-O cell line (human perirenal carcinoma),,CHEMBL883801,N,1,,391.0,Homo sapiens,9606.0,BAO_0000219,80640,,5333,,2496,F,,
Intermediate,,1,791T cell line,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression,,CHEMBL619288,N,1,,972.0,Homo sapiens,9606.0,BAO_0000219,80641,,5334,,11831,F,,
Intermediate,,1,791T cell line,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression (49% inhibition achieved at 100 micro g/mL),,CHEMBL619289,N,1,,972.0,Homo sapiens,9606.0,BAO_0000219,80641,,5335,,11831,F,,
Intermediate,,1,791T cell line,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression; <20% inhibition achieved,,CHEMBL619290,N,1,,972.0,Homo sapiens,9606.0,BAO_0000219,80641,,5336,,11831,F,,
Intermediate,,1,791T cell line,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H1: MSR-33),,CHEMBL619291,N,1,,972.0,Homo sapiens,9606.0,BAO_0000219,80641,,5337,,11831,F,,
Intermediate,,1,791T cell line,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H2: MSR-26),,CHEMBL619292,N,1,,972.0,Homo sapiens,9606.0,BAO_0000219,80641,,5338,,11831,F,,
Intermediate,,1,791T cell line,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H3: MSR-28); <20% inhibition achieved,,CHEMBL619293,N,1,,972.0,Homo sapiens,9606.0,BAO_0000219,80641,,5339,,11831,F,,
Intermediate,,1,791T cell line,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H1: MSR-33),,CHEMBL619294,N,1,,972.0,Homo sapiens,9606.0,BAO_0000219,80641,,5340,,11831,F,,
Intermediate,,1,791T cell line,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26),,CHEMBL619295,N,1,,972.0,Homo sapiens,9606.0,BAO_0000219,80641,,5341,,11831,F,,
Intermediate,,1,791T cell line,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26) (less than 20% inhibition achieved),,CHEMBL619296,N,1,,972.0,Homo sapiens,9606.0,BAO_0000219,80641,,5342,,11831,F,,
Intermediate,,1,791T cell line,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H3: MSR-28); <20% inhibition achieved,,CHEMBL619297,N,1,,972.0,Homo sapiens,9606.0,BAO_0000219,80641,,5343,,11831,F,,
Intermediate,,1,786-0,,Growth inhibitory concentration against tumor cells in culture renal cancer 796-0 cell line,,CHEMBL619298,N,1,,391.0,Homo sapiens,9606.0,BAO_0000219,80640,,5344,,12782,F,,
Intermediate,,1,,,In vitro anticancer activity against 8 NCI CNS cancer cell lines; inactive,,CHEMBL619299,U,0,,,,,BAO_0000019,22226,,5345,,1229,F,,
Expert,,1,RPMI-8226,,Inhibition of cell growth in drug resistant 8226 myeloma cell line,,CHEMBL619300,N,1,,741.0,Homo sapiens,9606.0,BAO_0000219,80433,,5346,,15313,F,,
Expert,,1,RPMI-8226,,Inhibition of cell growth in drug sensitive 8226 myeloma cell line,,CHEMBL619301,N,1,,741.0,Homo sapiens,9606.0,BAO_0000219,80433,,5347,,15313,F,,
Intermediate,,1,RPMI-8226,,In vitro inhibition of tumor cell growth in the human myeloma 8226 system.,,CHEMBL619302,N,1,,741.0,Homo sapiens,9606.0,BAO_0000219,80433,,5348,,11544,F,,
Intermediate,,1,RPMI-8226,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,,CHEMBL619303,N,1,,741.0,Homo sapiens,9606.0,BAO_0000219,80433,,5349,,9424,F,,
Intermediate,,1,RPMI-8226,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,,CHEMBL619304,N,1,,741.0,Homo sapiens,9606.0,BAO_0000219,80433,,5350,,9424,F,,
Intermediate,,1,RPMI-8226,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),,CHEMBL857706,N,1,,741.0,Homo sapiens,9606.0,BAO_0000219,80433,,5351,,9424,F,,
Intermediate,,1,RPMI-8226,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),,CHEMBL619305,N,1,,741.0,Homo sapiens,9606.0,BAO_0000219,80433,,5352,,9424,F,,
Intermediate,,1,RPMI-8226,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),,CHEMBL619306,N,1,,741.0,Homo sapiens,9606.0,BAO_0000219,80433,,5353,,9424,F,,
Intermediate,,1,RPMI-8226,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),,CHEMBL619307,N,1,,741.0,Homo sapiens,9606.0,BAO_0000219,80433,,5354,,9424,F,,
Intermediate,,1,RPMI-8226,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),,CHEMBL619308,N,1,,741.0,Homo sapiens,9606.0,BAO_0000219,80433,,5355,,9424,F,,
Intermediate,,1,RPMI-8226,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),,CHEMBL619309,N,1,,741.0,Homo sapiens,9606.0,BAO_0000219,80433,,5356,,9424,F,,
Intermediate,,1,RPMI-8226,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),,CHEMBL619310,N,1,,741.0,Homo sapiens,9606.0,BAO_0000219,80433,,5357,,9424,F,,
Intermediate,,1,A498,,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),,CHEMBL619311,N,1,,624.0,Homo sapiens,9606.0,BAO_0000219,80021,,5358,,14769,F,,
Intermediate,,1,A498,,Compound was tested for the growth inhibition of A498 renal tumor cell line,,CHEMBL619312,N,1,,624.0,Homo sapiens,9606.0,BAO_0000219,80021,,5359,,15354,F,,
Intermediate,,1,A498,,In vitro cytotoxicity against human tumor A498 cell line (renal cancer),,CHEMBL619313,N,1,,624.0,Homo sapiens,9606.0,BAO_0000219,80021,,5360,,17445,F,,
Intermediate,,1,A498,,In vitro inhibitory concentration against renal cancer cell line A498,,CHEMBL619314,N,1,,624.0,Homo sapiens,9606.0,BAO_0000219,80021,,5361,,4337,F,,
Intermediate,,1,A498,,Cytotoxicity against A 498 tumor cell line,,CHEMBL619959,N,1,,624.0,Homo sapiens,9606.0,BAO_0000219,80021,,5362,,15277,F,,
Intermediate,,1,A498,,In vitro antitumor activity against A498 human cancer cell line,,CHEMBL619960,N,1,,624.0,Homo sapiens,9606.0,BAO_0000219,80021,,5363,,4812,F,,
Intermediate,,1,A498,,In vitro antitumor activity against A498 human cancer cell line (Data from NCI-screening),,CHEMBL619961,N,1,,624.0,Homo sapiens,9606.0,BAO_0000219,80021,,5364,,4812,F,,
Intermediate,,1,A498,,Inhibitory dose required against A498 human tumor cell lines,,CHEMBL619962,N,1,,624.0,Homo sapiens,9606.0,BAO_0000219,80021,,5365,,4995,F,,
Intermediate,,1,A498,,Anticancer activity against one renal cancer (A498 cell line),,CHEMBL875586,N,1,,624.0,Homo sapiens,9606.0,BAO_0000219,80021,,5366,,5847,F,,
Intermediate,,1,A498,,In vitro cytotoxicity against melanoma A498 cell line,,CHEMBL619963,N,1,,624.0,Homo sapiens,9606.0,BAO_0000219,80021,,5367,,6557,F,,
Intermediate,,1,A498,,Compound was tested for growth inhibitory activity against A498 cell line,,CHEMBL619964,N,1,,624.0,Homo sapiens,9606.0,BAO_0000219,80021,,5368,,2597,F,,
Intermediate,,1,A498,,Compound tested for growth inhibition of renal cancer cell line A498,,CHEMBL620108,N,1,,624.0,Homo sapiens,9606.0,BAO_0000219,80021,,5369,,6058,F,,
Intermediate,,1,A498,,Compound was tested for 50% growth inhibition against human renal cancer A498 cell line,,CHEMBL620109,N,1,,624.0,Homo sapiens,9606.0,BAO_0000219,80021,,5370,,17708,F,,
Intermediate,,1,A498,,Growth inhibition of the A498 Renal cancer cell line for 2-day in vitro assay.,,CHEMBL620110,N,1,,624.0,Homo sapiens,9606.0,BAO_0000219,80021,,5371,,15176,F,,
Intermediate,,1,A498,,In vitro antitumor activity against Renal cancer A498 cell lines by 6-day assay,,CHEMBL620111,N,1,,624.0,Homo sapiens,9606.0,BAO_0000219,80021,,5372,,15300,F,,
Intermediate,,1,A498,,Tested for cytotoxicity against A498 cell lines in renal cancer,,CHEMBL620112,N,1,,624.0,Homo sapiens,9606.0,BAO_0000219,80021,,5373,,11970,F,,
Intermediate,,1,A498,,Tested in vitro for cytotoxicity in A498 cell line of Renal cancer,,CHEMBL620113,N,1,,624.0,Homo sapiens,9606.0,BAO_0000219,80021,,5374,,12400,F,,
Expert,,1,A498,,Cytotoxic effect on renal cancer lines A498,,CHEMBL620114,N,1,,624.0,Homo sapiens,9606.0,BAO_0000219,80021,,5375,,12888,F,,
Intermediate,,1,A498,,Antitumor activity was evaluated for reduction of growth of renal cancer (A498) cells at a concentration of 100 uM,,CHEMBL620115,N,1,,624.0,Homo sapiens,9606.0,BAO_0000219,80021,,5376,,3030,F,,
Intermediate,,1,A498,,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),,CHEMBL620116,N,1,,624.0,Homo sapiens,9606.0,BAO_0000219,80021,,5377,,14769,F,,
Intermediate,,1,A498,,Concentration of compound that cause 50% cytotoxicity of A498 renal cancer cell line,,CHEMBL620117,N,1,,624.0,Homo sapiens,9606.0,BAO_0000219,80021,,5378,,17376,F,,
Intermediate,,1,A498,,Growth inhibitory activity against A498-2LM human solid tumor cell line using MTT assay,,CHEMBL620118,N,1,,624.0,Homo sapiens,9606.0,BAO_0000219,80021,,5379,,16558,F,,
Intermediate,,1,A498,,Cytotoxicity against human kidney carcinoma cell lines A4982LM,,CHEMBL620119,N,1,,624.0,Homo sapiens,9606.0,BAO_0000219,80021,,5380,,5194,F,,
Intermediate,,1,A498,,Evaluated for the inhibitory concentration required to cause growth inhibition of A498Rem- renal cell line using the MTT Cytotoxicity Assay,,CHEMBL620120,N,1,,624.0,Homo sapiens,9606.0,BAO_0000219,80021,,5381,,10708,F,,
Expert,,1,A549,,Antiproliferative activity in vitro against A549 (human non-small lung carcinoma) cell line.,,CHEMBL620121,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5382,,16880,F,,
Intermediate,,1,A549,,Antitumor activity against A549 human lung carcinoma cell line,,CHEMBL620122,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5383,,10196,F,,
Intermediate,,1,A549,,Antitumor activity against A549 human lung carcinoma cell line in experiment 1,,CHEMBL620123,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5384,,10196,F,,
Intermediate,,1,A549,,Antitumor activity against A549 human lung carcinoma cell line in experiment 2,,CHEMBL620124,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5385,,10196,F,,
Intermediate,,1,A549,,"Concentration required to inhibit tumor growth in A549, human lung carcinoma (NSCLC) cell line",,CHEMBL620125,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5386,,12083,F,,
Expert,,1,A549,,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay,,CHEMBL620126,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5387,,16464,F,,
Intermediate,,1,A549,,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,CHEMBL883027,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5388,,16464,F,,
Expert,,1,A549,,In vitro cytotoxic activity against human lung A549 cell line,,CHEMBL620127,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5389,,16470,F,,
Intermediate,,1,A549,,In vitro cytotoxic activity against human lung A549 cell line ( standard deviation in parenthesis),,CHEMBL620128,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5390,,16470,F,,
Intermediate,,1,A549,,In vitro cytotoxic activity against human lung A549 cell line),,CHEMBL620129,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5391,,16470,F,,
Intermediate,,1,A549,,In vitro cytotoxic activity against human lung A549 cell line;NT is not tested,,CHEMBL620130,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5392,,16470,F,,
Expert,,1,A549,,In vitro cytotoxicity against human non small-cell-lung cell line A549.,,CHEMBL620131,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5393,,16582,F,,
Intermediate,,1,A549,,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors",,CHEMBL620132,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5394,,15935,F,,
Intermediate,,1,A549,,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors in folate deficient medium",,CHEMBL620133,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5395,,15935,F,,
Expert,,1,A549,,Inhibition of A549 human lung carcinoma cell proliferation,,CHEMBL620134,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5396,,16597,F,,
Intermediate,,1,A549,,Inhibitory activity against A549 lung adenocarcinoma cell line,,CHEMBL620135,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5397,,17376,F,,
Intermediate,,1,A549,,Inhibitory concentration required to reduce A549 tumor cell growth by 50% in MTT assay,,CHEMBL620136,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5398,,16496,F,,
Intermediate,,1,A549,,in vitro anticancer activity against cultured A549 human tumor(lung) cell line,,CHEMBL620137,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5399,,16152,F,,
Intermediate,,1,A549,,in vitro inhibition of tumor cell growth in cultured A549 human tumor cell line,,CHEMBL620268,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5400,,16152,F,,
Intermediate,,1,A549,,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,CHEMBL620269,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5401,,16464,F,,
Intermediate,,1,A549,,Cytotoxicity was evaluated against A549 non-small cell lung carcinoma human cancer cell line,,CHEMBL620270,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5402,,2288,F,,
Intermediate,,1,A549,,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,,CHEMBL620271,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5403,,17350,F,,
Expert,,1,A549,,Inhibition of A549 cancer cell proliferation,,CHEMBL620272,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5404,,4090,F,,
Expert,,1,A549,,Inhibition of A549 cancer cell proliferation (Not tested),,CHEMBL620273,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5405,,4090,F,,
Intermediate,,1,A549,,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,,CHEMBL620274,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5406,,17350,F,,
Intermediate,,1,A549,,In vitro inhibitory concentration required against human lung A549 carcinoma cells proliferation,,CHEMBL620275,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5407,,4197,F,,
Intermediate,,1,A549,,Antiproliferative potency determined as inhibitory concentration against A549 cells,,CHEMBL620276,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5408,,17072,F,,
Intermediate,,1,A549,,Percent assembly of bovine brain tubulin induced by compound at 10 uM versus that caused by 10 uM paclitaxel,,CHEMBL620277,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5409,,17072,F,,
Intermediate,,1,A549,,Cytotoxicity against Renal cell lines A549 was determined,,CHEMBL620278,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5410,,5194,F,,
Intermediate,,1,,,Area under curve was determined in dog after a 3 mg/kg of oral dose,,CHEMBL620279,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5411,,4257,A,,
Intermediate,,1,,,Area under curve was determined in dog after oral administration at 1 mg/kg,,CHEMBL620280,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5412,,6123,A,,
Intermediate,,1,,,Area under curve was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,,CHEMBL620281,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5413,,1337,A,,
Intermediate,,1,,,Area under curve was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,,CHEMBL620282,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5414,,1337,A,,
Intermediate,,1,,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-2 mins),,CHEMBL621134,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5415,,8833,A,,
Intermediate,,1,,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-5 mins),,CHEMBL621135,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5416,,8833,A,,
Intermediate,,1,,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of (0-15 mins),,CHEMBL621136,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5417,,8833,A,,
Intermediate,,1,,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of( 0-120 mins),,CHEMBL621137,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5418,,8833,A,,
Intermediate,,1,,,Area under plasma concentration time curve in dog upon oral administration,,CHEMBL621138,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5419,Plasma,17657,A,,1969.0
Intermediate,,1,,,Area under plasma concentration time curve was measured in dogs after an oral dose of 10 uM/kg,,CHEMBL875587,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5420,Plasma,17650,A,,1969.0
Intermediate,,1,,,Area under the curve for compound was evaluated in dog at a dose of 10 mg/kg.,,CHEMBL621139,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5421,,1977,A,,
Intermediate,,1,,,Area under the curve for compound was evaluated in dog at a dose of 20 mg/kg.,,CHEMBL621140,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5422,,1977,A,,
Intermediate,,1,,,Area under the curve for the compound was obtained when tested in dog,,CHEMBL621141,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5423,,3132,A,,
Intermediate,,1,,,Area under the curve at a dose of 1 mg/kg,,CHEMBL621142,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5424,,5473,A,,
Intermediate,,1,,,Area under the curve at a dose of 1 mg/kg (oral),,CHEMBL621143,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5425,,5474,A,,
Intermediate,,1,,,Area under the curve at i.v. dose of 0.2 mg/kg,,CHEMBL621144,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5426,,5474,A,,
Intermediate,,1,,,Area under the curve was measured in dog after an iv dose of 1 mg/kg,,CHEMBL621145,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5427,,6062,A,,
Intermediate,,1,,,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in dog,,CHEMBL621146,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5428,,4709,A,,
Intermediate,,1,,,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 1 mpk perorally,,CHEMBL622567,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5429,,2652,A,,
Intermediate,,1,,,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 5 mpk perorally,,CHEMBL622568,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5430,,2652,A,,
Intermediate,,1,,,Compound was evaluated for area under the curve in dog blood.,,CHEMBL622569,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5431,,2877,A,,
Intermediate,,1,,,In vivo area under curve was calculated by peroral administration at 1 mg/kg in fasted dog,,CHEMBL622570,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5432,,5444,A,,
Intermediate,,1,,,AUC in dog after oral dose (1 mg/kg),,CHEMBL622571,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5433,Plasma,5130,A,,1969.0
Intermediate,,1,,,Pharmacokinetic (PK) property (AUC) was determined in dog at the single oral dose of 1 mg/kg,,CHEMBL622572,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5434,,6265,A,,
Intermediate,,1,,,"Pharmacokinetic data in dogs at dose of 1 mg/kg perorally, and the area under curve (AUC) was reported.",,CHEMBL622573,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5435,,4657,A,,
Intermediate,,1,,,Pharmacokinetic parameter AUC after intravenous administration to dogs,,CHEMBL622574,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5436,,16367,A,,
Intermediate,,1,,,Pharmacokinetic parameter AUC after oral administration to dogs,,CHEMBL622575,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5437,,16367,A,,
Intermediate,,1,,,Pharmacokinetic parameter AUC was determined in dog after oral administration of 17b,,CHEMBL622576,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5438,,9579,A,,
Intermediate,,1,,,Pharmacokinetic parameter AUC was determined in dog after oral administration of 2b,,CHEMBL622577,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5439,,9579,A,,
Intermediate,,1,,,Pharmacokinetic property (AUC) was measured in dog at the dose of 0.032 mg/kg p.o.,,CHEMBL622578,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5440,,5983,A,,
Intermediate,,1,,,Pharmacokinetic property in dogs after oral administration at 1 mg/kg,,CHEMBL622579,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5441,,6241,A,,
Intermediate,,1,,,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog",,CHEMBL622580,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5442,,5313,A,,
Intermediate,,1,,,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog at dosage of 10 mpk",,CHEMBL622581,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5443,,5313,A,,
Intermediate,,1,,,Oral AUCN in dog ( (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,CHEMBL622582,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5444,,6642,A,,
Intermediate,,1,,,Oral AUCN in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,CHEMBL622583,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5445,,6642,A,,
Intermediate,,1,,,Oral AUCN in dog (dosed at 0.5 mpk iv ),,CHEMBL622584,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5446,,6641,A,,
Intermediate,,1,,,Oral AUCN in dog (dosed at 0.5 mpk iv ),,CHEMBL622585,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5447,,6642,A,,
Intermediate,,1,,,Compound was evaluated for oral bioavailability in dog; 90-100,,CHEMBL622586,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5448,,17791,A,,
Intermediate,,1,,,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay,,CHEMBL623281,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5449,,17655,A,,
Intermediate,,1,,,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay; Not determined,,CHEMBL623282,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5450,,17655,A,,
Intermediate,,1,,,PAPP (membrane permeability) in dog kidney cell monolayer assay,,CHEMBL623283,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5451,,6596,A,,
Intermediate,,1,,,Oral bioavailability in dog,,CHEMBL623284,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5452,,3880,A,,
Intermediate,,1,,,Bioavailability administered orally at a dose of 10 mg/kg to dogs,,CHEMBL623285,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5453,,16367,A,,
Intermediate,,1,,,Plasma protein binding towards dog plasma at 10 uM,,CHEMBL623463,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5454,Plasma,17409,A,,1969.0
Intermediate,,1,,,Plasma protein binding towards dog plasma at 100 uM,,CHEMBL875952,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5455,Plasma,17409,A,,1969.0
Intermediate,,1,,,Bioavailability in dog (dose 4 mg/kg p.o.),,CHEMBL621705,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5456,,2959,A,In vivo,
Intermediate,,1,,,Bioavailability was determined after oral administration of compound 18 at a dose of 2 mg/kg to dog,,CHEMBL621706,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5457,,13501,A,In vivo,
Intermediate,,1,,,Bioavailability by oral administration at a dose of 10 uM/kg in dog was determined,,CHEMBL621707,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5458,,4527,A,In vivo,
Intermediate,,1,,,Bioavailability in dogs,,CHEMBL621708,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5459,,15145,A,In vivo,
Intermediate,,1,,,Bioavailability,,CHEMBL621709,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5460,,4219,A,In vivo,
Intermediate,,1,,,Oral bioavailability in dog (dose 10 mg/kg),,CHEMBL621710,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5461,,17538,A,In vivo,
Intermediate,,1,,,Bioavailability in dog after po administration at a dose of 10 mg/kg; nd is not determined,,CHEMBL621711,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5462,,17538,A,In vivo,
Intermediate,,1,,,Bioavailability in dog (dose 10.0 mg/kg p.o.),,CHEMBL621712,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5463,,1466,A,In vivo,
Intermediate,,1,,,Bioavailability was measured in dogs after an oral dose of 10 uM/kg,,CHEMBL621713,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5464,,17650,A,In vivo,
Intermediate,,1,,,Bioavailability was obtained by the comparison of AUC of intravenous dosing and AUC of oral dosing in dog,,CHEMBL621714,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5465,,3132,A,In vivo,
Autocuration,,1,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 3 hour,,CHEMBL621715,U,0,,,Mus sp.,10095.0,BAO_0000218,22224,,5466,,2413,A,,
Autocuration,,1,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 1 hour,,CHEMBL623717,U,0,,,Mus sp.,10095.0,BAO_0000218,22224,,5467,Liver,2413,A,,2107.0
Autocuration,,1,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 24 hour,,CHEMBL623718,U,0,,,Mus sp.,10095.0,BAO_0000218,22224,,5468,Liver,2413,A,,2107.0
Autocuration,,1,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 3 hour,,CHEMBL623719,U,0,,,Mus sp.,10095.0,BAO_0000218,22224,,5469,Liver,2413,A,,2107.0
Autocuration,,1,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 1 hour,,CHEMBL623720,U,0,,,Mus sp.,10095.0,BAO_0000218,22224,,5470,,2413,A,,
Autocuration,,1,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 3 hour,,CHEMBL623721,U,0,,,Mus sp.,10095.0,BAO_0000218,22224,,5471,,2413,A,,
Autocuration,,1,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 1 hour,,CHEMBL623722,U,0,,,Mus sp.,10095.0,BAO_0000218,22224,,5472,Muscle tissue,2413,A,,2385.0
Autocuration,,1,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 24 hour,,CHEMBL623723,U,0,,,Mus sp.,10095.0,BAO_0000218,22224,,5473,Muscle tissue,2413,A,,2385.0
Autocuration,,1,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 3 hour,,CHEMBL618543,U,0,,,Mus sp.,10095.0,BAO_0000218,22224,,5474,Muscle tissue,2413,A,,2385.0
Autocuration,,1,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 1 hour,,CHEMBL618544,U,0,,,Mus sp.,10095.0,BAO_0000218,22224,,5475,Spleen,2413,A,,2106.0
Autocuration,,1,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 3 hour,,CHEMBL875155,U,0,,,Mus sp.,10095.0,BAO_0000218,22224,,5476,Spleen,2413,A,,2106.0
Autocuration,,1,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 1 hour,,CHEMBL618545,U,0,,,Mus sp.,10095.0,BAO_0000218,22224,,5477,,2413,A,,
Autocuration,,1,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 24 hour,,CHEMBL618546,U,0,,,Mus sp.,10095.0,BAO_0000218,22224,,5478,,2413,A,,
Autocuration,,1,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 3 hour,,CHEMBL623529,U,0,,,Mus sp.,10095.0,BAO_0000218,22224,,5479,,2413,A,,
Autocuration,,1,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 24 hour,,CHEMBL623530,U,0,,,Mus sp.,10095.0,BAO_0000218,22224,,5480,,2413,A,,
Autocuration,,1,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 3 hour,,CHEMBL621764,U,0,,,Mus sp.,10095.0,BAO_0000218,22224,,5481,,2413,A,,
Autocuration,,1,,,Compound (i.v.) was evaluated for elimination rate constants in brainstem of rhesus monkeys (Radiolabeled compound),,CHEMBL621765,U,0,,,Cercopithecidae,9527.0,BAO_0000019,22224,,5482,,17827,A,,
Autocuration,,1,,,Compound (i.v.) was evaluated for elimination rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),,CHEMBL621766,U,0,,,Cercopithecidae,9527.0,BAO_0000019,22224,,5483,Cerebellum,17827,A,,2037.0
Autocuration,,1,,,Compound (i.v.) was evaluated for elimination rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),,CHEMBL621767,U,0,,,Cercopithecidae,9527.0,BAO_0000019,22224,,5484,Frontal cortex,17827,A,,1870.0
Autocuration,,1,,,Compound (i.v.) was evaluated for elimination rate constants in jaw bone of rhesus monkeys; NA = not active (Radiolabeled compound),,CHEMBL621768,U,0,,,Cercopithecidae,9527.0,BAO_0000019,22224,,5485,,17827,A,,
Autocuration,,1,,,Compound (i.v.) was evaluated for elimination rate constants in striatum of rhesus monkey (Radiolabeled compound),,CHEMBL621769,U,0,,,Cercopithecidae,9527.0,BAO_0000019,22224,,5486,Striatum,17827,A,,2435.0
Autocuration,,1,,,Compound (i.v.) was evaluated for uptake rate constants in brainstem of rhesus monkeys (Radiolabeled compound),,CHEMBL621770,U,0,,,Cercopithecidae,9527.0,BAO_0000019,22224,,5487,,17827,A,,
Autocuration,,1,,,Compound (i.v.) was evaluated for uptake rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),,CHEMBL621771,U,0,,,Cercopithecidae,9527.0,BAO_0000019,22224,,5488,Cerebellum,17827,A,,2037.0
Autocuration,,1,,,Compound (i.v.) was evaluated for uptake rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),,CHEMBL621772,U,0,,,Cercopithecidae,9527.0,BAO_0000019,22224,,5489,Frontal cortex,17827,A,,1870.0
Autocuration,,1,,,Compound (i.v.) was evaluated for uptake rate constants in jaw bone of rhesus monkey (Radiolabeled compound),,CHEMBL621773,U,0,,,Cercopithecidae,9527.0,BAO_0000019,22224,,5490,,17827,A,,
Autocuration,,1,,,Compound (i.v.) was evaluated for uptake rate constants in striatum of rhesus monkeys (Radiolabeled compound),,CHEMBL621774,U,0,,,Cercopithecidae,9527.0,BAO_0000019,22224,,5491,Striatum,17827,A,,2435.0
Autocuration,,1,,,Compound was evaluated for oral bioavailability in rats,,CHEMBL621775,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,5492,,17791,A,,
Autocuration,,1,,,Maximum concentration of compound found in plasma at 5 mg/kg after oral administration,,CHEMBL621776,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,5493,Plasma,17667,A,In vivo,1969.0
Autocuration,,1,,,Half life period was evaluated in monkey,,CHEMBL621777,U,0,,,Cercopithecidae,9527.0,BAO_0000019,22224,,5494,,17791,A,,
Autocuration,,1,,,Half-life in rhesus monkeys by intravenous administration of dose,,CHEMBL875162,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,5495,,110,A,In vivo,
Intermediate,,1,,,AUC (0-6 hr) after oral administration at 30 mg/kg in ICR mouse,,CHEMBL621778,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5496,Plasma,5781,A,,1969.0
Intermediate,,1,,,AUC after intraperitoneal administration of 100 mg/kg in mice,,CHEMBL621779,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5497,Plasma,17734,A,,1969.0
Intermediate,,1,,,AUC value was determined after oral administration,,CHEMBL622479,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5498,Plasma,17718,A,,1969.0
Intermediate,,1,,,Area under curve (AUC) determined at a dose 10 mg/kg administered intraperitoneally to mice,,CHEMBL622480,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5499,,4573,A,,
Intermediate,,1,,,Area under curve (AUC) was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),,CHEMBL622481,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5500,,3277,A,,
Intermediate,,1,,,Area under curve by ioral administration in mouse,,CHEMBL622482,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5501,,2862,A,,
Intermediate,,1,,,Area under curve by iv administration in mouse,,CHEMBL622483,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5502,,2862,A,,
Intermediate,,1,,,Area under curve at 0-8 hr in IRC mice after peroral administration,,CHEMBL622484,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5503,,5951,A,,
Intermediate,,1,,,Area under curve when injected i.p. in mice at a dose of 50 mg/kg,,CHEMBL622641,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5504,,17729,A,,
Intermediate,,1,,,Area under curve when injected intraperitoneally in BALB/C mice at a dose of 20 mg/kg,,CHEMBL622642,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5505,,17728,A,,
Intermediate,,1,,,Area under curve when injected intravenously in BALB/C mice at a dose of 20 mg/kg,,CHEMBL622643,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5506,,17728,A,,
Intermediate,,1,,,Area under curve when injected intravenously in mice at a dose of 20 mg/kg,,CHEMBL622644,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5507,,17729,A,,
Intermediate,,1,RPMI-8226,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,,CHEMBL622645,N,1,,741.0,Homo sapiens,9606.0,BAO_0000219,80433,,5508,,9424,F,,
Intermediate,,1,RPMI-8226,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,,CHEMBL622646,N,1,,741.0,Homo sapiens,9606.0,BAO_0000219,80433,,5509,,9424,F,,
Intermediate,,1,RPMI-8226,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),,CHEMBL621238,N,1,,741.0,Homo sapiens,9606.0,BAO_0000219,80433,,5510,,9424,F,,
Intermediate,,1,RPMI-8226,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),,CHEMBL621239,N,1,,741.0,Homo sapiens,9606.0,BAO_0000219,80433,,5511,,9424,F,,
Intermediate,,1,RPMI-8226,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),,CHEMBL621240,N,1,,741.0,Homo sapiens,9606.0,BAO_0000219,80433,,5512,,9424,F,,
Intermediate,,1,RPMI-8226,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),,CHEMBL621241,N,1,,741.0,Homo sapiens,9606.0,BAO_0000219,80433,,5513,,9424,F,,
Intermediate,,1,RPMI-8226,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),,CHEMBL621242,N,1,,741.0,Homo sapiens,9606.0,BAO_0000219,80433,,5514,,9424,F,,
Intermediate,,1,RPMI-8226,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),,CHEMBL620350,N,1,,741.0,Homo sapiens,9606.0,BAO_0000219,80433,,5515,,9424,F,,
Intermediate,,1,RPMI-8226,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,,CHEMBL620351,N,1,,741.0,Homo sapiens,9606.0,BAO_0000219,80433,,5516,,9424,F,,
Intermediate,,1,RPMI-8226,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,,CHEMBL620352,N,1,,741.0,Homo sapiens,9606.0,BAO_0000219,80433,,5517,,9424,F,,
Intermediate,,1,RPMI-8226,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),,CHEMBL620353,N,1,,741.0,Homo sapiens,9606.0,BAO_0000219,80433,,5518,,9424,F,,
Intermediate,,1,RPMI-8226,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),,CHEMBL620354,N,1,,741.0,Homo sapiens,9606.0,BAO_0000219,80433,,5519,,9424,F,,
Intermediate,,1,RPMI-8226,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),,CHEMBL620355,N,1,,741.0,Homo sapiens,9606.0,BAO_0000219,80433,,5520,,9424,F,,
Intermediate,,1,RPMI-8226,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),,CHEMBL620356,N,1,,741.0,Homo sapiens,9606.0,BAO_0000219,80433,,5521,,9424,F,,
Intermediate,,1,RPMI-8226,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),,CHEMBL620357,N,1,,741.0,Homo sapiens,9606.0,BAO_0000219,80433,,5522,,9424,F,,
Intermediate,,1,RPMI-8226,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),,CHEMBL620358,N,1,,741.0,Homo sapiens,9606.0,BAO_0000219,80433,,5523,,9424,F,,
Expert,,1,RPMI-8226,,In vitro inhibition of human 8226 myeloma tumor cell line growth.,,CHEMBL620359,N,1,,741.0,Homo sapiens,9606.0,BAO_0000219,80433,,5524,,9424,F,,
Intermediate,,1,RPMI-8226,,In vitro inhibition of tumor cell growth in the human myeloma 8226/ADR system.,,CHEMBL620360,N,1,,741.0,Homo sapiens,9606.0,BAO_0000219,80433,,5525,,11544,F,,
Intermediate,,1,RPMI-8226,,Cytotoxicity of compound against 8226/DOX1V cells,,CHEMBL620361,N,1,,741.0,Homo sapiens,9606.0,BAO_0000219,80433,,5526,,17378,F,,
Intermediate,,1,RPMI-8226,,Cytotoxicity of compound against 8226/S cells,,CHEMBL620362,N,1,,741.0,Homo sapiens,9606.0,BAO_0000219,80433,,5527,,17378,F,,
Intermediate,,1,RPMI-8226,,Inhibitory concentration against 8226 myeloma cancer cell line,,CHEMBL620363,N,1,,741.0,Homo sapiens,9606.0,BAO_0000219,80433,,5528,,17079,F,,
Intermediate,,1,RPMI-8226,,Inhibitory concentration against 8226/Dox40 (Dox-Re) cancer cell line,,CHEMBL620364,N,1,,741.0,Homo sapiens,9606.0,BAO_0000219,80433,,5529,,17079,F,,
Intermediate,,1,833K,,Inhibition of cell growth was studied in human teratocarcinoma (833K).,,CHEMBL620365,N,1,,854.0,Homo sapiens,9606.0,BAO_0000219,80647,,5530,,13466,F,,
Intermediate,,1,833K,,Inhibition of cell growth was studied in human teratocarcinoma (833K); ND ='not determined',,CHEMBL620366,N,1,,854.0,Homo sapiens,9606.0,BAO_0000219,80647,,5531,,13466,F,,
Expert,,1,833K,,Tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells,,CHEMBL620367,N,1,,854.0,Homo sapiens,9606.0,BAO_0000219,80647,,5532,,2392,F,,
Intermediate,,1,833K,,The compound was tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells; No data,,CHEMBL620368,N,1,,854.0,Homo sapiens,9606.0,BAO_0000219,80647,,5533,,2392,F,,
Autocuration,,1,,,Inhibitory activity against caspase-1,,CHEMBL620369,U,0,,,,,BAO_0000019,22226,,5534,,6608,B,,
Autocuration,,1,,,Percent inhibition of DAla-DAla Ligase at 10e -3 M of the compound,,CHEMBL620370,H,8,,,Enterococcus faecalis,1351.0,BAO_0000357,45,,5535,,10199,B,,
Intermediate,,1,8701-BC,,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM) for 72 hr using MTT assay,,CHEMBL620371,N,1,,705.0,Homo sapiens,9606.0,BAO_0000219,80648,,5536,,17749,F,,
Intermediate,,1,8701-BC,,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM,,CHEMBL620372,N,1,,705.0,Homo sapiens,9606.0,BAO_0000219,80648,,5537,,17749,F,,
Intermediate,,1,,,In vitro anticancer activity against 9 NCI colon cancer cell lines; inactive,,CHEMBL876492,U,0,,,,,BAO_0000019,22226,,5538,,1229,F,,
Intermediate,,1,,,In vitro anticancer activity against 9 NCI melanoma cell lines; inactive,,CHEMBL620373,U,0,,,,,BAO_0000019,22226,,5539,,1229,F,,
Intermediate,,1,,,In vitro anticancer activity against 9 NCI renal cancer cell lines; inactive,,CHEMBL620374,U,0,,,,,BAO_0000019,22226,,5540,,1229,F,,
Autocuration,,1,,,Inhibitory activity was determined against 9-cis-epoxycarotenoid dioxygenase (NCED) expressed in Escherichia coli in presence of 9''-cis-neo-xanthin,,CHEMBL620375,U,0,,,,,BAO_0000019,22226,,5541,,6390,B,,
Autocuration,,1,,,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,,CHEMBL857902,U,0,,,Streptococcus pyogenes,1314.0,BAO_0000019,22226,,5542,,16219,F,,
Autocuration,,1,,,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,,CHEMBL620376,U,0,,,Streptococcus pyogenes,1314.0,BAO_0000019,22226,,5543,,16219,F,,
Autocuration,,1,,,Percent inhibition against Cdc25C phosphatase at 50 uM of compound,,CHEMBL620377,H,8,,,,,BAO_0000357,11922,,5544,,17043,B,,
Intermediate,,1,KB ,,Tested for in vitro cytotoxic potency of compound in 9KB assay,,CHEMBL620378,N,1,,324.0,Homo sapiens,9606.0,BAO_0000219,81115,,5545,,6929,F,,
Intermediate,,1,KB ,,Tested for in vitro cytotoxic potency of compound in 9KB assay,,CHEMBL620379,N,1,,324.0,Homo sapiens,9606.0,BAO_0000219,81115,,5546,,6929,A,,
Autocuration,,1,,,In vitro cytotoxicity of compound was tested against 9KB cells.,,CHEMBL620380,U,0,,,Homo sapiens,9606.0,BAO_0000219,22226,,5547,,7083,F,,
Intermediate,,1,9L,,Cytotoxic concentration against 9L cells was determined on day 3,,CHEMBL884006,N,1,,392.0,Rattus norvegicus,10116.0,BAO_0000219,80653,,5548,,12446,F,,
Expert,,1,9L,,Tested in vitro for anticancer activity against 9L cells,,CHEMBL620381,N,1,,392.0,Rattus norvegicus,10116.0,BAO_0000219,80653,,5549,,15345,F,,
Expert,,1,9L,,Tested in vitro for anticancer activity against 9L cells; Not determined,,CHEMBL620382,N,1,,392.0,Rattus norvegicus,10116.0,BAO_0000219,80653,,5550,,15345,F,,
Intermediate,,1,A549,,In vitro inhibitory activity against human A549 non-small cell lung tumor; Active,,CHEMBL620383,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5551,,6301,F,,
Intermediate,,1,A549,,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; No inhibition,,CHEMBL876493,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5552,,4833,F,,
Intermediate,,1,A549,,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Significant inhibition,,CHEMBL620384,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5553,,4833,F,,
Intermediate,,1,A549,,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Slight inhibition,,CHEMBL620385,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5554,,4833,F,,
Expert,,1,A549,,Cytotoxicity against human lung carcinoma A549 cell line,,CHEMBL620386,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5555,,13330,F,,
Expert,,1,A549,,Ability to induce human IL-6 assay in A549 lung carcinoma cell line.,,CHEMBL620387,D,9,,646.0,Homo sapiens,9606.0,BAO_0000219,25,,5556,,17517,F,,
Expert,,1,A549,,"Ability to induce human IL-6 assay in A549 lung carcinoma cell line; n.r.: not reported, EC50 values not reported in cases were %dex e 35%.",,CHEMBL621404,D,9,,646.0,Homo sapiens,9606.0,BAO_0000219,25,,5557,,17517,F,,
Intermediate,,1,A549,,"In vitro growth inhibition of A549, lung carcinoma",,CHEMBL621405,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5558,,14425,F,,
Intermediate,,1,A549,,"In vitro growth inhibition of A549, lung carcinoma.",,CHEMBL621406,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5559,,14425,F,,
Expert,,1,A549,,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,,CHEMBL621407,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5560,,5228,F,,
Intermediate,,1,A549,,Cytotoxic activity against human lung cancer A549 cell line was determined,,CHEMBL621408,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5561,,5351,F,,
Expert,,1,A549,,Cytotoxicity against human solid tumor lung carcinoma A549 cell line,,CHEMBL885345,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5562,,12198,F,,
Intermediate,,1,A549,,Cytotoxicity concentration against human lung carcinoma A-549 cell line,,CHEMBL621409,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5563,,13891,F,,
Expert,,1,A549,,Cytotoxicity in A549 (human carcinoma) cell line.,,CHEMBL876034,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5564,,5677,F,,
Intermediate,,1,A549,,Cytotoxicity on lung carcinoma (A-549) cell line,,CHEMBL621410,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5565,,13788,F,,
Expert,,1,A549,,Effective dose against 50% reduction in Human lung carcinoma (A-549) cell number after 3-day incubation.,,CHEMBL621411,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5566,,13384,F,,
Intermediate,,1,A549,,Effective dose of compound against replication of A549 cell line was evaluated,,CHEMBL621412,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5567,,6726,F,,
Expert,,1,A549,,In vitro cytotoxic activity was determined against lung carcinoma (A549) cell line,,CHEMBL621413,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5568,,3455,F,,
Intermediate,,1,A549,,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line),,CHEMBL621414,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5569,,5726,F,,
Intermediate,,1,A549,,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line); NA is not active,,CHEMBL621415,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5570,,5726,F,,
Intermediate,,1,A549,,The compound was evaluated for antiproliferative activity against A549 cell line,,CHEMBL621416,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5571,,3936,F,,
Intermediate,,1,A549,,The compound was tested for tumor cell growth inhibitory activity against human lung carcinoma (A549) cell line.,,CHEMBL621417,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5572,,14991,F,,
Intermediate,,1,A549,,Concentration required for growth inhibition of human lung carcinoma cell line A549,,CHEMBL621418,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5573,,5243,F,,
Intermediate,,1,A549,,Cytotoxic activity against A549/ATCC non-small cell-lung cancer cell line,,CHEMBL621419,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5574,,12858,F,,
Intermediate,,1,A549,,Growth inhibition against A549 cell line was evaluated,,CHEMBL621420,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5575,,6776,F,,
Intermediate,,1,A549,,Growth inhibitory activity against A549 human solid tumor cell line using MTT assay,,CHEMBL875823,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5576,,16558,F,,
Expert,,1,A549,,Inhibition of anchorage independent growth of human tumor cell line A549 K-ras-transformed in soft agar,,CHEMBL621421,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5577,,4583,F,,
Intermediate,,1,A549,,Inhibitor activity against A549 (Human lung carcinoma)cell line with varying concentration of the drug for 72 hrs,,CHEMBL621422,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5578,,13514,F,,
Expert,,1,A549,,Chemosensitivity against DT-diaphorase rich A549 cell lines,,CHEMBL884014,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5579,,15166,F,,
Intermediate,,1,A549,,Compound tested against A549 lung carcinoma in the sulforhodamine B assay.,,CHEMBL621423,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5580,,13873,F,,
Expert,,1,A549,,In vitro cytotoxicity against human A549 (lung cancer) cell line.,,CHEMBL621424,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5581,,6447,F,,
Intermediate,,1,A549,,In vitro antitumor activity against A549 (lung) human tumor cell lines.,,CHEMBL621425,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5582,,2068,F,,
Expert,,1,A549,,In vitro cytotoxic activity against human lung carcinoma A549 cell line,,CHEMBL621426,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5583,,1863,F,,
Intermediate,,1,A549,,Compound was tested against A549 lung cancer cell line in the sulforhodamine B assay.,,CHEMBL621427,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5584,,13873,F,,
Intermediate,,1,A549,,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,,CHEMBL621428,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5585,,13873,F,,
Expert,,1,A549,,Tested against A549 lung carcinoma in the sulforhodamine B assay.,,CHEMBL621429,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5586,,13873,F,,
Intermediate,,1,A549,,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction),,CHEMBL621430,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5587,,579,F,,
Intermediate,,1,A549,,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction).,,CHEMBL621431,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5588,,579,F,,
Intermediate,,1,A549,,Compound was tested for inhibition of growth of human lung carcinoma cell line A549 up to a conc of 10 uM; NI means no inhibition,,CHEMBL621432,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5589,,4584,F,,
Expert,,1,A549,,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line,,CHEMBL621433,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5590,,5421,F,,
Intermediate,,1,A549,,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,,CHEMBL875824,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5591,,5421,F,,
Intermediate,,1,A549,,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,,CHEMBL621434,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5592,,5421,F,,
Intermediate,,1,A549,,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line; NA=Not assayed,,CHEMBL621435,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5593,,5421,F,,
Intermediate,,1,A549,,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay.,,CHEMBL621436,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5594,,14188,F,,
Intermediate,,1,A549,,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay; UA=Potency was so low that the IC50 was unachievable.,,CHEMBL621437,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5595,,14188,F,,
Intermediate,,1,A549,,Compound was tested for the growth inhibition of A549 lung tumor cell line,,CHEMBL621438,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5596,,15354,F,,
Expert,,1,A549,,Growth inhibition of human non-small-lung carcinoma (A549) cell line,,CHEMBL621439,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5597,,14253,F,,
Intermediate,,1,A549,,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,,CHEMBL621440,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5598,,13873,F,,
Intermediate,,1,,,Oral bioavailability in dog (conscious),,CHEMBL621441,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5599,,3043,A,In vivo,
Intermediate,,1,,,Compound was evaluated for the oral bioavailability after oral administration in dog.,,CHEMBL621442,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5600,,3045,A,In vivo,
Intermediate,,1,,,Compound was tested for percent of oral bioavailability at 10 mg/ml dose in dogs,,CHEMBL621443,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5601,,3022,A,In vivo,
Intermediate,,1,,,Oral bioavailability in dog,,CHEMBL621444,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5602,,4453,A,In vivo,
Intermediate,,1,,,Oral bioavailability in dog,,CHEMBL625133,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5603,,1696,A,In vivo,
Intermediate,,1,,,Oral bioavailability in dog,,CHEMBL625134,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5604,,5045,A,In vivo,
Intermediate,,1,,,Oral bioavailability in dog (fasted),,CHEMBL625135,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5605,,5356,A,In vivo,
Intermediate,,1,,,Oral bioavailability after intravenous administration in dogs at 1.2 uM/kg,,CHEMBL625136,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5606,,17764,A,In vivo,
Intermediate,,1,,,Oral bioavailability in dog,,CHEMBL625137,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5607,,6448,A,In vivo,
Intermediate,,1,,,Oral bioavailability in dog,,CHEMBL625138,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5608,,1475,A,In vivo,
Intermediate,,1,,,Percent bioavailability in dog,,CHEMBL625139,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5609,,3788,A,In vivo,
Intermediate,,1,,,Percent oral bioavailability of intravenously administered compound (6 mg/kg) was tested in dog,,CHEMBL872264,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5610,,3639,A,In vivo,
Intermediate,,1,,,Oral bioavailability in dog,,CHEMBL625140,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5611,,13397,A,In vivo,
Intermediate,,1,,,The compound was evaluated for bioavailability in dogs; 34-44,,CHEMBL624436,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5612,,2137,A,In vivo,
Intermediate,,1,,,Bioavailability in dog (dose 4 mg/kg p.o.),,CHEMBL624437,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5613,,2959,A,In vivo,
Intermediate,,1,,,Oral bioavailability in dog,,CHEMBL872261,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5614,,6448,A,In vivo,
Intermediate,,1,,,8 hour trough Blood level in dog was measured after administration of compound,,CHEMBL624438,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5615,,6084,A,,
Intermediate,,1,,,The compound was tested for maximum concentration ( Cmax ) in dog plasma.,,CHEMBL624439,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5616,Plasma,3639,A,In vivo,1969.0
Intermediate,,1,,,C24 after oral administration at 5 mg/kg,,CHEMBL624440,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5617,,6316,A,,
Intermediate,,1,,,Clearance after oral and iv dosing in dogs,,CHEMBL624441,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5618,,5238,A,,
Intermediate,,1,,,Clearance of the drug was measured in the plasma of dog,,CHEMBL624442,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5619,Plasma,17796,A,,1969.0
Intermediate,,1,,,Compound was evaluated for Clearance in dogs at a dose of 1 mpk intravenously,,CHEMBL624443,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5620,,2652,A,,
Intermediate,,1,,,CL (clearance) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,,CHEMBL624444,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5621,,5654,A,In vivo,
Intermediate,,1,,,Clearance of compound was determined in dogs,,CHEMBL624445,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5622,,6621,A,In vivo,
Intermediate,,1,,,Clearance on i.v. administration of 2 mg/kg was measured in dog,,CHEMBL624446,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5623,,6505,A,In vivo,
Intermediate,,1,,,Clearance of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,,CHEMBL624447,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5624,,5802,A,In vivo,
Intermediate,,1,,,Plasma clearance in dog was determined,,CHEMBL624448,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5625,,17267,A,In vivo,
Intermediate,,1,,,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,,CHEMBL624449,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5626,,4521,A,In vivo,
Intermediate,,1,,,Plasma clearance in dog after administration of 0.25 mg/kg iv,,CHEMBL624450,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5627,,6535,A,In vivo,
Intermediate,,1,,,Plasma clearance in dog after administration of 1 mg/kg iv,,CHEMBL875942,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5628,,6535,A,In vivo,
Intermediate,,1,,,Plasma clearance in dogs,,CHEMBL624451,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5629,,6535,A,In vivo,
Intermediate,,1,,,Plasma clearance by iv administration in dog at a dose of 0.3 mg/kg,,CHEMBL624452,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5630,,5542,A,In vivo,
Intermediate,,1,,,Plasma clearance was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,,CHEMBL624453,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5631,,5199,A,In vivo,
Intermediate,,1,,,Plasma clearance after 15 mg/kg iv dose in Dogs,,CHEMBL624454,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5632,,16907,A,In vivo,
Intermediate,,1,,,Plasma clearance after 30 mg/kg po dose in Dogs,,CHEMBL624455,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5633,,16907,A,In vivo,
Intermediate,,1,,,Plasma administration to dogs,,CHEMBL624456,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5634,,16367,A,In vivo,
Intermediate,,1,,,Plasma clearance was determined,,CHEMBL624457,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5635,,5505,A,In vivo,
Intermediate,,1,,,Systemic clearance after intravenous administration (0.5 mg/kg) was determined in dog,,CHEMBL624458,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5636,,6215,A,In vivo,
Intermediate,,1,,,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in dog,,CHEMBL624459,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5637,,1466,A,In vivo,
Intermediate,,1,,,Intrinsic clearance in human liver microsomes,Microsomes,CHEMBL624460,S,2,,,Homo sapiens,9606.0,BAO_0000251,102164,,5638,Liver,5007,A,In vitro,2107.0
Intermediate,,1,,,Intrinsic clearance in human liver microsomes,Microsomes,CHEMBL624461,S,2,,,Homo sapiens,9606.0,BAO_0000251,102164,,5639,Liver,5007,A,In vitro,2107.0
Intermediate,,1,,,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,,CHEMBL875943,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5640,,16452,A,In vivo,
Intermediate,,1,,,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,,CHEMBL624462,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5641,,16452,A,In vivo,
Intermediate,,1,,,Clearance in dog (dose 1 mg/kg i.v.),,CHEMBL624463,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5642,,16452,A,In vivo,
Intermediate,,1,,,Plasma clearance after oral administration (2.5 mg/kg) in dog was determined,,CHEMBL624464,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5643,,6221,A,In vivo,
Intermediate,,1,,,Plasma clearance in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),,CHEMBL624465,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5644,,5007,A,In vivo,
Intermediate,,1,,,Plasma clearance after peroral administration at 10 mpk in dog,,CHEMBL624466,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5645,,5668,A,In vivo,
Intermediate,,1,,,Plasma clearance after peroral administration at 5 mpk in dog,,CHEMBL624467,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5646,,5668,A,In vivo,
Intermediate,,1,,,Plasma clearance after peroral administration at 5 mg/kg in dog,,CHEMBL624468,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5647,,5668,A,In vivo,
Intermediate,,1,,,Plasma clearance was measured in dog,,CHEMBL624469,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5648,,15660,A,In vivo,
Intermediate,,1,,,Plasma clearance was measured in dog,,CHEMBL624470,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5649,,15660,A,In vivo,
Intermediate,,1,,,Pharmacokinetic property (CLtot) was measured in dog at the dose of 0.032 mg/kg i.v.,,CHEMBL624471,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5650,,5983,A,In vivo,
Intermediate,,1,,,Total clearance was determined after 0.1 mg/kg iv administration in dog,,CHEMBL624472,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5651,,5600,A,In vivo,
Intermediate,,1,,,Clearance of compound after intravenous administration in dogs at 1.2 uM/kg,,CHEMBL622775,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5652,,17764,A,In vivo,
Intermediate,,1,,,Clearance after intravenous administration of 0.5 mg/kg in dog was determined,,CHEMBL622776,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5653,,6039,A,In vivo,
Intermediate,,1,,,Clearance after intravenous administration of 1.0 mg/kg in dog was determined,,CHEMBL622777,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5654,,6039,A,In vivo,
Intermediate,,1,,,Clearance after peroral administration of 0.2 mg/kg in dog was determined,,CHEMBL622778,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5655,,6039,A,In vivo,
Intermediate,,1,,,Clearance by intravenous administration of 1.2 mg/kg in dog,,CHEMBL622779,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5656,,4368,A,In vivo,
Intermediate,,1,,,Clearance by iv administration in dogs at a dose of 1 mg/kg,,CHEMBL622780,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5657,,4305,A,In vivo,
Intermediate,,1,,,Clearance value was evaluated in dog plasma,,CHEMBL622781,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5658,Plasma,1918,A,In vivo,1969.0
Intermediate,,1,,,Clearance was evaluated after i.v. administration in dog at a dose of 1 mg/kg,,CHEMBL622782,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5659,,6005,A,In vivo,
Intermediate,,1,,,Compound was tested for plasma clearance in dog,,CHEMBL622783,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5660,Plasma,4839,A,In vivo,1969.0
Intermediate,,1,,,Pharmacokinetic property (Plasma clearance) was measured in dog,,CHEMBL622784,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5661,,4239,A,In vivo,
Intermediate,,1,,,Area under curve when injected perorally in mice at a dose of 50 mg/kg,,CHEMBL622785,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5662,,17729,A,,
Intermediate,,1,,,Area under curve when injected perorally in BALB/C mice at a dose of 50 mg/kg,,CHEMBL622786,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5663,,17728,A,,
Intermediate,,1,,,Area under curve value in mouse at a dose of 10 mg/kg,,CHEMBL622787,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5664,,5302,A,,
Intermediate,,1,,,Area under curve was determined at a dose of 100 mg/kg (i.p.) in Mice,,CHEMBL875949,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5665,,5506,A,,
Intermediate,,1,,,Area under curve was determined at a dose of 200 mg/kg (i.p.) in Mice,,CHEMBL622788,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5666,,5506,A,,
Intermediate,,1,,,Area under curve was determined for compound after intraperitoneal administration in mice at 18 uM/kg,,CHEMBL622789,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5667,,17764,F,,
Intermediate,,1,,,Area under curve was determined for compound after intraperitoneal administration in mice at 23 uM/kg,,CHEMBL622790,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5668,,17764,F,,
Intermediate,,1,,,Area under curve was determined for compound after intraperitoneal administration in mice at 25 uM/kg,,CHEMBL622791,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5669,,17764,F,,
Intermediate,,1,,,Area under curve was determined for compound after intraperitoneal administration in mice at 26 uM/kg,,CHEMBL622792,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5670,,17764,F,,
Intermediate,,1,,,Area under curve was determined for compound after intravenous administration in mice at 24 uM/kg,,CHEMBL622793,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5671,,17764,A,,
Intermediate,,1,,,Area under curve was determined for the compound at 24 mg/Kg,,CHEMBL622794,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5672,,17753,A,,
Intermediate,,1,,,Area under curve was determined for the compound at 40 mg/Kg,,CHEMBL622795,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5673,,17753,A,,
Intermediate,,1,,,Area under curve was determined for the compound at 5 mg/Kg,,CHEMBL621803,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5674,,17753,A,,
Intermediate,,1,,,Area under the curve for the compound is obtained at dose 25 mg/kg,,CHEMBL621804,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5675,,3132,A,,
Intermediate,,1,,,Area under the curve for the compound was obtained when tested in mouse,,CHEMBL621805,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5676,,3132,A,,
Intermediate,,1,,,Area under the curve of compound in mouse blood following i.v. administration of 10 mg/kg,,CHEMBL621806,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5677,,17837,A,,
Intermediate,,1,,,Area under the curve of compound in mouse blood following p.o. administration of 30 mg/kg,,CHEMBL621807,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5678,,17837,A,,
Intermediate,,1,,,Area under the curve was measured in mouse after an iv dose of 1 mg/kg,,CHEMBL621808,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5679,,6062,A,,
Intermediate,,1,,,Area under the curve was determined for the compound at a single subcutaneous administration of 40 mg/kg in mice,,CHEMBL621809,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5680,,4066,A,,
Intermediate,,1,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),,CHEMBL621810,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5681,,16597,A,,
Intermediate,,1,,,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,,CHEMBL875164,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5682,,14239,A,,
Intermediate,,1,,,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,,CHEMBL621811,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5683,,14239,A,,
Intermediate,,1,,,"Compound was evaluated for the pharmacokinetic parameter, area under curve",,CHEMBL621812,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5684,,4890,A,,
Intermediate,,1,,,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr ),,CHEMBL621813,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5685,,429,A,,
Intermediate,,1,,,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr),,CHEMBL621814,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5686,,429,A,,
Intermediate,,1,,,In vivo area under curve (AUC) was determined in murine septicemia at dose of 100 mg/kg,,CHEMBL621815,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5687,,5969,A,,
Intermediate,,1,,,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg,,CHEMBL621816,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5688,,5969,A,,
Intermediate,,1,,,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,,CHEMBL621817,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5689,,5969,A,,
Intermediate,,1,,,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse,,CHEMBL621818,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5690,,6091,A,,
Intermediate,,1,,,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse;ND=Not determined,,CHEMBL621819,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5691,,6091,A,,
Intermediate,,1,,,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice,,CHEMBL621820,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5692,,6091,A,,
Intermediate,,1,,,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice;ND=Not determined,,CHEMBL621821,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5693,,6091,A,,
Intermediate,,1,,,Pharmacokinetic property (AUC) was determined after ip administration of 32 mg/kg in mice,,CHEMBL621822,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5694,,6178,A,,
Intermediate,,1,,,Pharmacokinetic property (AUC) was determined after po administration of 32 mg/kg in mice,,CHEMBL619474,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5695,,6178,A,,
Intermediate,,1,,,"Reduction in area under curve was determined in DIO mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",,CHEMBL619475,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5696,,6619,A,,
Intermediate,,1,,,"Reduction in area under curve was determined in ob/ob mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",,CHEMBL619476,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5697,,6619,A,,
Intermediate,,1,,,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered intravenously in mice",,CHEMBL619477,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5698,,3760,A,,
Intermediate,,1,,,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered perorally in mice",,CHEMBL619478,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5699,,3760,A,,
Intermediate,,1,,,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered intravenously in mice",,CHEMBL619479,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5700,,3760,A,,
Intermediate,,1,,,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered perorally in mice",,CHEMBL619480,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5701,,3760,A,,
Intermediate,,1,,,The area under curve in vivo in mouse blood level after oral administration at dose 50 mk/kg e-1,,CHEMBL619481,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5702,,3192,A,,
Intermediate,,1,,,The area under curve in vivo in mouse blood level after subcutaneous administration at dose 50 mk/kg e-1,,CHEMBL619482,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5703,,3192,A,,
Intermediate,,1,,,Area under the curve was evaluated in mice after intravenous administration,,CHEMBL619483,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5704,,2675,A,,
Intermediate,,1,,,Area under the curve was evaluated in mice after oral administration,,CHEMBL619484,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5705,,2675,A,,
Intermediate,,1,,,AUC total value at a dose of 10 mg/kg intravenous administration in mice.,,CHEMBL619485,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5706,Plasma,16597,A,,1969.0
Intermediate,,1,,,AUC total value at a dose of 10 mg/kg peroral administration in mice.,,CHEMBL619486,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5707,Plasma,16597,A,,1969.0
Intermediate,,1,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),,CHEMBL619487,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5708,,16597,A,,
Intermediate,,1,,,AUMC after intraperitoneal administration of 100 mg/kg in mice,,CHEMBL619488,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5709,,17734,A,,
Intermediate,,1,,,Biodistribution in blood was determined in mice after iv administration at 15 min Value expressed as percent injected dose per gram,,CHEMBL620106,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5710,Blood,7767,A,In vivo,178.0
Intermediate,,1,9L,,The compound was tested in vitro for anticancer activity against 9L cells,,CHEMBL620107,N,1,,392.0,,,BAO_0000219,80653,,5711,,15345,F,,
Autocuration,,1,,,Anti proliferation activity determined; Weak effect,,CHEMBL620283,U,0,,,Rattus norvegicus,10116.0,BAO_0000019,22226,,5712,,2181,F,,
Autocuration,,1,,,Inhibition of cell growth by compound at a concentration of 100 uM in 9Ltk+ cells; Completely stopped the process,,CHEMBL875176,U,0,,,Rattus norvegicus,10116.0,BAO_0000219,22226,,5713,,2181,F,,
Autocuration,,1,,,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells,,CHEMBL620284,U,0,,,Rattus norvegicus,10116.0,BAO_0000219,22226,,5714,,2181,F,,
Autocuration,,1,,,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells; Completely stopped the process,,CHEMBL623515,U,0,,,Rattus norvegicus,10116.0,BAO_0000219,22226,,5715,,2181,F,,
Autocuration,,1,,,The cytotoxic activity was in vitro tested by 9PS assay method,,CHEMBL623516,U,0,,,Mus musculus,10090.0,BAO_0000019,22226,,5716,,10486,F,,
Autocuration,,1,,,The cytotoxic activity was in vitro tested by 9PS assay method.,,CHEMBL623517,U,0,,,Mus musculus,10090.0,BAO_0000019,22226,,5717,,10486,F,,
Autocuration,,1,,,Partition coefficient (logD6.5),,CHEMBL857878,U,0,,,,,BAO_0000019,22224,,5718,,15508,A,,
Expert,,1,A2780,,Inhibitory concentration in vitro for cytotoxic activity against A 2780 human ovarian carcinoma cells,,CHEMBL623518,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,5719,,5242,F,,
Intermediate,,1,A-375,,Effective concentration against A 375 cell line growth (DFMO concentration is 5.0 mM),,CHEMBL624195,N,1,,455.0,Homo sapiens,9606.0,BAO_0000219,80018,,5720,,16167,F,,
Expert,,1,A-431,,Inhibitory concentration required against A 431 human epidermoid carcinoma cell line,,CHEMBL624196,N,1,,500.0,Homo sapiens,9606.0,BAO_0000219,80852,,5721,,4782,F,,
Expert,,1,A-431,,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,,CHEMBL624197,D,9,,500.0,Homo sapiens,9606.0,BAO_0000219,9,,5722,,16093,F,,
Intermediate,,1,A498,,Compound was evaluated for in vitro cytotoxicity against A 498 cancer cell line,,CHEMBL624198,N,1,,624.0,Homo sapiens,9606.0,BAO_0000219,80021,,5723,,2596,F,,
Intermediate,,1,A498,,in vitro cytotoxicity against A 498 cancer cell line,,CHEMBL621287,N,1,,624.0,Homo sapiens,9606.0,BAO_0000219,80021,,5724,,2596,F,,
Intermediate,,1,A498,,In vitro cytotoxic activity against renal (A 498) cancer cell line.,,CHEMBL621288,N,1,,624.0,Homo sapiens,9606.0,BAO_0000219,80021,,5725,,3239,F,,
Intermediate,,1,A498,,Cytotoxic activity against A 498 renal cancer cell lines.,,CHEMBL876496,N,1,,624.0,Homo sapiens,9606.0,BAO_0000219,80021,,5726,,1847,F,,
Intermediate,,1,A498,,In vitro cytotoxicity was determined against A 498 human renal tumor cell line using NCI screen,,CHEMBL621289,N,1,,624.0,Homo sapiens,9606.0,BAO_0000219,80021,,5727,,10553,F,,
Autocuration,,1,,,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,,CHEMBL621290,U,0,,,Staphylococcus aureus,1280.0,BAO_0000019,22226,,5728,,16219,F,,
Autocuration,,1,,,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,,CHEMBL621291,U,0,,,Staphylococcus aureus,1280.0,BAO_0000019,22226,,5729,,16219,F,,
Autocuration,,1,,,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,,CHEMBL621292,U,0,,,Staphylococcus aureus,1280.0,BAO_0000019,22226,,5730,,16219,F,,
Autocuration,,1,,,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,,CHEMBL621293,U,0,,,Staphylococcus aureus,1280.0,BAO_0000019,22226,,5731,,16219,F,,
Intermediate,,1,A549,,Inhibitory concentration required against A 549 lung cancer cell line,,CHEMBL621294,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5732,,4782,F,,
Intermediate,,1,A549,,Growth inhibition of A 549 cell line by MTT reduction for 3 days of incubation time,,CHEMBL621295,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5733,,11805,F,,
Intermediate,,1,A549,,Growth inhibition of A 549 cell line by MTT reduction for 7 days of incubation time,,CHEMBL884007,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5734,,11805,F,,
Intermediate,,1,A549,,In vitro cytotoxicity against lung cancer A 549 cell lines,,CHEMBL621296,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5735,,2007,F,,
Intermediate,,1,A549,,Compound was tested for its cytotoxicity against A 549 cell line,,CHEMBL621297,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5736,,4594,F,,
Expert,,1,A549,,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.",,CHEMBL839828,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5737,,6018,F,,
Intermediate,,1,A549,,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.; No data",,CHEMBL620397,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5738,,6018,F,,
Expert,,1,A549,,In vitro cytotoxic activity against A 549 (non-small cell lung) using SRB (sulforhodamine B) assay,,CHEMBL620398,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5739,,3599,F,,
Intermediate,,1,A549,,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,,CHEMBL620399,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5740,,2551,F,,
Expert,,1,A549,,In vitro inhibition of A549 (human lung cancer) cell growth.,,CHEMBL620400,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5741,,16132,F,,
Intermediate,,1,A549,,Cytotoxic related antitumor activity against human cancer cell lines A 549; No data available,,CHEMBL620401,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5742,,16132,F,,
Expert,,1,A549,,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,,CHEMBL620402,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5743,,2551,F,,
Expert,,1,A549,,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay; not active (> 100 uM),,CHEMBL620403,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5744,,2551,F,,
Autocuration,,1,,,Tested against A II at (100 ng/kg iv) in Dawley rats (n=2). 24 h,,CHEMBL620404,U,0,,,,,BAO_0000218,22226,,5745,,11913,F,,
Autocuration,,1,,,The duration of action for the % peak inhibition of A II pressor response for dose of 0.1 mg/kg intravenous administration in conscious dogs.,,CHEMBL620405,H,4,,,,,BAO_0000218,104694,,5746,,12621,F,In vivo,
Autocuration,,1,,,The duration of action for the % peak inhibition of A II pressor response for dose of 1.0 mg/kg peroral administration in rhesus monkeys.,,CHEMBL620406,H,4,,,,,BAO_0000218,104694,,5747,,12621,F,In vivo,
Autocuration,,1,,,The duration of action for the % peak inhibition of angiotensin II pressor response for dose of 0.1 mg/kg peroral administration in conscious rats.,,CHEMBL620407,H,4,,,,,BAO_0000218,104694,,5748,,12621,F,In vivo,
Autocuration,,1,,,The compound was evaluated for the % peak inhibition of A II pressor response for dose of 0.3 mg/kg peroral administration in rhesus monkeys.,,CHEMBL620408,H,4,,,,,BAO_0000218,104694,,5749,,12621,F,In vivo,
Autocuration,,1,,,The compound was evaluated for the percentage of inhibition of A II pressor response in rats for peroral administration.,,CHEMBL620409,H,4,,,,,BAO_0000218,104694,,5750,,12621,F,In vivo,
Expert,,1,A498,,Inhibition of A-498 human Renal cell proliferation,,CHEMBL620410,N,1,,624.0,Homo sapiens,9606.0,BAO_0000219,80021,,5751,,3600,F,,
Autocuration,,1,,,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 0.1 uM",,CHEMBL620411,U,0,,,Rattus norvegicus,10116.0,BAO_0000019,22226,,5752,,1796,F,,
Autocuration,,1,,,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 1 uM",,CHEMBL620412,U,0,,,Rattus norvegicus,10116.0,BAO_0000019,22226,,5753,,1796,F,,
Autocuration,,1,,,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 10 uM",,CHEMBL876596,U,0,,,Rattus norvegicus,10116.0,BAO_0000019,22226,,5754,,1796,F,,
Expert,,1,A 172,,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay,,CHEMBL620413,N,1,,622.0,Homo sapiens,9606.0,BAO_0000219,80012,,5755,,16464,F,,
Intermediate,,1,A 172,,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,CHEMBL620414,N,1,,622.0,Homo sapiens,9606.0,BAO_0000219,80012,,5756,,16464,F,,
Intermediate,,1,A 172,,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,CHEMBL620415,N,1,,622.0,Homo sapiens,9606.0,BAO_0000219,80012,,5757,,16464,F,,
Expert,,1,A549,,Concentration required to inhibit growth of human tumor A549 (NSCL) cell line.,,CHEMBL620416,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5758,,13617,F,,
Intermediate,,1,A549,,Concentration which produces 50% inhibition of growth of human lung carcinoma cell line A549,,CHEMBL620417,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5759,,4584,F,,
Expert,,1,A549,,Cytotoxic activity evaluated against A549 tumor cells,,CHEMBL620418,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5760,,13799,F,,
Intermediate,,1,A549,,Cytotoxic potentiation of Topotecan (TP) by the compound in human lung carcinoma A549 cell line,,CHEMBL620419,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5761,,16726,F,,
Intermediate,,1,A549,,Cytotoxicity against A549 cells when the drug is exposed for a time of 1 hr,,CHEMBL620420,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5762,,16109,F,,
Intermediate,,1,A549,,Cytotoxicity against A549 cells when the drug is exposed for a time of 96 hrs,,CHEMBL620421,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5763,,16109,F,,
Intermediate,,1,A549,,Cytotoxicity against A549 tumor cell line determined by WST-1 assay,,CHEMBL620422,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5764,,15474,F,,
Intermediate,,1,A549,,Cytotoxicity of compound against A549 cell line,,CHEMBL620423,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5765,,6851,F,,
Expert,,1,A549,,Cytotoxicity against human lung cell carcinoma A549 cell line,,CHEMBL620424,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5766,,17534,F,,
Intermediate,,1,A549,,Cytotoxicity against human lung carcinoma A549 cell line using MTT assay,,CHEMBL620425,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5767,,2621,F,,
Intermediate,,1,A549,,Cytotoxicity was evaluated in vitro against A549 (non-small cell lung carcinoma) human tumor cell lines,,CHEMBL620426,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5768,,830,F,,
Intermediate,,1,A549,,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum,,CHEMBL620427,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5769,,14255,F,,
Intermediate,,1,A549,,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum; Not determined,,CHEMBL620428,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5770,,14255,F,,
Intermediate,,1,A549,,In vitro antitumor activity against A549 human NSCLC lung carcinoma cells,,CHEMBL620429,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5771,,1590,F,,
Expert,,1,A549,,In vitro concentration required to inhibit the TNF-alpha-induced RANTES production in A549 human lung epithelium cell line,,CHEMBL620430,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5772,,6146,F,,
Expert,,1,A549,,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,,CHEMBL839887,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5773,,17427,F,,
Intermediate,,1,A549,,In vitro cytotoxicity against parental and drug resistant lung human tumor cell line A549,,CHEMBL620431,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5774,,5280,F,,
Intermediate,,1,A549,,In vitro cytotoxicity of compound against human A549 (non small cell lung) cancer cell line after 72 hr of drug exposure,,CHEMBL884010,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5775,,16786,F,,
Intermediate,,1,A549,,In vitro cytotoxicity against A549 (human lung cancer),,CHEMBL620538,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5776,,5895,F,,
Expert,,1,A549,,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,,CHEMBL620539,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5777,,14297,F,,
Intermediate,,1,A549,,In vivo antiproliferative activity against A549 cell line,,CHEMBL623373,N,1,,646.0,Homo sapiens,9606.0,BAO_0000218,80682,,5778,,17824,F,,
Intermediate,,1,A549,,Inhibition of non-small-cell lung adenocarcinoma (A549),,CHEMBL623374,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5779,,14368,F,,
Intermediate,,1,A549,,Inhibition of non-small-cell lung adenocarcinoma (A549) after 48-h treatment,,CHEMBL623375,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5780,,14368,F,,
Intermediate,,1,A549,,Inhibition of the growth against human non-small-lung carcinoma (A549) cell line after 72 hr exposure,,CHEMBL623376,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5781,,14254,F,,
Intermediate,,1,A549,,Inhibitory activity against A549 cell line using MTT assay(Wild type p53),,CHEMBL623377,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5782,,15897,F,,
Intermediate,,1,A549,,Inhibitory activity against A549 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,,CHEMBL623378,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5783,,13866,F,,
Intermediate,,1,A549,,Inhibitory activity of compound against human A549 lung carcinoma cell line.,,CHEMBL623379,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5784,,13370,F,,
Intermediate,,1,A549,,Inhibitory activity against A549 lung cancer cell line,,CHEMBL623380,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5785,,4862,F,,
Intermediate,,1,A549,,Inhibitory activity against Taxol-resistant A549 lung cancer cell line,,CHEMBL623381,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5786,,4862,F,,
Intermediate,,1,A549,,Inhibitory activity against Taxol-resistant A549 lung cancer cell line; not determined,,CHEMBL623382,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5787,,4862,F,,
Intermediate,,1,A549,,Inhibitory concentration against A549 (lung cancer) cell line,,CHEMBL623383,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5788,,15970,F,,
Expert,,1,A549,,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,,CHEMBL623384,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5789,,17713,F,,
Intermediate,,1,A549,,Tested in vitro for inhibitory effect on the growth of human A-549 cancer cell line,,CHEMBL623385,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5790,,4833,F,,
Expert,,1,A549,,Activity against A549 cancer cell line.,,CHEMBL623386,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5791,,13736,F,,
Intermediate,,1,A549,,The compound was evaluated for cytotoxicity against A549 cell line,,CHEMBL884105,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5792,,4312,F,,
Intermediate,,1,A549,,The compound was examined for its ability to block tumor necrosis factor alpha (TNF alpha) induced IL-8 production in A549 human lung carcinoma cell line using an ELISA,,CHEMBL623387,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5793,,5421,F,,
Intermediate,,1,A549,,The compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,,CHEMBL621568,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5794,,5421,F,,
Intermediate,,1,A549,,Growth inhibitory activity was measured for human A549 tumor cell line.,,CHEMBL621569,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5795,,14717,F,,
Intermediate,,1,A549,,Inhibitory activity against A549 lung cancer cell line,,CHEMBL621570,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5796,,4634,F,,
Intermediate,,1,A549,,Inhibitory activity against A549 cell line; inactive,,CHEMBL621571,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5797,,1149,F,,
Expert,,1,A549,,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,,CHEMBL621572,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5798,,5421,F,,
Expert,,1,A549,,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,,CHEMBL621573,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5799,,5421,F,,
Intermediate,,1,A549,,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,,CHEMBL621574,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5800,,5421,F,,
Intermediate,,1,A549,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-4 (M/L),,CHEMBL621575,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5801,,3320,F,,
Intermediate,,1,A549,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-5 (M/L),,CHEMBL621576,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5802,,3320,F,,
Intermediate,,1,A549,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-6 (M/L),,CHEMBL621577,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5803,,3320,F,,
Intermediate,,1,A549,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-7 (M/L),,CHEMBL621578,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5804,,3320,F,,
Intermediate,,1,A549,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-8 (M/L),,CHEMBL621579,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5805,,3320,F,,
Intermediate,,1,A549,,In vitro percent inhibition evaluated against human lung cancer (A549 cell line) at >20 ug/mL,,CHEMBL621580,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5806,,5726,F,,
Intermediate,,1,,,Plasma clearance (in vivo) in mongrel dogs was determined,,CHEMBL621581,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5807,,17800,A,In vivo,
Intermediate,,1,,,Plasma clearance was measured in dog,,CHEMBL621582,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5808,,5985,A,In vivo,
Intermediate,,1,,,Plasma clearance in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,,CHEMBL621583,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5809,,5530,A,In vivo,
Intermediate,,1,,,Plasma clearance in vivo in dog by intravenous administration at a dose of 1 mg/kg,,CHEMBL621584,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5810,,5530,A,In vivo,
Intermediate,,1,,,Tested for plasma clearance in dog,,CHEMBL621585,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5811,Plasma,4839,A,In vivo,1969.0
Intermediate,,1,,,The compound was tested for clearance in dog plasma.,,CHEMBL621586,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5812,,3639,A,In vivo,
Intermediate,,1,,,"The pharmacokinetic parameter, clearance was reported in dog after intravenous administration",,CHEMBL875835,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5813,,4838,A,In vivo,
Intermediate,,1,,,Clearance value of compound was determined after intravenous administration of 1 mg/kg/h in dog,,CHEMBL621587,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5814,,4137,A,In vivo,
Intermediate,,1,,,Compound was tested for its ability of plasma clearance when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),,CHEMBL621588,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5815,Plasma,5017,A,In vivo,1969.0
Intermediate,,1,,,In vitro clearance in dog liver microsomes,Microsomes,CHEMBL621589,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5816,Liver,17538,A,In vitro,2107.0
Intermediate,,1,,,Pharmacokinetic profile in terms of clearance was determined at a dose of 0.5 mg/kg administered intravenously in dog,,CHEMBL621590,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5817,,6161,A,In vivo,
Intermediate,,1,,,Pharmacokinetic profile in terms of clearance was determined at a dose of 5 mg/kg administered intravenously in dog,,CHEMBL621591,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5818,,6161,A,In vivo,
Intermediate,,1,,,Plasma clearance in dog,,CHEMBL621592,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5819,,1696,A,In vivo,
Intermediate,,1,,,Clearance rate in dog,,CHEMBL621593,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5820,,6762,A,In vivo,
Intermediate,,1,,,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,,CHEMBL621594,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5821,Plasma,5932,A,In vivo,1969.0
Intermediate,,1,,,Clearance in dogs,,CHEMBL621595,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5822,,6305,A,In vivo,
Intermediate,,1,,,Plasma clearance in dogs,,CHEMBL621596,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5823,,4942,A,In vivo,
Intermediate,,1,,,Plasma clearance was determined,,CHEMBL621597,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5824,,4219,A,In vivo,
Intermediate,,1,,,Lower clearance in dog (i.v.) at 0.5 mpk,,CHEMBL621598,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5825,,17853,A,In vivo,
Intermediate,,1,,,Plasma clearance in Beagle dogs,,CHEMBL621599,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5826,,4514,A,In vivo,
Intermediate,,1,,,Plasma clearance (Clp) in dog,,CHEMBL875836,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5827,,6448,A,In vivo,
Intermediate,,1,,,Plasma clearance (pharmacokinetic parameter) in dog (in vivo) at a dose of 1 mg/kg,,CHEMBL621600,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5828,,6227,A,In vivo,
Intermediate,,1,,,Plasma clearance (pharmacokinetic parameter) in dog was determined,,CHEMBL621601,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5829,,6227,A,In vivo,
Intermediate,,1,,,Plasma clearance for the compound was measured in dog after an iv dose of 1 mg/kg,,CHEMBL618474,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5830,,6062,A,In vivo,
Intermediate,,1,,,Plasma clearance of compound was determined in dog,,CHEMBL618475,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5831,,6821,A,In vivo,
Intermediate,,1,,,Plasma clearance after intravenous administration of 1 mg/kg in dog,,CHEMBL624524,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5832,,4709,A,In vivo,
Intermediate,,1,,,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,,CHEMBL624525,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5833,,4521,A,In vivo,
Intermediate,,1,,,Plasma clearance in dog was determined,,CHEMBL624526,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5834,,5374,A,In vivo,
Intermediate,,1,,,Plasma clearance was calculated in dog,,CHEMBL624527,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5835,,6057,A,In vivo,
Intermediate,,1,,,Plasma clearance at the dose of 2 mg/kg in dog,,CHEMBL624528,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5836,,4727,A,In vivo,
Intermediate,,1,,,Plasma clearance in dog,,CHEMBL624529,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5837,,5145,A,In vivo,
Intermediate,,1,,,Plasma clearance in dog,,CHEMBL624530,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5838,,17657,A,In vivo,
Intermediate,,1,,,Plasma clearance in dog; Unable to calculate,,CHEMBL624531,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5839,,17657,A,In vivo,
Intermediate,,1,,,Plasma clearance in rhesus monkey,,CHEMBL624532,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5840,,5145,A,In vivo,
Intermediate,,1,,,Plasma clearance in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,CHEMBL624533,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5841,,6642,A,In vivo,
Intermediate,,1,,,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,CHEMBL624534,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5842,,6641,A,In vivo,
Intermediate,,1,,,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,CHEMBL624535,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5843,,6642,A,In vivo,
Intermediate,,1,,,Plasma clearance was evaluated in dog,,CHEMBL624536,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5844,,5472,A,In vivo,
Intermediate,,1,,,Plasma clearance was evaluated in dog; Not tested,,CHEMBL624537,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5845,,5472,A,In vivo,
Intermediate,,1,,,Plasma clearance was evaluated in rhesus,,CHEMBL624538,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5846,,5472,A,In vivo,
Intermediate,,1,,,Plasma clearance was evaluated in rhesus; Not tested,,CHEMBL624539,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5847,,5472,A,In vivo,
Intermediate,,1,,,Plasma clearance value was determined in dog after a 3 mg/kg of iv dose,,CHEMBL624540,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5848,,4257,A,In vivo,
Intermediate,,1,,,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,CHEMBL624541,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5849,,6679,A,In vivo,
Intermediate,,1,,,Plasma clearance was determined in Beagle dog at a dose of 1 mg/kg by iv administration,,CHEMBL624542,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5850,,5546,A,In vivo,
Intermediate,,1,,,Plasma clearance was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,CHEMBL624543,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5851,,6348,A,In vivo,
Intermediate,,1,,,Clearance value at a dose of 0.2 mg/kg i.v.,,CHEMBL624544,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5852,,5474,A,In vivo,
Intermediate,,1,,,Cmax (Maximum (Peak) plasma drug concentration) was after oral administration at 5 mg/kg,,CHEMBL624545,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5853,Plasma,6316,A,In vivo,1969.0
Intermediate,,1,,,Cmax after oral dose of compound at 3 mg/kg in dogs,,CHEMBL624546,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5854,,17594,A,In vivo,
Intermediate,,1,,,Cmax after single intravenous bolus of 1 mg/kg in dogs,,CHEMBL875957,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5855,,17594,A,In vivo,
Intermediate,,1,,,Cmax of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,,CHEMBL624547,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5856,,5802,A,In vivo,
Intermediate,,1,,,Cmax in dog after administration of 0.25 mg/kg iv; ND = not determined,,CHEMBL624548,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5857,,6535,A,In vivo,
Intermediate,,1,,,Cmax in dog after administration of 1 mg/kg iv,,CHEMBL624549,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5858,,6535,A,In vivo,
Intermediate,,1,,,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in dog,,CHEMBL624550,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5859,Plasma,1466,A,In vivo,1969.0
Intermediate,,1,,,Cmax on p.o. administration of 10 mg/kg was measured in dog,,CHEMBL621613,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5860,,6505,A,In vivo,
Intermediate,,1,,,Cmax was determine after peroral administration at 10 mpk in dog,,CHEMBL621614,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5861,,5668,A,In vivo,
Intermediate,,1,,,Cmax was determine after peroral administration at 5 mpk in dog,,CHEMBL623431,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5862,,5668,A,In vivo,
Intermediate,,1,,,Cmax was determine after peroral administration at 5 mg/kg in dog,,CHEMBL623432,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5863,,5668,A,In vivo,
Intermediate,,1,,,Cmax after 0.3 mg/kg po administration in dog,,CHEMBL623433,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5864,,5600,A,In vivo,
Intermediate,,1,,,Cmax after peroral administration in dogs at 2.4 uM/kg,,CHEMBL623434,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5865,,17764,A,In vivo,
Intermediate,,1,,,Cmax in dog after oral administration at 1 mg/kg,,CHEMBL623435,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5866,,6123,A,In vivo,
Intermediate,,1,,,Cmax in dog after oral administration at 1 mg/kg; Below the level of quantitation,,CHEMBL623436,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5867,,6123,A,In vivo,
Intermediate,,1,,,Cmax upon oral administration in male Beagle dog at 10 mg/kg,,CHEMBL875958,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5868,,6757,A,In vivo,
Intermediate,,1,,,Cmax value after 15 mg/kg iv dose in Dogs,,CHEMBL623437,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5869,,16907,A,In vivo,
Intermediate,,1,,,Biodistribution in blood was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,CHEMBL623438,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5870,Blood,7767,A,In vivo,178.0
Intermediate,,1,,,Biodistribution in blood was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,CHEMBL623439,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5871,Blood,7767,A,In vivo,178.0
Intermediate,,1,,,Biodistribution in bone was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,CHEMBL623440,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5872,Bone,7767,A,In vivo,10000001.0
Intermediate,,1,,,Biodistribution in bone was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,CHEMBL623441,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5873,Bone,7767,A,In vivo,10000001.0
Intermediate,,1,,,Biodistribution in bone was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,CHEMBL623442,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5874,Bone,7767,A,In vivo,10000001.0
Intermediate,,1,,,Biodistribution in fat and fur was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,CHEMBL623469,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5875,,7767,A,In vivo,
Intermediate,,1,,,Biodistribution in fat and fur was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,CHEMBL623470,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5876,,7767,A,In vivo,
Intermediate,,1,,,Biodistribution in fat and fur was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,CHEMBL623471,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5877,,7767,A,In vivo,
Intermediate,,1,,,Biodistribution in heart was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,CHEMBL623472,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5878,Heart,7767,A,In vivo,948.0
Intermediate,,1,,,Biodistribution in heart was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,CHEMBL623473,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5879,Heart,7767,A,In vivo,948.0
Intermediate,,1,,,Biodistribution in heart was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,CHEMBL623474,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5880,Heart,7767,A,In vivo,948.0
Intermediate,,1,,,Biodistribution in kidney was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,CHEMBL623475,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5881,Kidney,7767,A,In vivo,2113.0
Intermediate,,1,,,Biodistribution in kidney was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,CHEMBL623476,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5882,Kidney,7767,A,In vivo,2113.0
Intermediate,,1,,,Biodistribution in kidney was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,CHEMBL623477,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5883,Kidney,7767,A,In vivo,2113.0
Intermediate,,1,,,Biodistribution in large intestine after iv administration at 1 hr; Value expressed as percent injected dose per gram,,CHEMBL621896,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5884,Intestine,7767,A,In vivo,160.0
Intermediate,,1,,,Biodistribution in large intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,CHEMBL621897,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5885,Intestine,7767,A,In vivo,160.0
Intermediate,,1,,,Biodistribution in large intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,CHEMBL621898,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5886,Intestine,7767,A,In vivo,160.0
Intermediate,,1,,,Biodistribution in liver was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,CHEMBL621899,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5887,Liver,7767,A,In vivo,2107.0
Intermediate,,1,,,Biodistribution in liver was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,CHEMBL621900,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5888,Liver,7767,A,In vivo,2107.0
Intermediate,,1,,,Biodistribution in liver was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,CHEMBL621901,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5889,Liver,7767,A,In vivo,2107.0
Intermediate,,1,,,Biodistribution in lung was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,CHEMBL621902,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5890,Lung,7767,A,In vivo,2048.0
Intermediate,,1,,,Biodistribution in lung was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,CHEMBL621903,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5891,Lung,7767,A,In vivo,2048.0
Intermediate,,1,,,Biodistribution in lung was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,CHEMBL622587,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5892,Lung,7767,A,In vivo,2048.0
Intermediate,,1,,,Biodistribution in muscle was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,CHEMBL620285,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5893,Muscle tissue,7767,A,In vivo,2385.0
Intermediate,,1,,,Biodistribution in muscle was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,CHEMBL875285,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5894,Muscle tissue,7767,A,In vivo,2385.0
Intermediate,,1,,,Biodistribution in muscle was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,CHEMBL620286,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5895,Muscle tissue,7767,A,In vivo,2385.0
Intermediate,,1,,,Biodistribution in pancreatic tissue was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,CHEMBL620287,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5896,,7767,A,In vivo,
Intermediate,,1,,,Biodistribution in pancreatic tissue was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,CHEMBL620288,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5897,,7767,A,In vivo,
Intermediate,,1,,,Biodistribution in pancreatic tissue was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,CHEMBL620289,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5898,,7767,A,In vivo,
Intermediate,,1,,,Biodistribution in small intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,CHEMBL620290,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5899,Intestine,7767,A,In vivo,160.0
Intermediate,,1,,,Biodistribution in small intestine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,CHEMBL620291,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5900,Intestine,7767,A,In vivo,160.0
Intermediate,,1,,,Biodistribution in small intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,CHEMBL620292,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5901,Intestine,7767,A,In vivo,160.0
Intermediate,,1,,,Biodistribution in spleen was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,CHEMBL620293,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5902,Spleen,7767,A,In vivo,2106.0
Intermediate,,1,,,Biodistribution in spleen was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,CHEMBL620294,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5903,Spleen,7767,A,In vivo,2106.0
Intermediate,,1,,,Biodistribution in spleen was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,CHEMBL618614,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5904,Spleen,7767,A,In vivo,2106.0
Intermediate,,1,,,Biodistribution in stomach was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,CHEMBL618615,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5905,Stomach,7767,A,In vivo,945.0
Intermediate,,1,,,Biodistribution in stomach was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,CHEMBL618616,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,5906,Stomach,7767,A,In vivo,945.0
Expert,,1,A 172,,Cytotoxicity against A-172 human tumor cell lines,,CHEMBL618617,N,1,,622.0,Homo sapiens,9606.0,BAO_0000219,80012,,5907,,2036,F,,
Intermediate,,1,A 172,,Compound was evaluated for the in vitro cytotoxicity against A-172 human glioblastoma cell line,,CHEMBL618618,N,1,,622.0,Homo sapiens,9606.0,BAO_0000219,80012,,5908,,2357,F,,
Intermediate,,1,A204,,Antiproliferative activity of compound was tested against rhabdomyosarcoma (A-204) human tumor cells,,CHEMBL618619,N,1,,623.0,Homo sapiens,9606.0,BAO_0000219,80014,,5909,,1457,F,,
Intermediate,,1,A2780,,Tested for antiproliferative activity against A-2780 tumoral cell line,,CHEMBL618620,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,5910,,4379,F,,
Intermediate,,1,A-375,,Inhibitory concentration against melanoma A-375 cell line for cytotoxicity was determined,,CHEMBL618621,N,1,,455.0,Homo sapiens,9606.0,BAO_0000219,80018,,5911,,1093,F,,
Intermediate,,1,A-375,,Tested in vitro against A-375 cell line human melanoma,,CHEMBL618622,N,1,,455.0,Homo sapiens,9606.0,BAO_0000219,80018,,5912,,12152,F,,
Expert,,1,A-427,,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay,,CHEMBL618623,N,1,,797.0,Homo sapiens,9606.0,BAO_0000219,80019,,5913,,16464,F,,
Intermediate,,1,A-427,,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,CHEMBL618624,N,1,,797.0,Homo sapiens,9606.0,BAO_0000219,80019,,5914,,16464,F,,
Expert,,1,A-427,,In vitro cytotoxicity against human non small-cell-lung cell line A-427.,,CHEMBL618625,N,1,,797.0,Homo sapiens,9606.0,BAO_0000219,80019,,5915,,16582,F,,
Intermediate,,1,A-427,,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,CHEMBL618626,N,1,,797.0,Homo sapiens,9606.0,BAO_0000219,80019,,5916,,16464,F,,
Intermediate,,1,A-427,,Antitumor activity on A-427 lung carcinoma cell lines,,CHEMBL618627,N,1,,797.0,Homo sapiens,9606.0,BAO_0000219,80019,,5917,,10413,F,,
Intermediate,,1,A-427,,Cytotoxic activity against human A-427 lung tumor cell line,,CHEMBL618628,N,1,,797.0,Homo sapiens,9606.0,BAO_0000219,80019,,5918,,6418,F,,
Expert,,1,A-427,,In vitro antitumor effects against human A-427 cell lines.,,CHEMBL618629,N,1,,797.0,Homo sapiens,9606.0,BAO_0000219,80019,,5919,,17134,F,,
Expert,,1,A-427,,In vitro inhibition of A-427 (human lung cancer) cell growth.,,CHEMBL618630,N,1,,797.0,Homo sapiens,9606.0,BAO_0000219,80019,,5920,,16132,F,,
Intermediate,,1,A-427,,Cytotoxic related antitumor activity against human cancer cell lines A-427; No data available,,CHEMBL618631,N,1,,797.0,Homo sapiens,9606.0,BAO_0000219,80019,,5921,,16132,F,,
Intermediate,,1,A-427,,Cytotoxic activity of compound against A-427 lung human tumor cell line,,CHEMBL618632,N,1,,797.0,Homo sapiens,9606.0,BAO_0000219,80019,,5922,,16780,F,,
Expert,,1,A-431,,Cytotoxicity measured for the growth inhibition of A-431 Human epidermoid carcinoma cell line,,CHEMBL618633,N,1,,500.0,Homo sapiens,9606.0,BAO_0000219,80852,,5923,,4085,F,,
Intermediate,,1,A498,,Cytotoxic activity was tested against human A-498 (Kidney carcinoma) cell line,,CHEMBL619315,N,1,,624.0,Homo sapiens,9606.0,BAO_0000219,80021,,5924,,1276,F,,
Expert,,1,A498,,Cytotoxicity against A-498 cell line in the purdue cell culture screen was determined,,CHEMBL619316,N,1,,624.0,Homo sapiens,9606.0,BAO_0000219,80021,,5925,,3498,F,,
Intermediate,,1,A498,,Cytotoxicity against human kidney carcinoma A-498cell lines,,CHEMBL619317,N,1,,624.0,Homo sapiens,9606.0,BAO_0000219,80021,,5926,,1169,F,,
Intermediate,,1,A498,,In vitro cytotoxic activity against A-498 (human kidney carcinoma) cell line,,CHEMBL619318,N,1,,624.0,Homo sapiens,9606.0,BAO_0000219,80021,,5927,,4450,F,,
Intermediate,,1,A498,,In vitro cytotoxicity against Renal A-498 human tumors following a 6 day exposure.,,CHEMBL619319,N,1,,624.0,Homo sapiens,9606.0,BAO_0000219,80021,,5928,,3311,F,,
Intermediate,,1,A498,,Antitumor cytotoxic activity against A-498 cell line was determined,,CHEMBL619739,N,1,,624.0,Homo sapiens,9606.0,BAO_0000219,80021,,5929,,4461,F,,
Intermediate,,1,A498,,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure.,,CHEMBL619740,N,1,,624.0,Homo sapiens,9606.0,BAO_0000219,80021,,5930,,3311,F,,
Intermediate,,1,A498,,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure; ND is no data,,CHEMBL883158,N,1,,624.0,Homo sapiens,9606.0,BAO_0000219,80021,,5931,,3311,F,,
Intermediate,,1,A498,,Antiproliferative activity of compound was tested against renal cancer (A-498) human tumor cells,,CHEMBL884012,N,1,,624.0,Homo sapiens,9606.0,BAO_0000219,80021,,5932,,1457,F,,
Intermediate,,1,A498,,In vitro inhibitory activity against A-498 ovarian cancer cell lines,,CHEMBL619741,N,1,,624.0,Homo sapiens,9606.0,BAO_0000219,80021,,5933,,3664,F,,
Intermediate,,1,A498,,"Cytotoxicity against NCI tumor panel, A-498 renal cancer cell line",,CHEMBL619742,N,1,,624.0,Homo sapiens,9606.0,BAO_0000219,80021,,5934,,15895,F,,
Intermediate,,1,A549,,Inhibition of growth lung non-small cell carcinoma A-549 cell line,,CHEMBL876610,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5935,,11843,F,,
Intermediate,,1,A549,,Inhibition of growth of lung non-small cell carcinoma A-549 cell line,,CHEMBL619743,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5936,,11843,F,,
Intermediate,,1,A549,,In vitro antiproliferative activity against human A-549 NSCL cell line,,CHEMBL619744,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5937,,17705,F,,
Intermediate,,1,A549,,In vitro antiproliferative activity against human A-549 NSCL cell line; NS = Not significant,,CHEMBL619745,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5938,,17705,F,,
Intermediate,,1,A549,,Growth inhibition of A-549 human lung adenocarcinoma at 0.01 uM compound concentration in standard MTT assay,,CHEMBL619746,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5939,,4369,F,,
Intermediate,,1,A549,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay,,CHEMBL619747,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5940,,4369,F,,
Intermediate,,1,A549,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay; ND means No data,,CHEMBL619748,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5941,,4369,F,,
Intermediate,,1,A549,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay,,CHEMBL619749,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5942,,4369,F,,
Intermediate,,1,A549,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay; ND means No data,,CHEMBL619750,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5943,,4369,F,,
Intermediate,,1,A549,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay,,CHEMBL624014,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5944,,4369,F,,
Intermediate,,1,A549,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay; ND means No data,,CHEMBL624015,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5945,,4369,F,,
Expert,,1,A549,,In vitro effective concentration required to reduce the number of human lung carcinoma (A-549) after 3-day incubation,,CHEMBL885344,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5946,,4787,F,,
Intermediate,,1,A549,,In vitro effective concentration required to reduce the number of human lung carcinoma cells (A-549) after 3-day incubation,,CHEMBL623224,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5947,,4787,F,,
Intermediate,,1,A549,,Cytotoxic activity against A-549 cell line,,CHEMBL623225,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5948,,6513,F,,
Intermediate,,1,A549,,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 0.01 to 0.03,,CHEMBL622698,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5949,,6690,F,,
Intermediate,,1,A549,,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 10.4 to 118.1,,CHEMBL622699,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5950,,6690,F,,
Expert,,1,A549,,"Cytotoxicity in vitro expressed as 50% reduction in cell number after a 3-day incubation, in human lung carcinoma A-549 cell line",,CHEMBL622700,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5951,,12263,F,,
Intermediate,,1,A549,,Compound was tested for cytotoxic activity against human lung carcinoma (A-549),,CHEMBL622701,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5952,,1054,F,,
Intermediate,,1,A549,,Compound was tested for its cytotoxic activity in MTT assay against A-549 cell line (human lung carcinoma),,CHEMBL622702,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5953,,1359,F,,
Intermediate,,1,A549,,Cytotoxic activity against human lung carcinoma (A-549) cell line,,CHEMBL622703,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5954,,3547,F,,
Expert,,1,A549,,Cytotoxic activity towards A-549 cells,,CHEMBL622704,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5955,,5771,F,,
Intermediate,,1,A549,,"In vitro percent inhibition of A549, lung carcinoma.",,CHEMBL622705,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5956,,14425,F,,
Intermediate,,1,A549,,"In vitro percent inhibition of A549, lung carcinoma",,CHEMBL622706,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5957,,14425,F,,
Intermediate,,1,A549,,"In vitro percent inhibition of A549, lung carcinoma.",,CHEMBL622707,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5958,,14425,F,,
Intermediate,,1,A549,,"In vitro percent inhibition of A549, lung carcinoma.; Range 18-23",,CHEMBL622708,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5959,,14425,F,,
Intermediate,,1,A549,,Percentage inhibition against parental and drug resistant lung human tumor cell line A549 at 10 uM,,CHEMBL622709,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5960,,5280,F,,
Intermediate,,1,A549,,Growth inhibition of the A549/ATCC non-small cell lung cancer cell line for 2-day in vitro assay.,,CHEMBL622710,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5961,,15176,F,,
Intermediate,,1,A549,,In vitro antitumor activity against Non-small cell lung cancer A549/ATCC cell lines by 6-day assay,,CHEMBL622711,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5962,,15300,F,,
Intermediate,,1,A549,,"Antitumor activity against A549 non small cell carcinoma at dose range of 1.56-6.25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,CHEMBL622712,N,1,,646.0,Homo sapiens,9606.0,BAO_0000218,80682,,5963,,17824,F,,
Intermediate,,1,A549,,"Antitumor activity against A549 non small cell carcinoma at dose range of 25-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,CHEMBL622713,N,1,,646.0,Homo sapiens,9606.0,BAO_0000218,80682,,5964,,17824,F,,
Intermediate,,1,A549,,"Antitumor activity against A549 non small cell carcinoma at dose range of 3.12-12.5 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,CHEMBL622714,N,1,,646.0,Homo sapiens,9606.0,BAO_0000218,80682,,5965,,17824,F,,
Intermediate,,1,A549,,"Antitumor activity against A549 non small cell carcinoma at dose range of 6.25-25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,CHEMBL622715,N,1,,646.0,Homo sapiens,9606.0,BAO_0000218,80682,,5966,,17824,F,,
Intermediate,,1,A549,,"Antitumor activity against A549 non small cell carcinoma at dose range of 70-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,CHEMBL622716,N,1,,646.0,Homo sapiens,9606.0,BAO_0000218,80682,,5967,,17824,F,,
Intermediate,,1,A549,,"Antitumor activity against A549 non small cell carcinoma on day 14, 21, 28; activity expressed as maximum tolerated dose; NT = Not tested",,CHEMBL622717,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5968,,17824,F,,
Intermediate,,1,A549,,Optimal dose required to inhibit human non small cell lung A549 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q7dX3),,CHEMBL622718,N,1,,646.0,Homo sapiens,9606.0,BAO_0000218,80682,,5969,,17528,F,,
Expert,,1,A549,,Cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration,,CHEMBL622719,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5970,,6870,F,,
Intermediate,,1,A549,,Compound was evaluated for cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,,CHEMBL622720,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5971,,6870,F,,
Intermediate,,1,A549,,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration,,CHEMBL622721,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5972,,6870,F,,
Intermediate,,1,A549,,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,,CHEMBL622722,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5973,,6870,F,,
Intermediate,,1,A549,,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,,CHEMBL876030,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5974,,16726,F,,
Intermediate,,1,A549,,"Concentration required for 50% inhibition of proliferation of lung cancer cell line, A549 with respect to paclitaxel was tested in vitro after 72 hr of incubation",,CHEMBL620206,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5975,,6170,F,,
Expert,,1,A549,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-4 mol/L,,CHEMBL620207,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5976,,6583,F,,
Expert,,1,A549,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-5 mol/L,,CHEMBL620208,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5977,,6583,F,,
Expert,,1,A549,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-6 mol/L,,CHEMBL620209,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5978,,6583,F,,
Expert,,1,A549,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-7 mol/L,,CHEMBL620210,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5979,,6583,F,,
Expert,,1,A549,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-8 mol/L,,CHEMBL621639,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5980,,6583,F,,
Intermediate,,1,A549,,Tested for cytotoxicity against human lung adenocarcinoma A549 cell line,,CHEMBL621640,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5981,,17321,F,,
Expert,,1,A549,,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,,CHEMBL621641,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5982,,17528,F,,
Expert,,1,A549,,Cytotoxic effect on non-small-cell lung cancer cell line A549/ATCC,,CHEMBL621642,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5983,,12888,F,,
Intermediate,,1,A549,,Cytotoxicity of compound in synergy in 94% BCNU (10 uM) against A549 cell line,,CHEMBL621643,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5984,,4312,F,,
Intermediate,,1,A549,,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line,,CHEMBL621644,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5985,,4312,F,,
Intermediate,,1,A549,,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line; No data,,CHEMBL621645,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,5986,,4312,F,,
Intermediate,,1,A549,,In vitro antiproliferative activity against A549 cell line,,CHEMBL621646,N,1,,646.0,Mus musculus,10090.0,BAO_0000219,80682,,5987,,17737,F,,
Intermediate,,1,A549,,Synergism with indomethacin in A549 cells,,CHEMBL621647,N,1,,646.0,,,BAO_0000219,80682,,5988,,6630,F,,
Intermediate,,1,A549,,Synergism with tolmetin in A549 cells,,CHEMBL621648,N,1,,646.0,,,BAO_0000219,80682,,5989,,6630,F,,
Intermediate,,1,A549,,Synergism with sulindac in A549 cells,,CHEMBL621649,N,1,,646.0,,,BAO_0000219,80682,,5990,,6630,F,,
Intermediate,,1,A549,,Antagonism of indomethacin in A549 cells,,CHEMBL621650,N,1,,646.0,,,BAO_0000219,80682,,5991,,6630,F,,
Intermediate,,1,A549,,Antagonism of sulindac in A549 cells,,CHEMBL621651,N,1,,646.0,,,BAO_0000219,80682,,5992,,6630,F,,
Intermediate,,1,A549,,Antagonism of tolmetin in A549 cells,,CHEMBL621652,N,1,,646.0,,,BAO_0000219,80682,,5993,,6630,F,,
Intermediate,,1,A549,,Synergism with indomethacin in A549 cells,,CHEMBL621653,N,1,,646.0,,,BAO_0000219,80682,,5994,,6630,F,,
Intermediate,,1,A549,,Synergism with sulindac in A549 cells,,CHEMBL621654,N,1,,646.0,,,BAO_0000219,80682,,5995,,6630,F,,
Intermediate,,1,A549,,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tolmetin; Not available,,CHEMBL621655,N,1,,646.0,,,BAO_0000219,80682,,5996,,6630,F,,
Intermediate,,1,,,Cmax value after 30 mg/kg po dose in Dogs,,CHEMBL621656,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5997,,16907,A,In vivo,
Intermediate,,1,,,Cmax value determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),,CHEMBL621657,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5998,,5944,A,In vivo,
Intermediate,,1,,,Cmax value determined in dog at a dose of 10 mg/kg by oral administration,,CHEMBL621658,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,5999,,5944,A,In vivo,
Intermediate,,1,,,Cmax value determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),,CHEMBL621659,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6000,,5944,A,In vivo,
Intermediate,,1,,,Cmax value determined in dog at a dose of 5 mg/kg by oral administration,,CHEMBL621660,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6001,,5944,A,In vivo,
Intermediate,,1,,,Cmax value after administration of 4 mg/Kg oral dose in dog,,CHEMBL621661,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6002,,2959,A,In vivo,
Intermediate,,1,,,Cmax value in dog,,CHEMBL621662,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6003,,6241,A,In vivo,
Intermediate,,1,,,Cmax value in dogs after oral administration at 1 mg/kg,,CHEMBL621663,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6004,,6241,A,In vivo,
Intermediate,,1,,,Bioavailability as Cmax in dogs at 5 mg/kg oral dose,,CHEMBL621664,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6005,,2652,A,In vivo,
Intermediate,,1,,,Compound was evaluated for maximum observed plasma concentration at dose 27.5 mg/kg DMP323 equiv in dogs,,CHEMBL621665,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6006,Plasma,1806,A,In vivo,1969.0
Intermediate,,1,,,Compound was evaluated for maximum observed plasma concentration at dose 7.7 mg/kg DMP323 equiv in dogs,,CHEMBL621666,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6007,Plasma,1806,A,In vivo,1969.0
Intermediate,,1,,,Concentration maxima after oral dosing in dogs,,CHEMBL621667,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6008,,1021,A,In vivo,
Intermediate,,1,,,Concentration maxima after oral dosing in dogs; not available,,CHEMBL876738,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6009,,1021,A,In vivo,
Intermediate,,1,,,Concentration maxima after oral dosing in dogs; not available,,CHEMBL621668,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6010,,1021,A,In vivo,
Intermediate,,1,,,In vivo maximal concentration was calculated at 0.4 mg/kg in dog; Not absorbed,,CHEMBL621669,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6011,,5444,A,In vivo,
Intermediate,,1,,,In vivo maximal concentration was calculated at 0.6 mg/kg in dog; Not absorbed,,CHEMBL621670,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6012,,5444,A,In vivo,
Intermediate,,1,,,In vivo maximal concentration was calculated at 1 mg/kg in dog,,CHEMBL621671,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6013,,5444,A,In vivo,
Intermediate,,1,,,In vivo maximal concentration was calculated at 1 mg/kg in dog; Not absorbed,,CHEMBL622360,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6014,,5444,A,In vivo,
Intermediate,,1,,,In vivo maximal concentration was calculated at 1 mg/kg in dog; Poor absorption,,CHEMBL622361,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6015,,5444,A,In vivo,
Intermediate,,1,,,Cmax in dog plasma after oral dose (1 mg/kg),,CHEMBL622362,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6016,Plasma,5130,A,In vivo,1969.0
Intermediate,,1,,,Maximal concentration (Cmax) in dog plasma at a dose of 5 mg/kg,,CHEMBL622363,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6017,Plasma,3249,A,In vivo,1969.0
Intermediate,,1,,,Maximal plasma concentration at a dose of 1 mg/kg,,CHEMBL622364,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6018,Plasma,5473,A,In vivo,1969.0
Intermediate,,1,,,Maximal plasma concentration at a dose of 1 mg/kg (oral),,CHEMBL622365,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6019,Plasma,5474,A,In vivo,1969.0
Intermediate,,1,,,Maximal plasma concentration required for pharmacokinetic data in dogs at dose of 1 mg/kg perorally,,CHEMBL622533,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6020,Plasma,4657,A,In vivo,1969.0
Intermediate,,1,,,Maximum concentration of compound in dog was evaluated.,,CHEMBL622534,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6021,,3031,A,In vivo,
Intermediate,,1,,,Maximum concentration by oral administration at a dose of 10 uM/kg in dog was determined,,CHEMBL622535,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6022,,4527,A,In vivo,
Intermediate,,1,,,Maximum concentration in dog after administration of 20 mg/kg dose through peroral route,,CHEMBL876739,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6023,,4186,A,In vivo,
Intermediate,,1,,,Maximum concentration in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),,CHEMBL622536,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6024,,5007,A,In vivo,
Intermediate,,1,,,Maximum concentration obtained in dog plasma was determined,,CHEMBL622537,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6025,Plasma,3132,A,In vivo,1969.0
Intermediate,,1,,,Maximum concentration was determined,,CHEMBL622538,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6026,,5006,A,In vivo,
Intermediate,,1,,,Maximum concentration at the dose of 2 mg/kg in dog,,CHEMBL627867,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6027,,4727,A,In vivo,
Intermediate,,1,,,Maximum concentration was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,CHEMBL627868,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6028,,1916,A,In vivo,
Intermediate,,1,,,Maximum concentration was evaluated in dog plasma,,CHEMBL627869,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6029,Plasma,1918,A,In vivo,1969.0
Intermediate,,1,,,Maximum concentration was evaluated after 75 min after administration in dog,,CHEMBL627870,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6030,,3045,A,In vivo,
Intermediate,,1,,,Maximum plasma concentration determined in dog after oral administration of 17b,,CHEMBL627871,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6031,Plasma,9579,A,In vivo,1969.0
Intermediate,,1,,,Maximum plasma concentration determined in dog after oral administration of 2b,,CHEMBL627872,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6032,Plasma,9579,A,In vivo,1969.0
Intermediate,,1,,,Maximum plasma concentration in dog,,CHEMBL627873,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6033,Plasma,933,A,In vivo,1969.0
Intermediate,,1,,,Maximum plasma concentration of compound in dog following p.o. administration of 0.5 mg/kg,,CHEMBL627874,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6034,Plasma,17839,A,In vivo,1969.0
Intermediate,,1,,,Maximum plasma concentration of compound in dog following p.o. administration of 0.9 mg/kg,,CHEMBL627875,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6035,Plasma,17839,A,In vivo,1969.0
Intermediate,,1,,,Maximum plasma concentration of compound in dog following p.o. administration of 0.95 mg/kg,,CHEMBL627876,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6036,Plasma,17839,A,In vivo,1969.0
Intermediate,,1,,,Maximum plasma concentration of compound in dog following p.o. administration of 1 mg/kg,,CHEMBL627877,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6037,Plasma,17839,A,In vivo,1969.0
Intermediate,,1,,,Maximum plasma concentration of compound was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,CHEMBL627878,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6038,Plasma,6348,A,In vivo,1969.0
Intermediate,,1,,,Maximum plasma concentration after oral administration to dogs at a dose of 10 mg/kg,,CHEMBL627879,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6039,Plasma,16367,A,In vivo,1969.0
Intermediate,,1,,,Maximum plasma concentration in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,,CHEMBL875355,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6040,Plasma,1337,A,In vivo,1969.0
Intermediate,,1,,,Maximum plasma concentration in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,,CHEMBL627880,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6041,Plasma,1337,A,In vivo,1969.0
Intermediate,,1,,,Maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,,CHEMBL627881,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6042,Plasma,5199,A,In vivo,1969.0
Intermediate,,1,,,Maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,,CHEMBL627882,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6043,Plasma,17650,A,In vivo,1969.0
Intermediate,,1,,,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,,CHEMBL627883,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6044,Plasma,6679,A,In vivo,1969.0
Intermediate,,1,,,Maximum plasma concentration was determined as in dogs at 1 mg/kg oral dosing Cmax; 0.05-0.2 ug/mL,,CHEMBL628526,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6045,Plasma,5356,A,In vivo,1969.0
Intermediate,,1,,,Maximum plasma concentration was determined in dogs at 1 mg/kg oral dosing; 0.05-0.2 ug/mL,,CHEMBL628527,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6046,Plasma,5356,A,In vivo,1969.0
Intermediate,,1,,,Maximum plasma concentration (Cmax) in dog (in vivo) at a dose of 1 mg/kg,,CHEMBL628528,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6047,Plasma,6227,A,In vivo,1969.0
Intermediate,,1,,,Maximum plasma concentration (Cmax) in dog at a dose of 0.5 mg/kg,,CHEMBL628529,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6048,Plasma,6227,A,In vivo,1969.0
Intermediate,,1,,,Maximum plasma concentration (Cmax) in dog at a dose of 0.7 mg/kg,,CHEMBL628530,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6049,Plasma,6227,A,In vivo,1969.0
Intermediate,,1,,,Maximum plasma concentration (Cmax) in dog at a dose of 1 mg/kg,,CHEMBL625243,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6050,Plasma,6227,A,In vivo,1969.0
Expert,,1,,,Maximum plasma drug concentration of compound determined in dog after iv administration at a dose of 10 mg/kg,,CHEMBL625244,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6051,Plasma,3598,A,In vivo,1969.0
Intermediate,,1,,,Maximum concentration by intravenous administration of 1.2 mg/kg in dog,,CHEMBL625245,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6052,,4368,A,In vivo,
Intermediate,,1,,,Pharmacokinetic (PK) property (Cmax) was determined in dog at the single dose of 1 mg/kg,,CHEMBL625246,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6053,,6265,A,In vivo,
Intermediate,,1,,,Biodistribution in stomach was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,CHEMBL625247,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6054,Stomach,7767,A,In vivo,945.0
Intermediate,,1,,,Biodistribution in urine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,CHEMBL625248,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6055,Urine,7767,A,In vivo,1088.0
Intermediate,,1,,,Biodistribution in urine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram; ND- No data,,CHEMBL625249,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6056,Urine,7767,A,In vivo,1088.0
Intermediate,,1,,,Biodistribution in urine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram; ND- No data,,CHEMBL625250,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6057,Urine,7767,A,In vivo,1088.0
Intermediate,,1,,,Compound (0.09% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 120 min; No increase,,CHEMBL625251,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6058,,17811,A,,
Intermediate,,1,,,Compound (0.31% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 30 min; Low increase,,CHEMBL875356,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6059,,17811,A,,
Intermediate,,1,,,Compound (i.v.) was tested for maximum activity in mice (Radiolabeled compound),,CHEMBL625252,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6060,,17827,A,,
Intermediate,,1,,,Compound was evaluated for elimination rate constants in vivo in whole blood of normal mice (Radiolabeled compound),,CHEMBL625253,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6061,Blood,17827,A,,178.0
Intermediate,,1,,,Compound was evaluated for rate of bone uptake after administration of radiolabeled in mice (Radiolabeled compound),,CHEMBL625254,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6062,,17827,A,,
Intermediate,,1,,,Compound was evaluated for rate of bone uptake in mice (Radiolabeled compound),,CHEMBL625255,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6063,,17827,A,,
Intermediate,,1,,,Compound was evaluated for rate of bone uptake in mice; NA - not active (Radiolabeled compound),,CHEMBL625256,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6064,,17827,A,,
Intermediate,,1,,,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice (Radiolabeled compound),,CHEMBL625257,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6065,Blood,17827,A,,178.0
Intermediate,,1,,,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice; NA = not active (Radiolabeled compound),,CHEMBL625258,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6066,Blood,17827,A,,178.0
Intermediate,,1,,,Compound was evaluated for washout rate in mice (Radiolabeled compound),,CHEMBL625259,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6067,,17827,A,,
Intermediate,,1,,,Compound was evaluated for washout rate in mice after radiolabeled ligand injected,,CHEMBL625260,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6068,,17827,A,,
Intermediate,,1,,,"Maximum activity (i.v.) after in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",,CHEMBL625261,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6069,,17827,A,,
Intermediate,,1,,,"Maximum activity in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",,CHEMBL625262,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6070,,17827,A,,
Intermediate,,1,,,"Residual activity in mice at 120 minutes, expressed as [(ID%-kg)/g] (Radiolabeled compound)",,CHEMBL622639,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6071,,17827,A,,
Intermediate,,1,,,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice,,CHEMBL622640,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6072,,17257,A,,
Intermediate,,1,,,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice; Not detected.,,CHEMBL622812,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6073,,17257,A,,
Intermediate,,1,,,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice,,CHEMBL622813,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6074,,17257,A,,
Intermediate,,1,,,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice; Not determined,,CHEMBL622814,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6075,,17257,A,,
Intermediate,,1,,,Time at maximum activity in mice (Radiolabeled compound),,CHEMBL622815,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6076,,17827,A,,
Intermediate,,1,,,Percent oral bioavailability was determined after administration of compound at 5 mg/kg perorally in mice,,CHEMBL625342,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6077,,3760,A,,
Intermediate,,1,,,Percent oral bioavailability was determined after administration of compound at 50 mg/kg perorally in mice,,CHEMBL625343,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6078,,3760,A,,
Intermediate,,1,,,Binding towards mouse plasma protein at 10 uM,,CHEMBL877591,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6079,,17409,A,,
Intermediate,,1,,,Binding towards mouse plasma protein at 100 uM,,CHEMBL625344,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6080,,17409,A,,
Intermediate,,1,,,Bioavailability was evaluated in mice after intravenous administration,,CHEMBL625345,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6081,,2675,A,In vivo,
Intermediate,,1,,,Bioavailability was evaluated in mice after oral administration,,CHEMBL625346,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6082,,2675,A,In vivo,
Intermediate,,1,,,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse,,CHEMBL625347,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6083,,3132,A,In vivo,
Intermediate,,1,,,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse at dose 25 mg/kg,,CHEMBL625348,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6084,,3132,A,In vivo,
Intermediate,,1,,,Bioavailability at a dose of 10 mg/kg peroral administration in mice.,,CHEMBL625349,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6085,,16597,A,In vivo,
Intermediate,,1,,,Oral bioavailability in mouse,,CHEMBL625350,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6086,,2862,A,In vivo,
Intermediate,,1,,,Oral bioavailability after intravenous administration in mice at 24 uM/kg,,CHEMBL882952,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6087,,17764,A,In vivo,
Intermediate,,1,,,Biodistribution of [123I]- labeled compound in mice brain was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,,CHEMBL625351,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6088,Brain,846,A,In vivo,955.0
Intermediate,,1,,,Biodistribution of [123I]- labeled compound in mice brain was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,,CHEMBL625352,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6089,Brain,846,A,In vivo,955.0
Intermediate,,1,,,Biodistribution of [123I]- labeled compound in mice brain was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,,CHEMBL877592,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6090,Brain,846,A,In vivo,955.0
Intermediate,,1,,,Biodistribution of [123I]- labeled compound in mice brain was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,,CHEMBL625353,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6091,Brain,846,A,In vivo,955.0
Intermediate,,1,,,Biodistribution of [123I]- labeled compound in mice brain was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,,CHEMBL625354,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6092,Brain,846,A,In vivo,955.0
Intermediate,,1,,,Biodistribution of [123I]- labeled compound in mice brain was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,,CHEMBL626019,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6093,Brain,846,A,In vivo,955.0
Intermediate,,1,,,Biodistribution of [123I]- labeled compound in mice heart was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,,CHEMBL626020,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6094,Heart,846,A,In vivo,948.0
Intermediate,,1,,,Biodistribution of [123I]- labeled compound in mice heart was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,,CHEMBL626021,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6095,Heart,846,A,In vivo,948.0
Intermediate,,1,,,Biodistribution of [123I]- labeled compound in mice heart was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,,CHEMBL626022,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6096,Heart,846,A,In vivo,948.0
Intermediate,,1,,,Biodistribution of [123I]- labeled compound in mice heart was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,,CHEMBL626192,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6097,Heart,846,A,In vivo,948.0
Intermediate,,1,A549,,Cytotoxic activity was tested against human prostate cell line A-549 (lung carcinoma),,CHEMBL626193,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6098,,1276,F,,
Expert,,1,A549,,Cytotoxicity against A-549 cell line in the purdue cell culture screen was determined,,CHEMBL626194,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6099,,3498,F,,
Intermediate,,1,A549,,Cytotoxicity against human lung carcinoma A-549 cell lines,,CHEMBL626195,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6100,,1169,F,,
Intermediate,,1,A549,,In vitro cytotoxic activity against A-549 (human lung carcinoma) cell line,,CHEMBL626196,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6101,,4450,F,,
Intermediate,,1,A549,,In vitro cytotoxicity against human lung carcinoma cell line A-549,,CHEMBL626197,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6102,,358,F,,
Intermediate,,1,A549,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 3.6*10e-5 M,,CHEMBL626198,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6103,,358,F,,
Intermediate,,1,A549,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.2*10e-5M,,CHEMBL626199,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6104,,358,F,,
Intermediate,,1,A549,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.3*10e-5M,,CHEMBL626200,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6105,,358,F,,
Intermediate,,1,A549,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 5.0*10e-5M,,CHEMBL626201,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6106,,358,F,,
Intermediate,,1,A549,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 6.1*10e-5 M,,CHEMBL626202,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6107,,358,F,,
Intermediate,,1,A549,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 7.4*10e-5 M,,CHEMBL626203,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6108,,358,F,,
Intermediate,,1,A549,,In vitro cytotoxicity against A-549 human lung cancer cells,,CHEMBL626204,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6109,,15167,F,,
Intermediate,,1,A549,,In vitro cytotoxicity against human lung carcinoma (A-549) cell line,,CHEMBL624701,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6110,,4139,F,,
Intermediate,,1,A549,,In vitro cytotoxicity in human tumor lung carcinoma A-549 cell lines,,CHEMBL624702,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6111,,833,F,,
Expert,,1,A549,,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,,CHEMBL624703,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6112,,15718,F,,
Intermediate,,1,A549,,Tested in vitro for cytotoxicity against A-549 lung cancer cells,,CHEMBL624704,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6113,,12373,F,,
Intermediate,,1,A549,,The compound was tested for cytotoxicity against A-549 cell in human lung carcinoma,,CHEMBL624705,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6114,,637,F,,
Expert,,1,A549,,Cytotoxicity against human lung carcinoma cells (A-549) using SRB assay.,,CHEMBL624706,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6115,,14867,F,,
Intermediate,,1,A549,,Antitumor cytotoxic activity against A-549 cell line was determined,,CHEMBL624707,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6116,,4461,F,,
Intermediate,,1,A549,,"Tested for the cytotoxicity against the Non-small cell lung cancer cell line A-549, growth inhibition by 50% is reported",,CHEMBL624708,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6117,,5406,F,,
Intermediate,,1,A549,,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,,CHEMBL624709,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6118,,4457,F,,
Expert,,1,A549,,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,,CHEMBL884107,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6119,,1386,F,,
Intermediate,,1,A549,,Antitumoral activity was assayed against A-549 cell line,,CHEMBL624710,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6120,,3265,F,,
Intermediate,,1,A549,,Compound was evaluated for the cytotoxicity against A-549 tumor cell line after 3 days of incubation,,CHEMBL624711,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6121,,2359,F,,
Intermediate,,1,A549,,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,,CHEMBL624712,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6122,,4457,F,,
Expert,,1,A549,,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,,CHEMBL624713,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6123,,12454,F,,
Intermediate,,1,A549,,Compound was tested for inhibition of cell growth of A-549 cells,,CHEMBL624714,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6124,,1481,F,,
Intermediate,,1,A549,,Compound was tested for its inhibitory effect on the growth of A-549 tumor cell line from lung.,,CHEMBL624715,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6125,,1750,F,,
Intermediate,,1,A549,,Concentration required for 50% inhibition of growth in human lung carcinoma cell line was determined,,CHEMBL624716,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6126,,5065,F,,
Expert,,1,A549,,In vitro cytotoxicity against A549-human lung carcinoma cells.,,CHEMBL619505,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6127,,808,F,,
Expert,,1,A549,,Cytotoxic activity against cultured cells of A-549 human lung carcinoma.,,CHEMBL619506,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6128,,16364,F,,
Intermediate,,1,A549,,Cytotoxic activity against A-549 cell lines.,,CHEMBL619507,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6129,,1847,F,,
Expert,,1,A549,,Cytotoxicity was measured against neoplastic cultured A-549 cells of human lung carcinoma.,,CHEMBL619508,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6130,,1747,F,,
Intermediate,,1,A549,,Cytotoxicity against human A549 non small cell lung cell lines,,CHEMBL619509,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6131,,1003,F,,
Expert,,1,A549,,Inhibition of cell growth in (A-549) lung cell line,,CHEMBL619510,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6132,,15313,F,,
Intermediate,,1,A549,,Growth inhibitory effect of compound was measured on A-549 human lung adenocarcinoma cancer cell line,,CHEMBL619511,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6133,,3122,F,,
Intermediate,,1,A549,,In vitro antitumor activity against A-549 tumor cells.,,CHEMBL619512,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6134,,16049,F,,
Expert,,1,A549,,In vitro antitumor effects against human A-549 cell lines.,,CHEMBL619513,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6135,,17134,F,,
Intermediate,,1,A549,,In vitro cytotoxic activity of compound against A-549 cell line,,CHEMBL619514,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6136,,6406,F,,
Intermediate,,1,A549,,In vitro cytotoxicity against human lung carcinoma A-549 cell line,,CHEMBL619515,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6137,,627,F,,
Intermediate,,1,A549,,In vitro cytotoxicity against human non-small cell lung carcinoma A549,,CHEMBL619516,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6138,,12307,F,,
Intermediate,,1,A549,,In vitro cytotoxicity against human A-549 cancer cell line was evaluated,,CHEMBL884005,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6139,,17861,F,,
Expert,,1,A549,,In vitro cytotoxicity against the A-549 (human lung carcinoma) neoplastic cell line,,CHEMBL619517,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6140,,6682,F,,
Intermediate,,1,A549,,Inhibitory concentration of compound against A-549 cell line,,CHEMBL619518,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6141,,6663,F,,
Intermediate,,1,A549,,Tested for the cytostatic activity as inhibitory concentration against A-549 human pulmonary adenocarcinoma cells,,CHEMBL619519,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6142,,2454,F,,
Intermediate,,1,A549,,cytotoxic activity against leukemia (A-549) cancer cell line,,CHEMBL876489,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6143,,14709,F,,
Expert,,1,A549,,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,,CHEMBL619520,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6144,,15718,F,,
Intermediate,,1,A549,,Percent inhibition for cytotoxic activity against lung carcinoma (A-549) cell line,,CHEMBL619521,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6145,,15718,F,,
Intermediate,,1,A549,,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.1(ug/ml),,CHEMBL619522,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6146,,17130,F,,
Intermediate,,1,A549,,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.4(ug/ml),,CHEMBL619523,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6147,,17130,F,,
Intermediate,,1,A549,,Cytotoxic activity of compound against A-549 cell lines at concentration of 1.1 (ug/ml),,CHEMBL619524,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6148,,17130,F,,
Intermediate,,1,A549,,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml),,CHEMBL619525,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6149,,17130,F,,
Intermediate,,1,A549,,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tometin; Not available,,CHEMBL619526,N,1,,646.0,,,BAO_0000219,80682,,6150,,6630,F,,
Intermediate,,1,A549,,Influence of PARP-1 cellular activity in human lung carcinoma A549 cells on %ADP Polymer formation at a concentration of 25 uM of the compound,,CHEMBL619527,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6151,,16726,F,,
Intermediate,,1,A549,,Cytotoxicity against A549 cells; No cytotoxicity,,CHEMBL619528,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6152,,17846,F,,
Expert,,1,A549,,Cytotoxicity against human lung carcinoma (A549) cell lines,,CHEMBL619529,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6153,,3415,F,,
Expert,,1,A549,,Cytotoxicity against human lung carcinoma (A549) cell lines; Not active,,CHEMBL619530,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6154,,3415,F,,
Intermediate,,1,A549,,In vitro anticancer activity against human lung (A549) cell line,,CHEMBL876490,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6155,,5609,F,,
Intermediate,,1,A549,,Percent growth inhibition at 200 uM PARP inhibitor in A549 cells,,CHEMBL619531,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6156,,17206,F,,
Intermediate,,1,A549,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..006 uM compound concentration in A549 cells,,CHEMBL619532,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6157,,17206,F,,
Intermediate,,1,A549,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..03 uM compound concentration in A549 cells,,CHEMBL619533,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6158,,17206,F,,
Intermediate,,1,A549,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..15 uM compound concentration in A549 cells,,CHEMBL619534,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6159,,17206,F,,
Intermediate,,1,A549,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..4 uM compound concentration in A549 cells,,CHEMBL620164,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6160,,17206,F,,
Intermediate,,1,A549,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,,CHEMBL620165,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6161,,17206,F,,
Expert,,1,A549,,Inhibition of A549 human lung tumor cell proliferation,,CHEMBL620166,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6162,,16295,F,,
Intermediate,,1,A549,,"Concentration required to inhibit the lung A549 cell growth by 50%,P53 status of cell line used was wild-type. ",,CHEMBL620167,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6163,,16825,F,,
Expert,,1,A549,,In vitro cytotoxicity against human tumor cell line A549,,CHEMBL620168,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6164,,3439,F,,
Intermediate,,1,A549,,In vitro growth inhibitory activity against A549 human nonsmall cell lung carcinoma cells. ,,CHEMBL620338,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6165,,10870,F,,
Intermediate,,1,A549,,Inhibitory concentration of compound against proliferation of lung carcinoma A549 cell line,,CHEMBL620339,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6166,,4845,F,,
Intermediate,,1,A549,,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells,,CHEMBL620340,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6167,,5822,F,,
Intermediate,,1,A549,,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells,,CHEMBL620341,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6168,,5822,F,,
Intermediate,,1,A549,,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells: Not tested,,CHEMBL876491,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6169,,5822,F,,
Intermediate,,1,A549,,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,,CHEMBL620342,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6170,,16381,F,,
Intermediate,,1,A549,,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,,CHEMBL620343,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6171,,16381,F,,
Intermediate,,1,A549,,% inhibition against A549 cells (lung cancer) at 4 ug/mL,,CHEMBL620344,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6172,,16381,F,,
Intermediate,,1,A549,,In vitro anticancer activity against human lung (A549) cell line,,CHEMBL620345,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6173,,5609,F,,
Intermediate,,1,A549,,Inhibition of proliferation of A549 cells at concentration of 0.1 uM was determined,,CHEMBL620346,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6174,,4644,F,,
Intermediate,,1,A549,,Inhibition of proliferation of A549 cells at concentration of 100 uM was determined,,CHEMBL620347,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6175,,4644,F,,
Intermediate,,1,A549,,Inhibition of proliferation of A549 cells at concentration of 10 uM was determined,,CHEMBL620348,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6176,,4644,F,,
Intermediate,,1,A549,,Inhibition of proliferation of A549 cells at concentration of 1 uM was determined,,CHEMBL620349,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6177,,4644,F,,
Intermediate,,1,A549,,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells at 20 uM,,CHEMBL618667,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6178,,5822,F,,
Expert,,1,A549,,Percentage inhibition of human lung carcinoma (A549) cell lines,,CHEMBL618668,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6179,,3415,F,,
Intermediate,,1,A549,,Influence of PARP-1 cellular activity on NAD+ levels at a concentration of 25 uM of the compound,,CHEMBL876031,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6180,,16726,F,,
Intermediate,,1,A549,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM); ND denotes not determined",,CHEMBL618759,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6181,,17206,F,,
Intermediate,,1,A549,,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells; ND denotes not determined,,CHEMBL618760,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6182,,17206,F,,
Intermediate,,1,A549,,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells; ND denotes not determined,,CHEMBL619000,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6183,,17206,F,,
Intermediate,,1,A549,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM)",,CHEMBL619001,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6184,,17206,F,,
Intermediate,,1,A549,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.006 uM",,CHEMBL619002,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6185,,17206,F,,
Intermediate,,1,A549,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.03 uM",,CHEMBL619003,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6186,,17206,F,,
Intermediate,,1,A549,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.15 uM",,CHEMBL619597,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6187,,17206,F,,
Intermediate,,1,A549,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.4 uM",,CHEMBL619598,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6188,,17206,F,,
Intermediate,,1,A549,,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells,,CHEMBL619599,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6189,,17206,F,,
Intermediate,,1,A549,,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells,,CHEMBL619600,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6190,,17206,F,,
Intermediate,,1,A549,,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,,CHEMBL619601,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6191,,16726,F,,
Intermediate,,1,A549,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.006 uM compound concentration in A549 cells,,CHEMBL619602,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6192,,17206,F,,
Intermediate,,1,A549,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.03 uM compound concentration in A549 cells,,CHEMBL619603,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6193,,17206,F,,
Intermediate,,1,A549,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.15 uM compound concentration in A549 cells,,CHEMBL619604,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6194,,17206,F,,
Intermediate,,1,A549,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.4 uM compound concentration in A549 cells,,CHEMBL619605,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6195,,17206,F,,
Intermediate,,1,,,Pharmacokinetic activity (Cmax) (10 mg/kg) was determined in dog,,CHEMBL619606,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6196,,6084,A,In vivo,
Intermediate,,1,,,Pharmacokinetic activity (Cmax) in dog,,CHEMBL876032,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6197,,6084,A,In vivo,
Intermediate,,1,,,Pharmacokinetic parameter Cmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),,CHEMBL619607,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6198,,4809,A,In vivo,
Intermediate,,1,,,Pharmacokinetic property (Cmax) was measured in dog at the dose of 0.032 mg/kg,,CHEMBL619608,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6199,,5983,A,In vivo,
Intermediate,,1,,,Plasma clearance rate by iv administration in dog at a dose of 6 mg/kg,,CHEMBL619609,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6200,,6251,A,In vivo,
Intermediate,,1,,,Cmax in dog plasma after 30mg/kg oral dose,,CHEMBL619610,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6201,Plasma,5932,A,In vivo,1969.0
Intermediate,,1,,,Tested for the peak blood level in dog,,CHEMBL619611,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6202,Blood,4273,A,In vivo,178.0
Intermediate,,1,,,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog",,CHEMBL619612,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6203,,5313,A,In vivo,
Intermediate,,1,,,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog at dosage of 10 mpk",,CHEMBL619613,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6204,,5313,A,In vivo,
Intermediate,,1,,,The peak blood concentration after 5 hr administration (2.5 mg/kg) in dog was determined,,CHEMBL619614,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6205,Blood,6221,A,In vivo,178.0
Intermediate,,1,,,Concentration in the plasma after intravenous administration of 1 mg/kg in dog,,CHEMBL619615,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6206,,4709,A,,
Intermediate,,1,,,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Dog at maximum of 0.3 hours,,CHEMBL619616,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6207,,167,A,,
Intermediate,,1,,,Final plasma concentration in dogs after oral administration at 1 mg/kg,,CHEMBL619617,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6208,Plasma,6241,A,,1969.0
Intermediate,,1,,,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 300 min,,CHEMBL619618,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6209,,344,A,,
Intermediate,,1,,,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 30 min,,CHEMBL876033,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6210,,344,A,,
Intermediate,,1,,,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 60 min,,CHEMBL619619,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6211,,344,A,,
Intermediate,,1,,,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by dogs,,CHEMBL619620,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6212,,2189,A,,
Intermediate,,1,,,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs,,CHEMBL619621,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6213,Urine,2189,A,,1088.0
Intermediate,,1,,,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs; NA is <10% inhibition at 1 uM for binding data,,CHEMBL619622,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6214,Urine,2189,A,,1088.0
Intermediate,,1,,,Percent of radioactive dose in urine and feces excreted in 0-24 hr by dogs; NA is <10% inhibition at 1 uM for binding data,,CHEMBL618874,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6215,Urine,2189,A,,1088.0
Intermediate,,1,,,Absolute bioavailability was evaluated in dog,,CHEMBL618875,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6216,,4257,A,In vivo,
Intermediate,,1,,,Bioavailability after oral administration (2.5 mg/kg) in dog was determined,,CHEMBL618876,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6217,,6221,A,In vivo,
Intermediate,,1,,,Bioavailability after peroral administration (1 mg/kg) was determined in dog,,CHEMBL618877,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6218,,6215,A,In vivo,
Intermediate,,1,,,Bioavailability in dog,,CHEMBL618878,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6219,,17267,A,In vivo,
Intermediate,,1,,,Bioavailability in dog,,CHEMBL618879,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6220,,6621,A,In vivo,
Intermediate,,1,,,Bioavailability after intravenous administration in dogs,,CHEMBL618880,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6221,,3854,A,In vivo,
Intermediate,,1,,,Bioavailability after peroral administration in dogs,,CHEMBL618881,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6222,,3854,A,In vivo,
Intermediate,,1,,,Bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),,CHEMBL618882,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6223,,5007,A,In vivo,
Intermediate,,1,,,Bioavailability in dog (Beagle) (male) (dose 3 mg/kg i.v. and 10 mg/kg p.o.) measured from 1 to 24 hr,,CHEMBL624226,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6224,,4333,A,In vivo,
Intermediate,,1,,,Bioavailability in plasma of male Beagle dogs treated with 3 mg/kg (i.v.) and 10 mg/kg (p.o.) measured from 1 to 24 hr; ND indicates not determined,,CHEMBL624227,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6225,Plasma,4333,A,In vivo,1969.0
Intermediate,,1,,,Bioavailability,,CHEMBL624228,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6226,,5006,A,In vivo,
Intermediate,,1,,,Bioavailability,,CHEMBL624229,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6227,,5199,A,In vivo,
Intermediate,,1,,,Bioavailability by intravenous administration of 1.2 mg/kg in dog,,CHEMBL624230,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6228,,4368,A,In vivo,
Intermediate,,1,,,Bioavailability in dog,,CHEMBL624231,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6229,,3771,A,In vivo,
Intermediate,,1,,,Bioavailability in dog,,CHEMBL624232,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6230,,4953,A,In vivo,
Intermediate,,1,,,Bioavailability in dog,,CHEMBL625127,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6231,,5064,A,In vivo,
Intermediate,,1,,,Bioavailability in dog,,CHEMBL625128,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6232,,17657,A,In vivo,
Intermediate,,1,,,Bioavailability in dog,,CHEMBL621675,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6233,,17796,A,In vivo,
Intermediate,,1,,,Bioavailability in dog (p.o.) at 2.0 mpk,,CHEMBL621676,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6234,,17853,A,In vivo,
Intermediate,,1,,,Bioavailability in dog (dose 2 mg/kg p.o. and 0.5 mg/kg i.v.),,CHEMBL621677,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6235,,4521,A,In vivo,
Intermediate,,1,,,Bioavailability in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,,CHEMBL621678,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6236,,4521,A,In vivo,
Intermediate,,1,,,Bioavailability in dog,,CHEMBL621679,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6237,,5006,A,In vivo,
Intermediate,,1,,,Bioavailability was evaluated after oral administration in dog,,CHEMBL621680,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6238,,16365,A,In vivo,
Intermediate,,1,,,Bioavailability was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,CHEMBL621681,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6239,,1916,A,In vivo,
Intermediate,,1,,,Bioavailability was evaluated in dog,,CHEMBL876740,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6240,,1918,A,In vivo,
Intermediate,,1,,,Bioavailability in dog,,CHEMBL621682,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6241,,4239,A,In vivo,
Intermediate,,1,,,Bioavailability in dog,,CHEMBL621683,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6242,,6505,A,In vivo,
Intermediate,,1,,,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),,CHEMBL621684,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6243,,5334,A,In vivo,
Intermediate,,1,,,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),,CHEMBL621685,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6244,,5334,A,In vivo,
Intermediate,,1,,,Bioavailability was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),,CHEMBL621686,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6245,,4809,A,In vivo,
Intermediate,,1,,,Bioavailability was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,CHEMBL621687,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6246,,6348,A,In vivo,
Intermediate,,1,,,Bioavailability was evaluated in dog after peroral administration at a dose of 1 mg/kg,,CHEMBL621688,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6247,,6005,A,In vivo,
Intermediate,,1,,,Bioavailability of compound in dog was determined after peroral administration,,CHEMBL621689,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6248,,17804,A,In vivo,
Intermediate,,1,,,Oral bioavailability in dog,,CHEMBL621690,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6249,,3184,A,In vivo,
Intermediate,,1,,,Compound was evaluated for oral bioavailability at different dose 27.5 mg/kg DMP323 equiv in dogs,,CHEMBL621691,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6250,,1806,A,In vivo,
Intermediate,,1,,,Compound was evaluated for oral bioavailability at different dose 7.7 mg/kg DMP323 equiv in dogs,,CHEMBL875941,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6251,,1806,A,In vivo,
Intermediate,,1,,,Compound was evaluated for oral bioavailability in dogs; 37-38 %,,CHEMBL621692,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6252,,1806,A,In vivo,
Intermediate,,1,,,Bioavailability in dog,,CHEMBL621693,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6253,,4839,A,In vivo,
Intermediate,,1,,,Oral bioavailability in dog (1 mg/kg p.o. and 0.2 mg/kg i.v.),,CHEMBL621694,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6254,,5017,A,In vivo,
Intermediate,,1,,,Biodistribution of [123I]- labeled compound in mice heart was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,,CHEMBL621695,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6255,Heart,846,A,In vivo,948.0
Intermediate,,1,,,Biodistribution of [123I]- labeled compound in mice heart was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,,CHEMBL621696,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6256,Heart,846,A,In vivo,948.0
Intermediate,,1,,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,,CHEMBL621697,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6257,Kidney,846,A,In vivo,2113.0
Intermediate,,1,,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,,CHEMBL621698,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6258,Kidney,846,A,In vivo,2113.0
Intermediate,,1,,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,,CHEMBL623420,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6259,Kidney,846,A,In vivo,2113.0
Intermediate,,1,,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,,CHEMBL623421,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6260,Kidney,846,A,In vivo,2113.0
Intermediate,,1,,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,,CHEMBL623422,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6261,Kidney,846,A,In vivo,2113.0
Intermediate,,1,,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,,CHEMBL623423,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6262,Kidney,846,A,In vivo,2113.0
Intermediate,,1,,,Biodistribution of [123I]- labeled compound in mice liver was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,,CHEMBL623424,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6263,Liver,846,A,In vivo,2107.0
Intermediate,,1,,,Biodistribution of [123I]- labeled compound in mice liver was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,,CHEMBL623425,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6264,Liver,846,A,In vivo,2107.0
Intermediate,,1,,,Biodistribution of [123I]- labeled compound in mice liver was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,,CHEMBL623426,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6265,Liver,846,A,In vivo,2107.0
Intermediate,,1,,,Biodistribution of [123I]- labeled compound in mice liver was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,,CHEMBL623427,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6266,Liver,846,A,In vivo,2107.0
Intermediate,,1,,,Biodistribution of [123I]- labeled compound in mice liver was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,,CHEMBL623428,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6267,Liver,846,A,In vivo,2107.0
Intermediate,,1,,,Biodistribution of [123I]- labeled compound in mice liver was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,,CHEMBL875947,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6268,Liver,846,A,In vivo,2107.0
Intermediate,,1,,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,,CHEMBL623429,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6269,Lung,846,A,In vivo,2048.0
Intermediate,,1,,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,,CHEMBL623430,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6270,Lung,846,A,In vivo,2048.0
Intermediate,,1,,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,,CHEMBL622588,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6271,Lung,846,A,In vivo,2048.0
Intermediate,,1,,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,,CHEMBL622589,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6272,Lung,846,A,In vivo,2048.0
Intermediate,,1,,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,,CHEMBL622751,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6273,Lung,846,A,In vivo,2048.0
Intermediate,,1,,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,,CHEMBL622752,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6274,Lung,846,A,In vivo,2048.0
Intermediate,,1,CCRF S-180,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 1 hour,,CHEMBL622753,N,1,,42.0,Mus musculus,10090.0,BAO_0000218,50594,,6275,,6599,A,,
Intermediate,,1,CCRF S-180,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 2 hours,,CHEMBL622647,N,1,,42.0,Mus musculus,10090.0,BAO_0000218,50594,,6276,,6599,A,,
Intermediate,,1,CCRF S-180,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 30 minutes,,CHEMBL875163,N,1,,42.0,Mus musculus,10090.0,BAO_0000218,50594,,6277,,6599,A,,
Intermediate,,1,CCRF S-180,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 4 hours,,CHEMBL622648,N,1,,42.0,Mus musculus,10090.0,BAO_0000218,50594,,6278,,6599,A,,
Intermediate,,1,CCRF S-180,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 8 hours,,CHEMBL622649,N,1,,42.0,Mus musculus,10090.0,BAO_0000218,50594,,6279,,6599,A,,
Intermediate,,1,CCRF S-180,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice brain bearing S180 tumor cell line for 1 hour,,CHEMBL622650,N,1,,42.0,Mus musculus,10090.0,BAO_0000218,50594,,6280,Brain,6599,A,,955.0
Intermediate,,1,CCRF S-180,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 2 hours,,CHEMBL622651,N,1,,42.0,Mus musculus,10090.0,BAO_0000218,50594,,6281,Brain,6599,A,,955.0
Intermediate,,1,CCRF S-180,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 30 minutes,,CHEMBL622652,N,1,,42.0,Mus musculus,10090.0,BAO_0000218,50594,,6282,Brain,6599,A,,955.0
Intermediate,,1,CCRF S-180,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 4 hours,,CHEMBL622653,N,1,,42.0,Mus musculus,10090.0,BAO_0000218,50594,,6283,Brain,6599,A,,955.0
Intermediate,,1,CCRF S-180,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 8 hours,,CHEMBL622654,N,1,,42.0,Mus musculus,10090.0,BAO_0000218,50594,,6284,Brain,6599,A,,955.0
Intermediate,,1,CCRF S-180,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 1 hour,,CHEMBL622655,N,1,,42.0,Mus musculus,10090.0,BAO_0000218,50594,,6285,Heart,6599,A,,948.0
Intermediate,,1,CCRF S-180,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 2 hours,,CHEMBL622656,N,1,,42.0,Mus musculus,10090.0,BAO_0000218,50594,,6286,Heart,6599,A,,948.0
Intermediate,,1,CCRF S-180,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 30 minutes,,CHEMBL622657,N,1,,42.0,Mus musculus,10090.0,BAO_0000218,50594,,6287,Heart,6599,A,,948.0
Intermediate,,1,CCRF S-180,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 4 hours,,CHEMBL622658,N,1,,42.0,Mus musculus,10090.0,BAO_0000218,50594,,6288,Heart,6599,A,,948.0
Intermediate,,1,CCRF S-180,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 8 hours,,CHEMBL622659,N,1,,42.0,Mus musculus,10090.0,BAO_0000218,50594,,6289,Heart,6599,A,,948.0
Intermediate,,1,CCRF S-180,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 1 hour,,CHEMBL624630,N,1,,42.0,Mus musculus,10090.0,BAO_0000218,50594,,6290,Kidney,6599,A,,2113.0
Intermediate,,1,CCRF S-180,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 2 hours,,CHEMBL624631,N,1,,42.0,Mus musculus,10090.0,BAO_0000218,50594,,6291,Kidney,6599,A,,2113.0
Intermediate,,1,CCRF S-180,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 30 minutes,,CHEMBL624632,N,1,,42.0,Mus musculus,10090.0,BAO_0000218,50594,,6292,Kidney,6599,A,,2113.0
Intermediate,,1,A549,,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml) on,,CHEMBL624633,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6293,,17130,F,,
Intermediate,,1,A549,,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml)on,,CHEMBL624634,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6294,,17130,F,,
Intermediate,,1,A549,,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml),,CHEMBL624635,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6295,,17130,F,,
Intermediate,,1,A549,,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml)),,CHEMBL624636,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6296,,17130,F,,
Expert,,1,A549,,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,,CHEMBL857055,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6297,,3263,F,,
Expert,,1,A549,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-4 mol/L,,CHEMBL624637,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6298,,6663,F,,
Expert,,1,A549,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-5 mol/L,,CHEMBL624638,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6299,,6663,F,,
Expert,,1,A549,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-6 mol/L,,CHEMBL874366,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6300,,6663,F,,
Expert,,1,A549,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-7 mol/L,,CHEMBL624639,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6301,,6663,F,,
Expert,,1,A549,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-8 mol/L,,CHEMBL624640,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6302,,6663,F,,
Intermediate,,1,A549,,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.0625 uM,,CHEMBL624641,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6303,,6663,F,,
Intermediate,,1,A549,,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.125 uM,,CHEMBL624642,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6304,,6663,F,,
Intermediate,,1,A549,,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.25 uM,,CHEMBL624643,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6305,,6663,F,,
Intermediate,,1,A549,,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.5 uM,,CHEMBL624644,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6306,,6663,F,,
Intermediate,,1,A549,,Rate of inhibition of A-549 tumor cell growth at a concentration of 1 uM,,CHEMBL624645,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6307,,6663,F,,
Intermediate,,1,A549,,The compound was evaluated for its cytotoxic potency against A-549 cell line,,CHEMBL619445,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6308,,3983,F,,
Expert,,1,A549,,Cytotoxic concentration required to inhibit 50% cell growth in A-549 lung carcinoma cell lines,,CHEMBL839886,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6309,,11141,F,,
Intermediate,,1,A549,,Cytotoxic activity of compound against A-549 tumor cell line.,,CHEMBL619446,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6310,,5076,F,,
Intermediate,,1,A549,,In vitro cytotoxicity against Lung A-549 human tumors following a 6 day exposure.,,CHEMBL619447,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6311,,3311,F,,
Intermediate,,1,A549,,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure.,,CHEMBL619448,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6312,,3311,F,,
Intermediate,,1,A549,,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure; ND is no data,,CHEMBL619449,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6313,,3311,F,,
Intermediate,,1,A549,,Cytotoxic activity of compound against A-549 tumor cell line at conc. of 20 ug/mL,,CHEMBL619450,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6314,,5076,F,,
Intermediate,,1,A549,,Compound was tested for cytotoxic activity against A-549 human lung carcinoma (ATCC:CCL-185),,CHEMBL619451,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6315,,4150,F,,
Expert,,1,A549,,In vitro inhibitory concentration against cell culture of A-549 human lung carcinoma,,CHEMBL619452,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6316,,2150,F,,
Intermediate,,1,A549,,Concentration for in vitro cytotoxicity against A-549 human lung tumor cells,,CHEMBL619453,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6317,,4644,F,,
Intermediate,,1,A549,,Dose required for in vitro cytotoxic activity against A-549 lung carcinoma cells at concentration of 10 ug/ml; NA is no cytotoxicity,,CHEMBL874367,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6318,,263,F,,
Intermediate,,1,A549,,Cytotoxic concentration against A-549 tumor cells.,,CHEMBL619454,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6319,,11333,F,,
Intermediate,,1,A549,,Cytotoxic concentration against A-549 tumor cells; Inactive at 10 ug/mL.,,CHEMBL619455,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6320,,11333,F,,
Intermediate,,1,A549,,"Cytotoxicity against NCI tumor panel, A-549/ATCC non small-cell lung cancer cell line",,CHEMBL619456,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6321,,15895,F,,
Expert,,1,,,Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Acinetobacter baumannii 118A,,CHEMBL619457,N,1,,,Acinetobacter baumannii,470.0,BAO_0000218,50191,,6322,,16677,F,,
Intermediate,,1,,,Activity against Acinetobacter calcoaceticus (AC54),,CHEMBL619458,N,1,,,Acinetobacter calcoaceticus,471.0,BAO_0000218,50192,,6323,,10624,F,,
Expert,,1,,,In vitro antifungal activity against Aspergillus flavus CM74,,CHEMBL619459,N,1,,,Aspergillus flavus,5059.0,BAO_0000218,50274,,6324,,16717,F,,
Expert,,1,,,In vitro antifungal activity against Aspergillus flavus CM74,,CHEMBL619460,N,1,,,Aspergillus flavus,5059.0,BAO_0000218,50274,,6325,,16717,F,,
Intermediate,,1,,,Inhibitory activity tested against Aspergillus fumigatus at 256 ug/mL concentration,,CHEMBL619461,N,1,,,Aspergillus fumigatus,746128.0,BAO_0000218,50416,,6326,,5513,F,,
Intermediate,,1,,,In vitro minimum fungicidal concentration required to inhibit Aspergillus fumigatus(MFC),,CHEMBL619462,N,1,,,Aspergillus fumigatus,746128.0,BAO_0000218,50416,,6327,,15962,F,,
Intermediate,,1,,,Antimicrobial activity against Aspergillus fumigatus (MIC),,CHEMBL620388,N,1,,,Aspergillus fumigatus,746128.0,BAO_0000218,50416,,6328,,15962,F,,
Intermediate,,1,,,Antimicrobial activity against Aspergillus fumigatus (MIC),,CHEMBL620389,N,1,,,Aspergillus fumigatus,746128.0,BAO_0000218,50416,,6329,,15962,F,,
Intermediate,,1,,,In vitro antimicrobial activity against Aspergillus fumigatus (MIC),,CHEMBL620390,N,1,,,Aspergillus fumigatus,746128.0,BAO_0000218,50416,,6330,,15962,F,,
Expert,,1,,,In vitro antifungal activity against Aspergillus fumigatus 48238E,,CHEMBL620391,N,1,,,Aspergillus fumigatus,746128.0,BAO_0000218,50416,,6331,,16717,F,,
Expert,,1,,,In vitro antifungal activity against Aspergillus fumigatus 48238E,,CHEMBL621073,N,1,,,Aspergillus fumigatus,746128.0,BAO_0000218,50416,,6332,,16717,F,,
Intermediate,,1,,,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces naeslundii 631,,CHEMBL621074,N,1,,,Actinomyces naeslundii,1655.0,BAO_0000218,50296,,6333,,8117,F,,
Intermediate,,1,,,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces viscosus M-100,,CHEMBL621075,N,1,,,Actinomyces viscosus,1656.0,BAO_0000218,50366,,6334,,8117,F,,
Intermediate,,1,,,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),,CHEMBL619554,N,1,,,Acanthocheilonema viteae,6277.0,BAO_0000218,50535,,6335,,15472,F,,
Intermediate,,1,,,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),,CHEMBL619555,N,1,,,Acanthocheilonema viteae,6277.0,BAO_0000218,50535,,6336,,15472,F,,
Intermediate,,1,,,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527,,CHEMBL619556,N,1,,,Aggregatibacter actinomycetemcomitans,714.0,BAO_0000218,50169,,6337,,16443,F,,
Intermediate,,1,,,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2,,CHEMBL619557,N,1,,,Aggregatibacter actinomycetemcomitans,714.0,BAO_0000218,50169,,6338,,16443,F,,
Intermediate,,1,,,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2; ND is Not Determined,,CHEMBL619558,N,1,,,Aggregatibacter actinomycetemcomitans,714.0,BAO_0000218,50169,,6339,,16443,F,,
Intermediate,,1,A549,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,,CHEMBL619559,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6340,,17206,F,,
Intermediate,,1,A549,,Percent ADP-ribose polymer formation at 25 uM compound concentration in A549 cells,,CHEMBL619560,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6341,,17206,F,,
Intermediate,,1,A549,,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,,CHEMBL619561,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6342,,16381,F,,
Intermediate,,1,A549,,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,,CHEMBL619562,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6343,,16381,F,,
Intermediate,,1,A549,,% inhibition against A549 cells (lung cancer) at 4 ug/mL,,CHEMBL619563,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6344,,16381,F,,
Intermediate,,1,A549,,GI values against A549 cells (lung cancer),,CHEMBL857457,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6345,,16381,F,,
Intermediate,,1,A549,,Effect on NAD+ depletion (% remaining versus vehicle control) 25 uM compound concentration in A549 cells,,CHEMBL619564,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6346,,17206,F,,
Intermediate,,1,A549,,Inhibitory activity against A549 human adenocarcinoma,,CHEMBL619565,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6347,,16325,F,,
Intermediate,,1,A549,,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 200 mg/kg,,CHEMBL619566,N,1,,646.0,Homo sapiens,9606.0,BAO_0000218,80682,,6348,,10708,F,,
Intermediate,,1,A549,,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 100 mg/kg,,CHEMBL619567,N,1,,646.0,Homo sapiens,9606.0,BAO_0000218,80682,,6349,,10708,F,,
Intermediate,,1,A549,,Inhibitory activity against A549 lung adenocarcinoma cell line,,CHEMBL619568,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6350,,17376,F,,
Intermediate,,1,A549,,Inhibitory activity against A549 lung adenocarcinoma cell line; not determined,,CHEMBL619569,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6351,,17376,F,,
Intermediate,,1,A549,,Cytotoxicity against human A549 lung cells,,CHEMBL619570,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6352,,17488,F,,
Intermediate,,1,A549,,In vivo percent inhibitory activity of intraperitoneally administered compound (50 mg/kg/day) against mice infected with A549 tumor,,CHEMBL619571,N,1,,646.0,Homo sapiens,9606.0,BAO_0000218,80682,,6353,,17404,F,,
Expert,,1,A549,,Growth inhibition of A549 (human lung carcinoma) cell line.,,CHEMBL619572,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6354,,10958,F,,
Expert,,1,A549,,Effective dose required for inhibitory activity against A549 human tumor cell line.,,CHEMBL619573,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6355,,17099,F,,
Intermediate,,1,A549,,Effective dose required for inhibitory activity against A549 human tumor cell line; Not active,,CHEMBL619574,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6356,,17099,F,,
Intermediate,,1,A549,,Cytotoxicity was evaluated against A549 tumor cell lines; Inactive,,CHEMBL619575,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6357,,4096,F,,
Expert,,1,A549,,Cytotoxicity evaluated against A549 tumor cell lines; significant activity,,CHEMBL619576,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6358,,4096,F,,
Intermediate,,1,A549,,Cytotoxicity was evaluated against A549 tumor cell lines; Slightly active,,CHEMBL619577,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6359,,4096,F,,
Intermediate,,1,A549,,In vitro inhibitory activity against A549 tumor cell culture,,CHEMBL619578,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6360,,2525,F,,
Intermediate,,1,A549,,In vitro inhibitory activity against A549 tumor cell culture; IA= Inactive,,CHEMBL884009,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6361,,2525,F,,
Intermediate,,1,A549,,Activity against human lung cancer with mutated beta-tubulin (A549-T2415),,CHEMBL619579,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6362,,5302,F,,
Intermediate,,1,A549,,Growth inhibitory activity was determined against A549/ATCC cancer cell line of non-small cell lung cancer,,CHEMBL619580,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6363,,16325,F,,
Intermediate,,1,A549,,Inhibition of growth of A549/ATCC nonsmall cell lung cancer cell line,,CHEMBL619581,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6364,,16939,F,,
Intermediate,,1,A549,,In vitro antitumor activity against NSCL A549/ATCC tumor cell lines,,CHEMBL619582,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6365,,17229,F,,
Intermediate,,1,A549,,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells,,CHEMBL619583,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6366,,17380,F,,
Intermediate,,1,A549,,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells; No data,,CHEMBL876502,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6367,,17380,F,,
Intermediate,,1,A549,,In vitro cytotoxicity against human Non-small cell lung cancer A549/ATCC cell line.,,CHEMBL619584,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6368,,1903,F,,
Intermediate,,1,A549,,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,,CHEMBL619585,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6369,,3838,F,,
Intermediate,,1,A549,,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,,CHEMBL619586,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6370,,14696,F,,
Intermediate,,1,A549,,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,,CHEMBL619587,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6371,,3838,F,,
Intermediate,,1,A549,,Tested for in vitro cytotoxicity against non-small cell lung cancer cell line A549/ATCC,,CHEMBL619588,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6372,,1522,F,,
Intermediate,,1,A549,,Tested in vitro for cytotoxicity in A549/ATCC cell lines,,CHEMBL619589,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6373,,12400,F,,
Intermediate,,1,A549,,inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,,CHEMBL619590,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6374,,14696,F,,
Intermediate,,1,A549,,Compound was evaluated for in vitro activity against A549/ATCC lung cancer cell lines (Human tumor cells ),,CHEMBL619591,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6375,,14769,F,,
Intermediate,,1,A549,,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line at 0.01 uM,,CHEMBL619592,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6376,,14696,F,,
Intermediate,,1,A549,,Compound was evaluated for cytotoxic activity against non-small lung cancer A549/ATCC cell lines.,,CHEMBL619593,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6377,,1888,F,,
Intermediate,,1,A549,,Tested for cytotoxic activity against non-small cell lung cancer A549/ATCC cell line,,CHEMBL620217,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6378,,12016,F,,
Intermediate,,1,A549,,Compound tested for growth inhibition of non-small cell lung cancer cell line A549/ATCC,,CHEMBL620218,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6379,,6058,F,,
Intermediate,,1,A549,,Compound was tested for 50% growth inhibition against human non-small cell lung cancer A549/ATCC cell line,,CHEMBL620219,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6380,,17708,F,,
Intermediate,,1,A549,,Antitumor activity against A549/ATCC cell line,,CHEMBL620220,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6381,,12301,F,,
Intermediate,,1,A549,,Tested for cytotoxicity against A549/ATCC cell lines in non-small-cell lung cancer,,CHEMBL625141,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6382,,11970,F,,
Expert,,1,A549,,In vitro cytotoxicity against A549/ATCC cell line.,,CHEMBL625142,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6383,,11818,F,,
Intermediate,,1,A549,,Tested in vitro for cytotoxicity in A549/ATCC cell line of Non-Small Cell Lung Cancer,,CHEMBL625143,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6384,,12400,F,,
Intermediate,,1,A549,,In vitro inhibition of Non-Small Cell Lung Cancer A549/ATCC cell lines,,CHEMBL625144,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6385,,3381,F,,
Intermediate,,1,A549,,Concentration of compound that cause 50% cytotoxicity of A549/ATCC non small cell lung cancer cell line,,CHEMBL622474,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6386,,17376,F,,
Intermediate,,1,A549,,Evaluated for the inhibitory concentration required to cause growth inhibition of A549Rem- cell line of lung using the MTT Cytotoxicity Assay,,CHEMBL884104,N,1,,646.0,Homo sapiens,9606.0,BAO_0000219,80682,,6387,,10708,F,,
Autocuration,,1,,,Cytotoxicity was evaluated against A649 human mammary carcinoma cells,,CHEMBL622475,U,0,,,Homo sapiens,9606.0,BAO_0000219,22226,,6388,,2964,F,,
Intermediate,,1,,,Compound was tested for oral bioavailability in dogs,,CHEMBL622476,U,0,,,Canis lupus familiaris,9615.0,BAO_0000218,22224,,6389,,5005,A,In vivo,
Intermediate,,1,,,Compound was tested for orally bioavailable in dogs with a half life of 0.7 hr,,CHEMBL875831,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6390,,6229,A,In vivo,
Intermediate,,1,,,Compound was tested for orally bioavailable in dogs with a half life of 1.2h,,CHEMBL622477,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6391,,6229,A,In vivo,
Intermediate,,1,,,Oral bioavailability in dog,,CHEMBL622478,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6392,,5374,A,In vivo,
Intermediate,,1,,,Compound was tested for the oral bioavailability in dog; No availability,,CHEMBL623172,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6393,,5374,A,In vivo,
Intermediate,,1,,,Oral bioavailability in dog (dose 5 mg/kg),,CHEMBL623173,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6394,,6265,A,In vivo,
Intermediate,,1,,,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,,CHEMBL623174,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6395,,5654,A,In vivo,
Intermediate,,1,,,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,,CHEMBL623175,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6396,,5654,A,In vivo,
Intermediate,,1,,,Oral bioavailability in Beagle dogs after Per oral administration at dose of 50(mg/kg),,CHEMBL623340,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6397,,16456,A,In vivo,
Intermediate,,1,,,Oral bioavailability in dog (dose 5 mg/kg),,CHEMBL623341,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6398,,5302,A,In vivo,
Intermediate,,1,,,Oral bioavailability in dog (p.o. dosing of 0.05 M citric acid/0.05 M hydrochloric acid solution),,CHEMBL623342,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6399,,3624,A,In vivo,
Intermediate,,1,,,Oral bioavailability of active FTIs in dogs,,CHEMBL623343,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6400,,16452,A,In vivo,
Intermediate,,1,,,Oral bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),,CHEMBL623344,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6401,,5802,A,In vivo,
Expert,,1,,,Oral bioavailability of compound determined in dog after iv administration at a dose of 10 mg/kg,,CHEMBL623345,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6402,,3598,A,In vivo,
Intermediate,,1,,,Oral bioavailability in dog,,CHEMBL875832,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6403,,17839,A,In vivo,
Intermediate,,1,,,Oral bioavailability in dog,,CHEMBL623346,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6404,,6762,A,In vivo,
Intermediate,,1,,,Oral bioavailability in dog,,CHEMBL623347,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6405,,6821,A,In vivo,
Intermediate,,1,,,Oral bioavailability of compound was determined in dog; Not tested,,CHEMBL623348,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6406,,6821,A,In vivo,
Intermediate,,1,,,Oral bioavailability in dog,,CHEMBL623349,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6407,,5210,A,In vivo,
Intermediate,,1,,,Oral bioavailability (10 mg/kg) was determined in dog,,CHEMBL623350,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6408,,6227,A,In vivo,
Intermediate,,1,,,Oral bioavailability,,CHEMBL623351,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6409,,761,A,In vivo,
Intermediate,,1,,,Oral bioavailability in dog (dosed as neat powder in hard gelatin capsule),,CHEMBL623352,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6410,,761,A,In vivo,
Intermediate,,1,,,Oral bioavailability administered in solution in rats,,CHEMBL623353,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6411,,761,A,In vivo,
Intermediate,,1,,,Oral bioavailability after 30 mg/kg po dose in Dogs,,CHEMBL875833,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6412,,16907,A,In vivo,
Intermediate,,1,,,Oral bioavailability at a dose of 1 mg/kg in dogs,,CHEMBL623354,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6413,,5474,A,In vivo,
Intermediate,,1,,,Oral bioavailability in dog (dose 1 mg/kg p.o.),,CHEMBL623355,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6414,,6535,A,In vivo,
Intermediate,,1,,,Oral bioavailability in Dog; ND = not determined,,CHEMBL623356,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6415,,6535,A,In vivo,
Intermediate,,1,,,Oral bioavailability in dog,,CHEMBL623357,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6416,,3352,A,In vivo,
Intermediate,,1,,,Oral bioavailability in dog,,CHEMBL623358,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6417,,6168,A,In vivo,
Intermediate,,1,,,Oral bioavailability in dog,,CHEMBL623359,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6418,,5988,A,In vivo,
Intermediate,,1,,,Oral bioavailability in dog,,CHEMBL623360,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6419,,4942,A,In vivo,
Intermediate,,1,,,Oral bioavailability in dogs; No data,,CHEMBL623361,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6420,,4942,A,In vivo,
Intermediate,,1,,,Oral bioavailability measured in dogs,,CHEMBL623362,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6421,,14541,A,In vivo,
Intermediate,,1,,,Oral bioavailability in dog,,CHEMBL623363,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6422,,4449,A,In vivo,
Intermediate,,1,,,Oral bioavailability was calculated in dog,,CHEMBL623364,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6423,,6057,A,In vivo,
Intermediate,,1,,,Oral bioavailability after 0.3 mg/kg po administration in dog,,CHEMBL875834,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6424,,5600,A,In vivo,
Intermediate,,1,,,Oral bioavailability in dog (i.v. dosing),,CHEMBL623365,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6425,,5542,A,In vivo,
Intermediate,,1,,,Oral bioavailability in dog,,CHEMBL623366,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6426,,5542,A,In vivo,
Intermediate,,1,,,Oral bioavailability in Beagle dog at a dose of 2 mg/kg by po administration,,CHEMBL623367,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6427,,5546,A,In vivo,
Intermediate,,1,,,Oral bioavailability in Beagle dogs,,CHEMBL623368,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6428,,4514,A,In vivo,
Intermediate,,1,,,Oral bioavailability in dog,,CHEMBL623369,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6429,,3624,A,In vivo,
Intermediate,,1,,,Oral bioavailability in dog,,CHEMBL623370,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6430,,3854,A,In vivo,
Intermediate,,1,,,Oral bioavailability in dog,,CHEMBL623371,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6431,,5836,A,In vivo,
Intermediate,,1,,,Oral bioavailability in dog,,CHEMBL623372,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6432,,5940,A,In vivo,
Intermediate,,1,,,Oral bioavailability in dog,,CHEMBL621351,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6433,,6168,A,In vivo,
Intermediate,,1,,,Oral bioavailability in dog,,CHEMBL621352,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6434,,6227,A,In vivo,
Intermediate,,1,,,Oral bioavailability in dog,,CHEMBL621353,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6435,,6251,A,In vivo,
Intermediate,,1,,,Oral bioavailability in dog,,CHEMBL621354,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6436,,6448,A,In vivo,
Intermediate,,1,,,Oral bioavailability in dog,,CHEMBL621355,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6437,,6647,A,In vivo,
Intermediate,,1,,,Oral bioavailability in dog,,CHEMBL621356,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6438,,5940,A,In vivo,
Intermediate,,1,,,Oral bioavailability in dog,,CHEMBL621357,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6439,,933,A,In vivo,
Intermediate,,1,,,Oral bioavailability in dog,,CHEMBL621358,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6440,,5210,A,In vivo,
Intermediate,,1,,,Oral bioavailability in dog (dosed as a mixture of five compounds at 0.5 mg/kg each via i.v. only),,CHEMBL621359,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6441,,6642,A,In vivo,
Intermediate,,1,,,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),,CHEMBL621360,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6442,,6641,A,In vivo,
Intermediate,,1,,,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),,CHEMBL621361,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6443,,6642,A,In vivo,
Intermediate,,1,,,Oral bioavailability in dog,,CHEMBL621362,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6444,,5472,A,In vivo,
Intermediate,,1,,,Oral bioavailability in dog,,CHEMBL621363,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6445,,5985,A,In vivo,
Intermediate,,1,,,Oral bioavailability in dog,,CHEMBL621364,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6446,,15660,A,In vivo,
Intermediate,,1,,,Oral bioavailability in dog (dose 0.2 mg/kg i.v.),,CHEMBL621166,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6447,,5530,A,In vivo,
Intermediate,,1,,,Oral bioavailability in dog (dose 1 mg/kg i.v.),,CHEMBL621167,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6448,,5530,A,In vivo,
Intermediate,,1,,,Oral bioavailability (F) in dogs,,CHEMBL621168,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6449,,6305,A,In vivo,
Intermediate,,1,,,Oral bioavailability in dog,,CHEMBL621169,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6450,,5210,A,In vivo,
Intermediate,,1,,,Bioavailability in dog,,CHEMBL875950,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6451,,5238,A,In vivo,
Intermediate,,1,,,Oral bioavailability in dog (dose 10 mg/kg),,CHEMBL621170,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6452,,5668,A,In vivo,
Intermediate,,1,,,Oral bioavailability after peroral administration at 5 mpk in Dog,,CHEMBL621171,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6453,,5668,A,In vivo,
Intermediate,,1,,,Oral bioavailability in dog (dose 5 mg/kg),,CHEMBL621172,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6454,,5668,A,In vivo,
Intermediate,,1,,,Oral bioavailability in dog (dose 10 mg/kg),,CHEMBL621173,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6455,,6084,A,In vivo,
Intermediate,,1,CCRF S-180,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 4 hours,,CHEMBL621174,N,1,,42.0,Mus musculus,10090.0,BAO_0000218,50594,,6456,Kidney,6599,A,,2113.0
Intermediate,,1,CCRF S-180,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 8 hours,,CHEMBL621175,N,1,,42.0,Mus musculus,10090.0,BAO_0000218,50594,,6457,Kidney,6599,A,,2113.0
Intermediate,,1,CCRF S-180,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 1 hour,,CHEMBL621176,N,1,,42.0,Mus musculus,10090.0,BAO_0000218,50594,,6458,Liver,6599,A,,2107.0
Intermediate,,1,CCRF S-180,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 2 hours,,CHEMBL621177,N,1,,42.0,Mus musculus,10090.0,BAO_0000218,50594,,6459,Liver,6599,A,,2107.0
Intermediate,,1,CCRF S-180,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 30 minutes,,CHEMBL621178,N,1,,42.0,Mus musculus,10090.0,BAO_0000218,50594,,6460,Liver,6599,A,,2107.0
Intermediate,,1,CCRF S-180,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 4 hours,,CHEMBL621179,N,1,,42.0,Mus musculus,10090.0,BAO_0000218,50594,,6461,Liver,6599,A,,2107.0
Intermediate,,1,CCRF S-180,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 8 hours,,CHEMBL621180,N,1,,42.0,Mus musculus,10090.0,BAO_0000218,50594,,6462,Liver,6599,A,,2107.0
Intermediate,,1,CCRF S-180,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 1 hour,,CHEMBL875951,N,1,,42.0,Mus musculus,10090.0,BAO_0000218,50594,,6463,Lung,6599,A,,2048.0
Intermediate,,1,CCRF S-180,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 2 hours,,CHEMBL621181,N,1,,42.0,Mus musculus,10090.0,BAO_0000218,50594,,6464,Lung,6599,A,,2048.0
Intermediate,,1,CCRF S-180,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 30 minutes,,CHEMBL621182,N,1,,42.0,Mus musculus,10090.0,BAO_0000218,50594,,6465,Lung,6599,A,,2048.0
Intermediate,,1,CCRF S-180,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 4 hours,,CHEMBL621183,N,1,,42.0,Mus musculus,10090.0,BAO_0000218,50594,,6466,Lung,6599,A,,2048.0
Intermediate,,1,CCRF S-180,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 8 hours,,CHEMBL621184,N,1,,42.0,Mus musculus,10090.0,BAO_0000218,50594,,6467,Lung,6599,A,,2048.0
Intermediate,,1,CCRF S-180,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 1 hour,,CHEMBL621185,N,1,,42.0,Mus musculus,10090.0,BAO_0000218,50594,,6468,,6599,A,,
Intermediate,,1,CCRF S-180,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice muscle bearing S180 tumor cell line for 2 hours,,CHEMBL621186,N,1,,42.0,Mus musculus,10090.0,BAO_0000218,50594,,6469,,6599,A,,
Intermediate,,1,CCRF S-180,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 30 minutes,,CHEMBL621187,N,1,,42.0,Mus musculus,10090.0,BAO_0000218,50594,,6470,,6599,A,,
Intermediate,,1,CCRF S-180,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 4 hours,,CHEMBL621188,N,1,,42.0,Mus musculus,10090.0,BAO_0000218,50594,,6471,,6599,A,,
Intermediate,,1,CCRF S-180,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 8 hours,,CHEMBL621189,N,1,,42.0,Mus musculus,10090.0,BAO_0000218,50594,,6472,,6599,A,,
Intermediate,,1,CCRF S-180,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice spleen bearing S180 tumor cell line for 1 hour,,CHEMBL621190,N,1,,42.0,Mus musculus,10090.0,BAO_0000218,50594,,6473,Spleen,6599,A,,2106.0
Intermediate,,1,CCRF S-180,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 2 hours,,CHEMBL618520,N,1,,42.0,Mus musculus,10090.0,BAO_0000218,50594,,6474,Spleen,6599,A,,2106.0
Intermediate,,1,CCRF S-180,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 30 minutes,,CHEMBL621739,N,1,,42.0,Mus musculus,10090.0,BAO_0000218,50594,,6475,Spleen,6599,A,,2106.0
Intermediate,,1,CCRF S-180,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 4 hours,,CHEMBL621740,N,1,,42.0,Mus musculus,10090.0,BAO_0000218,50594,,6476,Spleen,6599,A,,2106.0
Intermediate,,1,CCRF S-180,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 8 hours,,CHEMBL621741,N,1,,42.0,Mus musculus,10090.0,BAO_0000218,50594,,6477,Spleen,6599,A,,2106.0
Intermediate,,1,CCRF S-180,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 1 hour,,CHEMBL621742,N,1,,42.0,Mus musculus,10090.0,BAO_0000218,50594,,6478,,6599,A,,
Intermediate,,1,CCRF S-180,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 2 hours,,CHEMBL621743,N,1,,42.0,Mus musculus,10090.0,BAO_0000218,50594,,6479,,6599,A,,
Intermediate,,1,CCRF S-180,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 30 minutes,,CHEMBL621744,N,1,,42.0,Mus musculus,10090.0,BAO_0000218,50594,,6480,,6599,A,,
Intermediate,,1,CCRF S-180,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 4 hours,,CHEMBL621745,N,1,,42.0,Mus musculus,10090.0,BAO_0000218,50594,,6481,,6599,A,,
Intermediate,,1,CCRF S-180,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 8 hours,,CHEMBL621746,N,1,,42.0,Mus musculus,10090.0,BAO_0000218,50594,,6482,,6599,A,,
Intermediate,,1,CCRF S-180,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 1 hour,,CHEMBL621747,N,1,,42.0,Mus musculus,10090.0,BAO_0000218,50594,,6483,,6599,A,,
Intermediate,,1,CCRF S-180,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 2 hours,,CHEMBL621748,N,1,,42.0,Mus musculus,10090.0,BAO_0000218,50594,,6484,,6599,A,,
Intermediate,,1,CCRF S-180,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 30 minutes,,CHEMBL621749,N,1,,42.0,Mus musculus,10090.0,BAO_0000218,50594,,6485,,6599,A,,
Intermediate,,1,CCRF S-180,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 4 hours,,CHEMBL621750,N,1,,42.0,Mus musculus,10090.0,BAO_0000218,50594,,6486,,6599,A,,
Intermediate,,1,CCRF S-180,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 8 hours,,CHEMBL621751,N,1,,42.0,Mus musculus,10090.0,BAO_0000218,50594,,6487,,6599,A,,
Intermediate,,1,CCRF S-180,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 1 hour,,CHEMBL621752,N,1,,42.0,Mus musculus,10090.0,BAO_0000218,50594,,6488,Heart,6599,A,,948.0
Intermediate,,1,CCRF S-180,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 2 hours,,CHEMBL621753,N,1,,42.0,Mus musculus,10090.0,BAO_0000218,50594,,6489,Heart,6599,A,,948.0
Intermediate,,1,CCRF S-180,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 30 minutes,,CHEMBL875955,N,1,,42.0,Mus musculus,10090.0,BAO_0000218,50594,,6490,Heart,6599,A,,948.0
Intermediate,,1,CCRF S-180,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 4 hours,,CHEMBL621754,N,1,,42.0,Mus musculus,10090.0,BAO_0000218,50594,,6491,Heart,6599,A,,948.0
Intermediate,,1,CCRF S-180,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 8 hours,,CHEMBL621755,N,1,,42.0,Mus musculus,10090.0,BAO_0000218,50594,,6492,Heart,6599,A,,948.0
Intermediate,,1,CCRF S-180,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 1 hour,,CHEMBL621756,N,1,,42.0,Mus musculus,10090.0,BAO_0000218,50594,,6493,Liver,6599,A,,2107.0
Intermediate,,1,CCRF S-180,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 2 hours,,CHEMBL624199,N,1,,42.0,Mus musculus,10090.0,BAO_0000218,50594,,6494,Liver,6599,A,,2107.0
Intermediate,,1,CCRF S-180,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 30 minutes,,CHEMBL624200,N,1,,42.0,Mus musculus,10090.0,BAO_0000218,50594,,6495,Liver,6599,A,,2107.0
Intermediate,,1,CCRF S-180,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 4 hours,,CHEMBL624375,N,1,,42.0,Mus musculus,10090.0,BAO_0000218,50594,,6496,Liver,6599,A,,2107.0
Intermediate,,1,CCRF S-180,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 8 hours,,CHEMBL624376,N,1,,42.0,Mus musculus,10090.0,BAO_0000218,50594,,6497,Liver,6599,A,,2107.0
Intermediate,,1,CCRF S-180,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 1 hour,,CHEMBL624377,N,1,,42.0,Mus musculus,10090.0,BAO_0000218,50594,,6498,Lung,6599,A,,2048.0
Intermediate,,1,CCRF S-180,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/lung bearing S180 tumor cell line for 2 hours,,CHEMBL624378,N,1,,42.0,Mus musculus,10090.0,BAO_0000218,50594,,6499,Lung,6599,A,,2048.0
Intermediate,,1,,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,CHEMBL857901,N,1,,,aeinetobacter anitrotap,107673.0,BAO_0000218,50067,,6500,,12269,F,,
Intermediate,,1,,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,CHEMBL875274,N,1,,,Acinetobacter calcoaceticus subsp. anitratus,107673.0,BAO_0000218,50067,,6501,,12269,F,,
Intermediate,,1,,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,CHEMBL624379,N,1,,,Acinetobacter calcoaceticus subsp. anitratus,107673.0,BAO_0000218,50067,,6502,,12269,F,,
Intermediate,,1,,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,CHEMBL624380,N,1,,,aeinetobacter anitrotap,107673.0,BAO_0000218,50067,,6503,,12269,F,,
Intermediate,,1,,,Activity against Acinetobacter calcoaceticus (AC54),,CHEMBL624381,N,1,,,Acinetobacter calcoaceticus,471.0,BAO_0000218,50192,,6504,,10624,F,,
Intermediate,,1,,,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates no prolonged biological activity,,CHEMBL624382,N,1,,,Anolis carolinensis,28377.0,BAO_0000218,50714,,6505,,17216,F,,
Intermediate,,1,,,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates prolonged biological activity,,CHEMBL624383,N,1,,,Anolis carolinensis,28377.0,BAO_0000218,50714,,6506,,17216,F,,
Intermediate,,1,,,Chlorohexidine coefficient for Actinomyces naeslundii 631,,CHEMBL624384,N,1,,,Actinomyces naeslundii,1655.0,BAO_0000218,50296,,6507,,9560,F,,
Intermediate,,1,,,Chlorohexidine coefficient for Actinomyces naeslundii B74,,CHEMBL624385,N,1,,,Actinomyces naeslundii,1655.0,BAO_0000218,50296,,6508,,9560,F,,
Intermediate,,1,,,Chlorohexidine coefficient for Actinomyces naeslundii N/3,,CHEMBL624386,N,1,,,Actinomyces naeslundii,1655.0,BAO_0000218,50296,,6509,,9560,F,,
Intermediate,,1,,,Chlorohexidine coefficient for Actinomyces naeslundii N/9,,CHEMBL624387,N,1,,,Actinomyces naeslundii,1655.0,BAO_0000218,50296,,6510,,9560,F,,
Intermediate,,1,,,Plaque bactericidal index against Actinomyces naeslundii 631,,CHEMBL624388,N,1,,,Actinomyces naeslundii,1655.0,BAO_0000218,50296,,6511,,9560,F,,
Intermediate,,1,,,Plaque bactericidal index against Actinomyces naeslundii N/9,,CHEMBL624389,N,1,,,Actinomyces naeslundii,1655.0,BAO_0000218,50296,,6512,,9560,F,,
Intermediate,,1,,,Plaque bactericidal index against Actinomyces naeslundii B74,,CHEMBL624390,N,1,,,Actinomyces naeslundii,1655.0,BAO_0000218,50296,,6513,,9560,F,,
Intermediate,,1,,,Plaque bactericidal index against Actinomyces naeslundii N/3,,CHEMBL875275,N,1,,,Actinomyces naeslundii,1655.0,BAO_0000218,50296,,6514,,9560,F,,
Intermediate,,1,,,Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay,,CHEMBL624391,N,1,,,Artemia salina,85549.0,BAO_0000218,50056,,6515,,114,F,,
Intermediate,,1,,,"Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay; highest level tested, showed <100% activity",,CHEMBL623636,N,1,,,Artemia salina,85549.0,BAO_0000218,50056,,6516,,114,F,,
Intermediate,,1,,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 0 uM,,CHEMBL623637,N,1,,,Ascaris suum,6253.0,BAO_0000218,50532,,6517,,10841,F,,
Intermediate,,1,,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 10 uM,,CHEMBL623638,N,1,,,Ascaris suum,6253.0,BAO_0000218,50532,,6518,,10841,F,,
Intermediate,,1,,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 200 uM,,CHEMBL623639,N,1,,,Ascaris suum,6253.0,BAO_0000218,50532,,6519,,10841,F,,
Intermediate,,1,,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 25 uM,,CHEMBL623640,N,1,,,Ascaris suum,6253.0,BAO_0000218,50532,,6520,,10841,F,,
Intermediate,,1,,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 3 uM,,CHEMBL623641,N,1,,,Ascaris suum,6253.0,BAO_0000218,50532,,6521,,10841,F,,
Intermediate,,1,,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 50 uM.,,CHEMBL623642,N,1,,,Ascaris suum,6253.0,BAO_0000218,50532,,6522,,10841,F,,
Intermediate,,1,,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 0 uM,,CHEMBL623643,N,1,,,Ascaris suum,6253.0,BAO_0000218,50532,,6523,,10841,F,,
Intermediate,,1,,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 10 uM,,CHEMBL623644,N,1,,,Ascaris suum,6253.0,BAO_0000218,50532,,6524,,10841,F,,
Intermediate,,1,,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 200 uM,,CHEMBL623645,N,1,,,Ascaris suum,6253.0,BAO_0000218,50532,,6525,,10841,F,,
Intermediate,,1,,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 25 uM,,CHEMBL623646,N,1,,,Ascaris suum,6253.0,BAO_0000218,50532,,6526,,10841,F,,
Intermediate,,1,,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 3 uM,,CHEMBL623647,N,1,,,Ascaris suum,6253.0,BAO_0000218,50532,,6527,,10841,F,,
Intermediate,,1,,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 50 uM,,CHEMBL623648,N,1,,,Ascaris suum,6253.0,BAO_0000218,50532,,6528,,10841,F,,
Intermediate,,1,,,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,,CHEMBL623649,N,1,,,Actinomyces viscosus,1656.0,BAO_0000218,50366,,6529,,8117,F,,
Intermediate,,1,,,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,,CHEMBL623650,N,1,,,Actinomyces viscosus,1656.0,BAO_0000218,50366,,6530,,8117,F,,
Intermediate,,1,,,Chlorohexidine coefficient for Actinomyces viscosus 8A06,,CHEMBL623651,N,1,,,Actinomyces viscosus,1656.0,BAO_0000218,50366,,6531,,9560,F,,
Expert,,1,,,Chlorohexidine coefficient for Actinomyces viscosus M-100,,CHEMBL623652,N,1,,,Actinomyces viscosus,1656.0,BAO_0000218,50366,,6532,,9560,F,,
Intermediate,,1,,,Chlorohexidine coefficient for Actinomyces viscosus M-626,,CHEMBL623653,N,1,,,Actinomyces viscosus,1656.0,BAO_0000218,50366,,6533,,9560,F,,
Intermediate,,1,,,Chlorohexidine coefficient for Actinomyces viscosus T14V,,CHEMBL623654,N,1,,,Actinomyces viscosus,1656.0,BAO_0000218,50366,,6534,,9560,F,,
Intermediate,,1,,,Plaque bactericidal index against Actinomyces viscosus 8A06,,CHEMBL623655,N,1,,,Actinomyces viscosus,1656.0,BAO_0000218,50366,,6535,,9560,F,,
Intermediate,,1,,,Plaque bactericidal index against Actinomyces viscosus M-100,,CHEMBL623656,N,1,,,Actinomyces viscosus,1656.0,BAO_0000218,50366,,6536,,9560,F,,
Expert,,1,,,Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient,,CHEMBL623657,N,1,,,Actinomyces viscosus,1656.0,BAO_0000218,50366,,6537,,9560,F,,
Intermediate,,1,,,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; d=Not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",,CHEMBL623658,N,1,,,Actinomyces viscosus,1656.0,BAO_0000218,50366,,6538,,9560,F,,
Intermediate,,1,,,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",,CHEMBL623659,N,1,,,Actinomyces viscosus,1656.0,BAO_0000218,50366,,6539,,9560,F,,
Intermediate,,1,,,Plaque bactericidal index against Actinomyces viscosus 626,,CHEMBL623660,N,1,,,Actinomyces viscosus,1656.0,BAO_0000218,50366,,6540,,9560,F,,
Intermediate,,1,,,Plaque bactericidal index against Actinomyces viscosus T14V,,CHEMBL623661,N,1,,,Actinomyces viscosus,1656.0,BAO_0000218,50366,,6541,,9560,F,,
Intermediate,,1,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 1.56 mg/kg/day(5 days) dose,,CHEMBL875281,N,1,,,Acanthocheilonema viteae,6277.0,BAO_0000218,50535,,6542,,10986,F,,
Intermediate,,1,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 100 mg/kg/day(5 days) dose,,CHEMBL623662,N,1,,,Acanthocheilonema viteae,6277.0,BAO_0000218,50535,,6543,,10986,F,,
Intermediate,,1,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 12.5 mg/kg/day(5 days) dose,,CHEMBL623663,N,1,,,Acanthocheilonema viteae,6277.0,BAO_0000218,50535,,6544,,10986,F,,
Intermediate,,1,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 200 mg/kg/day(5 days) dose,,CHEMBL623664,N,1,,,Acanthocheilonema viteae,6277.0,BAO_0000218,50535,,6545,,10986,F,,
Intermediate,,1,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 25 mg/kg/day(5 days) dose,,CHEMBL623665,N,1,,,Acanthocheilonema viteae,6277.0,BAO_0000218,50535,,6546,,10986,F,,
Intermediate,,1,A673,,Evaluated for the inhibitory concentration required to cause growth inhibition of A673Mer+ sarcoma cell line using the MTT Cytotoxicity Assay,,CHEMBL621856,N,1,,165.0,Homo sapiens,9606.0,BAO_0000219,80023,,6547,,10708,F,,
Intermediate,,1,A704,,Evaluated for the inhibitory concentration required to cause growth inhibition of A704Rem- renal cell line using the MTT Cytotoxicity Assay,,CHEMBL620432,N,1,,645.0,Homo sapiens,9606.0,BAO_0000219,80661,,6548,,10708,F,,
Autocuration,,1,,,Tested for inhibition of ET-1 induced phosphoinositide (PI) turnover in A7r5 smooth muscle cells,,CHEMBL620433,U,0,,,Rattus norvegicus,10116.0,BAO_0000219,22226,,6549,,416,F,,
Intermediate,,1,A9,,Inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,,CHEMBL620434,N,1,,625.0,Mus musculus,10090.0,BAO_0000219,80024,,6550,,14354,F,,
Intermediate,,1,A9,,Percent inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,,CHEMBL620435,N,1,,625.0,Mus musculus,10090.0,BAO_0000219,80024,,6551,,14354,F,,
Intermediate,,1,A9,,Cytotoxicity against Beta- tubulin mutant expressing A9-PTX10 cell line of humans was tested,,CHEMBL620436,N,1,,625.0,Homo sapiens,9606.0,BAO_0000219,80024,,6552,,5116,F,,
Intermediate,,1,A9,,Percentage inhibition at higher concentration (100 nM) against Beta- tubulin mutant expressing A9-PTX10 cell line,,CHEMBL876597,N,1,,625.0,Homo sapiens,9606.0,BAO_0000219,80024,,6553,,5116,F,,
Expert,,1,Human ovarian carcinoma cell line,,Inhibition of human ovarian carcinoma (A90) FGF-R overexpressing cell proliferation,,CHEMBL620437,N,1,,874.0,Homo sapiens,9606.0,BAO_0000219,81037,,6554,,15694,F,,
Expert,,1,A9,,"Tested for stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells, activity expressed as EC50 mM.",,CHEMBL620438,N,1,,625.0,Mus musculus,10090.0,BAO_0000219,80024,,6555,,13038,F,,
Expert,,1,A9,,Stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells.,,CHEMBL620439,N,1,,625.0,Mus musculus,10090.0,BAO_0000219,80024,,6556,,13038,F,,
Expert,,1,A9,,Increase in phosphoinositide (PI) metabolism in A9L-m1 cells at 100 uM.,,CHEMBL619657,N,1,,625.0,Mus musculus,10090.0,BAO_0000219,80024,,6557,,10923,F,,
Intermediate,,1,A9,,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; - = Not determined,,CHEMBL619658,N,1,,625.0,Mus musculus,10090.0,BAO_0000219,80024,,6558,,10923,F,,
Intermediate,,1,A9,,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; i = inactive,,CHEMBL619659,N,1,,625.0,Mus musculus,10090.0,BAO_0000219,80024,,6559,,10923,F,,
Expert,,1,,,"Increase in phosphoinositide (PI) metabolism in A9L-cholinergic receptor, muscarinic 3 expressing cells was measured at 100 uMolar",,CHEMBL619660,H,8,,,,,BAO_0000019,10649,,6560,,10923,F,,
Intermediate,,1,A9,,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; - = Not determined,,CHEMBL619661,N,1,,625.0,Mus musculus,10090.0,BAO_0000219,80024,,6561,,10923,F,,
Intermediate,,1,A9,,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; i = inactive,,CHEMBL619662,N,1,,625.0,Mus musculus,10090.0,BAO_0000219,80024,,6562,,10923,F,,
Intermediate,,1,AA6,,Ability to inhibit growth of AA-6 cells (a mutant cell line resistant to 8-azaadenine and lacks adenine phosphoryltransferase) was determined,,CHEMBL619663,N,1,,975.0,Cricetulus griseus,10029.0,BAO_0000219,80663,,6563,,8158,F,,
Autocuration,,1,,,Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied after 5 hrs of Incubation.,,CHEMBL619664,U,0,,,Homo sapiens,9606.0,BAO_0000219,22226,,6564,,15494,F,,
Autocuration,,1,,,"Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied, after 5 hrs of Incubation.",,CHEMBL619665,U,0,,,Homo sapiens,9606.0,BAO_0000219,22226,,6565,,15494,F,,
Intermediate,,1,AA5,,Anti -HIV activity was measured against AA5/HIV-1(IIIB),,CHEMBL883244,N,1,,974.0,Homo sapiens,9606.0,BAO_0000219,80662,,6566,,12348,F,,
Intermediate,,1,AA5,,Cytotoxicity was measured against AA5/HIV-1(IIIB),,CHEMBL884011,N,1,,974.0,Homo sapiens,9606.0,BAO_0000219,80662,,6567,,12348,F,,
Intermediate,,1,AA5,,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in AA5 EBV-infected B-cell,,CHEMBL619666,N,1,,974.0,Homo sapiens,9606.0,BAO_0000219,80662,,6568,,2726,F,,
Intermediate,,1,U-937,,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in U937 monocytic cell,,CHEMBL619667,N,1,,379.0,Homo sapiens,9606.0,BAO_0000219,80566,,6569,,2726,F,,
Intermediate,,1,UV4,,Hypersensitivity factor obtained from in vitro cytotoxicities against Chinese hamster ovary derived AA8 / UV4 cell lines,,CHEMBL619668,N,1,,274.0,Cricetulus griseus,10029.0,BAO_0000219,80578,,6570,,10747,F,,
Expert,,1,CHO-AA8,,"Inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",,CHEMBL619669,N,1,,185.0,Cricetulus griseus,10029.0,BAO_0000219,80089,,6571,,11005,F,,
Intermediate,,1,CHO-AA8,,Average intracellular compound concentration when the hypoxic SER=1.6,,CHEMBL876608,N,1,,185.0,Cricetulus griseus,10029.0,BAO_0000219,80089,,6572,,12687,F,,
Intermediate,,1,CHO-AA8,,Average intracellular compound concentration when the hypoxic SER=1.6.,,CHEMBL619670,N,1,,185.0,Cricetulus griseus,10029.0,BAO_0000219,80089,,6573,,12687,F,,
Intermediate,,1,CHO-AA8,,Average intracellular compound concentration where the hypoxia sensitizer enhancement ratio (SER)=1.6,,CHEMBL619671,N,1,,185.0,Cricetulus griseus,10029.0,BAO_0000219,80089,,6574,,12687,F,,
Intermediate,,1,CHO-AA8,,Average intracellular compound concentration where the sensitizer enhancement ratio (SER)=1.6 under hypoxia,,CHEMBL619672,N,1,,185.0,Cricetulus griseus,10029.0,BAO_0000219,80089,,6575,,12687,F,,
Intermediate,,1,CHO-AA8,,Compound concentration at which sensitizer enhancement ratio =1.6 under hypoxia.,,CHEMBL619673,N,1,,185.0,Cricetulus griseus,10029.0,BAO_0000219,80089,,6576,,12687,F,,
Intermediate,,1,CHO-AA8,,"Compound was tested for the concentration required to reduce cell survival under hypoxic conditions, using the cell line AA8 in the clonogenic assay.",,CHEMBL619674,N,1,,185.0,Cricetulus griseus,10029.0,BAO_0000219,80089,,6577,,13436,F,,
Intermediate,,1,CHO-AA8,,"Concentration needed to reduce cell survival to 10% of control values, using 1 hour exposure of plateau phase AA8 cells at 10e6 cells/ml",,CHEMBL619675,N,1,,185.0,Cricetulus griseus,10029.0,BAO_0000219,80089,,6578,,13435,F,,
Intermediate,,1,CHO-AA8,,Activity to reduce the surviving fraction to 10% (CT10) was used as an inverse measure of cytotoxic potency in aerobic conditions,,CHEMBL619676,N,1,,185.0,Cricetulus griseus,10029.0,BAO_0000219,80089,,6579,,13302,F,,
Intermediate,,1,CHO-AA8,,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,,CHEMBL619677,N,1,,185.0,Cricetulus griseus,10029.0,BAO_0000219,80089,,6580,,12687,F,,
Intermediate,,1,CHO-AA8,,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,,CHEMBL619678,N,1,,185.0,Cricetulus griseus,10029.0,BAO_0000219,80089,,6581,,12687,A,,
Intermediate,,1,CHO-AA8,,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition.,,CHEMBL619679,N,1,,185.0,Cricetulus griseus,10029.0,BAO_0000219,80089,,6582,,12687,A,,
Expert,,1,CHO-AA8,,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay,,CHEMBL619680,N,1,,185.0,Cricetulus griseus,10029.0,BAO_0000219,80089,,6583,,12878,A,,
Intermediate,,1,CHO-AA8,,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay. Inactive at the solubility limit,,CHEMBL621457,N,1,,185.0,Cricetulus griseus,10029.0,BAO_0000219,80089,,6584,,12878,A,,
Expert,,1,CHO-AA8,,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% controls in clonogenic assay,,CHEMBL876609,N,1,,185.0,Cricetulus griseus,10029.0,BAO_0000219,80089,,6585,,14367,F,,
Intermediate,,1,CHO-AA8,,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% of controls in clonogenic assay,,CHEMBL621458,N,1,,185.0,Cricetulus griseus,10029.0,BAO_0000219,80089,,6586,,14367,F,,
Expert,,1,CHO-AA8,,Aerobic cytotoxicity was assessed in a growth inhibition assay using log phase cultures of the chinese hamster ovary fibroblast line AA8,,CHEMBL621459,N,1,,185.0,hampster,36483.0,BAO_0000219,80089,,6587,,12398,F,,
Expert,,1,CHO-AA8,,Aerobic growth inhibition in Chinese hamster cell line AA8,,CHEMBL621460,N,1,,185.0,Cricetulus griseus,10029.0,BAO_0000219,80089,,6588,,12878,F,,
Expert,,1,CHO-AA8,,Cytotoxicity against AA8 cell and IC50 values were determined as drug concentration required to inhibit cell protein to 50%.,,CHEMBL621461,N,1,,185.0,Cricetulus griseus,10029.0,BAO_0000219,80089,,6589,,13820,F,,
Expert,,1,CHO-AA8,,Inhibition of growth under aerobic conditions in AA8 cells,,CHEMBL621462,N,1,,185.0,Cricetulus griseus,10029.0,BAO_0000219,80089,,6590,,13436,F,,
Intermediate,,1,,,Oral bioavailability in dog (dose 10 mg/kg),,CHEMBL621463,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6591,,6084,A,In vivo,
Intermediate,,1,,,Oral bioavailability in dog at 10 mg/kg of the compound,,CHEMBL621464,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6592,,5711,A,In vivo,
Intermediate,,1,,,Oral bioavailability in dog (dose 5 uM/kg),,CHEMBL621465,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6593,,4353,A,In vivo,
Intermediate,,1,,,Oral bioavailability in dog (dose 5 uM/kg),,CHEMBL621466,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6594,,4353,A,In vivo,
Intermediate,,1,,,Oral bioavailability in dog (mongrel),,CHEMBL621467,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6595,,17800,A,In vivo,
Intermediate,,1,,,Oral bioavailability in dog (dose 10 mg/kg),,CHEMBL621468,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6596,,3994,A,In vivo,
Intermediate,,1,,,Oral bioavailability in dog (dose 10 mg/kg),,CHEMBL876734,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6597,,3994,F,In vivo,
Intermediate,,1,,,Bioavailability in dog,,CHEMBL618476,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6598,,5145,A,In vivo,
Intermediate,,1,,,Bioavailability in dog (dose 1 mg/kg i.v.),,CHEMBL618477,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6599,,16452,A,In vivo,
Intermediate,,1,,,Pharmacokinetic data for dose given to dogs intravenously (oral PK study in parentheses),,CHEMBL618478,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6600,,16452,A,In vivo,
Intermediate,,1,,,Pharmacokinetic property (F) was measured in dog at the dose of 0.032 mg/kg,,CHEMBL618479,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6601,,5983,A,In vivo,
Intermediate,,1,,,Bioavailability in dog,,CHEMBL618480,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6602,,4273,A,In vivo,
Intermediate,,1,,,Bioavailability in dog (dose 3-10 mg/kg),,CHEMBL618481,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6603,,12500,A,In vivo,
Intermediate,,1,,,The compound was tested for bioavailability of compound in plasma of dog; Complete,,CHEMBL618482,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6604,Plasma,12500,A,In vivo,1969.0
Intermediate,,1,,,Oral bioavailability in dog,,CHEMBL618483,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6605,,3639,A,In vivo,
Intermediate,,1,,,Oral bioavailability in dog,,CHEMBL618484,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6606,,3880,A,In vivo,
Intermediate,,1,,,Bioavailability in dog,,CHEMBL618485,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6607,,4838,A,In vivo,
Intermediate,,1,,,oral bioavailability was measured in dogs,,CHEMBL618486,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6608,,15600,A,In vivo,
Intermediate,,1,,,Compound was tested for plasma protein binding in dog; Not determined,,CHEMBL618487,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6609,,17248,A,,
Intermediate,,1,,,Compound was tested for plasma protein binding of dog,,CHEMBL618488,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6610,,17248,A,,
Intermediate,,1,,,Compound was tested for plasma protein binding of dog; Not determined,,CHEMBL876735,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6611,,17248,A,,
Intermediate,,1,,,Concentration in dogs after oral administration at dose of 1 mg/kg after 180 min.,,CHEMBL618489,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6612,,17443,A,,
Intermediate,,1,,,Apparent terminal elimination half-life in dog after administration of 20 mg/kg dose through peroral route,,CHEMBL618490,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6613,,4186,A,In vivo,
Intermediate,,1,,,Half life was determined,,CHEMBL618491,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6614,,3749,A,,
Intermediate,,1,,,Half life by ''Cr'' assay in dog at a dose of 5 mg/kg,,CHEMBL618492,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6615,,3249,A,In vivo,
Intermediate,,1,,,Half life was evaluated in dog,,CHEMBL873354,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6616,,3022,A,,
Intermediate,,1,,,Half life was determined,,CHEMBL618493,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6617,,3749,A,,
Intermediate,,1,,,Biodistribution of compound was measured in bile at 2 hr post-injection in canine deep vein thrombosis model (DVT),,CHEMBL618494,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6618,,2517,A,In vivo,
Intermediate,,1,,,Biodistribution of compound was measured in heart at 2 hr post-injection in canine deep vein thrombosis model (DVT),,CHEMBL618495,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6619,Heart,2517,A,In vivo,948.0
Intermediate,,1,,,Biodistribution of compound was measured in kidney at 2 hr post-injection in canine deep vein thrombosis model (DVT),,CHEMBL618496,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6620,Kidney,2517,A,In vivo,2113.0
Intermediate,,1,,,Biodistribution of compound was measured in liver at 2 hr post-injection in canine deep vein thrombosis model (DVT),,CHEMBL618497,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6621,Liver,2517,A,In vivo,2107.0
Intermediate,,1,,,Biodistribution of compound was measured in lung at 2 hr post-injection in canine deep vein thrombosis model (DVT),,CHEMBL618498,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6622,Lung,2517,A,In vivo,2048.0
Intermediate,,1,,,Biodistribution of compound was measured in spleen at 2 hr post-injection in canine deep vein thrombosis model (DVT),,CHEMBL618499,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6623,Spleen,2517,A,In vivo,2106.0
Intermediate,,1,,,LogP in dog,,CHEMBL876736,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6624,,3639,A,,
Intermediate,,1,,,Partition coefficient (logP),,CHEMBL618500,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6625,,6227,A,,
Intermediate,,1,,,Partition coefficient in dog,,CHEMBL857831,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6626,,6227,A,,
Intermediate,,1,,,Mean-residence time of compound after intravenous administration in dogs at 1.2 uM/kg,,CHEMBL618501,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6627,,17764,A,In vivo,
Intermediate,,1,,,Pharmacokinetic parameter MRT was determined in Beagle dogs after (po) administration of a dose of 28 (uM/kg),,CHEMBL618502,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6628,,4809,A,In vivo,
Intermediate,,1,,,In vitro metabolic stability determined after 30 min of incubation in dog hepatic microsomes,,CHEMBL618503,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6629,,5600,A,,
Intermediate,,1,,,Metabolism of compound in dog S9 microsomes ('++''indicates 20-50% largest observed peak),,CHEMBL618504,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6630,,14294,A,,
Intermediate,,1,,,Metabolism of compound in dog S9 microsomes ('++++' indicates largest observed peak),,CHEMBL618505,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6631,,14294,A,,
Intermediate,,1,,,Metabolism of compound in dog S9 microsomes; Trace,,CHEMBL618506,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6632,,14294,A,,
Intermediate,,1,,,In vitro metabolic potential in dog liver microsomes,,CHEMBL618507,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6633,Liver,6251,A,,2107.0
Intermediate,,1,,,Oral bioavailability of perorally administered compound (10 mg/kg) was tested in dogs,,CHEMBL876737,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6634,,3748,A,In vivo,
Intermediate,,1,,,Oral bioavailability in dog,,CHEMBL618508,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6635,,2713,A,In vivo,
Intermediate,,1,,,Oral bioavailability in dog,,CHEMBL618509,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6636,,6512,A,In vivo,
Intermediate,,1,,,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,CHEMBL618510,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6637,,6679,A,In vivo,
Intermediate,,1,,,The compound was tested for bioavailability in dogs,,CHEMBL618511,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6638,,3749,A,In vivo,
Intermediate,,1,,,The compound was tested for oral bioavailability in dogs,,CHEMBL618512,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6639,,3749,A,In vivo,
Intermediate,,1,,,Oral bioavailability in dog,,CHEMBL618513,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6640,,6742,A,In vivo,
Intermediate,,1,,,Compound was tested for percent protein binding (PB) in dog,,CHEMBL618514,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6641,,6227,A,,
Intermediate,,1,,,Apparent permeability coefficient (Papp) for apical to basolateral flux was determined in MadinDarby Canine Kidney cells,,CHEMBL620052,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6642,,6874,A,,
Intermediate,,1,,,Compound was evaluated for plasma clearance.,,CHEMBL620053,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6643,Plasma,2877,A,In vivo,1969.0
Intermediate,,1,,,The compound was tested for plasma clearance in dog,,CHEMBL620054,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6644,Plasma,12500,A,In vivo,1969.0
Intermediate,,1,,,The compound was tested for plasma clearance in dog at dose of 3-10 mgkg,,CHEMBL620055,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6645,Plasma,12500,A,In vivo,1969.0
Intermediate,,1,,,Plasma protein binding was determined after intravenous administration of 1 mg/kg in dog,,CHEMBL620056,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6646,,4709,A,,
Intermediate,,1,,,In vitro relative rate of metabolism was determined in dog liver microsomes,,CHEMBL620057,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6647,Liver,5542,A,,2107.0
Intermediate,,1,,,Relative bioavailability after oral dose of compound at 3 mg/kg in dogs,,CHEMBL618939,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6648,,17594,A,In vivo,
Intermediate,,1,,,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,,CHEMBL618940,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6649,,2652,A,In vivo,
Intermediate,,1,,,Half life after intravenous administration in dogs at 1.2 uM/kg,,CHEMBL618941,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6650,,17764,A,In vivo,
Intermediate,,1,CCRF S-180,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 30 minutes,,CHEMBL624473,N,1,,42.0,Mus musculus,10090.0,BAO_0000218,50594,,6651,Lung,6599,A,,2048.0
Intermediate,,1,CCRF S-180,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 4 hours,,CHEMBL624474,N,1,,42.0,Mus musculus,10090.0,BAO_0000218,50594,,6652,Lung,6599,A,,2048.0
Intermediate,,1,CCRF S-180,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 8 hours,,CHEMBL624475,N,1,,42.0,Mus musculus,10090.0,BAO_0000218,50594,,6653,Lung,6599,A,,2048.0
Intermediate,,1,CCRF S-180,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 1 hour,,CHEMBL624476,N,1,,42.0,Mus musculus,10090.0,BAO_0000218,50594,,6654,,6599,A,,
Intermediate,,1,CCRF S-180,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 2 hours,,CHEMBL623478,N,1,,42.0,Mus musculus,10090.0,BAO_0000218,50594,,6655,,6599,A,,
Intermediate,,1,CCRF S-180,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 30 minutes,,CHEMBL623479,N,1,,42.0,Mus musculus,10090.0,BAO_0000218,50594,,6656,,6599,A,,
Intermediate,,1,CCRF S-180,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 4 hours,,CHEMBL623480,N,1,,42.0,Mus musculus,10090.0,BAO_0000218,50594,,6657,,6599,A,,
Intermediate,,1,CCRF S-180,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 8 hours,,CHEMBL623481,N,1,,42.0,Mus musculus,10090.0,BAO_0000218,50594,,6658,,6599,A,,
Intermediate,,1,,,C2 in brain of mice at the oral dose of 50 mg/kg,,CHEMBL623482,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6659,Brain,17641,A,,955.0
Intermediate,,1,,,C2 in kidney of mice at the oral dose of 50 mg/kg,,CHEMBL623483,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6660,Kidney,17641,A,,2113.0
Intermediate,,1,,,C2 in liver of mice at the oral dose of 50 mg/kg,,CHEMBL623484,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6661,Liver,17641,A,,2107.0
Intermediate,,1,,,C2 in lungs of mice at the oral dose of 50 mg/kg,,CHEMBL623485,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6662,Lung,17641,A,,2048.0
Intermediate,,1,,,C2 in spleen of mice at the oral dose of 50 mg/kg,,CHEMBL623486,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6663,Spleen,17641,A,,2106.0
Intermediate,,1,,,Plasma clearance in mouse,,CHEMBL623487,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6664,,17852,A,In vivo,
Intermediate,,1,,,Clearance of compound after intravenous administration in mice at 24 uM/kg,,CHEMBL623488,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6665,,17764,A,In vivo,
Intermediate,,1,,,Clearance from mouse blood following i.v. administration of 10 mg/kg,,CHEMBL623489,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6666,,17837,A,In vivo,
Intermediate,,1,,,Clearance was evaluated in mice after intravenous administration,,CHEMBL875157,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6667,,2675,A,In vivo,
Intermediate,,1,,,Clearance was evaluated in mice after oral administration,,CHEMBL623490,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6668,,2675,A,In vivo,
Intermediate,,1,,,Pharmacokinetic property (Plasma clearance) was measured in mouse,,CHEMBL623491,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6669,,4239,A,In vivo,
Intermediate,,1,,,Plasma clearance of compound was determined at 40 mg/Kg,,CHEMBL623492,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6670,,17753,A,In vivo,
Intermediate,,1,,,Plasma clearance of at 24 mg/Kg,,CHEMBL623493,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6671,,17753,A,In vivo,
Intermediate,,1,,,Plasma clearance at 24 mg/Kg,,CHEMBL623494,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6672,,17753,A,In vivo,
Intermediate,,1,,,Plasma clearance at 5 mg/Kg,,CHEMBL623495,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6673,,17753,A,In vivo,
Intermediate,,1,,,Plasma clearance in mice,,CHEMBL623496,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6674,,5727,A,In vivo,
Intermediate,,1,,,Plasma clearance value upon iv administration in mouse,,CHEMBL623497,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6675,,2862,A,In vivo,
Intermediate,,1,,,Total plasma clearance in mice,,CHEMBL623498,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6676,Plasma,5980,A,In vivo,1969.0
Intermediate,,1,,,Clearance in mouse,,CHEMBL623499,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6677,,17592,A,In vivo,
Intermediate,,1,,,Clearance value was determined,,CHEMBL623500,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6678,,17718,A,In vivo,
Intermediate,,1,,,Plasma clearance at a dose of 10 mg/kg intravenous administration in mice.,,CHEMBL623501,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6679,,16597,A,In vivo,
Intermediate,,1,,,Calculated partition coefficient (clogP),,CHEMBL875158,U,0,,,,,BAO_0000100,22229,,6680,,17384,P,,
Intermediate,,1,,,Plasma clearance for the compound was measured in mouse after an iv dose of 1 mg/kg,,CHEMBL623502,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6681,,6062,A,In vivo,
Intermediate,,1,,,Plasma clearance rate after intraperitoneal administration of 100 mg/kg in mice,,CHEMBL623503,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6682,,17734,A,In vivo,
Intermediate,,1,,,Plasma clearance was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,CHEMBL623504,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6683,,6348,A,In vivo,
Intermediate,,1,,,In vivo total clearance was determined in murine septicemia at dose of 100 mg/kg,,CHEMBL623505,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6684,,5969,A,In vivo,
Intermediate,,1,,,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg,,CHEMBL623506,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6685,,5969,A,In vivo,
Intermediate,,1,,,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,,CHEMBL623507,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6686,,5969,A,In vivo,
Intermediate,,1,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for Cmax,,CHEMBL623508,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6687,,16597,A,In vivo,
Intermediate,,1,,,Cmax after oral administration at 30 mg/kg in ICR mouse,,CHEMBL623509,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6688,,5781,A,In vivo,
Intermediate,,1,,,Cmax after peroral administration in mice at 2.4 uM/kg,,CHEMBL875159,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6689,,17764,A,In vivo,
Intermediate,,1,,,Cmax in brain of mice at the oral dose of 50 mg/kg,,CHEMBL623510,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6690,Brain,17641,A,In vivo,955.0
Intermediate,,1,,,Cmax in kidney of mice at the oral dose of 50 mg/kg,,CHEMBL623511,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6691,Kidney,17641,A,In vivo,2113.0
Intermediate,,1,,,Cmax in liver of mice at the oral dose of 50 mg/kg,,CHEMBL623512,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6692,Liver,17641,A,In vivo,2107.0
Intermediate,,1,,,Cmax in lungs of mice at the oral dose of 50 mg/kg,,CHEMBL623513,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6693,Lung,17641,A,In vivo,2048.0
Intermediate,,1,,,Cmax in mice at 18 uM/kg i.p. administration,,CHEMBL623514,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6694,,17764,F,In vivo,
Intermediate,,1,,,Cmax in mice at 23 uM/kg i.v. administration,,CHEMBL622609,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6695,,17764,F,In vivo,
Intermediate,,1,,,Cmax in mice at 24 uM/kg i.p. administration,,CHEMBL622610,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6696,,17764,F,In vivo,
Intermediate,,1,,,Cmax in mice at 25 uM/kg i.p. administration,,CHEMBL621823,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6697,,17764,F,In vivo,
Intermediate,,1,,,Cmax in mice at 26 uM/kg i.p. administration,,CHEMBL621824,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6698,,17764,F,In vivo,
Intermediate,,1,,,Cmax in spleen of mice at the oral dose of 50 mg/kg,,CHEMBL621825,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6699,Spleen,17641,A,In vivo,2106.0
Intermediate,,1,,,Cmax value at a dose of 10 mg/kg intravenous administration in mice.,,CHEMBL621826,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6700,,16597,A,In vivo,
Intermediate,,1,,,Cmax value at a dose of 10 mg/kg peroral administration in mice.,,CHEMBL621827,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6701,,16597,A,In vivo,
Intermediate,,1,,,Cmax value was determined,,CHEMBL621828,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6702,,5727,A,In vivo,
Intermediate,,1,,,Cmax value in IRC mice,,CHEMBL621829,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6703,,5951,A,In vivo,
Intermediate,,1,,,Cmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,,CHEMBL621830,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6704,,5506,A,In vivo,
Intermediate,,1,,,Cmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,,CHEMBL621831,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6705,,5506,A,In vivo,
Intermediate,,1,,,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,,CHEMBL621832,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6706,Plasma,14239,A,In vivo,1969.0
Intermediate,,1,,,"Compound was evaluated for the pharmacokinetic parameter, maximum plasma concentration",,CHEMBL624579,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6707,Plasma,4890,A,In vivo,1969.0
Intermediate,,1,,,Evaluated for pharmacokinetic parameter Cmax in mouse at the dose 20 mg/kg,,CHEMBL624580,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6708,,429,A,In vivo,
Intermediate,,1,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 50 mg/kg/day(5 days) dose,,CHEMBL624581,N,1,,,Acanthocheilonema viteae,6277.0,BAO_0000218,50535,,6709,,10986,F,,
Intermediate,,1,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 6.25 mg/kg/day(5 days) dose,,CHEMBL624582,N,1,,,Acanthocheilonema viteae,6277.0,BAO_0000218,50535,,6710,,10986,F,,
Intermediate,,1,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 75 mg/kg/day(5 days) dose,,CHEMBL624583,N,1,,,Acanthocheilonema viteae,6277.0,BAO_0000218,50535,,6711,,10986,F,,
Intermediate,,1,A-375,,Inhibitory activity against human tumor cell line A0375 melanoma.,,CHEMBL624584,N,1,,455.0,Homo sapiens,9606.0,BAO_0000219,80018,,6712,,13227,F,,
Expert,,1,,,Displacement of [3H]N6-PIA binding from A1 receptor in whole rat brain membranes,Brain membranes,CHEMBL624585,D,9,,,Rattus norvegicus,10116.0,BAO_0000249,12512,,6713,,4481,B,,
Expert,,1,,,Forskolin-induced cAMP production at human A1 adenosine receptor,,CHEMBL875165,D,9,,,Homo sapiens,9606.0,BAO_0000019,114,,6714,,16931,F,,
Autocuration,,1,CHO,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1; change of less than 5% of allosteric enhancement.,,CHEMBL619490,H,8,,449.0,,,BAO_0000219,114,,6715,,3850,F,,
Autocuration,,1,CHO,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,,CHEMBL619491,H,8,,449.0,,,BAO_0000219,114,,6716,,3850,F,,
Expert,,1,CHO,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM,,CHEMBL619492,H,8,,449.0,,,BAO_0000219,114,,6717,,3850,F,,
Expert,,1,CHO,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration,,CHEMBL619493,H,8,,449.0,,,BAO_0000219,114,,6718,,3850,F,,
Autocuration,,1,CHO,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; An increase of cAmp content of cells,,CHEMBL619494,H,8,,449.0,,,BAO_0000219,114,,6719,,3850,F,,
Autocuration,,1,CHO,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement,,CHEMBL619495,H,8,,449.0,,,BAO_0000219,114,,6720,,3850,F,,
Autocuration,,1,CHO,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement.,,CHEMBL619496,H,8,,449.0,,,BAO_0000219,114,,6721,,3850,F,,
Expert,,1,CHO,,Percent response to 10 uM PD-81723 on CHO cells expressing human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,,CHEMBL619497,D,9,,449.0,Homo sapiens,9606.0,BAO_0000219,114,,6722,,3850,F,,
Autocuration,,1,CHO,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM,,CHEMBL619498,H,8,,449.0,,,BAO_0000219,114,,6723,,3850,F,,
Autocuration,,1,CHO,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; change of less than 5% of allosteric enhancement.,,CHEMBL619499,H,8,,449.0,,,BAO_0000219,114,,6724,,3850,F,,
Expert,,1,CHO,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration,,CHEMBL619500,H,8,,449.0,,,BAO_0000219,114,,6725,,3850,F,,
Autocuration,,1,CHO,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration; change of less than 5% of allosteric enhancement.,,CHEMBL619501,H,8,,449.0,,,BAO_0000219,114,,6726,,3850,F,,
Expert,,1,CHO,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; An increase of cAmp content of cells,,CHEMBL619502,H,8,,449.0,,,BAO_0000219,114,,6727,,3850,F,,
Autocuration,,1,CHO,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM,,CHEMBL619503,H,8,,449.0,,,BAO_0000219,114,,6728,,3850,F,,
Autocuration,,1,CHO,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,,CHEMBL619504,H,8,,449.0,,,BAO_0000219,114,,6729,,3850,F,,
Autocuration,,1,CHO,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; change of less than 5% of allosteric enhancement.,,CHEMBL621298,H,8,,449.0,,,BAO_0000219,114,,6730,,3850,F,,
Expert,,1,CHO,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration,,CHEMBL621299,H,8,,449.0,,,BAO_0000219,114,,6731,,3850,F,,
Autocuration,,1,CHO,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; An increase of cAmp content of cells,,CHEMBL621300,H,8,,449.0,,,BAO_0000219,114,,6732,,3850,F,,
Autocuration,,1,CHO,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; change of less than 5% of allosteric enhancement.,,CHEMBL621301,H,8,,449.0,,,BAO_0000219,114,,6733,,3850,F,,
Expert,,1,CHO,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,,CHEMBL621302,H,8,,449.0,,,BAO_0000219,114,,6734,,3850,F,,
Intermediate,,1,A10,,Ability to inhibit [125I]ET1 binding to vascular smooth muscle (vsm)- A10 cells,,CHEMBL621303,N,1,,164.0,Oryctolagus cuniculus,9986.0,BAO_0000219,80013,,6735,,12680,F,,
Autocuration,,1,A10,,In vitro potassium channel opening activity in A10 (smooth muscle) cells,,CHEMBL621304,U,0,,164.0,Rattus norvegicus,10116.0,BAO_0000219,22226,,6736,,1313,F,,
Autocuration,,1,A10,,In vitro potassium channel opening activity in A10 (smooth muscle) cells; Inactive,,CHEMBL621305,U,0,,164.0,Rattus norvegicus,10116.0,BAO_0000219,22226,,6737,,1313,F,,
Intermediate,,1,A10,,Effect on membrane potential of mitochondria in A10 smooth muscle cells from rats,,CHEMBL621306,N,1,,164.0,Rattus norvegicus,10116.0,BAO_0000219,80013,,6738,,17567,F,,
Intermediate,,1,A10,,Effect on membrane potential of mitochondria of A10 smooth muscle cells in rats,,CHEMBL618444,N,1,,164.0,Rattus norvegicus,10116.0,BAO_0000219,80013,,6739,,17567,F,,
Intermediate,,1,A10,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.001 uM,,CHEMBL618445,N,1,,164.0,Rattus norvegicus,10116.0,BAO_0000219,80013,,6740,,11819,F,,
Intermediate,,1,CHO-AA8,,Compound was tested for aerobic growth inhibition against AA8 cells after 4 hr of exposure,,CHEMBL618446,N,1,,185.0,Cricetulus griseus,10029.0,BAO_0000219,80089,,6741,,13436,F,,
Intermediate,,1,CHO-AA8,,Concentration required to reduce AA8 cell numbers to 50% of controls in a growth inhibition microassay,,CHEMBL618447,N,1,,185.0,Cricetulus griseus,10029.0,BAO_0000219,80089,,6742,,12687,F,,
Intermediate,,1,CHO-AA8,,Concentration of the drug to inhibit chinese hamster ovary derived cell (AA8) growth in culture,,CHEMBL618448,N,1,,185.0,Cricetulus griseus,10029.0,BAO_0000219,80089,,6743,,12651,F,,
Intermediate,,1,CHO-AA8,,Cytotoxicity in a growth inhibition assay against aerobic cultures of AA8 cells was determined,,CHEMBL618449,N,1,,185.0,Cricetulus griseus,10029.0,BAO_0000219,80089,,6744,,13300,F,,
Intermediate,,1,CHO-AA8,,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,,CHEMBL618637,N,1,,185.0,Cricetulus griseus,10029.0,BAO_0000219,80089,,6745,,15296,F,,
Intermediate,,1,CHO-AA8,,"Cytotoxicity in chinese hamster ovary tumor cell line-AA8, by growth inhibition assay.",,CHEMBL618638,N,1,,185.0,Cricetulus griseus,10029.0,BAO_0000219,80089,,6746,,15328,F,,
Intermediate,,1,CHO-AA8,,Growth inhibition activity was measured in repair proficient AA8 cells under aerobic conditions (4 hours drug exposure),,CHEMBL618639,N,1,,185.0,Cricetulus griseus,10029.0,BAO_0000219,80089,,6747,,13302,F,,
Expert,,1,CHO-AA8,,"Growth inhibition of aerobic AA8 cells, after 18 hours exposure",,CHEMBL618640,N,1,,185.0,Cricetulus griseus,10029.0,BAO_0000219,80089,,6748,,14367,F,,
Expert,,1,CHO-AA8,,In vitro cellular toxicity against chinese hamster AA8 cell line after 4 hr of compound exposure,,CHEMBL618641,N,1,,185.0,Cricetulus griseus,10029.0,BAO_0000219,80089,,6749,,17002,F,,
Intermediate,,1,CHO-AA8,,Inhibitory activity against AA8 cell growth in aerobic condition after 4 hr of exposure,,CHEMBL618642,N,1,,185.0,Cricetulus griseus,10029.0,BAO_0000219,80089,,6750,,13436,F,,
Intermediate,,1,CHO-AA8,,Inhibitory activity against aerobic growth of AA8 cells.,,CHEMBL618643,N,1,,185.0,Cricetulus griseus,10029.0,BAO_0000219,80089,,6751,,13435,F,,
Intermediate,,1,CHO-AA8,,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,,CHEMBL884013,N,1,,185.0,Cricetulus griseus,10029.0,BAO_0000219,80089,,6752,,10503,A,,
Expert,,1,CHO-AA8,,In vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,,CHEMBL622723,N,1,,185.0,Cricetulus griseus,10029.0,BAO_0000219,80089,,6753,,10503,F,,
Intermediate,,1,CHO-AA8,,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,,CHEMBL622724,N,1,,185.0,Cricetulus griseus,10029.0,BAO_0000219,80089,,6754,,10503,F,,
Expert,,1,CHO-AA8,,Tested for growth inhibition against AA8 tumor cell line(chinese hamster ovary).,,CHEMBL622725,N,1,,185.0,Cricetulus griseus,10029.0,BAO_0000219,80089,,6755,,15090,F,,
Expert,,1,CHO-AA8,,Cytotoxicity against AA8 cell line,,CHEMBL622726,N,1,,185.0,Cricetulus griseus,10029.0,BAO_0000219,80089,,6756,,10368,F,,
Intermediate,,1,CHO-AA8,,Hypersensitivity factor(HF) was determined as ratio of IC50(AA8) to IC50(UV4),,CHEMBL622727,N,1,,185.0,Cricetulus griseus,10029.0,BAO_0000219,80089,,6757,,12651,F,,
Intermediate,,1,CHO-AA8,,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),,CHEMBL622728,N,1,,185.0,Cricetulus griseus,10029.0,BAO_0000219,80089,,6758,,12687,A,,
Intermediate,,1,CHO-AA8,,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),,CHEMBL622729,N,1,,185.0,Cricetulus griseus,10029.0,BAO_0000219,80089,,6759,,12687,F,,
Intermediate,,1,CHO-AA8,,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),,CHEMBL622730,N,1,,185.0,Cricetulus griseus,10029.0,BAO_0000219,80089,,6760,,12687,A,,
Intermediate,,1,CHO-AA8,,Compound was evaluated for cytotoxicity against CHO AA8 cell lines for 4 hr at pH-7.4,,CHEMBL622731,N,1,,185.0,Cricetulus griseus,10029.0,BAO_0000219,80089,,6761,,1890,F,,
Intermediate,,1,CHO-AA8,,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,,CHEMBL622732,N,1,,185.0,Cricetulus griseus,10029.0,BAO_0000219,80089,,6762,,10747,F,,
Intermediate,,1,CHO-AA8,,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,,CHEMBL622733,N,1,,185.0,Cricetulus griseus,10029.0,BAO_0000219,80089,,6763,,10747,F,,
Autocuration,,1,,,Maximum tolerated dose (MTD) in C3H/HeN mice (single ip dose),,CHEMBL622734,U,0,,,Cricetulus griseus,10029.0,BAO_0000218,22224,,6764,,11616,F,,
Expert,,1,CHO-AA8,,Concentration required to increase radiation sensitivity by 1.3 when AA8 cells are exposed to drug for 30 min before and during irradiation under hypoxic condition.,,CHEMBL622735,N,1,,185.0,Cricetulus griseus,10029.0,BAO_0000219,80089,,6765,,11616,F,,
Autocuration,,1,CHO-AA8,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under anoxic conditions,,CHEMBL618746,U,0,,185.0,Cricetulus griseus,10029.0,BAO_0000219,22224,,6766,,3471,F,,
Autocuration,,1,CHO-AA8,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under anoxic conditions,,CHEMBL618747,U,0,,185.0,Cricetulus griseus,10029.0,BAO_0000219,22224,,6767,,3471,F,,
Autocuration,,1,CHO-AA8,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under anoxic conditions,,CHEMBL620540,U,0,,185.0,Cricetulus griseus,10029.0,BAO_0000219,22224,,6768,,3471,F,,
Autocuration,,1,CHO-AA8,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under aerobic conditions,,CHEMBL620541,U,0,,185.0,Cricetulus griseus,10029.0,BAO_0000219,22224,,6769,,3471,F,,
Autocuration,,1,CHO-AA8,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under aerobic conditions,,CHEMBL620542,U,0,,185.0,Cricetulus griseus,10029.0,BAO_0000219,22224,,6770,,3471,F,,
Autocuration,,1,CHO-AA8,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under aerobic conditions,,CHEMBL620543,U,0,,185.0,Cricetulus griseus,10029.0,BAO_0000219,22224,,6771,,3471,F,,
Autocuration,,1,CHO-AA8,,Ratio of oxygen dependence of cytotoxicities of AA8 cells in aerobic condition to anoxic condition,,CHEMBL618832,U,0,,185.0,Cricetulus griseus,10029.0,BAO_0000219,22224,,6772,,3471,F,,
Expert,,1,CHO-AA8,,Concentration required to reduce AA8 cell survival by 10%,,CHEMBL618833,N,1,,185.0,Cricetulus griseus,10029.0,BAO_0000219,80089,,6773,,11616,F,,
Autocuration,,1,CHO-AA8,,"Concentration required to reduce cell survival to 10% of controls under hypoxic conditions, using the AA8 (chinese hamster) aerobic cells",,CHEMBL618834,U,0,,185.0,Cricetulus griseus,10029.0,BAO_0000219,22224,,6774,,2656,F,,
Autocuration,,1,CHO-AA8,,Tested for the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,,CHEMBL618835,U,0,,185.0,Cricetulus griseus,10029.0,BAO_0000219,22224,,6775,,10518,F,,
Autocuration,,1,CHO-AA8,,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,,CHEMBL618836,U,0,,185.0,Cricetulus griseus,10029.0,BAO_0000219,22224,,6776,,10518,F,,
Autocuration,,1,CHO-AA8,,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 0.8-1.5,,CHEMBL618837,U,0,,185.0,Cricetulus griseus,10029.0,BAO_0000219,22224,,6777,,10518,F,,
Autocuration,,1,CHO-AA8,,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 1-2,,CHEMBL618838,U,0,,185.0,Cricetulus griseus,10029.0,BAO_0000219,22224,,6778,,10518,F,,
Autocuration,,1,CHO-AA8,,Ability to reduce cell density of AA8 cells to 50% after 4 hr of exposure to air,,CHEMBL618839,U,0,,185.0,Cricetulus griseus,10029.0,BAO_0000219,22224,,6779,,16156,F,,
Autocuration,,1,CHO-AA8,,Aerobic cytotoxic activity was evaluated by the growth inhibition of AA8 (chinese hamster) aerobic cells,,CHEMBL618840,U,0,,185.0,Cricetulus griseus,10029.0,BAO_0000219,22224,,6780,,2656,F,,
Autocuration,,1,,,"Compound was evaluated for the inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",,CHEMBL618841,U,0,,,Cricetulus griseus,10029.0,BAO_0000019,22224,,6781,,11005,F,,
Autocuration,,1,CHO-AA8,,Concentration for 50% inhibition of AA8 cells growth under aerobic conditions after 18 hours exposure,,CHEMBL618842,U,0,,185.0,Cricetulus griseus,10029.0,BAO_0000219,22224,,6782,,11942,F,,
Autocuration,,1,CHO-AA8,,Concentration required for 50% inhibition of growth of AA8 cells following 4 hr drug exposure,,CHEMBL618843,U,0,,185.0,Cricetulus griseus,10029.0,BAO_0000219,22224,,6783,,2128,F,,
Intermediate,,1,,,Half life period after 15 mg/kg iv dose in Dogs,,CHEMBL618844,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6784,,16907,A,In vivo,
Intermediate,,1,,,Half life period after 30 mg/kg po dose in Dogs,,CHEMBL618845,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6785,,16907,A,In vivo,
Intermediate,,1,,,Half life was measured after oral 2b administration (tested in 6 dogs),,CHEMBL618846,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6786,,9579,A,In vivo,
Intermediate,,1,,,Half life was measured in dog after oral 17b administration,,CHEMBL618847,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6787,,9579,A,In vivo,
Intermediate,,1,,,Pharmacokinetic parameter T max determined in dog after oral administration of 17b,,CHEMBL618848,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6788,,9579,A,In vivo,
Intermediate,,1,,,Pharmacokinetic parameter T max determined in dog after oral administration of 2b,,CHEMBL618849,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6789,,9579,A,In vivo,
Intermediate,,1,,,Tmax value after 15 mg/kg iv dose in Dogs,,CHEMBL618850,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6790,,16907,A,In vivo,
Intermediate,,1,,,Tmax value after 30 mg/kg po dose in Dogs,,CHEMBL618851,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6791,,16907,A,In vivo,
Intermediate,,1,,,Compound was evaluated for its half life when administered intravenously in dog,,CHEMBL873815,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6792,,3184,A,In vivo,
Intermediate,,1,,,Compound was tested for plasma half life when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),,CHEMBL618852,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6793,Plasma,5017,A,In vivo,1969.0
Intermediate,,1,,,Elimination Half-life of compound was determined in dog,,CHEMBL618853,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6794,,6821,A,,
Intermediate,,1,,,Half life of compound in dog following oral administration,,CHEMBL618854,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6795,,17839,A,In vivo,
Intermediate,,1,,,Half life of compound was determined in dog,,CHEMBL618855,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6796,,17267,A,,
Intermediate,,1,,,Half life of compound was determined in dog blood,,CHEMBL618856,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6797,Blood,4727,A,,178.0
Intermediate,,1,,,Half life after oral and iv dosing in dogs,,CHEMBL875827,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6798,,5238,A,In vivo,
Intermediate,,1,,,Half life in dogs in hours,,CHEMBL618857,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6799,,4942,A,,
Intermediate,,1,,,Half life on i.v. administration of 2 mg/kg was measured in dog,,CHEMBL618858,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6800,,6505,A,In vivo,
Intermediate,,1,,,t1/2 in dog after oral dose (1 mg/kg),,CHEMBL618859,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6801,,5130,A,In vivo,
Intermediate,,1,,,Half life was evaluated in dog,,CHEMBL618860,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6802,,1475,A,,
Intermediate,,1,,,Half life period of compound was determined after intravenous administration at 2 mg/kg,,CHEMBL618861,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6803,,17804,A,In vivo,
Intermediate,,1,,,Half life period of compound was determined after peroral administration at 2 mg/kg,,CHEMBL622539,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6804,,17804,A,In vivo,
Intermediate,,1,,,Half life period (10 mg/kg) was determined in dog,,CHEMBL622540,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6805,,6084,A,In vivo,
Intermediate,,1,,,Half life period (10 mg/kg) was determined in dog,,CHEMBL873803,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6806,,6084,A,In vivo,
Intermediate,,1,,,Half life period by iv administration in dog at a dose of 0.3 mg/kg,,CHEMBL873804,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6807,,5542,A,In vivo,
Intermediate,,1,,,Half life period by po administration in dog at a dose of 0.3 mg/kg,,CHEMBL624311,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6808,,5542,A,In vivo,
Intermediate,,1,,,Half life period in dog,,CHEMBL624312,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6809,,6084,A,,
Intermediate,,1,,,Half life period in dogs after oral administration at 1 mg/kg,,CHEMBL624313,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6810,,6241,A,In vivo,
Intermediate,,1,,,Half life period was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,CHEMBL624314,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6811,,1916,A,In vivo,
Intermediate,,1,,,Half-life of compound was determined in dogs,,CHEMBL624315,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6812,,6621,A,,
Intermediate,,1,,,Half-life in dog plasma,,CHEMBL624316,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6813,Plasma,1696,A,,1969.0
Intermediate,,1,,,Half-life in mongrel dogs was determined,,CHEMBL624317,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6814,,17800,A,,
Intermediate,,1,,,Half-life in dog upon oral administration,,CHEMBL624318,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6815,,17657,A,In vivo,
Intermediate,,1,,,Half-life in dog upon oral administration; Unable to calculate,,CHEMBL624319,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6816,,17657,A,In vivo,
Intermediate,,1,,,Half-life was measured in dog,,CHEMBL624496,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6817,,4239,A,,
Intermediate,,1,,,Half-life was measured in dog,,CHEMBL624497,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6818,,5985,A,,
Intermediate,,1,,,Half-recovery time (T1/2) of the vascular resistance decrease at ED30 in anesthetized dogs,,CHEMBL624498,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6819,,9932,A,,
Intermediate,,1,,,Oral half life was determined,,CHEMBL624499,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6820,,5199,A,In vivo,
Intermediate,,1,,,Plasma elimination half-life (08 h) was determined in canine following intravenous (iv) administration (1 mg/kg).,,CHEMBL624500,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6821,Plasma,5199,A,In vivo,1969.0
Intermediate,,1,,,Plasma half life was evaluated,,CHEMBL624501,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6822,Plasma,1475,A,,1969.0
Intermediate,,1,,,Plasma half life was evaluated in Dog,,CHEMBL623666,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6823,Plasma,1475,A,,1969.0
Intermediate,,1,,,Plasma half life was evaluated in dog,,CHEMBL623667,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6824,Plasma,1475,A,,1969.0
Intermediate,,1,,,T1/2 (Half-life) was after oral administration at 5 mg/kg,,CHEMBL623668,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6825,,6316,A,In vivo,
Intermediate,,1,,,Tested for the half life value in dog,,CHEMBL623669,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6826,,4883,A,,
Intermediate,,1,,,Maximum time at the dose of 2 mg/kg in dog,,CHEMBL623670,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6827,,4727,A,In vivo,
Intermediate,,1,,,Maximum time was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,CHEMBL623671,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6828,,1916,A,In vivo,
Intermediate,,1,,,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,,CHEMBL875945,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6829,Blood,1337,A,In vivo,178.0
Intermediate,,1,,,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,,CHEMBL623672,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6830,Blood,1337,A,In vivo,178.0
Intermediate,,1,,,Pharmacokinetic (PK) property (Tmax) was determined in dog at the single dose of 1 mg/kg,,CHEMBL623673,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6831,,6265,A,In vivo,
Intermediate,,1,,,Pharmacokinetic parameter Tmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),,CHEMBL623674,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6832,,4809,A,In vivo,
Intermediate,,1,,,Pharmacokinetic property (Tmax) was measured in dog at the dose of 0.032 mg/kg p.o.,,CHEMBL623675,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6833,,5983,A,In vivo,
Intermediate,,1,,,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog",,CHEMBL872526,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6834,,5313,A,,
Intermediate,,1,,,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog at dosage of 10 mpk",,CHEMBL623676,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6835,,5313,A,In vivo,
Intermediate,,1,,,Time for maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,,CHEMBL623677,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6836,Plasma,17650,A,In vivo,1969.0
Intermediate,,1,,,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,,CHEMBL623678,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6837,Plasma,5199,A,In vivo,1969.0
Intermediate,,1,,,Time taken for maximum plasma concentration in dog,,CHEMBL623679,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6838,Plasma,933,A,,1969.0
Intermediate,,1,,,Time to reach Cmax after oral administration to dogs,,CHEMBL623680,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6839,,16367,A,In vivo,
Intermediate,,1,,,Time to reach maximum plasma concentration was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,CHEMBL623681,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6840,Plasma,6348,A,In vivo,1969.0
Intermediate,,1,,,Tmax (time to reach maximum concentration) was after oral administration at 5 mg/kg,,CHEMBL623682,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6841,,6316,A,In vivo,
Intermediate,,1,,,Tmax after peroral administration (1 mg/kg) was determined in dog,,CHEMBL623683,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6842,,6215,A,In vivo,
Expert,,1,,,Tmax of compound determined in dog after iv administration at a dose of 10 mg/kg,,CHEMBL623684,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6843,,3598,A,In vivo,
Intermediate,,1,,,Tmax by oral administration at a dose of 10 uM/kg in dog was determined,,CHEMBL622745,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6844,,4527,A,In vivo,
Intermediate,,1,,,Tmax after peroral administration in dogs at 2.4 uM/kg,,CHEMBL622746,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6845,,17764,A,In vivo,
Intermediate,,1,,,In vivo Cmax in mice at dose of 100 mg/kg,,CHEMBL622747,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6846,,5969,A,In vivo,
Intermediate,,1,,,In vivo Cmax in mice at dose of 50 mg/kg,,CHEMBL622748,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6847,,5969,A,In vivo,
Intermediate,,1,,,Maximal concentration determined at a dose 10 mg/kg administered intraperitoneally to mice,,CHEMBL622749,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6848,,4573,A,In vivo,
Intermediate,,1,,,Maximum plasma concentration was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),,CHEMBL622750,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6849,Plasma,3277,A,In vivo,1969.0
Intermediate,,1,,,Maximum concentration in plasma was determined after intraperitoneal administration of 100 mg/kg in mice,,CHEMBL623411,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6850,Plasma,17734,A,In vivo,1969.0
Intermediate,,1,,,Maximum concentration obtained in mouse plasma was determined,,CHEMBL875946,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6851,Plasma,3132,A,In vivo,1969.0
Intermediate,,1,,,Maximum concentration obtained in mouse plasma was determined at dose 25 mg/kg,,CHEMBL623412,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6852,Plasma,3132,A,In vivo,1969.0
Intermediate,,1,,,Maximum plasma concentration of compound was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,CHEMBL623413,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6853,Plasma,6348,A,In vivo,1969.0
Intermediate,,1,,,Maximum plasma concentration when injected i.p. in mice at a dose of 50 mg/kg,,CHEMBL623414,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6854,Plasma,17729,A,In vivo,1969.0
Intermediate,,1,,,Maximum plasma concentration when injected intravenously in mice at a dose of 20 mg/kg,,CHEMBL623415,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6855,Plasma,17729,A,In vivo,1969.0
Intermediate,,1,,,Maximum plasma concentration when injected perorally in mice at a dose of 50 mg/kg,,CHEMBL623416,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6856,Plasma,17729,A,In vivo,1969.0
Intermediate,,1,,,Maximal plasma concentration in BALB/C mice after 20 mg/kg intraperitoneal dose,,CHEMBL623417,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6857,Plasma,17728,A,In vivo,1969.0
Intermediate,,1,,,Maximal plasma concentration in BALB/C mice after 20 mg/kg intravenous dose,,CHEMBL623418,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6858,Plasma,17728,A,In vivo,1969.0
Intermediate,,1,,,Maximal plasma concentration in BALB/C mice after 50 mg/kg oral dose,,CHEMBL623419,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6859,Plasma,17728,A,In vivo,1969.0
Intermediate,,1,,,Peak concentration at a single subcutaneous administration of 40 mg/kg in mice,,CHEMBL622816,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6860,,4066,A,In vivo,
Intermediate,,1,,,Pharmacokinetic property (C(max)) was determined after ip administration of 32 mg/kg in mice,,CHEMBL623313,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6861,,6178,A,In vivo,
Intermediate,,1,,,Pharmacokinetic property (C(max)) was determined after po administration of 32 mg/kg in mice,,CHEMBL623314,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6862,,6178,A,In vivo,
Intermediate,,1,,,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg intravenously in mice,,CHEMBL876788,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6863,,3760,A,In vivo,
Intermediate,,1,,,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg perorally in mice,,CHEMBL623315,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6864,,3760,A,In vivo,
Intermediate,,1,,,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg intravenously in mice,,CHEMBL623316,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6865,,3760,A,In vivo,
Intermediate,,1,,,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg perorally in mice,,CHEMBL623317,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6866,,3760,A,In vivo,
Intermediate,,1,,,Cmax in male mice after 2 mg/kg oral dose,,CHEMBL623319,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6868,,5961,A,In vivo,
Intermediate,,1,,,Plasma concentration of 5-FU in HT-3 (human cervical cancer) xenograft mice at 1.38 mg/kg oral dose co-administered with 135 mg/kg Capecitabine,,CHEMBL623320,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6869,,6137,A,In vivo,
Intermediate,,1,,,Tested for Cmax value at the dose of 10 mg/kg when administered perorally in mouse,,CHEMBL623321,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6870,,3802,A,In vivo,
Intermediate,,1,,,Concentration in plasma (systemic) following oral dose in mouse at 0.25 hr,,CHEMBL623322,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6871,,3535,A,,
Intermediate,,1,,,Concentration in plasma (systemic) following oral dose in mouse at 1 hr,,CHEMBL623323,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6872,,3535,A,,
Intermediate,,1,,,Concentration in plasma (systemic) following oral dose in mouse at 24 hr,,CHEMBL623324,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6873,,3535,A,,
Intermediate,,1,,,Concentration in plasma (systemic) following oral dose in mouse at 2 hr,,CHEMBL623325,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6874,,3535,A,,
Intermediate,,1,,,Concentration in plasma (systemic) following oral dose in mouse at 4 hr,,CHEMBL623326,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6875,,3535,A,,
Intermediate,,1,,,Concentration in plasma (systemic) following oral dose in mouse at 6 hr,,CHEMBL623327,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6876,,3535,A,,
Intermediate,,1,,,Maximum concentration in plasma upon oral administration in mouse,,CHEMBL623328,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6877,Plasma,2862,A,,1969.0
Intermediate,,1,,,Maximum plasma concentration was evaluated in mice after oral administration,,CHEMBL623329,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6878,Plasma,2675,A,,1969.0
Intermediate,,1,,,Maximum plasma concentration was evaluated in mice after intravenous administration; Cp max Not determined,,CHEMBL623330,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6879,Plasma,2675,A,In vivo,1969.0
Intermediate,,1,,,Dose at which the compound induced fecal excretion in mice,,CHEMBL876789,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,6880,,5399,A,,
Expert,,1,A10,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.01 uM,,CHEMBL623333,N,1,,164.0,Rattus norvegicus,10116.0,BAO_0000219,80013,,6893,,11819,F,,
Expert,,1,A10,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.1 uM,,CHEMBL623334,N,1,,164.0,Rattus norvegicus,10116.0,BAO_0000219,80013,,6894,,11819,F,,
Expert,,1,A10,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 1.0 uM,,CHEMBL627536,N,1,,164.0,Rattus norvegicus,10116.0,BAO_0000219,80013,,6895,,11819,F,,
Expert,,1,A10,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 10.0 uM,,CHEMBL627537,N,1,,164.0,Rattus norvegicus,10116.0,BAO_0000219,80013,,6896,,11819,F,,
Intermediate,,1,A10,,In vitro [14C]- creatine uptake (1 mM) was determined in rat A10 smooth muscle cells at a concentration of (1 mM),,CHEMBL627538,N,1,,164.0,Rattus norvegicus,10116.0,BAO_0000219,80013,,6897,,16361,F,,
Intermediate,,1,A121,,Cytotoxicity was evaluated against A121 ovarian carcinoma human cancer cell line,,CHEMBL884106,N,1,,393.0,Homo sapiens,9606.0,BAO_0000219,80655,,6898,,2288,F,,
Intermediate,,1,A121,,Anticancer activity against human ovarian carcinoma A121 cells,,CHEMBL625294,N,1,,393.0,Homo sapiens,9606.0,BAO_0000219,80655,,6899,,10404,F,,
Intermediate,,1,A121,,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 16.6 mM,,CHEMBL625295,N,1,,393.0,Homo sapiens,9606.0,BAO_0000219,80655,,6900,,14790,F,,
Intermediate,,1,A121,,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 83 mM,,CHEMBL625296,N,1,,393.0,Homo sapiens,9606.0,BAO_0000219,80655,,6901,,14790,F,,
Expert,,1,A121,,Growth inhibition of human ovarian carcinoma (A121) cell line,,CHEMBL625297,N,1,,393.0,Homo sapiens,9606.0,BAO_0000219,80655,,6902,,14253,F,,
Expert,,1,A121,,Concentration required to inhibit growth of human tumor A121 (ovarian) cell line.,,CHEMBL625298,N,1,,393.0,Homo sapiens,9606.0,BAO_0000219,80655,,6903,,13617,F,,
Intermediate,,1,A121,,Cytotoxicity against human A121 ovarian cells,,CHEMBL625960,N,1,,393.0,Homo sapiens,9606.0,BAO_0000219,80655,,6904,,1003,F,,
Intermediate,,1,A121,,Cytotoxicity was evaluated in vitro against A121 (ovarian carcinoma) human tumor cell lines,,CHEMBL625961,N,1,,393.0,Homo sapiens,9606.0,BAO_0000219,80655,,6905,,830,F,,
Intermediate,,1,A121,,In vitro cytotoxicity against human ovarian carcinoma A21,,CHEMBL625962,N,1,,393.0,Homo sapiens,9606.0,BAO_0000219,80655,,6906,,12307,F,,
Intermediate,,1,A121,,Inhibition of the growth against human Ovarian Carcinoma (A121) cell line after 72 hr exposure,,CHEMBL624717,N,1,,393.0,Homo sapiens,9606.0,BAO_0000219,80655,,6907,,14254,F,,
Intermediate,,1,A121,,Inhibitory activity of compound against human A121 ovarian cell line.,,CHEMBL624718,N,1,,393.0,Homo sapiens,9606.0,BAO_0000219,80655,,6908,,13370,F,,
Intermediate,,1,A121,,Dose at which compound exhibits cytotoxicity in the A121 ovarian carcinoma cell line.,,CHEMBL624719,N,1,,393.0,Homo sapiens,9606.0,BAO_0000219,80655,,6909,,14790,F,,
Intermediate,,1,A121,,Inhibition of growth of human ovarian tumor cell line (A121) after 72 hr of drug exposure,,CHEMBL624720,N,1,,393.0,Homo sapiens,9606.0,BAO_0000219,80655,,6910,,3614,F,,
Intermediate,,1,A 172,,Compound was evaluated for in vitro antiproliferative activity against A172 human CNS cancer cell line,,CHEMBL624721,N,1,,622.0,Homo sapiens,9606.0,BAO_0000219,80012,,6911,,2664,F,,
Expert,,1,A 172,,In vitro cytotoxicity against A172 human tumor cell lines.,,CHEMBL624722,N,1,,622.0,Homo sapiens,9606.0,BAO_0000219,80012,,6912,,2037,F,,
Intermediate,,1,A 172,,Growth inhibition time for A172 Human Glioma cell growth at concentration 5 uM,,CHEMBL877597,N,1,,622.0,Homo sapiens,9606.0,BAO_0000219,80012,,6913,,14539,F,,
Intermediate,,1,A 172,,Compound was evaluated for cytotoxicity against human glioblastoma (A172) cell line,,CHEMBL624723,N,1,,622.0,Homo sapiens,9606.0,BAO_0000219,80012,,6914,,2836,F,,
Intermediate,,1,A 172,,Evaluated for the inhibitory concentration required to cause growth inhibition of A172Mer- cell line of central nervous system (CNS) using the MTT Cytotoxicity Assay,,CHEMBL624724,N,1,,622.0,Homo sapiens,9606.0,BAO_0000219,80012,,6915,,10708,F,,
Autocuration,,1,,,Association constant against A2 adenosine receptor,,CHEMBL624725,H,4,,,Canis lupus familiaris,9615.0,BAO_0000224,104729,,6916,,8975,B,,
Intermediate,,1,A2,,In vitro effective dose that causes 50% inhibition of growth of A2 cell line - amelanotic melanoma,,CHEMBL624726,N,1,,1085.0,fish,,BAO_0000219,80656,,6917,,7645,F,,
Autocuration,,1,,,Ratio of Ki for adenosine A2 and A1 receptor binding,,CHEMBL857535,D,5,,,Rattus norvegicus,10116.0,BAO_0000224,104713,,6918,,11377,B,,
Expert,,1,A204,,In vitro cytotoxicity against A204 human rhabdomyosarcoma cancer cell line,,CHEMBL624727,N,1,,623.0,Homo sapiens,9606.0,BAO_0000219,80014,,6919,,13528,F,,
Expert,,1,A204,,In vitro antitumor activity against A204 rhabdomyosarcoma tumor cell line was determined,,CHEMBL624728,N,1,,623.0,Homo sapiens,9606.0,BAO_0000219,80014,,6920,,10160,F,,
Intermediate,,1,A2058,,The compound was tested in vitro for antiproliferative activity against A2058 tumor cell lines,,CHEMBL624729,N,1,,404.0,Homo sapiens,9606.0,BAO_0000219,80015,,6921,,15144,F,,
Intermediate,,1,A253 cell line,,Growth inhibition against Human squamous cell line(A 253),,CHEMBL624730,N,1,,973.0,Homo sapiens,9606.0,BAO_0000219,80657,,6922,,13160,F,,
Intermediate,,1,A253 cell line,,Growth inhibition of human squamous carcinoma cell lines following continuous (120 hours) exposure to MTX and compound A253 cell line,,CHEMBL624731,N,1,,973.0,Homo sapiens,9606.0,BAO_0000219,80657,,6923,,12898,F,,
Intermediate,,1,A253 cell line,,The compound was tested for Growth inhibition of the human squamous cell carcinoma A253 cells,,CHEMBL624732,N,1,,973.0,Homo sapiens,9606.0,BAO_0000219,80657,,6924,,13069,F,,
Intermediate,,1,A253 cell line,,Growth inhibition of A253 cell lines.,,CHEMBL883245,N,1,,973.0,Homo sapiens,9606.0,BAO_0000219,80657,,6925,,15984,F,,
Intermediate,,1,A253 cell line,,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h),,CHEMBL624733,N,1,,973.0,Homo sapiens,9606.0,BAO_0000219,80657,,6926,,15564,F,,
Intermediate,,1,A253 cell line,,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,,CHEMBL624734,N,1,,973.0,Homo sapiens,9606.0,BAO_0000219,80657,,6927,,15564,F,,
Intermediate,,1,A253 cell line,,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,,CHEMBL624735,N,1,,973.0,Homo sapiens,9606.0,BAO_0000219,80657,,6928,,15564,F,,
Intermediate,,1,A2780,,In vitro cytotoxicity causing 50% growth inhibition was determined against A270 (human ovarian cancer)cell line,,CHEMBL621780,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,6929,,4720,F,,
Intermediate,,1,A2780,,Antitumor activity of compound for 96-h exposure in A2780 human ovarian cell line,,CHEMBL877598,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,6930,,16112,F,,
Expert,,1,A2780,,Cytotoxic activity against A2780 human ovarian carcinoma cell line,,CHEMBL621781,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,6931,,16597,F,,
Intermediate,,1,A2780,,Cytotoxicity against human cancer cell lines A2780 (ovarian),,CHEMBL621782,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,6932,,16378,F,,
Expert,,1,A2780,,Growth and colony formation inhibition of A2780 ovarian cancer cell lines,,CHEMBL621783,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,6933,,16085,F,,
Intermediate,,1,A2780,,Inhibition of cell growth in human ovarian carcinoma cell line (A2780) using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay,,CHEMBL621784,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,6934,,16317,F,,
Intermediate,,1,A2780,,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),,CHEMBL621785,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,6935,,15748,F,,
Expert,,1,A2780,,Inhibition of A2780 / DDP-R human ovarian carcinoma cell proliferation,,CHEMBL621968,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,6936,,16597,F,,
Expert,,1,A2780,,Inhibition of A2780 / TAX-R human ovarian carcinoma cell proliferation,,CHEMBL621969,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,6937,,16597,F,,
Expert,,1,A2780,,Inhibition of A2780 / TAX-S human ovarian carcinoma cell proliferation,,CHEMBL621970,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,6938,,16597,F,,
Intermediate,,1,A2780,,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 2,,CHEMBL621971,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,6939,,15608,F,,
Intermediate,,1,A2780,,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 3,,CHEMBL621972,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,6940,,15608,F,,
Intermediate,,1,A2780,,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 5,,CHEMBL884108,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,6941,,15608,F,,
Autocuration,,1,,,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,,CHEMBL623826,U,0,,,Cricetulus griseus,10029.0,BAO_0000019,22224,,6942,,15296,F,,
Autocuration,,1,CHO-AA8,,Evaluated for cytotoxicity under aerobic conditions against AA8 cells using microassay,,CHEMBL623827,U,0,,185.0,Cricetulus griseus,10029.0,BAO_0000219,22224,,6943,,10251,A,,
Autocuration,,1,CHO-AA8,,Evaluated for growth inhibition of AA8 cells under aerobic conditions,,CHEMBL623828,U,0,,185.0,Cricetulus griseus,10029.0,BAO_0000219,22224,,6944,,10251,F,,
Autocuration,,1,CHO-AA8,,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions,,CHEMBL623829,U,0,,185.0,Cricetulus griseus,10029.0,BAO_0000219,22224,,6945,,10251,F,,
Autocuration,,1,CHO-AA8,,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions (air/N2),,CHEMBL623830,U,0,,185.0,Cricetulus griseus,10029.0,BAO_0000219,22224,,6946,,10251,F,,
Autocuration,,1,,,Growth inhibition against CHO-derived cell line AA8,,CHEMBL623831,U,0,,,Cricetulus griseus,10029.0,BAO_0000019,22224,,6947,,11858,F,,
Autocuration,,1,CHO-AA8,,Growth inhibition against CHO-derived cell line AA8 (Non toxic at solubility limit) [RB6145 used as positive control],,CHEMBL623832,U,0,,185.0,Cricetulus griseus,10029.0,BAO_0000219,22224,,6948,,11858,F,,
Expert,,1,CHO-AA8,,Growth inhibition in CHO subline AA8 cells exposed for 18 hr under aerobic(air) conditions,,CHEMBL623833,N,1,,185.0,hampster,36483.0,BAO_0000219,80089,,6949,,11616,F,,
Expert,,1,CHO-AA8,,Growth inhibitory activity against CHO subline AA8 cells exposed for 18 hr under aerobic conditions,,CHEMBL623834,N,1,,185.0,Cricetulus griseus,10029.0,BAO_0000219,80089,,6950,,11616,F,,
Autocuration,,1,CHO-AA8,,Tested for the concentration of the drug to reduce cell numbers to 50 percent of controls against AA8 cells in the microassay,,CHEMBL623835,U,0,,185.0,Cricetulus griseus,10029.0,BAO_0000219,22224,,6951,,10518,F,,
Autocuration,,1,CHO-AA8,,Growth inhibition of aerobic chinese hamster ovary fibroblast AA8 cell line using an exposure time of 18 hours,,CHEMBL623836,U,0,,185.0,Cricetulus griseus,10029.0,BAO_0000219,22224,,6952,,11396,F,,
Autocuration,,1,CHO-AA8,,IC50 (air/N2) ratio of the drug to reduce cell numbers to 50 percent of controls using AA8 cells in the microassay,,CHEMBL623837,U,0,,185.0,Cricetulus griseus,10029.0,BAO_0000219,22224,,6953,,10518,F,,
Expert,,1,CHO-AA8,,In vitro therapeutic index as ratio of CT10 and C1.3 calculated for AA8 cells.,,CHEMBL623838,N,1,,185.0,Cricetulus griseus,10029.0,BAO_0000219,80089,,6954,,11616,F,,
Autocuration,,1,,,compound was evaluated for association constant (Ka) of isolated serum protein AAG,,CHEMBL623839,H,8,,,,,BAO_0000019,12675,,6955,,14837,F,,
Autocuration,,1,,,Number of binding sites (n) of isolated serum protein AAG,,CHEMBL623840,H,8,,,,,BAO_0000019,12675,,6956,,14837,F,,
Intermediate,,1,,,Association constant for binding to AATT duplex,,CHEMBL623841,M,3,,,,,BAO_0000225,22222,,6957,,16037,B,,
Expert,,1,ABAE,,Inhibition of ABAE human fibroblast cell proliferation,,CHEMBL623842,N,1,,416.0,Homo sapiens,9606.0,BAO_0000219,100090,,6958,,16597,F,,
Intermediate,,1,AC755,,"Compound was evaluated for the antitumor activity against AC755 breast carcinoma for ip administration and daily x 10 schedule; Number of toxic deaths over total number of mice per group (T/C), 1/7 at dose of 25 mg/kg",,CHEMBL623843,N,1,,1064.0,Mus musculus,10090.0,BAO_0000218,80668,,6959,,8831,F,,
Expert,,1,,,Percent change in total cholesterol(TC) versus (T0)- at which drug intervention begins at a dose of 25 mg/kg in the chronic cholesterol-fed rabbit model,,CHEMBL618669,D,9,,,Oryctolagus cuniculus,9986.0,BAO_0000218,102444,,6960,,13419,F,,
Expert,,1,,,Oral bioactivity expressed as %inhibition after 4 hours of drug administration (dose 25 mg/kg) in rabbit bioassay,,CHEMBL618670,D,9,,,Oryctolagus cuniculus,9986.0,BAO_0000218,102444,,6961,,13419,F,In vivo,
Autocuration,,1,,,Inhibitory activity against angiotensin-converting enzyme (ACE).,,CHEMBL618671,H,8,,,,,BAO_0000357,69,,6962,,15778,B,,
Autocuration,,1,,,oral activity against angiotensin -converting enzyme ( ACE) and neutral endopeptidase in mouse.,,CHEMBL618672,H,8,,,,,BAO_0000357,69,,6963,,15778,B,,
Intermediate,,1,ACH-2 cell line,,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells,,CHEMBL618673,N,1,,978.0,Homo sapiens,9606.0,BAO_0000219,80669,,6964,,12988,F,,
Intermediate,,1,ACH-2 cell line,,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells in the presence of PMA(phorbol 12-myristate 13-acetate),,CHEMBL618674,N,1,,978.0,Homo sapiens,9606.0,BAO_0000219,80669,,6965,,12988,F,,
Autocuration,,1,T cell line,,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2,,CHEMBL618675,U,0,,998.0,Human immunodeficiency virus 1,11676.0,BAO_0000219,22224,,6966,,12988,F,,
Autocuration,,1,T cell line,,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2 in the presence of PMA(phorbol 12-myristate 13-acetate),,CHEMBL618676,U,0,,998.0,Human immunodeficiency virus 1,11676.0,BAO_0000219,22224,,6967,,12988,F,,
Autocuration,,1,T cell line,,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2i n the presence of PMA(phorbol 12-myristate 13-acetate),,CHEMBL618677,U,0,,998.0,Human immunodeficiency virus 1,11676.0,BAO_0000219,22224,,6968,,12988,F,,
Intermediate,,1,ACHN,,Inhibition of growth of renal cancer ACHN cell line,,CHEMBL618678,N,1,,626.0,Homo sapiens,9606.0,BAO_0000219,80025,,6969,,11843,F,,
Intermediate,,1,ACHN,,Inhibition of growth of ACHN renal cancer cell line,,CHEMBL618679,N,1,,626.0,Homo sapiens,9606.0,BAO_0000219,80025,,6970,,16939,F,,
Intermediate,,1,ACHN,,Inhibitory concentration required against ACHN renal cancer cell line,,CHEMBL618680,N,1,,626.0,Homo sapiens,9606.0,BAO_0000219,80025,,6971,,4782,F,,
Expert,,1,ACHN,,Concentration required to inhibit growth of human renal (ACHN) cell line,,CHEMBL618681,N,1,,626.0,Homo sapiens,9606.0,BAO_0000219,80025,,6972,,6310,F,,
Intermediate,,1,ACHN,,Concentration required to inhibit growth of human renal (ACHN) cell line; nt = not tested,,CHEMBL618682,N,1,,626.0,Homo sapiens,9606.0,BAO_0000219,80025,,6973,,6310,F,,
Intermediate,,1,ACHN,,Cytotoxic activity against ACHN Renal cancer cell line,,CHEMBL618683,N,1,,626.0,Homo sapiens,9606.0,BAO_0000219,80025,,6974,,12858,F,,
Intermediate,,1,ACHN,,Cytotoxicity evaluation against ACHN renal cancer cells,,CHEMBL618684,N,1,,626.0,Homo sapiens,9606.0,BAO_0000219,80025,,6975,,17380,F,,
Intermediate,,1,ACHN,,In vitro antitumor activity against human renal ACHN cell line,,CHEMBL618685,N,1,,626.0,Homo sapiens,9606.0,BAO_0000219,80025,,6976,,5858,F,,
Intermediate,,1,ACHN,,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,,CHEMBL876499,N,1,,626.0,Homo sapiens,9606.0,BAO_0000219,80025,,6977,,3838,F,,
Intermediate,,1,ACHN,,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,,CHEMBL618686,N,1,,626.0,Homo sapiens,9606.0,BAO_0000219,80025,,6978,,3838,F,,
Intermediate,,1,ACHN,,"Tested for the cytotoxicity against the Renal cancer cell line ACHN, growth inhibition by 50% is reported",,CHEMBL618687,N,1,,626.0,Homo sapiens,9606.0,BAO_0000219,80025,,6979,,5406,F,,
Intermediate,,1,ACHN,,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,,CHEMBL618688,N,1,,626.0,Homo sapiens,9606.0,BAO_0000219,80025,,6980,,4071,F,,
Expert,,1,ACHN,,Tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,,CHEMBL618689,N,1,,626.0,Homo sapiens,9606.0,BAO_0000219,80025,,6981,,4071,F,,
Intermediate,,1,ACHN,,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal); Not determined,,CHEMBL618690,N,1,,626.0,Homo sapiens,9606.0,BAO_0000219,80025,,6982,,4071,F,,
Intermediate,,1,ACHN,,Antitumor activity was evaluated against human renal adenocarcinoma cell line ACHN.,,CHEMBL618691,N,1,,626.0,Homo sapiens,9606.0,BAO_0000219,80025,,6983,,15002,F,,
Intermediate,,1,ACHN,,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),,CHEMBL619373,N,1,,626.0,Homo sapiens,9606.0,BAO_0000219,80025,,6984,,14769,F,,
Intermediate,,1,ACHN,,"Compound was tested for antiproliferative activity against ACHN, human renal adenocarcinoma",,CHEMBL884008,N,1,,626.0,Homo sapiens,9606.0,BAO_0000219,80025,,6985,,13958,F,,
Intermediate,,1,ACHN,,Compound was tested for its effect on the proliferation of ACHN human kidney adenocarcinoma,,CHEMBL619374,N,1,,626.0,Homo sapiens,9606.0,BAO_0000219,80025,,6986,,1665,F,,
Intermediate,,1,ACHN,,Compound was tested for the growth inhibition of ACHN renal tumor cell line,,CHEMBL619375,N,1,,626.0,Homo sapiens,9606.0,BAO_0000219,80025,,6987,,15354,F,,
Intermediate,,1,ACHN,,Compound was tested for the growth inhibition of ACHN renal tumor cell line; ND=Not determined,,CHEMBL619376,N,1,,626.0,Homo sapiens,9606.0,BAO_0000219,80025,,6988,,15354,F,,
Intermediate,,1,ACHN,,In vitro Growth Inhibitory activity against ACHN Human kidney cancer cell line,,CHEMBL619377,N,1,,626.0,Homo sapiens,9606.0,BAO_0000219,80025,,6989,,13978,F,,
Intermediate,,1,ACHN,,In vitro cytotoxicity against human renal adenocarcinoma (ACHN) tumor cell line,,CHEMBL619378,N,1,,626.0,Homo sapiens,9606.0,BAO_0000219,80025,,6990,,6798,F,,
Intermediate,,1,,,Tmax value after administration of 4 mg/Kg oral dose in dog,,CHEMBL872527,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6991,,2959,A,In vivo,
Intermediate,,1,,,"Time to peak response on lowering of vascular resistance, in dogs when administered intravenously",,CHEMBL876500,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6992,,9932,A,,
Intermediate,,1,,,Unbound plasma was determined in Beagle dog at a dose of 1 mg/kg by iv administration,,CHEMBL619379,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6993,,5546,A,,
Intermediate,,1,,,Volume distribution after 15 mg/kg iv dose in Dogs,,CHEMBL619538,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6994,,16907,A,In vivo,
Intermediate,,1,,,Volume distribution after 30 mg/kg po dose in Dogs,,CHEMBL619539,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6995,,16907,A,In vivo,
Intermediate,,1,,,Volume of distribution was determined in dog after a 3 mg/kg of iv dose,,CHEMBL619540,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6996,,4257,A,In vivo,
Intermediate,,1,,,Volume of distribution was determined by iv administration in dogs at a dose of 1 mg/kg,,CHEMBL619541,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6997,,4305,A,In vivo,
Intermediate,,1,,,Volume of distribution was evaluated in dog,,CHEMBL619542,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6998,,5472,A,In vivo,
Intermediate,,1,,,Terminal phase volume of distribution was measured in dog after an iv dose of 1 mg/kg,,CHEMBL619543,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,6999,,6062,A,In vivo,
Expert,,1,,,Apparent volume of the central plasma compartment (Vc) of compound determined in dog after iv administration at a dose of 10 mg/kg,,CHEMBL619544,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7000,,3598,A,,
Intermediate,,1,,,The compound was tested for volume of distribution in dog,,CHEMBL619545,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7001,,12500,A,In vivo,
Intermediate,,1,,,The compound was tested for volume of distribution in dog at dose of 3-10 mgkg,,CHEMBL619546,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7002,,12500,A,In vivo,
Intermediate,,1,,,Vd (1 mg/kg) was determined in dog (in vivo),,CHEMBL619547,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7003,,6227,A,In vivo,
Intermediate,,1,,,Vd in dog,,CHEMBL619548,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7004,,6227,A,In vivo,
Intermediate,,1,,,Volume distribution was determined,,CHEMBL619549,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7005,,4219,A,In vivo,
Intermediate,,1,,,Volume of distribution in dog,,CHEMBL619550,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7006,,1696,A,In vivo,
Intermediate,,1,,,Volume of distribution by as 4 fold increase by iv administration in dogs,,CHEMBL876501,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7007,,5542,A,In vivo,
Intermediate,,1,,,Volume of distribution was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,,CHEMBL619551,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7008,,5199,A,In vivo,
Intermediate,,1,,,Volume of distribution was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,CHEMBL619552,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7009,,6348,A,In vivo,
Intermediate,,1,,,Volume distribution at the dose of 2 mg/kg in dog,,CHEMBL619553,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7010,,4727,A,In vivo,
Intermediate,,1,,,Steady state volume of distribution was determined,,CHEMBL618722,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7011,,16367,A,In vivo,
Intermediate,,1,,,Bioavailability as Vdss in dogs at 1 mg/kg intravenous dose,,CHEMBL618723,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7012,,2652,A,In vivo,
Intermediate,,1,,,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,,CHEMBL618724,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7013,,16452,A,In vivo,
Intermediate,,1,,,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,,CHEMBL618725,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7014,,16452,A,In vivo,
Intermediate,,1,,,Bioavailability in dog (dose 1 mg/kg i.v.),,CHEMBL618726,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7015,,16452,A,In vivo,
Intermediate,,1,,,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),,CHEMBL618727,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7016,,5334,A,In vivo,
Intermediate,,1,,,Pharmacokinetic property (vdss) was measured in dog,,CHEMBL624233,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7017,,4239,A,In vivo,
Intermediate,,1,,,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in dog,,CHEMBL624234,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7018,,4709,A,In vivo,
Intermediate,,1,,,Vdss was determined after iv 0.1 mg/kg administration in dog,,CHEMBL624235,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7019,,5600,A,In vivo,
Intermediate,,1,,,Volume displacement was calculated in dog,,CHEMBL624236,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7020,,6057,A,In vivo,
Intermediate,,1,,,Volume distribution (Vdss) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,,CHEMBL624237,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7021,,5654,A,In vivo,
Intermediate,,1,,,Volume distribution constant was determined,,CHEMBL624238,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7022,,5505,A,In vivo,
Intermediate,,1,,,Volume distribution at a dose of 1 uM/kg in dog was determined,,CHEMBL624239,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7023,,4527,A,In vivo,
Intermediate,,1,,,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,,CHEMBL875829,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7024,,4521,A,In vivo,
Intermediate,,1,,,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,,CHEMBL624240,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7025,,4521,A,In vivo,
Intermediate,,1,,,Volume distribution (Vdss) was measured in dog,,CHEMBL624241,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7026,,15660,A,In vivo,
Intermediate,,1,,,Volume distribution (Vdss) was measured in dog,,CHEMBL624242,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7027,,15660,A,In vivo,
Intermediate,,1,,,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,CHEMBL624243,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7028,,6679,A,In vivo,
Intermediate,,1,,,Volume of distribution in steady state was determined in dog,,CHEMBL624244,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7029,,5145,A,In vivo,
Intermediate,,1,,,Volume of distribution of compound was determined in dog,,CHEMBL624245,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7030,,6821,A,In vivo,
Intermediate,,1,,,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,,CHEMBL624246,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7031,,4137,A,In vivo,
Intermediate,,1,,,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),,CHEMBL624247,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7032,,5334,A,In vivo,
Intermediate,,1,,,Volume of distribution (Vdss) was measured in dog,,CHEMBL624248,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7033,,15660,A,In vivo,
Intermediate,,1,,,Volumes of distribution in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,CHEMBL624249,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7034,,6642,A,In vivo,
Intermediate,,1,,,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,CHEMBL624250,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7035,,6641,A,In vivo,
Intermediate,,1,,,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,CHEMBL624251,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7036,,6642,A,In vivo,
Intermediate,,1,,,Maximum rate of depolarization of the upstroke of the action potential,,CHEMBL624252,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7037,,11659,A,,
Intermediate,,1,,,Steady state volume distribution in dog,,CHEMBL624253,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7038,,6448,A,In vivo,
Intermediate,,1,,,Steady state volume of distribution at a dose of 0.2 mg/kg i.v.,,CHEMBL624950,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7039,,5474,A,In vivo,
Intermediate,,1,,,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in dog,,CHEMBL624951,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7040,,1466,A,In vivo,
Intermediate,,1,,,Volume distribution in dog after administration of 0.25 mg/kg iv; ND = not determined,,CHEMBL875830,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7041,,6535,A,In vivo,
Intermediate,,1,,,Volume distribution in dog after administration of 1 mg/kg iv,,CHEMBL624952,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7042,,6535,A,In vivo,
Intermediate,,1,,,Volume of solubility in solution after intravenous administration in dogs at 1.2 uM/kg,,CHEMBL624953,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7043,,17764,A,In vivo,
Intermediate,,1,,,Vss after intravenous administration (0.5 mg/kg) was determined in dog,,CHEMBL624954,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7044,,6215,A,In vivo,
Intermediate,,1,,,Vss on i.v. administration of 2 mg/kg was measured in dog,,CHEMBL624955,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7045,,6505,A,In vivo,
Intermediate,,1,,,Vss was determined,,CHEMBL624956,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7046,,3639,A,,
Intermediate,,1,,,Vss in dog,,CHEMBL625129,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7047,,3639,A,,
Intermediate,,1,,,Volume of distribution was measured in dog after an iv dose of 1 mg/kg,,CHEMBL625130,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7048,,6062,A,In vivo,
Intermediate,,1,,,Volume distribution in dogs,,CHEMBL625131,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7049,,4942,A,In vivo,
Intermediate,,1,,,Volume of distribution in dog,,CHEMBL625132,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7050,,17796,A,In vivo,
Intermediate,,1,,,Tested for the oral bioavailability in dog,,CHEMBL872263,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7051,,4883,A,In vivo,
Intermediate,,1,,,Bioavailability of compound in mouse blood following p.o. administration of 30 mg/kg,,CHEMBL624336,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,7060,,17837,A,In vivo,
Intermediate,,1,,,Bioavailability after i.p. administration of 50 mg/kg of dose in mice,,CHEMBL624337,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,7061,,17729,A,In vivo,
Intermediate,,1,,,Bioavailability after peroral administration of 50 mg/kg of dose in mice,,CHEMBL624338,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,7062,,17729,A,In vivo,
Intermediate,,1,,,Bioavailability was measured in mouse,,CHEMBL624339,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,7063,,4239,A,In vivo,
Intermediate,,1,,,Bioavailability in mouse,,CHEMBL624340,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,7064,,17592,A,In vivo,
Intermediate,,1,,,Bioavailability was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,CHEMBL624341,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,7065,,6348,A,In vivo,
Intermediate,,1,,,Bioavailability in mouse,,CHEMBL624342,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,7066,,2801,A,In vivo,
Intermediate,,1,,,Compound was evaluated for its bioavailability in mice at a dose of 1 mg/kg,,CHEMBL624343,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,7067,,2801,A,In vivo,
Intermediate,,1,,,Oral bioavailability in mouse,,CHEMBL624344,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,7068,,17718,A,In vivo,
Intermediate,,1,,,Oral availability at 50 mg/kg po in male mice,,CHEMBL624345,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,7069,,5727,A,In vivo,
Intermediate,,1,,,Oral bioavailability in mouse (dose 10 mg/kg),,CHEMBL624346,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,7070,,5302,A,In vivo,
Expert,,1,,,Oral bioavailability of compound determined in mouse after iv administration at a dose of 10 mg/kg,,CHEMBL624347,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,7071,,3598,A,In vivo,
Intermediate,,1,,,"Bioavailability in male mice, 2mg/kg oral and 1 mg/kg intravenous dose",,CHEMBL624348,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,7072,,5961,A,In vivo,
Intermediate,,1,,,Oral bioavailability in mouse,,CHEMBL622754,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,7074,,6091,A,In vivo,
Intermediate,,1,,,Oral bioavailability in vivo in mice;ND=Not determined,,CHEMBL622755,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,7075,,6091,A,In vivo,
Intermediate,,1,,,Oral bioavailability in mouse at 10 mg/kg of the compound,,CHEMBL622756,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,7076,,5711,A,In vivo,
Intermediate,,1,,,Bioavailability in mouse (BALB/C) (dose 50 mg/kg i.p.),,CHEMBL622757,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,7077,,17728,A,In vivo,
Intermediate,,1,,,Bioavailability in mouse (BALB/C) (dose 20 mg/kg i.v.),,CHEMBL622758,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,7078,,17728,A,In vivo,
Intermediate,,1,,,Tested for bioavailability of the compound,,CHEMBL622759,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,7079,,3802,A,In vivo,
Intermediate,,1,,,Tested for half life at the dose of 10 mg/kg when administered intravenously,,CHEMBL622760,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,7080,,3802,A,In vivo,
Intermediate,,1,,,The plasma half life of compound was determined on EDTA prepared by mouse plasma. ,,CHEMBL622761,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,7081,Plasma,14029,A,,1969.0
Intermediate,,1,,,The plasma half life of compound was determined on heparin prepared by human plasma. ,,CHEMBL622762,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,7082,Plasma,14029,A,,1969.0
Intermediate,,1,,,The plasma half life of compound was determined on heparin prepared by human plasma; Not degraded,,CHEMBL622763,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,7083,Plasma,14029,A,,1969.0
Intermediate,,1,,,The plasma half life of compound was determined on heparin prepared by mouse plasma. ,,CHEMBL622764,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,7084,Plasma,14029,A,,1969.0
Intermediate,,1,,,The plasma half life of compound was determined on heparin prepared by mouse plasma; Not degraded,,CHEMBL622765,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,7085,Plasma,14029,A,,1969.0
Intermediate,,1,,,Inhibitory concentration of compound was determined after intravenous administration in mice after 6 hours of exposure at 40 mg/Kg,,CHEMBL622766,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,7086,,17753,F,,
Intermediate,,1,,,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 24 mg/Kg,,CHEMBL622767,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,7087,,17753,A,,
Intermediate,,1,,,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 5 mg/Kg,,CHEMBL622768,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,7088,,17753,A,,
Intermediate,,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,CHEMBL875948,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,7089,Blood,10107,A,In vivo,178.0
Intermediate,,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,CHEMBL622769,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,7090,Blood,10107,A,In vivo,178.0
Intermediate,,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,CHEMBL622770,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,7091,Blood,10107,A,In vivo,178.0
Intermediate,,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,CHEMBL622771,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,7092,Blood,10107,A,In vivo,178.0
Intermediate,,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,CHEMBL622772,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,7093,Blood,10107,A,In vivo,178.0
Intermediate,,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,CHEMBL622773,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,7094,Blood,10107,A,In vivo,178.0
Intermediate,,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,CHEMBL622774,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,7095,Blood,10107,A,In vivo,178.0
Intermediate,,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,CHEMBL621725,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,7096,Bone,10107,A,In vivo,10000001.0
Intermediate,,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,,CHEMBL621726,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,7097,Bone,10107,A,In vivo,10000001.0
Intermediate,,1,A2780,,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 8,,CHEMBL621727,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,7098,,15608,F,,
Expert,,1,A2780,,In vitro cytotoxicity against human ovarian carcinoma cell line A2780 using sulforhodamine B (SRB) assay,,CHEMBL622413,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,7099,,3290,F,,
Intermediate,,1,A2780,,Compound was evaluated for cytotoxicity against A2780 cell line,,CHEMBL622414,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,7100,,2859,F,,
Expert,,1,A2780,,Inhibition of A2780 cell clonogenic assay,,CHEMBL622415,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,7101,,15688,F,,
Expert,,1,A2780,,Cytotoxic effect on ovarian cancer cell line (A2780),,CHEMBL884001,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,7102,,5642,F,,
Intermediate,,1,A2780,,Concentration required to inhibit A2780 cell growth when compared with control after incubation for 96 hr at 37 C,,CHEMBL622416,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,7103,,6633,F,,
Intermediate,,1,A2780,,"MDR-reversing activity was measured by vincristine accumulation in the multidrug resistant 2780AD, a subline of A2780 ovarian carcinoma cells at 10 mg/mL",,CHEMBL622417,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,7104,,3906,F,,
Expert,,1,A2780,,50% growth inhibition of A2780 (Human ovarian carcinoma) cell line compared with untreated control cells,,CHEMBL622590,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,7105,,6788,F,,
Expert,,1,A2780,,Antiproliferative activity against human A2780 cells,,CHEMBL622591,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,7106,,17582,F,,
Expert,,1,A2780,,Inhibition of human A2780 cell proliferation,,CHEMBL622592,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,7107,,17764,F,,
Expert,,1,A2780,,Antiproliferative effect against human A2780 cell line was determined in a whole cell 72 hr cytotoxicity assay,,CHEMBL622593,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,7108,,17764,F,,
Expert,,1,A2780,,Inhibition of human A2780 cell proliferation (No data),,CHEMBL622594,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,7109,,17764,F,,
Intermediate,,1,A2780,,Cell cytotoxicity was determined against human ovarian cancer (A2780) cell line,,CHEMBL622595,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,7110,,2815,F,,
Intermediate,,1,A2780,,Compound was evaluated against human Ovarian carcinoma cell line A2780,,CHEMBL622596,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,7111,,16930,F,,
Expert,,1,A2780,,Growth inhibition against A2780 wild-type ovarian cell lines,,CHEMBL622597,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,7112,,17777,F,,
Intermediate,,1,A2780,,Compound was evaluated for growth inhibition against A2780 wild-type ovarian cell lines; No data,,CHEMBL622598,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,7113,,17777,F,,
Autocuration,,1,,,Inhibition of tubulin polymerization in human ovarian cancer cell lines,,CHEMBL622599,D,5,,,Homo sapiens,9606.0,BAO_0000019,104766,,7114,,16936,F,,
Intermediate,,1,A2780,,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,,CHEMBL622600,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,7115,,13759,F,,
Intermediate,,1,A2780,,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,,CHEMBL622601,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,7116,,13759,F,,
Intermediate,,1,A2780,,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,,CHEMBL622602,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,7117,,13759,F,,
Intermediate,,1,A2780,,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,,CHEMBL622603,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,7118,,13759,F,,
Intermediate,,1,A2780,,Compound was tested for inhibitory activity against A2780 human ovarian carcinoma cell line; activity expressed in Mean IC50 values,,CHEMBL622604,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,7119,,15292,F,,
Intermediate,,1,A2780,,Compound was tested for inhibitory activity against A2780cisR human ovarian carcinoma cell line; activity expressed in Mean IC50 values,,CHEMBL622605,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,7120,,15292,F,,
Expert,,1,A2780,,In vitro inhibition of human ovarian cell line A2780,,CHEMBL622606,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,7121,,15069,F,,
Expert,,1,A2780,,"In vitro inhibition of human ovarian cell line, resistant to cisplatin (A2780cisR).",,CHEMBL619463,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,7122,,15069,F,,
Intermediate,,1,A2780,,Concentration of compound to inhibit the growth of human A2780 ovarian carcinoma cells(in vitro),,CHEMBL619464,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,7123,,14073,F,,
Expert,,1,A2780,,Concentration required to inhibit A2780-cell growth by 50%,,CHEMBL619465,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,7124,,14553,F,,
Expert,,1,A2780,,Concentration required to inhibit the cell growth by 50 % after 96 hr A2780 leukemic cells.,,CHEMBL619466,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,7125,,13040,F,,
Expert,,1,A2780,,Cytotoxic effect on human ovarian (A2780) cancer cell line,,CHEMBL619467,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,7126,,6891,F,,
Intermediate,,1,A2780,,Cytotoxic activity in a panel of Human ovarian tumor A2780 cell line after 96h of drug exposure,,CHEMBL619468,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,7127,,15569,F,,
Expert,,1,A2780,,Cytotoxic potency required to inhibit A2780 cell growth by 50% after cell drug contact for 96 hrs,,CHEMBL619469,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,7128,,14190,F,,
Expert,,1,A2780,,Cytotoxicity measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,,CHEMBL619470,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,7129,,15014,F,,
Intermediate,,1,A2780,,Cytotoxicity activity of the compound was measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,,CHEMBL619471,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,7130,,15014,F,,
Intermediate,,1,A2780,,Cytotoxicity against human ovarian carcinoma A2780 cell line,,CHEMBL619472,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,7131,,17496,F,,
Intermediate,,1,A2780,,"Cytotoxicity against A2780-C25, oxaliplatin-resistant Ovarian carcinoma cell line",,CHEMBL619473,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,7132,,13617,F,,
Intermediate,,1,A2780,,"Cytotoxicity against A2780-CP3, cisplatin-resistant Ovarian carcinoma cell line",,CHEMBL874368,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,7133,,13617,F,,
Intermediate,,1,A2780,,"Cytotoxicity against A2780-DX5, Doxorubicin-resistant Ovarian carcinoma cell line",,CHEMBL884003,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,7134,,13617,F,,
Intermediate,,1,A2780,,"Cytotoxicity against A2780-WT, human ovarian carcinoma cell line",,CHEMBL622690,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,7135,,13617,F,,
Intermediate,,1,A2780,,Cytotoxicity against ovarian carcinoma A2780 tumor cell lines,,CHEMBL622691,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,7136,,17672,F,,
Intermediate,,1,A2780,,Dose of required to inhibit growth of cisplatin resistant human ovarian carcinoma (A2780 cisR) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,,CHEMBL622692,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,7137,,4544,F,,
Intermediate,,1,A2780,,Dose of required to inhibit growth of human ovarian carcinoma (A2780) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,,CHEMBL623406,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,7138,,4544,F,,
Intermediate,,1,A2780,,"Growth inhibition in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant) using the 96 hour exposure sulforhodamine B (SRB) growth delay assay",,CHEMBL884004,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,7139,,16317,F,,
Intermediate,,1,A2780,,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780,,CHEMBL623407,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,7140,,15099,F,,
Intermediate,,1,A2780,,In vitro Growth Inhibitory activity against A2780 Human ovarian cancer cell line,,CHEMBL623408,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,7141,,13978,F,,
Expert,,1,A2780,,In vitro antitumor activity against A2780 cell line.,,CHEMBL623409,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,7142,,12989,F,,
Intermediate,,1,A2780,,In vitro cytotoxic activity against human tumor cell line A2780 after incubation for 96 hours,,CHEMBL623410,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,7143,,5574,F,,
Expert,,1,A2780,,In vitro cytotoxicity against A2780 human ovarian cancer cell line,,CHEMBL623576,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,7144,,13528,F,,
Intermediate,,1,ACHN,,Inhibitory activity against kidney A-CHN tumor cell growth in culture,,CHEMBL623577,N,1,,626.0,Homo sapiens,9606.0,BAO_0000219,80025,,7145,,12782,F,,
Intermediate,,1,ACHN,,The IC50 value was measured on ACHN cell line in renal tumor type.,,CHEMBL623578,N,1,,626.0,Homo sapiens,9606.0,BAO_0000219,80025,,7146,,14255,F,,
Intermediate,,1,ACHN,,Concentration required for killing 50% of cells of renal ACHN cell lines was determined in vitro,,CHEMBL623579,N,1,,626.0,Homo sapiens,9606.0,BAO_0000219,80025,,7147,,16364,F,,
Expert,,1,ACHN,,In vitro lethal concentration against most sensitive ACHN cell line,,CHEMBL623580,N,1,,626.0,Homo sapiens,9606.0,BAO_0000219,80025,,7148,,17376,F,,
Intermediate,,1,ACHN,,Tested for cytotoxic activity against renal cancer ACHN cell line,,CHEMBL623581,N,1,,626.0,Homo sapiens,9606.0,BAO_0000219,80025,,7149,,12016,F,,
Intermediate,,1,ACHN,,Compound tested for growth inhibition of renal cancer cell line ACHN,,CHEMBL857456,N,1,,626.0,Homo sapiens,9606.0,BAO_0000219,80025,,7150,,6058,F,,
Intermediate,,1,ACHN,,Compound was tested for 50% growth inhibition against human renal cancer ACHN cell line,,CHEMBL623582,N,1,,626.0,Homo sapiens,9606.0,BAO_0000219,80025,,7151,,17708,F,,
Intermediate,,1,ACHN,,Growth inhibition of the ACHN Renal cancer cell line for 2-day in vitro assay.,,CHEMBL623583,N,1,,626.0,Homo sapiens,9606.0,BAO_0000219,80025,,7152,,15176,F,,
Intermediate,,1,ACHN,,In vitro anticancer activity against ACHN renal cancer cell line,,CHEMBL623584,N,1,,626.0,Homo sapiens,9606.0,BAO_0000219,80025,,7153,,2806,F,,
Intermediate,,1,ACHN,,In vitro antitumor activity against Renal cancer ACHN cell lines by 6-day assay,,CHEMBL623585,N,1,,626.0,Homo sapiens,9606.0,BAO_0000219,80025,,7154,,15300,F,,
Intermediate,,1,ACHN,,Percent selectivity was evaluated in renal ACHN cell lines,,CHEMBL623586,N,1,,626.0,Homo sapiens,9606.0,BAO_0000219,80025,,7155,,16364,F,,
Intermediate,,1,ACHN,,In vitro inhibitory activity against renal ACHN cancer cell line,,CHEMBL623587,N,1,,626.0,Homo sapiens,9606.0,BAO_0000219,80025,,7156,,13859,F,,
Intermediate,,1,ACHN,,Tested for cytotoxicity against ACHN cell lines in renal cancer,,CHEMBL875279,N,1,,626.0,Homo sapiens,9606.0,BAO_0000219,80025,,7157,,11970,F,,
Intermediate,,1,ACHN,,Tested for the in vitro cytotoxicity against ACHN renal cancer cell line,,CHEMBL623588,N,1,,626.0,Homo sapiens,9606.0,BAO_0000219,80025,,7158,,2450,F,,
Intermediate,,1,ACHN,,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,,CHEMBL623589,N,1,,626.0,Homo sapiens,9606.0,BAO_0000219,80025,,7159,,12696,F,,
Intermediate,,1,ACHN,,Tested in vitro for cytotoxicity in ACHN cell line of Renal cancer,,CHEMBL623590,N,1,,626.0,Homo sapiens,9606.0,BAO_0000219,80025,,7160,,12400,F,,
Expert,,1,ACHN,,Cytotoxic effect on renal cancer line ACHN,,CHEMBL623591,N,1,,626.0,Homo sapiens,9606.0,BAO_0000219,80025,,7161,,12888,F,,
Intermediate,,1,ACHN,,In vitro anti-cancer activity against ACHN(Renal) human tumor cell line,,CHEMBL623592,N,1,,626.0,Homo sapiens,9606.0,BAO_0000219,80025,,7162,,3156,F,,
Intermediate,,1,ACHN,,In vitro inhibition of Renal Cancer ACHN cell lines,,CHEMBL623593,N,1,,626.0,Homo sapiens,9606.0,BAO_0000219,80025,,7163,,3381,F,,
Intermediate,,1,ACHN,,Antitumor activity against human renal adenocarcinoma ACHN cells,,CHEMBL623594,N,1,,626.0,Homo sapiens,9606.0,BAO_0000219,80025,,7164,,16747,F,,
Expert,,1,ACHN,,Antitumor activity against human renal adenocarcinoma ACHN cells.,,CHEMBL621833,N,1,,626.0,Homo sapiens,9606.0,BAO_0000219,80025,,7165,,16748,F,,
Intermediate,,1,ACHN,,Inhibitory concentration required to decrease cell viability in cell growth culture against kidney cells ACHN,,CHEMBL621834,N,1,,626.0,Homo sapiens,9606.0,BAO_0000219,80025,,7166,,12062,F,,
Intermediate,,1,ACHN,,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),,CHEMBL621835,N,1,,626.0,Homo sapiens,9606.0,BAO_0000219,80025,,7167,,14769,F,,
Intermediate,,1,ACHN,,"Cytotoxicity against NCI tumor panel, ACHN renal cancer cell line",,CHEMBL621836,N,1,,626.0,Homo sapiens,9606.0,BAO_0000219,80025,,7168,,15895,F,,
Intermediate,,1,ACHN,,Concentration of compound that cause 50% cytotoxicity of ACHN renal cancer cell line,,CHEMBL621837,N,1,,626.0,Homo sapiens,9606.0,BAO_0000219,80025,,7169,,17376,F,,
Intermediate,,1,ACHN,,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration that inhibits 50% net cell growth).,,CHEMBL875280,N,1,,626.0,Homo sapiens,9606.0,BAO_0000219,80025,,7170,,14882,F,,
Intermediate,,1,ACHN,,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration leading to 50% net cell death).,,CHEMBL621838,N,1,,626.0,Homo sapiens,9606.0,BAO_0000219,80025,,7171,,14882,F,,
Intermediate,,1,ACHN,,Cytotoxicity was tested against renal cancer ACHN tumor cell lines.,,CHEMBL621839,N,1,,626.0,Homo sapiens,9606.0,BAO_0000219,80025,,7172,,15661,F,,
Autocuration,,1,,,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,,CHEMBL621840,U,0,,,,,BAO_0000019,22224,,7173,,9680,A,,
Autocuration,,1,,,Compound tested for relative response using 1 uM ACh as agonist against AChM1 receptor.,,CHEMBL621841,H,8,,,,,BAO_0000019,10647,,7174,,14579,F,,
Expert,,1,HEL,,Antiviral activity against AD169 strain of cytomegalovirus (CMV) in HEL (human erythroleukemia) cells.,,CHEMBL622979,N,1,,468.0,Cytomegalovirus,10358.0,BAO_0000218,50529,,7175,,17290,F,,
Intermediate,,1,,,Antiviral activity against AD169 strain of cytomegalovirus (CMV); ND=No data,,CHEMBL876595,N,1,,,Cytomegalovirus,10358.0,BAO_0000218,50529,,7176,,17290,F,,
Autocuration,,1,,,Compound was evaluated for its inhibitory activity against calf intestinal Adenosine deaminase (ADA),,CHEMBL620221,H,8,,,,,BAO_0000357,12159,,7177,,15891,B,,
Autocuration,,1,,,Evaluated for the inhibition of calf intestinal Adenosine deaminase (ADA),,CHEMBL620222,H,8,,,,,BAO_0000357,12159,,7178,,15890,B,,
Intermediate,,1,ADDP cell line,,Inhibitory activity against ovarian tumor cell line ADDP after 72 hr continuous exposure to compound,,CHEMBL620506,N,1,,979.0,Bos taurus,9913.0,BAO_0000219,80670,,7179,,3801,F,,
Intermediate,,1,ADJ/PC6,,Tumor growth inhibition activity after subcutaneous transplanted tumor in ADJ-PC6 plasmacytoma cells,,CHEMBL620507,N,1,,980.0,Mus musculus,10090.0,BAO_0000219,80671,,7180,,9222,F,,
Intermediate,,1,ADJ/PC6,,Tumor growth inhibition activity after subcutaneously transplanted tumor in ADJ-PC6 plasmacytoma cells,,CHEMBL620508,N,1,,980.0,Mus musculus,10090.0,BAO_0000219,80671,,7181,,9222,F,,
Intermediate,,1,ADJ/PC6,,"Compound was tested for dose producing 90% reduction in tumor weight, in ADJ/PC6 mouse plasma cell tumor",,CHEMBL620509,N,1,,980.0,Mus musculus,10090.0,BAO_0000219,80671,,7182,,7257,F,,
Intermediate,,1,ADJ/PC6,,Compound was tested for inhibition against ADJ/PC6 mouse plasma cell tumor at the dose of 320 mg/Kg,,CHEMBL620510,N,1,,980.0,Mus musculus,10090.0,BAO_0000219,80671,,7183,,7257,F,,
Intermediate,,1,ADJ/PC6,,Compound was tested for dose required to kill 50 % of ADJ/PC6 mouse plasma cell tumor in a group,,CHEMBL620511,N,1,,980.0,Mus musculus,10090.0,BAO_0000219,80671,,7184,,7257,A,,
Intermediate,,1,ADJ/PC6,,In vitro incorporation of the [3H]thymidine into the ADJ/PC6 Plasmacytoma cells,,CHEMBL620512,N,1,,980.0,Mus musculus,10090.0,BAO_0000219,80671,,7185,,8084,F,,
Autocuration,,1,,,Tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma,,CHEMBL620513,U,0,,,Mus musculus,10090.0,BAO_0000019,22224,,7186,,14943,F,,
Autocuration,,1,,,The compound was tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma; Not determined,,CHEMBL620514,U,0,,,Mus musculus,10090.0,BAO_0000019,22224,,7187,,14943,F,,
Autocuration,,1,,,Tested for cytotoxicity against ADJ/PC6 plasmacytoma,,CHEMBL620515,U,0,,,Mus musculus,10090.0,BAO_0000019,22224,,7188,,14943,F,,
Autocuration,,1,,,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),,CHEMBL620516,U,0,,,Bacillus subtilis,1423.0,BAO_0000218,22224,,7189,,10524,A,In vivo,
Intermediate,,1,,,AUC value in dog after IV administration at a dose of 5 mg/kg,,CHEMBL620517,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7190,Plasma,3546,A,,1969.0
Intermediate,,1,,,AUC value in dog after oral administration at a dose of 5 mg/kg,,CHEMBL620518,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7191,Plasma,3546,A,,1969.0
Intermediate,,1,,,Cmax value in dog after oral administration at a dose of 5 mg/kg,,CHEMBL620519,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7192,,3546,A,In vivo,
Intermediate,,1,,,Bioavailability in dog after oral administration at a dose of 5 mg/kg,,CHEMBL621386,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7193,,3546,A,In vivo,
Intermediate,,1,,,Tmax value in dog after oral administration at a dose of 5 mg/kg,,CHEMBL621387,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7194,,3546,A,In vivo,
Intermediate,,1,,,Compound was evaluated for its clearance when administered intravenously in dog,,CHEMBL621388,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7195,,3184,A,In vivo,
Intermediate,,1,,,Plasma clearance in Beagle dogs after intravenous administration at a dose of 10 mg/kg,,CHEMBL621389,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7196,,16456,A,In vivo,
Intermediate,,1,,,Plasma clearance was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),,CHEMBL621390,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7197,,4809,A,In vivo,
Intermediate,,1,,,Calculated partition coefficient (clogP),,CHEMBL621391,U,0,,,,,BAO_0000100,22229,,7198,,4219,P,,
Intermediate,,1,,,Half life in dog,,CHEMBL621392,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7199,,3748,A,,
Intermediate,,1,,,Time taken for EC90 was determined when tested in dog,,CHEMBL621393,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7200,,3132,A,,
Intermediate,,1,,,Half life (iv) was determined,,CHEMBL621394,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7201,,4219,A,,
Intermediate,,1,,,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,,CHEMBL621395,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7202,Liver,16907,A,,2107.0
Intermediate,,1,,,Area under the curve was calculated in dog after iv administration,,CHEMBL621396,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7203,,6057,A,,
Intermediate,,1,,,Area under the curve was calculated in dog after peroral administration,,CHEMBL621397,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7204,,6057,A,,
Intermediate,,1,,,Dose-normalized area under curve in dog (p.o.) at 2.0 mpk,,CHEMBL621398,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7205,,17853,A,,
Intermediate,,1,,,pKa was evaluated in dog,,CHEMBL618818,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7206,,3639,A,,
Intermediate,,1,,,Compound was evaluated for pronounced GH response at 100 mg (n=6)(area under concentration curve was determined from 0-8 hr following morning and evening dosing with 25 mg of the compound,,CHEMBL618819,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7207,,14541,A,,
Intermediate,,1,,,Alpha-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,,CHEMBL618820,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7208,,16456,A,In vivo,
Intermediate,,1,,,Beta-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,,CHEMBL873810,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7209,,16456,A,In vivo,
Intermediate,,1,,,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,,CHEMBL876606,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7210,,2652,A,In vivo,
Intermediate,,1,,,Compound was evaluated for the half-life (t 1/2) in hours,,CHEMBL618821,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7211,,3624,A,,
Intermediate,,1,,,Half life to reach the blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,,CHEMBL618822,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7212,Blood,1337,A,In vivo,178.0
Intermediate,,1,,,Half life to reach the blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,,CHEMBL618823,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7213,Blood,1337,A,In vivo,178.0
Intermediate,,1,,,Half life after intravenous administration of 1 mg/kg in dog,,CHEMBL618824,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7214,,4709,A,In vivo,
Intermediate,,1,,,Half life was measured in dog,,CHEMBL618825,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7215,,15660,A,,
Intermediate,,1,,,Half life period in dog after 5 mg/kg dose,,CHEMBL618826,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7216,,5302,A,In vivo,
Intermediate,,1,,,Half life period was evaluated in dog; 4-4.8,,CHEMBL618827,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7217,,17791,A,,
Intermediate,,1,,,Half life was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,CHEMBL618828,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7218,,6348,A,In vivo,
Intermediate,,1,,,Half-life was determined in dog after a3 mg/kg of iv dose,,CHEMBL618829,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7219,,4257,A,In vivo,
Intermediate,,1,,,Half-life was determined,,CHEMBL618830,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7220,,3771,A,,
Intermediate,,1,,,Half life in dogs,,CHEMBL618831,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7221,,6305,A,,
Intermediate,,1,,,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 2 mg/kg tp dog,,CHEMBL619489,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7222,Plasma,13501,A,In vivo,1969.0
Intermediate,,1,,,Apparent half-life after single intravenous bolus of 1 mg/kg in dogs,,CHEMBL619649,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7223,,17594,A,In vivo,
Intermediate,,1,,,Compound was evaluated for the half life period after iv administration in Beagle dog.,,CHEMBL876607,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7224,,3045,A,In vivo,
Intermediate,,1,,,Compound was evaluated for the half life period after oral administration in conscious dog.,,CHEMBL619650,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7225,,3043,A,In vivo,
Intermediate,,1,,,Compound was tested for half life in dog,,CHEMBL619651,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7226,,4839,A,,
Intermediate,,1,,,Compound was tested for its half life in dog,,CHEMBL619652,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7227,,4839,A,,
Intermediate,,1,,,Half life of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,,CHEMBL619653,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7228,,5802,A,In vivo,
Intermediate,,1,,,Half life of compound in dog was determined,,CHEMBL619654,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7229,,17839,A,,
Intermediate,,1,,,Half life (iv) was determined,,CHEMBL619655,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7230,,4219,A,In vivo,
Intermediate,,1,,,Half life following administration of 70 nM in canine whole blood (dose exceeding platelet binding capacity),,CHEMBL619656,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7231,Blood,13966,A,,178.0
Intermediate,,1,,,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,,CHEMBL873812,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7232,Plasma,3994,A,In vivo,1969.0
Intermediate,,1,,,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,,CHEMBL621365,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7233,Plasma,3994,F,In vivo,1969.0
Intermediate,,1,,,Half life in dog,,CHEMBL621366,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7234,,4453,A,,
Intermediate,,1,,,Half life in dog plasma,,CHEMBL621367,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7235,Plasma,6535,A,,1969.0
Intermediate,,1,,,Half life in dog plasma after administration of 0.25 mg/kg iv,,CHEMBL621368,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7236,Plasma,6535,A,In vivo,1969.0
Intermediate,,1,,,Half life in dog plasma after administration of 1 mg/kg iv,,CHEMBL621369,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7237,Plasma,6535,A,In vivo,1969.0
Intermediate,,1,,,Half life in dog plasma was determined at dose 10 mg/kg,,CHEMBL621370,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7238,Plasma,3132,A,In vivo,1969.0
Intermediate,,1,,,Half life in dog was determined,,CHEMBL621371,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7239,,5374,A,,
Intermediate,,1,,,Half life in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),,CHEMBL621372,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7240,,5007,A,In vivo,
Intermediate,,1,,,Half life upon exposure to human plasma,,CHEMBL621373,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7241,Plasma,16907,A,,1969.0
Intermediate,,1,,,Half life was calculated in dog,,CHEMBL621374,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7242,,6057,A,,
Intermediate,,1,,,Half life was determined,,CHEMBL621375,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7243,,5006,A,,
Intermediate,,1,,,Half life was determined,,CHEMBL621376,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7244,,5473,A,,
Intermediate,,1,,,Half life by intravenous administration of 1.2 mg/kg in dog,,CHEMBL619624,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7245,,4368,A,In vivo,
Intermediate,,1,,,Half life in dog,,CHEMBL875840,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7246,,6448,A,,
Intermediate,,1,,,Half life in dog after intra venous administration of the compound,,CHEMBL619625,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7247,,4353,A,,
Intermediate,,1,,,Half life in dog after intra venous administration of the compound; ND means Not determined,,CHEMBL619626,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7248,,4353,A,,
Intermediate,,1,,,Half life in dog after po administration of the compound,,CHEMBL619627,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7249,,4353,A,In vivo,
Intermediate,,1,,,Half life in dog after po administration of the compound; ND means Not determined,,CHEMBL873817,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7250,,4353,A,In vivo,
Intermediate,,1,,,Half life in dog at the single oral dose of 1 mg/kg,,CHEMBL619628,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7251,,6265,A,In vivo,
Intermediate,,1,,,Half life in dogs,,CHEMBL619629,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7252,,5006,A,,
Intermediate,,1,,,Half life in dogs at 1 mg/kg oral dosing; 35-100 min,,CHEMBL619630,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7253,,5356,A,In vivo,
Intermediate,,1,,,Half life in rat,,CHEMBL619631,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7254,,405,A,,
Intermediate,,1,,,Half life in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,CHEMBL619632,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7255,,6642,A,In vivo,
Intermediate,,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,CHEMBL619633,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,7256,Bone,10107,A,In vivo,10000001.0
Intermediate,,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,CHEMBL875841,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,7257,Bone,10107,A,In vivo,10000001.0
Intermediate,,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,CHEMBL619634,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,7258,Bone,10107,A,In vivo,10000001.0
Intermediate,,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,CHEMBL619635,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,7259,Bone,10107,A,In vivo,10000001.0
Intermediate,,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,CHEMBL619636,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,7260,Bone,10107,A,In vivo,10000001.0
Intermediate,,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,CHEMBL619637,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,7261,Gut,10107,A,In vivo,10000004.0
Intermediate,,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,CHEMBL619638,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,7262,Gut,10107,A,In vivo,10000004.0
Intermediate,,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,CHEMBL619639,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,7263,Gut,10107,A,In vivo,10000004.0
Intermediate,,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,CHEMBL619640,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,7264,Gut,10107,A,In vivo,10000004.0
Intermediate,,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,CHEMBL619641,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,7265,Gut,10107,A,In vivo,10000004.0
Intermediate,,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,CHEMBL619642,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,7266,Gut,10107,A,In vivo,10000004.0
Intermediate,,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,CHEMBL619643,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,7267,Gut,10107,A,In vivo,10000004.0
Intermediate,,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,CHEMBL619644,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,7268,Heart,10107,A,In vivo,948.0
Intermediate,,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,CHEMBL621112,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,7269,Heart,10107,A,In vivo,948.0
Intermediate,,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,CHEMBL621113,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,7270,Heart,10107,A,In vivo,948.0
Intermediate,,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,CHEMBL621114,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,7271,Heart,10107,A,In vivo,948.0
Intermediate,,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,CHEMBL621115,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,7272,Heart,10107,A,In vivo,948.0
Intermediate,,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,CHEMBL621116,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,7273,Heart,10107,A,In vivo,948.0
Intermediate,,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,CHEMBL621117,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,7274,Heart,10107,A,In vivo,948.0
Intermediate,,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,CHEMBL621118,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,7275,Kidney,10107,A,In vivo,2113.0
Intermediate,,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,,CHEMBL621119,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,7276,Kidney,10107,A,In vivo,2113.0
Intermediate,,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,CHEMBL621120,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,7277,Kidney,10107,A,In vivo,2113.0
Intermediate,,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,CHEMBL621757,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,7278,Kidney,10107,A,In vivo,2113.0
Intermediate,,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,CHEMBL621758,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,7279,Kidney,10107,A,In vivo,2113.0
Intermediate,,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,CHEMBL621759,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,7280,Kidney,10107,A,In vivo,2113.0
Intermediate,,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,CHEMBL621760,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,7281,Kidney,10107,A,In vivo,2113.0
Intermediate,,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,CHEMBL621761,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,7282,Liver,10107,A,In vivo,2107.0
Intermediate,,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,CHEMBL621762,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,7283,Liver,10107,A,In vivo,2107.0
Intermediate,,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,CHEMBL621763,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,7284,Liver,10107,A,In vivo,2107.0
Intermediate,,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,CHEMBL624502,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,7285,Liver,10107,A,In vivo,2107.0
Intermediate,,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,CHEMBL624503,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,7286,Liver,10107,A,In vivo,2107.0
Intermediate,,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,CHEMBL624504,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,7287,Liver,10107,A,In vivo,2107.0
Intermediate,,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,CHEMBL624505,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,7288,Liver,10107,A,In vivo,2107.0
Intermediate,,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,CHEMBL624506,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,7289,Lung,10107,A,In vivo,2048.0
Intermediate,,1,A2780,,In vitro cytotoxicity against A2780 (human ovarian cancer),,CHEMBL624507,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,7290,,5895,F,,
Intermediate,,1,A2780,,In vitro cytotoxicity against the paclitaxel sensitive human breast carcinoma cell line A2780,,CHEMBL624508,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,7291,,6338,F,,
Intermediate,,1,A2780,,In vitro cytotoxicity against. ovarian carcinoma cell line A2780.,,CHEMBL624509,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,7292,,15163,F,,
Intermediate,,1,A2780,,In vitro cytotoxicity against. ovarian carcinoma cell line A2780cisR (cisplatin resistant counter part of A2780).,,CHEMBL624510,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,7293,,15163,F,,
Expert,,1,A2780,,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cell line,,CHEMBL875956,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,7294,,15000,F,,
Expert,,1,A2780,,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cisplatin resistant cell line,,CHEMBL839885,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,7295,,15000,F,,
Expert,,1,A2780,,In vitro cytotoxicity against A2780 ovarian cells using the sulforhodamine B(SRB) assay.,,CHEMBL624511,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,7296,,14729,F,,
Intermediate,,1,A2780,,In vitro cytotoxicity against A2780 cell line,,CHEMBL624512,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,7297,,17270,F,,
Intermediate,,1,A2780,,In vitro growth inhibitory activity against A2780 human ovarium carcinoma cell line was determined,,CHEMBL624513,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,7298,,5685,F,,
Intermediate,,1,A2780,,In vitro inhibitory activity against human ovarian cancer A2780 cell line,,CHEMBL624514,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,7299,,3563,F,,
Intermediate,,1,A2780,,In vivo cytotoxic concentration of compound against A2780 cell line after 72 hr exposure,,CHEMBL618547,N,1,,478.0,Homo sapiens,9606.0,BAO_0000218,81034,,7300,,17753,F,,
Intermediate,,1,A2780,,"Inhibition of cell growth in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant)using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay",,CHEMBL618548,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,7301,,16317,F,,
Intermediate,,1,A2780,,Inhibition of tubulin polymerization in analogy of ca.,,CHEMBL618549,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,7302,,16936,F,,
Intermediate,,1,A2780,,Inhibitory activity against ovarian tumor cell line A2780 after 72 hr continuous exposure to compound,,CHEMBL618550,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,7303,,3801,F,,
Expert,,1,A2780,,Cytotoxic effect in ovarian cancer cell line (A2780),,CHEMBL618551,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,7304,,6181,F,,
Intermediate,,1,A2780,,Tested for cytotoxicity against Ovarian carcinoma parental type A2780 cell line expressing MDR-1 (-) gene,,CHEMBL618552,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,7305,,5318,F,,
Intermediate,,1,A2780,,Tested for the cytotoxicity in A2780 ovarian cell line,,CHEMBL618553,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,7306,,4840,F,,
Intermediate,,1,A2780,,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),,CHEMBL618554,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,7307,,15748,F,,
Intermediate,,1,A2780,,The compound was tested for cytotoxic activity against A2780/Cs cell line(human ovarian carcinoma,,CHEMBL618555,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,7308,,15748,F,,
Intermediate,,1,A2780cisR,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma,,CHEMBL618556,N,1,,481.0,,,BAO_0000219,80017,,7309,,15748,F,,
Intermediate,,1,A2780cisR,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),,CHEMBL618557,N,1,,481.0,,,BAO_0000219,80017,,7310,,15748,F,,
Intermediate,,1,A2780cisR,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ); ND means no data,,CHEMBL618558,N,1,,481.0,,,BAO_0000219,80017,,7311,,15748,F,,
Intermediate,,1,A2780cisR,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma),,CHEMBL618559,N,1,,481.0,,,BAO_0000219,80017,,7312,,15748,F,,
Intermediate,,1,A2780,,In vivo log of cells killed after administration of compound in A2780 cell line,,CHEMBL618560,N,1,,478.0,Homo sapiens,9606.0,BAO_0000218,81034,,7313,,17753,F,,
Intermediate,,1,A2780,,Compound was tested in vivo for maximum tolerated dose after i.v. administration twice a day for 5 days in A2780 cell line,,CHEMBL618561,N,1,,478.0,Homo sapiens,9606.0,BAO_0000218,81034,,7314,,17753,F,In vivo,
Intermediate,,1,A2780,,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.;NA means not active,,CHEMBL618562,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,7315,,16936,F,,
Intermediate,,1,A2780,,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines (at 5 uM );NA means not active,,CHEMBL618563,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,7316,,16936,F,,
Intermediate,,1,A2780,,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines; ND means no data,,CHEMBL618564,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,7317,,16936,F,,
Intermediate,,1,A2780,,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines. (at 5 uM ); ND means no data,,CHEMBL618565,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,7318,,16936,F,,
Intermediate,,1,A2780,,Optimal dose required to inhibit human ovarian A2780 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q4dX2),,CHEMBL618566,N,1,,478.0,Homo sapiens,9606.0,BAO_0000218,81034,,7319,,17528,F,,
Intermediate,,1,A2780,,Resistance factor was determined as IC50 cisplatin-resistant/parent for human A2780 ovarian cell line,,CHEMBL618567,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,7320,,6633,F,,
Expert,,1,A2780,,Resistance index is IC50 ratio of A2780 cell line and A2780cisR cell line,,CHEMBL618568,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,7321,,15000,F,,
Expert,,1,A2780,,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,,CHEMBL618569,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,7322,,17528,F,,
Intermediate,,1,A2780,,Compound was tested for Tubulin polymerization inhibition by using human ovarian cancer cell lines.,,CHEMBL621857,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,7323,,16936,F,,
Intermediate,,1,A2780,,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.,,CHEMBL621858,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,7324,,16936,F,,
Intermediate,,1,A2780,,Percent of Tubulin polymerization inhibition by using human ovarian cancer cell lines at a concentration of 5 uM,,CHEMBL621859,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,7325,,16936,F,,
Intermediate,,1,A2780,,"Colchicine Binding Inhibition ( CBI ) by using human ovarian cancer cell lines at 5 uM, (values are mean of 9 over 4 concentrations +/- SD)",,CHEMBL621860,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,7326,,16936,F,,
Intermediate,,1,A2780,,Compound tested for colchicine Binding Inhibition by using human ovarian cancer cell line (at 5 uM ),,CHEMBL621861,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,7327,,16936,F,,
Expert,,1,A2780,,"Tested for colchicine binding inhibition, using human ovarian cancer cell lines (at 5 uM )",,CHEMBL621862,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,7328,,16936,F,,
Intermediate,,1,A2780,,Compound tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),,CHEMBL621863,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,7329,,16936,F,,
Intermediate,,1,A2780,,Compound was tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),,CHEMBL621864,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,7330,,16936,F,,
Intermediate,,1,A2780,,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell line (at 5 uM ),,CHEMBL621865,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,7331,,16936,F,,
Intermediate,,1,A2780,,In vitro antiproliferative activity against A2780 cell line,,CHEMBL621866,N,1,,478.0,Mus musculus,10090.0,BAO_0000219,81034,,7332,,17737,F,,
Expert,,1,A2780,,Maximum tolerated dose in A2780 tumor in mice after intraperitoneal administration daily for 8 days,,CHEMBL621867,N,1,,478.0,Mus musculus,10090.0,BAO_0000219,81034,,7333,,17764,F,,
Intermediate,,1,A2780,,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C after 96 hr,,CHEMBL621868,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,7334,,3830,F,,
Intermediate,,1,A2780,,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C for 96 hr,,CHEMBL875282,N,1,,478.0,Homo sapiens,9606.0,BAO_0000219,81034,,7335,,3829,F,,
Intermediate,,1,,,Vc value in dog after IV administration at a dose of 5 mg/kg,,CHEMBL621869,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7336,,3546,A,,
Intermediate,,1,,,Half life period in dog after IV administration at a dose of 5 mg/kg,,CHEMBL621870,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7337,,3546,A,In vivo,
Autocuration,,1,,,Area under curve was determine after peroral administration at 10 mpk in Rhesus,,CHEMBL621871,U,0,,,Cercopithecidae,9527.0,BAO_0000019,22224,,7338,,5668,A,,
Autocuration,,1,,,AUC (area under curve) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,CHEMBL621243,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,7339,Plasma,3443,A,,1969.0
Autocuration,,1,,,AUC (area under curve) compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,CHEMBL621244,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,7340,Plasma,3443,A,,1969.0
Autocuration,,1,,,Area under curve determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,,CHEMBL621245,U,0,,,Macaca fascicularis,9541.0,BAO_0000218,22224,,7341,,4256,A,In vivo,
Autocuration,,1,,,Area under curve determined after peroral administration at a dose of 10 mg/kg in cynomolgus monkey,,CHEMBL621246,U,0,,,Macaca fascicularis,9541.0,BAO_0000218,22224,,7342,,4256,A,In vivo,
Autocuration,,1,,,Area under curve determined after peroral administration at a dose of 3 mg/kg in cynomolgus monkey,,CHEMBL621247,U,0,,,Macaca fascicularis,9541.0,BAO_0000218,22224,,7343,,4256,A,In vivo,
Autocuration,,1,,,Oral Bioavailability in rat,,CHEMBL618386,U,0,,,Rattus norvegicus,10116.0,BAO_0000218,22224,,7344,,4256,A,In vivo,
Autocuration,,1,,,Area under curve was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,CHEMBL618387,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,7345,,1916,A,,
Autocuration,,1,,,Area under curve value in monkey at a dose of 5 mg/kg,,CHEMBL618388,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,7346,,5302,A,,
Autocuration,,1,,,Area under curve was determined in monkey after a 3 mg/kg of oral dose,,CHEMBL618389,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,7347,,4257,A,,
Autocuration,,1,,,Area under curve was determined using trapezoidal rule after intravenous administration in cynomolgus monkeys,,CHEMBL618574,U,0,,,Cercopithecidae,9527.0,BAO_0000019,22224,,7348,,5355,A,,
Autocuration,,1,,,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys,,CHEMBL618575,U,0,,,Cercopithecidae,9527.0,BAO_0000019,22224,,7349,,5355,A,,
Autocuration,,1,,,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys; ND means Not determined,,CHEMBL618576,U,0,,,Cercopithecidae,9527.0,BAO_0000019,22224,,7350,,5355,A,,
Autocuration,,1,,,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in monkey,,CHEMBL618577,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,7351,,6078,A,,
Autocuration,,1,,,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in monkey,,CHEMBL876487,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,7352,,6078,A,,
Autocuration,,1,,,Area under the curve was measured in monkey after an iv dose of 1 mg/kg,,CHEMBL618578,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,7353,,6062,A,,
Autocuration,,1,,,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female cynomolgus monkey,,CHEMBL618579,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,7354,,2661,A,,
Autocuration,,1,,,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female cynomolgus monkey,,CHEMBL618580,U,0,,,Cercopithecidae,9527.0,BAO_0000019,22224,,7355,,2661,A,,
Autocuration,,1,,,Pharmacokinetic parameter Cmax was measured after administration into monkey at 3 mg/kg,,CHEMBL618581,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,7356,,5394,A,,
Autocuration,,1,,,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in cynomolgus monkeys (0 to 24 hr) p.o.,,CHEMBL618582,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,7357,,4397,A,,
Autocuration,,1,,,Area under curve value 24 hr after 2 mg/kg iv administration in monkeys,,CHEMBL618583,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,7358,,17509,A,,
Autocuration,,1,,,Area under curve value 24 hr after 2 mg/kg oral administration in monkeys,,CHEMBL618584,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,7359,,17509,A,,
Autocuration,,1,,,Oral AUCN in monkey (dosed at 0.5 mpk iv ),,CHEMBL618585,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,7360,,6641,A,In vivo,
Autocuration,,1,,,Bioavailability was reported in cynomolgus monkeys (ratio of AUC in oral administration to that of intravenous administration),,CHEMBL618586,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,7361,,5355,A,,
Autocuration,,1,,,Half life compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,CHEMBL618587,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,7362,,3443,A,In vivo,
Autocuration,,1,,,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,CHEMBL618588,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,7363,,3443,A,In vivo,
Autocuration,,1,,,Binding towards monkey plasma protein at 10 uM,,CHEMBL618589,U,0,,,Cercopithecidae,9527.0,BAO_0000019,22224,,7364,,17409,A,,
Autocuration,,1,,,Binding towards monkey plasma protein at 100 uM,,CHEMBL618590,U,0,,,Cercopithecidae,9527.0,BAO_0000019,22224,,7365,,17409,A,,
Autocuration,,1,,,Apparent bioavailability in squirrel monkey was determined,,CHEMBL872262,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,7366,,1052,A,In vivo,
Autocuration,,1,,,Bioavailability was determined after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,,CHEMBL618591,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,7367,,13501,A,In vivo,
Autocuration,,1,,,Bioavailability in monkey (dose 2 mg/kg),,CHEMBL618592,U,0,,,monkey,9443.0,BAO_0000218,22224,,7368,,17509,A,In vivo,
Autocuration,,1,,,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for bioavailability after administration into monkey at 3 mg/kg,,CHEMBL876488,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,7369,,5394,A,In vivo,
Autocuration,,1,,,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female cynomolgus monkey,,CHEMBL618593,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,7370,,2661,A,In vivo,
Autocuration,,1,,,Bioavailability in monkey (i.d. dosing),,CHEMBL618594,U,0,,,monkey,9443.0,BAO_0000218,22224,,7371,,11219,A,In vivo,
Autocuration,,1,,,Oral bioavailability after 5 mg/kg in cynomolgus monkey was determined,,CHEMBL618595,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,7372,,3045,A,In vivo,
Autocuration,,1,,,Clearance of the drug was measured in cynomolgus,,CHEMBL621469,U,0,,,Cercopithecidae,9527.0,BAO_0000019,22224,,7373,,17796,A,,
Autocuration,,1,,,Clearance was estimated in two squirrel monkeys after iv administration at 5 mg/kg,,CHEMBL621470,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,7374,,1399,A,In vivo,
Autocuration,,1,,,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female cynomolgus monkey,,CHEMBL621471,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,7375,,2661,A,In vivo,
Autocuration,,1,,,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,,CHEMBL621472,U,0,,,Macaca mulatta,9544.0,BAO_0000218,22224,,7376,Plasma,5005,A,In vivo,1969.0
Autocuration,,1,,,Plasma clearance in rhesus monkey was determined,,CHEMBL621473,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,7377,,17267,A,In vivo,
Autocuration,,1,,,Plasma clearance in monkey after administration of 1 mg/kg iv,,CHEMBL621474,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,7378,,6535,A,In vivo,
Autocuration,,1,,,Plasma clearance in cynomolgus monkey,,CHEMBL621475,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,7379,,5922,A,In vivo,
Autocuration,,1,,,Plasma clearance after oral administration (2.5 mg/kg) in monkey was determined,,CHEMBL621476,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,7380,,6221,A,In vivo,
Autocuration,,1,,,Plasma clearance after peroral administration at 10 mpk in Rhesus,,CHEMBL624290,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,7381,,5668,A,In vivo,
Autocuration,,1,,,The total clearance was determined after intravenous administration in cynomolgus monkeys,,CHEMBL624291,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,7382,,5355,A,In vivo,
Autocuration,,1,,,The total clearance was determined after oral administration in cynomolgus monkeys; NA means Not applicable,,CHEMBL624292,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,7383,,5355,A,In vivo,
Autocuration,,1,,,The total clearance was determined after oral administration in cynomolgus monkeys; NA means not applicable,,CHEMBL624293,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,7384,,5355,A,In vivo,
Autocuration,,1,,,Tested for Clearance upon iv administration to african green monkey,,CHEMBL624294,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,7385,,4578,A,In vivo,
Autocuration,,1,,,Clearance in monkey,,CHEMBL624295,U,0,,,Cercopithecidae,9527.0,BAO_0000218,22224,,7386,,17592,A,In vivo,
Intermediate,,1,,,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,CHEMBL624296,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7387,,6641,A,In vivo,
Intermediate,,1,,,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,CHEMBL624297,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7388,,6642,A,In vivo,
Intermediate,,1,,,Half life was evaluated after intravenous administration to dogs,,CHEMBL624298,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7389,,16367,A,In vivo,
Intermediate,,1,,,Half life was evaluated in dog,,CHEMBL624299,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7390,,5472,A,,
Intermediate,,1,,,Half life was evaluated in dog,,CHEMBL624300,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7391,,5474,A,,
Intermediate,,1,,,Half life period (t1/2) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,,CHEMBL624301,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7392,,5654,A,In vivo,
Intermediate,,1,,,Half life period after intravenous administration (1 mg/kg) was determined in dog (in vivo),,CHEMBL624302,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7393,,6227,A,In vivo,
Intermediate,,1,,,Half life period after intravenous administration in dog,,CHEMBL876026,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7394,,6227,A,In vivo,
Intermediate,,1,,,Half life period after oral administration (2.5 mg/kg) in dog was determined,,CHEMBL624303,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7395,,6221,A,In vivo,
Intermediate,,1,,,Half life period at a dose of 1 uM/kg in dog was determined,,CHEMBL624304,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7396,,4527,A,,
Intermediate,,1,,,Half life period was determine after peroral administration at 10 mpk in dog,,CHEMBL624305,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7397,,5668,A,In vivo,
Intermediate,,1,,,Half life period was determine after peroral administration at 5 mpk in dog,,CHEMBL624306,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7398,,5668,A,In vivo,
Intermediate,,1,,,Half life period was determined,,CHEMBL624307,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7399,,3854,A,,
Intermediate,,1,,,Half life period was determined,,CHEMBL624308,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7400,,5505,A,,
Intermediate,,1,,,Half life period by iv administration in dog at a dose of 6 mg/kg,,CHEMBL624309,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7401,,6251,A,In vivo,
Intermediate,,1,,,Half life period was evaluated in dog,,CHEMBL624310,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7402,,1918,A,,
Intermediate,,1,,,Half life period was determined in Beagle dog at a dose of 1 mg/kg by iv administration,,CHEMBL625003,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7403,,5546,A,In vivo,
Intermediate,,1,,,Half life period was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),,CHEMBL625004,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7404,,4809,A,In vivo,
Intermediate,,1,,,Half life time after intravenous administration (0.5 mg/kg) was determined in dog,,CHEMBL625005,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7405,,6215,A,In vivo,
Intermediate,,1,,,Half-life period by oral administration at a dose of 10 uM/kg in dog was determined,,CHEMBL873813,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7406,,4527,A,In vivo,
Intermediate,,1,,,Half-life after oral dose of compound at 3 mg/kg in dogs,,CHEMBL625006,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7407,,17594,A,In vivo,
Intermediate,,1,,,Half-life of compound in dog following p.o. administration of 0.5 mg/kg,,CHEMBL625007,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7408,,17839,A,In vivo,
Intermediate,,1,,,Half-life of compound in dog following p.o. administration of 0.9 mg/kg,,CHEMBL876027,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7409,,17839,A,In vivo,
Intermediate,,1,,,Half-life of compound in dog following p.o. administration of 0.95 mg/kg,,CHEMBL625008,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7410,,17839,A,In vivo,
Intermediate,,1,,,Half-life of compound in dog following p.o. administration of 1 mg/kg,,CHEMBL625009,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7411,,17839,A,In vivo,
Intermediate,,1,,,Half-life of compound in plasma of dog was determined,,CHEMBL625010,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7412,Plasma,5210,A,,1969.0
Intermediate,,1,,,Half-life of compound was determined in dogs,,CHEMBL625011,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7413,,5210,A,,
Intermediate,,1,,,Half-life after administration of 4 mg/Kg oral dose in dog,,CHEMBL621553,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7414,,2959,A,In vivo,
Intermediate,,1,,,Half-life after intravenous administration of 1 mg/kg/h in dog,,CHEMBL621554,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7415,,4137,A,In vivo,
Intermediate,,1,,,Half-life in Dog,,CHEMBL621555,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7416,,5064,A,,
Intermediate,,1,,,Half-life in Dog,,CHEMBL621556,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7417,,5147,A,,
Intermediate,,1,,,Half-life in dog,,CHEMBL621557,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7418,,5145,A,,
Intermediate,,1,,,Half-life in dog after oral administration at 1 mg/kg,,CHEMBL621558,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7419,,6123,A,In vivo,
Intermediate,,1,,,Half-life in dog after oral administration at 1 mg/kg; nd is not determined,,CHEMBL621559,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7420,,6123,A,In vivo,
Intermediate,,1,,,Half-life in dogs,,CHEMBL621560,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7421,,4333,A,,
Intermediate,,1,,,Half-life in dogs; ND indicates not determined,,CHEMBL876028,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7422,,4333,A,,
Intermediate,,1,,,Half-life in plasma of dog,,CHEMBL621561,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7423,Plasma,12500,A,,1969.0
Intermediate,,1,,,Half-life in plasma of dog at dose of 3-10 mgkg,,CHEMBL621562,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7424,Plasma,12500,A,,1969.0
Intermediate,,1,,,Half-life was evaluated after i.v. administration in dog at a dose of 1 mg/kg,,CHEMBL621563,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7425,,6005,A,In vivo,
Intermediate,,1,,,Half-life was measured in dog after an iv dose of 1 mg/kg,,CHEMBL621564,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7426,,6062,A,In vivo,
Intermediate,,1,,,Half-life was measured in dogs after an oral dose of 10 uM/kg,,CHEMBL621565,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7427,,17650,A,In vivo,
Intermediate,,1,,,Half-life in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,,CHEMBL621566,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7428,,5530,A,In vivo,
Intermediate,,1,,,Half-life in vivo in dog by intravenous administration at a dose of 1 mg/kg,,CHEMBL621567,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7429,,5530,A,In vivo,
Intermediate,,1,,,Half-life of the compound after 0.3 mg/kg po administration in dog,,CHEMBL622978,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7430,,5600,A,In vivo,
Intermediate,,1,,,Half-life period after intravenous administration of 0.5 mg/kg in dog was determined,,CHEMBL873814,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7431,,6039,A,In vivo,
Intermediate,,1,,,Half-life period after intravenous administration of 1.0 mg/kg in dog was determined,,CHEMBL623219,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7432,,6039,A,In vivo,
Intermediate,,1,,,Half-life period after peroral administration of 0.2 mg/kg in dog was determined,,CHEMBL624477,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7433,,6039,A,In vivo,
Intermediate,,1,,,t1/2 in dog,,CHEMBL624478,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7434,,6227,A,,
Intermediate,,1,,,Half-life period measured in dogs,,CHEMBL624479,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7435,,14541,A,,
Intermediate,,1,,,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,,CHEMBL624480,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7436,,4521,A,In vivo,
Intermediate,,1,,,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,,CHEMBL623595,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7437,,4521,A,In vivo,
Intermediate,,1,,,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,CHEMBL623596,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7438,,6679,A,In vivo,
Intermediate,,1,,,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in dog plasma",,CHEMBL623597,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7439,Plasma,1116,A,In vitro,1969.0
Intermediate,,1,,,In vivo half life period was calculated at 1 mg/kg in dog,,CHEMBL623598,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7440,,5444,A,In vivo,
Intermediate,,1,,,In vivo half life period was calculated at 1 mg/kg in dog; ND=Not determined,,CHEMBL623599,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7441,,5444,A,In vivo,
Intermediate,,1,,,Longer half-life in dog (i.v.) at 0.5 mpk,,CHEMBL623600,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7442,,17853,A,In vivo,
Intermediate,,1,,,Oral bioavailability in dog (dose 5 uM/kg),,CHEMBL623601,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7443,,4353,A,In vivo,
Intermediate,,1,,,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,,CHEMBL623602,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7444,,16452,A,In vivo,
Intermediate,,1,,,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,,CHEMBL623603,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7445,,16452,A,In vivo,
Intermediate,,1,,,Bioavailability in dog (dose 1 mg/kg i.v.),,CHEMBL623604,N,1,,,Canis lupus familiaris,9615.0,BAO_0000218,50588,,7446,,16452,A,In vivo,
Intermediate,,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,,CHEMBL623605,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,7447,Lung,10107,A,In vivo,2048.0
Intermediate,,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,CHEMBL623606,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,7448,Lung,10107,A,In vivo,2048.0
Intermediate,,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,CHEMBL623607,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,7449,Lung,10107,A,In vivo,2048.0
Intermediate,,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,CHEMBL623608,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,7450,Lung,10107,A,In vivo,2048.0
Intermediate,,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,CHEMBL623609,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,7451,Lung,10107,A,In vivo,2048.0
Intermediate,,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,CHEMBL623610,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,7452,Lung,10107,A,In vivo,2048.0
Intermediate,,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,CHEMBL623611,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,7453,Muscle tissue,10107,A,In vivo,2385.0
Intermediate,,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,,CHEMBL623612,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,7454,Muscle tissue,10107,A,In vivo,2385.0
Intermediate,,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,CHEMBL623613,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,7455,Muscle tissue,10107,A,In vivo,2385.0
Intermediate,,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,CHEMBL623614,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,7456,Muscle tissue,10107,A,In vivo,2385.0
Intermediate,,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,CHEMBL623615,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,7457,Muscle tissue,10107,A,In vivo,2385.0
Intermediate,,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,CHEMBL623616,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,7458,Muscle tissue,10107,A,In vivo,2385.0
Intermediate,,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,CHEMBL623617,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,7459,Muscle tissue,10107,A,In vivo,2385.0
Intermediate,,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,CHEMBL875944,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,7460,Zone of skin,10107,A,In vivo,14.0
Intermediate,,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,CHEMBL623618,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,7461,Zone of skin,10107,A,In vivo,14.0
Intermediate,,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,CHEMBL623619,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,7462,Zone of skin,10107,A,In vivo,14.0
Intermediate,,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,CHEMBL623620,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,7463,Zone of skin,10107,A,In vivo,14.0
Intermediate,,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,CHEMBL623621,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,7464,Zone of skin,10107,A,In vivo,14.0
Intermediate,,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,CHEMBL623622,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,7465,Zone of skin,10107,A,In vivo,14.0
Intermediate,,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,CHEMBL623623,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,7466,Zone of skin,10107,A,In vivo,14.0
Intermediate,,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,CHEMBL623624,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,7467,Spleen,10107,A,In vivo,2106.0
Intermediate,,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,CHEMBL618521,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,7468,Spleen,10107,A,In vivo,2106.0
Intermediate,,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,CHEMBL618522,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,7469,Spleen,10107,A,In vivo,2106.0
Intermediate,,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,CHEMBL618523,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,7470,Spleen,10107,A,In vivo,2106.0
Intermediate,,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,CHEMBL618524,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,7471,Spleen,10107,A,In vivo,2106.0
Intermediate,,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,CHEMBL618525,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,7472,Spleen,10107,A,In vivo,2106.0
Intermediate,,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,CHEMBL624586,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,7473,Spleen,10107,A,In vivo,2106.0
Intermediate,,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,CHEMBL624587,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,7474,Stomach,10107,A,In vivo,945.0
Intermediate,,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,CHEMBL624588,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,7475,Stomach,10107,A,In vivo,945.0
Intermediate,,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,CHEMBL624589,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,7476,Stomach,10107,A,In vivo,945.0
Intermediate,,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,CHEMBL624590,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,7477,Stomach,10107,A,In vivo,945.0
Intermediate,,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,CHEMBL624591,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,7478,Stomach,10107,A,In vivo,945.0
Intermediate,,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,CHEMBL624592,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,7479,Stomach,10107,A,In vivo,945.0
Intermediate,,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,CHEMBL624593,N,1,,,Mus musculus,10090.0,BAO_0000218,50594,,7480,Stomach,10107,A,In vivo,945.0
Intermediate,,1,,,Oral bioavailability in rat,,CHEMBL624594,N,1,,,Rattus norvegicus,10116.0,BAO_0000218,50597,,7481,,4689,A,In vivo,
Intermediate,,1,,,Tested for the bioavailability in rat,,CHEMBL624595,N,1,,,Rattus norvegicus,10116.0,BAO_0000218,50597,,7482,,4950,A,In vivo,
Intermediate,,1,,,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),,CHEMBL624596,N,1,,,Rattus norvegicus,10116.0,BAO_0000218,50597,,7483,,5328,A,In vivo,
Intermediate,,1,,,Bioavailability in rat,,CHEMBL624597,N,1,,,Rattus norvegicus,10116.0,BAO_0000218,50597,,7484,,406,A,In vivo,
Intermediate,,1,,,Bioavailability in rat,,CHEMBL624598,N,1,,,Rattus norvegicus,10116.0,BAO_0000218,50597,,7485,,12500,A,In vivo,
Intermediate,,1,,,Bioavailability in rat (dose 3-10 mg/kg),,CHEMBL624599,N,1,,,Rattus norvegicus,10116.0,BAO_0000218,50597,,7486,,12500,A,In vivo,
Intermediate,,1,,,Bioavailability in rat,,CHEMBL875166,N,1,,,Rattus norvegicus,10116.0,BAO_0000218,50597,,7487,,5247,A,In vivo,
Intermediate,,1,,,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,,CHEMBL624600,N,1,,,Rattus norvegicus,10116.0,BAO_0000218,50597,,7488,Plasma,4186,A,In vivo,1969.0
Intermediate,,1,,,Apparent terminal elimination half-life in rat plasma after administration of 50 mg/kg dose through subcutaneous route,,CHEMBL624601,N,1,,,Rattus norvegicus,10116.0,BAO_0000218,50597,,7489,Plasma,4186,A,In vivo,1969.0
Intermediate,,1,,,Half life after oral administration was determined in rats at 6 mg/kg,,CHEMBL624602,N,1,,,Rattus norvegicus,10116.0,BAO_0000218,50597,,7490,,6647,A,In vivo,
Intermediate,,1,,,Half life was determined,,CHEMBL624603,N,1,,,Rattus norvegicus,10116.0,BAO_0000218,50597,,7491,,6484,A,,
Intermediate,,1,,,Half life the of compound was determined by ''Cr'' assay in rat at a dose of 10 mg/kg,,CHEMBL624604,N,1,,,Rattus norvegicus,10116.0,BAO_0000218,50597,,7492,,3249,A,In vivo,
Intermediate,,1,,,Plasma half life in rat at oral dose 2.8 mg/mk body weight,,CHEMBL624605,N,1,,,Rattus norvegicus,10116.0,BAO_0000218,50597,,7493,Plasma,6281,A,In vivo,1969.0
Intermediate,,1,,,Half life in rats,,CHEMBL624606,N,1,,,Rattus norvegicus,10116.0,BAO_0000218,50597,,7494,,3307,A,,
Intermediate,,1,,,Half-lives were estimated from the elimination phase of the blood conc-time curve after oral administration,,CHEMBL624607,N,1,,,Rattus norvegicus,10116.0,BAO_0000218,50597,,7495,Blood,12058,A,In vivo,178.0
Intermediate,,1,,,Hill coefficient of the compound,,CHEMBL624608,N,1,,,Rattus norvegicus,10116.0,BAO_0000218,50597,,7496,,8833,A,,
Intermediate,,1,,,Compound was tested for percent hydrolysis in whole blood after a time interval of 0.5 min,,CHEMBL624609,N,1,,,Rattus norvegicus,10116.0,BAO_0000218,50597,,7497,Blood,3193,A,,178.0
Intermediate,,1,,,Compound was tested for percent hydrolysis in whole blood after a time interval of 180.0 min,,CHEMBL624610,N,1,,,Rattus norvegicus,10116.0,BAO_0000218,50597,,7498,Blood,3193,A,,178.0
Intermediate,,1,,,Compound was tested for percent hydrolysis in whole blood after a time interval of 2.0 min,,CHEMBL624611,N,1,,,Rattus norvegicus,10116.0,BAO_0000218,50597,,7499,Blood,3193,A,,178.0
Intermediate,,1,,,Compound was tested for percent hydrolysis in whole blood after a time interval of 5.0 min,,CHEMBL624612,N,1,,,Rattus norvegicus,10116.0,BAO_0000218,50597,,7500,Blood,3193,A,,178.0
Intermediate,,1,,,Compound was tested for percent hydrolysis in whole blood after a time interval of 60.0 min,,CHEMBL875167,N,1,,,Rattus norvegicus,10116.0,BAO_0000218,50597,,7501,Blood,3193,A,,178.0
Intermediate,,1,,,Compound was tested for percent hydrolysis in whole blood after a time interval of 7.0 min,,CHEMBL624613,N,1,,,Rattus norvegicus,10116.0,BAO_0000218,50597,,7502,Blood,3193,A,,178.0
Intermediate,,1,,,"Compound was tested for percent hydrolysis in whole blood, after a time interval of 15.0 min",,CHEMBL624614,N,1,,,Rattus norvegicus,10116.0,BAO_0000218,50597,,7503,Blood,3193,A,,178.0
Intermediate,,1,,,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,,CHEMBL624392,N,1,,,Rattus norvegicus,10116.0,BAO_0000218,50597,,7504,,5960,A,,
Intermediate,,1,,,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/organ,,CHEMBL624393,N,1,,,Rattus norvegicus,10116.0,BAO_0000218,50597,,7505,Brain,13950,A,In vivo,955.0
Intermediate,,1,,,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/organ,,CHEMBL624394,N,1,,,Rattus norvegicus,10116.0,BAO_0000218,50597,,7506,Brain,13950,A,In vivo,955.0
Intermediate,,1,,,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/organ,,CHEMBL624395,N,1,,,Rattus norvegicus,10116.0,BAO_0000218,50597,,7507,Brain,13950,A,In vivo,955.0
Intermediate,,1,,,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/organ,,CHEMBL624396,N,1,,,Rattus norvegicus,10116.0,BAO_0000218,50597,,7508,Brain,13950,A,In vivo,955.0
Intermediate,,1,,,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/organ,,CHEMBL624397,N,1,,,Rattus norvegicus,10116.0,BAO_0000218,50597,,7509,Brain,13950,A,In vivo,955.0
Intermediate,,1,,,Biodistribution of [123I]-label in rat thyroid was reported at 0.33 hr post injection. Value shown is %ID/organ,,CHEMBL624398,N,1,,,Rattus norvegicus,10116.0,BAO_0000218,50597,,7510,Thyroid gland,13950,A,In vivo,2046.0
Intermediate,,1,,,Biodistribution of [123I]-label in rat thyroid was reported at 1 hr post injection. Value shown is %ID/organ,,CHEMBL624399,N,1,,,Rattus norvegicus,10116.0,BAO_0000218,50597,,7511,Thyroid gland,13950,A,In vivo,2046.0
Intermediate,,1,,,Biodistribution of [123I]-label in rat thyroid was reported at 2 hr post injection. Value shown is %ID/organ,,CHEMBL624400,N,1,,,Rattus norvegicus,10116.0,BAO_0000218,50597,,7512,Thyroid gland,13950,A,In vivo,2046.0
Intermediate,,1,,,Biodistribution of [123I]-label in rat thyroid was reported at 24 hr post injection. Value shown is %ID/organ,,CHEMBL624401,N,1,,,Rattus norvegicus,10116.0,BAO_0000218,50597,,7513,Thyroid gland,13950,A,In vivo,2046.0
Intermediate,,1,,,Biodistribution of [123I]-label in rat thyroid was reported at 4 hr post injection. Value shown is %ID/organ,,CHEMBL624402,N,1,,,Rattus norvegicus,10116.0,BAO_0000218,50597,,7514,Thyroid gland,13950,A,In vivo,2046.0
Intermediate,,1,,,Biodistribution in normal rat blood in the presence of 0.005 M Gd/0.01 M lig at 2 hr,,CHEMBL624403,N,1,,,Rattus norvegicus,10116.0,BAO_0000218,50597,,7515,Blood,9866,A,In vivo,178.0
Intermediate,,1,,,Biodistribution in normal rat blood in the presence of 0.01 M Gd/0.05 M lig,,CHEMBL624404,N,1,,,Rattus norvegicus,10116.0,BAO_0000218,50597,,7516,Blood,9866,A,In vivo,178.0
Intermediate,,1,,,Biodistribution in normal rat blood in the presence of NAC Gd 0.01 M lig at 2 hr,,CHEMBL624405,N,1,,,Rattus norvegicus,10116.0,BAO_0000218,50597,,7517,Blood,9866,A,In vivo,178.0
Intermediate,,1,,,Biodistribution in normal rat bone in the presence of 0.005 M Gd/0.01 M lig at 2 hr,,CHEMBL624406,N,1,,,Rattus norvegicus,10116.0,BAO_0000218,50597,,7518,Bone,9866,A,In vivo,10000001.0
Intermediate,,1,,,Biodistribution in normal rat bone in the presence of 0.01 M Gd/0.05 M lig,,CHEMBL624407,N,1,,,Rattus norvegicus,10116.0,BAO_0000218,50597,,7519,Bone,9866,A,In vivo,10000001.0
Intermediate,,1,,,Biodistribution in normal rat bone in the presence of NAC Gd 0.01 M lig at 2 hr,,CHEMBL624408,N,1,,,Rattus norvegicus,10116.0,BAO_0000218,50597,,7520,Bone,9866,A,In vivo,10000001.0
Intermediate,,1,,,Biodistribution in normal rat heart in the presence of 0.005 M Gd/0.01 M lig at 2 hr,,CHEMBL618644,N,1,,,Rattus norvegicus,10116.0,BAO_0000218,50597,,7521,Heart,9866,A,In vivo,948.0
Intermediate,,1,,,Biodistribution in normal rat heart in the presence of 0.01 M Gd/0.05 M lig,,CHEMBL618645,N,1,,,Rattus norvegicus,10116.0,BAO_0000218,50597,,7522,Heart,9866,A,In vivo,948.0
Intermediate,,1,,,Biodistribution in normal rat heart in the presence of NAC Gd 0.01 M lig at 2 hr,,CHEMBL618646,N,1,,,Rattus norvegicus,10116.0,BAO_0000218,50597,,7523,Heart,9866,A,In vivo,948.0
